<SEC-DOCUMENT>0001628280-24-020467.txt : 20240506
<SEC-HEADER>0001628280-24-020467.hdr.sgml : 20240506
<ACCEPTANCE-DATETIME>20240506080623
ACCESSION NUMBER:		0001628280-24-020467
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240506
DATE AS OF CHANGE:		20240506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lyell Immunopharma, Inc.
		CENTRAL INDEX KEY:			0001806952
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				833006753
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40502
		FILM NUMBER:		24915647

	BUSINESS ADDRESS:	
		STREET 1:		201 HASKINS WAY
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650 695-0677

	MAIL ADDRESS:	
		STREET 1:		201 HASKINS WAY
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>lyel-20240331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:cc2ada24-6463-486d-8041-2176b9cca09e,g:4457644e-4c39-4c28-b3b7-d0adb2254c74,d:9c884009163249728202a1a7baf43489-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:lyel="http://lyell.com/20240331" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lyel-20240331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0001806952</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-26">December 31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-29">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="f-479">http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2023#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-149" name="lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" id="f-541">P27M</ix:nonNumeric><ix:nonNumeric contextRef="c-162" name="lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn" id="f-565">P2Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lyel-20240331.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyel:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:TenTimesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:TwentyTimesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:ThirtyTimesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:FortyTimesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:FiftyTimesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyel:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:TenTimesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:TwentyTimesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:ThirtyTimesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:FortyTimesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:FiftyTimesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">lyel:MarketableSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">lyel:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">lyel:MarketableSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">lyel:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="entity"><xbrli:measure>lyel:entity</xbrli:measure></xbrli:unit><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="y"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:SuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:SuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:SuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lyel:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:CowenAndCompanyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-28</xbrli:startDate><xbrli:endDate>2024-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lyel:DateOfEquityModificationsAxis">lyel:A2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-16</xbrli:startDate><xbrli:endDate>2023-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="grantee"><xbrli:measure>lyel:grantee</xbrli:measure></xbrli:unit><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9c884009163249728202a1a7baf43489_1"></div><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">March&#160;31, 2024</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-40502</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">Lyell Immunopharma, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">83-1300510</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:130%">(State or other jurisdiction of</span></div><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:130%">incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">201 Haskins Way</ix:nonNumeric></span></div><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-11">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">94080</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:130%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:130%">(Zip Code)</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">695-0677</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________________</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:37.139%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">LYEL</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"><div style="margin-top:6pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of May&#160;2, 2024, the registrant had <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">254,939,222</ix:nonFraction> shares of common stock, $0.0001 par value per share, outstanding.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i9c884009163249728202a1a7baf43489_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lyell Immunopharma, Inc.</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.355%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_10">Special Note Regarding Forward-Looking Statements</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_10">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_13">PART I&#8212;FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_16">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_19">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_22">Condensed Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:0.72pt;padding-left:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_25">Condensed Consolidated Statements of Stockholders</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_25">&#8217;</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_25"> Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_31">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_31">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_34">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_34">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_94">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_94">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_94">19</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_124">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_124">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_124">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_127">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_127">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_127">28</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_130">PART II&#8212;OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_133">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_133">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_133">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_136">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_136">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_136">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_166">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_166">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_166">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_169">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_169">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_169">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_172">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_172">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_172">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_175">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_175">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_175">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_178">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_178">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_178">69</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_181">Signature</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_181">70</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i</span></div></div></div><div id="i9c884009163249728202a1a7baf43489_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, business strategy, product candidates, planned nonclinical studies and clinical trials, results of nonclinical studies and clinical trials, research and development costs, planned regulatory submissions, regulatory approvals and the timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">the sufficiency of our existing cash to fund our future operating expenses and capital expenditure requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">the accuracy and timing of our estimates regarding expenses, revenue opportunities, capital requirements and needs for additional financing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">the scope, progress, results and costs of developing LYL797, LYL845, LYL119 or any other product candidates we may develop, and conducting nonclinical studies and clinical trials, including for LYL797, LYL845 and LYL119;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">the timing and costs involved in obtaining and maintaining regulatory approvals of LYL797, LYL845, LYL119 or any other product candidates we may develop, and the timing or likelihood of regulatory filings and approvals, including any expectations regarding seeking special designations for our product candidates for various diseases;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">our plans relating to the commercialization of LYL797, LYL845, LYL119 or any other product candidates we may develop, if approved, including the geographic areas of focus and our ability to grow a sales force;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">the size of the market opportunities for LYL797, LYL845, LYL119 or any other product candidates we may develop in each of the diseases we may target;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">our reliance on third parties to conduct research activities for LYL797, LYL845, LYL119 or any other product candidates we may develop;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">the characteristics, safety, efficacy and therapeutic effects of LYL797, LYL845, LYL119 or any other product candidates we may develop;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">our estimates of the number of patients in the United States who suffer from the diseases we target and the number of subjects that may enroll in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">the benefits associated with the U.S. Food and Drug Administration&#8217;s (FDA) Orphan Drug designation (ODD), including potential tax credits for qualified clinical trials, prescription drug user-fee exemptions and potential seven-year marketing exclusivity upon FDA approval and comparable benefits associated with foreign ODDs in other countries, if we receive ODD outside the United States;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">the progress and focus of our current and planned clinical trials of our product candidates, and the reporting of data from those trials, including the timing thereof;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">the ability of our clinical trials to sufficiently demonstrate the safety and efficacy of LYL797, LYL845, LYL119 or any other product candidates we may develop, and other clinical trial results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">the success of competing therapies that are, or may become, available;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">developments relating to our competitors and our industry, including any existing or future competing product candidates or therapies;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">our plans relating to the further development and manufacturing of LYL797, LYL845, LYL119 or any other product candidates we may develop, including additional indications that we may pursue;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">existing regulations and regulatory developments in the United States and other jurisdictions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">our potential and ability to successfully manufacture and supply or our ability to contract with third parties to manufacture and supply LYL797, LYL845, LYL119 or any other product candidates we may develop for clinical trials and for commercial use, if approved;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">the rate and degree of market acceptance, as well as the pricing and reimbursement, of LYL797, LYL845, LYL119 or any other product candidates we may develop, if approved;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">our continued reliance on third parties to assist us in conducting additional clinical trials of LYL797, LYL845, LYL119 or any other product candidates we may develop;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">the scope of protection we are able to establish and maintain for intellectual property rights, including covering our product candidates and technology platforms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">our ability to retain the continued service of our key personnel and to identify, hire and then retain additional qualified personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">our expectations regarding the impact of inflation, macroeconomic conditions and geopolitical conflicts on our business and operations, including on our manufacturing suppliers, collaborators, contract research organizations (CROs) and employees; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">our anticipated use of our existing cash, cash equivalents and marketable securities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described under &#8220;Risk Factors&#8221; in Part&#160;II, Item&#160;1A, and elsewhere in this Quarterly Report on Form 10-Q. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in these forward-looking statements. Except as required by applicable law, we undertake no obligation to update or supplement any forward-looking statements publicly, or to update or supplement the reasons that actual results could differ materially from those projected in these forward-looking statements, even if new information becomes available in the future. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</span></div></div></div><div id="i9c884009163249728202a1a7baf43489_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i9c884009163249728202a1a7baf43489_16"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. Financial Statements.</span></div><div><span><br/></span></div><div id="i9c884009163249728202a1a7baf43489_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lyell Immunopharma, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:130%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-30">125,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">145,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-32">400,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-33">400,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">7,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">8,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">534,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">554,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="f-38">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="f-39">284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="f-40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-41">16,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-42">19,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-43">32,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-44">97,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-45">102,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-46">38,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-47">39,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">4,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">4,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Total assets</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-50">694,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-51">750,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:130%">LIABILITIES AND STOCKHOLDERS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:130%"> EQUITY</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">4,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">4,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Accrued liabilities and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-54">24,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-55">28,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Success payment liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lyel:SuccessPaymentLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">2,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lyel:SuccessPaymentLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">1,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">32,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">34,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">55,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">56,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">3,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">3,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-64">91,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-65">95,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">Commitments and contingencies (Note 11)</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-66"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-67"/></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> equity:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-68"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-69">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-70"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-71">10,000</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31, 2024 and December&#160;31, 2023; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-72"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-73"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-74"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-75">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2024 and December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-78"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-79">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-80"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-81">500,000</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31, 2024 and December&#160;31, 2023; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-82"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-83">254,927</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-84"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-85">253,958</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2024 and December&#160;31, 2023, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-86">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-87">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-88">1,666,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-89">1,657,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-90">404</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-91">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-92">1,062,779</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-93">1,002,112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Total stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> equity</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-94">603,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-95">654,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Total liabilities and stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:130%"> equity</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-96">694,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-97">750,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><div id="i9c884009163249728202a1a7baf43489_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lyell Immunopharma, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.628%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Revenue</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-98">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-99">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-100">43,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-101">44,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-102">13,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-103">19,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Other operating income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-104">1,090</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-105">1,288</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-106">55,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-107">62,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-108">55,575</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-109">62,556</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-110">6,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-111">4,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Other income, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-112">1,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-113">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Impairment of other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="3" id="f-114">13,001</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="3" id="f-115">10,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total other loss, net</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-116">5,092</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-117">4,403</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-118">60,667</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-119">66,959</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Other comprehensive loss:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net unrealized (loss) gain on marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-120">310</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-121">3,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-122">60,977</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-123">63,239</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net loss per common share, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-124"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-125">0.24</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-126"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-127">0.27</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Weighted-average shares used to compute net loss per common share, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-128"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-129">254,252</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-130"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-131">249,591</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><div id="i9c884009163249728202a1a7baf43489_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lyell Immunopharma, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.344%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.238%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Three Months Ended March 31, 2024</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:31pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Paid-in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Loss</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Balance as of December&#160;31, 2023</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-132">253,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-133">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-134">1,657,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-135">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-136">1,002,112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-137">654,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Issuance of common stock upon exercise of stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-138">869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-139">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-140">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Issuance of common stock in connection with restricted stock units, net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-141">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-142">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-143">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Stock-based compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-144">9,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-145">9,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Other comprehensive income</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-146">310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-147">310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-148">60,667</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-149">60,667</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Balance as of March&#160;31, 2024</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-150">254,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-151">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-152">1,666,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-153">404</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-154">1,062,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-155">603,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.666%"><tr><td style="width:1.0%"/><td style="width:40.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Three Months Ended March 31, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:31pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Paid-in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Comprehensive Loss</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Balance as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-156">249,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-157">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-158">1,608,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-159">7,599</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-160">767,480</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-161">833,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Issuance of common stock in connection with restricted stock units, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-162">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-163">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-164">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-165">13,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-166">13,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-167">3,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-168">3,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-169">66,959</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-170">66,959</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Balance as of March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-171">249,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-172">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-173">1,622,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-174">3,879</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-175">834,439</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-176">783,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><div id="i9c884009163249728202a1a7baf43489_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lyell Immunopharma, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">CASH FLOWS FROM OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-177">60,667</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-178">66,959</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Impairment of other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="3" id="f-179">13,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="3" id="f-180">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-181">9,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-182">13,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-183">5,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-184">5,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net amortization and accretion on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-185">4,367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-186">1,850</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Gain on marketable equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" format="ixt:num-dot-decimal" scale="3" id="f-187">1,535</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" format="ixt:fixed-zero" scale="3" id="f-188">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Change in fair value of success payment liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lyel:FairValueAdjustmentOfSuccessPaymentLiabilities" scale="3" id="f-189">968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="lyel:FairValueAdjustmentOfSuccessPaymentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-190">1,708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Non-cash lease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lyel:NonCashLeaseIncomeExpense" scale="3" id="f-191">373</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lyel:NonCashLeaseIncomeExpense" scale="3" id="f-192">293</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Loss on property and equipment disposals, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="f-193">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:fixed-zero" scale="3" id="f-194">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Prepaid expenses, other current assets and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-195">595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-196">408</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-197">113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-198">2,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accrued liabilities and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-199">3,606</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-200">5,860</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="f-201">113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="f-202">112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-203">42,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-204">46,212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">CASH FLOWS FROM INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-205">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-206">1,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-207">108,011</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-208">108,560</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Maturities of marketable securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-209">130,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-210">142,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-211">21,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-212">32,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">CASH FLOWS FROM FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-213">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-214">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-215">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-216">69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-217">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-218">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-219">19,995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-220">14,127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-221">145,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-222">123,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-223">125,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-224">109,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Represented by:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-225">125,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-226">109,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="f-227">286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="f-228">281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-229">125,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-230">109,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">SUPPLEMENTAL CASH FLOW INFORMATION</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lyel:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-231">2,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lyel:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-232">2,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Purchases of property and equipment included in accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-233">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-234">395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><div id="i9c884009163249728202a1a7baf43489_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lyell Immunopharma, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div id="i9c884009163249728202a1a7baf43489_37"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-235" continuedAt="f-235-1" escape="true">Organization</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><ix:continuation id="f-235-1" continuedAt="f-235-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lyell Immunopharma, Inc. (the &#8220;Company&#8221;) was incorporated in Delaware in June 2018. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a clinical-stage cell therapy company advancing a pipeline of product candidates for patients with solid tumors utilizing its proprietary </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ex&#160;vivo</span></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-235-2"> genetic and epigenetic T&#8209;cell reprogramming technologies. The Company&#8217;s primary activities since incorporation have been to develop T&#8209;cell therapies, conduct research and development, acquire technology, enter into strategic collaboration and license arrangements, enable and execute manufacturing activities in support of its product candidate development efforts, organize and staff the Company, conduct business planning, establish its intellectual property portfolio, submit regulatory submissions, execute clinical trials, raise capital and provide general and administrative support for these activities.</ix:continuation> </span></div><div id="i9c884009163249728202a1a7baf43489_40"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="f-236" continuedAt="f-236-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-236-1" continuedAt="f-236-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-237" continuedAt="f-237-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-237-1">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiary.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-238" escape="true">All significant intercompany transactions and balances have been eliminated in consolidation.</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Condensed Consolidated Balance Sheet as of December&#160;31, 2023 included herein was derived from the audited consolidated financial statements as of that date. Certain information and footnote disclosures typically included in the Company&#8217;s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited Condensed Consolidated Financial Statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company&#8217;s financial position, results of operations and cash flows for the periods presented, but are not necessarily indicative of results to be expected for any future annual or interim period. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Company&#8217;s audited financial statements and notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Management&#8217;s Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company discovers and develops product candidates that involve experimental technologies. The product candidates may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources or from the issuance of equity or debt securities. The Company believes that its available cash, cash equivalents and marketable securities as of March&#160;31, 2024 will be adequate to fund its operations at least through the next 12&#160;months from the date these unaudited Condensed Consolidated Financial Statements are issued. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-239" continuedAt="f-239-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-239-1">The preparation of the Company&#8217;s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect reported amounts and related disclosures. Specific accounts that require management estimates include, but are not limited to, stock-based compensation, valuation of success payments, valuation of other investments and accrued expenses. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-240" continuedAt="f-240-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-balance Sheet Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash, cash equivalents and restricted cash with high quality, accredited financial institutions. Restricted cash is cash held in a bank account and is used as collateral associated with the Company&#8217;s corporate credit card program. Cash, cash equivalents and restricted cash amounts, at times, may exceed federally insured limits. The Company also makes short-term investments in money market funds, U.S. Treasury securities, U.S. government agency securities and corporate debt securities, which can be subject to certain credit risk. However, the Company mitigates the risks by investing in high&#8209;grade instruments, limiting exposure to any one issuer or type of investment and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><ix:continuation id="f-236-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-240-1">credit losses in such accounts and does not believe it is exposed to significant risk on these funds.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock" id="f-241" escape="true">The Company has no off&#8209;balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="lyel:SignificantAccountingPoliciesPolicyTextBlock" id="f-242" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the significant accounting policies from the Annual Report on Form 10-K for the year ended December&#160;31, 2023, except as set forth below regarding the Company&#8217;s stock-based compensation policy for performance-based restricted stock units (&#8220;PSUs&#8221;).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-243" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 718, the Company measures and recognizes expense for PSUs that settle in stock. The Company granted PSUs that vest upon the achievement of certain performance conditions to certain key employees. For awards with performance conditions that do not vest unless a performance condition is met, the Company recognizes expense if, and to the extent that, the Company estimates that the achievement of the performance condition is probable. At each reporting date, the Company is required to evaluate whether achievement of a performance condition is probable. Compensation expense is recorded over the appropriate service period based upon the Company&#8217;s assessment of accomplishing each performance condition. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s PSUs that have market-based metrics are estimated using Monte Carlo simulations. The Company applies an accelerated attribution method to recognize stock-based compensation expense over the applicable service period for these awards. The number of shares expected to be earned is considered in the grant date valuation; therefore, the expense is not subsequently adjusted to reflect the actual shares ultimately earned. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of PSUs that do not have market-based metrics are based upon the grant date stock price. Compensation expense is recognized for the number of shares expected to be earned after assessing the probability that a certain performance condition will be met and the targeted payout level associated with the performance condition expected to be achieved. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled. If performance conditions are not met or not expected to be met, any compensation expense previously recognized associated with the awards will be reversed.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-244" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Recently Adopted</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Not Yet Adopted</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which expands required disclosures about a public entity&#8217;s reportable segments and requires more enhanced information about a reportable segment&#8217;s expenses, interim segment profit or loss, and how a public entity&#8217;s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. Entities with a single reportable segment are required to provide all the updated and existing segment disclosures required by Topic 280. The amendments are effective for annual periods beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company is assessing the effect of the new disclosure requirements and does not anticipate the adoption will have a material impact to the Company&#8217;s financial statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for annual periods beginning after December 15, 2024 and may be applied either prospectively or retrospectively. The Company is assessing the effect of the new disclosure requirements and does not anticipate the adoption will have a material impact to the Company&#8217;s financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><div id="i9c884009163249728202a1a7baf43489_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-245" continuedAt="f-245-1" escape="true">License, Collaboration and Success Payment Agreements</ix:nonNumeric></span></div><ix:continuation id="f-245-1" continuedAt="f-245-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fred Hutch</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2018, the Company entered into a license agreement with Fred Hutchinson Cancer Center (&#8220;Fred Hutch&#8221;) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that grants the Company a worldwide, sublicensable license under certain patent rights (exclusive) and certain technology (non-exclusive) to research, develop and commercialize products and processes for all fields of use utilizing chimeric antigen receptors (&#8220;CARs&#8221;) and/or T-cell receptors (&#8220;TCRs&#8221;), subject to certain exceptions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay Fred Hutch annual license maintenance payments of $<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="lyel:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" format="ixt:num-dot-decimal" scale="0" id="f-246">50,000</ix:nonFraction> on the second anniversary of the effective date, and each anniversary of the effective date thereafter until the first commercial sale of a licensed product.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2018, the Company entered into a research and collaboration agreement with Fred Hutch (&#8220;Fred Hutch Collaboration Agreement&#8221;) focused on research and development of cancer immunotherapy products. The Company funded aggregate research performed by Fred Hutch of $<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsResearchPayments" format="ixt:num-dot-decimal" scale="6" id="f-247">12.0</ix:nonFraction>&#160;million under the Fred Hutch Collaboration Agreement, with the research conducted in accordance with a research plan and budget approved by the parties. The Fred Hutch Collaboration Agreement has a <ix:nonNumeric contextRef="c-32" name="lyel:CollaborativeArrangementRightsAndObligationsResearchTerm" format="ixt-sec:durwordsen" id="f-248">six-year</ix:nonNumeric> term. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-249">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-250">0.3</ix:nonFraction>&#160;million in expense in connection with the Fred Hutch Collaboration Agreement for the three months ended March&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Success Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2018, the Company granted Fred Hutch rights to certain success payments, pursuant to the terms of the Fred Hutch Collaboration Agreement. The potential payments for the Fred Hutch success payments are based on multiples of increased value ranging from <ix:nonFraction unitRef="number" contextRef="c-35" decimals="0" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" scale="0" id="f-251">10</ix:nonFraction> times to <ix:nonFraction unitRef="number" contextRef="c-36" decimals="0" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" scale="0" id="f-252">50</ix:nonFraction> times based on a comparison of the per share fair market value of the Company&#8217;s common stock relative to the original $<ix:nonFraction unitRef="usdPerShare" contextRef="c-37" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="f-253">1.83</ix:nonFraction> per share issuance price of the Company&#8217;s Series&#160;A convertible preferred stock, which converted into an equal number of shares of the Company&#8217;s common stock in connection with the closing of the Company&#8217;s initial public offering (&#8220;IPO&#8221;). The aggregate success payments to Fred Hutch are not to exceed $<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" format="ixt:num-dot-decimal" scale="6" id="f-254">200.0</ix:nonFraction>&#160;million, which would only occur upon a <ix:nonFraction unitRef="number" contextRef="c-36" decimals="0" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" scale="0" id="f-255">50</ix:nonFraction> times increase in value. Each threshold is associated with a success payment, ascending from $<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" format="ixt:num-dot-decimal" scale="6" id="f-256">10.0</ix:nonFraction>&#160;million at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-35" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-257">18.29</ix:nonFraction> per share to $<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" format="ixt:num-dot-decimal" scale="6" id="f-258">200.0</ix:nonFraction>&#160;million at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-36" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-259">91.44</ix:nonFraction> per share, payable if such threshold is reached during the measurement period. Any previous success payments made are credited against the success payment owed as of any valuation date, such that Fred Hutch does not receive multiple success payments in connection with the same threshold. The term of the success payment agreement ends on the earlier to occur of (i)&#160;the <ix:nonNumeric contextRef="c-32" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" format="ixt-sec:durwordsen" id="f-260">nine-year</ix:nonNumeric> anniversary of the date of the agreement and (ii)&#160;a change in control transaction.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="f-261" continuedAt="f-261-1" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate potential success payments, which are payable to Fred Hutch in cash or cash equivalents, or at the Company&#8217;s discretion, publicly-tradeable shares of the Company&#8217;s common stock:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.995%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Multiple of initial equity value at issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-38" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" scale="0" id="f-262">10</ix:nonFraction>x</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-39" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" scale="0" id="f-263">20</ix:nonFraction>x</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-40" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" scale="0" id="f-264">30</ix:nonFraction>x</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-41" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" scale="0" id="f-265">40</ix:nonFraction>x</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-42" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" scale="0" id="f-266">50</ix:nonFraction>x</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Per share common stock price required for payment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-38" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-267">18.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-39" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-268">36.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-40" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-269">54.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-41" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-270">73.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-42" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-271">91.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Aggregate success payment(s) (in millions)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-272">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-273">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-274">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-275">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-276">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success payments will be owed if the per share fair value of the Company&#8217;s common stock on the contractually specified valuation measurement dates during the term of the success payment agreement equals or exceeds the above outlined multiples. The valuation measurement dates are triggered by the following events: the <ix:nonNumeric contextRef="c-32" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" format="ixt-sec:durwordsen" id="f-277">one-year</ix:nonNumeric> anniversary of the Company&#8217;s IPO and each <ix:nonNumeric contextRef="c-32" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" format="ixt-sec:durwordsen" id="f-278">two-year</ix:nonNumeric> anniversary of the Company&#8217;s IPO thereafter, the closing of a change in control transaction and the last day of the term of the success payment agreement, unless the term has ended due to the closing of a change of control transaction. As of March&#160;31, 2024, <ix:nonFraction unitRef="usd" contextRef="c-43" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" format="ixt:fixed-zero" scale="0" id="f-279">no</ix:nonFraction> success payments have been incurred as the per share fair value of the Company&#8217;s common stock was below the price required for payment. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success payment liability was $<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" format="ixt:num-dot-decimal" scale="6" id="f-280">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" format="ixt:num-dot-decimal" scale="6" id="f-281">0.7</ix:nonFraction>&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively. With respect to the Fred Hutch Collaboration Agreement success payment obligations, the Company recognized success payment expense of $<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" format="ixt:num-dot-decimal" scale="6" id="f-282">0.4</ix:nonFraction>&#160;million and expense reversal of $<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" sign="-" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" format="ixt:num-dot-decimal" scale="6" id="f-283">1.1</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2024 and 2023, respectively, which are recognized in other income, net.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stanford</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In 2019, the Company entered into a license agreement with The Board of Trustees of the Leland Stanford Junior University (&#8220;Stanford&#8221;) to license specified patent rights. The Company is required to pay Stanford annual license maintenance payments of $<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="lyel:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" format="ixt:num-dot-decimal" scale="0" id="f-284">50,000</ix:nonFraction> on the second anniversary of the effective date, and each anniversary of the effective date thereafter until the date of the first commercial sale of a licensed product.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone payments to Stanford of up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-285">3.7</ix:nonFraction>&#160;million per target are payable upon achievement of certain specified clinical and regulatory milestones. The Company is also obligated to pay Stanford $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-286">2.5</ix:nonFraction>&#160;million </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><ix:continuation id="f-245-2" continuedAt="f-245-3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collectively for all licensed products upon the achievement of a certain commercial milestone. Additionally, low single&#8209;digit tiered royalties based on annual net sales of the licensed products are payable to Stanford.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In October 2020, the Company entered into a research and collaboration agreement with Stanford (&#8220;Stanford Collaboration Agreement&#8221;), focused on research and development of cellular immunotherapy products. The Stanford Collaboration Agreement has a <ix:nonNumeric contextRef="c-48" name="lyel:CollaborativeArrangementRightsAndObligationsResearchTerm" format="ixt-sec:durwordsen" id="f-287">four-year</ix:nonNumeric> term. The Company is committed to fund aggregate research performed by Stanford of $<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsResearchPayments" format="ixt:num-dot-decimal" scale="6" id="f-288">12.0</ix:nonFraction>&#160;million under the Stanford Collaboration Agreement, and the research will be conducted in accordance with a research plan and budget approved by the parties. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-289"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-290">0.8</ix:nonFraction></ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in expense in connection with the Stanford Collaboration Agreement for both of the three months ended March&#160;31, 2024 and 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Success Payments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In October 2020, the Company granted Stanford rights to certain success payments, pursuant to the terms of the Stanford Collaboration Agreement. The potential payments for the Stanford Collaboration Agreement success payments are based on multiples of increased value ranging from <ix:nonFraction unitRef="number" contextRef="c-51" decimals="0" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" scale="0" id="f-291">10</ix:nonFraction> times to <ix:nonFraction unitRef="number" contextRef="c-52" decimals="0" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" scale="0" id="f-292">50</ix:nonFraction> times based on a comparison of the per share fair market value of the Company&#8217;s common stock relative to the original $<ix:nonFraction unitRef="usdPerShare" contextRef="c-53" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="f-293">1.83</ix:nonFraction> per share issuance price of the Company&#8217;s Series&#160;A convertible preferred stock, which converted into an equal number of shares of the Company&#8217;s common stock in connection with the closing of the Company&#8217;s IPO. The aggregate success payments to Stanford are not to exceed $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" format="ixt:num-dot-decimal" scale="6" id="f-294">200.0</ix:nonFraction>&#160;million, which would only occur upon a <ix:nonFraction unitRef="number" contextRef="c-52" decimals="0" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" scale="0" id="f-295">50</ix:nonFraction> times increase in value. Each threshold is associated with a success payment, ascending from $<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" format="ixt:num-dot-decimal" scale="6" id="f-296">10.0</ix:nonFraction>&#160;million at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-51" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-297">18.29</ix:nonFraction> per share to $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" format="ixt:num-dot-decimal" scale="6" id="f-298">200.0</ix:nonFraction>&#160;million at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-52" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-299">91.44</ix:nonFraction> per share, payable if such threshold is reached during the measurement period. Any previous success payments made are credited against the success payment owed as of any valuation date, so that Stanford does not receive multiple success payments in connection with the same threshold. The term of each success payment agreement ends on the earlier to occur of (i)&#160;the <ix:nonNumeric contextRef="c-48" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" format="ixt-sec:durwordsen" id="f-300">nine-year</ix:nonNumeric> anniversary of the date of the agreement and (ii)&#160;a change in control transaction.</span></div><ix:continuation id="f-261-1"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate potential success payments, which are payable to Stanford in cash or cash equivalents, or at the Company&#8217;s discretion, publicly-tradeable shares of the Company&#8217;s common stock:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.995%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Multiple of initial equity value at issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-54" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" id="f-301">10</ix:nonFraction>x</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-55" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" id="f-302">20</ix:nonFraction>x</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-56" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" id="f-303">30</ix:nonFraction>x</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-57" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" id="f-304">40</ix:nonFraction>x</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-58" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" id="f-305">50</ix:nonFraction>x</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Per share common stock price required for payment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-54" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-306">18.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-55" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-307">36.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-56" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-308">54.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-57" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-309">73.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-58" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-310">91.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Aggregate success payment(s) (in millions)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-311">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-312">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-313">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-314">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-315">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success payments will be owed if the per share fair value of the Company&#8217;s common stock on the contractually specified valuation measurement dates during the term of the success payment agreement equals or exceeds the above outlined multiples. The valuation measurement dates are triggered by the following events: the <ix:nonNumeric contextRef="c-48" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" format="ixt-sec:durwordsen" id="f-316">one-year</ix:nonNumeric> anniversary of the Company&#8217;s IPO and each <ix:nonNumeric contextRef="c-48" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" format="ixt-sec:durwordsen" id="f-317">two-year</ix:nonNumeric> anniversary of the Company&#8217;s IPO thereafter, the closing of a change in control transaction and the last day of the term of the success payment agreement, unless the term has ended due to the closing of a change of control transaction. As of March&#160;31, 2024, <ix:nonFraction unitRef="usd" contextRef="c-59" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" format="ixt:fixed-zero" scale="0" id="f-318">no</ix:nonFraction> success payments have been incurred as the per share fair value of the Company&#8217;s common stock was below the price required for payment. </span></div></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-245-3">The estimated fair values of the success payments to Stanford as of March&#160;31, 2024 and December&#160;31, 2023 were $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" format="ixt:num-dot-decimal" scale="6" id="f-319">1.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" format="ixt:num-dot-decimal" scale="6" id="f-320">1.1</ix:nonFraction>&#160;million, respectively. The success payment liability is estimated at the fair value at inception and at each subsequent reporting period and the expense is accreted over the service period of the Stanford Collaboration Agreement as research and development expense. The success payment liability was $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" format="ixt:num-dot-decimal" scale="6" id="f-321">1.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" format="ixt:num-dot-decimal" scale="6" id="f-322">0.9</ix:nonFraction>&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively. With respect to the Stanford Collaboration Agreement success payment obligations, the Company recognized success payment expense of $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" format="ixt:num-dot-decimal" scale="6" id="f-323">0.5</ix:nonFraction>&#160;million and expense reversal of $<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-5" sign="-" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" format="ixt:num-dot-decimal" scale="6" id="f-324">0.6</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2024 and 2023, respectively</ix:continuation>.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><div id="i9c884009163249728202a1a7baf43489_52"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="f-325" continuedAt="f-325-1" escape="true">Cash Equivalents and Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="f-325-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="f-327" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-326" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of cash equivalents and fixed income marketable securities by major security type are as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-328">50,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-329">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-330">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-331">50,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-332">343,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-333">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-334">197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-335">343,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-336">38,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-338">139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-339">38,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-340">68,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-341">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-342">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-343">68,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and fixed income marketable securities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-344">501,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-345">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-346">406</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-347">501,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Classified as:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-348">101,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-349">399,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-350">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and fixed income marketable securities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-351">501,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-352">62,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-353">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-354">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-355">62,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-356">374,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-357">237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-358">95</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-359">374,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-360">48,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-361">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-362">177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-363">48,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-364">59,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-365">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-366">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-367">59,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and fixed income marketable securities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-368">544,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-369">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-370">334</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-371">544,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Classified as:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-372">127,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-373">400,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-374">16,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and fixed income marketable securities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-375">544,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of money market and fixed income marketable securities held by the Company in an unrealized loss position for less than 12&#160;months were $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="f-376">358.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="f-377">117.8</ix:nonFraction>&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively. The fair values of money market and fixed income marketable securities held by the Company in an unrealized loss position for greater than 12&#160;months were $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-378">11.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-379">43.6</ix:nonFraction>&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively. As of March&#160;31, 2024 and December&#160;31, 2023, all of the Company&#8217;s money market and fixed income marketable securities had a maturity date of <ix:nonNumeric contextRef="c-75" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="f-380"><ix:nonNumeric contextRef="c-76" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="f-381">two years</ix:nonNumeric></ix:nonNumeric> or less, were available for use and were classified as available&#8209;for&#8209;sale. The Company does not intend to sell these securities nor does the Company believe that it will be required to sell these securities before recovery of their amortized cost basis. The Company determined that there was no material change in the credit risk of the above investments as of both March&#160;31, 2024 and December&#160;31, 2023. As such, an allowance for credit losses has not been recognized. Gross realized gains and losses were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three months ended March&#160;31, 2024 and 2023 and as a result, amounts reclassified out of accumulated other comprehensive loss for the three months ended March&#160;31, 2024 and 2023 were also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de&#160;minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See Note&#160;6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information regarding cash equivalents and fixed income marketable securities.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><div id="i9c884009163249728202a1a7baf43489_55"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="lyel:OtherInvestmentsTextBlock" id="f-382" continuedAt="f-382-1" escape="true">Other Investments</ix:nonNumeric></span></div><ix:continuation id="f-382-1" continuedAt="f-382-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In prior years the Company made minority ownership strategic investments. As of March&#160;31, 2024 and December&#160;31, 2023, the aggregate carrying amount of the Company&#8217;s strategic investments in non-publicly traded companies was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="6" id="f-383">19.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="6" id="f-384">32.0</ix:nonFraction> million, respectively. These investments are measured at initial cost, minus impairment, if any, and plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Cumulative impairments of strategic investments in equity investments without readily determinable fair values still held as of March&#160;31, 2024 and December&#160;31, 2023 were $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" format="ixt:num-dot-decimal" scale="6" id="f-385">23.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" format="ixt:num-dot-decimal" scale="6" id="f-386">15.0</ix:nonFraction>&#160;million, respectively. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a part of the acquisition of each of the Company&#8217;s other investments, the Company determines whether an investment or other interest is considered a variable interest. As of both March&#160;31, 2024 and December&#160;31, 2023, the Company held an interest in <ix:nonFraction unitRef="entity" contextRef="c-3" decimals="INF" name="lyel:VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary" format="ixt-sec:numwordsen" scale="0" id="f-387"><ix:nonFraction unitRef="entity" contextRef="c-4" decimals="INF" name="lyel:VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary" format="ixt-sec:numwordsen" scale="0" id="f-388">one</ix:nonFraction></ix:nonFraction> entity that was concluded to be a variable interest for which the Company was not the primary beneficiary as the Company did not have the power to direct the activities that most significantly impact the economic performance of the variable interest entity. As of March&#160;31, 2024 and December&#160;31, 2023, the carrying value and maximum exposure to loss of the Company&#8217;s variable interests were <ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount" format="ixt:fixed-zero" scale="6" id="f-389"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="us-gaap:OtherInvestments" format="ixt:fixed-zero" scale="6" id="f-390">zero</ix:nonFraction></ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount" format="ixt:num-dot-decimal" scale="6" id="f-391"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="6" id="f-392">13.0</ix:nonFraction></ix:nonFraction>&#160;million, respectively, which are recorded in other investments in the Company&#8217;s Condensed Consolidated Balance Sheets.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-382-2">In connection with the preparation of the financial statements for the three months ended March&#160;31, 2024 and 2023, the Company performed a qualitative assessment of potential indicators of impairment and determined that indicators existed for certain of its other investments with carrying amounts of $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="6" id="f-393">13.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="6" id="f-394">10.0</ix:nonFraction>&#160;million, respectively. During the three months ended March&#160;31, 2024, the anticipated funding for one of its other investments was not secured within the expected timeframe. The Company considered both of the underlying companies&#8217; operating cash flow requirements over the next year, liquid asset balances to fund those requirements and the underlying companies&#8217; inability to raise funds as indicators of impairment. Due to these indicators, the Company assessed the valuation of these investments and determined the fair values to be negligible and the impairments to be other-than-temporary in nature. As a result, the Company recorded an impairment expense of $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="f-395">13.0</ix:nonFraction> million for the three months ended March&#160;31, 2024 and $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="f-396">10.0</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2023, which consisted of the full impairment of one of our other investments in each period. The impairment expenses were recorded within impairment of other investments on the Condensed Consolidated Statements of Operations and Comprehensive Loss and as a reduction to the investment balances within other investments on the Condensed Consolidated Balance Sheets.</ix:continuation> </span></div><div id="i9c884009163249728202a1a7baf43489_58"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-397" continuedAt="f-397-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-398" continuedAt="f-398-1" escape="true"><ix:continuation id="f-397-1" continuedAt="f-397-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-399">50,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-400">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-401">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-402">50,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-403">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-404">343,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-405">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-406">343,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-407">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-408">38,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-409">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-410">38,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-411">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-412">68,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-413">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-414">68,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-415">1,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="f-416">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="f-417">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-418">1,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-419">52,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-420">450,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-421">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-422">502,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Success payment liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="lyel:SuccessPaymentLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-423">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="lyel:SuccessPaymentLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-424">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="lyel:SuccessPaymentLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-425">2,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lyel:SuccessPaymentLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-426">2,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-427">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-428">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-429">2,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-430">2,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><ix:continuation id="f-397-2" continuedAt="f-397-3"><ix:continuation id="f-398-1"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-431">62,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-432">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-433">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-434">62,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-435">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-436">374,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-438">374,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-439">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-440">48,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-441">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-442">48,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-444">59,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-446">59,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-447">62,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-448">482,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-449">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-450">544,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Success payment liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="lyel:SuccessPaymentLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="lyel:SuccessPaymentLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-452">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="lyel:SuccessPaymentLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-453">1,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lyel:SuccessPaymentLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-454">1,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-455">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-456">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-457">1,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-458">1,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of money market funds based on quoted prices in active markets for identical assets or liabilities. The Company measures the fair value of marketable equity securities traded in active markets based on quoted prices of identical assets. The Level&#160;2 marketable securities include U.S. Treasury securities, U.S. government agency securities and corporate debt securities, which are valued using third-party pricing sources. The pricing services applied industry standard valuation models. Inputs utilized include market pricing based on real-time trade data for the same or similar securities and other significant inputs derived from or corroborated by observable market data.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketable equity securities were comprised of a company that began being publicly traded on the Nasdaq Global Market in February 2024 and had a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-459">1.5</ix:nonFraction> million as of March&#160;31, 2024. The Company recorded unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" format="ixt:num-dot-decimal" scale="6" id="f-460">1.5</ix:nonFraction> million and <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" format="ixt:fixed-zero" scale="6" id="f-461">zero</ix:nonFraction> for the three months ended March&#160;31, 2024 and 2023, respectively, within other income, net in the Company&#8217;s Condensed Consolidated Statement of Operations and Comprehensive Loss. As of December&#160;31, 2023, the investment was fully impaired and classified in the Company&#8217;s Condensed Consolidated Balance Sheet as other investments</span><span style="background-color:#f8f8f8;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s success payment liabilities are Level&#160;3 financial instruments, which were estimated using Monte&#160;Carlo simulations through December 31, 2023. Monte Carlo simulations model the future movement of stock prices based on several key variables combined with empirical knowledge of the process governing the behavior of the stock price. The following variables were incorporated in the Monte Carlo simulation to determine the estimated fair value of the success payment liabilities: fair value of the Company&#8217;s common stock, expected volatility, the risk-free interest rate and the estimated number and timing of valuation measurement dates on the basis of which payments may be triggered. The computation of expected volatility was estimated based on available information about the historical volatility of stocks of similar publicly traded companies for a period matching the expected term assumption. As of March 31, 2024, success payment liabilities were estimated by management using its historical experience of the correlation of success payment fair values relative to the Company&#8217;s stock price.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-462" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were incorporated into the calculation of the estimated fair value of the Fred Hutch success payment liability as of December&#160;31, 2023:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Fair value of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-117" decimals="2" name="lyel:SuccessPaymentLiabilityFairValueOfCommonStock" scale="0" id="f-463">1.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-118" decimals="4" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-464">3.51</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-119" decimals="4" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-465">5.19</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-120" decimals="3" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="-2" id="f-466">80.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="y" contextRef="c-121" decimals="2" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-467">0.46</ix:nonFraction> - <ix:nonFraction unitRef="y" contextRef="c-122" decimals="2" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-468">3.97</ix:nonFraction></span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were incorporated into the calculation of the estimated fair value of the Stanford success payment liability as of December&#160;31, 2023:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Fair value of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-123" decimals="2" name="lyel:SuccessPaymentLiabilityFairValueOfCommonStock" scale="0" id="f-469">1.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-124" decimals="4" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-470">3.51</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-125" decimals="4" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-471">5.19</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-126" decimals="3" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="-2" id="f-472">80.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="y" contextRef="c-127" decimals="2" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-473">0.46</ix:nonFraction> - <ix:nonFraction unitRef="y" contextRef="c-128" decimals="2" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-474">5.75</ix:nonFraction></span></div></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><ix:continuation id="f-397-3"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes estimates and assumptions in determining the estimated success payment liabilities and associated changes in fair value. A small change in the valuation of the Company&#8217;s common stock may have a relatively large change in the estimated fair value of the success payment liability and associated changes in fair value.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-475" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in the fair value of the Company&#8217;s Level 3&#160;financial liabilities (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Success Payment<br/>Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Balance at December&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-476">1,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Change in fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-477">968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Balance at March&#160;31, 2024</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-478">2,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The change in the fair value associated with the Fred Hutch success payment liabilities is recorded in <span style="-sec-ix-hidden:f-479">other income, net</span>. The change in the fair value associated with the Stanford success payment liabilities is recorded as research and development expenses. (See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements).</span></div></ix:nonNumeric></ix:continuation><div id="i9c884009163249728202a1a7baf43489_61"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-481" continuedAt="f-481-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:OperatingLeasesOfLessorDisclosureTextBlock" id="f-480" continuedAt="f-480-1" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-481-1" continuedAt="f-481-2"><ix:continuation id="f-480-1" continuedAt="f-480-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease portfolio is comprised of operating leases for laboratory, office and manufacturing facilities located in South San Francisco, California, and Seattle and Bothell, Washington with contractual periods expiring between December 2028 and March 2031. In addition to minimum rent, the leases require payment of real estate taxes, insurance, common area maintenance charges and other executory costs. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-483" escape="true"><ix:nonNumeric contextRef="c-1" name="lyel:LesseeCurrentAndNonCurrentLiabilitiesTableTextBlock" id="f-482" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s future minimum operating lease commitments, including expected lease incentives to be received, as of March&#160;31, 2024 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Year Ending December&#160;31:</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2024 (remaining nine months)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-484">8,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-485">11,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-486">12,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-487">12,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-488">12,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lyel:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="f-489">22,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-490">80,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-491">19,024</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-492">61,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Reported as of March&#160;31, 2024:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-493">6,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-494">55,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-495">61,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease costs for all operating leases were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-496">2.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-497">2.1</ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three months ended March&#160;31, 2024 and 2023, respectively. The operating lease costs and total commitments for short-term leases were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de&#160;minimis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three months ended March&#160;31, 2024 and 2023. Variable lease costs for operating leases were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-498">2.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-499">1.4</ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three months ended March&#160;31, 2024 and 2023, respectively. The weighted-average remaining lease terms for operating leases were <ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-500">6.6</ix:nonNumeric>&#160;and <ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-501">6.8</ix:nonNumeric> years as of March&#160;31, 2024 and December&#160;31, 2023, respectively. The weighted&#8209;average discount rate for operating leases was <ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-502"><ix:nonFraction unitRef="number" contextRef="c-3" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-503">8.5</ix:nonFraction></ix:nonFraction>% as of both March&#160;31, 2024 and December&#160;31, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a sublease, whereby the Company agreed to sublease approximately <ix:nonFraction unitRef="sqft" contextRef="c-132" decimals="-3" name="us-gaap:NetRentableArea" format="ixt:num-dot-decimal" scale="0" id="f-504">11,000</ix:nonFraction> square feet of its space in South San Francisco, California currently leased by the Company. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized sublease income for this sublease of $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-505"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-506">0.2</ix:nonFraction></ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for both the three months ended March&#160;31, 2024 and 2023.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><ix:continuation id="f-481-2"><ix:continuation id="f-480-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into a sublease with Sonoma Biotherapeutics, Inc. (&#8220;Sonoma&#8221;), a related party, whereby the Company agreed to sublease approximately <ix:nonFraction unitRef="sqft" contextRef="c-135" decimals="-3" name="us-gaap:NetRentableArea" format="ixt:num-dot-decimal" scale="0" id="f-507">18,000</ix:nonFraction> square feet of space in South San Francisco, California currently leased by the Company. See Note&#160;12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Transactions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As a part of the sublease, in September 2021, the Company received a $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="us-gaap:TenantImprovements" format="ixt:num-dot-decimal" scale="6" id="f-508">4.6</ix:nonFraction>&#160;million tenant improvement contribution payment, which is recognized over the term of the sublease. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized Sonoma sublease income of $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-509"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-510">0.5</ix:nonFraction></ix:nonFraction>&#160;million for both the three months ended March&#160;31, 2024 and 2023. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's sublease income is recognized within other operating income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss.</span></div></ix:continuation></ix:continuation><div id="i9c884009163249728202a1a7baf43489_67"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-511" continuedAt="f-511-1" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="f-511-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-512">10.0</ix:nonFraction>&#160;million shares of preferred stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-513">0.0001</ix:nonFraction> per share. As of March&#160;31, 2024 and December&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-514"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-515">no</ix:nonFraction></ix:nonFraction> shares of preferred stock were outstanding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-516">500.0</ix:nonFraction>&#160;million shares of common stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-517">0.0001</ix:nonFraction> per share. As of March&#160;31, 2024 and December&#160;31, 2023, there were <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-518">254,926,880</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-519">253,957,709</ix:nonFraction> shares of the Company&#8217;s common stock outstanding, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2024, the Company entered into a sales agreement with Cowen and Company, LLC (&#8220;Cowen&#8221;) acting as the Company&#8217;s sales agent (the &#8220;Sales Agreement&#8221;), pursuant to which the Company may offer and sell shares of common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="lyel:SaleOfStockMaximumConsiderationReceived" format="ixt:num-dot-decimal" scale="6" id="f-520">150.0</ix:nonFraction>&#160;million from time to time&#160;in a series of one or more at&#8209;the&#8209;market equity offerings. The Company will pay Cowen commissions of up to <ix:nonFraction unitRef="number" contextRef="c-139" decimals="3" name="lyel:SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds" scale="-2" id="f-521">3.0</ix:nonFraction>% of the gross proceeds of the sale, and reimbursement of certain expenses, under this agreement. Neither the Company nor Cowen is obligated to sell any shares and, to date, the Company has not made any sales under the Sales Agreement.</span></div></ix:continuation><div id="i9c884009163249728202a1a7baf43489_70"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-522" continuedAt="f-522-1" escape="true">Stock-based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-522-1" continuedAt="f-522-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company adopted the 2021 Equity Incentive Plan (&#8220;2021 Plan&#8221;), which on the date of the underwriting agreement related to the Company&#8217;s IPO became effective with an initial reserve of <ix:nonFraction unitRef="shares" contextRef="c-140" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-523">26,662,087</ix:nonFraction> shares, plus any shares subject to outstanding awards granted under the 2018 Equity Incentive Plan (&#8220;2018 Plan&#8221;) that, on or after the effectiveness of the 2021 Plan, terminate or expire before exercise or settlement, are not issued because the award is settled in cash, are forfeited because of the failure to vest, or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price. In addition, the number of shares reserved for issuance under the 2021 Plan automatically increases on January&#160;1 of each year for a period of <ix:nonNumeric contextRef="c-141" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-524">ten years</ix:nonNumeric>, beginning on January&#160;1, 2022 and continuing through January&#160;1, 2031, in an amount equal to (1)&#160;<ix:nonFraction unitRef="number" contextRef="c-141" decimals="INF" name="lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" scale="-2" id="f-525">5</ix:nonFraction>% of the total number of shares of the Company&#8217;s common stock outstanding on December&#160;31 of the immediately preceding year, or (2)&#160;a lesser number of shares determined by the Company&#8217;s board of directors no later than December&#160;31 of the immediately preceding year. On January&#160;1, 2024, the Company reserved an additional <ix:nonFraction unitRef="shares" contextRef="c-142" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-526">12,697,885</ix:nonFraction> shares of common stock for issuance under the 2021 Plan representing <ix:nonFraction unitRef="number" contextRef="c-142" decimals="INF" name="lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" scale="-2" id="f-527">5</ix:nonFraction>% of the total common shares outstanding as of December&#160;31, 2023. Under the 2021 Plan, the Company may grant incentive stock options, non-statutory stock options, restricted stock awards (&#8220;RSAs&#8221;), restricted stock units (&#8220;RSUs&#8221;), PSUs, stock appreciation rights, performance awards and other stock-based awards. Terms of stock awards, including vesting requirements, are determined by the Company&#8217;s board of directors or by a committee authorized by the Company&#8217;s board of directors, subject to provisions of the 2021 Plan. The term of any stock option granted under the 2021 Plan cannot exceed <ix:nonNumeric contextRef="c-143" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-528">ten years</ix:nonNumeric>. Generally, option and RSU awards granted by the Company vest over <ix:nonNumeric contextRef="c-144" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-529"><ix:nonNumeric contextRef="c-145" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-530">four years</ix:nonNumeric></ix:nonNumeric> but may be granted with different vesting terms. PSUs generally vest over <ix:nonNumeric contextRef="c-146" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-531">three years</ix:nonNumeric>, subject to the achievement of the associated performance conditions. In conjunction with adopting the 2021 Plan, the Company discontinued the 2018 Plan with respect to new equity awards.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-147" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-532">33,623,495</ix:nonFraction> shares were available for future issuance pursuant to the 2021 Plan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company adopted the 2021 Employee Stock Purchase Plan (&#8220;2021 ESPP&#8221;), which became effective immediately prior to the execution of the underwriting agreement related to the Company&#8217;s IPO with an initial reserve of <ix:nonFraction unitRef="shares" contextRef="c-148" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-533">2,470,000</ix:nonFraction> shares. The 2021 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="c-148" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="f-534">15</ix:nonFraction>% of their earnings, subject to plan limitations. Unless otherwise </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><ix:continuation id="f-522-2" continuedAt="f-522-3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determined by the Company&#8217;s board of directors, employees are able to purchase shares at <ix:nonFraction unitRef="number" contextRef="c-149" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-535">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock on the first date of an offering or on the purchase date. The number of shares of the Company&#8217;s common stock reserved for issuance under the 2021 ESPP automatically increases on January&#160;1 of each year for a period of <ix:nonNumeric contextRef="c-149" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-536">ten years</ix:nonNumeric>, beginning on January&#160;1, 2022 and continuing through January&#160;1, 2031, by the lesser of (1)&#160;<ix:nonFraction unitRef="number" contextRef="c-149" decimals="INF" name="lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" scale="-2" id="f-537">1</ix:nonFraction>% of the total number of shares of the Company&#8217;s common stock outstanding on December&#160;31 of the immediately preceding year, and (2)&#160;<ix:nonFraction unitRef="shares" contextRef="c-149" decimals="INF" name="lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" format="ixt:num-dot-decimal" scale="0" id="f-538">4,940,000</ix:nonFraction> shares; provided, however, that the Company&#8217;s board of directors may act to provide a lesser increase in number of shares. On January&#160;1, 2024, the Company reserved an additional <ix:nonFraction unitRef="shares" contextRef="c-150" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-539">2,539,577</ix:nonFraction> shares of common stock for issuance under the 2021 ESPP representing <ix:nonFraction unitRef="number" contextRef="c-149" decimals="INF" name="lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" scale="-2" id="f-540">1</ix:nonFraction>% of the total common shares outstanding as of December&#160;31, 2023. The Company may specify offerings with durations not more than <span style="-sec-ix-hidden:f-541">27&#160;months</span> and may specify shorter purchase periods within each offering. Under the 2021 ESPP, <ix:nonFraction unitRef="shares" contextRef="c-151" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:fixed-zero" scale="0" id="f-542"><ix:nonFraction unitRef="shares" contextRef="c-152" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:fixed-zero" scale="0" id="f-543">no</ix:nonFraction></ix:nonFraction> shares were issued for both the three months ended March&#160;31, 2024 and 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-153" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-544">6,001,206</ix:nonFraction> shares were available for future issuance pursuant to the 2021 ESPP.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company established the 2018&#160;Plan that provided for the grant of incentive stock options, non&#8209;statutory stock options, RSAs, RSUs, stock appreciation rights and other stock-based awards. Terms of stock awards, including vesting requirements, were determined by the board of directors or by a committee authorized by the Company&#8217;s board of directors, subject to provisions of the 2018&#160;Plan. The term of any stock option granted under the 2018&#160;Plan cannot exceed <ix:nonNumeric contextRef="c-154" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-545">ten years</ix:nonNumeric>. Generally, awards granted by the Company vest over <ix:nonNumeric contextRef="c-154" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-546">four years</ix:nonNumeric>, but could have been granted with different vesting terms. Pursuant to the terms of the 2021&#160;Plan, any shares subject to outstanding options originally granted under the 2018&#160;Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof become available for issuance pursuant to awards granted under the 2021&#160;Plan. While <ix:nonFraction unitRef="shares" contextRef="c-155" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:fixed-zero" scale="0" id="f-547">no</ix:nonFraction> shares are available for future issuance under the 2018&#160;Plan, it continues to govern outstanding equity awards granted thereunder.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-548" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by classification included within the Condensed Consolidated Statements of Operations and Comprehensive Loss was as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-549">3,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-550">4,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-551">5,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-552">9,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-553">9,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-554">13,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2024, total stock-based compensation cost related to unvested awards not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-555">66.0</ix:nonFraction>&#160;million, which is expected to be recognized over a remaining weighted-average period of <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-556">2.7</ix:nonNumeric> years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options Repricing</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Board of Directors of the Company approved, effective November 16, 2023, a one-time repricing of certain stock option awards that had been granted to date under the 2021 Plan and 2018 Plan. The repricing impacted stock options with exercise prices greater than $<ix:nonFraction unitRef="usdPerShare" contextRef="c-160" decimals="2" name="lyel:ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum" scale="0" id="f-557">2.37</ix:nonFraction> held by employees who remained employed as of November&#160;16, 2023 and were not impacted by the Company&#8217;s November 2023 reduction in workforce. The original exercise prices of the repriced stock options ranged from $<ix:nonFraction unitRef="usdPerShare" contextRef="c-160" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-558">2.61</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-160" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-559">17.95</ix:nonFraction> per share for <ix:nonFraction unitRef="grantee" contextRef="c-160" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" scale="0" id="f-560">200</ix:nonFraction> total grantees with <ix:nonFraction unitRef="shares" contextRef="c-160" decimals="INF" name="lyel:ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced" format="ixt:num-dot-decimal" scale="0" id="f-561">23,416,860</ix:nonFraction> shares repriced. Each stock option was repriced to have a per share exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-160" decimals="2" name="lyel:ShareBasedPaymentArrangementPlanModificationExercisePrice" scale="0" id="f-562">1.87</ix:nonFraction>, which was the closing price of the Company&#8217;s common stock on November 16, 2023. To receive the new exercise price, option holders must remain employed with the Company through November 15, 2024. Additionally, the vesting schedule for the unvested shares underlying repriced stock options held by executives at the level of senior vice president and above was extended for an additional year. There were no changes to the vesting schedules for employees below the level of senior vice president. No changes were made to the expiration dates of, or the number of shares underlying, the repriced stock options. Incremental stock-based compensation expense resulting from the repricing was $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:num-dot-decimal" scale="6" id="f-563">8.9</ix:nonFraction> million in the aggregate. Expense for vested awards will be recognized through November 15, 2024 and expense for unvested awards will be recognized over the remaining service life of the option.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based Restricted Stock Units</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024, the Company granted PSU awards to certain key employees. PSUs awarded to employees have a <ix:nonNumeric contextRef="c-161" name="lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" format="ixt-sec:durwordsen" id="f-564">three-year</ix:nonNumeric> performance period and vest based upon the Company&#8217;s performance against a <span style="-sec-ix-hidden:f-565">two</span> and <ix:nonNumeric contextRef="c-163" name="lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn" format="ixt-sec:durwordsen" id="f-566">three-year</ix:nonNumeric> relative total shareholder return (&#8220;rTSR&#8221;) metric, as well as upon the achievement of certain </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><ix:continuation id="f-522-3" continuedAt="f-522-4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical development milestones. For the portion of PSUs subject to certain clinical development milestones (other than the bonus clinical development milestone), <ix:nonFraction unitRef="number" contextRef="c-164" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-567">50</ix:nonFraction>% vest upon the achievement of the applicable milestone, and the remaining <ix:nonFraction unitRef="number" contextRef="c-165" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-568">50</ix:nonFraction>% vest upon the earlier of (a) <ix:nonNumeric contextRef="c-161" name="lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate" format="ixt-sec:durwordsen" id="f-569">one year</ix:nonNumeric> of service from the date of such achievement and (b) the end of the <ix:nonNumeric contextRef="c-161" name="lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" format="ixt-sec:durwordsen" id="f-570">three-year</ix:nonNumeric> performance period. The vesting of all PSU awards granted is also subject to the respective employee&#8217;s continued employment. The Company valued the portion of PSUs subject to the rTSR metric using a Monte Carlo simulation. The number of PSUs granted subject to the rTSR metrics represents the target number of units that are eligible to be earned based on the achievement of the metrics established at the beginning of the performance period, which ends on December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the <ix:nonNumeric contextRef="c-161" name="lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" format="ixt-sec:durwordsen" id="f-571">three year</ix:nonNumeric> performance period. For the portion of PSUs subject to the rTSR metrics, employees may ultimately earn between <ix:nonFraction unitRef="number" contextRef="c-162" decimals="INF" name="lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget" format="ixt:fixed-zero" scale="-2" id="f-572">zero</ix:nonFraction> and <ix:nonFraction unitRef="number" contextRef="c-163" decimals="INF" name="lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget" scale="-2" id="f-573">200</ix:nonFraction>% of the target number of PSUs granted based on the degree of achievement of the applicable rTSR metric. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" id="f-574" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s PSU activity was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Performance-Based Restricted Stock Units Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Value at Grant<br/>Date Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unvested PSUs as of December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-166" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="f-575">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-166" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-576">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">PSUs granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-161" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-577">2,703,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-161" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-578">1.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">PSUs vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-161" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="0" id="f-579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-161" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-580">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">PSUs forfeited or canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-161" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="f-581">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-161" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-582">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unvested PSUs as of March&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-167" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-583">2,703,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-167" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-584">1.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;PSU grants reflect the target number of shares eligible to be earned at the time of grant.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" id="f-585" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s RSU activity was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Value at Grant<br/>Date Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unvested RSUs as of December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-168" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-586">2,072,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-168" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-587">2.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-169" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-588">3,477,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-169" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-589">1.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="shares" contextRef="c-169" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-590">142,430</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-169" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-591">3.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs forfeited or canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="shares" contextRef="c-169" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-592">73,298</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-169" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-593">2.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unvested RSUs as of March&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-170" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-594">5,334,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-170" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-595">2.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-596" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Stock Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options outstanding as of December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-597">55,596,831</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-598">4.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-171" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-599">6.89</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-600">7,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-601">2,495,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-602">1.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-603">868,826</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-604">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-605">3,096,127</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-606">5.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options outstanding as of March&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-607">54,127,378</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-608">4.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-609">7.20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-610">8,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options exercisable as of March&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-611">31,963,665</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-612">5.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-613">6.19</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-614">6,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-615" escape="true"><ix:continuation id="f-522-4" continuedAt="f-522-5"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to employees and directors was estimated on the date of grant using the Black-Scholes option pricing model using the following weighted-average assumptions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-616">4.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-617">4.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-618">75.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-619">91.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-620">6.04</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-621">6.02</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-622">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-623">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-522-5">The weighted-average grant date fair value of options granted for the three months ended March&#160;31, 2024 and 2023 were $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-624">1.26</ix:nonFraction> per share and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-625">1.66</ix:nonFraction> per share, respectively.</ix:continuation> </span></div><div id="i9c884009163249728202a1a7baf43489_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-626" continuedAt="f-626-1" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-626-1">Basic and diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. The Company&#8217;s potentially dilutive shares, which include unvested RSUs, unvested PSUs and options to purchase common stock, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Shares subject to options to purchase common stock, unvested RSUs and unvested PSUs were all excluded from consideration in the calculation of diluted net loss per share in all periods presented due to their anti-dilutive effects.</ix:continuation> </span></div><div id="i9c884009163249728202a1a7baf43489_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-627" continuedAt="f-627-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-627-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into certain license and collaboration agreements, including those identified in Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">above, with third parties that include the funding of certain development, manufacturing and commercialization efforts with the potential for future milestone and royalty payments upon the achievement of pre-established developmental, regulatory and/or commercial milestones. The Company&#8217;s obligation to fund these efforts is contingent upon continued involvement in the programs and/or the lack of any adverse events that could cause the discontinuance of the programs, including termination of such agreements. Due to the nature of these agreements, the future potential payments are inherently uncertain, and accordingly no amounts had been recorded for the potential future achievement of these targets as of both March&#160;31, 2024 and December&#160;31, 2023.</span></div></ix:continuation><div id="i9c884009163249728202a1a7baf43489_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-628" continuedAt="f-628-1" escape="true">Related-party Transactions</ix:nonNumeric></span></div><ix:continuation id="f-628-1"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into a sublease with Sonoma (&#8220;Sonoma Sublease&#8221;), with whom the Company has common stockholders with board seats, whereby the Company agreed to sublease approximately <ix:nonFraction unitRef="sqft" contextRef="c-136" decimals="-3" name="us-gaap:NetRentableArea" format="ixt:num-dot-decimal" scale="0" id="f-629">18,000</ix:nonFraction> square feet of space in South San Francisco, California currently leased by the Company. Dr.&#160;Klausner, the Chair of the Company&#8217;s board of directors, also serves as Board Chair of the board of directors of Sonoma. As a part of the Sonoma Sublease, a $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="us-gaap:TenantImprovements" format="ixt:num-dot-decimal" scale="6" id="f-630">4.6</ix:nonFraction>&#160;million tenant improvement contribution payment was made by Sonoma, which is recognized over the term of the Sonoma Sublease. As of both March&#160;31, 2024 and December&#160;31, 2023, there were accrued liabilities and other current liabilities of $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-631"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-632">0.5</ix:nonFraction></ix:nonFraction>&#160;million and as of March&#160;31, 2024 and December&#160;31, 2023, other non-current liabilities of $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-633">2.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-634">3.0</ix:nonFraction>&#160;million, respectively, in connection with the Sonoma Sublease. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="f-635" continuedAt="f-635-1" escape="true">Total operating income from Sonoma and income solely attributable to the Sonoma Sublease are shown in the table below (in thousands). Total operating income includes income attributable to the sublease, as well as additional operating fees recognized in &#8220;other operating income, net&#8221; such as common area maintenance charges. See Note&#160;7, </ix:nonNumeric></span><ix:continuation id="f-635-1" continuedAt="f-635-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for more detail on the Sonoma Sublease.</span></ix:continuation></div><ix:continuation id="f-635-2"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Sonoma other operating income, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="f-636">807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="f-637">669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Sonoma sublease income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="f-638">465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="f-639">465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><div id="i9c884009163249728202a1a7baf43489_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited Condensed Consolidated Financial Statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q. This discussion and analysis and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements based upon current beliefs, plans and expectations related to future events and our future financial performance that involve risks, uncertainties and assumptions, such as statements regarding our intentions, plans, objectives and expectations for our business. Our actual results and the timing of selected events could differ materially from those described in or implied by these forward-looking statements as a result of several factors, including those set forth in the section titled &#8220;Risk Factors&#8221; in Part&#160;II, Item&#160;1A of this Quarterly Report on Form 10-Q. See also the section titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span></div><div id="i9c884009163249728202a1a7baf43489_97"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage cell therapy company advancing a pipeline of product candidates for patients with solid tumors utilizing our proprietary ex vivo genetic and epigenetic T&#8209;cell reprogramming technologies. Our investigational therapies use the patient&#8217;s own cells as the starting point to generate highly tumor-reactive, longer-lasting functional T cells with enhanced ability to defeat solid tumors. Our innovative reprogramming technologies address what we believe are the primary barriers that limit consistent and long-lasting responses to T&#8209;cell therapy in solid tumors: T&#8209;cell exhaustion and lack of durable stemness. Our technologies are designed to generate T cells with the ability to persist and self&#8209;renew while driving durable tumor cytotoxicity, even in the setting of an immunosuppressive tumor microenvironment. We apply our technologies with the aim of developing T&#8209;cell therapies with improved and durable antitumor responses for patients with solid tumors. Our technologies can be applied in a target agnostic manner to multiple T&#8209;cell modalities, including chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T&#8209;cell receptor (TCR) therapies. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our growing pipeline of promising cell product candidates targets solid tumor indications with large unmet needs that are collectively responsible for approximately 180,000 deaths in the United States annually. Each of our programs provide opportunities to expand into additional indications beyond the patient populations we are initially targeting. Our lead product candidates are summarized in Table 1 below:</span></div><div style="margin-top:6pt;text-align:center"><img src="lyel-20240331_g1.jpg" alt="Pipeline 2024.jpg" style="height:310px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in June 2018. Our primary activities to date have included clinical development of T-cell therapies, conducting research and development, acquiring technology, entering into strategic collaboration and license agreements, enabling and executing manufacturing activities in support of our product candidate development efforts, organizing and staffing our company, business planning, establishing our intellectual property portfolio, making regulatory submissions, executing clinical trials, raising capital and providing general and administrative support for these activities. We are early in our research and development efforts and are in Phase&#160;1 clinical development of LYL797, our ROR1&#8209;targeted CAR T&#8209;cell product candidate, and LYL845, our TIL product candidate. Two additional product candidates that each include novel genetic and epigenetic reprogramming technologies are in preclinical development: LYL119, a ROR1&#8209;targeted CAR T-cell product candidate and a second generation TIL product candidate. We do not have any products approved for sale. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pipeline Programs and Operational Updates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline Programs</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing four wholly-owned product candidates. Two product candidates, LYL797 and LYL845 are in Phase 1 clinical development. Two additional product candidates, LYL119 and a second-generation TIL product candidate, are in preclinical development. Research stage programs include our proprietary T-cell rejuvenation technology and a tumor-restricted interleukin (IL)-12 technology designed to generate a local proinflammatory immune response in the tumor microenvironment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LYL797 - A ROR1-targeted CAR T-cell product candidate genetically reprogrammed to overexpress c-Jun and epigenetically reprogrammed using Lyell&#8217;s proprietary Epi-R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> manufacturing protocol designed for differentiated potency and durability </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are applying our c-Jun and Epi&#8209;R technologies to our lead CAR T&#8209;cell product candidate, LYL797, which is expected to be an intravenously&#8209;administered CAR T&#8209;cell product targeting the receptor tyrosine kinase-like orphan receptor 1 (ROR1) protein. ROR1 is a fetal protein expressed during embryogenesis and is believed to be important in cell migration, polarity and survival. It is expressed in several cancer types, including triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), ovarian cancer and chronic lymphocytic leukemia, and is generally associated with a poor prognosis. LYL797 contains a CAR with a 4-1BB/CD3&#950; intracellular domain, a transmembrane domain, an optimized spacer domain and a single-chain variable fragment (scFv) derived from an R12 rabbit monoclonal antibody that recognizes and binds with high specificity to human ROR1. LYL797 also incorporates c-Jun and a proprietary optimized truncated version of human EGFR (EGFR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:1.4pt;vertical-align:baseline">opt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) used for tracking the CAR T cells in the peripheral blood post treatment and can also be used as a safety measure with the administration of cetuximab, if needed. LYL797 is manufactured utilizing Epi&#8209;R, our proprietary ex vivo manufacturing protocol that is designed to generate populations of T cells with stem-like qualities, reduced exhaustion and improved proliferation and antitumor activity.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are initially developing LYL797 for the treatment of ROR1-positive TNBC and NSCLC. Significant subsets of patients with common cancers express ROR1, including TNBC and NSCLC, two of the highest ROR1&#8209;expressing solid tumor indications. Results from our own ROR1 screening program are consistent with what is reported in the literature. Using our immunohistochemistry assay in the screening for our Phase 1 trial, as of September 2023, we have found that approximately 50% of patients with TNBC and approximately 33% of patients with NSCLC have tumors that express ROR1. If successful, we may expand into other ROR1-positive cancers, including potentially ovarian and other solid tumors. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Enrollment in the Phase&#160;1 clinical trial of LYL797 is ongoing. The study includes patients with relapsed or refractory TNBC or NSCLC.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Initial data from at least 20 patients from the Phase&#160;1 clinical trial of LYL797 are expected in the first half of 2024.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">The Phase 1 clinical trial is designed as an open label, dose escalation and expansion trial in patients with relapsed/refractory TNBC who have failed at least two lines of therapy and patients with relapsed/refractory NSCLC who have failed at least one line of therapy. All patients enrolled have tumor specimens positive for ROR1 protein expression by immunohistochemistry. The study will enroll at least 15 patients each with relapsed or refractory TNBC or with NSCLC in the expansion phase of the study.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LYL845 - A TIL product candidate epigenetically reprogrammed using Lyell&#8217;s proprietary Epi-R manufacturing protocol, designed for differentiated potency and durability</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are applying our epigenetic reprogramming technology, Epi&#8209;R, to develop LYL845, which is expected to be an intravenously&#8209;administered autologous TIL therapy for multiple solid tumors. Our Epi&#8209;R manufacturing protocol comprises proprietary media, optimized cytokine compositions and well-defined cell activation and expansion protocols used during our manufacturing process.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TIL have previously shown clinical benefit in patients with advanced melanoma and other solid tumors with high mutational burden. Published data from third-party TIL trials show that treating metastatic melanoma patients with TIL can result in complete and durable responses. Response rates to TIL therapy in patients with other advanced solid tumors such as lung, colorectal and breast have been much lower than those observed in advanced melanoma.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Broad TIL efficacy has been limited by poor enrichment of tumor-reactive T cells and the poor quality and limited growth potential of expanded T&#160;cells. Failure to maintain polyclonality of TIL during production may also limit their ability to eradicate cancer cells given the inherent heterogeneous nature of solid tumors. LYL845 incorporates our Epi&#8209;R technology that has shown promising improvements in enhancing T-cell phenotypes reported in the literature to be associated with improved clinical outcomes (Krishna et al., Science, Dec. 2020), antitumor activity and increased polyclonality of TIL with stem-like </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">qualities in nonclinical experiments. We received Orphan Drug Designation for LYL845 as a potential novel treatment for patients with advanced melanoma.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are initially developing LYL845 for advanced melanoma, NSCLC and colorectal cancer (CRC). Based on our success with those indications, we may include patients with other solid tumors, potentially including head and neck, cervical, breast and pancreatic cancer. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enrollment in the Phase&#160;1 clinical trial for LYL845 is ongoing. The study includes patients with relapsed or refractory metastatic or locally advanced melanoma, NSCLC and CRC.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Initial clinical and translational data from the Phase&#160;1 trial of LYL845 are expected in the second half of 2024.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Phase&#160;1 clinical trial is designed as an open label, dose escalation and expansion trial in patients with relapsed or refractory metastatic or locally advanced melanoma, NSCLC and CRC. The study will enroll at least 15 patients each with advanced melanoma, and relapsed or refractory NSCLC or CRC in the expansion phase of the study. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LYL119 - A ROR1-targeted CAR T-cell product candidate incorporating Lyell&#8217;s four stackable and complementary reprogramming technologies designed for enhanced cytotoxicity </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key pillar of our strategy is to continually innovate to develop and advance novel, breakthrough technologies that address key barriers to effective cell therapy for solid tumors. We have advanced a new genetic reprogramming technology, NR4A3 knockout, and a new epigenetic reprogramming technology, Stim&#8209;R, that are being applied in our new CAR T-cell product candidate, LYL119.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These technologies are stackable and complementary to c-Jun and Epi&#8209;R and are designed to further improve the antitumor potency and durability of T cells. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LYL119 is being advanced with the goal of potentially creating even greater benefit for patients with ROR1&#8209;positive solid tumors. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">LYL119 is a ROR1-targeted CAR T-cell product enhanced with Lyell&#8217;s four novel genetic and epigenetic reprogramming technologies: c-Jun overexpression, NR4A3 knockout, Epi-R manufacturing protocol and Stim&#8209;R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> T-cell activation technology.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An investigational new drug (IND) application for LYL119 is expected to be submitted in the first half of 2024.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Presented a poster with new nonclinical data on LYL119 at the American Association for Cancer Research (AACR) Annual Meeting 2024. In this study, LYL119, compared to ROR1 CAR T cells reprogramed with only two or three technologies, demonstrated reduced CAR T&#8209;cell exhaustion, enhanced CAR T&#8209;cell function, enhanced proliferation capacity and sustained antitumor activity in a mouse xenograft tumor model across a 10-fold dose range, including at very low cell doses. In addition, following repeated rounds of tumor cell killing, LYL119, displayed reduced expression of exhaustion-related gene signatures and retained unique cell subsets characterized by upregulation of memory and effector-associated gene signatures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rejuvenation &#8211; Novel partial reprogramming technology designed to maintain T-cell identity while reducing cells&#8217; epigenetic age</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and others have documented the impact of aging on T&#8209;cell function, which begins to decline after puberty, and at an increasingly accelerated rate after age 65. Morbidity and mortality from cancer also increase with age. Thus, we are working to advance another novel reprogramming technology that focuses on rejuvenation of antitumor T cells. We are developing a method designed to maintain T&#8209;cell identity while reducing the epigenetic age of the cells. This technology is currently in the research stage. We have generated data illustrating the ability to &#8220;turn back&#8221; the epigenetic clock in a process called cellular rejuvenation, without changing the T&#8209;cell&#8217;s identity as would occur in the setting of induced pluripotent stem cell-derived T cells.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delivered an oral presentation at AACR </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">highlighting new nonclinical data showing TIL rejuvenated with Lyell&#8217;s technology retain a broad T-cell receptor repertoire and demonstrate sustained proliferation and improved antitumor activities in vivo. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tumor-restricted IL-12 (trIL-12): A novel technology designed to enable potent IL-12 stimulation at the tumor site while avoiding systemic exposure</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IL-12 is an immune-stimulatory cytokine that can induce potent anti-tumor activity. This novel technology is designed to enable T cells to secrete trIL-12 upon encountering a tumor antigen, generating a favorable local proinflammatory immune response in the tumor microenvironment. trIL-12 rapidly auto-inactivates within minutes after secretion, thereby limiting systemic exposure. The technology was designed leveraging Outpace&#8217;s OUTSMART&#8482; technology and is being advanced under a collaboration between Lyell and Outpace.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Presented a poster presentation at AACR highlighting nonclinical data demonstrating the ability of trIL-12 technology to deliver potent IL-12 stimulation at the tumor site while avoiding systemic exposure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Manufacturing Capabilities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe it is critically important to control and continuously monitor all aspects of the cell therapy manufacturing process to mitigate risks, including challenges in managing production, supply chain, patient specimen chain of custody and quality control. As we developed our technologies, we made a strategic decision to invest in building our own manufacturing facility to control our supply chain, maximize efficiencies in cell product production time, optimize cost and quality, protect proprietary aspects of our reprogramming technologies and have the ability to rapidly incorporate advancements and new innovations. We view our manufacturing team and capabilities as a significant competitive advantage.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our LyFE Manufacturing Center&#8482; located in Bothell, Washington is approximately 73,000 square feet and is comprised of manufacturing suites, laboratories and offices. Our LyFE Manufacturing Center was designed to be in compliance with U.S. and European Union current Good Manufacturing Practices (cGMP) standards and has a flexible and modular design enabling CAR T-cell, TIL, TCR T-cell and cGMP viral vector production to control and de-risk the manufacturing sequence and timing of the major components of our supply chain. Owning our own facility has enabled seamless collaboration across research, process development and manufacturing for high-quality reproducibility at manufacturing scale.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently producing clinical supply for our Phase 1 trials at our LyFE Manufacturing Center. At full staffing and capacity, we expect to be able to manufacture approximately 500 infusions per year depending on product candidate mix. While we believe this capacity is sufficient to support our pipeline programs into pivotal trials and, if approved, early commercialization, we are also advancing multiple strategic alternatives to innovate and scale manufacturing in the future.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are evaluating third-party manufacturing options, such as the recently initiated CAR T-cell proof-of-concept collaboration with Cellares, as part of an overall CAR T&#8209;cell manufacturing strategy to build scale and reduce cost. For TIL, we are advancing our Epi-R P2 manufacturing protocol to shorten delivery time of TIL product to patients.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Macroeconomic Environment</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and operations may be affected by worldwide economic conditions, which may continue to be impacted by global macroeconomic challenges such as the effects of the ongoing geopolitical conflicts in Ukraine, armed conflicts and turmoil in the Middle East, tensions in U.S.-China relations, inflationary pressures, fluctuations in the interest rate environment, instability in the banking industry, supply constraints and overall market volatility. Economic uncertainty may persist in 2024, and the market dynamics discussed above and similar adverse conditions may negatively impact our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a further discussion of trends, uncertainties and other factors that could impact our operating results, see the section entitled &#8220;Risk Factors&#8221; in Part&#160;II, Item&#160;1A of this Quarterly Report on Form 10-Q.</span></div><div id="i9c884009163249728202a1a7baf43489_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for sale and have never generated any revenue from product sales. In the future, we may generate additional revenue from collaborations, strategic alliances, licensing agreements, product sales, or a combination of these.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, research and development expenses consist of costs incurred by us for the discovery and development of our technology platforms and product candidates and include costs incurred in connection with strategic collaborations, costs to license technology, personnel-related costs, including stock-based compensation expense, facility and technology related costs, research and laboratory expenses, as well as other expenses, which include consulting fees and other costs. Upfront payments and milestones paid to third parties in connection with technology platforms that have not reached technological feasibility and do not have an alternative future use are expensed as incurred.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses also include non-cash expenses related to the change in the estimated fair value of the success payment obligations over their respective requisite service terms granted to Fred Hutchinson Cancer Center (Fred&#160;Hutch) and The Board of Trustees of the Leland Stanford Junior University (Stanford). As of December&#160;31, 2022, Fred Hutch had provided the requisite service obligation to earn the potential success payment consideration under </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the continued collaboration. For the three months ended March 31, 2023 and future periods, the change in the Fred Hutch success payment liability fair value is recognized in other income, net, as the requisite service obligation had been met. See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the accompanying notes to the unaudited Condensed Consolidated Financial Statements included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form 10&#8209;Q. Research and development expenses related to our success payment liabilities are unpredictable and may vary significantly from quarter&#8209;to&#8209;quarter and year&#8209;to&#8209;year due to changes in our assumptions used in the calculation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We deploy our employee and infrastructure resources across multiple research and development programs for identifying and developing product candidates and establishing manufacturing capabilities. Due to the stage of development and number of ongoing programs and our ability to use resources across several programs, most of our research and development costs are not recorded on a program-specific basis. These include costs for personnel, laboratory and other indirect facility and operating costs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities account for a significant portion of our operating expenses. We anticipate that our research and development expenses will increase over the foreseeable future as we expand our research and development efforts including completing nonclinical studies, commencing planned clinical trials, conducting and completing current and planned clinical trials, seeking regulatory approvals of our product candidates, identifying new product candidates and incurring costs to acquire and license technology platforms. A change in the outcome of any of these variables could mean a significant change in the costs and timing associated with the development of our product candidates. Because we are early in our research and clinical development efforts of our product candidates, and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the nonclinical development, clinical development and commercialization of product candidates or whether, or when, we may achieve profitability.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses may vary significantly based on factors such as:</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number and scope of nonclinical and IND-enabling studies;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">per patient trial costs;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number of trials required for approval;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number of sites included in the trials;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the countries in which the trials are conducted;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the length of time required to enroll eligible patients;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number of patients that participate in the trials;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the drop-out or discontinuation rates of patients;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">potential additional safety monitoring requested by regulatory agencies;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the duration of patient participation in the trials and follow-up;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the cost and timing of manufacturing our product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the phase of development of our product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the efficacy and safety profile of our product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the extent to which we establish additional collaboration or license agreements; and</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">whether we choose to partner any of our product candidates and the terms of such partnership.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. We may never succeed in obtaining regulatory approval for any of our product candidates. We may obtain unexpected results from our nonclinical studies and clinical trials.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative costs include personnel-related expenses, including stock-based compensation expense for personnel in executive, legal, finance and other administrative functions, legal costs, transaction costs related to collaboration and licensing agreements, as well as fees paid for accounting and tax services, consulting fees and facilities costs not otherwise included in research and development expenses. Legal costs include those related to corporate, dispute and patent matters.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase over the foreseeable future to support our continued research and development activities, operations generally, future business development opportunities, consulting fees, as well as the costs of operating as a public company such as costs related to accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and Securities and Exchange Commission (SEC) requirements, director and officer insurance costs and investor and public relations costs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Operating Income, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income, net consists primarily of service and occupancy fees received associated with subleases.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net consists primarily of interest earned on our cash, cash equivalents and marketable securities balances.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net consists primarily of the change in fair value associated with our success payment liabilities to Fred Hutch and adjustments to the fair value of our marketable equity securities that are publicly traded.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Other Investments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of other investments consists of a reduction in the value of certain other investments.</span></div><div id="i9c884009163249728202a1a7baf43489_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended March&#160;31, 2024 and 2023</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the periods presented (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.810%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Change</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(62)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">43,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">44,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,456)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">13,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">19,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(5,785)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Other operating income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,288)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">55,578&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">62,621&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(7,043)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(55,575)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(62,556)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6,981&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6,819&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,497&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,322&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Other income, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Impairment of other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(13,001)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(10,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(3,001)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total other loss, net</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(5,092)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(4,403)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(689)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(60,667)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(66,959)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6,292&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our research and development expenses for the periods presented (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.266%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Change</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Personnel</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">16,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">19,644&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(3,170)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Facilities and technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">13,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research activities, collaborations and outside services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">13,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Success payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(608)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">43,174&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">44,630&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,456)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $43.2&#160;million and $44.6&#160;million for the three months ended March&#160;31, 2024 and 2023, respectively. The decrease of $1.5&#160;million was primarily due to a decrease of $3.2&#160;million in personnel&#8209;related expenses mainly due to a decrease in headcount associated with the Company&#8217;s November 2023 reduction in workforce; an increase of $1.1&#160;million associated with our success payment liabilities primarily driven by the change in our stock price; an increase of $0.8&#160;million in research activities, collaborations and outside services primarily driven by an increase in research and laboratory costs mainly due to clinical trials; and a decrease of $0.2&#160;million in facilities and technology costs primarily related to lower software implementation costs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $13.5&#160;million and $19.3&#160;million for the three months ended March&#160;31, 2024 and 2023, respectively. The decrease of $5.8&#160;million was primarily due to a decrease of $4.7&#160;million in personnel costs, including a $3.9&#160;million decrease in stock-based compensation expense, primarily related to significant awards being fully expensed in the previous periods and a decrease of $0.8 million in personnel&#8209;related expenses mainly due to a decrease in headcount associated with the Company&#8217;s November 2023 reduction in workforce. General and administrative expenses also decreased due to a reduction of $0.7 million in other administrative expenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Operating Income, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income, net was $1.1&#160;million and $1.3&#160;million for the three months ended March&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net was $6.8&#160;million and $4.5&#160;million for the three months ended March&#160;31, 2024 and 2023, respectively. The increase in interest income, net was primarily driven by higher interest rates in 2024.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net was $1.1&#160;million for both the three months ended March&#160;31, 2024 and 2023. Other income, net consists primarily of the change in fair value associated with our success payment liabilities to Fred Hutch and for the three months ended March 31, 2024, adjustments to the fair value of our marketable equity securities investments that are publicly traded.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Other Investments </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of other investments was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$13.0 million and $10.0 million for the three months ended March&#160;31, 2024 and 2023, respectively, which consisted of the full impairment of one of our other investments in each period. See Note&#160;5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the accompanying notes to the unaudited Condensed Consolidated Financial Statements included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form 10&#8209;Q, for additional details regarding the impairments of other investments.</span></div><div id="i9c884009163249728202a1a7baf43489_109"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, we had $526.3&#160;million in cash, cash equivalents and marketable securities. To date we have raised an aggregate of $1.4&#160;billion in gross proceeds from sales of common stock and convertible preferred stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant operating losses. We have not yet commercialized any product candidates, and we do not expect to generate revenue from sales of any product candidates for a number of years, if ever.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2024, we entered into a sales agreement (Sales Agreement) with Cowen and Company, LLC (Cowen) acting as our sales agent, pursuant to which we may offer and sell shares of our common stock having an aggregate offering price of up to $150.0 million from time to time&#160;in a series of one or more at-the-market equity offerings. We will pay Cowen commissions of up to 3.0% of the gross proceeds of the sale, and reimbursement of certain expenses, under this agreement. Neither us nor Cowen is obligated to sell any shares and, to date, we have not made any sales under the Sales Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur additional losses in the foreseeable future as we conduct and expand our research and development efforts, including conducting nonclinical studies and clinical trials, developing new product candidates, establishing internal manufacturing capabilities and funding our operations generally. Based on our current operating plan, we believe that our existing cash, cash equivalents and marketable securities will be sufficient to meet our working capital and capital expenditure needs into 2027. However, we anticipate that we will need to raise additional capital in the future to fund our operations, including further development of our product candidates and the commercialization of any approved product candidates. In addition, we regularly consider fund-raising opportunities and may decide, from time to time, to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">raise additional capital, including pursuant to the Sales Agreement, based on various factors, including market conditions and our plans of operation. We are subject to the risks typically related to the development of new products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the scope, timing, progress, costs and results of discovery, nonclinical development and clinical trials for our current and future product candidates and any additional nonclinical studies;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number of clinical trials required for regulatory approval of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the costs, timing and outcome of regulatory review of any of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the cost of manufacturing clinical and commercial supplies of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">further investment to build additional manufacturing facilities or expand the capacity of our existing ones;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to maintain existing, and establish new, collaborations, licenses, product acquisitions or other strategic transactions and the fulfillment of our financial obligations under any such agreements, including the timing and amount of any success payment, future contingent payments, milestone, royalty or other payments due under any such agreement;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expenses to attract, hire and retain skilled personnel;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the costs of operating as a public company, including legal, accounting and other related expenses as well as costs relating to maintaining or expanding our operational, financial and management systems and compliance programs;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">addressing or responding to any potential disputes or litigation; and</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the extent to which we acquire or invest in businesses, products and technology platforms.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time as we complete nonclinical and clinical development and receive regulatory approval of our product candidates and can generate significant revenue from product sales, if ever, we expect to finance our operations from the sale of additional equity or debt financings, or other capital that is generated from strategic collaborations, licensing or other arrangements. In the event that additional capital is required, we may not be able to raise it on terms acceptable to us, or at all. If we raise additional funds through the issuance of equity or convertible debt securities, including pursuant to the Sales Agreement, it may result in dilution to our existing stockholders. Debt financing or preferred equity financing, if available, may result in increased fixed payment obligations, and the existence of securities with rights that may be senior to those of our common stock. If we incur indebtedness, we could become subject to covenants that may restrict our operations. If we raise funds through strategic collaboration, licensing or other arrangements, we may relinquish significant rights or grant licenses on terms that are not favorable to us. Our ability to raise additional funds may be adversely impacted by potentially unfavorable global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from actual or perceived changes in interest rates and economic inflation, the anticipated impact of any geopolitical instability and otherwise. If we are unable to raise additional capital when desired, our business, results of operations and financial condition would be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material Cash Requirements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually evaluate our liquidity and capital resources to ensure that we can adequately and efficiently finance our operations. As of March&#160;31, 2024, our material cash requirements consisted primarily of paying salaries and benefits, administering clinical trials, conducting research, improving our manufacturing capabilities, providing the technology and facilities necessary to support our operations, funding operating lease obligations and other payments related to our collaborative agreements. See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Note&#160;7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the accompanying notes to the unaudited Condensed Consolidated Financial Statements included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form 10-Q, for additional information.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><div id="i9c884009163249728202a1a7baf43489_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(42,016)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(46,212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">21,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">32,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net decrease in cash, cash equivalents and restricted cash</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(19,995)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(14,127)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024, net cash used in operating activities was $42.0&#160;million, reflecting our net loss of $60.7&#160;million, partially offset by non-cash items primarily related to the impairment of other investments of $13.0 million, stock-based compensation expense of $9.2&#160;million and depreciation and amortization expense of $5.0&#160;million. Non-cash net amortization and accretion on marketable securities of $4.4&#160;million also contributed to net cash used in operating activities. Additionally, net operating assets and liabilities decreased $3.2 million primarily driven by a $3.6 million decrease in accrued liabilities and other current liabilities, partially offset by a $0.6 million increase in prepaid expenses, other current assets and other assets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, net cash used in operating activities was $46.2 million, primarily reflecting our net loss of $67.0&#160;million, partially offset by non-cash items mainly related to stock-based compensation expense of $13.9&#160;million, impairment of other investments of $10.0&#160;million and depreciation and amortization of $5.0&#160;million, partially offset by net amortization and accretion on marketable securities of $1.9 million and the change in fair value of the success payment liabilities of $1.7 million. Additionally, net operating assets and liabilities decreased $4.3 million primarily driven by a $5.9 million decrease in accrued liabilities and other current liabilities partially offset by a $2.1 million increase in accounts payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024, cash provided by investing activities was $22.0&#160;million, consisting of net maturities and purchases of marketable securities. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, cash provided by investing activities was $32.2&#160;million, consisting of net maturities and purchases of marketable securities of $33.7&#160;million offset by purchases of property and equipment of $1.5&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024, cash provided by financing activities was approximately zero as proceeds from the exercise of stock options of $0.1&#160;million were offset by taxes paid related to the net share settlement of equity awards of $0.1&#160;million. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, cash used in financing activities was $0.1&#160;million, consisting of taxes paid related to the net share settlement of equity awards.</span></div><div id="i9c884009163249728202a1a7baf43489_118"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we did not have, and we do not currently have, any off-balance sheet arrangements as defined under the applicable rules and regulations of the SEC.</span></div><div id="i9c884009163249728202a1a7baf43489_121"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited Condensed Consolidated Financial Statements are prepared in accordance with U.S. generally accepted accounting principles (GAAP). The preparation of these unaudited Condensed Consolidated Financial Statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited Condensed Consolidated Financial Statements, as well as the reported revenue and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our critical accounting policies and estimates as compared to those described in our Annual Report on Form 10&#8209;K for the year ended December&#160;31, 2023 (Annual Report) other than our stock&#8209;based compensation policy for performance-based restricted stock units. For information related to our stock&#8209;based compensation policy for performance-based restricted stock units, see Note&#160;2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the accompanying notes to the unaudited Condensed Consolidated Financial Statements included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form&#160;10&#8209;Q.</span></div><div id="i9c884009163249728202a1a7baf43489_124"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. Our primary risks include interest rate sensitivities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash equivalents of $102.0&#160;million as of March&#160;31, 2024, which consisted of money market funds and highly liquid investments purchased with original maturities of three months or less from the purchase date. We also had fixed income marketable securities of $399.1&#160;million as of March&#160;31, 2024. The primary objective of our investment activities is to preserve capital to fund our operations, and we currently do not hedge our interest rate risk exposure. Because our fixed income marketable securities are primarily short-term in duration, we believe that our exposure to interest rate risk is not significant, and a hypothetical 10% relative change in interest rates during any of the periods presented would not have had a material effect on our unaudited Condensed Consolidated Financial Statements included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form 10-Q. We had no debt outstanding as of March&#160;31, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our employees and operations are currently located in the United States and our expenses are generally denominated in U.S. dollars. We therefore are not currently exposed to significant market risk related to changes in foreign currency exchange rates. However, we have contracted with and may continue to contract with non-U.S. vendors who we may pay in their local currency. Our operations may be subject to fluctuations in foreign currency exchange rates in the future. To date, foreign currency transaction gains and losses have not been material to our Condensed Consolidated Financial Statements, and we have not had a formal hedging program with respect to foreign currency. We believe a hypothetical 10% change in exchange rates during any of the periods presented would not have a material effect on our unaudited Condensed Consolidated Financial Statements included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effects of Inflation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our cost of labor and our clinical trial costs. We believe that inflation has not had a material effect on our unaudited Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q.</span></div><div id="i9c884009163249728202a1a7baf43489_127"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, have evaluated our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (Exchange Act). Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of March&#160;31, 2024, the design and operation of our disclosure controls and procedures were effective at a reasonable assurance level.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in our internal control over financial reporting during the quarter ended March&#160;31, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><div id="i9c884009163249728202a1a7baf43489_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="i9c884009163249728202a1a7baf43489_133"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we have been or may become involved in material legal proceedings or be subject to claims arising in the ordinary course of our business. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently not party to any legal proceedings material to our operations or of which any of our property is the subject, nor are we aware of any such proceedings that are contemplated by a government authority.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of outcome, any such proceedings or claims is subject to inherent uncertainties and can have an adverse impact on us because of defense and settlement costs, diversion of time and resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></div><div id="i9c884009163249728202a1a7baf43489_136"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business involves significant risks, some of which are described below. You should carefully consider the risks described below, as well as the other information contained in this Quarterly Report on Form 10-Q, including our unaudited Condensed Consolidated Financial Statements and the related notes and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. The risk factors set forth below that are marked with an asterisk (*) contain substantive changes to the similarly titled risk factors included in, or did not appear as separate risk factors in, Item&#160;1A of our Annual Report, which was filed with the SEC on February 28, 2024.</span></div><div id="i9c884009163249728202a1a7baf43489_139"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face. Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face, follows this summary. This summary is qualified in its entirety by that more complete discussion of such risks and uncertainties. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are an early clinical stage biopharmaceutical company and have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing net losses for the foreseeable future.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We operate in a rapidly evolving field and have a limited operating history, which may make it difficult to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently have no products approved for sale and have never generated revenue from product sales. We may never generate revenue from product sales or achieve profitability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will require substantial additional capital to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success payment obligations in our success payment agreements may result in dilution to our stockholders or may be a drain on our cash resources to satisfy the payment obligations.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are early in our research and clinical development efforts for our product candidates. If we are unable to successfully develop, manufacture and commercialize product candidates or experience significant delays in doing so, our business may be harmed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates and technology platforms are based on novel technologies that are unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval, and we may not be successful in our efforts to use and expand our technology platforms to develop any product candidate.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently have no marketing, sales or distribution infrastructure, and we intend to either establish a sales and marketing infrastructure or outsource this function to a third party. Either of these commercialization strategies carries substantial risks to us.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently manufacture drug products for our clinical trials ourselves. Delays in further qualifying or in receiving regulatory approvals for any manufacturing facility or product candidates, or in expanding our manufacturing capacity or finding suitable third-party manufacturing partners, could delay our development plans and thereby limit our ability to generate product revenues.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The manufacturing of cellular therapies is very complex. We are subject to a multitude of manufacturing risks, including risks associated with supply chain complexity related to patient materials, any of which could substantially increase our costs, delay our programs or limit supply of our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our sole clinical or commercial manufacturing facility or any of our potential contract manufacturing organizations are damaged or destroyed or production at these facilities is otherwise interrupted, our business would be negatively affected.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may rely on third parties to manufacture our product candidates, which subjects us to risks and could delay or prevent our development and/or commercialization, if approved, of our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to conduct, supervise and monitor a significant portion of our research and nonclinical studies and clinical trials for our product candidates, and, if those third parties do not successfully carry out their contractual duties, comply with regulatory requirements or otherwise perform satisfactorily, we may not be able to obtain regulatory approval or commercialize product candidates, or such approval or commercialization may be delayed, and our business may be substantially harmed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have in the past, and we may in the future, form or seek collaborations or strategic alliances or enter into additional licensing arrangements, and we may not realize the benefits of such alliances or licensing arrangements.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on the enrollment and retention of patients in our current and planned clinical trials for our product candidates. If we experience delays or difficulties enrolling or retaining patients in our clinical trials, our research and development efforts and business, financial condition and results of operations could be materially adversely affected.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our cellular therapy product candidates represent new therapeutic approaches that could result in heightened regulatory scrutiny, delays in clinical development or delays in or our inability to achieve regulatory approvals, commercialization or payor coverage of our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The results of research, nonclinical studies or earlier clinical trials are not necessarily predictive of future results. Any product candidate we advance into clinical trials may not have favorable results in later clinical trials or receive regulatory approval.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical development involves a lengthy and expensive process with an uncertain outcome.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interim, topline or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available or as we make changes to our manufacturing processes and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our ability to commercialize our product candidates successfully and to compete effectively may be adversely affected.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have in-licensed a portion of our intellectual property from our partners. If we breach any of our license agreements with these partners, we could potentially lose the ability to continue the development and potential commercialization of one or more of our product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><div id="i9c884009163249728202a1a7baf43489_142"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Condition, Limited Operating History and Need for Additional Capital</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an early clinical stage biopharmaceutical company and have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing net losses for the foreseeable future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail to prove safe and effective, gain regulatory approval or become commercially viable. We are an early clinical stage biopharmaceutical company, and we do not have any products approved by regulatory authorities and have incurred significant research, development and other expenses related to our ongoing operations and expect to continue to incur such expenses. Since our inception, we have not generated any revenue from product sales and have incurred significant net losses. Substantially all of our net losses since inception have resulted from our research and development programs and general and administrative costs associated with our operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate revenue from product sales for the foreseeable future, if at all. We also expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate these losses to increase as we continue to research, develop and seek regulatory approvals for our product candidates, expand our manufacturing capabilities, in-license or acquire additional technologies and potentially begin to commercialize product candidates that may achieve regulatory approval. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. Moreover, our net losses may fluctuate significantly from quarter to quarter and year to year, such that a period&#8209;to&#8209;period comparison of our results of operations may not be a good indication of our future performance. If any of our product candidates fails in research and development or clinical trials or does not gain regulatory approval, or, if approved, fails to achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur additional expenses and operating losses in the foreseeable future, as we:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">continue nonclinical development of our current and future product candidates and initiate additional nonclinical studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">commence and continue clinical trials of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">advance our genetic and epigenetic reprogramming technologies as well as other research and development efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">attract, hire and retain qualified personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">seek regulatory approval of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expand our manufacturing and process development capabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expand our operational, financial and management systems and compliance programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">acquire and license technology or technology platforms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">continue to develop, protect and defend our intellectual property portfolio; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">incur additional legal, accounting or other expenses in operating our business, including the additional costs associated with operating as a public company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We operate in a rapidly evolving field and have a limited operating history, which may make it difficult to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a rapidly evolving field and, having commenced operations in June 2018, have a limited operating history, which makes it difficult to evaluate our business and prospects. Our primary activities to date have included clinical development of T&#8209;cell therapies, conducting research and development, acquiring technology, entering into strategic collaboration and license agreements, enabling and executing manufacturing activities in support of our product candidate development efforts, executing clinical trials, organizing and staffing the company, business planning, establishing our intellectual property portfolio, regulatory submissions and other preparations to initiate and execute clinical trials, raising capital and providing general and administrative support for these activities. Any predictions about our future success, performance or viability may not be as accurate as they could be if we had a longer operating history or approved products on the market.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition. We expect our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, any of our quarterly or annual periods&#8217; results are not indicative of future operating performance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no products approved for sale and have never generated revenue from product sales. We may never generate revenue from product sales or achieve profitability.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenues from product sales. Our ability to generate revenues from product sales and achieve profitability will depend on our ability to successfully develop and subsequently obtain regulatory approval for and commercialize our product candidates. Our ability to generate revenues and achieve profitability also depends on a number of additional factors, including our ability to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">successfully complete our research activities to identify the technologies and product candidates to further investigate in clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">successfully complete development activities, including the necessary clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">complete and submit regulatory submissions to the FDA, the European Medicines Agency (EMA) or other agencies and obtain regulatory approval for indications for which there is a commercial market;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">obtain coverage and adequate reimbursement from third parties, including government and private payors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">set commercially viable prices for our products, if any;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">develop manufacturing and distribution processes for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">produce commercial quantities of our products at acceptable cost levels;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">maintain adequate supply of our product candidates, including the starting materials and reagents needed;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">maintain the supply of our product candidates in a manner that is compliant with global legal requirements or to the extent necessary;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">establish and maintain manufacturing relationships with reliable third parties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">achieve market acceptance of our products, if any;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">attract, hire and retain qualified personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">protect our rights in our intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">develop a commercial organization capable of sales, marketing and distribution for any products we intend to sell ourselves in the markets in which we choose to commercialize on our own; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">find suitable distribution partners to help us market, sell and distribute our approved products in other markets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues for any product for which regulatory approval is obtained will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to get reimbursement at any price and whether we own the commercial rights for that territory. In addition, we anticipate incurring significant costs associated with commercializing any approved product. As a result, even if we generate revenue from product sales, we may not become profitable and may need to obtain additional funding to continue operations. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and may be forced to reduce our operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional capital to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to expend substantial resources for the foreseeable future to advance and expand our research pipeline, conduct nonclinical studies and pursue clinical development and manufacturing of our product candidates. We also expect to continue to expend resources for the development of our technology platforms. These expenditures will include costs associated with research and development, potentially acquiring or licensing new technologies, conducting nonclinical studies and clinical trials and potentially obtaining regulatory approvals and manufacturing products, as well as marketing and selling products approved for sale, if any. We will also need to make significant expenditures to develop a commercial organization capable of sales, marketing and distribution for any products, if any, that we intend to sell ourselves in the markets in which we choose to commercialize. In addition, we may be required to make substantial payments related to our success payment agreements and other contingent consideration payments under our license and collaboration agreements. Because the design and outcome of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimate the actual amounts necessary to successfully complete the discovery, development and commercialization of our existing and potential product candidates, and other unanticipated costs may arise.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, we had $526.3&#160;million in cash, cash equivalents and marketable securities. As a result of expense timing, as well as diligent expense management, we believe that our existing cash, cash equivalents and marketable securities will be sufficient to meet our working capital and capital expenditure needs into 2027. However, our future capital requirements and the period for which our existing resources will support our operations may vary significantly from what we expect, and we will in any event require additional capital to complete clinical development of any of our current programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any committed external source of funds. Additional funds may not be available when we need them on terms that are acceptable to us, or at all, and our ability to raise additional capital may be adversely impacted by potentially unfavorable global economic conditions or conditions in the biotechnology sector of the market, including disruptions to, or volatility in, the credit and financial markets in the United States and worldwide, actual or perceived changes in interest rates and economic inflation, the current or anticipated impact of geopolitical instability and otherwise. If adequate funds are not available to us on a timely basis, including pursuant to the Sales Agreement (as defined below), we may be required to delay, limit, reduce or terminate nonclinical studies, clinical trials or other development activities for our product candidates or delay, limit, reduce or terminate our establishment of sales, marketing and distribution capabilities or other activities that may be necessary to commercialize our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success payment obligations in our success payment agreements may result in dilution to our stockholders or may be a drain on our cash resources to satisfy the payment obligations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We agreed to make success payments payable in cash or publicly-tradeable shares of our common stock at our discretion pursuant to our success payment agreements with Fred Hutch and Stanford. On each contractually prescribed measurement date, we may be required to make success payments based on increases in the per share fair value of our common stock. The total amount of success payments that we may become obligated to make is currently $400.0&#160;million and may increase in the future due to amendments of our existing success payment agreements. For information related to our success payment obligations, see Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the accompanying notes to the unaudited Condensed Consolidated Financial Statements included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form&#160;10&#8209;Q.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to satisfy our obligations to make these success payments, if and when they are triggered, we may issue equity or convertible debt securities that may cause dilution to our stockholders, or we may use our existing cash to satisfy the success payment obligation in cash, which may adversely affect our financial position. In addition, these success payments may impede our ability to raise money in future public offerings of debt or equity securities or to obtain a third-party line of credit.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The success payment agreements may cause operating results to fluctuate significantly from quarter to quarter and year to year, which may reduce the usefulness of our consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success payment obligations are recorded as liabilities on our condensed consolidated balance sheets. Under U.S. generally accepted accounting principles (GAAP), we are required to estimate the fair value of these liabilities as of each quarter end and changes in the estimated fair value are accreted to research and development expense over the service period of the collaboration agreement. Once the requisite service obligation to earn the potential success payment consideration is met under our continued collaboration agreements, the change in the success payment liabilities fair value is recognized in other income or expense, net. For example, in December 2022, Fred Hutch had provided the requisite service obligation to earn the potential success payment consideration under the continued collaboration; accordingly in 2023 and future periods, the change in the success payments liability fair value is recognized in other income or expense, net.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may lead to increases or decreases in the estimated fair value of our success payment liabilities include, among others, changes in the value of the common stock, changes in volatility and changes in the risk-free rate. As a result, our operating results and financial condition as reported by GAAP may fluctuate significantly from quarter to quarter and from year to year and may reduce the usefulness of our GAAP consolidated financial statements. See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the accompanying notes to the unaudited Condensed Consolidated Financial Statements included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form 10-Q for additional information.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33</span></div></div></div><div id="i9c884009163249728202a1a7baf43489_145"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Industry</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are early in our research and clinical development efforts. If we are unable to successfully develop, manufacture and commercialize product candidates or experience significant delays in doing so, our business may be harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are early in our research and clinical development efforts for our product candidates. Besides LYL797 and LYL845, which are in Phase 1 clinical development, our other proprietary product candidates are currently in preclinical development. We have not yet demonstrated our ability to successfully complete any clinical trials (including any Phase&#160;3 or other pivotal clinical trials), obtain regulatory approvals, manufacture a commercial&#8209;scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. We have invested substantial resources in developing our technology platforms and our product candidates, conducting nonclinical studies, commencing clinical trials and building our manufacturing facilities and capabilities, each of which will be required prior to any regulatory approval and commercialization. Our ability to generate revenue from product sales, which we do not expect will occur for several years, if ever, will depend heavily on the successful research and development and eventual commercialization of one or more product candidates in profitable indications and markets. The success of our efforts to identify, develop, manufacture and commercialize product candidates will depend on many factors, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">timely and successful completion of our nonclinical studies and research activities to identify and develop product candidates to investigate in clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">submission of INDs to the FDA to proceed with clinical trials, or comparable applications to foreign regulatory authorities that allow the commencement of our planned clinical trials for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">successful enrollment and completion of clinical trials in compliance with Good Clinical Practice (GCP) requirements with positive results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the level of efficacy observed with our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the prevalence and severity of adverse events experienced with any of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">successfully developing, or making arrangements with third parties for, manufacturing and distribution processes for our product candidates and for commercial manufacturing and distribution for any of our product candidates that receive regulatory approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">receipt of timely regulatory approvals from applicable authorities for our product candidates for their intended uses;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">protecting our rights in our intellectual property portfolio, including by obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">establishing capabilities and infrastructure to obtain the tumor tissues needed to develop and, if successful, commercialize approved products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">manufacturing our product candidates at an acceptable cost;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">launching commercial sales of our products, if approved by applicable regulatory authorities, whether alone or in collaboration with others;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">acceptance of our products, if approved by applicable regulatory authorities, by patients and the medical community;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">obtaining and maintaining coverage and adequate reimbursement by third-party payors, including government payors, for our products, if approved by applicable regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">effectively competing with other marketed therapies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">maintaining compliance with regulatory requirements, including the cGMP requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">maintaining a continued acceptable benefit/risk profile of the products following approval; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">maintaining and growing an organization of scientists and functional experts who can develop and commercialize our products and technology.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully develop and commercialize our product candidates, which could harm our business. If we do not receive marketing approvals for any product candidate we develop, we may not be able to continue our operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates and technology platforms are based on novel technologies that are unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval, and we may not be successful in our efforts to use and expand our technology platforms to develop any product candidate.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are seeking to identify and develop a broad pipeline of product candidates using our proprietary technology platforms. The scientific research that forms the basis of our efforts to develop product candidates with our technology platforms is still ongoing. Further, the scientific evidence to support the feasibility of developing therapeutic treatments based on our technology platforms are both preliminary and limited. Additionally, although LYL797 and LYL845 are in Phase 1 clinical development, our current clinical data are limited, and nonclinical data from murine tumor models and in vitro experiments with tumor cell lines may not translate into humans or may not accurately predict the safety and efficacy of our product candidates in humans. As a result, we are exposed to a number of unforeseen risks, and it is difficult to predict the types of challenges and risks that we may encounter during development of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the novelty of our technology platforms, we intend to work closely with the FDA and comparable foreign regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates; however, the regulatory pathway with the FDA and comparable regulatory authorities may be more complex and time-consuming relative to other more well-known therapeutics. Even if we obtain human data to support our product candidates, the FDA or comparable foreign regulatory authorities may lack sufficient experience in evaluating the safety and efficacy of our product candidates developed using our technology platforms, which could result in a longer than expected regulatory review process, increase our expected development costs and delay or prevent commercialization of our product candidates. The validation process takes time and resources, may require independent third-party analyses and may not be accepted or approved by the FDA and comparable foreign regulatory authorities. There can be no assurance as to the length of clinical development, the number of patients that the FDA or comparable foreign regulatory authorities may require to be enrolled in clinical trials to establish the safety, purity and potency of our product candidates or the acceptability to the FDA or comparable foreign regulatory authorities of data generated in these clinical trials to support marketing approvals. We cannot be certain that our approach will lead to the development of approvable or marketable products, alone or in combination with other therapies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on our key personnel and, if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, manufacturing, scientific and medical personnel. The loss of the services of any of our executive officers, other key employees and other scientific and medical advisors and our inability to find suitable replacements could result in delays in product development and harm our business. We conduct substantially all of our operations at our facilities in the San Francisco, Seattle and Bothell metropolitan areas. These regions are headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in these markets is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided equity that vests over time. The value to employees of equity incentives that vest over time may be significantly affected by factors beyond our control, including market conditions and volatility, and may at any time be insufficient to counteract more lucrative offers from other companies. Because the trading price of our common stock was significantly below the exercise price for many of the options we had granted to our employees, which made the value of our equity as a retention tool decrease substantially, our Board of Directors authorized a repricing of the exercise price of such options for certain employees in November 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite our efforts to retain valuable employees, we may nevertheless experience attrition from members of our management, scientific and development teams. For example, over the past twelve months, there have been departures of executive officers, including most recently our chief medical officer. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#8220;key man&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in the fourth quarter of 2023, we announced a reduction in workforce of approximately 25%. This reduction in force may yield unintended consequences and costs, such as difficulty retaining and motivating remaining employees, increased difficulty in our day-to-day operations and loss of institutional knowledge and expertise and difficulty in attracting and hiring qualified employees in the future. We may also be subject to reputational risks and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">litigation risks and expenses and may not realize the savings or operational efficiencies anticipated, which could result in total costs and expenses that are greater than expected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any litigation or adversarial proceedings could be costly and time-consuming to defend.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been and may in the future become subject to legal proceedings and claims that arise in the ordinary course of business, such as claims brought by us or third parties in connection with commercial disputes or employment claims made by our current or former employees. Litigation or adversarial proceedings might result in substantial costs and may divert management&#8217;s attention and resources, which might seriously harm our business, reputation, overall financial condition and operating results. For example, in February 2021, we filed a demand for arbitration seeking, among other things, rescission of each of the joint-development agreement and stock purchase agreement we entered with PACT Pharma, Inc. (PACT) and recovery of the consideration paid thereunder and in October 2022, we entered into a settlement agreement with PACT to resolve the outstanding legal dispute. Insurance might not cover such claims, might not provide sufficient payments to cover all the costs to resolve one or more such claims and might not continue to be available on terms acceptable to us. Any claim brought by us or against us that is uninsured or underinsured could result in unanticipated costs, thereby harming our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot maintain our company culture as we grow, our success and our business may be harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our culture has been a key contributor to our success to date. Any failure to preserve our culture could negatively affect our ability to retain and recruit personnel, which is critical to our growth, and to effectively focus on and pursue our objectives. As we grow and are required to implement more complex organizational management structures, we may find it increasingly difficult to maintain the beneficial aspects of our culture. If we fail to maintain our company culture, our business may be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no marketing, sales or distribution infrastructure, and we intend to either establish a sales and marketing infrastructure or outsource this function to a third party. Either of these commercialization strategies carries substantial risks to us.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no marketing, sales and distribution capabilities. To support commercial marketing and distribution of any of our product candidates that complete clinical development and are approved, we would either establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize our product candidates in a legally compliant manner or outsource this function to a third party. There are risks involved if we decide to establish our own sales and marketing capabilities or enter into arrangements with third parties to perform these services. To the extent that we enter into collaboration agreements with respect to marketing, sales or distribution, our product revenue may be lower than if we directly marketed or sold any approved products. Such collaborative arrangements with partners may place the commercialization of our products outside of our control and would make us subject to a number of risks, including that we may not be able to control the amount or timing of resources that our collaborative partner devotes to our products or that our collaborator&#8217;s willingness or ability to complete its obligations, and our obligations under our arrangements may be adversely affected by business combinations or significant changes in our collaborator&#8217;s business strategy.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize any approved products. If we are not successful in commercializing any approved products, either on our own or through collaborations with one or more third parties, our future product revenue will suffer, and we may incur significant additional losses, which would have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global credit and financial markets have experienced extreme volatility and disruptions (including as a result of the COVID-19 pandemic and actual or perceived changes in interest rates and economic inflation), which included severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, high inflation, uncertainty about economic stability and swings in unemployment rates. The financial markets and the global economy may also be adversely affected by the impact of supply chain disruptions, labor shortages, fluctuations in currency exchange rates, changes in interest rates, military conflict, acts of terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in response to geopolitical conflicts, including the one in Ukraine, may also continue to adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. There can be no assurance that a deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions, including disruption to enrollment within our ongoing trials and our ability </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to purchase necessary supplies on acceptable terms, if at all. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse developments affecting the financial services industry could adversely affect our current and projected business operations and our financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse developments that affect financial institutions, such as events involving liquidity that are rumored or actual, have in the past and may in the future lead to bank failures and market-wide liquidity problems. For example, in March 2023, Silicon Valley Bank (SVB) was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (FDIC) as receiver. Similarly, later in March 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. While the U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25 billion of loans to financial institutions secured by certain of such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediate liquidity may exceed the capacity of such program, and there is no guarantee that such programs will be sufficient. Additionally, it is uncertain whether the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have not experienced any adverse impact to our liquidity or to our current and projected business operations, financial condition or results of operations as a result of the matters relating to SVB, Signature Bank and Silvergate Capital Corp, uncertainty remains over liquidity concerns in the broader financial services industry, and our business, our business partners or industry as a whole may be adversely impacted in ways that we cannot predict at this time.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we assess our banking relationships as we believe necessary or appropriate, our access to cash in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect the financial institutions with which we have banking relationships and, in turn, us. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could also include factors involving financial markets or the financial services industry generally. The results of events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations. These could include, but may not be limited to, delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets; or termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management arrangements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, widespread investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations.</span></div><div><span><br/></span></div><div id="i9c884009163249728202a1a7baf43489_148"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Manufacturing</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently manufacture drug products for our clinical trials ourselves. Delays in further qualifying or in receiving regulatory approvals for any manufacturing facility or product candidates, or in expanding our manufacturing capacity, could delay our development plans and thereby limit our ability to generate product revenues.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have built our own manufacturing facility in Bothell, Washington. The facility is designed to support the production of nonclinical and clinical development product candidates and early commercialization of products, and ongoing facility and equipment qualification to support clinical production is required. If we are not able to further qualify </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our existing facility or the appropriate regulatory approvals for the facility are delayed, or if we are unable to otherwise expand our manufacturing capacity, we may be unable to manufacture sufficient quantities of our product candidates, if at all, which would limit our development activities and our opportunities for growth.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our manufacturing facility will be subject to ongoing, periodic inspection by the FDA, competent authorities of European Union (EU) Member States and other comparable regulatory authorities to ensure compliance with cGMPs and current Good Tissue Practices (cGTPs). Our failure to follow and document our adherence to these regulations or other regulatory requirements may lead to significant delays in the availability of products for clinical or, in the future, commercial use. This may result in the modification or termination of or a hold on a clinical trial or may delay or prevent filing or approval of commercial marketing applications for our product candidates. We also may encounter problems with the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">achieving adequate or clinical-grade materials that meet regulatory authority standards or specifications with consistent and acceptable production yield and costs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">maintaining continuity among our key manufacturing-related electronic systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">shortages of qualified personnel, raw materials or key contractors; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">ongoing compliance with cGMP regulations and other requirements of the FDA, the EU or other competent regulatory authorities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable regulations could also result in sanctions being imposed on us, including fines, injunctions, civil and/or criminal penalties, a requirement to terminate, vary, suspend or put on hold one or more of our clinical trials, failure of regulatory authorities to grant marketing approval of our product candidates, delays, suspension, variation or withdrawal of approvals, license suspension or revocation, labelling restrictions or requirements in an approved label, seizures or recalls of product candidates or approved products, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions and criminal prosecutions, any of which could harm our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing advanced manufacturing techniques and process controls is required to fully utilize our facility. Without further investment, advances in manufacturing techniques may render our facility and equipment inadequate or obsolete. We may also require further investment to build additional manufacturing facilities or expand the capacity of our existing ones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The manufacturing of cellular therapies is very complex. We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs, delay our programs or limit supply of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing commercially viable manufacturing processes for cellular therapies is a difficult and uncertain task and requires significant expertise and capital investment. We are developing and implementing manufacturing processes for our product candidates. In particular, for autologous cell therapies, the starting material is the patient&#8217;s own cells, which inherently adds complexity and variability to the manufacturing process. In addition, our ability to consistently and reliably manufacture our cellular therapy product candidates is essential to our success, and there are risks associated with scaling to the level required for advanced clinical trials or commercialization, including cost overruns, potential problems with process scale-up, process reproducibility, stability issues, consistency and timely availability of reagents or raw materials. Furthermore, our manufacturing processes may have significant dependencies on third parties, which will pose additional risks to our manufacturing capabilities. Additionally, we do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing and processing of our product candidates, and the actual cost to manufacture and process our product candidates could materially and adversely affect the commercial viability of our product candidates. As a result, we may never be able to develop a commercially viable product.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the factors mentioned above, the overall process of manufacturing cellular therapies is extremely susceptible to product loss due to low cell viability, contamination, equipment failure or improper installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing and distribution processes for any of our product candidates could result in reduced production yields, impact to key product quality attributes and other supply disruptions. Product defects can also occur unexpectedly. These deviations and disruptions could delay our programs. If we are not able to capably manage this complexity and variability, our ability to timely and successfully provide our product candidates to patients could be delayed. In addition, the complexities of utilizing a patient&#8217;s own cells as the starting material requires that we have suitable cells capable of yielding a viable cellular therapy product, which may not be possible for severely immune-compromised or heavily pre-treated patients.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of successfully manufacturing products for clinical testing and commercialization may be particularly challenging, even if such products otherwise prove to be safe and effective. The manufacture of these product candidates involves complex processes. Some of these processes require specialized equipment and highly skilled and trained </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">personnel. The process of manufacturing these product candidates will be susceptible to additional risks, given the need to maintain aseptic conditions throughout the manufacturing process. Contamination with microbes, viruses or other pathogens in either the donor material or materials utilized in the manufacturing process or ingress of microbiological material at any point in the process may result in contaminated, unusable product or necessitate the closing of a manufacturing facility for an extended period of time to allow us to investigate and remedy the contamination. These types of contaminations could result in delays in the manufacture of products, which could result in delays in the development of our product candidates. These contaminations could also increase the risk of adverse side effects.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting manufacturing operations for our product candidates may result in lot failures, inventory shortages, shipment delays, product withdrawals or recalls or other interruptions in supply that could delay the development of our product candidates. If we are unable to obtain sufficient supply of our product candidates, whether due to production shortages or other supply interruptions, our clinical trials or regulatory approvals may be delayed. We may also have to write off inventory, incur other charges and expenses for supply of product that fails to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. In addition, parts of the supply chain may have long lead times or may come from a small number of suppliers. If we are not able to appropriately manage our supply chain, our ability to successfully produce our product candidates could be delayed or harmed. Inability to meet the demand for our product candidates could damage our reputation and the reputation of our products among physicians, healthcare payors, patients or the medical community that supports our product development efforts, including hospitals and outpatient clinics.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the manufacturing facilities in which our product candidates will be made could be adversely affected by earthquakes and other natural disasters, equipment failures, labor shortages, power failures, health epidemics and numerous other factors. If any of these events were to occur and impact our manufacturing facilities, our business would be materially and adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our sole clinical or commercial manufacturing facility or any of our potential contract manufacturing organizations is damaged or destroyed or production at these facilities is otherwise interrupted, our business would be negatively affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate a single manufacturing facility in Bothell, Washington and may rely on potential third-party contract manufacturing organizations to meet our current and future manufacturing needs. If our manufacturing facility or any facility in our manufacturing network, or the equipment in these facilities, is either damaged or destroyed, we may not be able to quickly or inexpensively replace our manufacturing capacity, if at all. In the event of a temporary or protracted loss of a facility or its equipment, we may not be able to transfer manufacturing to a third party in the time required to maintain supply. Even if we are able to transfer manufacturing to a third party, the shift would likely be expensive and time-consuming, particularly since the new facility would need to comply with the necessary regulatory requirements or may require regulatory approval before selling any products manufactured at that facility. Such an event could substantially delay our clinical trials or commercialization of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, we maintain insurance coverage against damage to our property and to cover business interruption and research and development restoration expenses. However, our insurance coverage may not reimburse us, or may not be sufficient to reimburse us, for any expenses or losses we may suffer. We may be unable to meet our requirements for our product candidates if there were a catastrophic event or failure of our current manufacturing facility or processes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may rely on third parties to manufacture our product candidates, which subjects us to risks and could delay or prevent our development and/or commercialization, if approved, of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may rely on third parties to manufacture our current or future product candidates. We may be unable to identify manufacturers for our product candidates or the materials required to develop the cellular therapy on acceptable terms or at all because the number of potential manufacturers is limited. We are currently evaluating third&#8209;party manufacturing options, including an automated manufacturing platform from Cellares for the manufacture of our LYL797 CAR T-cell therapy. Utilizing a third-party Good Manufacturing Practices manufacturer will require the transfer and testing of manufacturing and analytical methods to demonstrate substantially equivalent processes and performance for regulatory filings and interactions as required. Such potential third-party manufacturers may be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the facilities used by manufacturers are subject to ongoing periodic unannounced inspections by the FDA and corresponding state agencies and comparable foreign regulatory authorities to ensure strict compliance with government regulations and corresponding foreign standards. Despite our efforts to audit and verify regulatory compliance, third-party manufacturers may be found on regulatory inspection by the FDA or comparable foreign regulatory authorities to be noncompliant with cGMP regulations and requirements in relation to the manufacture of our product candidates. If </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable foreign regulatory authorities, we will not be able to obtain and/or maintain regulatory approval for our product candidates manufactured in these facilities. In addition, we have limited control over the ability of our third-party manufacturers to maintain adequate control, quality assurance and qualified personnel required to meet our clinical and commercial needs, if any. If the FDA or a comparable foreign regulatory authority does not approve the manufacture of our product candidates at these facilities or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. In addition, any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacturing of our product candidates or that any approvals we have obtained could be revoked, which would adversely affect our business and reputation. Moreover, noncompliance with cGMP regulations or requirements may result in shutdown of the third-party vendor or invalidation of drug product lots or processes. In some cases, a product recall may be warranted or required, which would materially affect our ability to supply and market our products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our products. Also, our third-party manufacturers could breach or terminate their agreement with us because of their own financial difficulties or business priorities at a time that is costly or otherwise inconvenient for us. If we were unable to find adequate replacement or another acceptable solution in time, our clinical trials could be delayed or our commercial activities could be harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our third-party manufacturers would also be subject to the same risks we face in developing our own manufacturing capabilities, as described above. Each of these risks could delay our clinical trials, the approval, if any, of our product candidates by the FDA or comparable foreign regulatory authorities or the commercialization of our product candidates or result in higher costs or deprive us of potential product revenue.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates require many specialty raw materials. As a result, we may be required to outsource aspects of our manufacturing supply chain. Many of the specialty raw materials may be manufactured by small companies with limited resources and experience to support a commercial product, and the suppliers may not be able to deliver raw materials to our specifications. In such case, identifying and engaging an alternative supplier or manufacturer could result in delay, and we may not be able to find other acceptable suppliers or manufacturers on acceptable terms, or at all. Switching suppliers or manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. If we change suppliers or manufacturers for commercial production, applicable regulatory agencies may require us to conduct additional studies or trials. If key suppliers or manufacturers are lost, or if the supply of the materials is diminished or discontinued, we may not be able to develop, manufacture and market our product candidates in a timely and competitive manner, or at all. An inability to continue to source product from any of these suppliers, which could be due to a number of issues, including regulatory actions or requirements affecting the supplier, adverse financial or other strategic developments experienced by a supplier, labor disputes or shortages, unexpected demands or quality issues, could adversely affect our ability to satisfy demand for our product candidates, which could adversely and materially affect our product sales and operating results or our ability to conduct clinical trials, either of which could significantly harm our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, those suppliers may not have the capacity to support commercial products manufactured by biopharmaceutical firms. The suppliers may be ill-equipped to support our needs, especially in non-routine circumstances like an FDA or comparable foreign regulatory authority inspection, or medical crises such as widespread contamination. We may not be able to contract with these companies on acceptable terms or at all. Accordingly, we may experience delays in receiving key raw materials to support clinical or commercial manufacturing. In addition, some raw materials are currently available from a single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. These factors could cause the delay of studies or trials, regulatory submissions, required approvals or commercialization of product candidates that we develop, cause us to incur higher costs and prevent us from commercializing our product candidates successfully.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40</span></div></div></div><div id="i9c884009163249728202a1a7baf43489_151"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We intend to rely on third parties to conduct, supervise and monitor a significant portion of our research and nonclinical studies and clinical trials for our product candidates, and, if those third parties do not successfully carry out their contractual duties, comply with regulatory requirements or otherwise perform satisfactorily, we may not be able to obtain regulatory approval or commercialize product candidates, or such approval or commercialization may be delayed, and our business may be substantially harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct GCP-compliant clinical trials on our product candidates properly and on time. For example, we are relying on CROs to conduct significant parts of our LYL797 and LYL845 Phase&#160;1 clinical trials. Negotiating budgets and contracts with CROs and study sites may result in delays to our development timelines and increased costs. Switching or adding CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any third parties conducting our clinical trials or nonclinical studies will not be our employees, and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our programs. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain are compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials or nonclinical studies may be extended, delayed or terminated, and we may not be able to obtain regulatory approval or successfully commercialize our product candidates. Consequently, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase substantially and our ability to generate revenue could be delayed significantly.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on these parties for execution of our nonclinical studies and clinical trials, and generally do not control their activities. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA and comparable foreign regulatory authorities require us to comply with standards, commonly referred to as GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. If we or any of our CROs or other third parties, including trial sites, fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with applicable GCPs. In addition, our clinical trials must be conducted with product produced under cGMP conditions. Our failure to comply with these regulations and requirements may require us to add patients to or repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal, state or foreign fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with the third parties that we currently use or that we may use in the future terminates, we may not be able to enter into arrangements with alternative third parties or do so on commercially reasonable terms. As a result, delays occur, which can materially impact our ability to meet desired research and clinical development timelines.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do and will continue to or intend to rely on outside scientists and clinical trial investigators and their third-party research institutions for research and development and early clinical testing of our product candidates. These scientists, investigators and institutions may have other commitments or conflicts of interest, which could limit our access to their expertise and harm our ability to leverage our technology platforms.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on our third-party research institution collaborators for some research capabilities. However, the research we are funding constitutes only a small portion of the overall research of each research institution. Other research being conducted by these institutions may at times receive higher priority than research on the programs we are funding. We typically have less control of the research, clinical trial protocols and patient enrollment than we might with activity led by our employees.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outside scientists and clinical trial investigators who conduct the research and development upon which portions of our product candidate pipeline depends are not our employees; rather, they serve as either independent contractors or the primary investigators under research collaboration agreements that we have with their sponsoring </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">academic or research institution. Such scientists and collaborators may have other commitments that would limit their availability to us. Although our scientific advisors generally agree not to do competing work, if an actual or potential conflict of interest between their work for us and their work for another entity arises, we may lose their services. These factors could adversely affect the timing of the clinical trials, the timing of receipt and reporting of clinical data, the timing of our IND submissions and comparable foreign applications and our ability to conduct our current and planned clinical trials. It is also possible that some of our valuable proprietary knowledge may become publicly known through these scientific advisors if they breach their confidentiality agreements with us, which would cause competitive harm to, and have an adverse effect on, our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have in the past, and we may in the future, form or seek collaborations or strategic alliances or enter into additional licensing arrangements, and we may not realize the benefits of such alliances or licensing arrangements. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into research and development collaborations in the past, and may in the future, enter into additional license and collaboration arrangements. Any collaboration arrangement that we enter into is subject to numerous risks, which may include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the collaborator has significant discretion in determining the efforts and resources that they will apply to a program or product candidate under the collaboration;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the collaborator may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the collaborator may delay or halt clinical trials, provide insufficient funding for a clinical trial, preferentially enroll patients on a portion of a clinical trial not testing our product candidates, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the collaborator could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the collaborator may not commit sufficient resources to marketing and distribution of our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the collaborator may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">disputes may arise between us and the collaborator that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the collaboration may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the collaborator may own or co-own intellectual property covering our product candidates that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, failure by any collaborator to meet its obligations under our collaboration agreements or to apply sufficient efforts at developing and commercializing collaboration products may adversely affect our business, financial condition and our results of operations. For example, we were previously party to a research and development collaboration with GSK for our NY-ESO-1 program and other potential product opportunities and, effective December 2022, GSK terminated the agreement and discontinued its development of product candidates targeting NY-ESO-1, including the second&#8209;generation product candidates that incorporated our genetic and epigenetic reprogramming technologies. No patients had been treated with these product candidates and, given the early stage of these second&#8209;generation programs, the termination was not based on any clinical efficacy or safety data from these programs. We have also discontinued any further work on these programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may form or seek further strategic alliances, create joint ventures or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates, our research and any future product candidates that we may pursue. Such alliances will be subject to many of the risks set forth above. Moreover, any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these risks, we may not be able to realize the benefit of our existing collaboration or any future collaborations or licensing agreements we may enter into. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not realize the benefits of potential future collaborations, licenses, product acquisitions or other strategic transactions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into, and may desire to enter into in the future, collaborations, licenses or other strategic transactions for the acquisition of products or business opportunities, in each case where we believe such arrangement will complement or augment our existing business. These relationships or transactions, or those like them, may require us to incur nonrecurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, reduce the potential profitability of the products that are the subject of the relationship or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic alliances and transactions and the negotiation process is time-consuming and complex, and there can be no assurance that we can enter into any of these transactions even if we desire to do so. Moreover, we may not be successful in our efforts to establish a strategic alliance or other alternative arrangements for any future product candidates and programs because our research and development pipeline may be insufficient, our product candidates or programs may be deemed to be at too early a stage of development for collaborative effort and third parties may not view our product candidates and programs as having the requisite potential to demonstrate a positive benefit/risk profile. Any delays in entering into new strategic alliance agreements related to our product candidates could also delay the development and commercialization of our product candidates and reduce their competitiveness even if they reach the market.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we license products or acquire businesses, we may not be able to realize the benefit of these transactions if we are unable to successfully integrate them with our existing operations and company culture. There are other risks and uncertainties involved in these transactions, including unanticipated liabilities related to acquired intellectual property rights, products or companies and disruption in our relationship with collaborators or suppliers as a result of such a transaction. We cannot be certain that, following an acquisition or license, we will achieve the financial or strategic results that would justify the transaction.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on the enrollment and retention of patients in our current and planned clinical trials for our product candidates. If we experience delays or difficulties enrolling or retaining patients in our clinical trials, our research and development efforts and business, financial condition, and results of operations could be materially adversely affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful and timely completion of clinical trials require that we enroll and retain a sufficient number of patient candidates. Any clinical trials we conduct may be subject to delays for a variety of reasons, including as a result of patient enrollment taking longer than anticipated, manufacturing failures resulting in patients being unable to be treated, patient withdrawal or adverse events.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These types of developments have in the past, and could in the future, cause us to delay a trial or halt further development. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trials compete with other clinical trials that are in the same therapeutic areas as our product candidates, and this competition reduces the number and types of patients available to us, as some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. We may also encounter additional challenges and slower than anticipated enrollment in our clinical trials if any of our competitors obtain FDA approval before us in the same therapeutic areas as our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, enrolling patients in clinical trials for diseases in which there is an approved standard of care is challenging, as patients will first receive the applicable standard of care. Many patients who respond positively to the standard of care do not enroll in clinical trials. This may limit the number of eligible patients able to enroll in our clinical trials who have the potential to benefit from our product candidates and could extend development timelines or increase costs for these programs. For example, lifileucel was approved for the treatment of unresectable or metastatic melanoma, and, if it is adopted as a standard of care, its availability may adversely impact enrollment in our trials of LYL845 in melanoma. Patients who fail to respond positively to the standard of care treatment will be eligible for clinical trials of unapproved drug candidates. However, these prior treatment regimens may render our therapies less effective in clinical trials.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the number of qualified clinical investigators and clinical trial sites is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience delays in enrollment in our current and planned clinical trials due to factors outside our control. For example, some patients may not be able to comply with clinical trial protocols due to lack of healthcare support or potential interruptions of healthcare services. Our ability to recruit and retain patients, principal investigators and site staff may also be hindered, which would adversely affect our trial operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment depends on many additional factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the size and nature of the patient population;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the severity of the disease under investigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">eligibility criteria for the trial;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the proximity of patients to clinical sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the design of the clinical protocol;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the ability to obtain and maintain patient consents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">perceived risks and benefits of the product candidate under evaluation, including any perceived risks associated with genetically modified product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the risk that patients enrolled in clinical trials will drop out of the trials before the administration of our product candidates or trial completion;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the availability of competing clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the availability of new drugs approved for the indication that the clinical trial is investigating; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available approved or investigational therapies.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors may make it difficult for us to enroll enough patients to complete our clinical trials in a timely and cost-effective manner. Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face competition from numerous pharmaceutical and biotechnology enterprises, as well as from academic institutions, government agencies and private and public research institutions. Our ability to enroll clinical trials or our commercial opportunities will be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects or are less expensive than any products that we may develop. Additionally, our commercial opportunities will be reduced or eliminated if novel upstream products or changes in treatment protocols reduce the overall incidence or prevalence of our current or future target diseases. Competition could result in reduced sales and pricing pressure on our product candidates, if approved by applicable regulatory authorities. In addition, significant delays in the development of our product candidates could allow our competitors to bring products to market before us and impair any ability to commercialize our product candidates.</span></div><div id="i9c884009163249728202a1a7baf43489_154"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulation and Legal Compliance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are in the first phase of clinical development of our product candidates, and our future success is dependent on the successful development and regulatory approval of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no products approved for commercial sale, and we are in the first phase of clinical development of our product candidates. Besides LYL797 and LYL845, which are in Phase 1 clinical development, our other proprietary product candidates are currently in preclinical development. The future success of our business is substantially dependent on our ability to obtain regulatory approval for our product candidates for the indications we seek, and, if approved, to successfully commercialize one or more product candidates in a timely manner. Each of our programs and product candidates will require clinical development, regulatory approval, obtaining manufacturing supply, capacity and expertise, building a commercial organization or successfully outsourcing commercialization, substantial investment and significant marketing efforts before we generate any revenue from product sales. We do not have any products that are approved for commercial sale, and we may never be able to develop or commercialize marketable products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot commercialize product candidates in the United States without first obtaining regulatory approval for the product from the FDA; similarly, we cannot commercialize product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of any product candidate for a target indication, we must demonstrate with substantial evidence from and to the satisfaction of the FDA and comparable foreign regulatory authorities, that the product candidate is safe, pure and potent for use for that target indication and that the manufacturing facilities, processes and controls are adequate with respect to such product candidate to assure safety, purity and potency.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of nonclinical studies and clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any future product candidates will ever obtain regulatory approval. Furthermore, the regulatory approval process for novel product candidates, such as T-cell product candidates and next-generation T-cell programs, can be more complex and consequently more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a product candidate were to successfully obtain approval from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval for one of our product candidates in one or more jurisdictions, or any approval contains significant limitations, we may not be able to obtain sufficient funding to continue the development of that product or generate revenues attributable to that product candidate. Also, any regulatory approval of our current or future product candidates, once obtained, may be withdrawn.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our cellular therapy product candidates represent new therapeutic approaches that could result in heightened regulatory scrutiny, delays in clinical development or delays in or our inability to achieve regulatory approval, commercialization or payor coverage of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is dependent on the successful development of our cellular therapies in general and our development product candidates, in particular. Because these programs represent a new approach to the treatment of cancer, developing and, if approved, commercializing our product candidates subject us to a number of challenges. Moreover, we cannot be sure that the manufacturing processes used in connection with our cellular therapy product candidates will yield a sufficient supply of satisfactory products that are safe, pure and potent, scalable or profitable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to oversight by the FDA and by institutional review boards (IRBs) under guidelines promulgated by the National Institutes of Health (NIH), clinical trials such as those for LYL797, which evaluates T cells expressing a synthetic CAR and overexpressing c-Jun, are also subject to review and oversight by an institutional biosafety committee (IBC), a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment. While the NIH guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. Although the FDA decides whether trials of cell therapies that involve genetic engineering may proceed, the review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical trial, even if the FDA has reviewed the trial and approved its initiation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual or perceived safety issues, including adoption of new therapeutics or novel approaches to treatment, may adversely influence the willingness of subjects to participate in clinical trials, or if approved by applicable regulatory authorities, of physicians to subscribe to the novel treatment mechanics. The FDA or other comparable foreign regulatory authorities may ask for specific post-marketing requirements, and additional information informing benefits or risks of our products may emerge at any time prior to or after regulatory approval.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physicians, hospitals and third-party payors often are slow to adopt new products, technologies and treatment practices that require additional upfront costs and training. Physicians may not be willing to undergo training to adopt this novel therapy, may decide the therapy is too complex to adopt without appropriate training or not cost-efficient and may choose not to administer the therapy. Based on these and other factors, hospitals and payors may decide that the benefits of this new therapy do not or will not outweigh its costs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of research, nonclinical studies or earlier clinical trials are not necessarily predictive of future results. Any product candidate we advance into clinical trials may not have favorable results in later clinical trials or receive regulatory approval.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Success in research, nonclinical studies and early clinical trials does not ensure that later clinical trials will generate similar results and otherwise provide adequate data to demonstrate the efficacy and safety of an investigational product. Likewise, a number of companies in the pharmaceutical and biotechnology industries, including those with greater resources and experience than us, have suffered significant setbacks in late-stage clinical trials, even after seeing promising results in earlier nonclinical studies or clinical trials. Thus, even if the results from our initial research and nonclinical activities appear positive, we do not know whether subsequent late-stage clinical trials we may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market any product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, final study results may not be consistent with interim study results. If later-stage clinical trials do not produce favorable results, our ability to achieve regulatory approval for any of our product candidates may be adversely impacted. Even if we believe that we have adequate data to support an application for regulatory approval to market any of our product candidates, the FDA or other regulatory authorities may not agree and may require that we conduct additional clinical trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical development involves a lengthy and expensive process with an uncertain outcome.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in the first phase of clinical development of our product candidates. Besides LYL797 and LYL845, which are in Phase 1 clinical development, our other proprietary product candidates are currently in preclinical development. The risk of failure of our product candidates is high. The clinical trials and manufacturing of our product candidates are, and the manufacturing and marketing of our products, if approved, will be subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in other countries where we intend to test and market our product candidates. Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive nonclinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication. In particular, because our product candidates are subject to regulation as biological products, we will need to demonstrate that they are safe, pure and potent for use in their target indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical testing that will be required for any product candidates we choose to advance is expensive and can take many years to complete, and its outcome is inherently uncertain. The FDA may not clear the IND applications for any planned clinical trials. Even if cleared by the FDA and initiated, we cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. Failure can occur at any time during the clinical trial process. Even if our current and planned clinical trials are completed as planned, we cannot be certain that their results will support the safety and effectiveness of our product candidates for their targeted indications or support continued clinical development of such product candidates. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through nonclinical and clinical trials.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if such trials are successfully completed, we cannot guarantee that the FDA or comparable foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. Moreover, results acceptable to support approval in one jurisdiction may be deemed inadequate by another regulatory authority to support regulatory approval in that other jurisdiction. To the extent that the results of the trials are not satisfactory to the FDA or comparable foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not fully enrolled or completed any clinical trials required for the approval of our product candidates. We may experience delays in initiating, enrolling or conducting our current and planned clinical trials, and we do not know whether clinical trials will begin or enroll subjects on time, will need to be redesigned, will achieve expected enrollment rates or will be completed on schedule, if at all. Identifying candidate patients with ROR1+ tumors for the LYL797 clinical study and obtaining sufficient and specific tumor tissues for the LYL845 clinical study is necessary to support our Phase 1 clinical trials. Our inability to identify candidates with ROR1+ tumors or obtain specific tumor tissues or sufficient amounts of tumor tissues in a timely manner or at all could delay or preclude our ability to execute and complete the clinical trials. There can be no assurance that the FDA or comparable foreign regulatory authorities will not put clinical trials of any of our product candidates on clinical hold in the future. Clinical trials can be delayed, suspended or terminated for a variety of reasons, including in connection with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">inability to generate sufficient nonclinical, toxicology or other in vivo or in vitro data to support the initiation of clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for advanced clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays in reaching agreement with the FDA or other regulatory authorities, including comparable foreign regulatory authorities, as to the design or implementation of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">obtaining regulatory authorization to commence a clinical trial;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">reaching an agreement on acceptable terms with clinical trial sites or prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different clinical trial sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">obtaining IRB approval at each trial site or positive ethics committees opinions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">recruiting suitable patients to participate in a clinical trial;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">having patients complete a clinical trial or return for post-treatment follow-up;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">inspections of clinical trial sites or operations by applicable regulatory authorities, or the imposition of a clinical hold;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">clinical sites, CROs or other third parties deviating from trial protocol or dropping out of a trial;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">failure to perform in accordance with applicable regulatory requirements, including the FDA&#8217;s and comparable foreign regulatory authorities&#8217; GCP requirements, or other applicable regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">addressing patient safety concerns that arise during the course of a trial, including occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">adding a sufficient number of clinical trial sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">manufacturing sufficient quantities of product candidates for use in clinical trials; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">suspensions or terminations by IRBs or ethics committees of the institutions at which such trials are being conducted, by the Data Safety Monitoring Committee for such trial or by the FDA or other regulatory authorities, including comparable foreign regulatory authorities, due to a number of factors, including those described above.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, a clinical trial may be suspended or terminated by us, the IRBs or ethics committees for the institutions in which such trials are being conducted, the Data Safety Monitoring Committee for such trial or the FDA or other regulatory authorities, including comparable foreign regulatory authorities, due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities, including comparable foreign regulatory authorities, resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict with any certainty whether or when we might complete a given clinical trial, if at all. If we experience delays or quality issues in the conduct, completion or termination of any clinical trial of our product candidates, the approval and commercial prospects of such product candidate will be harmed, and our ability to generate product revenues from such product candidate will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following any regulatory approval. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authority. As a result of safety or toxicity issues that we may experience in our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials, we may not continue the development of nor receive approval to market any product candidates, which could prevent us from ever generating product revenues or achieving profitability. For example, previous clinical trials utilizing CAR T cells to treat hematologic tumors have shown an increased risk of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, and approved CAR T products carry a boxed warning concerning the risk of developing secondary T cell malignancies. Adverse events may also be associated with the lymphodepletion or IL-2 regimen utilized with cellular therapies. Additionally, ROR1 is expressed on a number of normal tissues. As a result, ROR1 could cause on-target, off-tumor toxicity. c-Jun is also potentially an oncogene and could cause healthy cells to transform into malignant cells. Results of our trials could reveal an unacceptably high severity and incidence of side effects, or side effects outweighing the benefits of our product candidates. In such an event, our trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development or deny approval of our product candidates for any or all targeted indications. The side effects experienced could affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that any of our product candidates receives regulatory approval and we or others later identify undesirable or unacceptable side effects caused by such products, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulatory authorities may withdraw or limit approvals of such products and require us to take our approved product off the market;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies, or issue other communications containing warnings or other safety information about the product;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulatory authorities may require a medication guide outlining the risks of such side effects for distribution to patients, or that we implement a risk evaluation and mitigation strategy (REMS) plan or risk management plan to ensure that the benefits of the product outweigh its risks;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may be required to change the dose or the way the product is administered, conduct additional clinical trials or change the labeling of the product;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may be subject to limitations on how we may promote or manufacture the product;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">sales of the product may decrease significantly;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may be subject to litigation or product liability claims; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our reputation may suffer.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of any products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, topline or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available or as we make changes to our manufacturing processes and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose interim, topline or preliminary data from our nonclinical studies and clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. Further, modifications or improvements to our manufacturing processes for a therapy may result in changes to the characteristics or behavior of the product candidate that could cause our product candidates to perform differently and affect the results of our ongoing clinical trials. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also disclose preliminary or interim data from our nonclinical studies and clinical trials. Preliminary or interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Additionally, disclosure of preliminary or interim data by us or by our competitors could result in volatility in the price of our common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate and our company in general. If the interim, topline or preliminary data we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, any of our potential product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA and comparable foreign regulatory approval processes are lengthy, time-consuming and inherently unpredictable. If we are not able to obtain required regulatory approvals of our product candidates, our business will be substantially harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the novel nature of our product candidates to create challenges in obtaining regulatory approval. For example, the FDA has limited experience with commercial development of T-cell therapies for cancer. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to obtaining approval to commercialize any drug product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe, pure and potent for their intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities may also require us to conduct additional nonclinical studies or clinical trials for our product candidates either prior to or after approval, or it may object to elements of our clinical development programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates could fail to receive regulatory approval for many reasons, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the large number of products in development, only a small percentage successfully complete the FDA or comparable foreign regulatory approval processes and are commercialized. The lengthy approval and marketing authorization process as well as the unpredictability of clinical trial results may result in our failing to obtain regulatory approval and marketing authorization to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter delays if physicians experience unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles, including treatments offered by our competitors if they obtain FDA approval before us in the same therapeutic areas as our product candidates. For example, enrollment in clinical trials of LYL845 for melanoma may be adversely impacted by the commercial availability of lifileucel, a TIL therapy that was approved by the FDA in February 2024 for the treatment of melanoma. Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or a regulatory authority </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of the marketing application we submit. Any such delay or rejection could prevent or delay us from commercializing our current or future product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our product candidates obtain regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, testing, labeling, packaging, distribution, import, export, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs for any clinical trials that we conduct post-approval, all of which may result in significant expense and limit our ability to commercialize such products. In addition, any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase&#160;4 clinical trials, and surveillance to monitor the safety and efficacy of the product if approved.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations and requirements, as well as, for the manufacture of certain of our product candidates, the FDA&#8217;s cGTPs for the use of human cellular and tissue products to prevent the introduction, transmission or spread of communicable diseases. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMPs, cGTPs and adherence to commitments made in any approved marketing application. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, quality control and distribution.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there are changes in the application of legislation or regulatory policies, or if problems are discovered with a product or our manufacture of a product, or if we or one of our distributors, licensees or co-marketers fails to comply with regulatory requirements, the regulators could take various actions. These include issuing warning letters or untitled letters, imposing fines on us, imposing restrictions on the product or its manufacture and requiring us to recall or remove the product from the market. The regulators could also suspend or withdraw our marketing authorizations, requiring us to conduct additional clinical trials, change our product labeling or submit additional applications for marketing authorization. If any of these events occurs, our ability to sell such product may be impaired, and we may incur substantial additional expense to comply with regulatory requirements, which could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we have any product candidate approved, our product labeling, advertising and promotion will be subject to regulatory requirements and continuing regulatory review. In the United States, the FDA and the Federal Trade Commission (FTC) strictly regulate the promotional claims that may be made about pharmaceutical products to ensure that any claims about such products are consistent with regulatory approvals, not misleading or false in any particular way and adequately substantiated by clinical data. The promotion of a drug product in a manner that is false, misleading, unsubstantiated or for unapproved (or off-label) uses may result in enforcement letters, inquiries and investigations and civil and criminal sanctions by the FDA, FTC and other regulatory authorities. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The FDA and other agencies and comparable foreign regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions and may result in false claims litigation under federal and state statutes, which can lead to consent decrees, civil monetary penalties, restitution, criminal fines and imprisonment, and exclusion from participation in Medicare, Medicaid and other federal and state healthcare programs. The federal government has </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The government has also required that companies enter into consent decrees and/or imposed permanent injunctions under which specified promotional conduct is changed or curtailed. Equivalent requirements and penalties are provided in the EU both at the EU level and at the national level in individual EU Member States.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a regulatory authority discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory authority may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory authority or enforcement authority may, among other things:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">issue warning letters;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">issue, or require us to issue, safety-related communications, such as safety alerts, field alerts, &#8220;Dear Doctor&#8221; letters to healthcare professionals, or import alerts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">impose civil or criminal penalties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">suspend, limit, vary or withdraw regulatory approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">suspend, vary or terminate any of our nonclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">refuse to approve pending applications or supplements to approved applications submitted by us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">impose restrictions on our operations, including closing our and our contract manufacturers&#8217; facilities; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">seize or detain products, refuse to permit the import or export of products, or require us to conduct a product recall.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products, if approved. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the policies of the FDA and of comparable foreign regulatory authorities may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, during the Trump administration several executive actions were taken, including the issuance of a number of Executive Orders, that imposed significant burdens on, or otherwise delayed, the FDA&#8217;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance and review and approval of marketing applications. It is difficult to predict how similar orders in the future would be implemented and the extent to which they would impact the FDA&#8217;s ability to exercise its regulatory authority. If executive actions are taken that impose restrictions on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have received Orphan Drug Designation (ODD) for LYL845 in the United States, and we may seek ODD in other regions or indications in the future, or for other product candidates. We may not be able to obtain or maintain ODD for any product candidates, and we may be unable to take advantage of the benefits associated with ODD, including the potential for market exclusivity. If our competitors are able to obtain orphan drug exclusivity for products that constitute the same drug and treat the same indications as our lead compounds before us, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product as an orphan product if it is intended to treat a rare disease or condition, which is generally defined as a diagnosed patient population of fewer than 200,000 individuals in the United States, or a patient population of greater than 200,000 individuals in the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States, but for which there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received ODD from the FDA for LYL845 for the treatment of stage IIB-IV melanoma; however, we may not be able to maintain this status. There can be no assurance that the FDA or other comparable foreign regulatory authorities will grant ODD for LYL845 to treat any other condition for which we may apply. We may also seek similar orphan designation for LYL845 for the treatment of stage IIB-IV melanoma outside the United States and for other and future product candidates, and we may be unsuccessful in obtaining this designation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, orphan designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product candidate that has ODD subsequently receives the first FDA approval for the disease for which it has such designation, it is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. More than one product may be approved by the FDA for the same orphan indication or disease, as long as the products are different drugs. The failure to successfully obtain orphan drug market exclusivity would adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to obtain any future ODDs that we apply for and receiving ODDs does not guarantee that we will be able to successfully develop our product candidates. There is no guarantee that we will be able to maintain any ODDs that we receive. ODDs may be revoked if the FDA finds that the request for designation contained an untrue statement of a material fact or omitted material information, or if the FDA finds that the product candidate was not eligible for designation at the time of the submission of the request. Moreover, even if we were able to receive and maintain ODDs, we may ultimately not receive any period of regulatory exclusivity if our product candidates are approved. For example, we may not receive orphan product regulatory exclusivity if the indication for which we receive FDA regulatory approval is different than the ODD. ODD exclusivity may be lost if we are unable to assure a sufficient quantity of the product to meet the needs of patients with the rare disease or condition. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain orphan exclusivity for any of our current or future product candidates, that exclusivity may not effectively protect the product candidate, if approved, from competition as different products can be approved for the same condition or products that are the same as ours can be approved for different conditions. Even after an orphan product is approved, the FDA can also subsequently approve a product containing the same principal molecular features for the same condition if the regulatory authority concludes that the latter product is clinically superior by means of greater effectiveness, greater safety or providing a major contribution to patient care. If another sponsor receives approval for such product before we do, we would be prevented from launching our product for the orphan indication during the period of marketing exclusivity unless we can demonstrate clinical superiority.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ODD neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. While we may seek ODD for LYL845 for other indications or for any future product candidates for applicable indications, we may never receive such designations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to applicable fraud and abuse, including anti-kickback and false claims, transparency, health information privacy and security and other healthcare laws. Failure to comply with such laws, may result in substantial penalties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to broadly applicable healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we conduct research, market, sell and distribute any product candidates for which we obtain marketing approval. The healthcare laws that may affect us include: the federal fraud and abuse laws, including the federal anti-kickback, and false claims and civil monetary penalties laws; federal data privacy and security laws, including the Health Insurance Portability and Accountability Act, as amended by the Health Information Technology for Economic and Clinical Health Act (as amended, HIPAA); and federal transparency laws related to ownership and investment interests and payments and/or other transfers of value made to or held by physicians (including doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members. In addition, many states have similar laws and regulations that may differ from each other and federal law in significant ways, thus complicating compliance efforts. Moreover, several states require biopharmaceutical companies to comply with the biopharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. Additionally, some state and local laws require the registration of biopharmaceutical sales representatives in the jurisdiction. Similar requirements are applicable in foreign countries. Outside the United States, interactions between pharmaceutical companies and healthcare professionals are also governed by strict laws, such as </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">national anti-bribery laws of European countries, national sunshine rules, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians and other healthcare providers, some of whom are compensated in the form of stock options for consulting services provided, may not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, disgorgement, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid or comparable foreign programs, additional reporting requirements and/or oversight if a corporate integrity agreement or similar agreement is executed to resolve allegations of non-compliance with these laws and the curtailment or restructuring of operations. In addition, violations may also result in reputational harm, diminished profits and lower future earnings. For additional detail on healthcare laws that may affect our business, see &#8220;Other Healthcare Laws&#8221; in the business section of our Annual Report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in healthcare policies, laws and regulations may impact our ability to obtain approval for, or commercialize our product candidates, if approved.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions there have been, and continue to be, several legislative and regulatory changes and proposed reforms of the healthcare system in an effort to contain costs, improve quality and expand access to care. In the United States, there have been and continue to be a number of healthcare-related legislative initiatives, as well as executive, judicial and Congressional challenges to existing healthcare laws that have significantly affected, and could continue to significantly affect, the healthcare industry. For example, there have been efforts to repeal, substantially modify or invalidate some or all of the provisions of the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the ACA), some of which have been successful. While the U.S. Supreme Court dismissed in June 2021 a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress, such efforts may continue. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there continues to be heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. presidential executive orders, Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs and review the relationship between pricing and manufacturer patient programs. For example, President Biden issued an executive order in July 2021 supporting legislation to enact drug pricing reforms and, in response, the U.S. Department of Health and Human Services (HHS) released a Comprehensive Plan for Addressing High Drug Prices in September 2021 with specific legislative and administrative policies that Congress could enact to help improve affordability of, and access to, prescription drugs. Further, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (IRA) into law, which among other things: (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law, and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. Additionally, the IRA also extends enhanced subsidies for individuals purchasing health insurance coverage in the ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented. These provisions started taking effect progressively in fiscal year 2023, although the Medicare drug price negotiation program is currently subject to legal challenges. It is currently unclear how the IRA will be effectuated, but it is likely to have a significant impact on the pharmaceutical industry. Further, in response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the Centers for Medicare and Medicaid Services (CMS) Innovation Center, which will be evaluated on their ability to lower the cost of drugs, promote accessibility and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act of 1980 (Bayh-Dole Act). On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights that for the first time includes the price of a product as one factor an agency can use when </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. For additional detail on healthcare reform that may affect our business, see &#8220;Healthcare Reform&#8221; in the business section of our Annual Report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as our product candidates, assuming FDA approval. Our ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our product candidates. Our cell therapies are novel and may require additional education and support to achieve reimbursement, if at all.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a payor-by-payor basis. Reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that a procedure is safe, effective and medically necessary; appropriate for the specific patient; cost effective; supported by peer-reviewed medical journals; included in clinical practice guidelines; and neither cosmetic, experimental, nor investigational. Assuming we obtain coverage for our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the EU or elsewhere will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future. Additionally, we or our collaborators may develop companion diagnostic tests for use with our product candidates. We or our collaborators will be required to fulfill applicable regulatory requirements for companion diagnostic testing and to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we may seek for our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, a significant trend in the healthcare industry is cost containment. Governmental authorities have announced initiatives to control the cost of prescription drugs through the use of march-in rights under the Bayh-Dole Act, and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. For additional detail on healthcare reform that may affect our cost containment, see &#8220;Healthcare Reform&#8221; in the business section of our Annual Report. As such, cost containment reform efforts may result in an adverse effect on our operations. Obtaining coverage and adequate reimbursement for our product candidates may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Similarly, because our product candidates will be physician-administered, separate reimbursement for the product itself may or may not be available. Instead, the administering physician may or may not be reimbursed for providing the treatment or procedure in which our product is used.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA and other government agencies or comparable foreign regulatory authorities caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA and comparable foreign regulatory authorities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to review and approve new products can be affected by a variety of factors, including, as applicable, government budget and funding levels, statutory, regulatory, and policy changes, the authority&#8217;s ability to hire and retain key personnel and accept the payment of user fees and other events that may otherwise affect the authority&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of the FDA and other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies and authorities may also slow the time necessary for new biologics or modifications to be cleared or approved biologics to be reviewed and/or approved, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times, and certain regulatory agencies, such as the FDA, have had to furlough FDA employees and stop critical activities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a prolonged government shutdown occurs, or if the FDA or other regulatory authorities are prevented from conducting their regular inspections, reviews or other regulatory activities for any reason, it could significantly impact the ability of the FDA or other regulatory authorities, including comparable foreign regulatory authorities, to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div id="i9c884009163249728202a1a7baf43489_157"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We, and our partners and vendors, are subject to stringent and evolving United States and foreign laws, regulations and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions, litigation (including class claims) and mass arbitration demands, fines and penalties, disruptions of our business operations, reputational harm, loss of revenue or profits and other adverse business consequences.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, and our partners and vendors, including CROs, collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit and share (collectively, process) personal data and other sensitive information (collectively, sensitive data) in connection with the operations of our business, such as storage or otherwise processing sensitive data to support the conduct of our clinical trials. These processing activities subject us, and our partners and vendors, to various federal, state, local and foreign data privacy and security laws, regulations, guidance and industry standards and may be subject to external and internal privacy and security policies, contractual requirements and other obligations relating to data privacy and security. If we fail to comply with applicable requirements for processing sensitive data, including in connection with the development of our product candidates or otherwise, or if a partner or vendor fails to comply with the same or misuses sensitive data we provide to it, we may be subject to litigation, regulatory investigations, enforcement actions, fines and criminal or civil penalties, mass arbitration demands, additional reporting requirements and/or oversight, bans on processing personal data and orders to destroy or not use personal data, as well as negative publicity, reputational harm and other adverse business consequences.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, our and our partners&#8217; and vendors&#8217; operations are subject to numerous federal and state laws and regulations, including state data breach notification laws and federal and state data privacy laws and regulations that govern the collection, use, disclosure and protection of health information and other personal data, including information of our employees. For example, HIPAA imposes specific requirements relating to the privacy, security and transmission of individually identifiable protected health information, and we could potentially face substantial criminal or civil penalties if we knowingly receive protected health information from a HIPAA&#8209;covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of such health information, or otherwise violate applicable HIPAA requirements related to the protection of such information. Even when HIPAA does not apply, failure to take appropriate steps to keep consumers&#8217; personal data secure may constitute a violation of the Federal Trade Commission Act and other similar laws (e.g., wiretapping laws).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past few years, numerous U.S. states&#8212;including California, Virginia, Colorado, Connecticut and Utah&#8212;have enacted comprehensive data privacy and security laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct or delete certain personal data and to opt&#8209;out of certain data processing activities. The exercise of these rights may impact our business and ability to advance our product candidates effectively. Certain states also impose more stringent requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020 (CPRA) (collectively, CCPA), applies to personal data of consumers, business representatives and employees who are California residents and requires businesses to provide specific disclosures in privacy notices and honor requests of such individuals to exercise certain privacy rights. The CCPA provides for fines of up to $7,500 per intentional violation and allows private litigants affected by certain data breaches to recover significant statutory damages. Although the CCPA exempts some data processed in the context of clinical trials, the CCPA increases compliance costs and potential liability.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future. These state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to confidential, sensitive and personal data than federal, international or other state laws, and such laws may differ from each other and have potentially conflicting requirements that would make compliance challenging, require us to expend significant resources achieve compliance and restrict our ability to process certain sensitive and personal data.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, an increasing number of laws, regulations and industry standards may govern data privacy and security. For example, the European Union&#8217;s General Data Protection Regulation and the United Kingdom&#8217;s GDPR impose strict requirements for processing personal data.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any clinical trial programs, including related regulatory filings, and research collaborations that we engage in outside the United States in the future may implicate international laws and regulations concerning data protection and privacy, including those governing various aspects of clinical research in the EU and the UK. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to data privacy and security laws, we are or may become contractually subject to industry standards adopted by industry groups. We are also bound by other contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that we will need to expend significant capital and other resources to ensure ongoing compliance with applicable data privacy and security laws. Claims that we have violated individuals&#8217; privacy rights or breached our contractual obligations related to data privacy and security, even if we are not found liable, could be expensive and time&#8209;consuming to defend and could result in negative publicity that could harm our business. Moreover, even if we take all necessary action to comply with legal and regulatory requirements, we could be subject to a data breach or other unauthorized access of sensitive data, which could subject us to fines and penalties, as well as litigation and reputational damage. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business or financial condition, including but not limited to delays in the development of our product candidates due to inability to process personal data or to operate in certain jurisdictions, limited ability to develop or commercialize our products, expenditure of time and resources to defend any claim or inquiry, adverse publicity or substantial changes to our planned candidate pipeline development and business operations. If we fail to keep apprised of and comply with applicable international, federal, state or local regulatory requirements and changes thereto, we could be subject to a range of regulatory actions that could affect our or any vendors&#8217; or partners&#8217; ability to seek to commercialize our product candidates. Any threatened or actual government enforcement action, or litigation when private rights of action are available, could also generate negative publicity, damage our reputation, result in liabilities, fines and adverse business consequences and require that we devote substantial resources that could otherwise be used in support of other aspects of our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our ability to commercialize our product candidates successfully and to compete effectively may be adversely affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon a combination of patents, trademarks, trade secrets and confidentiality agreements to protect the intellectual property related to our technology and product candidates. We own or possess certain intellectual property, and other intellectual property are owned or possessed by our partners and are in-licensed to us. When we refer to &#8220;our&#8221; technologies, inventions, patents, patent applications or other intellectual property rights, we are referring to both the rights that we own or possess as well as those that we in-license, many of which are critical to our intellectual property protection and our business. If the intellectual property that we rely on is not adequately protected, competitors may be able to use our technologies and erode or negate any competitive advantage we may have.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patentability of inventions and the validity, enforceability and scope of patents in the biotechnology field is uncertain because it involves complex legal, scientific and factual considerations, and it has in recent years been the subject of significant litigation. Moreover, the standards applied by the U.S. Patent and Trademark Office (USPTO) and non-U.S. patent offices in granting patents are not always applied uniformly or predictably. There is also no assurance that all potentially relevant prior art relating to our patents and patent applications is known to us or has been found in the instances where searching was done. We may be unaware of prior art that could be used to invalidate an issued patent or prevent a pending patent application from issuing as a patent. There also may be prior art of which we are aware, but which we do not believe affects the validity, enforceability or patentability of a claim of one of our patents or patent applications, which may, nonetheless, ultimately be found to affect the validity, enforceability or patentability of such claim. As a consequence of these and other factors, our patent applications may fail to result in issued patents with claims that cover our product candidates in the United States or in other countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if patents have issued or do successfully issue from patent applications, and even if these patents cover our product candidates, third parties may challenge the validity, enforceability or scope thereof, which may result in these patents being narrowed, invalidated or held to be unenforceable. No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable. Even if unchallenged, our patents and patent applications or other intellectual property rights may not adequately protect our intellectual property, provide exclusivity for our product candidates or prevent others from designing around our claims. The possibility exists that others will develop products on an independent basis which have the same effect as our product candidates and which do not infringe our patents or other </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intellectual property rights, or that others will design around the claims of patents that we have had issued that cover our product candidates. If the breadth or strength of protection provided by our patents and patent applications with respect to our product candidates is threatened, it could jeopardize our ability to commercialize our product candidates and dissuade companies from collaborating with us.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also desire to seek licenses from third parties who own or have rights to intellectual property that may be useful for providing exclusivity for our product candidates, or for providing the ability to develop and commercialize a product candidate in an unrestricted manner. There is no guarantee that we will be able to obtain such licenses from third parties on commercially reasonable terms, or at all.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the USPTO and various foreign governmental or inter-governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during and after the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete, irreversible loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market, which could have a material adverse effect on our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States patent applications containing or that at any time contained a claim not entitled to a priority date before March&#160;16, 2013 are subject to the &#8220;first to file&#8221; system implemented by the America Invents Act (2011). The first to file system requires us to be cognizant going forward of the time from invention to filing of a patent application. Because patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our partners were the first to file any patent application related to a product candidate.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our registered or unregistered trademarks or trade names may be challenged, infringed or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we view as valuable to building name recognition among potential partners and customers in our markets of interest. At times, competitors or other third parties have adopted or may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion and/or litigation. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce, protect or defend our proprietary rights related to trademarks may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The lives of our patents may not be sufficient to effectively protect our products and business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first nonprovisional effective filing date. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic medications. In addition, although upon issuance in the United States a patent&#8217;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. While the patent term of certain patents can also be extended with respect to a specific product to recapture time lost in clinical trials and regulatory review by the FDA, a patent&#8217;s life also can be shortened by a terminal disclaimer over an earlier filed patent or patent application. If we do not have sufficient patent life to protect our products, our business and results of operations will be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, enforcing and defending patents on all of our product candidates in all countries throughout the world would be prohibitively expensive. Our intellectual property rights in certain countries outside the United States may be less extensive than those in the United States. In addition, the laws of certain foreign countries do not protect intellectual property rights to the same extent as laws in the United States. Consequently, we and our partners may not be able to prevent third parties from practicing our inventions in countries outside the United States, or from selling or importing infringing products made using our inventions in other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection or where we do not have exclusive rights under the relevant patents to develop their own products and, further, may export otherwise-infringing products to territories where we and our partners have patent protection but where enforcement is not as strong as that in the United States. These infringing products may compete with our product candidates in jurisdictions where we or our partners have no issued patents or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">where we do not have exclusive rights under the relevant patents, or our patent claims and other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us and our partners to stop the infringement of our patents or marketing of competing products in violation of our intellectual property rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us or our partners. We or our partners may not prevail in any lawsuits that we or our licensors initiate, and even if we or our licensors are successful, the damages or other remedies awarded, if any, may not be commercially meaningful.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, we or our partners may have limited remedies, which could materially diminish the value of such patent. If we or our partners are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are sued for infringing or misappropriating the intellectual property rights of third parties, the resulting litigation could be costly and time-consuming and could prevent or delay our development and commercialization efforts.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends, in part, on us and our partners not infringing the patents and proprietary rights of third parties. There is a substantial amount of litigation and other adversarial proceedings, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interference or derivation proceedings, oppositions, and inter partes and post-grant review proceedings before the USPTO and non-U.S. patent offices. Numerous U.S. and non-U.S. issued patents and pending patent applications owned by third parties exist in the fields in which we are developing, and may develop, product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of third parties&#8217; patent rights, as it may not always be clear to industry participants, including us, which patents cover various types of products, methods of making or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform or predictable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert infringement or misappropriation claims against us based on existing or future intellectual property rights, alleging that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacturing of our product candidates that we failed to identify. For example, patent applications covering our product candidates could have been filed by others without our knowledge, since these applications generally remain confidential for some period of time after their filing date. Even pending patent applications that have been published, including some of which we are aware, could be later amended in a manner that could cover our product candidates or their use or manufacture. In addition, we may have analyzed patents or patent applications of third parties that we believe are relevant to our activities and believe that we are free to operate in relation to any of our product candidates, but our competitors may obtain issued claims, including in patents we consider to be unrelated, which may block our efforts or potentially result in any of our product candidates or our activities infringing their claims.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our partners are sued for patent infringement, we would need to demonstrate that our product candidates, products and methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving that a patent is invalid is difficult and even if we are successful in the relevant proceedings, we may incur substantial costs, and the time and attention of our management and scientific personnel could be diverted from other activities. If one or more claims of any issued third-party patents were held by a court of competent jurisdiction to cover aspects of our materials, formulations, methods of manufacture or methods for treatment, we could be forced, including by court order, to cease developing, manufacturing or commercializing the relevant product candidate until the relevant patent expired. Alternatively, we may desire or be required to obtain a license from such third party in order to use the infringing technology and to continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonably terms, or at all. Even if we were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property licensed to us. If we are unable to obtain a necessary license on </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face claims that we misappropriated the confidential information or trade secrets of a third party. If we are found to have misappropriated a third-party&#8217;s trade secrets, we may be prevented from further using these trade secrets, which could limit our ability to develop our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defending against intellectual property claims, regardless of their merit, could be costly and time consuming, regardless of the outcome. Thus, even if we were to ultimately prevail, or to settle before a final judgment, any litigation could burden us with substantial unanticipated costs. In addition, litigation or threatened litigation could result in significant demands on the time and attention of our management team, distracting them from the pursuit of other company business. During the course of any intellectual property litigation, there could be public announcements of the results of hearings, rulings on motions and other interim proceedings in the litigation and these announcements may have negative impact on the perceived value of our product candidates, programs or intellectual property. In the event of a successful intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent, or to redesign our infringing product candidates, which may be impossible or require substantial time and monetary expenditure. In addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, and the parties making claims against us may obtain injunctive or other equitable relief, which could impose limitations on the conduct of our business. We may also elect to enter into license agreements in order to settle patent infringement claims prior to litigation, and any of these license agreements may require us to pay royalties and other fees that could be significant. As a result of all of the foregoing, any actual or threatened intellectual property claim could prevent us from developing or commercializing a product candidate or force us to cease some aspect of our business operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have in-licensed a portion of our intellectual property from our partners. If we breach any of our license agreements with these partners, we could potentially lose the ability to continue the development and potential commercialization of one or more of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hold rights under license agreements with our partners. Our discovery and development technology platforms are built, in part, around intellectual property rights in-licensed from our partners. Under our existing license agreements, we are subject to various obligations, which may include diligence obligations with respect to development and commercialization activities, payment obligations upon achievement of certain milestones and royalties on product sales. If there is any conflict, dispute, disagreement or issue of nonperformance between us and our counterparties regarding our rights or obligations under these license agreements, including any conflict, dispute or disagreement arising from our failure to satisfy diligence or payment obligations, we may be liable to pay damages and our counterparties may have a right to terminate the affected license. The termination of any license agreement with one of our partners could adversely affect our ability to utilize the intellectual property that is subject to that license agreement in our discovery and development efforts, our ability to enter into future collaboration, licensing and/or marketing agreements for one or more affected product candidates and our ability to commercialize the affected product candidates. Furthermore, disagreements under any of these license agreements may arise, including those related to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">whether and the extent to which our technology and processes may infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our right to sublicense patent and other rights to third parties under collaborative development relationships; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These disagreements may harm our relationship with the partner, which could have negative impacts on other aspects of our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presently we have rights to the intellectual property, through licenses from third parties and under patent applications that we own or will own, to develop our product candidates. Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates may also require specific formulations, manufacturing methods or technologies to work effectively and efficiently, and these rights may be held by others. We may be unable to acquire or in-license any </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms; such failure would harm our business. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies that may be more established or have greater resources than we do may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property discovered through government funded programs may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have acquired or licensed, or may require in the future, intellectual property rights that have been generated through the use of U.S. government funding or grant. Pursuant to the Bayh-Dole Act, the U.S. government has certain rights in inventions developed with government funding. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). For example, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights, which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and have an adverse effect on the success of our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may infringe our patents or misappropriate or otherwise violate our intellectual property rights. Our patent applications cannot be enforced against third parties practicing the technology claimed in these applications unless and until a patent issues from the applications, and then only to the extent the issued claims cover the technology. In the future, we or our partners may elect to initiate legal proceedings to enforce or defend our or our partners&#8217; intellectual property rights, to protect our or our partners&#8217; trade secrets or to determine the validity or scope of our intellectual property rights. Any claims that we or our partners assert against perceived infringers could also provoke these parties to assert counterclaims against us or our partners alleging that we or our partners infringe their intellectual property rights or that our intellectual property rights are invalid. In patent litigation in the United States, defendant counterclaims alleging noninfringement, invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert noninfringement, invalidity or unenforceability of a patent. The outcome following legal assertions of noninfringement, unpatentability, invalidity and unenforceability is unpredictable. With respect to the validity of patent rights, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of unpatentability, invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference, derivation or opposition proceedings provoked by third parties, brought by us or our partners, or brought by the USPTO or any non-U.S. patent authority may be necessary to determine the priority of inventions or matters of inventorship with respect to our patents or patent applications. We or our partners may also become involved in other proceedings, such as reexamination or opposition proceedings, inter partes review, post-grant review or other pre-issuance or post-grant proceedings in the USPTO or its foreign counterparts relating to our intellectual property or the intellectual property of others. Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover and protect our product candidates. An unfavorable outcome in any of these proceedings could require us or our partners to cease using the related technology and commercializing our product candidates, or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us or our partners a license on commercially reasonable terms if any license is offered at all. Even if we or our licensors obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us or our licensors. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any intellectual property proceedings can be expensive and time-consuming. Our or our partners&#8217; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our partners can. Accordingly, despite our or our partners&#8217; efforts, we or our partners may not be able to prevent third parties from infringing upon or misappropriating our intellectual property rights, particularly in countries where the laws may not protect our rights as fully as the laws in the United States. Even if we are successful in the relevant proceedings, we may incur substantial costs, and the time and attention of our management and scientific personnel could be diverted from other activities. In addition, in an infringement proceeding, a court may decide that one or more of our patents is invalid or unenforceable, in whole or in part, may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question and/or may require us to pay the other party attorneys&#8217; fees. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets and other proprietary information, the value of our technology could be adversely affected and our business could be harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and other elements of our technology, discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, including by enabling them to develop and commercialize products substantially similar to or competitive with our product candidates, thus eroding our competitive position in the market.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade secrets can be difficult to protect. We seek to protect our proprietary, confidential technology and processes, in part, by entering into confidentiality agreements and invention assignment agreements with our employees, consultants and outside scientific advisors, contractors and collaborators. These agreements are designed to protect our proprietary information. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, or outside scientific advisors might intentionally or inadvertently disclose our trade secrets or confidential, proprietary information to competitors. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, the laws of certain foreign countries do not protect proprietary rights such as trade secrets to the same extent or in the same manner as the laws of the U.S. Misappropriation or unauthorized disclosure of our trade secrets to third parties could impair our competitive advantage in the market and could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have breached non-compete or non-solicit obligations and/or wrongfully used or disclosed confidential information of third parties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise breached non-compete or non-solicit obligations with respect to such individuals&#8217; prior employers, or used or disclosed confidential information of these third parties or such individuals&#8217; former employers. Dealing with such claims and negotiating with potential claimants could result in substantial cost and be a distraction to our management and employees. In addition, litigation may be necessary to defend against these claims, and even if we are successful in defending against these claims, such litigation could result in further costs to us and distraction to our management and employees.</span></div><div id="i9c884009163249728202a1a7baf43489_160"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delaware law and provisions in our amended and restated certificate of incorporation and bylaws might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our amended and restated certificate of incorporation and bylaws may discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares of our common stock. These provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our organizational documents:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">establish that our board of directors is divided into three classes, Class&#160;I, Class&#160;II and Class&#160;III, with each class serving staggered three-year terms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">provide that our directors may be removed only for cause;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">eliminate cumulative voting in the election of directors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">authorize our board of directors to issue shares of preferred stock and determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">permit stockholders to take actions only at a duly called annual or special meeting and not by unanimous written consent;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">prohibit stockholders from calling a special meeting of stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">require that stockholders give advance notice to nominate directors or submit proposals for consideration at stockholder meetings;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">authorize our board of directors, by a majority vote, to amend certain provisions of the bylaws; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">require the affirmative vote of at least 66 2/3% or more of the outstanding shares of common stock to amend many of the provisions described above.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Section&#160;203 of the General Corporation Law of the State of Delaware (DGCL) prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, which is generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any provision of our amended and restated certificate of incorporation, amended and restated bylaws, or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">any derivative action or proceeding brought on our behalf;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees, or stockholders to us or our stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">any action asserting a claim arising pursuant to any provision of the DGCL or our amended and restated certificate of incorporation and bylaws; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">any action asserting a claim governed by the internal affairs doctrine.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, to prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation also provides that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. However, these provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Any person purchasing or otherwise acquiring or holding any interest in shares of our capital stock is deemed to have received notice of and consented to the foregoing provisions. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds more favorable for disputes with us or with our directors, officers, other employees or agents or our other stockholders, which may discourage such lawsuits against us and such other persons, or may result in additional expense to a stockholder seeking to bring a claim against us. Alternatively, if a court were to find this choice of forum provision inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal controls over financial reporting or identify additional material weaknesses in the future, we may not be able to accurately or timely report our financial condition or results of operations, which may significantly harm our business and the value of our common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal control. Section&#160;404 of the Sarbanes-Oxley Act (Section&#160;404) requires that we evaluate and determine the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. Our independent registered public accounting firm is also required to attest to the effectiveness of our internal control over financial reporting. These assessments need to include the disclosure of any material weaknesses in such internal control. A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our consolidated financial statements will not be prevented or detected on a timely basis. We and our independent auditors have previously identified a material weakness in our internal control over financial reporting, and we cannot assure you that we will not identify other material weaknesses in the future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we may not have identified all material weaknesses, and our current controls and any new controls that we develop may become inadequate because of changes in personnel or conditions in our business or otherwise. Accordingly, we cannot assure you that any future material weaknesses will not result in a material misstatement of our consolidated financial statements and/or our failure to meet our public reporting obligations. In addition, if we and/or our independent registered public accounting firm are unable to conclude that our internal control over financial reporting is effective in the future, investor confidence in the accuracy and completeness of our consolidated financial statements would be adversely affected, which could significantly harm our business and the value of our common stock. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">63</span></div></div></div><div id="i9c884009163249728202a1a7baf43489_163"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the periodic reporting requirements of the Exchange Act, and we must maintain disclosure controls and procedures designed to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement, causing us to fail to make a required related party transaction disclosure or identify a potential conflict of interest. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock has been, and may continue to be, volatile, which could result in substantial losses for investors.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock has been, and may continue to be, volatile and may fluctuate substantially as a result of a variety of factors, many of which are beyond our control. Some of the factors that may cause the market price of our common stock to fluctuate are listed below and other factors described in this &#8220;Risk Factors&#8221; section:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the timing and results of nonclinical studies and clinical trials for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">failure or discontinuation of any of our product development and research programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the success of existing or new competitive product candidates or technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">results of clinical trials or regulatory approvals of our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">commencement or termination of collaborations for our product development and research programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulatory or legal developments in the United States and other countries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the recruitment or departure of key personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">developments or disputes including those concerning patent applications, issued patents, or other proprietary rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">labor discord or disruption, geopolitical events and tensions, social unrest, war, armed conflicts and turmoil, terrorism, political instability, acts of public violence, boycotts, hostilities and social unrest and health pandemics;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the level of expenses related to any of our research programs or clinical development programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">actual or anticipated changes in our estimates as to our financial results or development timelines;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">whether our financial results, forecasts and development timelines meet the expectations of securities analysts or investors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">announcement or expectation of additional financing efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">sales of our common stock by us, our insiders, or other stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">changes in estimates or recommendations by securities analysts, if any, that cover our stock;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">market conditions in the healthcare sector;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">general economic, industry and market conditions beyond our control, such as inflationary pressures, the interest rate environment, labor shortages and supply chain constraints, instability in the banking industry and other macroeconomic factors and associated economic downturn; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, stock markets in general, and the market for biotechnology companies in particular, have experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors have affected and may seriously affect the market price of our common stock, regardless of our actual operating performance. Following periods of such volatility in the market price of a company&#8217;s securities, securities class </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">action litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&#8217;s attention and resources from our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or reports about our business, or if they publish negative or neutral evaluations of our stock, the price of our stock could decline.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock relies in part on the research and reports that industry or securities analysts publish about us or our business. If one or more of the analysts covering our business initiate coverage with a neutral or sell rating or downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock by our existing stockholders could cause the price of our common stock to decline.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time, sales of a substantial number of shares of our common stock in the public market could occur, or there could be a perception in the market that the holders of a large number of shares of common stock intend to sell shares, and any such event could reduce the market price of our common stock. As of March&#160;31, 2024, we have 254,926,880 shares of common stock outstanding. Substantially all of the shares of our common stock outstanding and shares issued upon the exercise of stock options outstanding under our equity incentive plans, subject to applicable securities law restrictions, may be able to be sold in the public market. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, certain holders of shares of our common stock have rights, subject to conditions, to require us to file registration statements with the SEC covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or our products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. We, and indirectly, our stockholders, will bear the cost of issuing and servicing securities issued in any such transactions. Because our decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of any future offerings. In February 2024, we entered into a Sales Agreement pursuant to which we may offer and sell, from time to time, up to $150.0 million in shares of our common stock. To the extent that we raise additional capital through the sale of equity or debt securities, including pursuant to the Sales Agreement, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell, or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow and revenue in the future. If we raise additional funds through strategic partnerships, alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or our products, or grant licenses on terms unfavorable to us. Certain of the foregoing transactions may require us to obtain stockholder approval, which we may not be able to obtain.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future acquisitions, strategic investments, partnerships or alliances could be difficult to identify and integrate, divert the attention of management, disrupt our business, dilute stockholder value and adversely affect our operating results and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future seek to acquire or invest in businesses, products or technologies that we believe could complement or expand our technology platforms, enhance our technical capabilities, or otherwise offer growth opportunities. The pursuit of potential acquisitions or strategic investments may divert the attention of management and cause us to incur various expenses in identifying, investigating and pursuing suitable acquisitions or investments, whether or not such transactions are completed. In addition, we have only limited experience in acquiring or investing in other businesses, and we may not successfully identify desirable targets, or if we acquire additional businesses, we may not be able to integrate them effectively following the acquisition. Acquisitions could also result in dilutive issuances of equity securities or the incurrence of debt, as well as unfavorable accounting treatment and exposure to claims and disputes by third parties, including intellectual property claims. We also may not generate sufficient financial returns to offset the costs and expenses related to any acquisitions. In addition, if an acquired business fails to meet our expectations, our business, operating results and financial condition may suffer.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The requirements of being a public company require our management to devote substantial time to compliance initiatives and corporate governance practices and could divert management&#8217;s attention and strain our resources.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we incur and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. Section&#160;404, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the rules and regulations of the Securities and Exchange Commission, the listing requirements and rules of The Nasdaq Stock Market LLC and other applicable U.S. rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We continue to need to hire additional accounting, finance and other personnel in connection with our efforts to comply with the requirements of being a public company, and our management and other personnel will continue to need to devote a substantial amount of time towards maintaining compliance with these requirements. These requirements have and will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, the rules and regulations applicable to us as a public company have made it more expensive for us to obtain director and officer liability insurance. We cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the Tax Cuts and Jobs Act of 2017 (the Tax Act), the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) and the recently enacted IRA made many significant changes to the U.S. tax laws. For example, the Tax Act made broad and complex changes to the U.S. tax code, including, among other things, reducing the federal corporate tax rate. Additionally, beginning in 2022, the Tax Act required the capitalization of research and experimentation expenses (R&amp;E expenses) with amortization periods over five and fifteen years pursuant to Section 174 of the U.S. Internal Revenue Code of 1986, as amended (the Code). If the requirement to capitalize Section 174 expenditures is not modified, it may impact our effective tax rate and our cash tax liability in future years. There have been legislative proposals to repeal or defer the Section 174 R&amp;E expense capitalization rules, including legislation recently passed by the U.S. House of Representatives that would restore the deductibility of U.S. based R&amp;E expenses but not non-U.S. R&amp;E expenses, but there can be no assurance that any such legislation will ultimately be enacted. Future guidance from the U.S. Internal Revenue Service and other tax authorities with respect to any such tax legislation may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our U.S. operations and the deductibility of expenses under the Tax Act or future tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges in the current or future taxable years and could increase our future U.S. tax expense. The foregoing items, as well as any other future changes in tax laws, could have a material adverse effect on our business, cash flow, financial condition or results of operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Tax Act, as modified by the CARES Act, our net operating losses (NOLs) generated in tax years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of taxable income. There is variation in how states have responded and may continue to respond to the Tax Act and CARES Act. In addition, under Sections 382 and 383 of the Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income or taxes may be limited. We may have experienced ownership changes in the past, including as a result of our initial public offering (IPO), and may experience future ownership changes as a result of subsequent shifts in our stock ownership (some of which may be outside our control). As a result, our ability to use our pre-change NOLs and tax credits to offset post-change taxable income, if any, could be subject to limitations. Similar provisions of state tax law may also apply. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, even if we attain profitability, we may be unable to use a material portion of our NOLs and tax credits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our information technology systems or those of third parties upon which we rely, or our data, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">regulatory investigations or actions, litigation, fines and penalties, disruptions of our business operations, reputational harm and other adverse consequences.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the third parties on which we rely face a variety of evolving threats that could cause security incidents, including but not limited to social-engineering attacks (including through deep fakes, which may be increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks, credential stuffing, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, attacks enhanced or facilitated by artificial intelligence, natural disasters, fire, terrorism, war, telecommunication and electrical failures and other similar threats. Cyber-attacks, malicious internet-based activity, online and offline fraud and other similar activities threaten the confidentiality, integrity and availability of our sensitive data and information technology systems, and those of the third parties upon which we rely. Such threats are prevalent and continue to rise, are increasingly difficult to detect and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states and nation-state-supported actors. In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, ability to advance our programs, loss of sensitive data, reputational harm and diversion of funds. To the extent that any disruption or security breach results in a loss of or damage to our data or applications or inappropriate disclosure of confidential or proprietary information, we could incur liability, the further development of our product candidates could be delayed and our business could be otherwise adversely affected. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on third parties could introduce new cybersecurity risks and vulnerabilities, including supply-chain attacks, and other threats to our business operations. We rely on third-party service providers and technologies to operate critical business systems to process sensitive data in a variety of contexts, including, without limitation, cloud-based infrastructure, data center facilities, encryption and authentication technology, employee email, clinical research and development and other functions. We also rely on third-party service providers to provide other products, services or otherwise to operate our business. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their data privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have implemented security measures designed to protect against security incidents, we cannot assure you that our data protection efforts and our investment in information technology will detect all vulnerabilities on a timely basis, prevent significant breakdowns, data leakages, breaches in our systems or other cyber incidents that could have a material adverse effect upon our reputation, business, operations or financial condition. For example, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs, and the development of our product candidates could be delayed. In addition, the loss of clinical trial data for our product candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. Furthermore, significant disruptions of our internal information technology systems or security breaches could result in the loss, misappropriation and/or unauthorized access, use or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information and personal data), which could result in financial, legal, business and reputational harm to us. For example, any such event that leads to unauthorized access, use or disclosure of personal data, including personal data regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply with potentially costly federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, including expending significant resources or modifying our business practices such as our clinical trial activities, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal data, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business. We take steps designed to detect, mitigate and remediate vulnerabilities in our information systems; however, we may not detect and remediate all such vulnerabilities, including on a timely basis.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, certain data privacy and security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive data or to notify relevant stakeholders, including affected individuals, regulators and investors, of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our data privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnity provisions in various agreements potentially expose us to substantial liability for intellectual property infringement, data protection and other losses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our agreements with third parties may include indemnification provisions under which we agree to indemnify them for losses suffered or incurred as a result of claims of intellectual property infringement or other liabilities relating to or arising from our contractual obligations. Large indemnity payments could harm our business and financial condition. Although we normally contractually limit our liability with respect to such obligations, we may still incur substantial liability. Any dispute with a third party with respect to such obligations could have adverse effects on our relationship with that third party and relationships with other existing or new partners, harming our business.</span></div><div id="i9c884009163249728202a1a7baf43489_166"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i9c884009163249728202a1a7baf43489_169"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i9c884009163249728202a1a7baf43489_172"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i9c884009163249728202a1a7baf43489_175"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rule 10b5-1 Trading Plans</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2024, none of our directors or executive officers <ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-640"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-641">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-642"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-643">terminated</ix:nonNumeric></ix:nonNumeric> a Rule&#160;10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement as defined in Item 408(a) and (c) of Regulation&#160;S-K, respectively.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">68</span></div></div></div><div id="i9c884009163249728202a1a7baf43489_178"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.627%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Form</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">File Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Exhibit/<br/>Appendix<br/>Reference</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Filing<br/>Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Filed<br/>Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1806952/000119312521195237/d136326dex41.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">S-8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">333-257249</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">06/21/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1806952/000162828023037360/lyel-20230930x10qxexx32.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">001-40502</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">11/07/2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1806952/000119312521185918/d168165dex41.htm">Form of Common Stock Certificate.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">333-256470</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">06/09/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1806952/000119312521172500/d168165dex42.htm">Amended and Restated Investors' Rights Agreement, by and among the Registrant and certain of its stockholders, dated March&#160;5,&#160;2020</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">333-256470</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">05/25/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="lyel-20240331x10qxexx311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="lyel-20240331x10qxexx312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">32.1*&#171;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="lyel-20240331x10qxexx321.htm">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">XBRL Instance Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The XBRL instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr></table></div><div style="margin-bottom:1pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Filed herewith.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#171;&#160;&#160;&#160;&#160;The certification attached as Exhibit&#160;32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">69</span></div></div></div><div id="i9c884009163249728202a1a7baf43489_181"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9c884009163249728202a1a7baf43489_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:46.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.907%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Lyell Immunopharma, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Date: May&#160;6, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">/s/ CHARLES NEWTON</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Charles Newton</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Chief Financial Officer</span></div><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">(Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>lyel-20240331x10qxexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i82f2346c92c640ccbe14a1722797c1d8_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Lynn Seely, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Lyell Immunopharma, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:46.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Date&#58; May&#160;6, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#47;s&#47; LYNN SEELY</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Lynn Seely, M.D.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">President and Chief Executive Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>lyel-20240331x10qxexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i926f8b46b67847d6ac601aad64596200_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Charles Newton, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Lyell Immunopharma, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.393%"><tr><td style="width:1.0%"></td><td style="width:46.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Date&#58; May&#160;6, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#47;s&#47; CHARLES NEWTON</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Charles Newton</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>lyel-20240331x10qxexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i5970eaefef634b41b1aee9dcb7097399_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), each of the undersigned hereby certifies in her or his capacity as an officer of Lyell Immunopharma, Inc, Inc. (the&#160;&#8220;Company&#8221;), that, to the best of her or his knowledge&#58;</font></div><div style="margin-top:12pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:6.34pt">The Company&#8217;s Quarterly Report on Form 10-Q for the period ended March&#160;31, 2024, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:46.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Date&#58; May&#160;6, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#47;s&#47; LYNN SEELY</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Lynn Seely, M.D.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">President and Chief Executive Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:46.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Date&#58; May&#160;6, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#47;s&#47; CHARLES NEWTON</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Charles Newton</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Financial Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>lyel-20240331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:cc2ada24-6463-486d-8041-2176b9cca09e,g:4457644e-4c39-4c28-b3b7-d0adb2254c74-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lyel="http://lyell.com/20240331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://lyell.com/20240331">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyel-20240331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyel-20240331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyel-20240331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyel-20240331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://lyell.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://lyell.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://lyell.com/role/Organization">
        <link:definition>0000007 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://lyell.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandSuccessPaymentAgreements" roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreements">
        <link:definition>0000009 - Disclosure - License, Collaboration, and Success Payment Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecurities" roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecurities">
        <link:definition>0000010 - Disclosure - Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherInvestments" roleURI="http://lyell.com/role/OtherInvestments">
        <link:definition>0000011 - Disclosure - Other Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://lyell.com/role/FairValueMeasurements">
        <link:definition>0000012 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://lyell.com/role/Leases">
        <link:definition>0000013 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://lyell.com/role/StockholdersEquity">
        <link:definition>0000014 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation" roleURI="http://lyell.com/role/StockbasedCompensation">
        <link:definition>0000015 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://lyell.com/role/NetLossPerShare">
        <link:definition>0000016 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://lyell.com/role/CommitmentsandContingencies">
        <link:definition>0000017 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartyTransactions" roleURI="http://lyell.com/role/RelatedpartyTransactions">
        <link:definition>0000018 - Disclosure - Related-party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandSuccessPaymentAgreementsTables" roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsTables">
        <link:definition>9954472 - Disclosure - License, Collaboration, and Success Payment Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecuritiesTables" roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesTables">
        <link:definition>9954473 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://lyell.com/role/FairValueMeasurementsTables">
        <link:definition>9954474 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://lyell.com/role/LeasesTables">
        <link:definition>9954475 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationTables" roleURI="http://lyell.com/role/StockbasedCompensationTables">
        <link:definition>9954476 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartyTransactionsTables" roleURI="http://lyell.com/role/RelatedpartyTransactionsTables">
        <link:definition>9954477 - Disclosure - Related-party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails" roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails">
        <link:definition>9954478 - Disclosure - License, Collaboration, and Success Payment Agreements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails" roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails">
        <link:definition>9954479 - Disclosure - License, Collaboration, and Success Payment Agreements - Schedule of Aggregate Potential Success Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails" roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails">
        <link:definition>9954480 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Fair Value and Amortized Cost of Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecuritiesNarrativeDetails" roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails">
        <link:definition>9954481 - Disclosure - Cash Equivalents and Marketable Securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherInvestmentsDetails" roleURI="http://lyell.com/role/OtherInvestmentsDetails">
        <link:definition>9954482 - Disclosure - Other Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>9954483 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://lyell.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>9954484 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails" roleURI="http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails">
        <link:definition>9954485 - Disclosure - Fair Value Measurements - Schedule of Estimated Fair Value of Success Payment Liability Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails" roleURI="http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails">
        <link:definition>9954486 - Disclosure - Fair Value Measurements - Schedule of Changes in Estimated Fair Value of Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails" roleURI="http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails">
        <link:definition>9954487 - Disclosure - Leases - Schedule of Operating Lease Commitments Including Expected Lease Incentives to be Received (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1" roleURI="http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1">
        <link:definition>9954487 - Disclosure - Leases - Schedule of Operating Lease Commitments Including Expected Lease Incentives to be Received (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://lyell.com/role/LeasesNarrativeDetails">
        <link:definition>9954488 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://lyell.com/role/StockholdersEquityDetails">
        <link:definition>9954489 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationNarrativeDetails" roleURI="http://lyell.com/role/StockbasedCompensationNarrativeDetails">
        <link:definition>9954490 - Disclosure - Stock-based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails" roleURI="http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails">
        <link:definition>9954491 - Disclosure - Stock-based Compensation - Schedule of Stock-Based Compensation Expense by Classification (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofPerformanceSharesUnitsDetails" roleURI="http://lyell.com/role/StockbasedCompensationScheduleofPerformanceSharesUnitsDetails">
        <link:definition>9954492 - Disclosure - Stock-based Compensation - Schedule of Performance Shares Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofRestrictedStockUnitsDetails" roleURI="http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails">
        <link:definition>9954493 - Disclosure - Stock-based Compensation - Schedule of Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofStockOptionActivityDetails" roleURI="http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails">
        <link:definition>9954494 - Disclosure - Stock-based Compensation - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails" roleURI="http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails">
        <link:definition>9954495 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartyTransactionsNarrativeDetails" roleURI="http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails">
        <link:definition>9954496 - Disclosure - Related-party Transactions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails" roleURI="http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails">
        <link:definition>9954497 - Disclosure - Related-party Transactions - Schedule of Total Income Attributable to Sonoma Sublease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lyel_FairValueAdjustmentOfSuccessPaymentLiabilities" abstract="false" name="FairValueAdjustmentOfSuccessPaymentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandTwentyOneEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_SuccessPaymentLiabilitiesFairValueDisclosure" abstract="false" name="SuccessPaymentLiabilitiesFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_SuccessPaymentLiabilityMeasurementInput" abstract="false" name="SuccessPaymentLiabilityMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="lyel_FortyTimesMember" abstract="true" name="FortyTimesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" abstract="false" name="CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_TwentyTimesMember" abstract="true" name="TwentyTimesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract" abstract="true" name="CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lyel_MarketableSecuritiesNoncurrentMember" abstract="true" name="MarketableSecuritiesNoncurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lyel_TenTimesMember" abstract="true" name="TenTimesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_SignificantAccountingPoliciesPolicyTextBlock" abstract="false" name="SignificantAccountingPoliciesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="lyel_DateOfEquityModificationsDomain" abstract="true" name="DateOfEquityModificationsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" abstract="false" name="CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="lyel_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" abstract="false" name="CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract" abstract="true" name="RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" abstract="false" name="CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lyel_StanfordSuccessPaymentLiabilityMember" abstract="true" name="StanfordSuccessPaymentLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_SuccessPaymentLiabilitiesCurrent" abstract="false" name="SuccessPaymentLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_FredHutchSuccessPaymentLiabilityMember" abstract="true" name="FredHutchSuccessPaymentLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_ShareBasedPaymentArrangementPlanModificationExercisePrice" abstract="false" name="ShareBasedPaymentArrangementPlanModificationExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" abstract="false" name="CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lyel_DateOfEquityModificationsAxis" abstract="true" name="DateOfEquityModificationsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="lyel_SeriesAConvertiblePreferredStockMember" abstract="true" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_OtherInvestmentsTextBlock" abstract="false" name="OtherInvestmentsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="lyel_SouthSanFranciscoCaliforniaMember" abstract="true" name="SouthSanFranciscoCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_SaleOfStockMaximumConsiderationReceived" abstract="false" name="SaleOfStockMaximumConsiderationReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lyel_FredHutchMember" abstract="true" name="FredHutchMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum" abstract="false" name="ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="lyel_SonomaMember" abstract="true" name="SonomaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lyel_TwoThousandTwentyOneEquityIncentivePlanMember" abstract="true" name="TwoThousandTwentyOneEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary" abstract="false" name="VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lyel_ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced" abstract="false" name="ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lyel_StanfordMember" abstract="true" name="StanfordMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_TwoThousandEighteenEquityIncentivePlanMember" abstract="true" name="TwoThousandEighteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lyel_A2023Member" abstract="true" name="A2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" abstract="false" name="CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lyel_EquityMultipleDomain" abstract="true" name="EquityMultipleDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_SuccessPaymentLiabilityFairValueOfCommonStock" abstract="false" name="SuccessPaymentLiabilityFairValueOfCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="lyel_OtherInvestmentMember" abstract="true" name="OtherInvestmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" abstract="false" name="CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lyel_CowenAndCompanyLLCMember" abstract="true" name="CowenAndCompanyLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsResearchTerm" abstract="false" name="CollaborativeArrangementRightsAndObligationsResearchTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" abstract="false" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_NonCashLeaseIncomeExpense" abstract="false" name="NonCashLeaseIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_SuccessPaymentLiabilityMember" abstract="true" name="SuccessPaymentLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_MarketableSecuritiesCurrentMember" abstract="true" name="MarketableSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsResearchPayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsResearchPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_FiftyTimesMember" abstract="true" name="FiftyTimesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" abstract="false" name="CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lyel_SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds" abstract="false" name="SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lyel_EquityMultipleAxis" abstract="true" name="EquityMultipleAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="lyel_LesseeCurrentAndNonCurrentLiabilitiesTableTextBlock" abstract="false" name="LesseeCurrentAndNonCurrentLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lyel_ThirtyTimesMember" abstract="true" name="ThirtyTimesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>lyel-20240331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:cc2ada24-6463-486d-8041-2176b9cca09e,g:4457644e-4c39-4c28-b3b7-d0adb2254c74-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="lyel-20240331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://lyell.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9491b6a2-5d0d-43a7-94ee-8c3c395aa28e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_60d5595a-d77e-4e93-bded-9e5a9b7b766d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9491b6a2-5d0d-43a7-94ee-8c3c395aa28e" xlink:to="loc_us-gaap_AccountsPayableCurrent_60d5595a-d77e-4e93-bded-9e5a9b7b766d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_443ef566-bd54-4204-8e59-36068e5a39d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9491b6a2-5d0d-43a7-94ee-8c3c395aa28e" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_443ef566-bd54-4204-8e59-36068e5a39d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilitiesCurrent_35e0f92d-36d4-4acd-884f-e30c6d474468" xlink:href="lyel-20240331.xsd#lyel_SuccessPaymentLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9491b6a2-5d0d-43a7-94ee-8c3c395aa28e" xlink:to="loc_lyel_SuccessPaymentLiabilitiesCurrent_35e0f92d-36d4-4acd-884f-e30c6d474468" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_68b06b62-46a8-442e-9e85-0c9579a02685" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66cb094b-a950-4452-94bf-af1ff3c3ed27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_68b06b62-46a8-442e-9e85-0c9579a02685" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66cb094b-a950-4452-94bf-af1ff3c3ed27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_15072109-4b3a-43d2-ab24-ab74c9358b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_68b06b62-46a8-442e-9e85-0c9579a02685" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_15072109-4b3a-43d2-ab24-ab74c9358b3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_aa8c3775-5bd6-4b12-9b2e-089e2fef6a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_68b06b62-46a8-442e-9e85-0c9579a02685" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_aa8c3775-5bd6-4b12-9b2e-089e2fef6a0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d77dd301-61f4-4b46-8af9-d7f1141df108" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_10bbb9e7-6ec4-4f82-b77e-74bd05ca9dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d77dd301-61f4-4b46-8af9-d7f1141df108" xlink:to="loc_us-gaap_LiabilitiesCurrent_10bbb9e7-6ec4-4f82-b77e-74bd05ca9dbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cbc33c42-6223-4cf9-956a-b79b0675cc30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d77dd301-61f4-4b46-8af9-d7f1141df108" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cbc33c42-6223-4cf9-956a-b79b0675cc30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ea37ad08-3292-4384-99ae-ef7124a779b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d77dd301-61f4-4b46-8af9-d7f1141df108" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ea37ad08-3292-4384-99ae-ef7124a779b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5e96f1bd-1088-47ef-8413-ba89622f30fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8848ffad-d37a-4389-a62f-2677e490831b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5e96f1bd-1088-47ef-8413-ba89622f30fb" xlink:to="loc_us-gaap_AssetsCurrent_8848ffad-d37a-4389-a62f-2677e490831b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_5da33980-90b7-4faa-995c-39d81cb7f712" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5e96f1bd-1088-47ef-8413-ba89622f30fb" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_5da33980-90b7-4faa-995c-39d81cb7f712" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments_9fe1d1e1-7dab-4a96-ad4b-6937fa149ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5e96f1bd-1088-47ef-8413-ba89622f30fb" xlink:to="loc_us-gaap_OtherInvestments_9fe1d1e1-7dab-4a96-ad4b-6937fa149ecb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_49acef2d-fd41-4cc3-9b02-6c66873997fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5e96f1bd-1088-47ef-8413-ba89622f30fb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_49acef2d-fd41-4cc3-9b02-6c66873997fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_23a0476c-b064-435c-b5b9-70aba7413be6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5e96f1bd-1088-47ef-8413-ba89622f30fb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_23a0476c-b064-435c-b5b9-70aba7413be6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2fdb81a3-4b4e-4182-bdb5-3e60a8c0cf24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5e96f1bd-1088-47ef-8413-ba89622f30fb" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2fdb81a3-4b4e-4182-bdb5-3e60a8c0cf24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_d5e62507-ac5b-4e8e-8b0c-fe39e29c5caa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5e96f1bd-1088-47ef-8413-ba89622f30fb" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_d5e62507-ac5b-4e8e-8b0c-fe39e29c5caa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3f7de6a4-f576-4c99-87e1-1a5b36b76c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2fd045c0-ff1c-44cf-956c-d05d87c13e15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3f7de6a4-f576-4c99-87e1-1a5b36b76c7c" xlink:to="loc_us-gaap_PreferredStockValue_2fd045c0-ff1c-44cf-956c-d05d87c13e15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f1d6156a-df76-4e07-a4a8-d954d379f3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3f7de6a4-f576-4c99-87e1-1a5b36b76c7c" xlink:to="loc_us-gaap_CommonStockValue_f1d6156a-df76-4e07-a4a8-d954d379f3fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_90cecfb7-fef0-4b21-a10c-808cc0c702fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3f7de6a4-f576-4c99-87e1-1a5b36b76c7c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_90cecfb7-fef0-4b21-a10c-808cc0c702fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e3313278-f448-4b2c-9a4c-6f0f26720c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3f7de6a4-f576-4c99-87e1-1a5b36b76c7c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e3313278-f448-4b2c-9a4c-6f0f26720c6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ca1dd54a-7cc6-431e-929f-24cd807b2ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3f7de6a4-f576-4c99-87e1-1a5b36b76c7c" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ca1dd54a-7cc6-431e-929f-24cd807b2ad7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_79cf8f3b-1568-4071-a534-97a5fcab3cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_935daded-a7d8-4a27-8924-d1e6d6a089e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_79cf8f3b-1568-4071-a534-97a5fcab3cc8" xlink:to="loc_us-gaap_Liabilities_935daded-a7d8-4a27-8924-d1e6d6a089e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6d4c01b5-50c7-4a73-8ae7-73af904d2aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_79cf8f3b-1568-4071-a534-97a5fcab3cc8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6d4c01b5-50c7-4a73-8ae7-73af904d2aa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e8229755-8799-4b27-9e27-77b9c1bc8478" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_79cf8f3b-1568-4071-a534-97a5fcab3cc8" xlink:to="loc_us-gaap_StockholdersEquity_e8229755-8799-4b27-9e27-77b9c1bc8478" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="lyel-20240331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_042719f6-310d-4765-8f6d-67498ed73f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d9aef20e-515e-4aba-9562-50cb42b7eecb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_042719f6-310d-4765-8f6d-67498ed73f2b" xlink:to="loc_us-gaap_OperatingExpenses_d9aef20e-515e-4aba-9562-50cb42b7eecb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_adb4c6c6-307b-42bd-b7a1-364223233747" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_042719f6-310d-4765-8f6d-67498ed73f2b" xlink:to="loc_us-gaap_Revenues_adb4c6c6-307b-42bd-b7a1-364223233747" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_18562e27-f7f4-48a5-acb0-c8e6dd2f4268" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_60d89dcb-c3e7-46a3-a6d3-652be47debea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_18562e27-f7f4-48a5-acb0-c8e6dd2f4268" xlink:to="loc_us-gaap_NetIncomeLoss_60d89dcb-c3e7-46a3-a6d3-652be47debea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5fba7d78-627f-4422-b192-7e0e9da80751" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_18562e27-f7f4-48a5-acb0-c8e6dd2f4268" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5fba7d78-627f-4422-b192-7e0e9da80751" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_79ea6da4-c346-4ca5-aa8a-40fb59653ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_30a69f97-567e-4ba4-ad44-ac4e5bf4381b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_79ea6da4-c346-4ca5-aa8a-40fb59653ec2" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_30a69f97-567e-4ba4-ad44-ac4e5bf4381b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bcdbdec1-446d-4d53-b542-a7891cb14ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_79ea6da4-c346-4ca5-aa8a-40fb59653ec2" xlink:to="loc_us-gaap_OperatingIncomeLoss_bcdbdec1-446d-4d53-b542-a7891cb14ed0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d2ae9a47-5e5e-4853-8040-d14340923810" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c1b4c4cf-7151-4511-bb71-a7663f7217e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d2ae9a47-5e5e-4853-8040-d14340923810" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c1b4c4cf-7151-4511-bb71-a7663f7217e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_b4b64391-8a7f-4ed1-8372-e8fd95ccccd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d2ae9a47-5e5e-4853-8040-d14340923810" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_b4b64391-8a7f-4ed1-8372-e8fd95ccccd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_491982ab-7ad4-4213-86d1-e6097e2af760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d2ae9a47-5e5e-4853-8040-d14340923810" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_491982ab-7ad4-4213-86d1-e6097e2af760" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_17081375-211f-4ab6-aca9-14395b90a605" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f49d99f3-e2cf-4ae5-af8b-affe184ef421" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_17081375-211f-4ab6-aca9-14395b90a605" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f49d99f3-e2cf-4ae5-af8b-affe184ef421" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_d896dbdf-ea19-42e9-b778-f8f6c70468a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_17081375-211f-4ab6-aca9-14395b90a605" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_d896dbdf-ea19-42e9-b778-f8f6c70468a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_5392c59c-fe13-4b01-968e-8bbbad7b2011" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_17081375-211f-4ab6-aca9-14395b90a605" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_5392c59c-fe13-4b01-968e-8bbbad7b2011" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="lyel-20240331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1635138a-815a-414d-882e-1abf53a7d4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2e70a0be-b84a-4bbf-8d3c-d97705d7fe46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1635138a-815a-414d-882e-1abf53a7d4cc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2e70a0be-b84a-4bbf-8d3c-d97705d7fe46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_76ce4960-7b57-41b2-b956-19875ef340ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1635138a-815a-414d-882e-1abf53a7d4cc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_76ce4960-7b57-41b2-b956-19875ef340ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c462c7c8-8179-4010-b3bb-4bb6221ebf42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1635138a-815a-414d-882e-1abf53a7d4cc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c462c7c8-8179-4010-b3bb-4bb6221ebf42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4298ef59-c942-4aa4-9974-70df70fd992b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c0276b62-da33-42a6-a877-e99df09add36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4298ef59-c942-4aa4-9974-70df70fd992b" xlink:to="loc_us-gaap_ShareBasedCompensation_c0276b62-da33-42a6-a877-e99df09add36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_291979a6-729e-445f-9321-83d690b35afa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4298ef59-c942-4aa4-9974-70df70fd992b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_291979a6-729e-445f-9321-83d690b35afa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_29a37426-384f-47f1-89f9-31b5d81c88bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4298ef59-c942-4aa4-9974-70df70fd992b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_29a37426-384f-47f1-89f9-31b5d81c88bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_5122226b-4d99-49c6-b114-3a8fdfb683fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4298ef59-c942-4aa4-9974-70df70fd992b" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_5122226b-4d99-49c6-b114-3a8fdfb683fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities_301287ed-99dc-4536-87d2-56b699fbccb6" xlink:href="lyel-20240331.xsd#lyel_FairValueAdjustmentOfSuccessPaymentLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4298ef59-c942-4aa4-9974-70df70fd992b" xlink:to="loc_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities_301287ed-99dc-4536-87d2-56b699fbccb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3615640a-1d47-4e35-baa8-7448d587eaa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4298ef59-c942-4aa4-9974-70df70fd992b" xlink:to="loc_us-gaap_NetIncomeLoss_3615640a-1d47-4e35-baa8-7448d587eaa9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_47831fb8-e24a-4a3c-b5aa-b2db5b4d8a23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4298ef59-c942-4aa4-9974-70df70fd992b" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_47831fb8-e24a-4a3c-b5aa-b2db5b4d8a23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_90e3d2f1-2f12-4b18-acc4-dd45e4e52aba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4298ef59-c942-4aa4-9974-70df70fd992b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_90e3d2f1-2f12-4b18-acc4-dd45e4e52aba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f485166c-e1f0-4aac-8ee6-a094e9cf8788" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4298ef59-c942-4aa4-9974-70df70fd992b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f485166c-e1f0-4aac-8ee6-a094e9cf8788" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_NonCashLeaseIncomeExpense_012bae3c-48ed-4908-b0c4-bd581224ffd5" xlink:href="lyel-20240331.xsd#lyel_NonCashLeaseIncomeExpense"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4298ef59-c942-4aa4-9974-70df70fd992b" xlink:to="loc_lyel_NonCashLeaseIncomeExpense_012bae3c-48ed-4908-b0c4-bd581224ffd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ff42cc93-2410-4d4f-be3b-73a7bacd45d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4298ef59-c942-4aa4-9974-70df70fd992b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ff42cc93-2410-4d4f-be3b-73a7bacd45d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_55a3178e-3c7a-4cbe-b213-4a911a6dcaa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4298ef59-c942-4aa4-9974-70df70fd992b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_55a3178e-3c7a-4cbe-b213-4a911a6dcaa7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_67c1e399-d804-4089-b4a9-62ca8006e94f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4298ef59-c942-4aa4-9974-70df70fd992b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_67c1e399-d804-4089-b4a9-62ca8006e94f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f89f7b02-ff68-4d91-9772-461d8020c369" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d4358dd6-b0e8-4401-ad39-13cc4906334a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f89f7b02-ff68-4d91-9772-461d8020c369" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d4358dd6-b0e8-4401-ad39-13cc4906334a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_946575b6-1630-4f11-abee-57f2014145e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f89f7b02-ff68-4d91-9772-461d8020c369" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_946575b6-1630-4f11-abee-57f2014145e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17e31083-5fa9-4782-977c-03023859e426" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a0d85629-165a-492d-9f29-1f5be2e0b0db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17e31083-5fa9-4782-977c-03023859e426" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a0d85629-165a-492d-9f29-1f5be2e0b0db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_8802b9eb-5613-413d-b196-bebbebeac7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17e31083-5fa9-4782-977c-03023859e426" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_8802b9eb-5613-413d-b196-bebbebeac7ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c4c1a0c2-4e58-4c0f-8a2d-bfe7d288c54f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b761f04c-10ac-4aba-a682-0a46de9bedcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c4c1a0c2-4e58-4c0f-8a2d-bfe7d288c54f" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b761f04c-10ac-4aba-a682-0a46de9bedcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d94684a0-b8cb-4962-92f8-6bb242096e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c4c1a0c2-4e58-4c0f-8a2d-bfe7d288c54f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d94684a0-b8cb-4962-92f8-6bb242096e0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_24b8fb38-b834-4754-9af4-6b1237988b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c4c1a0c2-4e58-4c0f-8a2d-bfe7d288c54f" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_24b8fb38-b834-4754-9af4-6b1237988b0c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_915a62a2-446a-4ba8-8b73-34d8bcf50fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2fa0b093-c560-4eba-8dd9-8970d49ca76f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_915a62a2-446a-4ba8-8b73-34d8bcf50fd8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2fa0b093-c560-4eba-8dd9-8970d49ca76f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_61968965-6303-49b8-9579-8dfa7135ea69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_915a62a2-446a-4ba8-8b73-34d8bcf50fd8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_61968965-6303-49b8-9579-8dfa7135ea69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6fb3e036-d239-4ccc-8172-898d557a8e10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_915a62a2-446a-4ba8-8b73-34d8bcf50fd8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6fb3e036-d239-4ccc-8172-898d557a8e10" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_7c5092c2-f577-433d-b94d-f8f09ae23696" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_efa26322-9809-4ffc-ad31-fda02bcc9bb5" xlink:href="lyel-20240331.xsd#lyel_SuccessPaymentLiabilitiesFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_7c5092c2-f577-433d-b94d-f8f09ae23696" xlink:to="loc_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_efa26322-9809-4ffc-ad31-fda02bcc9bb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f249b1cf-79ac-486c-86a4-41ddfcec4666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_065ebc69-d803-47ed-9896-46f52277e217" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f249b1cf-79ac-486c-86a4-41ddfcec4666" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_065ebc69-d803-47ed-9896-46f52277e217" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c8a1e96c-eb2e-4193-8d12-48bf38b20a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f249b1cf-79ac-486c-86a4-41ddfcec4666" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c8a1e96c-eb2e-4193-8d12-48bf38b20a6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0a7341df-290f-416e-ba39-e921da0421b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f249b1cf-79ac-486c-86a4-41ddfcec4666" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0a7341df-290f-416e-ba39-e921da0421b1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"/>
  <link:calculationLink xlink:role="http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_aaba3b32-766b-4623-b4ba-60ae3dc93df9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_49788d20-2e06-49b7-b1d3-1baa0dc64499" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_aaba3b32-766b-4623-b4ba-60ae3dc93df9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_49788d20-2e06-49b7-b1d3-1baa0dc64499" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ffb082e7-91c2-4598-b060-8da2cea35a44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_aaba3b32-766b-4623-b4ba-60ae3dc93df9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ffb082e7-91c2-4598-b060-8da2cea35a44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0b24d3bd-26b4-435b-8875-af90b8ce41ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_90a82dab-242b-44e5-b3e3-9d88e686277e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0b24d3bd-26b4-435b-8875-af90b8ce41ba" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_90a82dab-242b-44e5-b3e3-9d88e686277e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4b1b9330-d14b-4e4c-b737-839daad09374" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0b24d3bd-26b4-435b-8875-af90b8ce41ba" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4b1b9330-d14b-4e4c-b737-839daad09374" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a9e86fcb-782c-425a-9705-247f0062e9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0b24d3bd-26b4-435b-8875-af90b8ce41ba" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a9e86fcb-782c-425a-9705-247f0062e9e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e8a08c69-981b-4fa6-a832-6c3de08b8947" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0b24d3bd-26b4-435b-8875-af90b8ce41ba" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e8a08c69-981b-4fa6-a832-6c3de08b8947" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_15f29793-5a26-4c32-9fec-ef0033eb80bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0b24d3bd-26b4-435b-8875-af90b8ce41ba" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_15f29793-5a26-4c32-9fec-ef0033eb80bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_18bed91c-bb21-4edd-b660-75d52fb84160" xlink:href="lyel-20240331.xsd#lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0b24d3bd-26b4-435b-8875-af90b8ce41ba" xlink:to="loc_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_18bed91c-bb21-4edd-b660-75d52fb84160" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1" xlink:type="simple" xlink:href="lyel-20240331.xsd#LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1"/>
  <link:calculationLink xlink:role="http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_58c1d6a8-6573-4bf4-bc46-795cce75513a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ff49563d-d0f4-42ca-986f-fe5e4cffbf1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_58c1d6a8-6573-4bf4-bc46-795cce75513a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ff49563d-d0f4-42ca-986f-fe5e4cffbf1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a536413b-e918-4d5b-b16b-4eef68b1fc09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_58c1d6a8-6573-4bf4-bc46-795cce75513a" xlink:to="loc_us-gaap_OperatingLeaseLiability_a536413b-e918-4d5b-b16b-4eef68b1fc09" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>lyel-20240331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:cc2ada24-6463-486d-8041-2176b9cca09e,g:4457644e-4c39-4c28-b3b7-d0adb2254c74-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="lyel-20240331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1966459c-eda8-4a15-987e-bd561a7925b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e18dbd04-5662-4360-8af7-68dc99abc399" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1966459c-eda8-4a15-987e-bd561a7925b3" xlink:to="loc_us-gaap_StatementTable_e18dbd04-5662-4360-8af7-68dc99abc399" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f7550461-3931-4677-b0a8-93f3156c45fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e18dbd04-5662-4360-8af7-68dc99abc399" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f7550461-3931-4677-b0a8-93f3156c45fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f7550461-3931-4677-b0a8-93f3156c45fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f7550461-3931-4677-b0a8-93f3156c45fa" xlink:to="loc_us-gaap_EquityComponentDomain_f7550461-3931-4677-b0a8-93f3156c45fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b4d5917f-d9b2-4772-be48-08d010ac41d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f7550461-3931-4677-b0a8-93f3156c45fa" xlink:to="loc_us-gaap_EquityComponentDomain_b4d5917f-d9b2-4772-be48-08d010ac41d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1354244d-1b50-4c0d-8550-d3ed6b55d473" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b4d5917f-d9b2-4772-be48-08d010ac41d3" xlink:to="loc_us-gaap_CommonStockMember_1354244d-1b50-4c0d-8550-d3ed6b55d473" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_142ffa7e-d00c-4b29-acc4-abf2c680af33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b4d5917f-d9b2-4772-be48-08d010ac41d3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_142ffa7e-d00c-4b29-acc4-abf2c680af33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_654b929a-26f5-4bf8-82d4-e90b47eddf83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b4d5917f-d9b2-4772-be48-08d010ac41d3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_654b929a-26f5-4bf8-82d4-e90b47eddf83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_483eafa3-c3d5-4397-b98e-83d742194de8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b4d5917f-d9b2-4772-be48-08d010ac41d3" xlink:to="loc_us-gaap_RetainedEarningsMember_483eafa3-c3d5-4397-b98e-83d742194de8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0afd4337-aa8c-49ee-aaeb-6bbbe5d2b9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1966459c-eda8-4a15-987e-bd561a7925b3" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0afd4337-aa8c-49ee-aaeb-6bbbe5d2b9c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_020fbe97-d9e9-4dbc-944f-7f00bbdddabc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0afd4337-aa8c-49ee-aaeb-6bbbe5d2b9c5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_020fbe97-d9e9-4dbc-944f-7f00bbdddabc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4d116ede-85d3-4c58-a0f1-76a5e8b527ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0afd4337-aa8c-49ee-aaeb-6bbbe5d2b9c5" xlink:to="loc_us-gaap_StockholdersEquity_4d116ede-85d3-4c58-a0f1-76a5e8b527ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b0d9174f-f79c-49fa-aee0-b25ae31069f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0afd4337-aa8c-49ee-aaeb-6bbbe5d2b9c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b0d9174f-f79c-49fa-aee0-b25ae31069f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3907685c-abce-40b6-ad39-7ef090da3593" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0afd4337-aa8c-49ee-aaeb-6bbbe5d2b9c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3907685c-abce-40b6-ad39-7ef090da3593" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_9c87b9b5-47a2-4662-8320-6eb447d18926" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0afd4337-aa8c-49ee-aaeb-6bbbe5d2b9c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_9c87b9b5-47a2-4662-8320-6eb447d18926" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_186c6148-61db-44d0-b0aa-2ebcf7d49df5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0afd4337-aa8c-49ee-aaeb-6bbbe5d2b9c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_186c6148-61db-44d0-b0aa-2ebcf7d49df5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0e50e944-e909-45a4-8f1d-eec9c1eb8414" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0afd4337-aa8c-49ee-aaeb-6bbbe5d2b9c5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0e50e944-e909-45a4-8f1d-eec9c1eb8414" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cc840dd3-6099-47aa-9310-1c14e9e70c19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0afd4337-aa8c-49ee-aaeb-6bbbe5d2b9c5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cc840dd3-6099-47aa-9310-1c14e9e70c19" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0f691d28-6950-4910-bfd9-4cc2fa78ffb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0afd4337-aa8c-49ee-aaeb-6bbbe5d2b9c5" xlink:to="loc_us-gaap_NetIncomeLoss_0f691d28-6950-4910-bfd9-4cc2fa78ffb8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b07b0558-d717-418e-aa31-e5d7f8e1b46b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8ea1862d-148a-4ab6-a0bd-37fbaaf2b17c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_38c0a282-c697-427d-891d-d018a4e6d896" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_38c0a282-c697-427d-891d-d018a4e6d896" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e9eedb7b-c1e4-4557-8b58-b85ea503751f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_38c0a282-c697-427d-891d-d018a4e6d896" xlink:to="loc_srt_CounterpartyNameAxis_e9eedb7b-c1e4-4557-8b58-b85ea503751f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9eedb7b-c1e4-4557-8b58-b85ea503751f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e9eedb7b-c1e4-4557-8b58-b85ea503751f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9eedb7b-c1e4-4557-8b58-b85ea503751f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3738b496-5174-46a1-afd2-6faf4c77c16c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e9eedb7b-c1e4-4557-8b58-b85ea503751f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3738b496-5174-46a1-afd2-6faf4c77c16c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchMember_f83fad97-a3d1-4b5c-adc8-5acb87ead47c" xlink:href="lyel-20240331.xsd#lyel_FredHutchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3738b496-5174-46a1-afd2-6faf4c77c16c" xlink:to="loc_lyel_FredHutchMember_f83fad97-a3d1-4b5c-adc8-5acb87ead47c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordMember_68ac4e31-7d53-45ea-99e7-d9c48f09749d" xlink:href="lyel-20240331.xsd#lyel_StanfordMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3738b496-5174-46a1-afd2-6faf4c77c16c" xlink:to="loc_lyel_StanfordMember_68ac4e31-7d53-45ea-99e7-d9c48f09749d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5818ff90-dc2f-4536-b621-e9f1f643fe77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_38c0a282-c697-427d-891d-d018a4e6d896" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5818ff90-dc2f-4536-b621-e9f1f643fe77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5818ff90-dc2f-4536-b621-e9f1f643fe77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5818ff90-dc2f-4536-b621-e9f1f643fe77" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5818ff90-dc2f-4536-b621-e9f1f643fe77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a32c1c8c-b5f7-465f-80f2-a2009f909a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5818ff90-dc2f-4536-b621-e9f1f643fe77" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a32c1c8c-b5f7-465f-80f2-a2009f909a6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_70c5dc62-aa7d-432b-b66f-792ba5f52ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a32c1c8c-b5f7-465f-80f2-a2009f909a6f" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_70c5dc62-aa7d-432b-b66f-792ba5f52ae1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f2350a6a-8b39-49df-baff-53e0023da604" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_38c0a282-c697-427d-891d-d018a4e6d896" xlink:to="loc_srt_RangeAxis_f2350a6a-8b39-49df-baff-53e0023da604" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f2350a6a-8b39-49df-baff-53e0023da604_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f2350a6a-8b39-49df-baff-53e0023da604" xlink:to="loc_srt_RangeMember_f2350a6a-8b39-49df-baff-53e0023da604_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fc963d0b-e5ee-468d-adb4-4600a4a9b48a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f2350a6a-8b39-49df-baff-53e0023da604" xlink:to="loc_srt_RangeMember_fc963d0b-e5ee-468d-adb4-4600a4a9b48a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d4b584f1-1103-4230-8a38-ce9ad03ecb70" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fc963d0b-e5ee-468d-adb4-4600a4a9b48a" xlink:to="loc_srt_MinimumMember_d4b584f1-1103-4230-8a38-ce9ad03ecb70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_48b5e7da-3bee-4a14-94b4-00abc011899c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fc963d0b-e5ee-468d-adb4-4600a4a9b48a" xlink:to="loc_srt_MaximumMember_48b5e7da-3bee-4a14-94b4-00abc011899c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a6f170d1-ed46-48b2-aa35-f760542acadf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_38c0a282-c697-427d-891d-d018a4e6d896" xlink:to="loc_srt_ProductOrServiceAxis_a6f170d1-ed46-48b2-aa35-f760542acadf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a6f170d1-ed46-48b2-aa35-f760542acadf_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a6f170d1-ed46-48b2-aa35-f760542acadf" xlink:to="loc_srt_ProductsAndServicesDomain_a6f170d1-ed46-48b2-aa35-f760542acadf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6f0c4663-7f92-491d-b866-d93b47559f73" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a6f170d1-ed46-48b2-aa35-f760542acadf" xlink:to="loc_srt_ProductsAndServicesDomain_6f0c4663-7f92-491d-b866-d93b47559f73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_191d0dbb-bcba-440f-aaf8-764b887fa727" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6f0c4663-7f92-491d-b866-d93b47559f73" xlink:to="loc_us-gaap_LicenseMember_191d0dbb-bcba-440f-aaf8-764b887fa727" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_971ff75f-cf37-4f6d-a116-4e5ac9f8d4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_38c0a282-c697-427d-891d-d018a4e6d896" xlink:to="loc_us-gaap_StatementClassOfStockAxis_971ff75f-cf37-4f6d-a116-4e5ac9f8d4ba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_971ff75f-cf37-4f6d-a116-4e5ac9f8d4ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_971ff75f-cf37-4f6d-a116-4e5ac9f8d4ba" xlink:to="loc_us-gaap_ClassOfStockDomain_971ff75f-cf37-4f6d-a116-4e5ac9f8d4ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_23ff01e3-cd27-409e-a439-098879f1e7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_971ff75f-cf37-4f6d-a116-4e5ac9f8d4ba" xlink:to="loc_us-gaap_ClassOfStockDomain_23ff01e3-cd27-409e-a439-098879f1e7b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SeriesAConvertiblePreferredStockMember_5e46a32f-24b0-449c-99ff-f784a4093741" xlink:href="lyel-20240331.xsd#lyel_SeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_23ff01e3-cd27-409e-a439-098879f1e7b0" xlink:to="loc_lyel_SeriesAConvertiblePreferredStockMember_5e46a32f-24b0-449c-99ff-f784a4093741" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments_dc8f8f9d-5dea-43b1-87bb-7ceaccd4c750" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments_dc8f8f9d-5dea-43b1-87bb-7ceaccd4c750" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments_066527e1-af77-470a-8247-99c46b58acf9" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsResearchPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments_066527e1-af77-470a-8247-99c46b58acf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm_f40e2e81-097f-4c86-a580-484464d3fc2f" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsResearchTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm_f40e2e81-097f-4c86-a580-484464d3fc2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f23627f9-0d2a-4df3-aef2-53429fd50b04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f23627f9-0d2a-4df3-aef2-53429fd50b04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_caa1f3f5-13e2-4d7d-a1ac-3246bd18f143" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_caa1f3f5-13e2-4d7d-a1ac-3246bd18f143" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_ade39a44-9260-4e67-b69d-2181cbbe8b57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_ade39a44-9260-4e67-b69d-2181cbbe8b57" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_759457e5-d389-4685-b914-3f8056dd2181" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_759457e5-d389-4685-b914-3f8056dd2181" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_3870d1bd-bda2-4013-8b99-95f9fe6fa1a3" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_3870d1bd-bda2-4013-8b99-95f9fe6fa1a3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm_914609ca-f7a1-4ef2-8b95-28da4abbbf56" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm_914609ca-f7a1-4ef2-8b95-28da4abbbf56" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate_437f7311-1e56-473b-ad9e-fbbd2d9a2fe2" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate_437f7311-1e56-473b-ad9e-fbbd2d9a2fe2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering_2110df4c-d4ae-46ce-8a04-9f5e60768ee2" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering_2110df4c-d4ae-46ce-8a04-9f5e60768ee2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability_8640711a-9b16-48bf-bf06-5031c8d3c819" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability_8640711a-9b16-48bf-bf06-5031c8d3c819" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_fb6c0bb3-8557-418c-af35-af047313fb5c" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_fb6c0bb3-8557-418c-af35-af047313fb5c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments_5f991c3d-b7bc-40df-bba4-b26577b25895" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments_5f991c3d-b7bc-40df-bba4-b26577b25895" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments_e3b3f16e-861a-4bc4-a934-2cc7b0e0f938" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments_e3b3f16e-861a-4bc4-a934-2cc7b0e0f938" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability_4533a3d8-5068-4e68-9edf-a53ff8684210" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability_4533a3d8-5068-4e68-9edf-a53ff8684210" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96aa59-fb2b-420c-8a7c-9a0e91d1728a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee278bd7-d00d-4592-9399-f95447ed7f20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96aa59-fb2b-420c-8a7c-9a0e91d1728a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee278bd7-d00d-4592-9399-f95447ed7f20" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e178d26d-760d-4822-85ba-de8df74845f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee278bd7-d00d-4592-9399-f95447ed7f20" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e178d26d-760d-4822-85ba-de8df74845f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e178d26d-760d-4822-85ba-de8df74845f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e178d26d-760d-4822-85ba-de8df74845f1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e178d26d-760d-4822-85ba-de8df74845f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c7d4ca2c-72bb-4a84-9fb4-0d1736704793" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e178d26d-760d-4822-85ba-de8df74845f1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c7d4ca2c-72bb-4a84-9fb4-0d1736704793" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_10b05a57-947f-4994-963a-079977bcff66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c7d4ca2c-72bb-4a84-9fb4-0d1736704793" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_10b05a57-947f-4994-963a-079977bcff66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityMultipleAxis_aac9c2a6-edca-48e3-9509-6b8358876c51" xlink:href="lyel-20240331.xsd#lyel_EquityMultipleAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee278bd7-d00d-4592-9399-f95447ed7f20" xlink:to="loc_lyel_EquityMultipleAxis_aac9c2a6-edca-48e3-9509-6b8358876c51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityMultipleDomain_aac9c2a6-edca-48e3-9509-6b8358876c51_default" xlink:href="lyel-20240331.xsd#lyel_EquityMultipleDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_lyel_EquityMultipleAxis_aac9c2a6-edca-48e3-9509-6b8358876c51" xlink:to="loc_lyel_EquityMultipleDomain_aac9c2a6-edca-48e3-9509-6b8358876c51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityMultipleDomain_d24d52e9-eed1-4158-bd11-e7913b0ed7ad" xlink:href="lyel-20240331.xsd#lyel_EquityMultipleDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_lyel_EquityMultipleAxis_aac9c2a6-edca-48e3-9509-6b8358876c51" xlink:to="loc_lyel_EquityMultipleDomain_d24d52e9-eed1-4158-bd11-e7913b0ed7ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TenTimesMember_bc26e323-e64b-4abf-badc-c91a1acbb78c" xlink:href="lyel-20240331.xsd#lyel_TenTimesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lyel_EquityMultipleDomain_d24d52e9-eed1-4158-bd11-e7913b0ed7ad" xlink:to="loc_lyel_TenTimesMember_bc26e323-e64b-4abf-badc-c91a1acbb78c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwentyTimesMember_9c80a032-1bba-4630-ba19-f2e347d6acde" xlink:href="lyel-20240331.xsd#lyel_TwentyTimesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lyel_EquityMultipleDomain_d24d52e9-eed1-4158-bd11-e7913b0ed7ad" xlink:to="loc_lyel_TwentyTimesMember_9c80a032-1bba-4630-ba19-f2e347d6acde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ThirtyTimesMember_56dc1375-0a8c-4654-ae0c-7ba90125b2fe" xlink:href="lyel-20240331.xsd#lyel_ThirtyTimesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lyel_EquityMultipleDomain_d24d52e9-eed1-4158-bd11-e7913b0ed7ad" xlink:to="loc_lyel_ThirtyTimesMember_56dc1375-0a8c-4654-ae0c-7ba90125b2fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FortyTimesMember_ae699b12-e680-4267-8033-f20ffb4fe988" xlink:href="lyel-20240331.xsd#lyel_FortyTimesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lyel_EquityMultipleDomain_d24d52e9-eed1-4158-bd11-e7913b0ed7ad" xlink:to="loc_lyel_FortyTimesMember_ae699b12-e680-4267-8033-f20ffb4fe988" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FiftyTimesMember_5d81386c-caeb-4701-af97-af9b985cc655" xlink:href="lyel-20240331.xsd#lyel_FiftyTimesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lyel_EquityMultipleDomain_d24d52e9-eed1-4158-bd11-e7913b0ed7ad" xlink:to="loc_lyel_FiftyTimesMember_5d81386c-caeb-4701-af97-af9b985cc655" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_761d7b91-11da-4a92-bb88-cbb289bc5782" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee278bd7-d00d-4592-9399-f95447ed7f20" xlink:to="loc_srt_CounterpartyNameAxis_761d7b91-11da-4a92-bb88-cbb289bc5782" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_761d7b91-11da-4a92-bb88-cbb289bc5782_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_761d7b91-11da-4a92-bb88-cbb289bc5782" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_761d7b91-11da-4a92-bb88-cbb289bc5782_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9682ee3-67f2-402e-84f2-3ba5318807b6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_761d7b91-11da-4a92-bb88-cbb289bc5782" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9682ee3-67f2-402e-84f2-3ba5318807b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchMember_10288974-aa53-4c01-9f02-1ad5bc7bb0a6" xlink:href="lyel-20240331.xsd#lyel_FredHutchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9682ee3-67f2-402e-84f2-3ba5318807b6" xlink:to="loc_lyel_FredHutchMember_10288974-aa53-4c01-9f02-1ad5bc7bb0a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordMember_8368e5fc-9df8-403f-a867-181812b8b4f8" xlink:href="lyel-20240331.xsd#lyel_StanfordMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9682ee3-67f2-402e-84f2-3ba5318807b6" xlink:to="loc_lyel_StanfordMember_8368e5fc-9df8-403f-a867-181812b8b4f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_051bb74c-2e22-404e-8dcb-6eea3ef79b60" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96aa59-fb2b-420c-8a7c-9a0e91d1728a" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_051bb74c-2e22-404e-8dcb-6eea3ef79b60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_ac42250e-41bf-41d6-9a62-c004f1a6eccb" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96aa59-fb2b-420c-8a7c-9a0e91d1728a" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_ac42250e-41bf-41d6-9a62-c004f1a6eccb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_3add3e13-ddee-4c21-b5c3-0e061dd797cb" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96aa59-fb2b-420c-8a7c-9a0e91d1728a" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_3add3e13-ddee-4c21-b5c3-0e061dd797cb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_e5637a1e-5328-4ef0-b0dc-2bbd19d0226d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_8fb53c87-ad0d-40a9-bc98-7011fdb2d5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_e5637a1e-5328-4ef0-b0dc-2bbd19d0226d" xlink:to="loc_us-gaap_MarketableSecuritiesTable_8fb53c87-ad0d-40a9-bc98-7011fdb2d5f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5eaca226-8733-4553-b091-e8c968aafc17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_8fb53c87-ad0d-40a9-bc98-7011fdb2d5f1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5eaca226-8733-4553-b091-e8c968aafc17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5eaca226-8733-4553-b091-e8c968aafc17_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5eaca226-8733-4553-b091-e8c968aafc17" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5eaca226-8733-4553-b091-e8c968aafc17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bb75b8b1-f9c3-42c8-84b5-bc666e6d4bba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5eaca226-8733-4553-b091-e8c968aafc17" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bb75b8b1-f9c3-42c8-84b5-bc666e6d4bba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b4f0c880-109b-46ca-aa46-7641457c20d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bb75b8b1-f9c3-42c8-84b5-bc666e6d4bba" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b4f0c880-109b-46ca-aa46-7641457c20d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_10f555ba-ff7c-45a0-ac12-65763b625c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bb75b8b1-f9c3-42c8-84b5-bc666e6d4bba" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_10f555ba-ff7c-45a0-ac12-65763b625c7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_544ddba9-0950-443c-b393-e739ab1b7fca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bb75b8b1-f9c3-42c8-84b5-bc666e6d4bba" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_544ddba9-0950-443c-b393-e739ab1b7fca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c31b79fc-3d72-4bcf-8cc5-07e9715c4540" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bb75b8b1-f9c3-42c8-84b5-bc666e6d4bba" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c31b79fc-3d72-4bcf-8cc5-07e9715c4540" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2b5e9cd8-31c1-4a44-b185-01ff60776861" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_8fb53c87-ad0d-40a9-bc98-7011fdb2d5f1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2b5e9cd8-31c1-4a44-b185-01ff60776861" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2b5e9cd8-31c1-4a44-b185-01ff60776861_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2b5e9cd8-31c1-4a44-b185-01ff60776861" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2b5e9cd8-31c1-4a44-b185-01ff60776861_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5c8c7089-5f58-4a03-8712-b714f997a241" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2b5e9cd8-31c1-4a44-b185-01ff60776861" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5c8c7089-5f58-4a03-8712-b714f997a241" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_f5be90a2-fde9-49c4-ad93-190763a67af3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5c8c7089-5f58-4a03-8712-b714f997a241" xlink:to="loc_us-gaap_CashEquivalentsMember_f5be90a2-fde9-49c4-ad93-190763a67af3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_MarketableSecuritiesCurrentMember_52d7e787-31da-44ca-b451-548bfd3a749a" xlink:href="lyel-20240331.xsd#lyel_MarketableSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5c8c7089-5f58-4a03-8712-b714f997a241" xlink:to="loc_lyel_MarketableSecuritiesCurrentMember_52d7e787-31da-44ca-b451-548bfd3a749a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_MarketableSecuritiesNoncurrentMember_fa7ad2c4-82b1-4554-8488-2879373ff391" xlink:href="lyel-20240331.xsd#lyel_MarketableSecuritiesNoncurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5c8c7089-5f58-4a03-8712-b714f997a241" xlink:to="loc_lyel_MarketableSecuritiesNoncurrentMember_fa7ad2c4-82b1-4554-8488-2879373ff391" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3618ba8d-33ef-4b70-81a6-cc784739fe33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_e5637a1e-5328-4ef0-b0dc-2bbd19d0226d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3618ba8d-33ef-4b70-81a6-cc784739fe33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d8c6b070-c6be-405c-8177-65ced4c8f80c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_e5637a1e-5328-4ef0-b0dc-2bbd19d0226d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d8c6b070-c6be-405c-8177-65ced4c8f80c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8b7418d0-27ab-4609-9145-ef77e67d94fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_e5637a1e-5328-4ef0-b0dc-2bbd19d0226d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8b7418d0-27ab-4609-9145-ef77e67d94fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_db81b6ed-ee0d-4832-b074-c49e6ad59197" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_e5637a1e-5328-4ef0-b0dc-2bbd19d0226d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_db81b6ed-ee0d-4832-b074-c49e6ad59197" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_99f40ed4-adde-4f71-9d2b-9baa1278a1da" xlink:href="lyel-20240331.xsd#lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_e5637a1e-5328-4ef0-b0dc-2bbd19d0226d" xlink:to="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_99f40ed4-adde-4f71-9d2b-9baa1278a1da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_792db5f9-103b-4f4d-8c59-775eb070263a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#CashEquivalentsandMarketableSecuritiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_5d53bd0f-b7f0-4ca1-98e7-58198c7aa3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_bbde30a2-af91-4da7-b60d-e923ab463652" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_5d53bd0f-b7f0-4ca1-98e7-58198c7aa3a6" xlink:to="loc_us-gaap_MarketableSecuritiesTable_bbde30a2-af91-4da7-b60d-e923ab463652" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d2c590f5-5662-4bb8-9300-63c14f700779" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_bbde30a2-af91-4da7-b60d-e923ab463652" xlink:to="loc_srt_RangeAxis_d2c590f5-5662-4bb8-9300-63c14f700779" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d2c590f5-5662-4bb8-9300-63c14f700779_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d2c590f5-5662-4bb8-9300-63c14f700779" xlink:to="loc_srt_RangeMember_d2c590f5-5662-4bb8-9300-63c14f700779_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_03c42b40-100a-4683-ac71-ae11cf641314" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d2c590f5-5662-4bb8-9300-63c14f700779" xlink:to="loc_srt_RangeMember_03c42b40-100a-4683-ac71-ae11cf641314" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_10979c1e-23eb-4b0d-bbc8-d35cbe802e9a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_03c42b40-100a-4683-ac71-ae11cf641314" xlink:to="loc_srt_MaximumMember_10979c1e-23eb-4b0d-bbc8-d35cbe802e9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_a334f936-3910-4adc-958e-7f63094940a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_5d53bd0f-b7f0-4ca1-98e7-58198c7aa3a6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_a334f936-3910-4adc-958e-7f63094940a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_68ea7fe6-ee86-4607-b9ff-e7236ad70e01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_5d53bd0f-b7f0-4ca1-98e7-58198c7aa3a6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_68ea7fe6-ee86-4607-b9ff-e7236ad70e01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_86863e3d-8e96-43a5-8501-d28850717075" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_5d53bd0f-b7f0-4ca1-98e7-58198c7aa3a6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_86863e3d-8e96-43a5-8501-d28850717075" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/OtherInvestmentsDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#OtherInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/OtherInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_347cb699-2a2f-4ea9-a2b0-e71ea42fa45b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_a9d8d630-e163-4af9-80e6-325e1551f4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_347cb699-2a2f-4ea9-a2b0-e71ea42fa45b" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_a9d8d630-e163-4af9-80e6-325e1551f4a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_58231db3-9895-4959-af09-9834d7e8967d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_a9d8d630-e163-4af9-80e6-325e1551f4a7" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_58231db3-9895-4959-af09-9834d7e8967d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_58231db3-9895-4959-af09-9834d7e8967d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_58231db3-9895-4959-af09-9834d7e8967d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_58231db3-9895-4959-af09-9834d7e8967d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_833ed8b0-9ef6-4cac-bd3e-cc82fd12b44a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_58231db3-9895-4959-af09-9834d7e8967d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_833ed8b0-9ef6-4cac-bd3e-cc82fd12b44a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_OtherInvestmentMember_af6e52f9-4a42-487e-aaca-4b2fc4d702ef" xlink:href="lyel-20240331.xsd#lyel_OtherInvestmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_833ed8b0-9ef6-4cac-bd3e-cc82fd12b44a" xlink:to="loc_lyel_OtherInvestmentMember_af6e52f9-4a42-487e-aaca-4b2fc4d702ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_7985fabd-9949-40c4-aef6-f3afdc1b73cb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_a9d8d630-e163-4af9-80e6-325e1551f4a7" xlink:to="loc_srt_ConsolidatedEntitiesAxis_7985fabd-9949-40c4-aef6-f3afdc1b73cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_7985fabd-9949-40c4-aef6-f3afdc1b73cb_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_7985fabd-9949-40c4-aef6-f3afdc1b73cb" xlink:to="loc_srt_ConsolidatedEntitiesDomain_7985fabd-9949-40c4-aef6-f3afdc1b73cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_84d79ec1-c270-4516-bff6-b1ad93717163" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_7985fabd-9949-40c4-aef6-f3afdc1b73cb" xlink:to="loc_srt_ConsolidatedEntitiesDomain_84d79ec1-c270-4516-bff6-b1ad93717163" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_2043c2f4-54b0-48a3-a90b-06256d320ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_84d79ec1-c270-4516-bff6-b1ad93717163" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_2043c2f4-54b0-48a3-a90b-06256d320ba1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments_642e8774-8a45-4530-a201-15ffe5139514" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_347cb699-2a2f-4ea9-a2b0-e71ea42fa45b" xlink:to="loc_us-gaap_OtherInvestments_642e8774-8a45-4530-a201-15ffe5139514" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_2fa0ed29-896e-493e-9c0a-5e4eefb14945" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_347cb699-2a2f-4ea9-a2b0-e71ea42fa45b" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_2fa0ed29-896e-493e-9c0a-5e4eefb14945" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary_ccc53475-7ae3-4d65-8751-f2bc5945e109" xlink:href="lyel-20240331.xsd#lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_347cb699-2a2f-4ea9-a2b0-e71ea42fa45b" xlink:to="loc_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary_ccc53475-7ae3-4d65-8751-f2bc5945e109" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_a5b045bd-8ceb-464b-96df-b89d960b7385" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_347cb699-2a2f-4ea9-a2b0-e71ea42fa45b" xlink:to="loc_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_a5b045bd-8ceb-464b-96df-b89d960b7385" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_d91fbeda-6460-4b46-b30c-19fec71291d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_347cb699-2a2f-4ea9-a2b0-e71ea42fa45b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_d91fbeda-6460-4b46-b30c-19fec71291d5" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_260b1527-1cb0-405e-94d4-1016448d25e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1ba188f-7260-41e8-89b6-8a55f800272d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_260b1527-1cb0-405e-94d4-1016448d25e2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1ba188f-7260-41e8-89b6-8a55f800272d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f5c77448-8819-4376-83b7-3bf3c214b5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1ba188f-7260-41e8-89b6-8a55f800272d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f5c77448-8819-4376-83b7-3bf3c214b5c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f5c77448-8819-4376-83b7-3bf3c214b5c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f5c77448-8819-4376-83b7-3bf3c214b5c1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f5c77448-8819-4376-83b7-3bf3c214b5c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b3123c74-a184-43ad-923e-e367c2d4c010" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f5c77448-8819-4376-83b7-3bf3c214b5c1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b3123c74-a184-43ad-923e-e367c2d4c010" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cda0e13a-836a-4899-a5d2-aeceab4e4d90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b3123c74-a184-43ad-923e-e367c2d4c010" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cda0e13a-836a-4899-a5d2-aeceab4e4d90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9b644edb-47d8-4ea5-8ba7-d2ebc655bff1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b3123c74-a184-43ad-923e-e367c2d4c010" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9b644edb-47d8-4ea5-8ba7-d2ebc655bff1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3b2d28a8-2b18-44fc-b5c6-1800601b5ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b3123c74-a184-43ad-923e-e367c2d4c010" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3b2d28a8-2b18-44fc-b5c6-1800601b5ec8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_5df7296e-1f28-4c7d-bfb1-69d6c47d7a05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1ba188f-7260-41e8-89b6-8a55f800272d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_5df7296e-1f28-4c7d-bfb1-69d6c47d7a05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5df7296e-1f28-4c7d-bfb1-69d6c47d7a05_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_5df7296e-1f28-4c7d-bfb1-69d6c47d7a05" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5df7296e-1f28-4c7d-bfb1-69d6c47d7a05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_584d5315-168e-42c8-b0a6-96ebc682a0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_5df7296e-1f28-4c7d-bfb1-69d6c47d7a05" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_584d5315-168e-42c8-b0a6-96ebc682a0b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_883f75a5-4dab-429f-aa80-ce9b9b736f02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_584d5315-168e-42c8-b0a6-96ebc682a0b6" xlink:to="loc_us-gaap_MoneyMarketFundsMember_883f75a5-4dab-429f-aa80-ce9b9b736f02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6026a6f4-9ec7-47ca-9a9f-f5de67f9d386" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1ba188f-7260-41e8-89b6-8a55f800272d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6026a6f4-9ec7-47ca-9a9f-f5de67f9d386" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6026a6f4-9ec7-47ca-9a9f-f5de67f9d386_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6026a6f4-9ec7-47ca-9a9f-f5de67f9d386" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6026a6f4-9ec7-47ca-9a9f-f5de67f9d386_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f0c8c5fa-5865-4a8f-bc92-742a755dc2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6026a6f4-9ec7-47ca-9a9f-f5de67f9d386" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f0c8c5fa-5865-4a8f-bc92-742a755dc2fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_6825857d-5e9d-48bf-8228-18e2081b4d94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f0c8c5fa-5865-4a8f-bc92-742a755dc2fa" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_6825857d-5e9d-48bf-8228-18e2081b4d94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6645c209-ee70-48a6-8f39-76939716ee60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f0c8c5fa-5865-4a8f-bc92-742a755dc2fa" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6645c209-ee70-48a6-8f39-76939716ee60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_35b408e4-00fa-4063-b743-0968158290fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f0c8c5fa-5865-4a8f-bc92-742a755dc2fa" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_35b408e4-00fa-4063-b743-0968158290fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_86708e8f-435d-4072-85ce-0d5325df5a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_260b1527-1cb0-405e-94d4-1016448d25e2" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_86708e8f-435d-4072-85ce-0d5325df5a5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c530c75a-479d-405b-8aa7-e91f7eb3ac51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_86708e8f-435d-4072-85ce-0d5325df5a5c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c530c75a-479d-405b-8aa7-e91f7eb3ac51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5b42caeb-df3d-4a4b-8329-217b30822359" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_86708e8f-435d-4072-85ce-0d5325df5a5c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5b42caeb-df3d-4a4b-8329-217b30822359" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_d013f945-a7dc-4fc2-8867-efc91a6d8c58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_86708e8f-435d-4072-85ce-0d5325df5a5c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_d013f945-a7dc-4fc2-8867-efc91a6d8c58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d3d973d5-1844-4d53-aeee-9942d643b769" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_86708e8f-435d-4072-85ce-0d5325df5a5c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d3d973d5-1844-4d53-aeee-9942d643b769" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_d7fa8571-5e2f-4c6f-970b-814f109f4cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_260b1527-1cb0-405e-94d4-1016448d25e2" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_d7fa8571-5e2f-4c6f-970b-814f109f4cf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_54610a7f-155e-4d33-8b15-0cefffbf7297" xlink:href="lyel-20240331.xsd#lyel_SuccessPaymentLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_d7fa8571-5e2f-4c6f-970b-814f109f4cf0" xlink:to="loc_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_54610a7f-155e-4d33-8b15-0cefffbf7297" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_f5461fc8-5e91-4136-9d02-f8ac87d0ddea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_d7fa8571-5e2f-4c6f-970b-814f109f4cf0" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_f5461fc8-5e91-4136-9d02-f8ac87d0ddea" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7adbad14-8786-4f69-887a-f1bde535b2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0071b926-1b71-4bf0-9eec-10060b942e01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7adbad14-8786-4f69-887a-f1bde535b2cc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0071b926-1b71-4bf0-9eec-10060b942e01" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_11facc7e-9f8c-4b1d-8ac6-8d3e3971093d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0071b926-1b71-4bf0-9eec-10060b942e01" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_11facc7e-9f8c-4b1d-8ac6-8d3e3971093d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_11facc7e-9f8c-4b1d-8ac6-8d3e3971093d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_11facc7e-9f8c-4b1d-8ac6-8d3e3971093d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_11facc7e-9f8c-4b1d-8ac6-8d3e3971093d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9abc6524-b5c3-4e35-b5c5-73b6e7433da7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_11facc7e-9f8c-4b1d-8ac6-8d3e3971093d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9abc6524-b5c3-4e35-b5c5-73b6e7433da7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchSuccessPaymentLiabilityMember_26e6c2a9-a047-4475-bac4-f010fc869d7e" xlink:href="lyel-20240331.xsd#lyel_FredHutchSuccessPaymentLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9abc6524-b5c3-4e35-b5c5-73b6e7433da7" xlink:to="loc_lyel_FredHutchSuccessPaymentLiabilityMember_26e6c2a9-a047-4475-bac4-f010fc869d7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordSuccessPaymentLiabilityMember_eb071f08-b200-473a-a883-64274a5f8e52" xlink:href="lyel-20240331.xsd#lyel_StanfordSuccessPaymentLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9abc6524-b5c3-4e35-b5c5-73b6e7433da7" xlink:to="loc_lyel_StanfordSuccessPaymentLiabilityMember_eb071f08-b200-473a-a883-64274a5f8e52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_898a1954-ea3c-4536-a130-dee0b2442de0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0071b926-1b71-4bf0-9eec-10060b942e01" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_898a1954-ea3c-4536-a130-dee0b2442de0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_898a1954-ea3c-4536-a130-dee0b2442de0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_898a1954-ea3c-4536-a130-dee0b2442de0" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_898a1954-ea3c-4536-a130-dee0b2442de0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_98b16575-122e-4eda-b731-87e5a805ce1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_898a1954-ea3c-4536-a130-dee0b2442de0" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_98b16575-122e-4eda-b731-87e5a805ce1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_7c2f416a-cd59-4945-ba30-949d138217c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_98b16575-122e-4eda-b731-87e5a805ce1c" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_7c2f416a-cd59-4945-ba30-949d138217c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_5cad97d4-d3ba-4e97-8e22-013f3318b8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_98b16575-122e-4eda-b731-87e5a805ce1c" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_5cad97d4-d3ba-4e97-8e22-013f3318b8e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_b2aa2be2-b4a1-4281-83de-1e741bb6fc24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_98b16575-122e-4eda-b731-87e5a805ce1c" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_b2aa2be2-b4a1-4281-83de-1e741bb6fc24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aa9f771e-5f95-420d-881e-16a2d623eca1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0071b926-1b71-4bf0-9eec-10060b942e01" xlink:to="loc_srt_RangeAxis_aa9f771e-5f95-420d-881e-16a2d623eca1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aa9f771e-5f95-420d-881e-16a2d623eca1_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_aa9f771e-5f95-420d-881e-16a2d623eca1" xlink:to="loc_srt_RangeMember_aa9f771e-5f95-420d-881e-16a2d623eca1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aea0183d-8b86-412e-be9c-cf29165bbfc0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_aa9f771e-5f95-420d-881e-16a2d623eca1" xlink:to="loc_srt_RangeMember_aea0183d-8b86-412e-be9c-cf29165bbfc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d6f4ecbe-cb8c-4570-832c-61ccb546b3eb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_aea0183d-8b86-412e-be9c-cf29165bbfc0" xlink:to="loc_srt_MinimumMember_d6f4ecbe-cb8c-4570-832c-61ccb546b3eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ceffa24c-6260-417f-934c-1a4c5e1781ed" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_aea0183d-8b86-412e-be9c-cf29165bbfc0" xlink:to="loc_srt_MaximumMember_ceffa24c-6260-417f-934c-1a4c5e1781ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilityFairValueOfCommonStock_60bb1539-6cbe-4f6f-a108-2092b96ba20c" xlink:href="lyel-20240331.xsd#lyel_SuccessPaymentLiabilityFairValueOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7adbad14-8786-4f69-887a-f1bde535b2cc" xlink:to="loc_lyel_SuccessPaymentLiabilityFairValueOfCommonStock_60bb1539-6cbe-4f6f-a108-2092b96ba20c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilityMeasurementInput_147289a2-6b8a-4e3a-832d-a7de6b045a83" xlink:href="lyel-20240331.xsd#lyel_SuccessPaymentLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7adbad14-8786-4f69-887a-f1bde535b2cc" xlink:to="loc_lyel_SuccessPaymentLiabilityMeasurementInput_147289a2-6b8a-4e3a-832d-a7de6b045a83" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a4869880-3a23-4b8e-a61c-cb7f4cce81c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d23b0691-cd9c-4b58-a47b-359fa9d7a850" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a4869880-3a23-4b8e-a61c-cb7f4cce81c6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d23b0691-cd9c-4b58-a47b-359fa9d7a850" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_598f73f5-61d0-405f-99cc-e22a4dd447c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d23b0691-cd9c-4b58-a47b-359fa9d7a850" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_598f73f5-61d0-405f-99cc-e22a4dd447c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_598f73f5-61d0-405f-99cc-e22a4dd447c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_598f73f5-61d0-405f-99cc-e22a4dd447c1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_598f73f5-61d0-405f-99cc-e22a4dd447c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5ac2350e-8f2c-4b62-90bc-b78db281c68e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_598f73f5-61d0-405f-99cc-e22a4dd447c1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5ac2350e-8f2c-4b62-90bc-b78db281c68e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6990bc29-15b5-483f-adc5-d3d9c3b4852e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5ac2350e-8f2c-4b62-90bc-b78db281c68e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6990bc29-15b5-483f-adc5-d3d9c3b4852e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_3d1a2481-a584-4983-8444-bc294fb705fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d23b0691-cd9c-4b58-a47b-359fa9d7a850" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_3d1a2481-a584-4983-8444-bc294fb705fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3d1a2481-a584-4983-8444-bc294fb705fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_3d1a2481-a584-4983-8444-bc294fb705fb" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3d1a2481-a584-4983-8444-bc294fb705fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1f31ab76-e88b-467b-99d8-dd3d36f1cd00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_3d1a2481-a584-4983-8444-bc294fb705fb" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1f31ab76-e88b-467b-99d8-dd3d36f1cd00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilityMember_250d0c68-580e-4be6-9cbb-cb4fc3dbf980" xlink:href="lyel-20240331.xsd#lyel_SuccessPaymentLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1f31ab76-e88b-467b-99d8-dd3d36f1cd00" xlink:to="loc_lyel_SuccessPaymentLiabilityMember_250d0c68-580e-4be6-9cbb-cb4fc3dbf980" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1149a249-69e4-4db9-8e9a-b31343fabe13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a4869880-3a23-4b8e-a61c-cb7f4cce81c6" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1149a249-69e4-4db9-8e9a-b31343fabe13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_328d05a8-e7e5-43a3-a201-df7e5732d6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1149a249-69e4-4db9-8e9a-b31343fabe13" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_328d05a8-e7e5-43a3-a201-df7e5732d6a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2826df80-5262-4691-8c2c-f2276da2dcdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1149a249-69e4-4db9-8e9a-b31343fabe13" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2826df80-5262-4691-8c2c-f2276da2dcdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_914fa664-2bd5-4687-9a4a-4b6314cd092e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_75128ef5-445d-4c96-b420-86f87a1acdfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a4869880-3a23-4b8e-a61c-cb7f4cce81c6" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_75128ef5-445d-4c96-b420-86f87a1acdfe" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_362499c4-f74f-4a89-b17a-b91f91b24308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_98139d71-e199-4d56-ba5d-10141cc2cb8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_362499c4-f74f-4a89-b17a-b91f91b24308" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_98139d71-e199-4d56-ba5d-10141cc2cb8a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5440f013-8ea6-4fb7-adcc-e379bf62f033" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_98139d71-e199-4d56-ba5d-10141cc2cb8a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5440f013-8ea6-4fb7-adcc-e379bf62f033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5440f013-8ea6-4fb7-adcc-e379bf62f033_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5440f013-8ea6-4fb7-adcc-e379bf62f033" xlink:to="loc_us-gaap_RelatedPartyDomain_5440f013-8ea6-4fb7-adcc-e379bf62f033_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1ba0cf31-7d91-4d56-9004-8bdea9b1d2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5440f013-8ea6-4fb7-adcc-e379bf62f033" xlink:to="loc_us-gaap_RelatedPartyDomain_1ba0cf31-7d91-4d56-9004-8bdea9b1d2d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_9d3e6848-4bf7-4185-994a-b8c860f79fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1ba0cf31-7d91-4d56-9004-8bdea9b1d2d9" xlink:to="loc_us-gaap_RelatedPartyMember_9d3e6848-4bf7-4185-994a-b8c860f79fb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d791c867-e5ef-4821-9f17-82a0cee1934e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_98139d71-e199-4d56-ba5d-10141cc2cb8a" xlink:to="loc_srt_StatementGeographicalAxis_d791c867-e5ef-4821-9f17-82a0cee1934e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d791c867-e5ef-4821-9f17-82a0cee1934e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_d791c867-e5ef-4821-9f17-82a0cee1934e" xlink:to="loc_srt_SegmentGeographicalDomain_d791c867-e5ef-4821-9f17-82a0cee1934e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a09fafea-8dcd-420e-a05d-1b05c249eff2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_d791c867-e5ef-4821-9f17-82a0cee1934e" xlink:to="loc_srt_SegmentGeographicalDomain_a09fafea-8dcd-420e-a05d-1b05c249eff2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SouthSanFranciscoCaliforniaMember_87c5e29a-ffe0-4e2f-87ba-938abf15f40b" xlink:href="lyel-20240331.xsd#lyel_SouthSanFranciscoCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a09fafea-8dcd-420e-a05d-1b05c249eff2" xlink:to="loc_lyel_SouthSanFranciscoCaliforniaMember_87c5e29a-ffe0-4e2f-87ba-938abf15f40b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a930d566-2df0-4503-bdb3-83a542e0e781" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_98139d71-e199-4d56-ba5d-10141cc2cb8a" xlink:to="loc_srt_CounterpartyNameAxis_a930d566-2df0-4503-bdb3-83a542e0e781" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a930d566-2df0-4503-bdb3-83a542e0e781_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a930d566-2df0-4503-bdb3-83a542e0e781" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a930d566-2df0-4503-bdb3-83a542e0e781_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_459e8cb3-5787-4701-a5b0-3d53b330185e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a930d566-2df0-4503-bdb3-83a542e0e781" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_459e8cb3-5787-4701-a5b0-3d53b330185e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SonomaMember_df93ed22-b5fe-4a5c-bdaf-1a16052d5731" xlink:href="lyel-20240331.xsd#lyel_SonomaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_459e8cb3-5787-4701-a5b0-3d53b330185e" xlink:to="loc_lyel_SonomaMember_df93ed22-b5fe-4a5c-bdaf-1a16052d5731" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_47078f98-5f7b-4ac6-b75c-5d89ad40c1db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_362499c4-f74f-4a89-b17a-b91f91b24308" xlink:to="loc_us-gaap_OperatingLeaseCost_47078f98-5f7b-4ac6-b75c-5d89ad40c1db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_325d8401-fb70-42c5-a9e5-573a4fd0976a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_362499c4-f74f-4a89-b17a-b91f91b24308" xlink:to="loc_us-gaap_VariableLeaseCost_325d8401-fb70-42c5-a9e5-573a4fd0976a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c74b82f7-30eb-4457-8128-4e6ecb262954" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_362499c4-f74f-4a89-b17a-b91f91b24308" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c74b82f7-30eb-4457-8128-4e6ecb262954" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_aa89f644-e0ee-4818-be27-156993109fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_362499c4-f74f-4a89-b17a-b91f91b24308" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_aa89f644-e0ee-4818-be27-156993109fd3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_e4b73b5a-26dd-47f0-9cab-2b140f6705c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_362499c4-f74f-4a89-b17a-b91f91b24308" xlink:to="loc_us-gaap_NetRentableArea_e4b73b5a-26dd-47f0-9cab-2b140f6705c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_227875d4-e071-471d-8e93-d17d62f9ce34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_362499c4-f74f-4a89-b17a-b91f91b24308" xlink:to="loc_us-gaap_SubleaseIncome_227875d4-e071-471d-8e93-d17d62f9ce34" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_65175401-1485-4aea-b886-0e5e6ffc044e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_362499c4-f74f-4a89-b17a-b91f91b24308" xlink:to="loc_us-gaap_TenantImprovements_65175401-1485-4aea-b886-0e5e6ffc044e" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_22946bba-9575-41f8-8257-24fd5a3ead42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a6905302-c298-498a-8ad2-e634267c8a58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_22946bba-9575-41f8-8257-24fd5a3ead42" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a6905302-c298-498a-8ad2-e634267c8a58" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8939a4a8-86b8-4f0e-89a8-9ea7f1e83f8b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a6905302-c298-498a-8ad2-e634267c8a58" xlink:to="loc_srt_CounterpartyNameAxis_8939a4a8-86b8-4f0e-89a8-9ea7f1e83f8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8939a4a8-86b8-4f0e-89a8-9ea7f1e83f8b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8939a4a8-86b8-4f0e-89a8-9ea7f1e83f8b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8939a4a8-86b8-4f0e-89a8-9ea7f1e83f8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_60c3f589-fa2d-46b0-a1a1-b10c0377375f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8939a4a8-86b8-4f0e-89a8-9ea7f1e83f8b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_60c3f589-fa2d-46b0-a1a1-b10c0377375f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CowenAndCompanyLLCMember_771c9393-bbe4-4293-a0f5-1d450434f8cb" xlink:href="lyel-20240331.xsd#lyel_CowenAndCompanyLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_60c3f589-fa2d-46b0-a1a1-b10c0377375f" xlink:to="loc_lyel_CowenAndCompanyLLCMember_771c9393-bbe4-4293-a0f5-1d450434f8cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_715188b4-df84-4af7-809e-b93286c1c77c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a6905302-c298-498a-8ad2-e634267c8a58" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_715188b4-df84-4af7-809e-b93286c1c77c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_715188b4-df84-4af7-809e-b93286c1c77c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_715188b4-df84-4af7-809e-b93286c1c77c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_715188b4-df84-4af7-809e-b93286c1c77c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bfa988ce-0ffc-4e51-a408-c106be06d30d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_715188b4-df84-4af7-809e-b93286c1c77c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bfa988ce-0ffc-4e51-a408-c106be06d30d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_AtTheMarketOfferingMember_6b8bd0e6-669b-4ed6-8a6a-8bbfee29a3ac" xlink:href="lyel-20240331.xsd#lyel_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bfa988ce-0ffc-4e51-a408-c106be06d30d" xlink:to="loc_lyel_AtTheMarketOfferingMember_6b8bd0e6-669b-4ed6-8a6a-8bbfee29a3ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8822a7c2-849f-4371-8fed-355526141b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_22946bba-9575-41f8-8257-24fd5a3ead42" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8822a7c2-849f-4371-8fed-355526141b2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a4b24963-3cd9-4bec-ba7f-faef8071efbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_22946bba-9575-41f8-8257-24fd5a3ead42" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a4b24963-3cd9-4bec-ba7f-faef8071efbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_eb7b0e50-042f-4b1f-b339-fcee91b5737e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_22946bba-9575-41f8-8257-24fd5a3ead42" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_eb7b0e50-042f-4b1f-b339-fcee91b5737e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ad4aed4b-3ce6-4d29-bdfd-8f78cdcbc3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_22946bba-9575-41f8-8257-24fd5a3ead42" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ad4aed4b-3ce6-4d29-bdfd-8f78cdcbc3f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c4616997-d18a-4d45-bb9a-6ac74221fb5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_22946bba-9575-41f8-8257-24fd5a3ead42" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c4616997-d18a-4d45-bb9a-6ac74221fb5b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5e07048b-7bdf-4515-b465-1911ad30c73a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_22946bba-9575-41f8-8257-24fd5a3ead42" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5e07048b-7bdf-4515-b465-1911ad30c73a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SaleOfStockMaximumConsiderationReceived_9e1c3c34-bae7-40ad-8a02-4c9cc6e0ca66" xlink:href="lyel-20240331.xsd#lyel_SaleOfStockMaximumConsiderationReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_22946bba-9575-41f8-8257-24fd5a3ead42" xlink:to="loc_lyel_SaleOfStockMaximumConsiderationReceived_9e1c3c34-bae7-40ad-8a02-4c9cc6e0ca66" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds_8cd1c5b6-d147-41fc-9ce3-2e4c1bd812f9" xlink:href="lyel-20240331.xsd#lyel_SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_22946bba-9575-41f8-8257-24fd5a3ead42" xlink:to="loc_lyel_SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds_8cd1c5b6-d147-41fc-9ce3-2e4c1bd812f9" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#StockbasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/StockbasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2721044-95e2-426b-936d-d1566510bdac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2721044-95e2-426b-936d-d1566510bdac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2cadec34-1ec1-4bc6-87ac-92d87588b4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2721044-95e2-426b-936d-d1566510bdac" xlink:to="loc_us-gaap_PlanNameAxis_2cadec34-1ec1-4bc6-87ac-92d87588b4dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2cadec34-1ec1-4bc6-87ac-92d87588b4dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2cadec34-1ec1-4bc6-87ac-92d87588b4dd" xlink:to="loc_us-gaap_PlanNameDomain_2cadec34-1ec1-4bc6-87ac-92d87588b4dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5c3223aa-51ad-4e09-b96b-1c13bb552bac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2cadec34-1ec1-4bc6-87ac-92d87588b4dd" xlink:to="loc_us-gaap_PlanNameDomain_5c3223aa-51ad-4e09-b96b-1c13bb552bac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandTwentyOneEquityIncentivePlanMember_96ad4a69-c0f7-4e0c-9221-f07e9823643b" xlink:href="lyel-20240331.xsd#lyel_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5c3223aa-51ad-4e09-b96b-1c13bb552bac" xlink:to="loc_lyel_TwoThousandTwentyOneEquityIncentivePlanMember_96ad4a69-c0f7-4e0c-9221-f07e9823643b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_54720cb3-935c-44e0-820d-ae0c78bda663" xlink:href="lyel-20240331.xsd#lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5c3223aa-51ad-4e09-b96b-1c13bb552bac" xlink:to="loc_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_54720cb3-935c-44e0-820d-ae0c78bda663" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandEighteenEquityIncentivePlanMember_047f0aae-bd1b-4bee-989a-12f9e42083c7" xlink:href="lyel-20240331.xsd#lyel_TwoThousandEighteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5c3223aa-51ad-4e09-b96b-1c13bb552bac" xlink:to="loc_lyel_TwoThousandEighteenEquityIncentivePlanMember_047f0aae-bd1b-4bee-989a-12f9e42083c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bab4cebc-21df-40cf-9431-4a614a02b68f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2721044-95e2-426b-936d-d1566510bdac" xlink:to="loc_srt_RangeAxis_bab4cebc-21df-40cf-9431-4a614a02b68f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bab4cebc-21df-40cf-9431-4a614a02b68f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bab4cebc-21df-40cf-9431-4a614a02b68f" xlink:to="loc_srt_RangeMember_bab4cebc-21df-40cf-9431-4a614a02b68f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d9025d42-1354-421f-b223-af925aeb5feb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bab4cebc-21df-40cf-9431-4a614a02b68f" xlink:to="loc_srt_RangeMember_d9025d42-1354-421f-b223-af925aeb5feb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_73faa32a-76d0-45c8-8705-3cf966fbcb05" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d9025d42-1354-421f-b223-af925aeb5feb" xlink:to="loc_srt_MaximumMember_73faa32a-76d0-45c8-8705-3cf966fbcb05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e73ec682-05e2-4844-a32e-f63eab488ce1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d9025d42-1354-421f-b223-af925aeb5feb" xlink:to="loc_srt_MinimumMember_e73ec682-05e2-4844-a32e-f63eab488ce1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_DateOfEquityModificationsAxis_d7566709-47c9-4be3-8df9-9f15e7bda41f" xlink:href="lyel-20240331.xsd#lyel_DateOfEquityModificationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2721044-95e2-426b-936d-d1566510bdac" xlink:to="loc_lyel_DateOfEquityModificationsAxis_d7566709-47c9-4be3-8df9-9f15e7bda41f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_DateOfEquityModificationsDomain_d7566709-47c9-4be3-8df9-9f15e7bda41f_default" xlink:href="lyel-20240331.xsd#lyel_DateOfEquityModificationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_lyel_DateOfEquityModificationsAxis_d7566709-47c9-4be3-8df9-9f15e7bda41f" xlink:to="loc_lyel_DateOfEquityModificationsDomain_d7566709-47c9-4be3-8df9-9f15e7bda41f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_DateOfEquityModificationsDomain_9ab40e60-cea7-4ccd-9ec2-18b1a371b61a" xlink:href="lyel-20240331.xsd#lyel_DateOfEquityModificationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_lyel_DateOfEquityModificationsAxis_d7566709-47c9-4be3-8df9-9f15e7bda41f" xlink:to="loc_lyel_DateOfEquityModificationsDomain_9ab40e60-cea7-4ccd-9ec2-18b1a371b61a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_A2023Member_05dcfc05-88f1-4586-a978-9ca61d2b32c1" xlink:href="lyel-20240331.xsd#lyel_A2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lyel_DateOfEquityModificationsDomain_9ab40e60-cea7-4ccd-9ec2-18b1a371b61a" xlink:to="loc_lyel_A2023Member_05dcfc05-88f1-4586-a978-9ca61d2b32c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_15e99406-51ef-4bb8-aadc-1994819e2db8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2721044-95e2-426b-936d-d1566510bdac" xlink:to="loc_us-gaap_AwardTypeAxis_15e99406-51ef-4bb8-aadc-1994819e2db8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15e99406-51ef-4bb8-aadc-1994819e2db8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_15e99406-51ef-4bb8-aadc-1994819e2db8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15e99406-51ef-4bb8-aadc-1994819e2db8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df0e200a-54ac-4ae5-a88c-440f4253d170" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_15e99406-51ef-4bb8-aadc-1994819e2db8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df0e200a-54ac-4ae5-a88c-440f4253d170" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_45ff7cab-8b94-4f56-953c-a340d55ae1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df0e200a-54ac-4ae5-a88c-440f4253d170" xlink:to="loc_us-gaap_EmployeeStockOptionMember_45ff7cab-8b94-4f56-953c-a340d55ae1f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5c41acaa-3ef8-4417-be5c-64c8366be9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df0e200a-54ac-4ae5-a88c-440f4253d170" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5c41acaa-3ef8-4417-be5c-64c8366be9a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_4b9209d8-e090-46ca-89bd-2965f431ab8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df0e200a-54ac-4ae5-a88c-440f4253d170" xlink:to="loc_us-gaap_PerformanceSharesMember_4b9209d8-e090-46ca-89bd-2965f431ab8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_371fb5d2-4bbe-47ec-930a-17a76754d585" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2721044-95e2-426b-936d-d1566510bdac" xlink:to="loc_us-gaap_VestingAxis_371fb5d2-4bbe-47ec-930a-17a76754d585" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_371fb5d2-4bbe-47ec-930a-17a76754d585_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_371fb5d2-4bbe-47ec-930a-17a76754d585" xlink:to="loc_us-gaap_VestingDomain_371fb5d2-4bbe-47ec-930a-17a76754d585_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_009d4bea-af4c-402c-b1b4-4d5871c589ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_371fb5d2-4bbe-47ec-930a-17a76754d585" xlink:to="loc_us-gaap_VestingDomain_009d4bea-af4c-402c-b1b4-4d5871c589ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f071f877-8891-4f2f-a614-bae793787af2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_009d4bea-af4c-402c-b1b4-4d5871c589ce" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f071f877-8891-4f2f-a614-bae793787af2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_123e89df-4ffe-4b65-9821-e970016679ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_009d4bea-af4c-402c-b1b4-4d5871c589ce" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_123e89df-4ffe-4b65-9821-e970016679ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8ea6f5f6-d877-4c08-9303-ee0a6079be9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8ea6f5f6-d877-4c08-9303-ee0a6079be9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_32fbe2f8-33e6-45a6-b663-ba82a3f8327e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_32fbe2f8-33e6-45a6-b663-ba82a3f8327e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_b575ec89-cf7c-4bc4-bf92-54393fc8d5f7" xlink:href="lyel-20240331.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_b575ec89-cf7c-4bc4-bf92-54393fc8d5f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_51408558-7c1a-4f55-9b7d-dc49a1a78900" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_51408558-7c1a-4f55-9b7d-dc49a1a78900" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding_bab3c73e-1373-4f50-a2a1-4028950ef846" xlink:href="lyel-20240331.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding_bab3c73e-1373-4f50-a2a1-4028950ef846" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d7fae897-6b6e-42f4-bcf8-b5fb3db26fec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d7fae897-6b6e-42f4-bcf8-b5fb3db26fec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7254951b-2ede-4309-9a41-b1405f37abe4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7254951b-2ede-4309-9a41-b1405f37abe4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_524e0094-928b-48fc-8efa-84d145ee341b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_524e0094-928b-48fc-8efa-84d145ee341b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1c808912-3373-4bfe-aa7b-6a1545b16f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1c808912-3373-4bfe-aa7b-6a1545b16f5d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_b3e2c504-4e0a-46e5-ac72-509291057fb6" xlink:href="lyel-20240331.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_b3e2c504-4e0a-46e5-ac72-509291057fb6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod_dfd6c262-f751-4fb5-81e0-60dcd051985d" xlink:href="lyel-20240331.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod_dfd6c262-f751-4fb5-81e0-60dcd051985d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_3c78fbca-2469-4682-b538-b871d8491a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_3c78fbca-2469-4682-b538-b871d8491a6a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a49c4ca3-717e-4bb5-b21e-e85d38458a29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a49c4ca3-717e-4bb5-b21e-e85d38458a29" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8a59e3fb-83b2-4f99-810d-2cedd49610d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8a59e3fb-83b2-4f99-810d-2cedd49610d8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum_5fb7b7f9-66ff-4119-af7f-13e6ea6e0f35" xlink:href="lyel-20240331.xsd#lyel_ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_lyel_ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum_5fb7b7f9-66ff-4119-af7f-13e6ea6e0f35" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1381407c-2df3-4ebe-8778-1f19889c4996" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1381407c-2df3-4ebe-8778-1f19889c4996" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_4fe9d483-c9b9-4845-89fa-429aebb7f1be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_4fe9d483-c9b9-4845-89fa-429aebb7f1be" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_de1ec443-a144-4674-8e1b-bb3e086beba2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_de1ec443-a144-4674-8e1b-bb3e086beba2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced_d94cdb0b-25fe-40b0-ac01-f30f55ee1d8c" xlink:href="lyel-20240331.xsd#lyel_ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_lyel_ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced_d94cdb0b-25fe-40b0-ac01-f30f55ee1d8c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedPaymentArrangementPlanModificationExercisePrice_49b2003b-0fee-4bb5-9128-d5d3d7aa935d" xlink:href="lyel-20240331.xsd#lyel_ShareBasedPaymentArrangementPlanModificationExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_lyel_ShareBasedPaymentArrangementPlanModificationExercisePrice_49b2003b-0fee-4bb5-9128-d5d3d7aa935d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_f893b95d-a0eb-477b-b419-247e6c44cb78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_f893b95d-a0eb-477b-b419-247e6c44cb78" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod_03ce7921-6ec2-4343-bc3a-e5ea26efe13f" xlink:href="lyel-20240331.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod_03ce7921-6ec2-4343-bc3a-e5ea26efe13f" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn_94a6a0f2-db2e-4ea6-88da-b085d3b8f773" xlink:href="lyel-20240331.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn_94a6a0f2-db2e-4ea6-88da-b085d3b8f773" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7f0134ac-c691-4f1a-99ae-f4701df0fff3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7f0134ac-c691-4f1a-99ae-f4701df0fff3" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate_cce40308-b9cb-4b1e-8ff5-296e40185d84" xlink:href="lyel-20240331.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate_cce40308-b9cb-4b1e-8ff5-296e40185d84" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget_5921b557-d594-4f4a-a188-9768bcd3860a" xlink:href="lyel-20240331.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget_5921b557-d594-4f4a-a188-9768bcd3860a" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_166e55e4-dd77-4355-beaa-ea7e4818a8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_166e55e4-dd77-4355-beaa-ea7e4818a8b0" xlink:type="arc" order="26"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_34b5af87-cd76-446f-8595-92de83d2160b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_61e6645d-5e53-414e-b337-53829048d82a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_34b5af87-cd76-446f-8595-92de83d2160b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_61e6645d-5e53-414e-b337-53829048d82a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_044e8a21-434e-4e07-8a5a-401fa8bc480a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_61e6645d-5e53-414e-b337-53829048d82a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_044e8a21-434e-4e07-8a5a-401fa8bc480a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_044e8a21-434e-4e07-8a5a-401fa8bc480a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_044e8a21-434e-4e07-8a5a-401fa8bc480a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_044e8a21-434e-4e07-8a5a-401fa8bc480a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4e87f77e-9d33-442f-8b9c-9e1f9a11d57e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_044e8a21-434e-4e07-8a5a-401fa8bc480a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4e87f77e-9d33-442f-8b9c-9e1f9a11d57e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_46fa4edf-7288-4a78-87ac-eeead930a3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4e87f77e-9d33-442f-8b9c-9e1f9a11d57e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_46fa4edf-7288-4a78-87ac-eeead930a3c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3522796e-34da-4f5d-8bea-d622ac767961" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4e87f77e-9d33-442f-8b9c-9e1f9a11d57e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3522796e-34da-4f5d-8bea-d622ac767961" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1660062f-a91f-4974-91ea-8ad9bc2e9040" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_34b5af87-cd76-446f-8595-92de83d2160b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1660062f-a91f-4974-91ea-8ad9bc2e9040" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationScheduleofPerformanceSharesUnitsDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#StockbasedCompensationScheduleofPerformanceSharesUnitsDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/StockbasedCompensationScheduleofPerformanceSharesUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58222d34-d039-4101-b455-a9d5dd4af225" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88e3a2a8-2cfd-4942-b3a5-dd501f5c1820" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58222d34-d039-4101-b455-a9d5dd4af225" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88e3a2a8-2cfd-4942-b3a5-dd501f5c1820" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_16ba93a6-eff9-44a5-a832-f49b477a1585" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88e3a2a8-2cfd-4942-b3a5-dd501f5c1820" xlink:to="loc_us-gaap_AwardTypeAxis_16ba93a6-eff9-44a5-a832-f49b477a1585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16ba93a6-eff9-44a5-a832-f49b477a1585_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_16ba93a6-eff9-44a5-a832-f49b477a1585" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16ba93a6-eff9-44a5-a832-f49b477a1585_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35752ddc-5ec7-4506-8da9-42f013b03344" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_16ba93a6-eff9-44a5-a832-f49b477a1585" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35752ddc-5ec7-4506-8da9-42f013b03344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ede278d9-41e7-4f1d-a3b6-5401fb5ee897" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35752ddc-5ec7-4506-8da9-42f013b03344" xlink:to="loc_us-gaap_PerformanceSharesMember_ede278d9-41e7-4f1d-a3b6-5401fb5ee897" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8b661f42-27a7-4634-baaa-07a6a4d744e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58222d34-d039-4101-b455-a9d5dd4af225" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8b661f42-27a7-4634-baaa-07a6a4d744e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2dd21a66-ea71-456b-b152-f34467d038e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8b661f42-27a7-4634-baaa-07a6a4d744e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2dd21a66-ea71-456b-b152-f34467d038e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3d44579c-f4e5-4ab0-a53c-276aac01e88b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8b661f42-27a7-4634-baaa-07a6a4d744e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3d44579c-f4e5-4ab0-a53c-276aac01e88b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_db793bae-0cfe-45b2-85f3-52d485553d18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8b661f42-27a7-4634-baaa-07a6a4d744e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_db793bae-0cfe-45b2-85f3-52d485553d18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a83763e2-6e68-4098-b95f-a656959075ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8b661f42-27a7-4634-baaa-07a6a4d744e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a83763e2-6e68-4098-b95f-a656959075ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2e1cd027-e73e-4c47-a37f-d2475eaa355d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e06153d5-2bad-4106-b35e-9a2a2531d4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58222d34-d039-4101-b455-a9d5dd4af225" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e06153d5-2bad-4106-b35e-9a2a2531d4b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3436ef6b-ced0-4f23-89cd-ac2da8ba5732" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e06153d5-2bad-4106-b35e-9a2a2531d4b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3436ef6b-ced0-4f23-89cd-ac2da8ba5732" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_986e8b89-999c-42ca-b7e5-552f512c5887" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e06153d5-2bad-4106-b35e-9a2a2531d4b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_986e8b89-999c-42ca-b7e5-552f512c5887" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_97002555-a4c1-401c-aafc-78b4521fbfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e06153d5-2bad-4106-b35e-9a2a2531d4b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_97002555-a4c1-401c-aafc-78b4521fbfa0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ec370155-b83e-4f31-8960-f5e622a9277c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e06153d5-2bad-4106-b35e-9a2a2531d4b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ec370155-b83e-4f31-8960-f5e622a9277c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a01c20c7-efbe-4553-b247-0bbdf3270f93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#StockbasedCompensationScheduleofRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69d3e203-1738-4552-b1b2-f6d95084e356" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c1325397-263d-4432-bc07-95224d22aac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69d3e203-1738-4552-b1b2-f6d95084e356" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c1325397-263d-4432-bc07-95224d22aac1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2c56d2a0-337e-479c-afc3-73edec485372" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c1325397-263d-4432-bc07-95224d22aac1" xlink:to="loc_us-gaap_AwardTypeAxis_2c56d2a0-337e-479c-afc3-73edec485372" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c56d2a0-337e-479c-afc3-73edec485372_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2c56d2a0-337e-479c-afc3-73edec485372" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c56d2a0-337e-479c-afc3-73edec485372_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb934f4f-cb00-4b87-8c8f-e3077b5e5ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2c56d2a0-337e-479c-afc3-73edec485372" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb934f4f-cb00-4b87-8c8f-e3077b5e5ca2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_995afbdf-e6ee-4c0c-8232-89f2836a1541" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb934f4f-cb00-4b87-8c8f-e3077b5e5ca2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_995afbdf-e6ee-4c0c-8232-89f2836a1541" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c31e060-b366-4080-b9cd-efe69213983e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69d3e203-1738-4552-b1b2-f6d95084e356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c31e060-b366-4080-b9cd-efe69213983e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d74dc3f3-f0aa-4f87-94c5-1a3973e43a34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c31e060-b366-4080-b9cd-efe69213983e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d74dc3f3-f0aa-4f87-94c5-1a3973e43a34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_953af00f-1938-4df0-8285-035c4978f739" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c31e060-b366-4080-b9cd-efe69213983e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_953af00f-1938-4df0-8285-035c4978f739" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d2a12311-ebcb-4901-a6a9-20f0f154f390" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c31e060-b366-4080-b9cd-efe69213983e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d2a12311-ebcb-4901-a6a9-20f0f154f390" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_98a6ae04-acba-4f19-9d66-bab7a424e85d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c31e060-b366-4080-b9cd-efe69213983e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_98a6ae04-acba-4f19-9d66-bab7a424e85d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2eae47a3-91a5-46a2-af2a-c0ba53792c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_78975170-0929-48df-8057-112bb1720a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69d3e203-1738-4552-b1b2-f6d95084e356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_78975170-0929-48df-8057-112bb1720a2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a6d1e9a1-a305-4a94-a461-af2df17754ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_78975170-0929-48df-8057-112bb1720a2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a6d1e9a1-a305-4a94-a461-af2df17754ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_87ebd34e-173e-4d65-a137-7fcced762596" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_78975170-0929-48df-8057-112bb1720a2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_87ebd34e-173e-4d65-a137-7fcced762596" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_51388179-e52a-4a05-8119-5f893dc46f39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_78975170-0929-48df-8057-112bb1720a2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_51388179-e52a-4a05-8119-5f893dc46f39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b512b775-9c20-47c4-bd9b-cb809d1a0a77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_78975170-0929-48df-8057-112bb1720a2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b512b775-9c20-47c4-bd9b-cb809d1a0a77" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3615a81c-c2d3-46b3-a8cb-2440bc824da6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#RelatedpartyTransactionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_34c93887-ed94-4f3d-b304-30009a627ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7dd6bd53-c294-4a19-85cf-f0c49866e4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_34c93887-ed94-4f3d-b304-30009a627ed1" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7dd6bd53-c294-4a19-85cf-f0c49866e4bd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_227e8d5a-5323-4a81-81e9-cfec9c2009bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7dd6bd53-c294-4a19-85cf-f0c49866e4bd" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_227e8d5a-5323-4a81-81e9-cfec9c2009bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_227e8d5a-5323-4a81-81e9-cfec9c2009bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_227e8d5a-5323-4a81-81e9-cfec9c2009bf" xlink:to="loc_us-gaap_RelatedPartyDomain_227e8d5a-5323-4a81-81e9-cfec9c2009bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9895ebba-1dfe-43e1-8571-f9b167364fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_227e8d5a-5323-4a81-81e9-cfec9c2009bf" xlink:to="loc_us-gaap_RelatedPartyDomain_9895ebba-1dfe-43e1-8571-f9b167364fe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_68b4bcf2-b97f-4627-80d4-a2ee70cb6d80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9895ebba-1dfe-43e1-8571-f9b167364fe6" xlink:to="loc_us-gaap_RelatedPartyMember_68b4bcf2-b97f-4627-80d4-a2ee70cb6d80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d9fbebfd-d389-4bd9-a729-1e7df1b946bb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7dd6bd53-c294-4a19-85cf-f0c49866e4bd" xlink:to="loc_srt_CounterpartyNameAxis_d9fbebfd-d389-4bd9-a729-1e7df1b946bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d9fbebfd-d389-4bd9-a729-1e7df1b946bb_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d9fbebfd-d389-4bd9-a729-1e7df1b946bb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d9fbebfd-d389-4bd9-a729-1e7df1b946bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2f7b5ae-db07-4893-9caa-f3f99591783f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d9fbebfd-d389-4bd9-a729-1e7df1b946bb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2f7b5ae-db07-4893-9caa-f3f99591783f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SonomaMember_e9ed7a54-532b-4230-8f77-3765c48acefb" xlink:href="lyel-20240331.xsd#lyel_SonomaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2f7b5ae-db07-4893-9caa-f3f99591783f" xlink:to="loc_lyel_SonomaMember_e9ed7a54-532b-4230-8f77-3765c48acefb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_c0074d39-24f0-4c4f-a788-fe86801c4fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_34c93887-ed94-4f3d-b304-30009a627ed1" xlink:to="loc_us-gaap_NetRentableArea_c0074d39-24f0-4c4f-a788-fe86801c4fa6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_0a5e27ef-b168-4bba-b43f-c0403d2b770f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_34c93887-ed94-4f3d-b304-30009a627ed1" xlink:to="loc_us-gaap_TenantImprovements_0a5e27ef-b168-4bba-b43f-c0403d2b770f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_52336a84-e209-41a0-bb31-5d2b8e1a2d11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_34c93887-ed94-4f3d-b304-30009a627ed1" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_52336a84-e209-41a0-bb31-5d2b8e1a2d11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_48683257-bda7-429d-8cec-8ddbd75f62a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_34c93887-ed94-4f3d-b304-30009a627ed1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_48683257-bda7-429d-8cec-8ddbd75f62a6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_e0f562b0-36ab-4840-87c0-9a2052085d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_be8ceb81-d7fe-4815-96c0-5762fe56ae3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e0f562b0-36ab-4840-87c0-9a2052085d3e" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_be8ceb81-d7fe-4815-96c0-5762fe56ae3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_55c0058d-ed3a-4aed-8cc3-16e62abad102" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_be8ceb81-d7fe-4815-96c0-5762fe56ae3c" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_55c0058d-ed3a-4aed-8cc3-16e62abad102" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_55c0058d-ed3a-4aed-8cc3-16e62abad102_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_55c0058d-ed3a-4aed-8cc3-16e62abad102" xlink:to="loc_us-gaap_RelatedPartyDomain_55c0058d-ed3a-4aed-8cc3-16e62abad102_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a2cf7547-90aa-4503-b1f4-171dbd1b0cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_55c0058d-ed3a-4aed-8cc3-16e62abad102" xlink:to="loc_us-gaap_RelatedPartyDomain_a2cf7547-90aa-4503-b1f4-171dbd1b0cf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_04bd21b9-18ef-408e-bcc2-21c98981b537" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a2cf7547-90aa-4503-b1f4-171dbd1b0cf5" xlink:to="loc_us-gaap_RelatedPartyMember_04bd21b9-18ef-408e-bcc2-21c98981b537" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_66d42eee-12a9-483f-8acc-a46cbd2672b6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_be8ceb81-d7fe-4815-96c0-5762fe56ae3c" xlink:to="loc_srt_CounterpartyNameAxis_66d42eee-12a9-483f-8acc-a46cbd2672b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_66d42eee-12a9-483f-8acc-a46cbd2672b6_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_66d42eee-12a9-483f-8acc-a46cbd2672b6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_66d42eee-12a9-483f-8acc-a46cbd2672b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_43644a11-0138-41e5-8490-e6e17fbad389" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_66d42eee-12a9-483f-8acc-a46cbd2672b6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_43644a11-0138-41e5-8490-e6e17fbad389" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SonomaMember_b40e63af-ffdc-4b4a-b79c-91f1284ca54b" xlink:href="lyel-20240331.xsd#lyel_SonomaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_43644a11-0138-41e5-8490-e6e17fbad389" xlink:to="loc_lyel_SonomaMember_b40e63af-ffdc-4b4a-b79c-91f1284ca54b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_14ae9d72-9e69-42b8-b10f-45252b08318e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e0f562b0-36ab-4840-87c0-9a2052085d3e" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_14ae9d72-9e69-42b8-b10f-45252b08318e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_486994a3-017f-40be-adca-a9be0b7e90ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e0f562b0-36ab-4840-87c0-9a2052085d3e" xlink:to="loc_us-gaap_SubleaseIncome_486994a3-017f-40be-adca-a9be0b7e90ed" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_PerformanceSharesMember" xlink:type="arc" order="5"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>lyel-20240331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:cc2ada24-6463-486d-8041-2176b9cca09e,g:4457644e-4c39-4c28-b3b7-d0adb2254c74-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod_492d7503-fa28-4c21-bc71-13ded936e920_terseLabel_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum offering period</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod_label_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Maximum Offering Period</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod_documentation_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Maximum Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" xlink:href="lyel-20240331.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" xlink:to="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_950af9ab-6504-459f-b77e-b9e2c7087043_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4cfba8f0-e58c-4a50-8b21-e6053fe119f3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_1f87cc66-fb57-4c71-9e04-4278a307f76f_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_f4f9ed6e-a8a5-4834-be74-9a85d771360c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_3447f856-910b-4b8c-87c4-a533a6b922a5_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_888bf404-097b-44b8-80c5-ef194c1ce7ff_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_a21466e4-c1de-40b8-994b-099b88692536_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3479b2f1-0468-4317-9dff-1ff7ef5095dc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_551783d2-0095-43cf-9d27-77688e260359_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_088f0c48-1495-42f4-a8c9-67ea1af26227_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f1f82feb-1c69-4ddc-90e0-19de031646b9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c3b84974-b184-43a9-acd3-324de8939454_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_38c583d3-b074-450b-a780-c53d6a60aade_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_2723cd96-2e40-4b69-875d-5624c39e25f7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_b896b434-43b0-421e-917a-0de0afd61e81_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value and Amortized Cost of Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_5b03506c-406e-40ec-9e51-b63f70c85510_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_b9cdd3da-256f-47c4-a2cb-011ef46862bc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6e5fb1cf-6015-4b22-8311-a688489d551d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_82f011d6-f6ff-45b9-b934-5e59f9c02267_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_2e3a5e3c-25df-4f31-b47d-51d5f16c6198_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_3000d87b-3922-4726-9a8a-226afcec7134_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_0263c755-881d-4254-9428-b5bef5c22b99_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other loss, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_9e49f923-e490-42c0-8164-a05536e5ce6b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_de805896-0feb-4d1d-bb20-188a8184637b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5fc202cd-6ceb-462f-894d-2d535a2b73c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_c165c5cd-19c3-48ca-b128-f3fe27f9e4f2_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2d82be59-650e-4daa-b5f5-45cfaa99d7a2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_990d99a4-5e8f-45e5-a4ed-1b14e747eb11_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_87d5dbd5-c050-456b-8d98-0b846c4dab2b_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_8fe46eb4-7a07-4d6c-a719-b0a4adb77ca6_terseLabel_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Success payment liabilities</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Success Payment Liabilities, Fair Value Disclosure</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_documentation_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Success Payment Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilitiesFairValueDisclosure" xlink:href="lyel-20240331.xsd#lyel_SuccessPaymentLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SuccessPaymentLiabilitiesFairValueDisclosure" xlink:to="lab_lyel_SuccessPaymentLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_aa9b132c-bb21-4295-b5f7-e067a5cdd358_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_55792c1d-d347-4d69-bb07-15973f582546_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with restricted stock units, net of tax (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_db78075d-e995-416e-b8e5-96edf66d9a3e_totalLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total financial liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_411851db-090a-4bff-bc8a-139e74244145_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm_c4429ef8-366d-49ed-bfac-c4d3056efc74_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of success payment agreement</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Term</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_8e6d61b2-374c-4cf1-9f1c-a614d841e4bd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_1f12770c-7084-4017-a1a3-8cef61c8cfe1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000 shares authorized at March&#160;31, 2024 and December&#160;31, 2023; no shares issued and outstanding at March&#160;31, 2024 and December&#160;31, 2023</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba4b7d95-92af-4f6b-8710-bae8bf45c772_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Value at Grant Date Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b8c2c7f0-6229-4ce2-a390-58b6a888eec3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_8c3d032d-6507-426e-ad43-62bc9a9a617b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled or forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_126d93d9-4a11-48ff-9f1c-9bcb9fa846a4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per common share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_6b28b4ab-e843-4792-93a4-61b445aac539_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_EquityMultipleDomain_41e82ac5-7f75-4534-aae9-7bb0846d110c_terseLabel_en-US" xlink:label="lab_lyel_EquityMultipleDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Multiple [Domain]</link:label>
    <link:label id="lab_lyel_EquityMultipleDomain_label_en-US" xlink:label="lab_lyel_EquityMultipleDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Multiple [Domain]</link:label>
    <link:label id="lab_lyel_EquityMultipleDomain_documentation_en-US" xlink:label="lab_lyel_EquityMultipleDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Multiple Domain.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityMultipleDomain" xlink:href="lyel-20240331.xsd#lyel_EquityMultipleDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_EquityMultipleDomain" xlink:to="lab_lyel_EquityMultipleDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_EquityMultipleAxis_f5cda8f0-dbcf-4207-80e5-55e9b17dacfa_terseLabel_en-US" xlink:label="lab_lyel_EquityMultipleAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Multiple [Axis]</link:label>
    <link:label id="lab_lyel_EquityMultipleAxis_label_en-US" xlink:label="lab_lyel_EquityMultipleAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Multiple [Axis]</link:label>
    <link:label id="lab_lyel_EquityMultipleAxis_documentation_en-US" xlink:label="lab_lyel_EquityMultipleAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Multiple Axis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityMultipleAxis" xlink:href="lyel-20240331.xsd#lyel_EquityMultipleAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_EquityMultipleAxis" xlink:to="lab_lyel_EquityMultipleAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_9e215698-2fb6-406e-bd03-86d90d9065ff_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_e2e14e0b-9e09-4405-ad92-2893f7a91d68_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:to="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod_c49b8237-5e49-48a1-b822-65cee176932c_terseLabel_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award performance period</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod_label_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Performance Period</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod_documentation_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Performance Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" xlink:href="lyel-20240331.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" xlink:to="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_ThirtyTimesMember_3c622989-a106-49c9-9c90-5eb806c214a4_terseLabel_en-US" xlink:label="lab_lyel_ThirtyTimesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thirty Times</link:label>
    <link:label id="lab_lyel_ThirtyTimesMember_label_en-US" xlink:label="lab_lyel_ThirtyTimesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Thirty Times [Member]</link:label>
    <link:label id="lab_lyel_ThirtyTimesMember_documentation_en-US" xlink:label="lab_lyel_ThirtyTimesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Thirty Times (30x).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ThirtyTimesMember" xlink:href="lyel-20240331.xsd#lyel_ThirtyTimesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_ThirtyTimesMember" xlink:to="lab_lyel_ThirtyTimesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b03656a6-13ac-45f2-bc93-740c6ad72396_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_66e95104-ed5a-412e-bf90-9df6ef4fa761_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_ShareBasedPaymentArrangementPlanModificationExercisePrice_939baa61-8b6c-45c6-a670-0c875109173c_terseLabel_en-US" xlink:label="lab_lyel_ShareBasedPaymentArrangementPlanModificationExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan modification, exercise price (in dollars per share)</link:label>
    <link:label id="lab_lyel_ShareBasedPaymentArrangementPlanModificationExercisePrice_label_en-US" xlink:label="lab_lyel_ShareBasedPaymentArrangementPlanModificationExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Plan Modification, Exercise Price</link:label>
    <link:label id="lab_lyel_ShareBasedPaymentArrangementPlanModificationExercisePrice_documentation_en-US" xlink:label="lab_lyel_ShareBasedPaymentArrangementPlanModificationExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Plan Modification, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedPaymentArrangementPlanModificationExercisePrice" xlink:href="lyel-20240331.xsd#lyel_ShareBasedPaymentArrangementPlanModificationExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_ShareBasedPaymentArrangementPlanModificationExercisePrice" xlink:to="lab_lyel_ShareBasedPaymentArrangementPlanModificationExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ac534dc8-c8af-43c3-948f-f4b1568ae356_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ed4b4257-fb96-4965-94cd-b78bca4b3a38_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e0e7ac55-c95f-40d8-88a6-844d7d30481c_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. government agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b0a9641f-2bac-4c49-b4da-c0f22a4a3d21_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e6fa5931-56cc-4e90-ae50-fb90f5e3df29_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e11478e-f6ca-4d42-9b2e-3da684265c67_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_19943837-e5ea-4783-8382-85d94e1793bb_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_6cba09b4-a3e2-498d-a69e-6c80e8066080_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1aa15ca3-18e5-4adb-9361-7aca48aeeaf1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_0554637c-0096-4e30-9903-b7f02ec341a9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_52c1399b-6795-4c30-b121-d2c25b6d2346_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e75835a9-e5a5-4682-b10d-bd079d49a9a1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_119c3c14-b14c-4e30-930c-ce6d8f3ad199_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_96e2ff18-41dd-4f2a-9c08-3f63e0c13252_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_093156ee-f546-4b21-b649-a7ba43a9f8a6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e919f59e-b1a7-4f77-bf87-2ab521c25677_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d84013c0-796c-477d-907d-9a43725c0679_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1b837db7-b2de-41a7-a4e8-0290413dba99_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Performance-Based Restricted Stock Units Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e0c06f4a-fb07-4f11-a906-d3b581c5f646_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_eb49bb13-628d-452b-a4b8-3972cc7f32b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_58a6237a-33fb-4b7a-b2c2-cf6d48a69d37_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_ae5f7775-1a5a-4c0b-829e-dc86f67ea936_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_69d55718-5e53-4c39-a007-74ecbf0303e6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fda4dec1-b0f0-4034-9c5e-d65ccc88a950_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_MarketableSecuritiesNoncurrentMember_26c96dbe-2f5d-4b3d-9559-818567b03501_terseLabel_en-US" xlink:label="lab_lyel_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, non-current</link:label>
    <link:label id="lab_lyel_MarketableSecuritiesNoncurrentMember_label_en-US" xlink:label="lab_lyel_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Noncurrent [Member]</link:label>
    <link:label id="lab_lyel_MarketableSecuritiesNoncurrentMember_documentation_en-US" xlink:label="lab_lyel_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_MarketableSecuritiesNoncurrentMember" xlink:href="lyel-20240331.xsd#lyel_MarketableSecuritiesNoncurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_MarketableSecuritiesNoncurrentMember" xlink:to="lab_lyel_MarketableSecuritiesNoncurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_e64a9841-eb25-44b8-8eb3-3ec8c9de9c7d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_65cfd09d-a440-4d89-99dc-b45a66ef9c7b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_de1e6289-2d95-4fbf-a981-99b239998c86_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_a31e0545-8331-43c1-abd2-f15546939467_terseLabel_en-US" xlink:label="lab_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_label_en-US" xlink:label="lab_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Paid For Amounts Included In Measurement Of Lease Liabilities</link:label>
    <link:label id="lab_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_documentation_en-US" xlink:label="lab_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:href="lyel-20240331.xsd#lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:to="lab_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_826674aa-0e43-4bf7-90c6-b60bc91d95b7_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_55dd8f45-8418-4f15-a16b-1cb73744af46_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized (loss) gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ccba4db2-2531-431e-b213-75ba4b87fe7d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8b426b17-7fdb-41cb-9e6a-c351b8d696be_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_e5ad5674-154b-4340-8696-0efca76bcec0_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_3c3d1f6c-62a4-4c49-96a7-fb18a27476bb_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding_d6dc7f8d-f5ca-4163-8948-d8f96321edaf_terseLabel_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in proportion of common shares reserved for future issuance (as a percent)</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding_label_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Additional Shares Authorized, Number Of Shares As Percentage Of Common Shares Outstanding</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding_documentation_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Additional Shares Authorized, Number Of Shares As Percentage Of Common Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:href="lyel-20240331.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:to="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_323b37d9-72fc-442b-8752-fda4221ef32b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Success Payment Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_3f245065-f7d1-42b7-bf76-14b1b574cf1a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c902a4ae-90da-456c-af21-840aad961522_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_56ed897d-f56c-4ba1-a87f-5f96b4edf75d_terseLabel_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proportion of stock outstanding (as a percent)</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_label_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number Of Shares Available For Grant, Percentage Of Shares Outstanding</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_documentation_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number Of Shares Available For Grant, Percentage Of Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:href="lyel-20240331.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:to="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SuccessPaymentLiabilityMeasurementInput_7f1d07d1-207d-4c5f-978e-cf2c30ca70e0_terseLabel_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Success payment liability, measurement input (as a percent)</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilityMeasurementInput_label_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Success Payment Liability, Measurement Input</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilityMeasurementInput_documentation_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Success Payment Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilityMeasurementInput" xlink:href="lyel-20240331.xsd#lyel_SuccessPaymentLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SuccessPaymentLiabilityMeasurementInput" xlink:to="lab_lyel_SuccessPaymentLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_43cad49c-ccbb-449f-8530-a53f109e3eb2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Operating Lease Commitments, Including Expected Lease Incentives to be Received</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate_3a131231-3fbe-4ae7-9594-984e5a1ad2ea_terseLabel_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service period from the milestone achievement date</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate_label_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Service Period from Milestone Achievement Date</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate_documentation_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Service Period from Milestone Achievement Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate" xlink:href="lyel-20240331.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate" xlink:to="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_4ba10b4c-2a21-44a8-90ac-ad61cb06cdbb_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative impairments of strategic investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_c6bc67b2-f032-447f-8a52-ff56a34c8f22_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_1e032825-9f03-467f-809d-fca177993384_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_233086aa-a5db-467e-9447-965ce3801dae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_6a9da3a7-a19c-4ec4-a8df-20c0ce3c1c7d_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_67d44334-3f93-4d94-8d31-5bc6a7d087c8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53520b19-e2d2-4a00-8af4-f1c66accedba_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_ddb3ed20-cb13-49e4-b43b-8fc7af24463e_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d7b26950-aa9c-402c-81a2-05c9875b7465_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">PSUs granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7f327a80-a9a1-4e32-9bb2-c44ef9f4e2bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_3e9b40e0-5135-4229-a700-7209d0bc0303_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_4fff3aaf-eaf1-43ad-81ab-aa8e1212b9b2_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_bd85a0d0-1d6c-4bbd-a60a-516a7c96cc31_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_ae4b5dc5-b2ce-4626-a702-336515657999_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_75fd33bd-7ad5-4aed-9f5f-1562890b7d42_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_c279e32c-2194-4d93-90ea-431d2786f1b6_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9be817c0-a2de-48b0-84cc-73d9ef9ac3a6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_371d4541-98a7-4a9a-ba81-3caecd8b4637_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_b8d76671-7633-4009-87e7-032e1a95ad3f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related-party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f9860b91-dce8-45c3-9a0f-3e6daa2efdd0_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_91afbff9-34cd-4fdd-b469-c658822462cf_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_83756304-7982-4434-8b1d-9fc9e35c909d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c020f357-8492-40b6-8013-dbe4369da28c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_aa9e7bbb-92f7-4e97-9e34-53187f89b0c8_verboseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Aggregate success payments</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_ea993fc0-a099-4688-a79f-3526abd99b1c_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate success payment(s) (in millions)</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_8ef3ff87-0cab-4554-891e-751e3872c33f_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Multiple of initial equity value at issuance</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Potential Payment Multiplier</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Potential Payment Multiplier</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_67cb1d07-f4e8-477f-913c-7bb6ef493e89_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_e7f77fa4-21b7-4ffa-88f7-142788bb1987_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_55e43656-e882-4bd0-abe8-77dde2323a96_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_072c534b-776a-4581-8902-fe8534644ebd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5ebcc2dd-65e8-4768-8197-155be2f6c202_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_FortyTimesMember_6f4e55f5-2de2-4cea-9074-59ef0f420a0a_terseLabel_en-US" xlink:label="lab_lyel_FortyTimesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forty Times</link:label>
    <link:label id="lab_lyel_FortyTimesMember_label_en-US" xlink:label="lab_lyel_FortyTimesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forty Times [Member]</link:label>
    <link:label id="lab_lyel_FortyTimesMember_documentation_en-US" xlink:label="lab_lyel_FortyTimesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forty Times (40x).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FortyTimesMember" xlink:href="lyel-20240331.xsd#lyel_FortyTimesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_FortyTimesMember" xlink:to="lab_lyel_FortyTimesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_ab36ce0c-d652-40ef-bff5-8954990c2352_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b5d1b5f8-a31b-429e-8501-314de4e336d9_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_575ebd7c-5331-4eff-8a49-6611dc9c5079_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6d6ac9aa-26d5-4144-88b2-eace7dceb899_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_27de7501-26a5-4d05-83e0-42024963d745_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_4c7ef38b-866e-4205-8fbd-ae61759e4da2_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_96ee508a-6488-4238-a231-3f0bee63c1be_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_d05c69f1-8d9a-4147-921a-ae1242c151df_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_0c9669ce-c77b-4059-9c87-f73adcf9a078_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of securities held in a continuous unrealized loss position for greater than twelve months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_4c08de1a-746c-47c4-a969-f6a8f538a156_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_91a275a8-743a-4331-a6a5-7b559d69418c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">PSUs vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cc42cebe-9ae2-4e20-9a3f-1c0459492554_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">RSUs vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c63949e4-74df-472b-9fe0-c76d4fe35a11_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_dbd7cef6-76bb-4266-9c6b-d3e54270e096_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_f73e8827-477a-49ae-9da0-44d0a673f1d2_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_08fb84b6-aa45-4e3f-806c-cc532476c454_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_88a44aa7-d112-4708-852a-ac8e8d560168_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c59e92ad-9f49-4d56-8241-668768a10664_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting rights, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_45416a0d-51e3-45f8-ae64-a9851c2bca3a_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License, Collaboration, and Success Payment Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_0c92448b-a35f-4b4f-b7b3-8f088e2a8733_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0a430bdd-3291-4554-99b3-59f38ad7ac5f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected weighted-average period compensation cost to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_eb3d051a-b25f-4178-8b64-19d1d2795aa3_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_863a800e-2b5f-4b98-9e2a-65218e64f4d7_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7b7f2248-0994-4590-8aea-e82bbda8c748_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation cost related to unvested awards not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7d45471f-b88d-4e19-be09-3db5bacd9ced_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_d33a21f0-d367-4d80-a998-f8344ed3fc69_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Total Income Attributable to Sonoma Sublease</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_776fabac-d76a-4738-b1ae-26f7c260e2cb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address Line</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_718350da-3b8a-4f6c-bb8b-1edab0764a7c_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, non-current</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_e11bb3c2-15d6-4e2d-9545-678f55268588_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_403e6b60-e054-49ab-b39b-0680ae46801e_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable interest entity maximum loss exposure, amount</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" xlink:to="lab_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_07a49e6d-c314-43fc-af51-69eabbcd2de0_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c21c5c1a-6832-4d56-bb68-bfebce2e60aa_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_ded99627-83ba-4015-bdf8-d5121e649230_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e6851f35-50ad-48ad-9699-662898fd3a9e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_54fa4b53-9152-442a-ab56-64df66718818_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment of other investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_ab261e63-bd4b-4582-b603-e058fd2472c9_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of other investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary_18d3f58d-5eaf-4052-843c-d79e8e505a6c_terseLabel_en-US" xlink:label="lab_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable interest entity, number of entities company is not primary beneficiary</link:label>
    <link:label id="lab_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary_label_en-US" xlink:label="lab_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Number of Investments that Company is Not the Primary Beneficiary</link:label>
    <link:label id="lab_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary_documentation_en-US" xlink:label="lab_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Number of Investments that Company is Not the Primary Beneficiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary" xlink:href="lyel-20240331.xsd#lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary" xlink:to="lab_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_a2e1fe62-c007-49d8-bc99-3c0b70abb2c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of common stock at discount (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_ea9a2265-25f1-41fa-9303-8c260f806d97_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_e09e6b60-2d63-4aef-ac79-0c540c1f98cd_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Per share common stock price required for payment (in dollars per share)</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments, Share Price</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_d1b4b661-f7ca-4b88-9a94-15733e411c48_terseLabel_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum number of shares to be purchased under ESPP (in shares)</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_label_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Maximum Shares Issuable</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_documentation_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Maximum Shares Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:href="lyel-20240331.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:to="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_f7747874-094c-4f68-a7cb-d83b86f570b5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_08f85ace-7085-41e5-bd41-a31765e2f680_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security12b Title</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_15f1a13c-5a25-46f6-a1b9-3eb71a50729a_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering_977d48e0-a38c-4237-87ad-366ef15d5060_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trigger period thereafter</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period After Initial Public Offering</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_a151874b-174d-4137-a756-2de49372ca0e_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_b355cf15-3a4f-4dfc-a20a-84b5b69fe630_verboseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sonoma sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_5a66fe29-37f8-4207-9ec7-2cdc0a8c80b5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_7e427fd2-6fc6-40b6-a05f-71397eb4f5db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incremental stock-based compensation expense of modifications</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Plan Modification, Incremental Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SeriesAConvertiblePreferredStockMember_ea1778d6-d18d-4a97-8db0-04e401884d5c_terseLabel_en-US" xlink:label="lab_lyel_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_lyel_SeriesAConvertiblePreferredStockMember_label_en-US" xlink:label="lab_lyel_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_lyel_SeriesAConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_lyel_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SeriesAConvertiblePreferredStockMember" xlink:href="lyel-20240331.xsd#lyel_SeriesAConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SeriesAConvertiblePreferredStockMember" xlink:to="lab_lyel_SeriesAConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_b7fb0afe-7617-43cb-88dc-80a9f03eafce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_98ad4be9-297e-4a07-8eef-9fd286bf6a08_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e6f45716-c094-45c3-be4d-5d5e43ad770e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_1eeb60e9-44dd-4c6d-8404-2e97541b142d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_9e196a0f-72dc-4d1c-a951-0b6b7172d35e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value (in thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635a6bf8-b871-4950-8317-c97e8563c3d6_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_627da2c3-5bb0-448d-a562-4a258d5ccbef_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_071b10ae-e734-4497-ae4d-08f61d415b25_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_1450762e-33e4-48cb-a9e3-e9a4eb5b677c_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_ef500b79-0633-4915-97dc-6e941d80e4e0_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_39dcbc46-2260-4f93-8502-19188912f9b0_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_2b0fd811-8484-49dd-96a5-7c32e02b202d_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_AtTheMarketOfferingMember_c4eede32-e0f5-45e0-96c1-c6a127f78e8c_terseLabel_en-US" xlink:label="lab_lyel_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At The Market Offering</link:label>
    <link:label id="lab_lyel_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_lyel_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_lyel_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_lyel_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_AtTheMarketOfferingMember" xlink:href="lyel-20240331.xsd#lyel_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_AtTheMarketOfferingMember" xlink:to="lab_lyel_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_bd7b9e0a-0b14-41f1-a6a7-fc1b7b126a10_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0f67b36b-4194-4a53-a9a0-ee8e1a79892a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_4ef27c5e-c08e-4793-b149-c67c20a6bc29_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e28024f3-4269-4d82-b680-8f07efa1ba64_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c2382dab-0f63-4db9-ac18-da4d578a07f1_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_2425e6fd-e1d3-46c6-94f4-6dd44517c4c5_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_be14f68e-cdb8-480e-8848-243546898277_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_95edb6b9-33f1-4c3d-8174-d1832ace6489_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_c6a8216d-df4f-4292-883b-a96e4af512cd_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_50887e77-ed6a-41bd-be67-42e2624f3b15_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d5bc0619-9d7a-4f7e-8cfa-4a19d53e7544_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_7c4f4992-e428-4a7c-a290-ef28c8fd3f64_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget_ac4fda92-75be-43c0-8e12-1cd12acd08f8_terseLabel_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards granted, percentage of target</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget_label_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Awards Granted, Percentage of Target</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget_documentation_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Awards Granted, Percentage of Target</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget" xlink:href="lyel-20240331.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget" xlink:to="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f88c86fd-45f7-48cf-83d5-65bb1805ed81_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bcc287c6-9bb2-48fd-a1dc-d47854a49803_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b857b964-c7aa-4dad-b7a9-b3e5df2e782b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_cd887524-cc14-417a-a729-d29d45fd0e8f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1386a2d1-368a-4b29-af8e-06896023ed1c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestments_4d46d77f-fc75-4a1d-bbe6-91ea855a1489_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other investments</link:label>
    <link:label id="lab_us-gaap_OtherInvestments_label_en-US" xlink:label="lab_us-gaap_OtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestments" xlink:to="lab_us-gaap_OtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_c502903f-4b40-4d00-81fd-25ec2863d12d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_b9a3887b-06e1-4aac-a90d-3db6ec0efd92_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced_14b95fe8-fc8c-439f-aef9-350b101ea5e5_terseLabel_en-US" xlink:label="lab_lyel_ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares repriced (in shares)</link:label>
    <link:label id="lab_lyel_ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced_label_en-US" xlink:label="lab_lyel_ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Plan Modification, Number of Shares Repriced</link:label>
    <link:label id="lab_lyel_ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced_documentation_en-US" xlink:label="lab_lyel_ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Plan Modification, Number of Shares Repriced</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced" xlink:href="lyel-20240331.xsd#lyel_ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced" xlink:to="lab_lyel_ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_056e1413-9c0c-42a9-9725-2a7b2b507736_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_3f19404a-99d0-480e-b842-ec6d7ef76b2c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_ae08f6ea-6eea-4690-978f-a4fb934a9fcc_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1a18aa8f-031e-4441-af4d-18bc89556977_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_DateOfEquityModificationsAxis_cb09d287-4269-403d-a51b-cb8a35ad6a94_terseLabel_en-US" xlink:label="lab_lyel_DateOfEquityModificationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Date Of Equity Modifications [Axis]</link:label>
    <link:label id="lab_lyel_DateOfEquityModificationsAxis_label_en-US" xlink:label="lab_lyel_DateOfEquityModificationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Date Of Equity Modifications [Axis]</link:label>
    <link:label id="lab_lyel_DateOfEquityModificationsAxis_documentation_en-US" xlink:label="lab_lyel_DateOfEquityModificationsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Date Of Equity Modifications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_DateOfEquityModificationsAxis" xlink:href="lyel-20240331.xsd#lyel_DateOfEquityModificationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_DateOfEquityModificationsAxis" xlink:to="lab_lyel_DateOfEquityModificationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0e0beae3-19e3-4559-9d11-1f2160f386bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_6b9a0871-9991-483b-9d7a-35bf797fe1ed_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_129f95c8-17f4-4cce-be3c-170e0e0aabee_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_0f7e4d9c-34de-41f1-8485-2d353ffec83d_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SaleOfStockMaximumConsiderationReceived_45f0b9b7-189a-4849-8077-0a8344e176de_terseLabel_en-US" xlink:label="lab_lyel_SaleOfStockMaximumConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, maximum aggregate offering amount</link:label>
    <link:label id="lab_lyel_SaleOfStockMaximumConsiderationReceived_label_en-US" xlink:label="lab_lyel_SaleOfStockMaximumConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Maximum Consideration Received</link:label>
    <link:label id="lab_lyel_SaleOfStockMaximumConsiderationReceived_documentation_en-US" xlink:label="lab_lyel_SaleOfStockMaximumConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Maximum Consideration Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SaleOfStockMaximumConsiderationReceived" xlink:href="lyel-20240331.xsd#lyel_SaleOfStockMaximumConsiderationReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SaleOfStockMaximumConsiderationReceived" xlink:to="lab_lyel_SaleOfStockMaximumConsiderationReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_2e85250f-2137-4223-9f4a-1a4196740cb7_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_NonCashLeaseIncomeExpense_477a7bf5-24ca-43e7-9aa1-2c3c494e4963_negatedTerseLabel_en-US" xlink:label="lab_lyel_NonCashLeaseIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease income</link:label>
    <link:label id="lab_lyel_NonCashLeaseIncomeExpense_label_en-US" xlink:label="lab_lyel_NonCashLeaseIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Lease Income (Expense)</link:label>
    <link:label id="lab_lyel_NonCashLeaseIncomeExpense_documentation_en-US" xlink:label="lab_lyel_NonCashLeaseIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Lease Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_NonCashLeaseIncomeExpense" xlink:href="lyel-20240331.xsd#lyel_NonCashLeaseIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_NonCashLeaseIncomeExpense" xlink:to="lab_lyel_NonCashLeaseIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3e13555e-4c92-48c4-9f65-f75cf2175338_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_91439061-80a2-43ca-9762-c4ec348a072f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_886b5637-532e-40f7-8057-59d96467e774_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_94a7b8b7-0202-4fcb-809c-72d5096a9dbf_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3b8efb3f-c610-4aa1-9a92-fdac1dec1bcc_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses, other current assets and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c9ac4a2e-0b2b-4d18-a8ac-84b589249b00_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum_e0d54e45-557c-45d3-8368-2566b4e5e818_terseLabel_en-US" xlink:label="lab_lyel_ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum exercise price of plan modifications (in dollars per share)</link:label>
    <link:label id="lab_lyel_ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum_label_en-US" xlink:label="lab_lyel_ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Plan Modification, Exercise Price, Minimum</link:label>
    <link:label id="lab_lyel_ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum_documentation_en-US" xlink:label="lab_lyel_ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Plan Modification, Exercise Price, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum" xlink:href="lyel-20240331.xsd#lyel_ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum" xlink:to="lab_lyel_ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a1a32177-60e3-4429-9d85-f7cb74f877fb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future issuance of common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_TwoThousandEighteenEquityIncentivePlanMember_d71fdb48-a52f-4019-ba58-50a7acbf718b_terseLabel_en-US" xlink:label="lab_lyel_TwoThousandEighteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 Equity Incentive Plan</link:label>
    <link:label id="lab_lyel_TwoThousandEighteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_lyel_TwoThousandEighteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Eighteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_lyel_TwoThousandEighteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_lyel_TwoThousandEighteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Eighteen Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandEighteenEquityIncentivePlanMember" xlink:href="lyel-20240331.xsd#lyel_TwoThousandEighteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_TwoThousandEighteenEquityIncentivePlanMember" xlink:to="lab_lyel_TwoThousandEighteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_1d283151-3e9f-40da-bc5a-5e1a7b5dcdfd_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_44c5505b-abfe-46aa-a9b0-66555f8dd0b0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2b545375-9d02-4deb-a1ad-f9c0b0747c12_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value; 500,000 shares authorized at March&#160;31, 2024 and December&#160;31, 2023; 254,927 and 253,958 shares issued and outstanding at March&#160;31, 2024 and December&#160;31, 2023, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_12c4c1dc-0df3-4371-82a0-4e98b18f27b2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of securities held in a continuous unrealized loss position for less than twelve months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments_3909b06f-e79b-431e-8b2b-48b880baa2d0_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual license maintenance payments</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Annual License Maintenance Payments</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Annual License Maintenance Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_ba8520e2-0be4-4637-8977-f266ea417f07_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8041fcc1-fc55-46b9-99e1-0b04b7678511_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities_376fae75-4367-4438-8ed0-724bf5fae85f_terseLabel_en-US" xlink:label="lab_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of success payment liabilities</link:label>
    <link:label id="lab_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities_label_en-US" xlink:label="lab_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment Of Success Payment Liabilities</link:label>
    <link:label id="lab_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities_documentation_en-US" xlink:label="lab_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value adjustment of success payment liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities" xlink:href="lyel-20240331.xsd#lyel_FairValueAdjustmentOfSuccessPaymentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities" xlink:to="lab_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_3f324844-05c7-49ec-ae95-38261969121d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_81292941-d926-4a97-9466-2fac255daa26_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUPPLEMENTAL CASH FLOW INFORMATION</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm_33a1197a-1cae-40c9-89aa-71fe82ce56d2_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of collaborative arrangement for research</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Research Term</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Research Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsResearchTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_ff1c4246-d3ad-45a9-8164-5f83033c29a7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_42cfc004-2a9d-4d86-8890-7e5791381c4b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_0ac6cea0-6495-4b43-ab5c-54b793c3656c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_ec7e4f2c-7849-4eba-ac19-2d446feba3b4_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_d4175b60-4ffa-4786-acfe-d866944784b4_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_8857c4d5-8495-4002-b2a2-ba78a7671f4b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity of marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_892cc112-ce11-43ef-8730-26fc971b7491_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_cbd8933b-5d70-43be-82b4-0fa2efd03fcf_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_c9c9bd64-da07-4e69-ab0b-56b87f7c3eee_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TenantImprovements_3f716baa-2f25-4f97-b742-c0f85507a66a_terseLabel_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tenant improvements</link:label>
    <link:label id="lab_us-gaap_TenantImprovements_label_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TenantImprovements" xlink:to="lab_us-gaap_TenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_382547a9-781d-4b29-b553-21403ecbfdf2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PSUs granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_984fad47-7dfd-4f2b-93d0-a59b5f40ad30_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RSUs granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_af245432-ea33-4da4-877d-335b9f91c704_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_d33839a2-2dce-4ff9-8d1a-c40eb737354b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_6e9601e9-eab5-4c10-9b32-c50d779abdc4_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems" xlink:to="lab_us-gaap_MarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_724e0712-cb8f-4d1b-8be3-f04ad4325ea3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_fda27a00-07e8-4624-8cc1-6ae8c82ae6a8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_f65715cd-7e84-435a-95c8-751f6ebe1f52_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_4d7b33a0-b4ca-4c6e-8082-a1262a97c0fb_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_6614bdb9-b883-45bb-baec-0782885a4e87_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other operating income, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_fa2be70c-7ed5-4156-a7d8-858c3ca42fa1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sonoma other operating income, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_7920ceda-38e3-48a7-953b-5b47260ac4e1_terseLabel_en-US" xlink:label="lab_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="lyel-20240331.xsd#lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_05aad24b-5792-44d6-ab7a-00d7b8eecb16_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_48938696-0540-4f04-b08f-f4c8d0f29b95_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_566ae6ca-5e66-4848-98f6-2ecaa16cad1a_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1eb1c102-06c9-4520-b2f7-9d84857ef3d7_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CowenAndCompanyLLCMember_cab3ccdc-a1a8-4b58-8e7e-f1c376c0f1a2_terseLabel_en-US" xlink:label="lab_lyel_CowenAndCompanyLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cowen and Company, LLC</link:label>
    <link:label id="lab_lyel_CowenAndCompanyLLCMember_label_en-US" xlink:label="lab_lyel_CowenAndCompanyLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cowen and Company, LLC [Member]</link:label>
    <link:label id="lab_lyel_CowenAndCompanyLLCMember_documentation_en-US" xlink:label="lab_lyel_CowenAndCompanyLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cowen and Company, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CowenAndCompanyLLCMember" xlink:href="lyel-20240331.xsd#lyel_CowenAndCompanyLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CowenAndCompanyLLCMember" xlink:to="lab_lyel_CowenAndCompanyLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments_571298f5-b5b2-4d7a-a540-c71919f1d5c0_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential milestone payments due</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Commercial Milestone Payments</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Commercial Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_542a81f2-99c8-4ec6-8c5b-b14f0d592014_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_78ef3dba-ffbc-409b-89ee-23182b019da4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Estimated Fair Value of Success Payment Liability Assumptions</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_122c78ec-9b79-457f-a5e0-61e43fd036f9_terseLabel_en-US" xlink:label="lab_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classified as:</link:label>
    <link:label id="lab_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_label_en-US" xlink:label="lab_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Debt Securities, Available-For-Sale [Abstract]</link:label>
    <link:label id="lab_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_documentation_en-US" xlink:label="lab_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Debt Securities, Available-For-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract" xlink:href="lyel-20240331.xsd#lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract" xlink:to="lab_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SignificantAccountingPoliciesPolicyTextBlock_52a47a1e-3bec-4ab9-87b3-591defa8d0ad_terseLabel_en-US" xlink:label="lab_lyel_SignificantAccountingPoliciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_lyel_SignificantAccountingPoliciesPolicyTextBlock_label_en-US" xlink:label="lab_lyel_SignificantAccountingPoliciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Policy Text Block]</link:label>
    <link:label id="lab_lyel_SignificantAccountingPoliciesPolicyTextBlock_documentation_en-US" xlink:label="lab_lyel_SignificantAccountingPoliciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SignificantAccountingPoliciesPolicyTextBlock" xlink:href="lyel-20240331.xsd#lyel_SignificantAccountingPoliciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SignificantAccountingPoliciesPolicyTextBlock" xlink:to="lab_lyel_SignificantAccountingPoliciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_85138603-bdce-4e9b-9f8c-cfb8f8b582c0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4c29b257-3129-4bb2-b6dd-933bf7fdc4c2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SouthSanFranciscoCaliforniaMember_79b13b85-7abc-444f-9171-5d552df5e24f_terseLabel_en-US" xlink:label="lab_lyel_SouthSanFranciscoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">South San Francisco, California</link:label>
    <link:label id="lab_lyel_SouthSanFranciscoCaliforniaMember_label_en-US" xlink:label="lab_lyel_SouthSanFranciscoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">South San Francisco, California [Member]</link:label>
    <link:label id="lab_lyel_SouthSanFranciscoCaliforniaMember_documentation_en-US" xlink:label="lab_lyel_SouthSanFranciscoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">South San Francisco, California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SouthSanFranciscoCaliforniaMember" xlink:href="lyel-20240331.xsd#lyel_SouthSanFranciscoCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SouthSanFranciscoCaliforniaMember" xlink:to="lab_lyel_SouthSanFranciscoCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_b2f9a2c8-5ca7-448d-8866-b25ab29e0d38_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_dfc80147-3471-4491-92e2-c7ad55ebf90b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_DateOfEquityModificationsDomain_43c6bcd5-59e2-4b8f-b39e-ba7b086c8e1c_terseLabel_en-US" xlink:label="lab_lyel_DateOfEquityModificationsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Date Of Equity Modifications [Domain]</link:label>
    <link:label id="lab_lyel_DateOfEquityModificationsDomain_label_en-US" xlink:label="lab_lyel_DateOfEquityModificationsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Date Of Equity Modifications [Domain]</link:label>
    <link:label id="lab_lyel_DateOfEquityModificationsDomain_documentation_en-US" xlink:label="lab_lyel_DateOfEquityModificationsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Date Of Equity Modifications [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_DateOfEquityModificationsDomain" xlink:href="lyel-20240331.xsd#lyel_DateOfEquityModificationsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_DateOfEquityModificationsDomain" xlink:to="lab_lyel_DateOfEquityModificationsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_FiftyTimesMember_650a10c7-7391-4363-882d-1791ae24ce23_terseLabel_en-US" xlink:label="lab_lyel_FiftyTimesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fifty Times</link:label>
    <link:label id="lab_lyel_FiftyTimesMember_label_en-US" xlink:label="lab_lyel_FiftyTimesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fifty Times [Member]</link:label>
    <link:label id="lab_lyel_FiftyTimesMember_documentation_en-US" xlink:label="lab_lyel_FiftyTimesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fifty Times (50x).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FiftyTimesMember" xlink:href="lyel-20240331.xsd#lyel_FiftyTimesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_FiftyTimesMember" xlink:to="lab_lyel_FiftyTimesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_36f727b1-4382-4ed7-8604-ef9b93108694_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_df5b679d-60a9-42ff-8a0a-957ebad5b160_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_a465bff4-4ca0-43b7-b9a3-3a868d309f13_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f94095e5-9a31-408f-aedd-418d06885d71_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_9f68f2a0-70be-457d-9bde-ed3456a23a62_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability_521dc29e-b38e-420f-8aa6-11f75f765e06_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Success payment liability</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Liability</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0c807327-4907-422a-93b6-df82b4b031b4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_861fb488-9f15-47d4-bbb9-62902e6e5e8a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b55bc403-1ee6-4dc8-af22-ae7c3e858199_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_89c3ffea-d560-45f6-86d4-ee0640516757_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_ab91f938-d729-4fbc-a598-1d44b002eb13_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9370fecf-2dbd-44cc-a341-61ef57b19d58_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6ea6dc8e-1cfa-4c53-8c6f-585f12ac9491_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_044f771f-60bc-4393-b66c-ea1319307d5a_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_f4ce71f7-2751-4a95-a8cb-ba50a687ae9e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_1eaa251a-e92d-42bd-94b8-1066ab70ca47_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_5857f111-d97d-48ea-9dce-ffce09a100a7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in the Estimated Fair Value of Level 3 Financial Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_df91f8af-b549-47a9-8df1-681ed7b85959_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_373f24d0-994b-462e-81a1-ea577dd21b2f_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_593e7fb7-03ff-4c2b-80eb-df0aa2a54df1_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTable" xlink:to="lab_us-gaap_MarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability_e84455d4-2ab6-4ca5-beed-8dedd1d0f542_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of potential success payments due</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Fair Value Of Liability</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Fair Value Of Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_070e1302-0d5e-436c-8dc0-a6bd148ff99a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Aggregate Potential Success Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_c2657e89-44a7-4697-b330-9e322e1f247f_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_040942a8-310c-418e-90e0-9764e926daf2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_26dcafed-673d-4f7e-a174-de9f37cf06b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Original exercise price lower range (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_42b9f3ba-69fb-4a98-95f1-077b87ecd2ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_StanfordMember_131bac93-fc33-4c7f-8793-3d2b8570f528_terseLabel_en-US" xlink:label="lab_lyel_StanfordMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stanford</link:label>
    <link:label id="lab_lyel_StanfordMember_label_en-US" xlink:label="lab_lyel_StanfordMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stanford [Member]</link:label>
    <link:label id="lab_lyel_StanfordMember_documentation_en-US" xlink:label="lab_lyel_StanfordMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stanford.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordMember" xlink:href="lyel-20240331.xsd#lyel_StanfordMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_StanfordMember" xlink:to="lab_lyel_StanfordMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fdf59e48-29ad-4ff8-92de-43bae47125c6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate_41487c07-133f-4193-ade5-4b68c888618e_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trigger period from IPO date</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period From Initial Public Offering Date</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period From Initial Public Offering Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_a9ae683e-1ce1-4345-b697-de17306402fa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_TwoThousandTwentyOneEquityIncentivePlanMember_be3ed25f-a6f8-45d4-a7d8-7a480946bc09_terseLabel_en-US" xlink:label="lab_lyel_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 Plan</link:label>
    <link:label id="lab_lyel_TwoThousandTwentyOneEquityIncentivePlanMember_label_en-US" xlink:label="lab_lyel_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty One Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_lyel_TwoThousandTwentyOneEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_lyel_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand twenty one equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:href="lyel-20240331.xsd#lyel_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:to="lab_lyel_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_2146696e-8630-4fa2-8667-d28f3da08965_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b51755bc-03b8-4a70-9650-f687f1c19300_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_159fe9ff-a312-48a5-8787-831231358ff1_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_7266872c-765d-4147-90db-3713be080477_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_ed752763-5e0e-468b-870a-e52cc1b8e312_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8b789ec1-5c8b-49f4-83e7-84b33237ca00_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_56a04f05-8ce1-40f5-b2c8-c88614eb5d87_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f721ac31-8dc5-4b71-a61c-c017b4ebf223_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-based Compensation Expense by Classification</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_f922ff24-be73-4684-b809-73b5cee775a3_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net amortization and accretion on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_a87669c9-883d-412f-afa9-ee5d186f5d09_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ca48c8ad-6660-4d54-bdfe-4a28d2c7c4d4_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_7b861e48-10c3-4f18-9b02-0fc8388b3eb4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6d256825-2bd2-4e3a-a743-366ce8ffb806_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_36ecd4d6-e1e0-4aae-aaf8-1834c52017df_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per common share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_d186ed15-dca6-4fcd-88ba-6682cb1ff3fd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_b9bc539f-a73e-4d0d-a39f-515dd07c9785_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_ffe921b0-c2de-4218-9161-238deb598b1c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_37832ee4-5107-4f8f-92a3-ab45ddb998bc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 (remaining nine months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SonomaMember_1d34ad6b-f2bc-4721-b774-a055a9b7c505_terseLabel_en-US" xlink:label="lab_lyel_SonomaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sonoma</link:label>
    <link:label id="lab_lyel_SonomaMember_label_en-US" xlink:label="lab_lyel_SonomaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sonoma [Member]</link:label>
    <link:label id="lab_lyel_SonomaMember_documentation_en-US" xlink:label="lab_lyel_SonomaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sonoma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SonomaMember" xlink:href="lyel-20240331.xsd#lyel_SonomaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SonomaMember" xlink:to="lab_lyel_SonomaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1acb6d15-5905-46de-8728-b7bf942fb2b8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_5f18a0c1-5e14-4f35-afc4-1b769b3aa2a0_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_fa0670f4-d230-4585-bdac-75614826b498_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidations</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds_7c18c8c8-d948-456c-a2e7-93c8cdc065d1_terseLabel_en-US" xlink:label="lab_lyel_SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commissions payment, percentage of gross sale proceeds</link:label>
    <link:label id="lab_lyel_SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds_label_en-US" xlink:label="lab_lyel_SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Commissions Payment, Percentage of Gross Sale Proceeds</link:label>
    <link:label id="lab_lyel_SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds_documentation_en-US" xlink:label="lab_lyel_SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Commissions Payment, Percentage of Gross Sale Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds" xlink:href="lyel-20240331.xsd#lyel_SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds" xlink:to="lab_lyel_SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_MarketableSecuritiesCurrentMember_3d8dbf26-228c-4481-801f-14b48973bed6_terseLabel_en-US" xlink:label="lab_lyel_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_lyel_MarketableSecuritiesCurrentMember_label_en-US" xlink:label="lab_lyel_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current [Member]</link:label>
    <link:label id="lab_lyel_MarketableSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_lyel_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_MarketableSecuritiesCurrentMember" xlink:href="lyel-20240331.xsd#lyel_MarketableSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_MarketableSecuritiesCurrentMember" xlink:to="lab_lyel_MarketableSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_47f5ffde-7963-419b-9ef1-d3229d3d88ba_terseLabel_en-US" xlink:label="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Off-balance Sheet Risk</link:label>
    <link:label id="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:to="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_e8e3bb40-21c6-48a5-9619-6098aff5ee8f_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SuccessPaymentLiabilitiesCurrent_1220e0fc-0ba8-43aa-9559-5d5bbd32203f_terseLabel_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Success payment liabilities</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilitiesCurrent_label_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Success Payment Liabilities, Current</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilitiesCurrent_documentation_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Success Payment Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilitiesCurrent" xlink:href="lyel-20240331.xsd#lyel_SuccessPaymentLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SuccessPaymentLiabilitiesCurrent" xlink:to="lab_lyel_SuccessPaymentLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_64ed4189-3c73-4f41-aac3-2379659b6892_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_ce330ec2-4a03-4d3a-9884-ce4670e08e9f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2d7b598c-6f3c-4426-8e8b-24301c02b3ae_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_820da68a-11de-4ea5-a637-4ac2b9c7fb0f_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain_267081c9-d3dd-4f01-9435-1127cef44769_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain_89b7b5ed-7950-4623-afb7-e4cdb1f2fcf0_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_1da6d017-5813-4009-8b86-ff74d4ba4f15_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Success payment expense (reversal)</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Expense (Gain)</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Expense (Gain)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_85896f2f-110e-484c-88e6-25a3520ea5c5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5716031e-5028-4b24-abaf-54afec6bd0b6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1cf1c438-3db7-48d3-913c-9b04a6aeb318_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_c007a5f9-af9f-48f0-af66-03c8aad49b92_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_FredHutchMember_8eb47996-efcf-4c9f-bb69-f1582df34574_terseLabel_en-US" xlink:label="lab_lyel_FredHutchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fred Hutch</link:label>
    <link:label id="lab_lyel_FredHutchMember_label_en-US" xlink:label="lab_lyel_FredHutchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fred Hutch [Member]</link:label>
    <link:label id="lab_lyel_FredHutchMember_documentation_en-US" xlink:label="lab_lyel_FredHutchMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fred Hutch</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchMember" xlink:href="lyel-20240331.xsd#lyel_FredHutchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_FredHutchMember" xlink:to="lab_lyel_FredHutchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_ec67c796-4888-4290-8b9d-2239b90e811a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_f70835c7-7f19-47d9-9cec-bfee8716a791_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_A2023Member_cc17016b-4385-461a-83ae-75e56dd64420_terseLabel_en-US" xlink:label="lab_lyel_A2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_lyel_A2023Member_label_en-US" xlink:label="lab_lyel_A2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 [Member]</link:label>
    <link:label id="lab_lyel_A2023Member_documentation_en-US" xlink:label="lab_lyel_A2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_A2023Member" xlink:href="lyel-20240331.xsd#lyel_A2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_A2023Member" xlink:to="lab_lyel_A2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_60e1539c-5f87-4b75-bb60-acf01bc80974_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c325e69f-cbfe-4921-944c-251515c2a640_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PSUs forfeited or canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e96b977f-6f99-40aa-998d-4478772602b7_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RSUs forfeited or canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_cfba72a3-e0a0-42e3-8815-7899794dc5bd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_438076de-5dae-4729-b56a-18310f46660c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_4754ac72-1fdd-49de-8f01-20f961d846fc_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on property and equipment disposals, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_048e4a94-5c3f-420c-b48c-ac1acb1c116e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c80e2dd4-5335-46f7-81c1-79d3e3a0f8ab_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bfaa72bf-80ec-4948-bee9-72119876c3da_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">PSUs forfeited or canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b1460aab-601b-4c44-a3cd-bbfdf09251df_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">RSUs forfeited or canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments_2bdbe268-7cf6-4f4f-b297-5eb6adc4e17c_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential milestone payments due</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Milestone Payments</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b42fa339-4cb3-425d-a4fa-5345acf236bc_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9799ad77-7afe-4215-9bde-c65032fd279b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_df321d2d-4754-48ba-a982-cb021f4b6b05_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_23e17511-b28d-4b74-b3c9-aba09098b84e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Original exercise price upper range (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_463ec9b1-478c-477c-9340-39396f71a1d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earlier of one year of service from achievement date and three-year performance period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_69b93c09-7060-46c6-ae27-9576409ae1ae_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract_0777648d-ca2f-4369-9b3d-aaf2a3203b18_terseLabel_en-US" xlink:label="lab_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Represented by:</link:label>
    <link:label id="lab_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract_label_en-US" xlink:label="lab_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Represented By Cash And Cash Equivalents And Restricted Cash [Abstract]</link:label>
    <link:label id="lab_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract_documentation_en-US" xlink:label="lab_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represented by Cash and Cash Equivalents and Restricted Cash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract" xlink:href="lyel-20240331.xsd#lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract" xlink:to="lab_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_35db6491-b634-4c05-8569-3e1250ea22aa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with restricted stock units, net of tax</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_786134ff-49d3-44e9-add4-691455381b06_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6a16d940-4ef6-4e20-a2da-62e1c2c351d0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_14fb30fa-13bb-44a6-876e-fc078e447c23_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_c15df6f4-b115-49e8-af44-e3b7c6880417_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_b17a9776-5c2b-4fbc-ac5a-00560da1717a_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_OtherInvestmentMember_702db1ab-a4e8-4ffc-a6b5-cd874e38f742_terseLabel_en-US" xlink:label="lab_lyel_OtherInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Investment</link:label>
    <link:label id="lab_lyel_OtherInvestmentMember_label_en-US" xlink:label="lab_lyel_OtherInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Investment [Member]</link:label>
    <link:label id="lab_lyel_OtherInvestmentMember_documentation_en-US" xlink:label="lab_lyel_OtherInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Investment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_OtherInvestmentMember" xlink:href="lyel-20240331.xsd#lyel_OtherInvestmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_OtherInvestmentMember" xlink:to="lab_lyel_OtherInvestmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SuccessPaymentLiabilityMember_a52b4c56-29ab-45d7-88c3-410db5fc5bd8_verboseLabel_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Success Payment Liabilities</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilityMember_label_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Success Payment Liability [Member]</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilityMember_documentation_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Success Payment Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilityMember" xlink:href="lyel-20240331.xsd#lyel_SuccessPaymentLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SuccessPaymentLiabilityMember" xlink:to="lab_lyel_SuccessPaymentLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_65f35aa2-79d9-4681-bfdb-54e502f302e5_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_a3055b83-0b55-4c8b-972a-c718c886e1e0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_0718da0d-da77-4b3f-84c6-513726e63e31_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_14c513ea-0f6a-49df-9d08-81b1513d19a4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term of operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetRentableArea_0e45058f-e72c-4a0c-bdeb-920b918b49aa_terseLabel_en-US" xlink:label="lab_us-gaap_NetRentableArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rentable area (in square feet)</link:label>
    <link:label id="lab_us-gaap_NetRentableArea_label_en-US" xlink:label="lab_us-gaap_NetRentableArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Rentable Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetRentableArea" xlink:to="lab_us-gaap_NetRentableArea" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c1eb1fca-5263-4f19-81f1-cf4d5b9ae131_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_78704196-4129-44b5-b179-3daa5b634f4b_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_1176ad47-dedd-401b-bf67-5125afcb8289_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_1873f2b0-5f15-4c1b-95ef-b82ba3a28c24_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of PSU Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_OtherInvestmentsTextBlock_78b6a136-a9fe-4d76-9b95-ccf954c6fc73_terseLabel_en-US" xlink:label="lab_lyel_OtherInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Investments</link:label>
    <link:label id="lab_lyel_OtherInvestmentsTextBlock_label_en-US" xlink:label="lab_lyel_OtherInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Investments [Text Block]</link:label>
    <link:label id="lab_lyel_OtherInvestmentsTextBlock_documentation_en-US" xlink:label="lab_lyel_OtherInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for other investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_OtherInvestmentsTextBlock" xlink:href="lyel-20240331.xsd#lyel_OtherInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_OtherInvestmentsTextBlock" xlink:to="lab_lyel_OtherInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_79dfea4c-8dfb-4d88-8009-70161fa06fc1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_f65a393d-8c0e-4043-a5ea-0563901993a3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangement, plan modification, number of grantees affected</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Plan Modification, Number of Grantees Affected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d7ebc1db-34be-43c2-be5d-2d522f28c395_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, weighted average discount rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_a90c1e5a-fc1b-432e-9eeb-7bc7f8d8df1e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_36730e12-d799-4d81-8356-bebdcafc5db4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cb651ce1-f47d-4831-8f7b-c8e19c818e56_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used to compute net loss per common share, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_fb3dd520-05e5-4443-bc5b-bd86b5b4b8d5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_a10b0b6f-20b5-47b0-b1f7-53e9ea9972b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_8acb20de-5098-495b-9d33-19844726d1ce_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SuccessPaymentLiabilityFairValueOfCommonStock_acfcbeff-4851-4004-b4ba-df0a811f6cfc_terseLabel_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilityFairValueOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of common stock (USD per share)</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilityFairValueOfCommonStock_label_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilityFairValueOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Success Payment Liability, Fair Value of Common Stock</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilityFairValueOfCommonStock_documentation_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilityFairValueOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Success Payment Liability, Fair Value of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilityFairValueOfCommonStock" xlink:href="lyel-20240331.xsd#lyel_SuccessPaymentLiabilityFairValueOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SuccessPaymentLiabilityFairValueOfCommonStock" xlink:to="lab_lyel_SuccessPaymentLiabilityFairValueOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1b99bc5f-b3b6-44ec-8598-ec60537ec5a9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_StanfordSuccessPaymentLiabilityMember_a382ba99-14fc-4f40-a007-0333e466ef95_terseLabel_en-US" xlink:label="lab_lyel_StanfordSuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stanford</link:label>
    <link:label id="lab_lyel_StanfordSuccessPaymentLiabilityMember_label_en-US" xlink:label="lab_lyel_StanfordSuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stanford Success Payment Liability [Member]</link:label>
    <link:label id="lab_lyel_StanfordSuccessPaymentLiabilityMember_documentation_en-US" xlink:label="lab_lyel_StanfordSuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stanford Success Payment Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordSuccessPaymentLiabilityMember" xlink:href="lyel-20240331.xsd#lyel_StanfordSuccessPaymentLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_StanfordSuccessPaymentLiabilityMember" xlink:to="lab_lyel_StanfordSuccessPaymentLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_dfe46dca-3b20-41c1-9bd1-dc2fb6c14632_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_414f9dd1-ad3b-41a1-a49a-1f64b2d545e4_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_d092a97f-2cf1-4e10-a1d7-b6f4feecf988_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_FredHutchSuccessPaymentLiabilityMember_e595fb7c-6b03-4298-afd1-7713bc525705_terseLabel_en-US" xlink:label="lab_lyel_FredHutchSuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fred Hutch</link:label>
    <link:label id="lab_lyel_FredHutchSuccessPaymentLiabilityMember_label_en-US" xlink:label="lab_lyel_FredHutchSuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fred Hutch Success Payment Liability [Member]</link:label>
    <link:label id="lab_lyel_FredHutchSuccessPaymentLiabilityMember_documentation_en-US" xlink:label="lab_lyel_FredHutchSuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fred Hutch Success Payment Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchSuccessPaymentLiabilityMember" xlink:href="lyel-20240331.xsd#lyel_FredHutchSuccessPaymentLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_FredHutchSuccessPaymentLiabilityMember" xlink:to="lab_lyel_FredHutchSuccessPaymentLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_1497f672-ea07-455d-b5bd-78da67df4ba9_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn_44a3dd18-bc36-406b-9617-af44ec7e749e_terseLabel_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance period relative to total shareholder return</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn_label_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Period Relative to Total Shareholder Return</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn_documentation_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Period Relative to Total Shareholder Return</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn" xlink:href="lyel-20240331.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn" xlink:to="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_TenTimesMember_1413a955-fcc6-482a-a7e2-c6c711957e26_terseLabel_en-US" xlink:label="lab_lyel_TenTimesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ten Times</link:label>
    <link:label id="lab_lyel_TenTimesMember_label_en-US" xlink:label="lab_lyel_TenTimesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ten Times [Member]</link:label>
    <link:label id="lab_lyel_TenTimesMember_documentation_en-US" xlink:label="lab_lyel_TenTimesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ten Times (10x).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TenTimesMember" xlink:href="lyel-20240331.xsd#lyel_TenTimesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_TenTimesMember" xlink:to="lab_lyel_TenTimesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2ca3dcec-cfa1-4585-be38-f71c08e0d6a3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_948b8792-48d3-4889-b739-bdafa293ab15_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_79d8b39e-dae3-497b-b7bc-b3088d4ca73f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PSUs vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e01c4d6e-a31f-44ce-9a16-45e44e7259ac_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RSUs vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_8925617b-1080-41a5-812f-71069249dbdf_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Canceled or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6ffb1766-60d4-45f4-94a9-ca03d121d0cc_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_9f5d4f02-dc61-4e77-b114-3a6c5d2019aa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease Liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_c0291908-eaed-407b-af64-d6563b0b7ba8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2eea3c18-d913-4332-b2e3-4765f6dbeaf8_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e88f0a15-af2f-402c-b6bd-179120a89772_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_bf86cdff-cef6-4177-8fb2-22860a206b69_terseLabel_en-US" xlink:label="lab_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 ESPP</link:label>
    <link:label id="lab_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty One Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand twenty one employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:href="lyel-20240331.xsd#lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:to="lab_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_fc6d03e9-2098-4fc3-82e0-c7127d7bf883_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_LesseeCurrentAndNonCurrentLiabilitiesTableTextBlock_3a66a988-579e-406a-834b-9af5114dbb1e_terseLabel_en-US" xlink:label="lab_lyel_LesseeCurrentAndNonCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Current and Non-current Lease Liabilities</link:label>
    <link:label id="lab_lyel_LesseeCurrentAndNonCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_lyel_LesseeCurrentAndNonCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Current and Non-Current Liabilities [Table Text Block]</link:label>
    <link:label id="lab_lyel_LesseeCurrentAndNonCurrentLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_lyel_LesseeCurrentAndNonCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Current and Non-Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_LesseeCurrentAndNonCurrentLiabilitiesTableTextBlock" xlink:href="lyel-20240331.xsd#lyel_LesseeCurrentAndNonCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_LesseeCurrentAndNonCurrentLiabilitiesTableTextBlock" xlink:to="lab_lyel_LesseeCurrentAndNonCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_f94f649b-aeda-4829-8160-974be86485ab_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee purchase of shares, proportion of fair value (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_TwentyTimesMember_8109a246-0877-447c-9d61-e498ceeea262_terseLabel_en-US" xlink:label="lab_lyel_TwentyTimesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Twenty Times</link:label>
    <link:label id="lab_lyel_TwentyTimesMember_label_en-US" xlink:label="lab_lyel_TwentyTimesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Times [Member]</link:label>
    <link:label id="lab_lyel_TwentyTimesMember_documentation_en-US" xlink:label="lab_lyel_TwentyTimesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Times (20x).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwentyTimesMember" xlink:href="lyel-20240331.xsd#lyel_TwentyTimesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_TwentyTimesMember" xlink:to="lab_lyel_TwentyTimesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_61af0fa9-33d5-42f6-9c0e-2b4eaaed30f7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used to compute net loss per common share, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_6673a2da-c458-492f-8ff5-1bb5525d9fc5_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3726db5f-eb96-4e16-8a51-70cdfcd09f63_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_fdb3103f-f78c-4549-ac8f-9e9252f8da9a_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eda68919-924c-4b44-aad4-f12cfd331ed9_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_db8d0354-af55-4700-85c0-0c44b762edc7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_419e5615-a801-4cb5-b388-f0c6d87eb187_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d1eb987-8bb9-4f2e-bdd2-f607f0d2bbde_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Remaining Contractual Life (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_fe4800c8-5ebb-4fd6-8581-798de22399fd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value and Amortized Cost of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments_a8ccf498-4127-4c2c-b109-74e7468486c6_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate research payments due</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Research Payments</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Research Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsResearchPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_64767eec-d72d-4584-ba03-9035dbf3e54a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_ae7ec6b5-ab0b-4015-aea9-246088ca722c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achievement of applicable milestone</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>lyel-20240331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:cc2ada24-6463-486d-8041-2176b9cca09e,g:4457644e-4c39-4c28-b3b7-d0adb2254c74-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://lyell.com/role/Cover" xlink:type="simple" xlink:href="lyel-20240331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://lyell.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_892ca03d-7ca4-437e-be32-279bf1da6956" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_DocumentType_892ca03d-7ca4-437e-be32-279bf1da6956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_b9e1cbad-ebae-450e-b8c2-251831ba308b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_DocumentQuarterlyReport_b9e1cbad-ebae-450e-b8c2-251831ba308b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_dc28a125-95fd-43d0-893d-7a81c27c8e1e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_DocumentPeriodEndDate_dc28a125-95fd-43d0-893d-7a81c27c8e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a6c82fcd-8dcf-4ecd-9b04-24359b4af44e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_DocumentTransitionReport_a6c82fcd-8dcf-4ecd-9b04-24359b4af44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5253c47f-0c1d-4839-91b6-0b67e64128ca" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_EntityFileNumber_5253c47f-0c1d-4839-91b6-0b67e64128ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_50cde019-ab4c-4ce7-b7ec-9b7329cbaccb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_EntityRegistrantName_50cde019-ab4c-4ce7-b7ec-9b7329cbaccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ff22953a-6af9-4965-b62b-ade655b5c48d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ff22953a-6af9-4965-b62b-ade655b5c48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_0a812869-b3eb-42ab-8620-839fb94904be" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_EntityTaxIdentificationNumber_0a812869-b3eb-42ab-8620-839fb94904be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c825014c-ab7a-4277-9d76-0c1f885bc932" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_EntityAddressAddressLine1_c825014c-ab7a-4277-9d76-0c1f885bc932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_80ca8fd3-cfc1-4dc5-990b-8e030250251b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_EntityAddressCityOrTown_80ca8fd3-cfc1-4dc5-990b-8e030250251b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_373939c2-1cd0-4f45-b350-d405ab55b5cb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_EntityAddressStateOrProvince_373939c2-1cd0-4f45-b350-d405ab55b5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_eddfc1f4-242b-42bc-962f-ba434cfa7e8f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_EntityAddressPostalZipCode_eddfc1f4-242b-42bc-962f-ba434cfa7e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4cb7953c-ddcc-4909-a07d-b708aa0059d3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_CityAreaCode_4cb7953c-ddcc-4909-a07d-b708aa0059d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c0f4ff2a-4f88-4102-abf7-f5a2621a39f7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_LocalPhoneNumber_c0f4ff2a-4f88-4102-abf7-f5a2621a39f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_82789f6c-12cd-4b97-99ba-1e8f087f1ac3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_Security12bTitle_82789f6c-12cd-4b97-99ba-1e8f087f1ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_69e188b8-8db8-4c08-b159-8c99c13faae8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_TradingSymbol_69e188b8-8db8-4c08-b159-8c99c13faae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_750c4bf1-f4d7-4247-b552-cd03ad29c41f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_SecurityExchangeName_750c4bf1-f4d7-4247-b552-cd03ad29c41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_641458ba-3bb7-455b-ac0d-addcc4fbc0e4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_EntityCurrentReportingStatus_641458ba-3bb7-455b-ac0d-addcc4fbc0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_42470f32-edc8-4f18-a375-83fd6df18f47" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_EntityInteractiveDataCurrent_42470f32-edc8-4f18-a375-83fd6df18f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_881c255e-0f57-40f9-99ae-723abb0855b1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_EntityFilerCategory_881c255e-0f57-40f9-99ae-723abb0855b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ba1e97cc-e123-4e0d-8c49-0be8720e32cb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_EntitySmallBusiness_ba1e97cc-e123-4e0d-8c49-0be8720e32cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_304be511-2432-4761-9ce3-c2ac148aed1f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_EntityEmergingGrowthCompany_304be511-2432-4761-9ce3-c2ac148aed1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_abbaaec5-73ce-4c09-bb1d-5c15b4db0aab" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_EntityShellCompany_abbaaec5-73ce-4c09-bb1d-5c15b4db0aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_da6e9321-fb91-4eb7-9dc7-c39616c13b9d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_da6e9321-fb91-4eb7-9dc7-c39616c13b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2221b5ce-f7a5-4c52-9ac5-814047053092" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_EntityCentralIndexKey_2221b5ce-f7a5-4c52-9ac5-814047053092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9fc991f8-bd66-40d1-9178-89629a32bbc4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_CurrentFiscalYearEndDate_9fc991f8-bd66-40d1-9178-89629a32bbc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_5090f6d0-e553-43ac-852a-e258bc10cfc7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_DocumentFiscalYearFocus_5090f6d0-e553-43ac-852a-e258bc10cfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_d730ffc1-8182-4ebc-9451-2eac3914577d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_DocumentFiscalPeriodFocus_d730ffc1-8182-4ebc-9451-2eac3914577d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1f92d760-5be4-48eb-b560-d9fd710be97f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5efc26c-1adf-460d-b7f8-07277f105736" xlink:to="loc_dei_AmendmentFlag_1f92d760-5be4-48eb-b560-d9fd710be97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="lyel-20240331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_60cfafd2-b357-4917-a779-bdbc9a35ab92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_20e16518-651a-465b-92ef-dae40a3da6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60cfafd2-b357-4917-a779-bdbc9a35ab92" xlink:to="loc_us-gaap_AssetsAbstract_20e16518-651a-465b-92ef-dae40a3da6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f560d6ea-f109-48b3-8f59-d87217be2f63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_20e16518-651a-465b-92ef-dae40a3da6b4" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f560d6ea-f109-48b3-8f59-d87217be2f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_72e2c97f-923a-47d6-a8db-2076e1eb8df6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f560d6ea-f109-48b3-8f59-d87217be2f63" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_72e2c97f-923a-47d6-a8db-2076e1eb8df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_b3f6a024-5108-483c-ac02-d5e32df55618" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f560d6ea-f109-48b3-8f59-d87217be2f63" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_b3f6a024-5108-483c-ac02-d5e32df55618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c4c0e38c-3f9d-40fc-9f6a-54f752d14d64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f560d6ea-f109-48b3-8f59-d87217be2f63" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c4c0e38c-3f9d-40fc-9f6a-54f752d14d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_db4d9a7b-64c4-4987-b6f0-fd94e02a70b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f560d6ea-f109-48b3-8f59-d87217be2f63" xlink:to="loc_us-gaap_AssetsCurrent_db4d9a7b-64c4-4987-b6f0-fd94e02a70b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_c1934a1c-faa5-4e8d-b9de-505f66482e36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_20e16518-651a-465b-92ef-dae40a3da6b4" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_c1934a1c-faa5-4e8d-b9de-505f66482e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_298c2256-2ccd-4eb8-ad08-a40d045acf0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_20e16518-651a-465b-92ef-dae40a3da6b4" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_298c2256-2ccd-4eb8-ad08-a40d045acf0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments_e4b9ac4a-6883-4b0c-903d-c84680e2142a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_20e16518-651a-465b-92ef-dae40a3da6b4" xlink:to="loc_us-gaap_OtherInvestments_e4b9ac4a-6883-4b0c-903d-c84680e2142a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_65aeb0e1-0080-4cb6-937e-01b551bf56d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_20e16518-651a-465b-92ef-dae40a3da6b4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_65aeb0e1-0080-4cb6-937e-01b551bf56d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_37189e09-fd25-4ef4-ac5b-facf478612d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_20e16518-651a-465b-92ef-dae40a3da6b4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_37189e09-fd25-4ef4-ac5b-facf478612d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ecae8e14-1a29-433f-a52f-ac91f9d35d12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_20e16518-651a-465b-92ef-dae40a3da6b4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ecae8e14-1a29-433f-a52f-ac91f9d35d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4b1b46fa-6257-4794-ac58-a16404182515" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_20e16518-651a-465b-92ef-dae40a3da6b4" xlink:to="loc_us-gaap_Assets_4b1b46fa-6257-4794-ac58-a16404182515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d4b1a750-61ec-479b-a375-173eea0d4cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60cfafd2-b357-4917-a779-bdbc9a35ab92" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d4b1a750-61ec-479b-a375-173eea0d4cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_afe8d6c1-a82c-4546-b799-f3da76ea4ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d4b1a750-61ec-479b-a375-173eea0d4cb1" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_afe8d6c1-a82c-4546-b799-f3da76ea4ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_15ddd292-fb3f-4748-9365-8966f59397ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_afe8d6c1-a82c-4546-b799-f3da76ea4ff8" xlink:to="loc_us-gaap_AccountsPayableCurrent_15ddd292-fb3f-4748-9365-8966f59397ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1f6c18ec-27fd-41d1-8e79-9b8ca49b8405" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_afe8d6c1-a82c-4546-b799-f3da76ea4ff8" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1f6c18ec-27fd-41d1-8e79-9b8ca49b8405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilitiesCurrent_ca6b8b66-61f6-4e54-996d-cee2cd3813e1" xlink:href="lyel-20240331.xsd#lyel_SuccessPaymentLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_afe8d6c1-a82c-4546-b799-f3da76ea4ff8" xlink:to="loc_lyel_SuccessPaymentLiabilitiesCurrent_ca6b8b66-61f6-4e54-996d-cee2cd3813e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d0900907-24f4-4a6d-b530-c6b23c410798" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_afe8d6c1-a82c-4546-b799-f3da76ea4ff8" xlink:to="loc_us-gaap_LiabilitiesCurrent_d0900907-24f4-4a6d-b530-c6b23c410798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7c63a27d-7505-4579-8534-566055be9b95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d4b1a750-61ec-479b-a375-173eea0d4cb1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7c63a27d-7505-4579-8534-566055be9b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_134a0ef4-2c68-491a-a20a-cbd888c270c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d4b1a750-61ec-479b-a375-173eea0d4cb1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_134a0ef4-2c68-491a-a20a-cbd888c270c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ec9f9677-5fe3-4d55-ba60-f9ae13861459" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d4b1a750-61ec-479b-a375-173eea0d4cb1" xlink:to="loc_us-gaap_Liabilities_ec9f9677-5fe3-4d55-ba60-f9ae13861459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1e675464-3d30-44d8-ac1d-e720d54b7295" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d4b1a750-61ec-479b-a375-173eea0d4cb1" xlink:to="loc_us-gaap_CommitmentsAndContingencies_1e675464-3d30-44d8-ac1d-e720d54b7295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4e75c819-8001-4c39-8d0b-7e2f67b021f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d4b1a750-61ec-479b-a375-173eea0d4cb1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4e75c819-8001-4c39-8d0b-7e2f67b021f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_fd5e2fb3-0003-428c-82f7-560cf862744d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4e75c819-8001-4c39-8d0b-7e2f67b021f4" xlink:to="loc_us-gaap_PreferredStockValue_fd5e2fb3-0003-428c-82f7-560cf862744d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_eb940ff8-b0b6-4b62-bfdc-f641f64df0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4e75c819-8001-4c39-8d0b-7e2f67b021f4" xlink:to="loc_us-gaap_CommonStockValue_eb940ff8-b0b6-4b62-bfdc-f641f64df0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_cdc35841-f123-4e22-b92f-1c815568a56b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4e75c819-8001-4c39-8d0b-7e2f67b021f4" xlink:to="loc_us-gaap_AdditionalPaidInCapital_cdc35841-f123-4e22-b92f-1c815568a56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_37692925-1e06-498d-8e8c-7b9364e5b522" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4e75c819-8001-4c39-8d0b-7e2f67b021f4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_37692925-1e06-498d-8e8c-7b9364e5b522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c960e79f-57c5-40d9-a492-f01c79463517" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4e75c819-8001-4c39-8d0b-7e2f67b021f4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c960e79f-57c5-40d9-a492-f01c79463517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_647d6a8b-0a7c-4289-a5d1-78e01c11f503" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4e75c819-8001-4c39-8d0b-7e2f67b021f4" xlink:to="loc_us-gaap_StockholdersEquity_647d6a8b-0a7c-4289-a5d1-78e01c11f503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_54400434-e1b8-4ea6-8887-617191c24e59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d4b1a750-61ec-479b-a375-173eea0d4cb1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_54400434-e1b8-4ea6-8887-617191c24e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="lyel-20240331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_564b90e4-f782-4a9e-a30c-e3e21b05e4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_93633d4e-bfae-4b37-96fd-a29e6f15345c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_564b90e4-f782-4a9e-a30c-e3e21b05e4d3" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_93633d4e-bfae-4b37-96fd-a29e6f15345c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_7a1b048a-5d12-447a-9369-9f72f29e8e64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_564b90e4-f782-4a9e-a30c-e3e21b05e4d3" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_7a1b048a-5d12-447a-9369-9f72f29e8e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_fc795d75-1bd1-40b4-876a-ee6880075198" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_564b90e4-f782-4a9e-a30c-e3e21b05e4d3" xlink:to="loc_us-gaap_PreferredStockSharesIssued_fc795d75-1bd1-40b4-876a-ee6880075198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_92a06bad-a03a-4f0d-afb3-b8c520d203fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_564b90e4-f782-4a9e-a30c-e3e21b05e4d3" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_92a06bad-a03a-4f0d-afb3-b8c520d203fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_44d0a608-76e7-49db-b238-5b289bd6377a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_564b90e4-f782-4a9e-a30c-e3e21b05e4d3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_44d0a608-76e7-49db-b238-5b289bd6377a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7b905596-7646-4c2b-a77a-b283cadb269d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_564b90e4-f782-4a9e-a30c-e3e21b05e4d3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7b905596-7646-4c2b-a77a-b283cadb269d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2e3ad790-21b8-47cc-8179-29a3463a8f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_564b90e4-f782-4a9e-a30c-e3e21b05e4d3" xlink:to="loc_us-gaap_CommonStockSharesIssued_2e3ad790-21b8-47cc-8179-29a3463a8f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_712c7e2c-f98f-47cf-81ac-a087167bfaa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_564b90e4-f782-4a9e-a30c-e3e21b05e4d3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_712c7e2c-f98f-47cf-81ac-a087167bfaa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="lyel-20240331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7f586c6a-ded0-444a-870b-d9cc6b3f5551" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_27768f9b-1c71-46d9-8f0f-1bd55edde56b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7f586c6a-ded0-444a-870b-d9cc6b3f5551" xlink:to="loc_us-gaap_Revenues_27768f9b-1c71-46d9-8f0f-1bd55edde56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_f2e550ae-0335-4495-9af7-859efbf04caa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7f586c6a-ded0-444a-870b-d9cc6b3f5551" xlink:to="loc_us-gaap_OperatingExpensesAbstract_f2e550ae-0335-4495-9af7-859efbf04caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_642c7e24-d669-4dc1-910f-bb483a0b80f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f2e550ae-0335-4495-9af7-859efbf04caa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_642c7e24-d669-4dc1-910f-bb483a0b80f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_40c746a4-3beb-4852-84ff-475b115cb28e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f2e550ae-0335-4495-9af7-859efbf04caa" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_40c746a4-3beb-4852-84ff-475b115cb28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_0c2b7221-08f5-4e18-aeb4-8ddc4c28f589" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f2e550ae-0335-4495-9af7-859efbf04caa" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_0c2b7221-08f5-4e18-aeb4-8ddc4c28f589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a017e7a7-faa9-4029-bcbe-96d2b0ff0b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f2e550ae-0335-4495-9af7-859efbf04caa" xlink:to="loc_us-gaap_OperatingExpenses_a017e7a7-faa9-4029-bcbe-96d2b0ff0b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_37682ee8-4928-4087-ac81-44decef7e601" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7f586c6a-ded0-444a-870b-d9cc6b3f5551" xlink:to="loc_us-gaap_OperatingIncomeLoss_37682ee8-4928-4087-ac81-44decef7e601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_a6fb8aca-27d9-4f17-bfa3-3dddaa0af378" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7f586c6a-ded0-444a-870b-d9cc6b3f5551" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_a6fb8aca-27d9-4f17-bfa3-3dddaa0af378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7ba89f4c-8069-4024-a9e3-20d6333ce675" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7f586c6a-ded0-444a-870b-d9cc6b3f5551" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7ba89f4c-8069-4024-a9e3-20d6333ce675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_0677e6e9-640a-4e13-9995-b0c6a4fe3031" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7f586c6a-ded0-444a-870b-d9cc6b3f5551" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_0677e6e9-640a-4e13-9995-b0c6a4fe3031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6e6f407c-6385-417a-b54c-db051db29e73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7f586c6a-ded0-444a-870b-d9cc6b3f5551" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6e6f407c-6385-417a-b54c-db051db29e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_10d6ef97-a6d9-41b1-a686-9da77574e3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7f586c6a-ded0-444a-870b-d9cc6b3f5551" xlink:to="loc_us-gaap_NetIncomeLoss_10d6ef97-a6d9-41b1-a686-9da77574e3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_072a6df9-b696-4f93-86e4-da047ceaa009" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7f586c6a-ded0-444a-870b-d9cc6b3f5551" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_072a6df9-b696-4f93-86e4-da047ceaa009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9d761c94-1e57-4227-8a65-28e8b7f76763" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_072a6df9-b696-4f93-86e4-da047ceaa009" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9d761c94-1e57-4227-8a65-28e8b7f76763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_aab790dc-4bcd-4931-94b3-6d3ada2f04c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7f586c6a-ded0-444a-870b-d9cc6b3f5551" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_aab790dc-4bcd-4931-94b3-6d3ada2f04c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_47986723-399f-4420-8c6d-d4e1d4baff78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7f586c6a-ded0-444a-870b-d9cc6b3f5551" xlink:to="loc_us-gaap_EarningsPerShareBasic_47986723-399f-4420-8c6d-d4e1d4baff78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5660b3fb-fb8d-4a90-8f7d-51c9ab986323" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7f586c6a-ded0-444a-870b-d9cc6b3f5551" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5660b3fb-fb8d-4a90-8f7d-51c9ab986323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9f5efb96-ee30-4d0f-80f7-613a14619849" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7f586c6a-ded0-444a-870b-d9cc6b3f5551" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9f5efb96-ee30-4d0f-80f7-613a14619849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1aea69cb-c6aa-473f-ab24-e8f20c1333ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7f586c6a-ded0-444a-870b-d9cc6b3f5551" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1aea69cb-c6aa-473f-ab24-e8f20c1333ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="lyel-20240331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ce1ba1cf-2e22-4d16-97fa-a0ef3f451ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e18dbd04-5662-4360-8af7-68dc99abc399" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ce1ba1cf-2e22-4d16-97fa-a0ef3f451ee9" xlink:to="loc_us-gaap_StatementTable_e18dbd04-5662-4360-8af7-68dc99abc399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f7550461-3931-4677-b0a8-93f3156c45fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e18dbd04-5662-4360-8af7-68dc99abc399" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f7550461-3931-4677-b0a8-93f3156c45fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b4d5917f-d9b2-4772-be48-08d010ac41d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f7550461-3931-4677-b0a8-93f3156c45fa" xlink:to="loc_us-gaap_EquityComponentDomain_b4d5917f-d9b2-4772-be48-08d010ac41d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1354244d-1b50-4c0d-8550-d3ed6b55d473" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b4d5917f-d9b2-4772-be48-08d010ac41d3" xlink:to="loc_us-gaap_CommonStockMember_1354244d-1b50-4c0d-8550-d3ed6b55d473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_142ffa7e-d00c-4b29-acc4-abf2c680af33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b4d5917f-d9b2-4772-be48-08d010ac41d3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_142ffa7e-d00c-4b29-acc4-abf2c680af33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_654b929a-26f5-4bf8-82d4-e90b47eddf83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b4d5917f-d9b2-4772-be48-08d010ac41d3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_654b929a-26f5-4bf8-82d4-e90b47eddf83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_483eafa3-c3d5-4397-b98e-83d742194de8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b4d5917f-d9b2-4772-be48-08d010ac41d3" xlink:to="loc_us-gaap_RetainedEarningsMember_483eafa3-c3d5-4397-b98e-83d742194de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1966459c-eda8-4a15-987e-bd561a7925b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e18dbd04-5662-4360-8af7-68dc99abc399" xlink:to="loc_us-gaap_StatementLineItems_1966459c-eda8-4a15-987e-bd561a7925b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0afd4337-aa8c-49ee-aaeb-6bbbe5d2b9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1966459c-eda8-4a15-987e-bd561a7925b3" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0afd4337-aa8c-49ee-aaeb-6bbbe5d2b9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_020fbe97-d9e9-4dbc-944f-7f00bbdddabc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0afd4337-aa8c-49ee-aaeb-6bbbe5d2b9c5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_020fbe97-d9e9-4dbc-944f-7f00bbdddabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4d116ede-85d3-4c58-a0f1-76a5e8b527ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0afd4337-aa8c-49ee-aaeb-6bbbe5d2b9c5" xlink:to="loc_us-gaap_StockholdersEquity_4d116ede-85d3-4c58-a0f1-76a5e8b527ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b0d9174f-f79c-49fa-aee0-b25ae31069f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0afd4337-aa8c-49ee-aaeb-6bbbe5d2b9c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b0d9174f-f79c-49fa-aee0-b25ae31069f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3907685c-abce-40b6-ad39-7ef090da3593" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0afd4337-aa8c-49ee-aaeb-6bbbe5d2b9c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3907685c-abce-40b6-ad39-7ef090da3593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_9c87b9b5-47a2-4662-8320-6eb447d18926" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0afd4337-aa8c-49ee-aaeb-6bbbe5d2b9c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_9c87b9b5-47a2-4662-8320-6eb447d18926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_186c6148-61db-44d0-b0aa-2ebcf7d49df5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0afd4337-aa8c-49ee-aaeb-6bbbe5d2b9c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_186c6148-61db-44d0-b0aa-2ebcf7d49df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0e50e944-e909-45a4-8f1d-eec9c1eb8414" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0afd4337-aa8c-49ee-aaeb-6bbbe5d2b9c5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0e50e944-e909-45a4-8f1d-eec9c1eb8414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cc840dd3-6099-47aa-9310-1c14e9e70c19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0afd4337-aa8c-49ee-aaeb-6bbbe5d2b9c5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cc840dd3-6099-47aa-9310-1c14e9e70c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0f691d28-6950-4910-bfd9-4cc2fa78ffb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0afd4337-aa8c-49ee-aaeb-6bbbe5d2b9c5" xlink:to="loc_us-gaap_NetIncomeLoss_0f691d28-6950-4910-bfd9-4cc2fa78ffb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b07b0558-d717-418e-aa31-e5d7f8e1b46b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0afd4337-aa8c-49ee-aaeb-6bbbe5d2b9c5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b07b0558-d717-418e-aa31-e5d7f8e1b46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8ea1862d-148a-4ab6-a0bd-37fbaaf2b17c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0afd4337-aa8c-49ee-aaeb-6bbbe5d2b9c5" xlink:to="loc_us-gaap_StockholdersEquity_8ea1862d-148a-4ab6-a0bd-37fbaaf2b17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="lyel-20240331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_3e2db10f-d5b8-43d1-958e-4b9d9776d30a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bc243b64-5cbc-42cf-ba3d-83b452c958af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e2db10f-d5b8-43d1-958e-4b9d9776d30a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bc243b64-5cbc-42cf-ba3d-83b452c958af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_14df2d48-64ed-4c38-8364-dae8aa8d704d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bc243b64-5cbc-42cf-ba3d-83b452c958af" xlink:to="loc_us-gaap_NetIncomeLoss_14df2d48-64ed-4c38-8364-dae8aa8d704d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5d758f4f-6530-4713-a82f-11543d4fb999" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bc243b64-5cbc-42cf-ba3d-83b452c958af" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5d758f4f-6530-4713-a82f-11543d4fb999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_cbc421b3-9eb2-41f7-9f94-7e5b6c9f013b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5d758f4f-6530-4713-a82f-11543d4fb999" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_cbc421b3-9eb2-41f7-9f94-7e5b6c9f013b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8581f833-6cd2-4d8f-b53b-b2dbbabac882" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5d758f4f-6530-4713-a82f-11543d4fb999" xlink:to="loc_us-gaap_ShareBasedCompensation_8581f833-6cd2-4d8f-b53b-b2dbbabac882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4066dced-15fc-450e-af03-d8da609043e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5d758f4f-6530-4713-a82f-11543d4fb999" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4066dced-15fc-450e-af03-d8da609043e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_11d10834-8e99-43a1-983d-188cad51f343" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5d758f4f-6530-4713-a82f-11543d4fb999" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_11d10834-8e99-43a1-983d-188cad51f343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_bf190dcb-6214-44d1-b72b-be8974bfff1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5d758f4f-6530-4713-a82f-11543d4fb999" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_bf190dcb-6214-44d1-b72b-be8974bfff1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities_f210945f-ee8c-46e3-bd83-788fa42bb4b6" xlink:href="lyel-20240331.xsd#lyel_FairValueAdjustmentOfSuccessPaymentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5d758f4f-6530-4713-a82f-11543d4fb999" xlink:to="loc_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities_f210945f-ee8c-46e3-bd83-788fa42bb4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_NonCashLeaseIncomeExpense_e27f85e3-f98a-4886-8b94-38d6050f14ba" xlink:href="lyel-20240331.xsd#lyel_NonCashLeaseIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5d758f4f-6530-4713-a82f-11543d4fb999" xlink:to="loc_lyel_NonCashLeaseIncomeExpense_e27f85e3-f98a-4886-8b94-38d6050f14ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_c1486c81-e1c0-4b91-836a-d723cdfe8ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5d758f4f-6530-4713-a82f-11543d4fb999" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_c1486c81-e1c0-4b91-836a-d723cdfe8ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6e19a4dc-9d7e-400c-b6e4-bec98d6d12f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5d758f4f-6530-4713-a82f-11543d4fb999" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6e19a4dc-9d7e-400c-b6e4-bec98d6d12f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b030a459-f192-4767-9c1d-1b9d3c93e7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6e19a4dc-9d7e-400c-b6e4-bec98d6d12f9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b030a459-f192-4767-9c1d-1b9d3c93e7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3856ed9b-ffcb-4789-9211-cf86b6ce08b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6e19a4dc-9d7e-400c-b6e4-bec98d6d12f9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3856ed9b-ffcb-4789-9211-cf86b6ce08b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_ea9297a3-15f0-4872-ab96-ef6192da8eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6e19a4dc-9d7e-400c-b6e4-bec98d6d12f9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_ea9297a3-15f0-4872-ab96-ef6192da8eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_84adfca8-9110-4cd0-962d-27da99820df5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6e19a4dc-9d7e-400c-b6e4-bec98d6d12f9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_84adfca8-9110-4cd0-962d-27da99820df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3d15e2d3-4a86-4196-a7f5-e6847526d1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bc243b64-5cbc-42cf-ba3d-83b452c958af" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3d15e2d3-4a86-4196-a7f5-e6847526d1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b575d8b0-413f-4f78-bb2b-9c2b99c365fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e2db10f-d5b8-43d1-958e-4b9d9776d30a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b575d8b0-413f-4f78-bb2b-9c2b99c365fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a45f61ea-47eb-4db1-8099-920c1946e3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b575d8b0-413f-4f78-bb2b-9c2b99c365fa" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a45f61ea-47eb-4db1-8099-920c1946e3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_979be2a6-993c-4dd9-9e4b-24d4d3a87a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b575d8b0-413f-4f78-bb2b-9c2b99c365fa" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_979be2a6-993c-4dd9-9e4b-24d4d3a87a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_bb32308a-58c6-46d7-87d3-ce5934d417ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b575d8b0-413f-4f78-bb2b-9c2b99c365fa" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_bb32308a-58c6-46d7-87d3-ce5934d417ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d12ba0cb-6d5e-4f0c-90e4-4278848f22b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b575d8b0-413f-4f78-bb2b-9c2b99c365fa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d12ba0cb-6d5e-4f0c-90e4-4278848f22b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a20af4b1-a512-4dca-bb0c-ae992b4790b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e2db10f-d5b8-43d1-958e-4b9d9776d30a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a20af4b1-a512-4dca-bb0c-ae992b4790b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_93591221-5cc1-473c-9899-52894d9841b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a20af4b1-a512-4dca-bb0c-ae992b4790b6" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_93591221-5cc1-473c-9899-52894d9841b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b20c1c93-9481-4ba2-9b0e-0d3a9a61c5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a20af4b1-a512-4dca-bb0c-ae992b4790b6" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b20c1c93-9481-4ba2-9b0e-0d3a9a61c5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f8d37cde-7aa1-436b-a47d-a4d944029b33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a20af4b1-a512-4dca-bb0c-ae992b4790b6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f8d37cde-7aa1-436b-a47d-a4d944029b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_443e61ef-57d6-4eb6-8ea7-fead9a1dcc4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e2db10f-d5b8-43d1-958e-4b9d9776d30a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_443e61ef-57d6-4eb6-8ea7-fead9a1dcc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_afd73752-74c3-46ee-8747-26003c2b7866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e2db10f-d5b8-43d1-958e-4b9d9776d30a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_afd73752-74c3-46ee-8747-26003c2b7866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14271ca9-db66-495e-b45a-285a64d3fce8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e2db10f-d5b8-43d1-958e-4b9d9776d30a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14271ca9-db66-495e-b45a-285a64d3fce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract_ed151e07-9b35-4143-b77e-aa3e424fe4b8" xlink:href="lyel-20240331.xsd#lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e2db10f-d5b8-43d1-958e-4b9d9776d30a" xlink:to="loc_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract_ed151e07-9b35-4143-b77e-aa3e424fe4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ea61874f-89ee-42c1-b543-02e26814986a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract_ed151e07-9b35-4143-b77e-aa3e424fe4b8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ea61874f-89ee-42c1-b543-02e26814986a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_1b30ab55-71e7-48eb-8012-d942b2b93466" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract_ed151e07-9b35-4143-b77e-aa3e424fe4b8" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_1b30ab55-71e7-48eb-8012-d942b2b93466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ca4d4f3a-3892-49b0-9682-54e0569fa09d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract_ed151e07-9b35-4143-b77e-aa3e424fe4b8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ca4d4f3a-3892-49b0-9682-54e0569fa09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_468e3889-29ed-4c4f-8ef2-1156db2f6aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e2db10f-d5b8-43d1-958e-4b9d9776d30a" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_468e3889-29ed-4c4f-8ef2-1156db2f6aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_fd139cf3-bbbe-4dac-8674-18552fe3e3aa" xlink:href="lyel-20240331.xsd#lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_468e3889-29ed-4c4f-8ef2-1156db2f6aeb" xlink:to="loc_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_fd139cf3-bbbe-4dac-8674-18552fe3e3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_5b71e3ae-f5b0-4530-ad91-8fa79a88ed89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_468e3889-29ed-4c4f-8ef2-1156db2f6aeb" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_5b71e3ae-f5b0-4530-ad91-8fa79a88ed89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0229dcc0-08e8-4f26-bea2-a589631821f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_5b71e3ae-f5b0-4530-ad91-8fa79a88ed89" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0229dcc0-08e8-4f26-bea2-a589631821f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/Organization" xlink:type="simple" xlink:href="lyel-20240331.xsd#Organization"/>
  <link:presentationLink xlink:role="http://lyell.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b9ce54a8-e60f-4dd8-9296-c2c461573f84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_420e58bf-3a21-44f1-91d7-cf762403de68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b9ce54a8-e60f-4dd8-9296-c2c461573f84" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_420e58bf-3a21-44f1-91d7-cf762403de68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="lyel-20240331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://lyell.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f9d4c8e8-5cf0-4ab4-b90f-68bc305ce3db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_21197d9d-b022-45bf-b55f-47d3eec11116" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f9d4c8e8-5cf0-4ab4-b90f-68bc305ce3db" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_21197d9d-b022-45bf-b55f-47d3eec11116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreements" xlink:type="simple" xlink:href="lyel-20240331.xsd#LicenseCollaborationandSuccessPaymentAgreements"/>
  <link:presentationLink xlink:role="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d477a39a-8179-47b4-bedd-e8f0d17c1162" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_2e0c3e22-ee12-4a6e-9d89-28d7e012dcc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d477a39a-8179-47b4-bedd-e8f0d17c1162" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_2e0c3e22-ee12-4a6e-9d89-28d7e012dcc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="lyel-20240331.xsd#CashEquivalentsandMarketableSecurities"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CashEquivalentsandMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_e019ccf1-1f74-444a-9046-2b6661b484f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_6394f980-f9aa-42ec-aefc-bf5b000b0056" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_e019ccf1-1f74-444a-9046-2b6661b484f9" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_6394f980-f9aa-42ec-aefc-bf5b000b0056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/OtherInvestments" xlink:type="simple" xlink:href="lyel-20240331.xsd#OtherInvestments"/>
  <link:presentationLink xlink:role="http://lyell.com/role/OtherInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_e853f38b-2ca6-4565-8217-bf5cd6e16f62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_OtherInvestmentsTextBlock_75608d0d-8760-45b2-9d1c-08754552d94e" xlink:href="lyel-20240331.xsd#lyel_OtherInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_e853f38b-2ca6-4565-8217-bf5cd6e16f62" xlink:to="loc_lyel_OtherInvestmentsTextBlock_75608d0d-8760-45b2-9d1c-08754552d94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="lyel-20240331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://lyell.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c228c7c9-c498-45b7-a5c0-0d1ecb918c57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_76b55040-389d-4173-a72b-1d1a88663bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c228c7c9-c498-45b7-a5c0-0d1ecb918c57" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_76b55040-389d-4173-a72b-1d1a88663bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/Leases" xlink:type="simple" xlink:href="lyel-20240331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://lyell.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f299d8e2-d0c4-460e-ac0d-5cf38db0ab76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_7b58c3ea-1d93-44bc-99c8-a71d79954d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f299d8e2-d0c4-460e-ac0d-5cf38db0ab76" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_7b58c3ea-1d93-44bc-99c8-a71d79954d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_a024b317-2327-4a3a-8171-8211ef52309c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f299d8e2-d0c4-460e-ac0d-5cf38db0ab76" xlink:to="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_a024b317-2327-4a3a-8171-8211ef52309c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockholdersEquity" xlink:type="simple" xlink:href="lyel-20240331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7009c0f6-301d-44de-917c-7eb64ef915f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5a49546a-b65a-4bf7-ac9e-43319ac5f2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7009c0f6-301d-44de-917c-7eb64ef915f8" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5a49546a-b65a-4bf7-ac9e-43319ac5f2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="lyel-20240331.xsd#StockbasedCompensation"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockbasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fcd8f8a2-059c-4419-b6cd-be797b53198f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5487671c-a6cc-4782-8ef3-fda461b555db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fcd8f8a2-059c-4419-b6cd-be797b53198f" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5487671c-a6cc-4782-8ef3-fda461b555db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/NetLossPerShare" xlink:type="simple" xlink:href="lyel-20240331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://lyell.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0fe18617-4256-45bc-8310-4194c2be703d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_3a6b4229-6196-4993-a80d-00a0964f2b31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0fe18617-4256-45bc-8310-4194c2be703d" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_3a6b4229-6196-4993-a80d-00a0964f2b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="lyel-20240331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5e58b585-3f31-40a9-9733-6a48433b52e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9ae06b28-495e-4838-9235-9b0ea2b10b75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5e58b585-3f31-40a9-9733-6a48433b52e6" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9ae06b28-495e-4838-9235-9b0ea2b10b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/RelatedpartyTransactions" xlink:type="simple" xlink:href="lyel-20240331.xsd#RelatedpartyTransactions"/>
  <link:presentationLink xlink:role="http://lyell.com/role/RelatedpartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_6fe4c0ff-d77e-4ec5-b852-f0b8fabb43d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_5f4da74f-6d95-425f-9234-3186340168eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_6fe4c0ff-d77e-4ec5-b852-f0b8fabb43d8" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_5f4da74f-6d95-425f-9234-3186340168eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lyel-20240331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_545b31a8-50ca-4e13-9966-0527545c92b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_245e348e-fd66-4af8-a6bd-8de0ab3198bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_545b31a8-50ca-4e13-9966-0527545c92b6" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_245e348e-fd66-4af8-a6bd-8de0ab3198bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_36fbdee2-6f7e-4293-8602-bf592206e264" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_545b31a8-50ca-4e13-9966-0527545c92b6" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_36fbdee2-6f7e-4293-8602-bf592206e264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_5318999e-9461-4fa8-9ab4-fc4c50a95d05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_545b31a8-50ca-4e13-9966-0527545c92b6" xlink:to="loc_us-gaap_UseOfEstimates_5318999e-9461-4fa8-9ab4-fc4c50a95d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_d4bf385e-3046-41ed-9b8f-451ffab63898" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_545b31a8-50ca-4e13-9966-0527545c92b6" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_d4bf385e-3046-41ed-9b8f-451ffab63898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_6ab9fb4f-b7b0-405f-8854-63ebe8c91923" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_545b31a8-50ca-4e13-9966-0527545c92b6" xlink:to="loc_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_6ab9fb4f-b7b0-405f-8854-63ebe8c91923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SignificantAccountingPoliciesPolicyTextBlock_bd970237-8734-4aef-b8dd-8ecf764a4915" xlink:href="lyel-20240331.xsd#lyel_SignificantAccountingPoliciesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_545b31a8-50ca-4e13-9966-0527545c92b6" xlink:to="loc_lyel_SignificantAccountingPoliciesPolicyTextBlock_bd970237-8734-4aef-b8dd-8ecf764a4915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_90386bcb-0a8a-4ed7-8fba-f41a18aaf6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_545b31a8-50ca-4e13-9966-0527545c92b6" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_90386bcb-0a8a-4ed7-8fba-f41a18aaf6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_04b05079-c0ed-4e78-a1b4-81f25f3eff03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_545b31a8-50ca-4e13-9966-0527545c92b6" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_04b05079-c0ed-4e78-a1b4-81f25f3eff03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsTables" xlink:type="simple" xlink:href="lyel-20240331.xsd#LicenseCollaborationandSuccessPaymentAgreementsTables"/>
  <link:presentationLink xlink:role="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_255316f3-b7e9-4afc-87ad-21d5f4aefe77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_00662051-23c1-4ee8-a9d6-0bffb5f48acf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_255316f3-b7e9-4afc-87ad-21d5f4aefe77" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_00662051-23c1-4ee8-a9d6-0bffb5f48acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="lyel-20240331.xsd#CashEquivalentsandMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_771e20b3-837c-4022-8e34-075aec296d49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_a90eead0-d738-454a-96e2-d0c0fdb0e92f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_771e20b3-837c-4022-8e34-075aec296d49" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_a90eead0-d738-454a-96e2-d0c0fdb0e92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1d44088d-901f-427a-adb7-eeacb25a15b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_771e20b3-837c-4022-8e34-075aec296d49" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1d44088d-901f-427a-adb7-eeacb25a15b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="lyel-20240331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://lyell.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5f9c58d8-9228-4bf5-86e7-437a0386a6db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ad1ab3f9-2cd4-45c1-a392-efe1b6871aac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5f9c58d8-9228-4bf5-86e7-437a0386a6db" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ad1ab3f9-2cd4-45c1-a392-efe1b6871aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_5b4301e7-14e5-4e49-a7fa-04cf8781b95d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5f9c58d8-9228-4bf5-86e7-437a0386a6db" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_5b4301e7-14e5-4e49-a7fa-04cf8781b95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ab7a628e-132a-4244-ab8d-dd3c0c595c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5f9c58d8-9228-4bf5-86e7-437a0386a6db" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ab7a628e-132a-4244-ab8d-dd3c0c595c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/LeasesTables" xlink:type="simple" xlink:href="lyel-20240331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://lyell.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4ecfe3c9-9cc1-4057-a8a4-3b18a68eb275" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c42c7ed1-ce5f-42cc-a4be-81a81365212f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4ecfe3c9-9cc1-4057-a8a4-3b18a68eb275" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c42c7ed1-ce5f-42cc-a4be-81a81365212f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_LesseeCurrentAndNonCurrentLiabilitiesTableTextBlock_5dc05bd6-c621-47d4-b9df-1b94fb350b33" xlink:href="lyel-20240331.xsd#lyel_LesseeCurrentAndNonCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4ecfe3c9-9cc1-4057-a8a4-3b18a68eb275" xlink:to="loc_lyel_LesseeCurrentAndNonCurrentLiabilitiesTableTextBlock_5dc05bd6-c621-47d4-b9df-1b94fb350b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="lyel-20240331.xsd#StockbasedCompensationTables"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockbasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b1b982ad-342c-42bd-93b2-13f01c8f4b31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5639102f-60fe-44b4-af3b-b533b6577825" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b1b982ad-342c-42bd-93b2-13f01c8f4b31" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5639102f-60fe-44b4-af3b-b533b6577825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_bfa61178-5a4e-4a6e-b659-bda05e3b6c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b1b982ad-342c-42bd-93b2-13f01c8f4b31" xlink:to="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_bfa61178-5a4e-4a6e-b659-bda05e3b6c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_faecf5b9-367b-4227-9fe3-434253a074f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b1b982ad-342c-42bd-93b2-13f01c8f4b31" xlink:to="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_faecf5b9-367b-4227-9fe3-434253a074f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_66aba014-2ca4-4c70-a36f-ceca6feac03f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b1b982ad-342c-42bd-93b2-13f01c8f4b31" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_66aba014-2ca4-4c70-a36f-ceca6feac03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8a45bdf0-3ae2-4199-b4f1-6d7e1cf7e3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b1b982ad-342c-42bd-93b2-13f01c8f4b31" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8a45bdf0-3ae2-4199-b4f1-6d7e1cf7e3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/RelatedpartyTransactionsTables" xlink:type="simple" xlink:href="lyel-20240331.xsd#RelatedpartyTransactionsTables"/>
  <link:presentationLink xlink:role="http://lyell.com/role/RelatedpartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_642b797e-f3c5-4d56-b52d-d96197b25c94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_0fbce2e8-9241-4df9-a26d-da1571eac12a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_642b797e-f3c5-4d56-b52d-d96197b25c94" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_0fbce2e8-9241-4df9-a26d-da1571eac12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_90a3641e-e532-4723-9e81-c440f0bb8a57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_38c0a282-c697-427d-891d-d018a4e6d896" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_90a3641e-e532-4723-9e81-c440f0bb8a57" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_38c0a282-c697-427d-891d-d018a4e6d896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e9eedb7b-c1e4-4557-8b58-b85ea503751f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_38c0a282-c697-427d-891d-d018a4e6d896" xlink:to="loc_srt_CounterpartyNameAxis_e9eedb7b-c1e4-4557-8b58-b85ea503751f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3738b496-5174-46a1-afd2-6faf4c77c16c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e9eedb7b-c1e4-4557-8b58-b85ea503751f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3738b496-5174-46a1-afd2-6faf4c77c16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchMember_f83fad97-a3d1-4b5c-adc8-5acb87ead47c" xlink:href="lyel-20240331.xsd#lyel_FredHutchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3738b496-5174-46a1-afd2-6faf4c77c16c" xlink:to="loc_lyel_FredHutchMember_f83fad97-a3d1-4b5c-adc8-5acb87ead47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordMember_68ac4e31-7d53-45ea-99e7-d9c48f09749d" xlink:href="lyel-20240331.xsd#lyel_StanfordMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3738b496-5174-46a1-afd2-6faf4c77c16c" xlink:to="loc_lyel_StanfordMember_68ac4e31-7d53-45ea-99e7-d9c48f09749d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5818ff90-dc2f-4536-b621-e9f1f643fe77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_38c0a282-c697-427d-891d-d018a4e6d896" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5818ff90-dc2f-4536-b621-e9f1f643fe77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a32c1c8c-b5f7-465f-80f2-a2009f909a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5818ff90-dc2f-4536-b621-e9f1f643fe77" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a32c1c8c-b5f7-465f-80f2-a2009f909a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_70c5dc62-aa7d-432b-b66f-792ba5f52ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a32c1c8c-b5f7-465f-80f2-a2009f909a6f" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_70c5dc62-aa7d-432b-b66f-792ba5f52ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f2350a6a-8b39-49df-baff-53e0023da604" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_38c0a282-c697-427d-891d-d018a4e6d896" xlink:to="loc_srt_RangeAxis_f2350a6a-8b39-49df-baff-53e0023da604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fc963d0b-e5ee-468d-adb4-4600a4a9b48a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f2350a6a-8b39-49df-baff-53e0023da604" xlink:to="loc_srt_RangeMember_fc963d0b-e5ee-468d-adb4-4600a4a9b48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d4b584f1-1103-4230-8a38-ce9ad03ecb70" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fc963d0b-e5ee-468d-adb4-4600a4a9b48a" xlink:to="loc_srt_MinimumMember_d4b584f1-1103-4230-8a38-ce9ad03ecb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_48b5e7da-3bee-4a14-94b4-00abc011899c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fc963d0b-e5ee-468d-adb4-4600a4a9b48a" xlink:to="loc_srt_MaximumMember_48b5e7da-3bee-4a14-94b4-00abc011899c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a6f170d1-ed46-48b2-aa35-f760542acadf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_38c0a282-c697-427d-891d-d018a4e6d896" xlink:to="loc_srt_ProductOrServiceAxis_a6f170d1-ed46-48b2-aa35-f760542acadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6f0c4663-7f92-491d-b866-d93b47559f73" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a6f170d1-ed46-48b2-aa35-f760542acadf" xlink:to="loc_srt_ProductsAndServicesDomain_6f0c4663-7f92-491d-b866-d93b47559f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_191d0dbb-bcba-440f-aaf8-764b887fa727" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6f0c4663-7f92-491d-b866-d93b47559f73" xlink:to="loc_us-gaap_LicenseMember_191d0dbb-bcba-440f-aaf8-764b887fa727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_971ff75f-cf37-4f6d-a116-4e5ac9f8d4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_38c0a282-c697-427d-891d-d018a4e6d896" xlink:to="loc_us-gaap_StatementClassOfStockAxis_971ff75f-cf37-4f6d-a116-4e5ac9f8d4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_23ff01e3-cd27-409e-a439-098879f1e7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_971ff75f-cf37-4f6d-a116-4e5ac9f8d4ba" xlink:to="loc_us-gaap_ClassOfStockDomain_23ff01e3-cd27-409e-a439-098879f1e7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SeriesAConvertiblePreferredStockMember_5e46a32f-24b0-449c-99ff-f784a4093741" xlink:href="lyel-20240331.xsd#lyel_SeriesAConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_23ff01e3-cd27-409e-a439-098879f1e7b0" xlink:to="loc_lyel_SeriesAConvertiblePreferredStockMember_5e46a32f-24b0-449c-99ff-f784a4093741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_38c0a282-c697-427d-891d-d018a4e6d896" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments_dc8f8f9d-5dea-43b1-87bb-7ceaccd4c750" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments_dc8f8f9d-5dea-43b1-87bb-7ceaccd4c750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments_066527e1-af77-470a-8247-99c46b58acf9" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsResearchPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments_066527e1-af77-470a-8247-99c46b58acf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm_f40e2e81-097f-4c86-a580-484464d3fc2f" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsResearchTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm_f40e2e81-097f-4c86-a580-484464d3fc2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f23627f9-0d2a-4df3-aef2-53429fd50b04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f23627f9-0d2a-4df3-aef2-53429fd50b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_caa1f3f5-13e2-4d7d-a1ac-3246bd18f143" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_caa1f3f5-13e2-4d7d-a1ac-3246bd18f143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_ade39a44-9260-4e67-b69d-2181cbbe8b57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_ade39a44-9260-4e67-b69d-2181cbbe8b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_759457e5-d389-4685-b914-3f8056dd2181" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_759457e5-d389-4685-b914-3f8056dd2181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_3870d1bd-bda2-4013-8b99-95f9fe6fa1a3" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_3870d1bd-bda2-4013-8b99-95f9fe6fa1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm_914609ca-f7a1-4ef2-8b95-28da4abbbf56" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm_914609ca-f7a1-4ef2-8b95-28da4abbbf56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate_437f7311-1e56-473b-ad9e-fbbd2d9a2fe2" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate_437f7311-1e56-473b-ad9e-fbbd2d9a2fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering_2110df4c-d4ae-46ce-8a04-9f5e60768ee2" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering_2110df4c-d4ae-46ce-8a04-9f5e60768ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability_8640711a-9b16-48bf-bf06-5031c8d3c819" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability_8640711a-9b16-48bf-bf06-5031c8d3c819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_fb6c0bb3-8557-418c-af35-af047313fb5c" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_fb6c0bb3-8557-418c-af35-af047313fb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments_5f991c3d-b7bc-40df-bba4-b26577b25895" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments_5f991c3d-b7bc-40df-bba4-b26577b25895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments_e3b3f16e-861a-4bc4-a934-2cc7b0e0f938" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments_e3b3f16e-861a-4bc4-a934-2cc7b0e0f938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability_4533a3d8-5068-4e68-9edf-a53ff8684210" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f9010753-dae5-4ebc-aa57-3420dfc611d9" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability_4533a3d8-5068-4e68-9edf-a53ff8684210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14248e16-8115-44af-a668-b3b8a6590195" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee278bd7-d00d-4592-9399-f95447ed7f20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14248e16-8115-44af-a668-b3b8a6590195" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee278bd7-d00d-4592-9399-f95447ed7f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e178d26d-760d-4822-85ba-de8df74845f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee278bd7-d00d-4592-9399-f95447ed7f20" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e178d26d-760d-4822-85ba-de8df74845f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c7d4ca2c-72bb-4a84-9fb4-0d1736704793" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e178d26d-760d-4822-85ba-de8df74845f1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c7d4ca2c-72bb-4a84-9fb4-0d1736704793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_10b05a57-947f-4994-963a-079977bcff66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c7d4ca2c-72bb-4a84-9fb4-0d1736704793" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_10b05a57-947f-4994-963a-079977bcff66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityMultipleAxis_aac9c2a6-edca-48e3-9509-6b8358876c51" xlink:href="lyel-20240331.xsd#lyel_EquityMultipleAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee278bd7-d00d-4592-9399-f95447ed7f20" xlink:to="loc_lyel_EquityMultipleAxis_aac9c2a6-edca-48e3-9509-6b8358876c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityMultipleDomain_d24d52e9-eed1-4158-bd11-e7913b0ed7ad" xlink:href="lyel-20240331.xsd#lyel_EquityMultipleDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_EquityMultipleAxis_aac9c2a6-edca-48e3-9509-6b8358876c51" xlink:to="loc_lyel_EquityMultipleDomain_d24d52e9-eed1-4158-bd11-e7913b0ed7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TenTimesMember_bc26e323-e64b-4abf-badc-c91a1acbb78c" xlink:href="lyel-20240331.xsd#lyel_TenTimesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_EquityMultipleDomain_d24d52e9-eed1-4158-bd11-e7913b0ed7ad" xlink:to="loc_lyel_TenTimesMember_bc26e323-e64b-4abf-badc-c91a1acbb78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwentyTimesMember_9c80a032-1bba-4630-ba19-f2e347d6acde" xlink:href="lyel-20240331.xsd#lyel_TwentyTimesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_EquityMultipleDomain_d24d52e9-eed1-4158-bd11-e7913b0ed7ad" xlink:to="loc_lyel_TwentyTimesMember_9c80a032-1bba-4630-ba19-f2e347d6acde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ThirtyTimesMember_56dc1375-0a8c-4654-ae0c-7ba90125b2fe" xlink:href="lyel-20240331.xsd#lyel_ThirtyTimesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_EquityMultipleDomain_d24d52e9-eed1-4158-bd11-e7913b0ed7ad" xlink:to="loc_lyel_ThirtyTimesMember_56dc1375-0a8c-4654-ae0c-7ba90125b2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FortyTimesMember_ae699b12-e680-4267-8033-f20ffb4fe988" xlink:href="lyel-20240331.xsd#lyel_FortyTimesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_EquityMultipleDomain_d24d52e9-eed1-4158-bd11-e7913b0ed7ad" xlink:to="loc_lyel_FortyTimesMember_ae699b12-e680-4267-8033-f20ffb4fe988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FiftyTimesMember_5d81386c-caeb-4701-af97-af9b985cc655" xlink:href="lyel-20240331.xsd#lyel_FiftyTimesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_EquityMultipleDomain_d24d52e9-eed1-4158-bd11-e7913b0ed7ad" xlink:to="loc_lyel_FiftyTimesMember_5d81386c-caeb-4701-af97-af9b985cc655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_761d7b91-11da-4a92-bb88-cbb289bc5782" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee278bd7-d00d-4592-9399-f95447ed7f20" xlink:to="loc_srt_CounterpartyNameAxis_761d7b91-11da-4a92-bb88-cbb289bc5782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9682ee3-67f2-402e-84f2-3ba5318807b6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_761d7b91-11da-4a92-bb88-cbb289bc5782" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9682ee3-67f2-402e-84f2-3ba5318807b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchMember_10288974-aa53-4c01-9f02-1ad5bc7bb0a6" xlink:href="lyel-20240331.xsd#lyel_FredHutchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9682ee3-67f2-402e-84f2-3ba5318807b6" xlink:to="loc_lyel_FredHutchMember_10288974-aa53-4c01-9f02-1ad5bc7bb0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordMember_8368e5fc-9df8-403f-a867-181812b8b4f8" xlink:href="lyel-20240331.xsd#lyel_StanfordMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9682ee3-67f2-402e-84f2-3ba5318807b6" xlink:to="loc_lyel_StanfordMember_8368e5fc-9df8-403f-a867-181812b8b4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96aa59-fb2b-420c-8a7c-9a0e91d1728a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee278bd7-d00d-4592-9399-f95447ed7f20" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96aa59-fb2b-420c-8a7c-9a0e91d1728a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_051bb74c-2e22-404e-8dcb-6eea3ef79b60" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96aa59-fb2b-420c-8a7c-9a0e91d1728a" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_051bb74c-2e22-404e-8dcb-6eea3ef79b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_ac42250e-41bf-41d6-9a62-c004f1a6eccb" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96aa59-fb2b-420c-8a7c-9a0e91d1728a" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_ac42250e-41bf-41d6-9a62-c004f1a6eccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_3add3e13-ddee-4c21-b5c3-0e061dd797cb" xlink:href="lyel-20240331.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96aa59-fb2b-420c-8a7c-9a0e91d1728a" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_3add3e13-ddee-4c21-b5c3-0e061dd797cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_d10a6252-18e7-473c-8929-e8e9753f1168" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_8fb53c87-ad0d-40a9-bc98-7011fdb2d5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_d10a6252-18e7-473c-8929-e8e9753f1168" xlink:to="loc_us-gaap_MarketableSecuritiesTable_8fb53c87-ad0d-40a9-bc98-7011fdb2d5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5eaca226-8733-4553-b091-e8c968aafc17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_8fb53c87-ad0d-40a9-bc98-7011fdb2d5f1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5eaca226-8733-4553-b091-e8c968aafc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bb75b8b1-f9c3-42c8-84b5-bc666e6d4bba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5eaca226-8733-4553-b091-e8c968aafc17" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bb75b8b1-f9c3-42c8-84b5-bc666e6d4bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b4f0c880-109b-46ca-aa46-7641457c20d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bb75b8b1-f9c3-42c8-84b5-bc666e6d4bba" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b4f0c880-109b-46ca-aa46-7641457c20d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_10f555ba-ff7c-45a0-ac12-65763b625c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bb75b8b1-f9c3-42c8-84b5-bc666e6d4bba" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_10f555ba-ff7c-45a0-ac12-65763b625c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_544ddba9-0950-443c-b393-e739ab1b7fca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bb75b8b1-f9c3-42c8-84b5-bc666e6d4bba" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_544ddba9-0950-443c-b393-e739ab1b7fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c31b79fc-3d72-4bcf-8cc5-07e9715c4540" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bb75b8b1-f9c3-42c8-84b5-bc666e6d4bba" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c31b79fc-3d72-4bcf-8cc5-07e9715c4540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2b5e9cd8-31c1-4a44-b185-01ff60776861" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_8fb53c87-ad0d-40a9-bc98-7011fdb2d5f1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2b5e9cd8-31c1-4a44-b185-01ff60776861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5c8c7089-5f58-4a03-8712-b714f997a241" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2b5e9cd8-31c1-4a44-b185-01ff60776861" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5c8c7089-5f58-4a03-8712-b714f997a241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_f5be90a2-fde9-49c4-ad93-190763a67af3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5c8c7089-5f58-4a03-8712-b714f997a241" xlink:to="loc_us-gaap_CashEquivalentsMember_f5be90a2-fde9-49c4-ad93-190763a67af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_MarketableSecuritiesCurrentMember_52d7e787-31da-44ca-b451-548bfd3a749a" xlink:href="lyel-20240331.xsd#lyel_MarketableSecuritiesCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5c8c7089-5f58-4a03-8712-b714f997a241" xlink:to="loc_lyel_MarketableSecuritiesCurrentMember_52d7e787-31da-44ca-b451-548bfd3a749a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_MarketableSecuritiesNoncurrentMember_fa7ad2c4-82b1-4554-8488-2879373ff391" xlink:href="lyel-20240331.xsd#lyel_MarketableSecuritiesNoncurrentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5c8c7089-5f58-4a03-8712-b714f997a241" xlink:to="loc_lyel_MarketableSecuritiesNoncurrentMember_fa7ad2c4-82b1-4554-8488-2879373ff391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_e5637a1e-5328-4ef0-b0dc-2bbd19d0226d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_8fb53c87-ad0d-40a9-bc98-7011fdb2d5f1" xlink:to="loc_us-gaap_MarketableSecuritiesLineItems_e5637a1e-5328-4ef0-b0dc-2bbd19d0226d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3618ba8d-33ef-4b70-81a6-cc784739fe33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_e5637a1e-5328-4ef0-b0dc-2bbd19d0226d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3618ba8d-33ef-4b70-81a6-cc784739fe33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d8c6b070-c6be-405c-8177-65ced4c8f80c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_e5637a1e-5328-4ef0-b0dc-2bbd19d0226d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d8c6b070-c6be-405c-8177-65ced4c8f80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8b7418d0-27ab-4609-9145-ef77e67d94fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_e5637a1e-5328-4ef0-b0dc-2bbd19d0226d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8b7418d0-27ab-4609-9145-ef77e67d94fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_db81b6ed-ee0d-4832-b074-c49e6ad59197" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_e5637a1e-5328-4ef0-b0dc-2bbd19d0226d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_db81b6ed-ee0d-4832-b074-c49e6ad59197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_99f40ed4-adde-4f71-9d2b-9baa1278a1da" xlink:href="lyel-20240331.xsd#lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_e5637a1e-5328-4ef0-b0dc-2bbd19d0226d" xlink:to="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_99f40ed4-adde-4f71-9d2b-9baa1278a1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_792db5f9-103b-4f4d-8c59-775eb070263a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_99f40ed4-adde-4f71-9d2b-9baa1278a1da" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_792db5f9-103b-4f4d-8c59-775eb070263a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#CashEquivalentsandMarketableSecuritiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_caa35808-c683-45a5-b1d5-1d74f0d61256" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_bbde30a2-af91-4da7-b60d-e923ab463652" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_caa35808-c683-45a5-b1d5-1d74f0d61256" xlink:to="loc_us-gaap_MarketableSecuritiesTable_bbde30a2-af91-4da7-b60d-e923ab463652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d2c590f5-5662-4bb8-9300-63c14f700779" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_bbde30a2-af91-4da7-b60d-e923ab463652" xlink:to="loc_srt_RangeAxis_d2c590f5-5662-4bb8-9300-63c14f700779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_03c42b40-100a-4683-ac71-ae11cf641314" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d2c590f5-5662-4bb8-9300-63c14f700779" xlink:to="loc_srt_RangeMember_03c42b40-100a-4683-ac71-ae11cf641314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_10979c1e-23eb-4b0d-bbc8-d35cbe802e9a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_03c42b40-100a-4683-ac71-ae11cf641314" xlink:to="loc_srt_MaximumMember_10979c1e-23eb-4b0d-bbc8-d35cbe802e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_5d53bd0f-b7f0-4ca1-98e7-58198c7aa3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_bbde30a2-af91-4da7-b60d-e923ab463652" xlink:to="loc_us-gaap_MarketableSecuritiesLineItems_5d53bd0f-b7f0-4ca1-98e7-58198c7aa3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_a334f936-3910-4adc-958e-7f63094940a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_5d53bd0f-b7f0-4ca1-98e7-58198c7aa3a6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_a334f936-3910-4adc-958e-7f63094940a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_68ea7fe6-ee86-4607-b9ff-e7236ad70e01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_5d53bd0f-b7f0-4ca1-98e7-58198c7aa3a6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_68ea7fe6-ee86-4607-b9ff-e7236ad70e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_86863e3d-8e96-43a5-8501-d28850717075" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_5d53bd0f-b7f0-4ca1-98e7-58198c7aa3a6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_86863e3d-8e96-43a5-8501-d28850717075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/OtherInvestmentsDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#OtherInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/OtherInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_dd735b70-d345-4590-973f-cd27f1a59beb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_a9d8d630-e163-4af9-80e6-325e1551f4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_dd735b70-d345-4590-973f-cd27f1a59beb" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_a9d8d630-e163-4af9-80e6-325e1551f4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_58231db3-9895-4959-af09-9834d7e8967d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_a9d8d630-e163-4af9-80e6-325e1551f4a7" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_58231db3-9895-4959-af09-9834d7e8967d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_833ed8b0-9ef6-4cac-bd3e-cc82fd12b44a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_58231db3-9895-4959-af09-9834d7e8967d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_833ed8b0-9ef6-4cac-bd3e-cc82fd12b44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_OtherInvestmentMember_af6e52f9-4a42-487e-aaca-4b2fc4d702ef" xlink:href="lyel-20240331.xsd#lyel_OtherInvestmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_833ed8b0-9ef6-4cac-bd3e-cc82fd12b44a" xlink:to="loc_lyel_OtherInvestmentMember_af6e52f9-4a42-487e-aaca-4b2fc4d702ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_7985fabd-9949-40c4-aef6-f3afdc1b73cb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_a9d8d630-e163-4af9-80e6-325e1551f4a7" xlink:to="loc_srt_ConsolidatedEntitiesAxis_7985fabd-9949-40c4-aef6-f3afdc1b73cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_84d79ec1-c270-4516-bff6-b1ad93717163" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_7985fabd-9949-40c4-aef6-f3afdc1b73cb" xlink:to="loc_srt_ConsolidatedEntitiesDomain_84d79ec1-c270-4516-bff6-b1ad93717163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_2043c2f4-54b0-48a3-a90b-06256d320ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_84d79ec1-c270-4516-bff6-b1ad93717163" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_2043c2f4-54b0-48a3-a90b-06256d320ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_347cb699-2a2f-4ea9-a2b0-e71ea42fa45b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_a9d8d630-e163-4af9-80e6-325e1551f4a7" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_347cb699-2a2f-4ea9-a2b0-e71ea42fa45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments_642e8774-8a45-4530-a201-15ffe5139514" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_347cb699-2a2f-4ea9-a2b0-e71ea42fa45b" xlink:to="loc_us-gaap_OtherInvestments_642e8774-8a45-4530-a201-15ffe5139514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_2fa0ed29-896e-493e-9c0a-5e4eefb14945" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_347cb699-2a2f-4ea9-a2b0-e71ea42fa45b" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_2fa0ed29-896e-493e-9c0a-5e4eefb14945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary_ccc53475-7ae3-4d65-8751-f2bc5945e109" xlink:href="lyel-20240331.xsd#lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_347cb699-2a2f-4ea9-a2b0-e71ea42fa45b" xlink:to="loc_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary_ccc53475-7ae3-4d65-8751-f2bc5945e109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_a5b045bd-8ceb-464b-96df-b89d960b7385" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_347cb699-2a2f-4ea9-a2b0-e71ea42fa45b" xlink:to="loc_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_a5b045bd-8ceb-464b-96df-b89d960b7385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_d91fbeda-6460-4b46-b30c-19fec71291d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_347cb699-2a2f-4ea9-a2b0-e71ea42fa45b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_d91fbeda-6460-4b46-b30c-19fec71291d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_87877422-8b52-4209-be1c-a993da624b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1ba188f-7260-41e8-89b6-8a55f800272d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_87877422-8b52-4209-be1c-a993da624b0d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1ba188f-7260-41e8-89b6-8a55f800272d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f5c77448-8819-4376-83b7-3bf3c214b5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1ba188f-7260-41e8-89b6-8a55f800272d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f5c77448-8819-4376-83b7-3bf3c214b5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b3123c74-a184-43ad-923e-e367c2d4c010" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f5c77448-8819-4376-83b7-3bf3c214b5c1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b3123c74-a184-43ad-923e-e367c2d4c010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cda0e13a-836a-4899-a5d2-aeceab4e4d90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b3123c74-a184-43ad-923e-e367c2d4c010" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cda0e13a-836a-4899-a5d2-aeceab4e4d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9b644edb-47d8-4ea5-8ba7-d2ebc655bff1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b3123c74-a184-43ad-923e-e367c2d4c010" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9b644edb-47d8-4ea5-8ba7-d2ebc655bff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3b2d28a8-2b18-44fc-b5c6-1800601b5ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b3123c74-a184-43ad-923e-e367c2d4c010" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3b2d28a8-2b18-44fc-b5c6-1800601b5ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_5df7296e-1f28-4c7d-bfb1-69d6c47d7a05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1ba188f-7260-41e8-89b6-8a55f800272d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_5df7296e-1f28-4c7d-bfb1-69d6c47d7a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_584d5315-168e-42c8-b0a6-96ebc682a0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_5df7296e-1f28-4c7d-bfb1-69d6c47d7a05" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_584d5315-168e-42c8-b0a6-96ebc682a0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_883f75a5-4dab-429f-aa80-ce9b9b736f02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_584d5315-168e-42c8-b0a6-96ebc682a0b6" xlink:to="loc_us-gaap_MoneyMarketFundsMember_883f75a5-4dab-429f-aa80-ce9b9b736f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6026a6f4-9ec7-47ca-9a9f-f5de67f9d386" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1ba188f-7260-41e8-89b6-8a55f800272d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6026a6f4-9ec7-47ca-9a9f-f5de67f9d386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f0c8c5fa-5865-4a8f-bc92-742a755dc2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6026a6f4-9ec7-47ca-9a9f-f5de67f9d386" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f0c8c5fa-5865-4a8f-bc92-742a755dc2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_6825857d-5e9d-48bf-8228-18e2081b4d94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f0c8c5fa-5865-4a8f-bc92-742a755dc2fa" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_6825857d-5e9d-48bf-8228-18e2081b4d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6645c209-ee70-48a6-8f39-76939716ee60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f0c8c5fa-5865-4a8f-bc92-742a755dc2fa" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6645c209-ee70-48a6-8f39-76939716ee60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_35b408e4-00fa-4063-b743-0968158290fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f0c8c5fa-5865-4a8f-bc92-742a755dc2fa" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_35b408e4-00fa-4063-b743-0968158290fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_260b1527-1cb0-405e-94d4-1016448d25e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1ba188f-7260-41e8-89b6-8a55f800272d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_260b1527-1cb0-405e-94d4-1016448d25e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_86708e8f-435d-4072-85ce-0d5325df5a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_260b1527-1cb0-405e-94d4-1016448d25e2" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_86708e8f-435d-4072-85ce-0d5325df5a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c530c75a-479d-405b-8aa7-e91f7eb3ac51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_86708e8f-435d-4072-85ce-0d5325df5a5c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c530c75a-479d-405b-8aa7-e91f7eb3ac51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5b42caeb-df3d-4a4b-8329-217b30822359" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_86708e8f-435d-4072-85ce-0d5325df5a5c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5b42caeb-df3d-4a4b-8329-217b30822359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_d013f945-a7dc-4fc2-8867-efc91a6d8c58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_86708e8f-435d-4072-85ce-0d5325df5a5c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_d013f945-a7dc-4fc2-8867-efc91a6d8c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d3d973d5-1844-4d53-aeee-9942d643b769" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_86708e8f-435d-4072-85ce-0d5325df5a5c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d3d973d5-1844-4d53-aeee-9942d643b769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_d7fa8571-5e2f-4c6f-970b-814f109f4cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_260b1527-1cb0-405e-94d4-1016448d25e2" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_d7fa8571-5e2f-4c6f-970b-814f109f4cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_54610a7f-155e-4d33-8b15-0cefffbf7297" xlink:href="lyel-20240331.xsd#lyel_SuccessPaymentLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_d7fa8571-5e2f-4c6f-970b-814f109f4cf0" xlink:to="loc_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_54610a7f-155e-4d33-8b15-0cefffbf7297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_f5461fc8-5e91-4136-9d02-f8ac87d0ddea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_d7fa8571-5e2f-4c6f-970b-814f109f4cf0" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_f5461fc8-5e91-4136-9d02-f8ac87d0ddea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_83db68e7-d3a9-475b-bb95-a82c5f7cf826" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_d28dc8c6-41fb-4f07-8b76-cbe2dbe243ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_83db68e7-d3a9-475b-bb95-a82c5f7cf826" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_d28dc8c6-41fb-4f07-8b76-cbe2dbe243ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_306b351f-d450-450d-833d-330a6863589a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_83db68e7-d3a9-475b-bb95-a82c5f7cf826" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_306b351f-d450-450d-833d-330a6863589a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_de0cd202-8ade-4875-be91-135fed51f8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0071b926-1b71-4bf0-9eec-10060b942e01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_de0cd202-8ade-4875-be91-135fed51f8f9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0071b926-1b71-4bf0-9eec-10060b942e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_11facc7e-9f8c-4b1d-8ac6-8d3e3971093d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0071b926-1b71-4bf0-9eec-10060b942e01" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_11facc7e-9f8c-4b1d-8ac6-8d3e3971093d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9abc6524-b5c3-4e35-b5c5-73b6e7433da7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_11facc7e-9f8c-4b1d-8ac6-8d3e3971093d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9abc6524-b5c3-4e35-b5c5-73b6e7433da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchSuccessPaymentLiabilityMember_26e6c2a9-a047-4475-bac4-f010fc869d7e" xlink:href="lyel-20240331.xsd#lyel_FredHutchSuccessPaymentLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9abc6524-b5c3-4e35-b5c5-73b6e7433da7" xlink:to="loc_lyel_FredHutchSuccessPaymentLiabilityMember_26e6c2a9-a047-4475-bac4-f010fc869d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordSuccessPaymentLiabilityMember_eb071f08-b200-473a-a883-64274a5f8e52" xlink:href="lyel-20240331.xsd#lyel_StanfordSuccessPaymentLiabilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9abc6524-b5c3-4e35-b5c5-73b6e7433da7" xlink:to="loc_lyel_StanfordSuccessPaymentLiabilityMember_eb071f08-b200-473a-a883-64274a5f8e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_898a1954-ea3c-4536-a130-dee0b2442de0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0071b926-1b71-4bf0-9eec-10060b942e01" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_898a1954-ea3c-4536-a130-dee0b2442de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_98b16575-122e-4eda-b731-87e5a805ce1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_898a1954-ea3c-4536-a130-dee0b2442de0" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_98b16575-122e-4eda-b731-87e5a805ce1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_7c2f416a-cd59-4945-ba30-949d138217c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_98b16575-122e-4eda-b731-87e5a805ce1c" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_7c2f416a-cd59-4945-ba30-949d138217c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_5cad97d4-d3ba-4e97-8e22-013f3318b8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_98b16575-122e-4eda-b731-87e5a805ce1c" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_5cad97d4-d3ba-4e97-8e22-013f3318b8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_b2aa2be2-b4a1-4281-83de-1e741bb6fc24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_98b16575-122e-4eda-b731-87e5a805ce1c" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_b2aa2be2-b4a1-4281-83de-1e741bb6fc24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aa9f771e-5f95-420d-881e-16a2d623eca1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0071b926-1b71-4bf0-9eec-10060b942e01" xlink:to="loc_srt_RangeAxis_aa9f771e-5f95-420d-881e-16a2d623eca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aea0183d-8b86-412e-be9c-cf29165bbfc0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_aa9f771e-5f95-420d-881e-16a2d623eca1" xlink:to="loc_srt_RangeMember_aea0183d-8b86-412e-be9c-cf29165bbfc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d6f4ecbe-cb8c-4570-832c-61ccb546b3eb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_aea0183d-8b86-412e-be9c-cf29165bbfc0" xlink:to="loc_srt_MinimumMember_d6f4ecbe-cb8c-4570-832c-61ccb546b3eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ceffa24c-6260-417f-934c-1a4c5e1781ed" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_aea0183d-8b86-412e-be9c-cf29165bbfc0" xlink:to="loc_srt_MaximumMember_ceffa24c-6260-417f-934c-1a4c5e1781ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7adbad14-8786-4f69-887a-f1bde535b2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0071b926-1b71-4bf0-9eec-10060b942e01" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7adbad14-8786-4f69-887a-f1bde535b2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilityFairValueOfCommonStock_60bb1539-6cbe-4f6f-a108-2092b96ba20c" xlink:href="lyel-20240331.xsd#lyel_SuccessPaymentLiabilityFairValueOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7adbad14-8786-4f69-887a-f1bde535b2cc" xlink:to="loc_lyel_SuccessPaymentLiabilityFairValueOfCommonStock_60bb1539-6cbe-4f6f-a108-2092b96ba20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilityMeasurementInput_147289a2-6b8a-4e3a-832d-a7de6b045a83" xlink:href="lyel-20240331.xsd#lyel_SuccessPaymentLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7adbad14-8786-4f69-887a-f1bde535b2cc" xlink:to="loc_lyel_SuccessPaymentLiabilityMeasurementInput_147289a2-6b8a-4e3a-832d-a7de6b045a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b2f4963f-1c34-424e-9e3c-e282fbfaa70e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d23b0691-cd9c-4b58-a47b-359fa9d7a850" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b2f4963f-1c34-424e-9e3c-e282fbfaa70e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d23b0691-cd9c-4b58-a47b-359fa9d7a850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_598f73f5-61d0-405f-99cc-e22a4dd447c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d23b0691-cd9c-4b58-a47b-359fa9d7a850" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_598f73f5-61d0-405f-99cc-e22a4dd447c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5ac2350e-8f2c-4b62-90bc-b78db281c68e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_598f73f5-61d0-405f-99cc-e22a4dd447c1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5ac2350e-8f2c-4b62-90bc-b78db281c68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6990bc29-15b5-483f-adc5-d3d9c3b4852e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5ac2350e-8f2c-4b62-90bc-b78db281c68e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6990bc29-15b5-483f-adc5-d3d9c3b4852e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_3d1a2481-a584-4983-8444-bc294fb705fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d23b0691-cd9c-4b58-a47b-359fa9d7a850" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_3d1a2481-a584-4983-8444-bc294fb705fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1f31ab76-e88b-467b-99d8-dd3d36f1cd00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_3d1a2481-a584-4983-8444-bc294fb705fb" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1f31ab76-e88b-467b-99d8-dd3d36f1cd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilityMember_250d0c68-580e-4be6-9cbb-cb4fc3dbf980" xlink:href="lyel-20240331.xsd#lyel_SuccessPaymentLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1f31ab76-e88b-467b-99d8-dd3d36f1cd00" xlink:to="loc_lyel_SuccessPaymentLiabilityMember_250d0c68-580e-4be6-9cbb-cb4fc3dbf980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a4869880-3a23-4b8e-a61c-cb7f4cce81c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d23b0691-cd9c-4b58-a47b-359fa9d7a850" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a4869880-3a23-4b8e-a61c-cb7f4cce81c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1149a249-69e4-4db9-8e9a-b31343fabe13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a4869880-3a23-4b8e-a61c-cb7f4cce81c6" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1149a249-69e4-4db9-8e9a-b31343fabe13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_328d05a8-e7e5-43a3-a201-df7e5732d6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1149a249-69e4-4db9-8e9a-b31343fabe13" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_328d05a8-e7e5-43a3-a201-df7e5732d6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2826df80-5262-4691-8c2c-f2276da2dcdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1149a249-69e4-4db9-8e9a-b31343fabe13" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2826df80-5262-4691-8c2c-f2276da2dcdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_914fa664-2bd5-4687-9a4a-4b6314cd092e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1149a249-69e4-4db9-8e9a-b31343fabe13" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_914fa664-2bd5-4687-9a4a-4b6314cd092e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_75128ef5-445d-4c96-b420-86f87a1acdfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a4869880-3a23-4b8e-a61c-cb7f4cce81c6" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_75128ef5-445d-4c96-b420-86f87a1acdfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_995a4a9a-1975-4b7e-a7ef-8eb034301ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_cf19eb14-8e39-403a-a62a-3c291d2a774f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_995a4a9a-1975-4b7e-a7ef-8eb034301ae3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_cf19eb14-8e39-403a-a62a-3c291d2a774f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1a78ad52-b066-474e-8258-49d50d2ef1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_995a4a9a-1975-4b7e-a7ef-8eb034301ae3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1a78ad52-b066-474e-8258-49d50d2ef1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0bec33df-ccf5-4c37-bd88-2895002df0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_995a4a9a-1975-4b7e-a7ef-8eb034301ae3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0bec33df-ccf5-4c37-bd88-2895002df0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6f499e8a-c807-4154-8ad6-1e40d2fad3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_995a4a9a-1975-4b7e-a7ef-8eb034301ae3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6f499e8a-c807-4154-8ad6-1e40d2fad3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_699c3f8b-bc63-40a6-bfd6-db9dbe67796d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_995a4a9a-1975-4b7e-a7ef-8eb034301ae3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_699c3f8b-bc63-40a6-bfd6-db9dbe67796d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_c0a4b8e7-9a70-4303-b972-93acab1fe6b1" xlink:href="lyel-20240331.xsd#lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_995a4a9a-1975-4b7e-a7ef-8eb034301ae3" xlink:to="loc_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_c0a4b8e7-9a70-4303-b972-93acab1fe6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_23170800-2735-4cfb-b4b1-ec1be99d1df8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_995a4a9a-1975-4b7e-a7ef-8eb034301ae3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_23170800-2735-4cfb-b4b1-ec1be99d1df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0fe60711-4395-4694-9744-ecee86cbd3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_995a4a9a-1975-4b7e-a7ef-8eb034301ae3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0fe60711-4395-4694-9744-ecee86cbd3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4477b2fc-d9f7-45c2-8a65-b6990ceb0f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_995a4a9a-1975-4b7e-a7ef-8eb034301ae3" xlink:to="loc_us-gaap_OperatingLeaseLiability_4477b2fc-d9f7-45c2-8a65-b6990ceb0f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_d3a9116d-cc83-4c8d-9cf6-f8c06a55d476" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_995a4a9a-1975-4b7e-a7ef-8eb034301ae3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_d3a9116d-cc83-4c8d-9cf6-f8c06a55d476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_287cf260-2340-439d-923c-cdca820cf60d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_d3a9116d-cc83-4c8d-9cf6-f8c06a55d476" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_287cf260-2340-439d-923c-cdca820cf60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_293e58dd-f4a7-4a66-bec5-bd709bdbde09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_d3a9116d-cc83-4c8d-9cf6-f8c06a55d476" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_293e58dd-f4a7-4a66-bec5-bd709bdbde09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_84729088-125d-4215-988e-b5309f2da289" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_d3a9116d-cc83-4c8d-9cf6-f8c06a55d476" xlink:to="loc_us-gaap_OperatingLeaseLiability_84729088-125d-4215-988e-b5309f2da289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d7875798-9ce9-4bac-ab32-c883814e28bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_98139d71-e199-4d56-ba5d-10141cc2cb8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d7875798-9ce9-4bac-ab32-c883814e28bb" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_98139d71-e199-4d56-ba5d-10141cc2cb8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5440f013-8ea6-4fb7-adcc-e379bf62f033" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_98139d71-e199-4d56-ba5d-10141cc2cb8a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5440f013-8ea6-4fb7-adcc-e379bf62f033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1ba0cf31-7d91-4d56-9004-8bdea9b1d2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5440f013-8ea6-4fb7-adcc-e379bf62f033" xlink:to="loc_us-gaap_RelatedPartyDomain_1ba0cf31-7d91-4d56-9004-8bdea9b1d2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_9d3e6848-4bf7-4185-994a-b8c860f79fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1ba0cf31-7d91-4d56-9004-8bdea9b1d2d9" xlink:to="loc_us-gaap_RelatedPartyMember_9d3e6848-4bf7-4185-994a-b8c860f79fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d791c867-e5ef-4821-9f17-82a0cee1934e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_98139d71-e199-4d56-ba5d-10141cc2cb8a" xlink:to="loc_srt_StatementGeographicalAxis_d791c867-e5ef-4821-9f17-82a0cee1934e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a09fafea-8dcd-420e-a05d-1b05c249eff2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_d791c867-e5ef-4821-9f17-82a0cee1934e" xlink:to="loc_srt_SegmentGeographicalDomain_a09fafea-8dcd-420e-a05d-1b05c249eff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SouthSanFranciscoCaliforniaMember_87c5e29a-ffe0-4e2f-87ba-938abf15f40b" xlink:href="lyel-20240331.xsd#lyel_SouthSanFranciscoCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a09fafea-8dcd-420e-a05d-1b05c249eff2" xlink:to="loc_lyel_SouthSanFranciscoCaliforniaMember_87c5e29a-ffe0-4e2f-87ba-938abf15f40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a930d566-2df0-4503-bdb3-83a542e0e781" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_98139d71-e199-4d56-ba5d-10141cc2cb8a" xlink:to="loc_srt_CounterpartyNameAxis_a930d566-2df0-4503-bdb3-83a542e0e781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_459e8cb3-5787-4701-a5b0-3d53b330185e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a930d566-2df0-4503-bdb3-83a542e0e781" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_459e8cb3-5787-4701-a5b0-3d53b330185e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SonomaMember_df93ed22-b5fe-4a5c-bdaf-1a16052d5731" xlink:href="lyel-20240331.xsd#lyel_SonomaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_459e8cb3-5787-4701-a5b0-3d53b330185e" xlink:to="loc_lyel_SonomaMember_df93ed22-b5fe-4a5c-bdaf-1a16052d5731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_362499c4-f74f-4a89-b17a-b91f91b24308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_98139d71-e199-4d56-ba5d-10141cc2cb8a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_362499c4-f74f-4a89-b17a-b91f91b24308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_47078f98-5f7b-4ac6-b75c-5d89ad40c1db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_362499c4-f74f-4a89-b17a-b91f91b24308" xlink:to="loc_us-gaap_OperatingLeaseCost_47078f98-5f7b-4ac6-b75c-5d89ad40c1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_325d8401-fb70-42c5-a9e5-573a4fd0976a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_362499c4-f74f-4a89-b17a-b91f91b24308" xlink:to="loc_us-gaap_VariableLeaseCost_325d8401-fb70-42c5-a9e5-573a4fd0976a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c74b82f7-30eb-4457-8128-4e6ecb262954" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_362499c4-f74f-4a89-b17a-b91f91b24308" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c74b82f7-30eb-4457-8128-4e6ecb262954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_aa89f644-e0ee-4818-be27-156993109fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_362499c4-f74f-4a89-b17a-b91f91b24308" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_aa89f644-e0ee-4818-be27-156993109fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_e4b73b5a-26dd-47f0-9cab-2b140f6705c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_362499c4-f74f-4a89-b17a-b91f91b24308" xlink:to="loc_us-gaap_NetRentableArea_e4b73b5a-26dd-47f0-9cab-2b140f6705c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_227875d4-e071-471d-8e93-d17d62f9ce34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_362499c4-f74f-4a89-b17a-b91f91b24308" xlink:to="loc_us-gaap_SubleaseIncome_227875d4-e071-471d-8e93-d17d62f9ce34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_65175401-1485-4aea-b886-0e5e6ffc044e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_362499c4-f74f-4a89-b17a-b91f91b24308" xlink:to="loc_us-gaap_TenantImprovements_65175401-1485-4aea-b886-0e5e6ffc044e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3fe3c356-cad8-4dc3-a5eb-9b3580e819be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a6905302-c298-498a-8ad2-e634267c8a58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3fe3c356-cad8-4dc3-a5eb-9b3580e819be" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a6905302-c298-498a-8ad2-e634267c8a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8939a4a8-86b8-4f0e-89a8-9ea7f1e83f8b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a6905302-c298-498a-8ad2-e634267c8a58" xlink:to="loc_srt_CounterpartyNameAxis_8939a4a8-86b8-4f0e-89a8-9ea7f1e83f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_60c3f589-fa2d-46b0-a1a1-b10c0377375f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8939a4a8-86b8-4f0e-89a8-9ea7f1e83f8b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_60c3f589-fa2d-46b0-a1a1-b10c0377375f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CowenAndCompanyLLCMember_771c9393-bbe4-4293-a0f5-1d450434f8cb" xlink:href="lyel-20240331.xsd#lyel_CowenAndCompanyLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_60c3f589-fa2d-46b0-a1a1-b10c0377375f" xlink:to="loc_lyel_CowenAndCompanyLLCMember_771c9393-bbe4-4293-a0f5-1d450434f8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_715188b4-df84-4af7-809e-b93286c1c77c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a6905302-c298-498a-8ad2-e634267c8a58" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_715188b4-df84-4af7-809e-b93286c1c77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bfa988ce-0ffc-4e51-a408-c106be06d30d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_715188b4-df84-4af7-809e-b93286c1c77c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bfa988ce-0ffc-4e51-a408-c106be06d30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_AtTheMarketOfferingMember_6b8bd0e6-669b-4ed6-8a6a-8bbfee29a3ac" xlink:href="lyel-20240331.xsd#lyel_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bfa988ce-0ffc-4e51-a408-c106be06d30d" xlink:to="loc_lyel_AtTheMarketOfferingMember_6b8bd0e6-669b-4ed6-8a6a-8bbfee29a3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_22946bba-9575-41f8-8257-24fd5a3ead42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a6905302-c298-498a-8ad2-e634267c8a58" xlink:to="loc_us-gaap_ClassOfStockLineItems_22946bba-9575-41f8-8257-24fd5a3ead42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8822a7c2-849f-4371-8fed-355526141b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_22946bba-9575-41f8-8257-24fd5a3ead42" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8822a7c2-849f-4371-8fed-355526141b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a4b24963-3cd9-4bec-ba7f-faef8071efbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_22946bba-9575-41f8-8257-24fd5a3ead42" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a4b24963-3cd9-4bec-ba7f-faef8071efbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_eb7b0e50-042f-4b1f-b339-fcee91b5737e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_22946bba-9575-41f8-8257-24fd5a3ead42" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_eb7b0e50-042f-4b1f-b339-fcee91b5737e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ad4aed4b-3ce6-4d29-bdfd-8f78cdcbc3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_22946bba-9575-41f8-8257-24fd5a3ead42" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ad4aed4b-3ce6-4d29-bdfd-8f78cdcbc3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c4616997-d18a-4d45-bb9a-6ac74221fb5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_22946bba-9575-41f8-8257-24fd5a3ead42" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c4616997-d18a-4d45-bb9a-6ac74221fb5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5e07048b-7bdf-4515-b465-1911ad30c73a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_22946bba-9575-41f8-8257-24fd5a3ead42" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5e07048b-7bdf-4515-b465-1911ad30c73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SaleOfStockMaximumConsiderationReceived_9e1c3c34-bae7-40ad-8a02-4c9cc6e0ca66" xlink:href="lyel-20240331.xsd#lyel_SaleOfStockMaximumConsiderationReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_22946bba-9575-41f8-8257-24fd5a3ead42" xlink:to="loc_lyel_SaleOfStockMaximumConsiderationReceived_9e1c3c34-bae7-40ad-8a02-4c9cc6e0ca66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds_8cd1c5b6-d147-41fc-9ce3-2e4c1bd812f9" xlink:href="lyel-20240331.xsd#lyel_SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_22946bba-9575-41f8-8257-24fd5a3ead42" xlink:to="loc_lyel_SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds_8cd1c5b6-d147-41fc-9ce3-2e4c1bd812f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#StockbasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockbasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_785b8ea5-fc66-4638-973c-63d8728c928b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2721044-95e2-426b-936d-d1566510bdac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_785b8ea5-fc66-4638-973c-63d8728c928b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2721044-95e2-426b-936d-d1566510bdac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2cadec34-1ec1-4bc6-87ac-92d87588b4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2721044-95e2-426b-936d-d1566510bdac" xlink:to="loc_us-gaap_PlanNameAxis_2cadec34-1ec1-4bc6-87ac-92d87588b4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5c3223aa-51ad-4e09-b96b-1c13bb552bac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2cadec34-1ec1-4bc6-87ac-92d87588b4dd" xlink:to="loc_us-gaap_PlanNameDomain_5c3223aa-51ad-4e09-b96b-1c13bb552bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandTwentyOneEquityIncentivePlanMember_96ad4a69-c0f7-4e0c-9221-f07e9823643b" xlink:href="lyel-20240331.xsd#lyel_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5c3223aa-51ad-4e09-b96b-1c13bb552bac" xlink:to="loc_lyel_TwoThousandTwentyOneEquityIncentivePlanMember_96ad4a69-c0f7-4e0c-9221-f07e9823643b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_54720cb3-935c-44e0-820d-ae0c78bda663" xlink:href="lyel-20240331.xsd#lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5c3223aa-51ad-4e09-b96b-1c13bb552bac" xlink:to="loc_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_54720cb3-935c-44e0-820d-ae0c78bda663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandEighteenEquityIncentivePlanMember_047f0aae-bd1b-4bee-989a-12f9e42083c7" xlink:href="lyel-20240331.xsd#lyel_TwoThousandEighteenEquityIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5c3223aa-51ad-4e09-b96b-1c13bb552bac" xlink:to="loc_lyel_TwoThousandEighteenEquityIncentivePlanMember_047f0aae-bd1b-4bee-989a-12f9e42083c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bab4cebc-21df-40cf-9431-4a614a02b68f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2721044-95e2-426b-936d-d1566510bdac" xlink:to="loc_srt_RangeAxis_bab4cebc-21df-40cf-9431-4a614a02b68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d9025d42-1354-421f-b223-af925aeb5feb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bab4cebc-21df-40cf-9431-4a614a02b68f" xlink:to="loc_srt_RangeMember_d9025d42-1354-421f-b223-af925aeb5feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_73faa32a-76d0-45c8-8705-3cf966fbcb05" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d9025d42-1354-421f-b223-af925aeb5feb" xlink:to="loc_srt_MaximumMember_73faa32a-76d0-45c8-8705-3cf966fbcb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e73ec682-05e2-4844-a32e-f63eab488ce1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d9025d42-1354-421f-b223-af925aeb5feb" xlink:to="loc_srt_MinimumMember_e73ec682-05e2-4844-a32e-f63eab488ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_DateOfEquityModificationsAxis_d7566709-47c9-4be3-8df9-9f15e7bda41f" xlink:href="lyel-20240331.xsd#lyel_DateOfEquityModificationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2721044-95e2-426b-936d-d1566510bdac" xlink:to="loc_lyel_DateOfEquityModificationsAxis_d7566709-47c9-4be3-8df9-9f15e7bda41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_DateOfEquityModificationsDomain_9ab40e60-cea7-4ccd-9ec2-18b1a371b61a" xlink:href="lyel-20240331.xsd#lyel_DateOfEquityModificationsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_DateOfEquityModificationsAxis_d7566709-47c9-4be3-8df9-9f15e7bda41f" xlink:to="loc_lyel_DateOfEquityModificationsDomain_9ab40e60-cea7-4ccd-9ec2-18b1a371b61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_A2023Member_05dcfc05-88f1-4586-a978-9ca61d2b32c1" xlink:href="lyel-20240331.xsd#lyel_A2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_DateOfEquityModificationsDomain_9ab40e60-cea7-4ccd-9ec2-18b1a371b61a" xlink:to="loc_lyel_A2023Member_05dcfc05-88f1-4586-a978-9ca61d2b32c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_15e99406-51ef-4bb8-aadc-1994819e2db8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2721044-95e2-426b-936d-d1566510bdac" xlink:to="loc_us-gaap_AwardTypeAxis_15e99406-51ef-4bb8-aadc-1994819e2db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df0e200a-54ac-4ae5-a88c-440f4253d170" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_15e99406-51ef-4bb8-aadc-1994819e2db8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df0e200a-54ac-4ae5-a88c-440f4253d170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_45ff7cab-8b94-4f56-953c-a340d55ae1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df0e200a-54ac-4ae5-a88c-440f4253d170" xlink:to="loc_us-gaap_EmployeeStockOptionMember_45ff7cab-8b94-4f56-953c-a340d55ae1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5c41acaa-3ef8-4417-be5c-64c8366be9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df0e200a-54ac-4ae5-a88c-440f4253d170" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5c41acaa-3ef8-4417-be5c-64c8366be9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_4b9209d8-e090-46ca-89bd-2965f431ab8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df0e200a-54ac-4ae5-a88c-440f4253d170" xlink:to="loc_us-gaap_PerformanceSharesMember_4b9209d8-e090-46ca-89bd-2965f431ab8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_371fb5d2-4bbe-47ec-930a-17a76754d585" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2721044-95e2-426b-936d-d1566510bdac" xlink:to="loc_us-gaap_VestingAxis_371fb5d2-4bbe-47ec-930a-17a76754d585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_009d4bea-af4c-402c-b1b4-4d5871c589ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_371fb5d2-4bbe-47ec-930a-17a76754d585" xlink:to="loc_us-gaap_VestingDomain_009d4bea-af4c-402c-b1b4-4d5871c589ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f071f877-8891-4f2f-a614-bae793787af2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_009d4bea-af4c-402c-b1b4-4d5871c589ce" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f071f877-8891-4f2f-a614-bae793787af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_123e89df-4ffe-4b65-9821-e970016679ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_009d4bea-af4c-402c-b1b4-4d5871c589ce" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_123e89df-4ffe-4b65-9821-e970016679ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2721044-95e2-426b-936d-d1566510bdac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8ea6f5f6-d877-4c08-9303-ee0a6079be9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8ea6f5f6-d877-4c08-9303-ee0a6079be9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_32fbe2f8-33e6-45a6-b663-ba82a3f8327e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_32fbe2f8-33e6-45a6-b663-ba82a3f8327e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_b575ec89-cf7c-4bc4-bf92-54393fc8d5f7" xlink:href="lyel-20240331.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_b575ec89-cf7c-4bc4-bf92-54393fc8d5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_51408558-7c1a-4f55-9b7d-dc49a1a78900" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_51408558-7c1a-4f55-9b7d-dc49a1a78900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding_bab3c73e-1373-4f50-a2a1-4028950ef846" xlink:href="lyel-20240331.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding_bab3c73e-1373-4f50-a2a1-4028950ef846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d7fae897-6b6e-42f4-bcf8-b5fb3db26fec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d7fae897-6b6e-42f4-bcf8-b5fb3db26fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7254951b-2ede-4309-9a41-b1405f37abe4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7254951b-2ede-4309-9a41-b1405f37abe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_524e0094-928b-48fc-8efa-84d145ee341b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_524e0094-928b-48fc-8efa-84d145ee341b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1c808912-3373-4bfe-aa7b-6a1545b16f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1c808912-3373-4bfe-aa7b-6a1545b16f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_b3e2c504-4e0a-46e5-ac72-509291057fb6" xlink:href="lyel-20240331.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_b3e2c504-4e0a-46e5-ac72-509291057fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod_dfd6c262-f751-4fb5-81e0-60dcd051985d" xlink:href="lyel-20240331.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod_dfd6c262-f751-4fb5-81e0-60dcd051985d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_3c78fbca-2469-4682-b538-b871d8491a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_3c78fbca-2469-4682-b538-b871d8491a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a49c4ca3-717e-4bb5-b21e-e85d38458a29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a49c4ca3-717e-4bb5-b21e-e85d38458a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8a59e3fb-83b2-4f99-810d-2cedd49610d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8a59e3fb-83b2-4f99-810d-2cedd49610d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum_5fb7b7f9-66ff-4119-af7f-13e6ea6e0f35" xlink:href="lyel-20240331.xsd#lyel_ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_lyel_ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum_5fb7b7f9-66ff-4119-af7f-13e6ea6e0f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1381407c-2df3-4ebe-8778-1f19889c4996" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1381407c-2df3-4ebe-8778-1f19889c4996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_4fe9d483-c9b9-4845-89fa-429aebb7f1be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_4fe9d483-c9b9-4845-89fa-429aebb7f1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_de1ec443-a144-4674-8e1b-bb3e086beba2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_de1ec443-a144-4674-8e1b-bb3e086beba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced_d94cdb0b-25fe-40b0-ac01-f30f55ee1d8c" xlink:href="lyel-20240331.xsd#lyel_ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_lyel_ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced_d94cdb0b-25fe-40b0-ac01-f30f55ee1d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedPaymentArrangementPlanModificationExercisePrice_49b2003b-0fee-4bb5-9128-d5d3d7aa935d" xlink:href="lyel-20240331.xsd#lyel_ShareBasedPaymentArrangementPlanModificationExercisePrice"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_lyel_ShareBasedPaymentArrangementPlanModificationExercisePrice_49b2003b-0fee-4bb5-9128-d5d3d7aa935d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_f893b95d-a0eb-477b-b419-247e6c44cb78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_f893b95d-a0eb-477b-b419-247e6c44cb78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod_03ce7921-6ec2-4343-bc3a-e5ea26efe13f" xlink:href="lyel-20240331.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod_03ce7921-6ec2-4343-bc3a-e5ea26efe13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn_94a6a0f2-db2e-4ea6-88da-b085d3b8f773" xlink:href="lyel-20240331.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn_94a6a0f2-db2e-4ea6-88da-b085d3b8f773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7f0134ac-c691-4f1a-99ae-f4701df0fff3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7f0134ac-c691-4f1a-99ae-f4701df0fff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate_cce40308-b9cb-4b1e-8ff5-296e40185d84" xlink:href="lyel-20240331.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate_cce40308-b9cb-4b1e-8ff5-296e40185d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget_5921b557-d594-4f4a-a188-9768bcd3860a" xlink:href="lyel-20240331.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget_5921b557-d594-4f4a-a188-9768bcd3860a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_166e55e4-dd77-4355-beaa-ea7e4818a8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92783b7a-806e-4187-abca-87e846d4e145" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_166e55e4-dd77-4355-beaa-ea7e4818a8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3ce78fe9-ea18-4c80-9c4d-4129a495055d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_61e6645d-5e53-414e-b337-53829048d82a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3ce78fe9-ea18-4c80-9c4d-4129a495055d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_61e6645d-5e53-414e-b337-53829048d82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_044e8a21-434e-4e07-8a5a-401fa8bc480a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_61e6645d-5e53-414e-b337-53829048d82a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_044e8a21-434e-4e07-8a5a-401fa8bc480a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4e87f77e-9d33-442f-8b9c-9e1f9a11d57e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_044e8a21-434e-4e07-8a5a-401fa8bc480a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4e87f77e-9d33-442f-8b9c-9e1f9a11d57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_46fa4edf-7288-4a78-87ac-eeead930a3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4e87f77e-9d33-442f-8b9c-9e1f9a11d57e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_46fa4edf-7288-4a78-87ac-eeead930a3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3522796e-34da-4f5d-8bea-d622ac767961" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4e87f77e-9d33-442f-8b9c-9e1f9a11d57e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3522796e-34da-4f5d-8bea-d622ac767961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_34b5af87-cd76-446f-8595-92de83d2160b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_61e6645d-5e53-414e-b337-53829048d82a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_34b5af87-cd76-446f-8595-92de83d2160b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1660062f-a91f-4974-91ea-8ad9bc2e9040" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_34b5af87-cd76-446f-8595-92de83d2160b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1660062f-a91f-4974-91ea-8ad9bc2e9040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationScheduleofPerformanceSharesUnitsDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#StockbasedCompensationScheduleofPerformanceSharesUnitsDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockbasedCompensationScheduleofPerformanceSharesUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d67e1610-8b8d-4c83-9c0d-02e9a8b5cbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88e3a2a8-2cfd-4942-b3a5-dd501f5c1820" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d67e1610-8b8d-4c83-9c0d-02e9a8b5cbe2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88e3a2a8-2cfd-4942-b3a5-dd501f5c1820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_16ba93a6-eff9-44a5-a832-f49b477a1585" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88e3a2a8-2cfd-4942-b3a5-dd501f5c1820" xlink:to="loc_us-gaap_AwardTypeAxis_16ba93a6-eff9-44a5-a832-f49b477a1585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35752ddc-5ec7-4506-8da9-42f013b03344" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_16ba93a6-eff9-44a5-a832-f49b477a1585" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35752ddc-5ec7-4506-8da9-42f013b03344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ede278d9-41e7-4f1d-a3b6-5401fb5ee897" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35752ddc-5ec7-4506-8da9-42f013b03344" xlink:to="loc_us-gaap_PerformanceSharesMember_ede278d9-41e7-4f1d-a3b6-5401fb5ee897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58222d34-d039-4101-b455-a9d5dd4af225" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88e3a2a8-2cfd-4942-b3a5-dd501f5c1820" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58222d34-d039-4101-b455-a9d5dd4af225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8b661f42-27a7-4634-baaa-07a6a4d744e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58222d34-d039-4101-b455-a9d5dd4af225" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8b661f42-27a7-4634-baaa-07a6a4d744e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2dd21a66-ea71-456b-b152-f34467d038e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8b661f42-27a7-4634-baaa-07a6a4d744e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2dd21a66-ea71-456b-b152-f34467d038e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3d44579c-f4e5-4ab0-a53c-276aac01e88b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8b661f42-27a7-4634-baaa-07a6a4d744e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3d44579c-f4e5-4ab0-a53c-276aac01e88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_db793bae-0cfe-45b2-85f3-52d485553d18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8b661f42-27a7-4634-baaa-07a6a4d744e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_db793bae-0cfe-45b2-85f3-52d485553d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a83763e2-6e68-4098-b95f-a656959075ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8b661f42-27a7-4634-baaa-07a6a4d744e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a83763e2-6e68-4098-b95f-a656959075ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2e1cd027-e73e-4c47-a37f-d2475eaa355d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8b661f42-27a7-4634-baaa-07a6a4d744e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2e1cd027-e73e-4c47-a37f-d2475eaa355d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e06153d5-2bad-4106-b35e-9a2a2531d4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58222d34-d039-4101-b455-a9d5dd4af225" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e06153d5-2bad-4106-b35e-9a2a2531d4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3436ef6b-ced0-4f23-89cd-ac2da8ba5732" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e06153d5-2bad-4106-b35e-9a2a2531d4b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3436ef6b-ced0-4f23-89cd-ac2da8ba5732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_986e8b89-999c-42ca-b7e5-552f512c5887" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e06153d5-2bad-4106-b35e-9a2a2531d4b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_986e8b89-999c-42ca-b7e5-552f512c5887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_97002555-a4c1-401c-aafc-78b4521fbfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e06153d5-2bad-4106-b35e-9a2a2531d4b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_97002555-a4c1-401c-aafc-78b4521fbfa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ec370155-b83e-4f31-8960-f5e622a9277c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e06153d5-2bad-4106-b35e-9a2a2531d4b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ec370155-b83e-4f31-8960-f5e622a9277c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a01c20c7-efbe-4553-b247-0bbdf3270f93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e06153d5-2bad-4106-b35e-9a2a2531d4b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a01c20c7-efbe-4553-b247-0bbdf3270f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#StockbasedCompensationScheduleofRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2af73c32-74fa-418c-85ba-048494fdadbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c1325397-263d-4432-bc07-95224d22aac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2af73c32-74fa-418c-85ba-048494fdadbd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c1325397-263d-4432-bc07-95224d22aac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2c56d2a0-337e-479c-afc3-73edec485372" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c1325397-263d-4432-bc07-95224d22aac1" xlink:to="loc_us-gaap_AwardTypeAxis_2c56d2a0-337e-479c-afc3-73edec485372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb934f4f-cb00-4b87-8c8f-e3077b5e5ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2c56d2a0-337e-479c-afc3-73edec485372" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb934f4f-cb00-4b87-8c8f-e3077b5e5ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_995afbdf-e6ee-4c0c-8232-89f2836a1541" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb934f4f-cb00-4b87-8c8f-e3077b5e5ca2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_995afbdf-e6ee-4c0c-8232-89f2836a1541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69d3e203-1738-4552-b1b2-f6d95084e356" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c1325397-263d-4432-bc07-95224d22aac1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69d3e203-1738-4552-b1b2-f6d95084e356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c31e060-b366-4080-b9cd-efe69213983e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69d3e203-1738-4552-b1b2-f6d95084e356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c31e060-b366-4080-b9cd-efe69213983e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d74dc3f3-f0aa-4f87-94c5-1a3973e43a34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c31e060-b366-4080-b9cd-efe69213983e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d74dc3f3-f0aa-4f87-94c5-1a3973e43a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_953af00f-1938-4df0-8285-035c4978f739" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c31e060-b366-4080-b9cd-efe69213983e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_953af00f-1938-4df0-8285-035c4978f739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d2a12311-ebcb-4901-a6a9-20f0f154f390" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c31e060-b366-4080-b9cd-efe69213983e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d2a12311-ebcb-4901-a6a9-20f0f154f390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_98a6ae04-acba-4f19-9d66-bab7a424e85d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c31e060-b366-4080-b9cd-efe69213983e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_98a6ae04-acba-4f19-9d66-bab7a424e85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2eae47a3-91a5-46a2-af2a-c0ba53792c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c31e060-b366-4080-b9cd-efe69213983e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2eae47a3-91a5-46a2-af2a-c0ba53792c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_78975170-0929-48df-8057-112bb1720a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69d3e203-1738-4552-b1b2-f6d95084e356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_78975170-0929-48df-8057-112bb1720a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a6d1e9a1-a305-4a94-a461-af2df17754ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_78975170-0929-48df-8057-112bb1720a2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a6d1e9a1-a305-4a94-a461-af2df17754ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_87ebd34e-173e-4d65-a137-7fcced762596" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_78975170-0929-48df-8057-112bb1720a2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_87ebd34e-173e-4d65-a137-7fcced762596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_51388179-e52a-4a05-8119-5f893dc46f39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_78975170-0929-48df-8057-112bb1720a2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_51388179-e52a-4a05-8119-5f893dc46f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b512b775-9c20-47c4-bd9b-cb809d1a0a77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_78975170-0929-48df-8057-112bb1720a2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b512b775-9c20-47c4-bd9b-cb809d1a0a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3615a81c-c2d3-46b3-a8cb-2440bc824da6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_78975170-0929-48df-8057-112bb1720a2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3615a81c-c2d3-46b3-a8cb-2440bc824da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#StockbasedCompensationScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_26e7db98-dc43-40a6-ae31-8f09a64b7e16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_887a754a-8376-4698-be7d-ae57b80cd849" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_26e7db98-dc43-40a6-ae31-8f09a64b7e16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_887a754a-8376-4698-be7d-ae57b80cd849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_00adadc4-4b2e-425a-8020-fc77100e7202" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_887a754a-8376-4698-be7d-ae57b80cd849" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_00adadc4-4b2e-425a-8020-fc77100e7202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_49dc122c-0175-48c0-8284-b0280851f976" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_887a754a-8376-4698-be7d-ae57b80cd849" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_49dc122c-0175-48c0-8284-b0280851f976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4bb55f46-5126-463a-83f3-3e46d0e473d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_887a754a-8376-4698-be7d-ae57b80cd849" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4bb55f46-5126-463a-83f3-3e46d0e473d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_f9e3da62-6117-487d-90c2-d3a8fd95aa65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_887a754a-8376-4698-be7d-ae57b80cd849" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_f9e3da62-6117-487d-90c2-d3a8fd95aa65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_82e10284-35af-416c-8f49-364c4c15d1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_887a754a-8376-4698-be7d-ae57b80cd849" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_82e10284-35af-416c-8f49-364c4c15d1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_335f7ec3-3f41-4d64-bb95-fa6c1beb3cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_26e7db98-dc43-40a6-ae31-8f09a64b7e16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_335f7ec3-3f41-4d64-bb95-fa6c1beb3cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b53661ac-2e7e-4a20-8eee-08392250acbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_26e7db98-dc43-40a6-ae31-8f09a64b7e16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b53661ac-2e7e-4a20-8eee-08392250acbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0d971b8a-dc67-4de6-ba8e-2107926b6771" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b53661ac-2e7e-4a20-8eee-08392250acbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0d971b8a-dc67-4de6-ba8e-2107926b6771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0714002c-88e8-4704-8570-81535c5f7aae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b53661ac-2e7e-4a20-8eee-08392250acbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0714002c-88e8-4704-8570-81535c5f7aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_81d78e47-c7ec-4378-872c-b38a27e72433" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b53661ac-2e7e-4a20-8eee-08392250acbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_81d78e47-c7ec-4378-872c-b38a27e72433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_d5307f3c-6f84-4afc-a1f8-38432589fa8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b53661ac-2e7e-4a20-8eee-08392250acbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_d5307f3c-6f84-4afc-a1f8-38432589fa8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d805e898-3407-44ae-834f-ac5c2647cc1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b53661ac-2e7e-4a20-8eee-08392250acbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d805e898-3407-44ae-834f-ac5c2647cc1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7bda7077-ca3d-4a2f-8ebd-fdb1461e45fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_26e7db98-dc43-40a6-ae31-8f09a64b7e16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7bda7077-ca3d-4a2f-8ebd-fdb1461e45fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_78043fa7-bef8-4253-bd11-539721ee29df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_26e7db98-dc43-40a6-ae31-8f09a64b7e16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_78043fa7-bef8-4253-bd11-539721ee29df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0a02e209-fb89-4f8e-b243-38e2bacb2670" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_78043fa7-bef8-4253-bd11-539721ee29df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0a02e209-fb89-4f8e-b243-38e2bacb2670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a242da8d-7cc6-47bd-8032-f9cf9942ce75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_78043fa7-bef8-4253-bd11-539721ee29df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a242da8d-7cc6-47bd-8032-f9cf9942ce75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a695cc38-34fa-4d16-99c6-b4e367363c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_26e7db98-dc43-40a6-ae31-8f09a64b7e16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a695cc38-34fa-4d16-99c6-b4e367363c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a303a95a-b22b-42d9-a150-52109c0c0d00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a695cc38-34fa-4d16-99c6-b4e367363c5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a303a95a-b22b-42d9-a150-52109c0c0d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bbf46c95-d50c-487f-b203-35e05d79b95a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a695cc38-34fa-4d16-99c6-b4e367363c5b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bbf46c95-d50c-487f-b203-35e05d79b95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d24d0194-b46b-4966-8ede-71118cc3f5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ebf42d6f-2689-4278-a2bf-43d48bc9c1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d24d0194-b46b-4966-8ede-71118cc3f5fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ebf42d6f-2689-4278-a2bf-43d48bc9c1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b95182a6-ef3f-4991-a0e1-11ed2e89eea5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d24d0194-b46b-4966-8ede-71118cc3f5fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b95182a6-ef3f-4991-a0e1-11ed2e89eea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cee699a3-a1a1-4bc9-88c8-2b76aa9a5a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d24d0194-b46b-4966-8ede-71118cc3f5fc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cee699a3-a1a1-4bc9-88c8-2b76aa9a5a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_14846823-eca8-4296-a7d5-ad0c65354dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d24d0194-b46b-4966-8ede-71118cc3f5fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_14846823-eca8-4296-a7d5-ad0c65354dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#RelatedpartyTransactionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_5963e17b-e0c0-4d66-85d0-35cf8f555926" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7dd6bd53-c294-4a19-85cf-f0c49866e4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_5963e17b-e0c0-4d66-85d0-35cf8f555926" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7dd6bd53-c294-4a19-85cf-f0c49866e4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_227e8d5a-5323-4a81-81e9-cfec9c2009bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7dd6bd53-c294-4a19-85cf-f0c49866e4bd" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_227e8d5a-5323-4a81-81e9-cfec9c2009bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9895ebba-1dfe-43e1-8571-f9b167364fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_227e8d5a-5323-4a81-81e9-cfec9c2009bf" xlink:to="loc_us-gaap_RelatedPartyDomain_9895ebba-1dfe-43e1-8571-f9b167364fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_68b4bcf2-b97f-4627-80d4-a2ee70cb6d80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9895ebba-1dfe-43e1-8571-f9b167364fe6" xlink:to="loc_us-gaap_RelatedPartyMember_68b4bcf2-b97f-4627-80d4-a2ee70cb6d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d9fbebfd-d389-4bd9-a729-1e7df1b946bb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7dd6bd53-c294-4a19-85cf-f0c49866e4bd" xlink:to="loc_srt_CounterpartyNameAxis_d9fbebfd-d389-4bd9-a729-1e7df1b946bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2f7b5ae-db07-4893-9caa-f3f99591783f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d9fbebfd-d389-4bd9-a729-1e7df1b946bb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2f7b5ae-db07-4893-9caa-f3f99591783f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SonomaMember_e9ed7a54-532b-4230-8f77-3765c48acefb" xlink:href="lyel-20240331.xsd#lyel_SonomaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2f7b5ae-db07-4893-9caa-f3f99591783f" xlink:to="loc_lyel_SonomaMember_e9ed7a54-532b-4230-8f77-3765c48acefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_34c93887-ed94-4f3d-b304-30009a627ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7dd6bd53-c294-4a19-85cf-f0c49866e4bd" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_34c93887-ed94-4f3d-b304-30009a627ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_c0074d39-24f0-4c4f-a788-fe86801c4fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_34c93887-ed94-4f3d-b304-30009a627ed1" xlink:to="loc_us-gaap_NetRentableArea_c0074d39-24f0-4c4f-a788-fe86801c4fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_0a5e27ef-b168-4bba-b43f-c0403d2b770f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_34c93887-ed94-4f3d-b304-30009a627ed1" xlink:to="loc_us-gaap_TenantImprovements_0a5e27ef-b168-4bba-b43f-c0403d2b770f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_52336a84-e209-41a0-bb31-5d2b8e1a2d11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_34c93887-ed94-4f3d-b304-30009a627ed1" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_52336a84-e209-41a0-bb31-5d2b8e1a2d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_48683257-bda7-429d-8cec-8ddbd75f62a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_34c93887-ed94-4f3d-b304-30009a627ed1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_48683257-bda7-429d-8cec-8ddbd75f62a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails" xlink:type="simple" xlink:href="lyel-20240331.xsd#RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_f163bbed-2009-41fe-8f37-77f6f52f9078" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_be8ceb81-d7fe-4815-96c0-5762fe56ae3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_f163bbed-2009-41fe-8f37-77f6f52f9078" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_be8ceb81-d7fe-4815-96c0-5762fe56ae3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_55c0058d-ed3a-4aed-8cc3-16e62abad102" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_be8ceb81-d7fe-4815-96c0-5762fe56ae3c" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_55c0058d-ed3a-4aed-8cc3-16e62abad102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a2cf7547-90aa-4503-b1f4-171dbd1b0cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_55c0058d-ed3a-4aed-8cc3-16e62abad102" xlink:to="loc_us-gaap_RelatedPartyDomain_a2cf7547-90aa-4503-b1f4-171dbd1b0cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_04bd21b9-18ef-408e-bcc2-21c98981b537" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a2cf7547-90aa-4503-b1f4-171dbd1b0cf5" xlink:to="loc_us-gaap_RelatedPartyMember_04bd21b9-18ef-408e-bcc2-21c98981b537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_66d42eee-12a9-483f-8acc-a46cbd2672b6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_be8ceb81-d7fe-4815-96c0-5762fe56ae3c" xlink:to="loc_srt_CounterpartyNameAxis_66d42eee-12a9-483f-8acc-a46cbd2672b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_43644a11-0138-41e5-8490-e6e17fbad389" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_66d42eee-12a9-483f-8acc-a46cbd2672b6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_43644a11-0138-41e5-8490-e6e17fbad389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SonomaMember_b40e63af-ffdc-4b4a-b79c-91f1284ca54b" xlink:href="lyel-20240331.xsd#lyel_SonomaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_43644a11-0138-41e5-8490-e6e17fbad389" xlink:to="loc_lyel_SonomaMember_b40e63af-ffdc-4b4a-b79c-91f1284ca54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_e0f562b0-36ab-4840-87c0-9a2052085d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_be8ceb81-d7fe-4815-96c0-5762fe56ae3c" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_e0f562b0-36ab-4840-87c0-9a2052085d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_14ae9d72-9e69-42b8-b10f-45252b08318e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e0f562b0-36ab-4840-87c0-9a2052085d3e" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_14ae9d72-9e69-42b8-b10f-45252b08318e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_486994a3-017f-40be-adca-a9be0b7e90ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e0f562b0-36ab-4840-87c0-9a2052085d3e" xlink:to="loc_us-gaap_SubleaseIncome_486994a3-017f-40be-adca-a9be0b7e90ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_PerformanceSharesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>lyel-20240331_g1.jpg
<TEXT>
begin 644 lyel-20240331_g1.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +(!>D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH SM'NY+ZQ2:1K=G+.-UK
M*9(^&(X8@<\<\<'(K1K,T-S)IJ,69_G?EK8V_P#&?X#R/KWZ]ZTZ "BD]*6@
M HHHH **** "BBB@ HHHH **** "LW[<_P#;7V3?;>7]G\W;YI\_.[&=F,;/
M]K/7C%:59?F'_A("NYL?9@=GV8X^^>?-Z?\  .O>@#4HI,BEH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **K174,TLD4<T;RQ\.BL"R
MY]1VJS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 9MU?20ZI96R-:JDRR$K),5E.W&-B8^8<\\C'%:59-XY
M76+!=S ,LGRBV9P< =9!PGT/WOPK6H **3(I: "BBB@ HHHH **** "BBB@
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M*6@ HKF]5^('AC0?$%EH.I>(]+T_6[X VFFW5[''<7&20"D98,W((X':NDH
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M=O*]Q6/K3XA?\% OA!\+_%7BGPWKVJ:E!K/AV1(;BV2P9C-(P4A83T8X8$]
M!5_Q5^W9\*/ _P .?#7C'6]4O+*#Q%;?:]-TK[*7OY8MQ7<8E)"C(/)('O7R
M[\'_  7HGC#_ (*F?%@ZWIMKJB:?%-<V\5W$LJ)+Y=LH?:P(R S8/;)K.^*+
M^'/!?_!4/2;OXEQVEIX/_LV+^R)-0C46,/[@K"<'Y0JR^9[!B":7LHWMY7'8
M^M/@?^W/\*/CYXB_X1_0-5NK#Q P+1:9K%L;>6< 9/EG)5B!SM#9]J/CE^W+
M\+/V?_%"^&_$&H7U_KP57FT_2+4W$D"L,J9#D*"1SMSG!SBODC]KKQ!X.\<?
MMD? ]/A9<Z=J?BJ'4[<ZC>: 4=-HN(V7>\?#%8Q*3R<*<&H/@7XR\*?!W_@H
M%\9)_BW=6FD:C=33G2M4UA0(DW2AU*NW"[X2@5NX4C/:CV,?B\M@/KSX=_MV
M?"3XI>./#?A/PUK%YJ&LZ]"\MO']B=%B*!RT<I;&QP(V.,=QZUA>,O\ @HY\
M&/ ^H>)M.U+4]4&JZ!?MIL]C'I[&6:96=7\KD!E4H<L2!ROK7R=X/\8^!_'7
M_!53P_K'P^%M)H4OFH]U9)L@N;A;&42R(  ,$X^;^(@GO74?L8^!]"\5?MU?
M'N\UG2[74Y=-OKYK07D*RK"SWSAG 8$;L#&?0FATH1NWVN,^HOB5^WA\*?A3
MH'AW4-<U"_\ MNO6,6I6FC6UH9;P02+E&D0':F?=N<'&:Q?"_P#P4=^"WBW6
M/#FDZ=J>JG5-<N1:16<FFNKP2EE4++V7.X8()& :^:?"M]X8\$?\%1/&LWQ.
M-GI\#Q-_8%QJNU+:%BD7V=E9_E4>4'53T## YK%_:R\4> /%7[=WPFF\$7.F
MZA>QW=FFLWFE,CQ2S?:,Q@NGRLX3.3Z%0>E-48-VL]KB/LOXE?MW?";X1^-M
M>\*>)=5O[/6M'B266%+%Y!,7"E8XB/O,0P..,8.36!X=_P""D_P.\0>&=8UJ
M77KS2#I93S-/U"S9+N;<VU?*12WF<]@>.IP*\,\/^&-+\4?\%:O$B:K8PZA%
M9:6U[!'<('19E@A57P>,C>V/0X-9?Q4\!Z!=?\%7O!FGRZ/9M8W=K!?3VOD+
MY4LRV\Y#LN,$Y1"<CDJ*/90V?:X'U5\#/VZ/A;^T%XJ;PUX>O[ZRU_8TD5AJ
MUJ8'G51EC&02I(')&<X[5G>//^"A'P?^'/B?Q3X<UG4]2BUKP[<"UN+2.P=V
MGE/\,)'#8ZDG  KYY_:*T2QT/_@IY\&)].M(;&6]2W>Y:W0)YK SKEL8R=N!
MGT J+]G/PSI?B+_@IY\:;C4;&"^DTW[1/:^?&'$4A>!=X!Z-@D ]LFI]G'?I
M:X6/>M+_ ."E7P-U+P5?>(GU^\LFM9UMVTFXLF%]([9V^7&,AAP<L#@8Y(KL
M?@#^VA\,_P!H[5KO2/"VHW5OKEM&9FTO5+<P3/&#@NG)5@,C.#D9Y%?)OAOX
M?^')/^"LVLV+:/9FR@L'U..U,*^4MR;>,^8%QC=EB>G4YZUH:QH]GX=_X*Z:
M)'I=M%81W6DB>=+9 BN[6DH9B!W.U<^N*;I0V7:XK'??LM^&?AMX>_:T^-NI
M^'/&'B36?$UN]PNK:;J-KY=M;YN-S[9/^6Q#*0IXPI-=#??\%0_@;;:''J,>
MI:S=S/,\7]GP::WVA54*3(P8A0GS8!+<D'CBO)_V0_\ D]7]J;_KM=?^E+UF
M_P#!)CP3H6M?#OXEZAJ&EVE[=SWD=B\ES LA\CR,F/D?=)))'?%$H1U<M;6$
M?:/PW_:4^'OQ4^&-[\0-$U^./PS8"3[?<7JF!K)D4,ZRJWW2 0>^<C&:\>T7
M_@IW\#-:\1'3/[6U2Q@W,D>J7FG.EI(P&<;N67/;<HZBO@CX3Z5K.I?L+_'Z
MVT59G2UU_3YKF&$$_P"C(V7.!V&%)]E/I7T1H_QZ_9]A_P""?J^&;FYT=M7&
M@FUD\/>4OVY]3V$>:%QG<9/G$F>!W[4>QC=Z-ZV'8^WO@7\=_"W[1'@EO%?A
M"2\ETE+J2R+7MN8'\Q I8;3V^8<UZ/7Q3_P25_Y-=NN<G_A([[_T&&OM:N6I
M'EDTA!1114@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% &5=;VU:P98[HQ@2;FCE58AP,;U)!8^F <<YQ7B7[2?P<^+7Q.UK1KGX<
M?%5_A[9VMM)'=VRP-)]ID+@J_![ $?C7M-]Y/]O:7O\ L?G;9MGG/B?&%SY8
M[C^]Z<5L-TIK1W0'Y1?L[M^T;^T/XP\=>'[#X[:AHT_A6Y^S2S7$9D6<^9(F
M5 QM_P!7GGU%?4^N_MR?#O\ 9RL])\!^-O%.H>-/'&DVL5MK%UH]DTV9U4;V
M<D@!B>2H)(SS7D'_  31W?\ "ZOV@MAPW]IG'U^TW&*Y/_@G?XD\'>!_C)\8
M+?XCWVFZ/XY;4&$=SKTL<3%1++YZH\F,$L5+#.2"O45W5(J3=UM;8L^O?A7^
MW-\*/C-\0M-\&^%-4OM0UC4+5[N(M8O'$JHNYU9FQA@.HQUKE?$G_!2[X)^&
M5U=+G4M6DO\ 3=0?3I-/BTYO/DD0L'9 2 4!4C<2.<5\O?!'6/!VO?\ !5*]
MOO GV5O#TD-]LDL0!;R2"V42O&!QM+[NG!Y(K>_X)T^!= \2?M#?''5-6TJS
MU.\L=2FBMFNX5E\D/=SERH8'!.T GK@5#I0BG)]D0?4/Q8_;V^$_P=FTJTUN
M]U*YU?4+2*]72["S,UQ!%(H=#+R%0D$';NS[4O@7]OCX0?$KQAX6\,:!K%[>
MZQXBW"WA^PNODNNXF.8G[C80G'(((P:^2?A'XL\*?!W_ (*&_%6Y^+<UKI-U
M=/*='U35D ABW.K(RNW"AH=JJW3Y2*Q6\:> _B!_P5"\&ZM\//LLND-<K'<W
MEB@2"ZNA;3>9(@  .?E!;^(@FG[&/X7N58^T?C1^WI\)_@=XLD\,ZSJ=]JFO
MP8^TV.BVAN#;9 .)&R%!P0=H)(SS3[K]M[X::M\"==^(^@:U/>Z?II6VEA2S
M<W5K<R?+$LL)P0"Q!STQSFOSR^!0^('A_P#:"^*-G8_$/PI\./&9U"<7<WC:
MUB>2Z4S2$B*25&"\%20"-P9>H%?0G['OP9N=&\3_ !C\4Q?$/PAXY34M-N+/
M4+'PJA2..\^9U81!%0+RV"HQDG%$J,(H+'1?L-_M_P WQ;O8_"7Q$O9+GQMJ
M>HR)IIL=,\NV^SK"' =UX#963K[5]Y9K\\?^"2?BKPY9_#7Q'H-YJNG0^(KC
MQ#++;:?-.@NI$^SQ?,B'YB/E?D>AK]#ZPK)*;458D****Q **** "BBB@ HH
MHH *8WW3QDX[&GU')_JVZ=/XNE %#0UDCTFV$B72.$Y6\D624?[S*2"?H37Y
ME_#O5OCY^T9^T'\6/"_AOXSZAX3M?#FI7!@CF0RQ^7]HD1(U Q@ +[U^F/AK
MRO[ L_(^QF'R_E^P/O@Q_L'N*_)OX&^"/BOXX_:F^.<'PI\:6?@N_AU6Z:^G
MO(O,$\9NY0JCY&P003VZUT4K6DP/H/\ 9?\ VC/BGX1_:1\0_ [XN:Q;^*+F
MQM);JVUBWC42#RXUEQE57<K1MGYAN!&,UZ#)_P %.O@@]I82VU_K%]=WMT;2
M/3X=-;[0IRHWLK$ *2P YR<'BJ/[/7[$NH?!WQ5XH^)7C[QB_CGQ[J-E-#]J
M\MECA5E&]MS'<S$*JYX 48 KQ_\ X)*^ = U7PCX\U^[TBROM834X[6*ZNH%
MD>*-8PP5"1\HW')QUP*TDJ4KR[6'H?2?QD_;X^$OP3\3-X<UC4;[5->B4&XL
M=(M#<-;9&=LC9"AL8RH)(SR*]!^"_P"T5X#^/GA6XU_P?K:WEI:';>QW"&":
MT;&<2HWW>,G/0X.#7Y:? 5O'OA_X]?$VST_XA>$OASXR^WSBZF\9VD;R7(,K
MEA%)*C!>H)&1N!4\BO2OAG\%?$.E>!?VC?$WAWXC>%_&]]J6B3VE]8^#MR>7
M<A_,<B)450#&90NP8.2!3E1@E:X['TWXB_X*>_ WP[XBGTM=5U;5HX)/*EU'
M3M.:2U4YQD,2"P]U!![5XW_P4V^)NG>-O@;\,O$O@W7VN](U#5G>&]T^X9!(
MOE=#@@Y!X*GD$'-+^PK\1_@1HG[(]QH_C/4?#=E>;[K^W[/5O+$]R&=BA"'Y
MI!Y>P+MR01QS7+?\%"G^'LG[,_PFF^&$>FQ^#I=8D>T72D"1<Q?-N'4/G(;=
M\V0<\T1A&,TDF2>M?M>^%/ASX@^,GP-E\8^,/$F@:ZS1+IMII-MYL-P5FC(W
M/G]T2Y4%N<J37L_Q2_;:^%?P7\?7O@[Q7JMYIVK6=BM\Y%F\D3(RY1$9<[G;
MLN/6OFG]N[_DY#]F+_KNG_H^"L_XF>'=-\4?\%9/#EGJEG#?6JZ=;3^1<('0
MNEM(R$J>#@X/U%+D4DK]F!]0? G]N3X7_M">*I_#?AN]U"TUV.-IH['5;0P/
M,B_>9""0<=2N<XYQ7EO[-?A/X<Z9^VI\7;WP]XP\1ZKXO03)J6DZA;>7:V^Z
M52VV7_EKA@ O3 )KS?Q_IMKHO_!63PA_9]M%9BXT^*6;[.@0.QMYP6..I(5?
MK@51^"MOJ5W^V%^UG!HQD_M>73=02S\KA_.+8CV^^[&/?%'LTDW'JBK'T+\0
M?^"DOP4^'_BJ[T&;5=2UNYLY#%=3Z/9&>"%@<,"Y(#8.0=N1Q7IT/[4WPPN/
MA _Q.3Q7:_\ "'K\IO"K;Q+T\GRL;_-SQLQG\.:^)?\ @FOX]^$7A#X/^,=*
M\<:AH.C^(VU"4ZC'KQC22>UV( O[S[R@AP4&<-GCFN9_;B3X;7WP%^&>J?"*
MVL1\,5U^;^U%T>)D N"J#$P.&$A02 ;^>1CM2]C'FY;,6A].:;_P5(^!NH+>
MM+?:YIZ6\9DB:ZTMA]JP0-L6TG+<YP<< UYK_P %$/C!I_Q0_8]\'^,_"%_?
M6^EZGKL+P3?/;3%0DP(8 @CD=/:K?[:?Q'^!NL_L;KI^@:EX=OKB2*V'AVRT
MZ2)I[>4,I)V+\T8";PV<>AKPWXT_\HN?A%Z?VNG\[FKA3C=22MJ4?J;\.6+>
M ?#C,2S'3K<EF.2?W2UTE<W\.?\ DG_AK_L&V_\ Z*6NDKB>Y 4444@"LJZ6
M3^V+0JMT8A%)N>.51$#E<;U)W,>N" 0,'/6M6L>Z\G_A(+#=]C\[RI=GF/BX
MQE<[!W7^\?\ =H ^3/\ @IQ\6/&'PC^$OA?4?!OB"\\/7]SK2V\MQ9,%9X_)
MD;:<@\9 /X5XQ\3[/]J+]G#X9V?Q3'QEC\7Z3$+>6ZTR^M<X64J%!5@=PRP!
M*E6&<BN\_P""P&?^%(>#\<'_ (2!?_1$M8$W[%'Q\^.GA'0=)\??&JV?P2\<
M$YT^QM6WE H*@J%168#&"Q(!&<5VT^54XMV*."_:N^.3>//$G[+WC^:[FT&P
MU*W34+^..X=(8P)XC+NP>5&&ZYXKZI\$?\%'O@MXY\>67A2SU74K6ZO)EMK2
M^O;!HK6XD8X4*^<C<< %@ <BOF7]O3X7Z#X3^)G[-G@*TM\^'K1(]-$,AR9(
M1<0J0WKN&<^N372?\%0O"^D:#J/P/GTS3K73Y8]5^SHUK"L6(ED@*I\H' /0
M=LFGRPDHJV]QGUG\?/VNOAO^S@UI;^+]6F_M2\3S(-+TZ SW+IG&\@8"C/&6
M(SVKSWP__P %+/@GXBN=%L[;4=834]4O4L([&73'$L4CNJ)YG8*2XY!(Z^E?
M.6O:AX?\+_\ !4J\O_B<]O;Z-+91'2+K5\?98V-M&(FRWRJ PE )X#$]*Q/V
M[/%GP^\5?M7?"*3P=>Z7JFJQ7]DNJWFDNDD;9O(C$KNG#.!N[D@$ U,:,=$T
M]5<FQ]I_'C]MWX8_L\^(8O#_ (BN]0O=>DB6<Z=I-H9Y(D;[I<DA5R.0,YQS
MBNA^#_[5GPW^.'@_6/$OAW7#'IVBKOU/^T86MGLAM+9DW<8P"<@D<5\F_M1_
M#F*#]JJ3QA\-_C!X;\(_%*/386N=#\1.D2,GE[ 4E=6CRR*,QL,]#D UYC<?
M'#Q3\8OV3OC?X3/AK1=,\0^';JWN=7O_  I"B6^I1-,1-(PCRK,#%N+J2K*,
M@ "DJ,915@L?4[_\%1/@6FO_ -G_ -IZPUEYGE?VNNER?9,YZY^_CWVU]4Z'
MK=AXDT>SU73+N*_TV\B6>WNH&#)+&PRK*1U!!K\AO -GXE\5?LM1Z.?C;\+O
M#_@22W_TK0M3LH4OX),Y._$1E:7=T=22<C!Q7Z,_L9_#V[^%W[._A?P_=>(K
M#Q2D*226VI:9(TEN\$DC/$$8\D!6 _"HJTXP5T(Y#]K^^_:&^T:?8_!XZ5I^
M@R6<TNJ:S<;!<6C)R0"Y(P5Z;4+9!Y%<9_P3$^*WC+XK?#OQE=>,O$5]XCO+
M/61;PSWTF\HGDQMM4XZ9)/XU]'_&#XE>$_!OAG5+#7O$NDZ+>W6GW!@M[^\C
MA>4>6P^56(+<\<=Z^)?^"4?Q$\+>&?!'C'2M6\1:7IFIZAX@7[)9W=W'%-<;
MH8U78C$%LMQQWJDKTGH/H?H_1117*(**** "BBB@ HHHH AFSY;8!)P?NG!_
M"J>C*ZZ7:ATN(W$8RMU(LDH./XF4D$^X)%7)L>3)G;C:<[C\O3O[51\/>5_8
MEEY!M3%Y2[?L3[H<8_@/=?2@#\R/A5JGQ_\ VD/C-\4M!\.?&C4/"UMX<U*8
M113H94,9GD5$7&,!0F.]=[\!?VC/BAI_Q*^)GP/^*>JP>(]7TO1KV:SUJV14
M?,<7(+*%W*5=6!*A@<YKQ']G;P+\6O''[07QJA^%/C>S\%74.JS&^FNX?,\]
M#<R[ OR-@C#>G6OJOX,_L4WGP1M?B)\0/&GBU_&_CW5])NXY+[RF5(E:-F<@
ML2SLQ"Y)QPH %>A4Y(Z.W0L^=_V%_P!L[P1^S[\']:M_'6KZKJ.K7NL22065
MK&]W/Y(C0;R6;"KD$<MSCI7Z"_"W]I#P#\8OAO=^-O#^MK_8%EYGVZ2]4P/9
ME%W.)5;[N 0>X(Z9KXW_ ."4?@?0-3^#WC_5;O2;.\O[J_>RDFN(5D8P"%3Y
M62#\N6)(Z$GFOGSX56.J/^QK^TA9Z(LNR#7+0R1PY.+=63S,^P &?84I4X3D
M^FHC[E7_ (*@? MO$3Z;_:NK"U63R_[6_LR3[(3ZY^\ ?4K7IGP__:^^&GQ*
M^'/B7QWINJW%KX9\.RF+4+O4+9H=C!%;Y1R6R'4#'4G%?./P+^)'P+TW]@U=
M.U+4_#<&W1IH]4TRZ>+[9+>E&!S&?G9RQ!5@#U!!P*\B_8O\-^%O%_[#_P :
MM+\6:X/#/AV;5=TNJ,N\VQ2&W:-MHY?YU4;1RV<#FH=*%GHU9A8^HO"__!3C
MX(^)O$EOH_V[6M+%U,((+Z_TUDMW8G"C*EB,G'W@.O->D?'C]L#X:_LZR6=K
MXKU::35;R/SK?2].MS<7+QDX#D# 4$@XW$9QQ7Y[6?Q2\9_LJZ3X(%UXB^'?
MQJ^&MO>1C2H;<P37EKW#QKM$T+@9P3O . >31\7+CQ7:?\% ]7U%/%&B>!]5
MOH([C1M7\6VBRVB1-"GE*OF(RHVT,H;C!5AD&G[&/-Y!8_0KX"?M>?#?]HZ:
M\M/"6JSC5K1=\^EZE;&WN53.-P4Y#+GC*DXSS7K'B234[?0=2DT2W@N]82WD
M:SM[J0QQ23!3L5V )"EL9-?GK^S[\)]?U[]LBR\::E\8O /BSQ)I]LSZK8^%
MP(I+B%XFC!VQHL;D-L+'D\*3VK]$-8U:T\/Z5>:EJ%S':6%G"\]Q/*<+'&HW
M,Q]@ :YZD5&6A)^</BOP#^UY?^!_%'Q2\4_%(^!)])6>[C\,V\WEQ&*(G(PG
M[L @?*&WELC/)KZF_8=^.>N?'_X!Z;XD\3+&-9AN)K*YN84\M+@QM@2A>@)!
M&0.,@XXXKXO^.G[4$G[;'Q$_X5QH7BK3_A]\)[:42:CK6KW*V[7ZJWWMK$;L
MG[D7MN;I@?3OC[XF?#O]GC]BO7C\,-:T[4=-TNT.DV4VGW2S$W<PP69U/,GS
M-(3UXS6\HOE46M7^!1Y;^S^O_#3'[?OCWXCS#[3X?\%J=-TMNJ>9S&C+^"R/
M]7!K]#*^7/\ @G3\)6^&'[-^C7=W#LU?Q(QUF[9AA_W@'EJ?H@7\2:^I*YZK
M]ZRZ$A11168!1110 4444 9<RR-K%LP2Z,0B<,RRJ(@<CAESDMZ$# P>:^1/
M^"FOQ6\:_"OX<>#[KP3K][H&HWVL&V>2Q8*TJF,[4.0?XL5]<7'E?\)%: _8
M_.\B3;O?_2-NY<[1_=Z9/KBOB3_@K,?^+?\ PV.<'_A)$_\ 0*VI).HKC1VO
M[*7[45_\9OV=/$J:Q>-!\1?"MA<6^I;ALE+I$_E7&/5MO/HRM5;]@'XZ:OXH
M_9Q\0>+_ (C^*I;U--U6Y$VJ:I(,0P(B$ D <#)XZY->*_M;>#=4_97^*EM\
M9?"]LS>%?%UC)I'B*QMQA%EEB(+8Z98_.#_>5A_%7DW@^SU?4O\ @F'XR;25
ME>&/Q5YUZL.23;#9DG'\(8H3]*Z'3C)76S?W#L?9]K_P5"^!=SXA73FU/6(;
M1I?*&K2Z8ZVF<XR3]X#W*UZ1\1?VP?AS\*_%?AW1/$5Y?6B>($BET[5DM2^G
MSI(0%;S@<  D9],@G@YK\[M#TSQ)XT_9CT_1KOXY_"K2/ C6\8?1[RQACO;6
M0$<,%B\T2ANKCD\G)!KV']HS0O!_PG_8%\)^"?'.JV7C'Q/Y87P[>:1-O+ON
M)66-B,^4$95/][*@<X(ET8720K'UUX\_:M\!?#_XF:-X N[G4-2\5:LB206.
MDV;7!57SM+D'"\ MST49/%?(\O\ P4ZCTW]IS4K:\O[@?"2")HTA31\WPG6-
M0<X^;'F!_P ,5RW_  3;;2_!OQV\1Z+\2['4+'XKW%K'_9L^N,2S6^P$QINY
MWE=K=3E!@8VG/1ZEK>A>"O\ @JMK%YXAOM/T;2VTM +B_=(8<FTBQ\S87)P?
MQ%4J<(R<6KZ!L?HCX;U^U\4:#IVL6)<V=];I<PF1-K;'4,N1V.#TK5JM:SP7
M%M'+;.LENZAHVC(*E3T(QVJS7"(**** "BBB@ HHHH **** "BBB@ HHHH *
M*** /.#^S_X%;XP#XH_V(O\ PG B\@:IYTF=GE>5C9NV_<XZ5Z/111=]0/.O
M"'P#\#> ?B)XB\<:'HBV/B?Q &&I7PFD8SY8.?E9BH^8 \ =*C^+W[//P\^/
M%G;6_CCPQ9ZX;4$6]Q)NCFA!ZA9$(8 ^F<>U>DT4^9WO<#R7X._LN?#+X"S7
M%SX)\)VFD7]PGERWQ9IKAE_N^8Y) ]AC.!FL_P"+W[(/PE^.FL)JWC#PA;ZA
MJJH(VOH9)()G4= [1L-^/?)X%>U44<\KWOJ!XKX7_8]^$7@GQ/X;\0:%X,L]
M*U7P[$8=.N+:21?+!+Y+#=AV/F/\S9//L*9\5OV.?A'\:O$R>(/%_@^WU/6=
MJI)=I-+"TJK]T2;& ?'3)YQ7MM%/GE>]P/+?AW^S;\-_A'XLOO$?A#PO;Z%J
MU]:K9326KN$,*[,*$+;1_JUZ#/%<EX^_87^"/Q*\33^(-;\"VCZK<2>;<36D
MTMN)G/5G6-@I)[G&3DYKW^BES2O>X'"VOP5\#6?PWD^'\'A?3XO!DD)MWT9(
ML0LA.3GN3D [LYR,YS6'\&/V9?AW^S[<:K-X$T'^Q)-5""[;[1++Y@0DH/G8
MXQN;\S7JU%+FEM< HHHH **** ,K06>33T9WFE;?(-T\!@;[YXV$# ]#CD '
MO7*_%WX(^#/CMH%KHOC?1UUK3;6X%U% TSQ[9 I4-E&!Z,>_>NKT2-XK!%E6
M96W/Q/,)6^^<?,/T]!@5J4[M.Z YO6/ 7A_Q%X-?PIJNDVVH^'I+9;1]/NT\
MR-HE "J<^F!@]00#UKQ71?\ @GW\!/#]U?SVO@"U:2\@DMV,]Q-+Y:.I5A'N
M<[#@GYAR.Q%?1U%-3E'9@>.:M^R;\+-<^%NB_#J]\,)/X.T>Y:\LM.^TS 12
ML9"6WA]QSYTG4_Q5U/Q"TW7--^$NM:?X'TNPO];ATQK72]/U-\6SL$V(CDY!
M&.QX/0G!S7=44N9]0/R7NO!_Q"N-%U'0]*_9 M-"^(NHPR6$WBRWA86<7F#:
M\T*-F&)B"<,K[5)R/2ONG]EO]F>U^#O[-^G?#KQ/!9ZW)=+--K%NR"6VDDF.
M7C 8?,H&T9QR5S7OW%%:2K.2ML!\XZ7_ ,$]O@#I/B!-8@^'MF]PDGF)#/<3
M2P!@<C]VSE2/8@BO3OBK\"_ _P ;/#-OH/C+P];:OIMLXDMHFW1FW8#&8V0@
MKQQ@'&*]!HK/FDW>X'%?"GX1^%O@CX/@\+^#M,_LG1(9))DM_->3#N<L<N2>
M37:T44F[ZL HHHH *RO,;_A(-F^;9]F!\O[/^[SOZ^;C[W^QGISBM1JS/)E_
MM[S=LWD_9]N[SAY6[=G'E]=V/XO3B@#C/BI\ ? OQJO-!N_&&B+K$^AS-/I[
M-/)'Y+DJ2?E89YC7KZ5?^*OP@\(?&KPO_P ([XTT6'6]($R7"PREE*R+G#*R
MD,#@D<'D$BNVW#UI=P]:?-+34#R^\_9N^'.J?"^Q^'FH^&;?4_"5CQ:6%](\
MQM^21Y<C,77&2!AN <=*YOX7_L4_!GX/^)(_$'AKP3:VVLPMN@O+F66X> GN
MGF,0I]P,CUKW3</6C</6CFEM<#\Y_!O[.,?Q)_;X^,J^/O UQJ?@C4K.8P75
M_:.MM))OMMK12\8? ;!4YX-?6GP?_9)^$_P)U5]5\&^$+;3-6=&B^W2223S*
MAZJK2,=H/MC->Q\>M+N'K5RJ2D@/.O#WP#\"^%?BEK7Q%TO1%MO&&LH8[[41
M/(QF4A,C:6VC_5IT':G?%SX"^ _CIID%AXX\-VFNPV[%H'F!26$GKLD4AESQ
MD9P<"O0]P]:-P]:SYI7O<#R#X/\ [)_PK^!-_)J7@SPC:Z7JDB&,WTC//.%/
M55>0DJ#WQC/>OFO]L#0_'&H?& W>M?L[:5\8O *6L<.GSZ?N_M&.3&7,DD8W
M@9)&PJ4P 0<DU]Y[AZTA(]:N-1I\SU _/3]DW]G'QKXH_:0A^+_BKP!:_"OP
MUHUB;/0O"\*B.128S&"4P&X#2,SN 69N!BOL;P'\ ? OPT\:^(_%OAW0UT[7
M_$4C2:G>":1S.S2&1CAF(&7)/ '6O1=PI=P]:)5')@>5?&3]F7X;?'W[,_C?
MPQ;:S<VJE(+O>\,Z*3DKYB$$K['(Y-<UH?[#_P $_#<GAZ73O UI:7&@W/VR
MQN(YI1(LQ93O=M^7.5&-V0,<5[UN'K1N'K4\\DK7 \\L/@+X'TOXM7OQ+M=#
M6+QK>6YMI]3\Z0EXR%!786V]$7MVJ/5/V?\ P)K'Q:T_XF7>AK+XUL8A!;ZI
MYT@*(%=0-@;;T=AT[UZ/N'K1N'K1S/N!YUXH^ /@7QE\2]"\?ZOH:W?BW1%5
M;#4#-(IA +$?*&"G[S=1WH\+_ +P+X,^)>O>/]'T1;3Q;KJLNH:@)I&,P)4G
MY2Q4<JO0=J]%W#UHW#UI<TMK@>=VOP%\#6?Q<N?B;#HBIXWG@^S2:IYTF6C*
MA=NS=MZ*!T[477P#\#7WQ<M_B=/HBOXWMX!;1ZIYTF5C"L@79NV_=9AT[UZ)
MN'K1N'K1S/N!YQX1^ /@3P+XT\4^+-$T-;+7_$S,VK78FD8W!9BS?*6(7))/
M '6I/A'\!? _P*TO4--\$:(NBV5_,)[F)9I)-[A=H.78D<>E>A[AZT;AZTW*
M7<#Q72_@)HOP*^''C2U^#_A?3[;7=4A>:.RO[F1K:YN=A5!(7+87D\=#T-?
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MFV203*X7D7$PF?\ %QU/O6G1=K0""XMTNK>2&0;HY%*.OJ",&N$^$/P)\$_
MG2[_ $_P1HJZ+9WTXN;B-9I)-\F N<NQ(X%>A447=K >,?%W]D;X3?'+5%U3
MQAX/M=1U4*$_M"*1X)V4= S1D;L>^3Q72_"?X%^!/@=I,^F^"?#5GH-M<$-<
M-""TDQ P"[L2S8YZG R<5Z%13YI6M<#YX\4?L#_ GQAXEFUW4/ %F+Z>3S9A
M:S2P12.3DDQHX49[X KK_''[+_PQ^(GA#0O"NM^%+67P_H;[]/T^W9[>.W.W
M;D",CMZUZQ13]I+34#S?QU^S[X#^)7B/PQKOB+05U'5?#;!M+N#/(GV<AE8<
M*P!Y53R#TIUW^S_X$O/BU;_$V?0UD\;00B"/5/.DR$"% -F[;]TD=.]>C44N
M9]P/-M4_9^\!ZU\6+'XE7FAK+XTLXE@@U/SI 41590-@;;T=AT[U+X1^ W@;
MP+\0_$/CC1-#6R\3^("3J-\)I&,^6W'Y2Q4<C/ %>B44<SVN!X'\0OV'/@G\
M3O$TWB#7O UI)JUP_F7$]K++;B=N[.L;!23W.,GO7?6WP+\ V?PW;P#%X2TM
M/![1^6VD^0/)(Z[CW+9YW9W9YSFN^HHYY-6N!\Y:'_P3Z^ OA]]0:V\ 6C-?
M0M!(UQ<32E$;J(RSG8>!R.?>NOUK]E3X8>(/A?I'P[O_  S'/X0TF83V>G?:
M)0(G&[G<&W'[[=3WKUZBFYR?4"GIVG0:38VUE:IY=M;QK%$F2=JJ  /R%7**
M*D HHHH *RKB1QKEF@DF"-%)F-;<M&<%>6DQ\I'89YR?2M6LRXCD;6+-PLQC
M6.0,RS 1@DKC<G\1]#VY]: .2^+WP-\%_';1;/2?&VC+K6GVEQ]J@A::2/9)
MM*[LHP/1C^==KI]C#I6GVUE;)Y=O;QK%&GHJC 'Y"K=%%W:P'G'Q'_9_\"?%
MCQ-X>\0>*="75-6T!_,TZX:>1/(;>KYPK 'YE4\@]*7XK? /P-\;)-%;QEH:
MZPVC3_:;'=-)'Y4F5.?D89Y5>OI7HU%',^X'F'Q@_9Q^'7QVL[2#QOX8M=;:
MS!6WN&+13Q ]561"&P?0G%<9I/["?P/T.VT>&Q\"6EN=)O1J%M.L\OF^>"I5
MV??E\%%P&) QTY-?05%4IR2LF!XQ\7?V1OA/\<M2&J>,?!]KJ.K*JQ_;XG>"
M=E'0,T;#=CWR< "NA^%?P"\!?!3PY=:'X-\-6FDZ=>$FZCYE:Y.W;^\9R2_&
M1@G&":]&HI<TK6N!\X:C_P $]_@%JGB!M7F^'MFD\C^8T,-Q-' 6)R?W:N%
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q_"_D_V/'Y!LS%YDF/L/\
MJO\ 6-G'OG.??-;%9>BR23Z<K3/-*^]QNN8/*?ASCY<#@=CW ![UJ4 %%%%
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M_/,4?88?^>8JQ12 K_88?^>8H^PP_P#/,58HH K_ &&'_GF*/L,/_/,58HH
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M #S%'V&'_GF*L44 5_L,/_/,4?88?^>8JQ10!7^PP_\ /,4OV.'_ )YBIZ*
M,>XN%L]8L;9);6(3K(3%(Q\U]H'W!TP,\Y]17S=_P42^.7C#X _!73/$'@K4
M8]-U:;68K.2:6W28&)HI6(VN".J+S[5]*7<SKK%C&DEPL;+(62.#=&V ,;WQ
M\A'.!D9S[5\7?\%>O^3;=%_[&.#_ -$3UK32E-)@>_']I#PC\/\ P+\/;WX@
M>)+?1M3\465NT$DT3!)YFB1GY52J#+YYP!FLOPI^W'\$O&GCB+PEI'CNSN=9
MFG^RP*T4J13RYQL25E"L2>G//;-?&/\ P4!T^+5OA=^S+83@^1=Q06\F#@[7
MBME/Z$UH?\%)_A'X/^%MC\&+GPGX?L/#]Q%J?V/S=/@6%GC0Q,N\J!N(()#'
MGD\UO[&$K7ZW*L?=OQA_:)^'GP%L[6?QQXFM=$-UG[/;L&DGF ZE8T!; ]<8
MKX?_ &OOVP=*^(6N?!Z\^$GQ$NOL<VM>1J=OI=S+;.098,+-&=I((+8R,')K
M*\16&A>,O^"I=SIWQ06"YT2"V5-*M=6(%K(PMT:!<-A2"YD('0L,<UC?\%#/
M"?PZ\*_M$_"R/PA9Z7IFOS7EN=6L])1(T51<Q>2SHG"N1N[ D &JITXQDD][
M7 ^D/C/X=L;[]N;X9WDOQCN/#FHK:Q/!X-6&<F\4-+D*R_N@LF&#;N?E^E>W
M_&+]J;X8? 6Y@L_&WBVUTG4+A/,CL51YIRG]XH@)4>YQG'%?*?[1/_*3[X)_
M]@N+_P!"NJX;]G?3O"GC+_@H!\8?^%K1Z?>ZS#=7":1:Z^$:,[9]JA%D^5B(
M?+VC'W22*CV:DDWT1)]^_"WX]^ ?C1X?NM;\&^);/6-/M3BZ=28VM\#/[Q'
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M-)-I-M)+)/+(R99[F#R9#_O)@;3[8K1H **** "BBB@ HHHH **** "BBB@
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MJ2 Z.K+@'GBOF/\ 9V'QK;]H+XU#X,'0UO#JLPU!M:"X"_:)=FS/?.ZOJ?\
M9J_8\\9?#_QYXQ^+7Q5U^SUOQSJ]I-$L6GY,<(< NQ;"@D[54*JA5"]Z]":@
MKIV\NY90_8_\5^#O@;\-?B%XEUKXU3>/M @UA([N^DM+OR]/D(  (<,VY]RD
MD?*#BOK7P_\ %3PMXJ^'L?CG2]8ANO"KVKW@U)0P3R4!+L00&&-IXQGCI7P=
M_P $X_ EA\3O@C\<O"FI('LM7UB6U?(SM+6Z;7'NK8;Z@5X'I?QVUCX4?LN?
M$;X"7GG#Q@OB#^R[.VP=_D2/F95'^^A7'7][6;I<\G;=?D(_43P]^U%\+?$_
M@#4?'%CXOL_^$5TZ8V]SJ=PLD$2R!0VQ=Z@LV&'"@DYKF_ 7[='P0^)7B>'0
M-$\=VDFJW$GE6\-U#+;B=CT5&D4*2>PSDYXKX0_:L^%2_!7X>_LW^ M;>2U\
M(^<T^OR(2L;W+R1&=V([A7?![#.,5Z+_ ,%&? ?P;\*? 'PW?^$++P_I7B)+
MR$:3-H?EI+-;[27;,?+J,(0QS@XP<T*C#3?4+'I_[5?_  4 B^!WQF\-^#=$
MGTB]MX[F)/$S7D,QEL(W=#E2I )\MBW ;I^%?0=E^TW\,KSX6_\ "Q5\7V2>
M#C(T/]J3!XT,BL5**I4,S9!X SQ7Y]?M4Z6D_BS]EO5?$FFVL&JZK#I[:W/<
M0(K7+^9 '\\D?/A>#NSQQTKI?^"BFEZ#8_%#X(:!+%:Z3\+I;DR7D6GHL-GO
M:X19F.P!0=F,D<@$FCV<9<J#R/J;2_\ @H1\ M6L;Z[C^(5I$EGM\U9[:=)"
M"< JA3+#/H#CO7B?_!03XT:M;V/P/UKP)XKU+3M(U_4EE,^FW,ENMW [0%-X
M&"058\$?Q5SO_!2OP!\(O#/P!\/W6@:9X?TKQ ;N%-*.D1Q1R7%L4;S,[,;X
M^$.XYYQ@\UP/[5__ "07]DC_ ';/_P! M:=.G&ZD@/U5LV+6L);EBBY_*IZ@
ML?\ CSM_]Q?Y5/7&2%%%%( HHHH **** "BBB@#&N/(_X22RW&S\_P"SR;?,
M_P"/C;N7.W_9Z9]\5\O_ /!13X]^./@'\/\ PKJ/@2_CT_4=1U4VDK26T<^]
M=A(4!P<'=CI7U+-))_;=M&'G\IHG)C6',1(*X+28X8=ESSDGM7P__P %:&*_
M#WX<$'D>)$.?3Y:VI).HKC1ZQ^P;^T5JW[0GPAGN?$US'-XNTB]DLM2V1"(D
MYW1L47 &5(''<&ODOXU?\% OB?#^T9J&C^"M6M[3P/;:Y#H\>;"*42LKHLI\
MQ@3EOF;V!%'C/QY+^PK^T;\1YXHY8?#_ (U\.MJ&F)&IV"^9?W9 Z861I1[#
M%>8^./A3<?#;X!? /4=1C9-:\5>*9=:O#(/GP[6XB#=\A I^K&NR-.',Y/9[
M%'VA^TQH-CJO[3GP=O+OXQ7/@N[S#]G\-QP3L-082DG8R?("^=C;^PK!USXA
M>*8?^"G^G^%D\1:HOAIM*61M(6Z?[*S?9MV[R\[<[N>G6N>_;0_Y/2_9N_ZZ
MP_\ HXTOB#_E+9IGK_9"_P#I)644OP8'U'\7/VN_A-\#=772?&/C"UTW5F4.
M;*..2>5%/0L(U.W/O@XKL/A[\9_!/Q6\)R>)O"WB2QU?0X@QFNXY-H@VC+>8
M&P4P.3N XYZ5^4'P1L_B+XH_:"^)LVDZ!X%\3>,6O91=6_Q P\R+YK[O)C9E
M'4 -P2,*.!7N'[,?[-?BVUD^-::_J_A70/"GB+3)[6]C\+:HD]KIET"6YC#'
M8J(QR"V=O&:4J,(K?41]-6__  4(^ 4WB0Z(/B%9K=>9Y7G/;S+;ELX_UI3;
MCW)Q[UYM^UM_P4 @^!_Q#\+>&_"MSH^K>9*KZ\;J.5S:0.8VC=&4@-E&=N-W
M05\G6^B^)OV9OA[8S>*?AY\/?C!\)1?K)!X@T]HGF9F?>I$Z$2 _[+H1_"3B
MO2?V_P"?PSXHUS]G?Q7IVDV=CI^O2)/+));)&9(&-L424XY"HV,'( XIJE!2
M75"L?=7A_P#:8^&GB/X8S_$&U\7V(\(V[M#-J<VZ*-9%."@# ,6SV )/:N5\
M!_MT_!#XD>)H- T3QW:/JMP_E6\5S#+;K.W94:10I)[#.3VKY/\ ^"CVGZ+I
M.H?!C18;:TT;X97&H&34$TJ-(;?>98UE8B,!=RQD\]1EO>K?_!1/P'\&O"O[
M/F@W_A.Q\/Z5XD6Z@&DRZ*(DGFAVL7),?+*/E.X_Q8P>:B-.&F^HC[:^(W[1
M'P\^$OB'2]$\7>)[70M1U*)IK5+I'VNBYRQ<*54<'J1TKEOAO^VA\'?BUXP7
MPQX8\9VM]K4A80V[PRPB?:,GRRZ@,<#.!S@5\+_M,://\0/B7^RIIGB^*2YF
MU32[&+4HI\[I=TJ[P_N><CW-=7^V5\._#7PU_:P^ 4_A;1++PZUQ>VR2C38%
M@5]ERJ@E5 !.UB,]QUIJC&R75E6/M?XR?M0?#+X"2V\/C?Q7:Z1>W";XK,(\
ML[+G&[8@) ]SC..*UOA'\=O GQTT>;4O _B6UUZW@<).L65DA8C(#HP#+GW&
M#VK\P=4A\<>(OV\OB*MCI/A#7O$\5W/'967CPYM_(#8C\A&90S!-N.ORDD#O
M7N/[(?P1^(GA?]JO7?%VH1^"=&L9K1[?6=%\'ZBC1V\C!63-N&8IEE+<GC<V
M,9Q2E1C&-[ZA8_1"BBBN4D**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#,T.-X=/171X6WO\DD_G'[Y_B_IVSCM6G6/X8:!M
M'C-LUFT7F28-BFR+/F-G ]<YS[YK8H **** "BBB@ HHHH **** "BBB@ HH
MHH *R]C?\) 9/+DV?9@OF>?\F=_3R_7_ &OPK4K%W0?\)65S9_:OL0.W9_I.
MSS/[W_///;US0!\?_M8:;_PO/]K7X2_!C59Y5\&/:7'B+5;%&*K?-%NV1OCD
MC"$>VXUW7QTTO]ESPWI8^'_Q$B\'^&UFM%F@LVA2TN(HR65)(W10RG*-@@\E
M3G-1?M8?"#QI-\0O GQD^&EG%K'B[P?YL%UH<LGEG4[&3[\2-T#C+8SUW<<C
M!\]^)'QE\5_'C0[W0?#_ .S7KUGXSOK-[)M;\9Z3%':Z8A5LN)F!9RNYBJC&
M2<X[5T1]Y1L]$!VWQH_:<TGX._!GX>6GPDETO7+CQ3/'HOAJZOKLFQABC&QI
MY9'8$JF .2.3R<"O/;K]HKXJ? '7O#>K^.OB;X'^*7@[5-0ATW4K?04B@O-.
M:4[5FC"$%T!QG(/X=:Y*Z_9;\8^)?V/?@?=Q^#QK'BGP)<3W-[X-UV(PMJ%L
M\SF2 JV,,0$(!QD'UQ70>!M&\!^,O&7AW2=(_8WU31WDND&IZEKVF1V-OIT8
MY,BN<^8P."%X) ]:KE@EW'H=_P#'CXX?%RQ_:HTCX4?#=])0:WX>^U)<:M;[
MH]/D$K>9=,1\S[8T("="6'6I/A/\7?B[\//VF++X0_%O5=)\6QZ_I<VIZ-KN
MEV8M&!BR7C=  ,85NV<[>2#QKZMX+U^;_@H9H/B9-$OV\.1^#9;1]6%NQM5F
M,K$1F3&T-C'RYSS1\4/!OB#4/V]/@[XCM-$U"Y\/Z?H6IPWFJ16[-;6\CHX1
M'D VJQR, GG(J/=VMT#H><7'[2'Q,^/'CKQ:GP_^(?@WX6>#?#U_)I=O=>($
MBGO-4FCX>39(?ECST( X/<YQU/PO^./Q#^.GPP^)/A!-:T#1OBAX/N5M+K7+
M&$7FFWENREUFC7)'SHKC&>#@\=!XQ;_ W3OV=?'7C#3/'/[/UU\7?#&I:G-J
M.B>)M#TY;ZYBCE;=]FG3(*[3P#Z^N>/I_P#9?\)Z?)X%\37]A\&H_@Q)JTC6
M\-C)L6XNK=4(BEF11F,@N_RGI[U<N1+1%'C?_!,OP[\2E^$?A+5#XMTD_#;-
M\H\/KIN+L2>:X#>?Z>9EL>AQ7H7P?_:>U0Z3^T!XA\;W$,VC> ];N8;9;6W6
M)Q;1H2$)'WF) &X^M<_^P?K_ (E^%_AG3/@QXE^''BS3-3TNYO\ S?$$M@?[
M*9/,:1&$^<'?G P.>*H?"'X Z[XS\)_M1>$=?TR_\.P>+M?NUT^[O;=HUE1T
M.R:/(^9-VWD5,K-RN0'@O6OVL?C-X(@^)&A>(_"?A:RU*,WNE>#;K3?-,L')
M19;@C<K. .<CKGY>WUWX&O-?U#PCI%SXIT^UTGQ%+;(]_96<QFAAFQ\RH_<
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M >%QJWPRO/AUX2M?$FG><=<NXWO+Z[:7$<<,:?P+\S%CUXKT3]I_X"7NE?M
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MIL@Q_L#L*V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]:M_ ']D'X<_LVSWMYX0T^Z.J7B"*XU'4+EIIW0'(7LH&>> *]NHHYY6M?0
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M?..O\./>M>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MIDF=I(SG':GTR3[C#V]<4 4=#:232;9IFN'DV?,UW&$E)_VE' /TK1K+\/1F
M/1;1#&8MJ ;#<&X(_P"VAY;ZUJ4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %9EQ)*NL6@5[@1&.3<JQJ8B?EQN;J#Z =>:TZR;J/.N6
M3^66"Q2#?]I*[<E>/+Z/GU[8]Z -:BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@"*;(C<C<#@_=&3^%5-&:1M+MFE:=I"@+-<H$D)Q
M_$HX!]A5J8;H9!U^4]\=O7M5/0XS'H]FI0Q%8U&TSF?''3S#RWU[T :5%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &9,T@UB!0]QY
M7E.2JHIBSE<%FZANN!TQFM.LJ9-VN6S["0(9!YGV@J!\R\>7T;_>[8QWK5H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,?PTT+:1$UNUJT1DEQ]
MCB\N//F-G"^N<Y]3DUL5F:*TDEA&9OM6_>__ !^*JR??.,A>,8QCVQGFM.@
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M][=Z8XQFM2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO1Z\R\#6OF?$36"I<QZ/I5EI3''R&7YYG&?4!TR/]H5Z;7Y%4MS.QUA1114
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MV[[<O)T7.V3HG;(/7\*V: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "HY/N-QV]<?K4E1R8\LYZ8[C- &=X<01Z':*%6,!,;4N6N /\
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MUJS-LO\ ;Q.+KR/LV/O)]GW;_3[V_'X8]Z -.BBB@"&:9+>-I)&5$4%F9C@
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M[=Q@#[K>C=J0&LOW12TB]*6@#P#XG?M:Z-\)OVA/"WPTUW2Y8K/7K*.X&O\
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M10 4444 %%%% !1110 4444 %%%% !1110 5')_JV[#'IFI*9)_JVZYQVZT
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M.>U:]9DRR_VU;E?M7D^4^[:R>1G(QN'WMWICC&<]JTZ "BBB@ HHHH ****
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ML+0? GAKPK=7%WHOA_2M(N;C_736-E% \G.?F95!//K4GVZ;_GJWZ4?;IO\
MGJWZ4P-O:*Y_1_ WASP_JEUJ.EZ!I>FZC=9^T7=I91Q32Y.3O=5!;)YY-2_;
MIO\ GJWZ4?;IO^>K?I0!#?> O#6J:R-8O/#^E76K*NP7\]C$\X7&,>85W8QD
M=>AJU9^%='T^XL[BVTBQMY[*W^R6LL5LBM!#_P \T(&53I\HXXJ/[=-_SU;]
M*/MTW_/5OTHU MV>BV.GWEY=VEC;6UW>NKW,\,*H\[*, NP&6(' )SQ6C6']
MNF_YZM^E'VZ;_GJWZ4K ;E9FK>;Y=MY1NA_I$>[[+LSMSSNW?P>N.<=*K?;I
MO^>K?I4%XOV]8EG+N(Y%E7#%<,IR#\I&?H>/6BP'1T5A_;IO^>K?I1]NF_YZ
MM^E%@+G]CV']K#4_L5N=3\K[/]L\I?.\K.[9OQNVYR<9QDU&/#NE#6CK(TVS
M_M<Q>0;_ .SIYYCSG9YF-VWVSBJ_VZ;_ )ZM^E'VZ;_GJWZ4@+>FZ+I^CQS1
MZ?86UBD\K3RK;0K&))&^\[!0,L>Y/)IFC^']+\.6C6VE:;9Z9;-(TK0V<"0H
M78_,Q"@#)[GO5?[=-_SU;]*/MTW_ #U;]* %O/!^@W\>HI=:)IURFI%3?+-:
M1N+K;]WS<CY\=MV<5I_9HC;_ &<Q+Y&W9Y6T;=N,8QTQCM67]NF_YZM^E'VZ
M;_GJWZ4 ,N/!'AVZT&+0YM TR;18\"/39+.-K9,=,1E=HQ].]7=%T'3?#NGQ
MV.DZ?:Z98QYV6UG L,:YZX50 /RJK]NF_P">K?I1]NF_YZM^E5J!N56NMOV6
M;?M";&SYAPN,=SZ5F?;IO^>K?I0;R9@09&(^E*P$WAL0_P!@:>+<VY@\A-GV
M1R\.W:,;&/)7T-:U82W4L:A58HHX"J!@4OVZ;_GJWZ46 L:UH.F^)-/>QU;3
M[75+)R"UM>0+-&2#D$JP(.#[5R]Y\'?"D.D:K#HOAK0]$U&\LI[-+ZSTV&)X
M_,C*$Y10<<\C/.*Z#[=-_P ]6_2C[=-_SU;]*>H' _!?X!:)\,_AYX+T?5--
MT?6O$/AW38+$:Y_9\?G,8UQN1V!=1Z<\5Z3)H]B^JQZH]C;MJ,<30)>-$IF2
M,D$H'QD*2 2,XXJI]NF_YZM^E'VZ;_GJWZ4:[L#<K.CT6PM]4FU..QMH]1GC
M6*:\6%1-(B_=5GQN(&3@$X&:J?;IO^>K?I1]NF_YZM^E*P%BU\/:78ZI>:E;
M:;9V^H7NT75Y# JS3[>%WN!EL=LGBM2L/[=-_P ]6_2C[=-_SU;]*0&Y16']
MNF_YZM^E'VZ;_GJWZ4[ 6-/\[[=J'F&[*>:OE_: FS&P?ZO;SMSG.[G.>U:E
M<W;J+6XN9HBZR7#!Y6+DY8  <$D#@#I@58^W3?\ /5OTHL!7UKX>^%O$>HQ:
MAJWAK2-4OH\!+J]L(II5QTP[*2,?6K>O^%=%\5:>MEK6D6.L6:,'6WOK9)XP
MPZ$*X(R*9]NF_P">K?I1]NF_YZM^E/4"=?#>DI<QW":79K<1VWV-)1;H'6#_
M )Y XR$Z?+TXZ5"WA+0Y-!71&T:P;1E 5=.:UC-N #D 1XV\'GIUI/MTW_/5
MOTH^W3?\]6_2C4"U=:+I]]=65S<V%M//8L7M9)859H&*[28R1E21QQCBM*L/
M[=-_SU;]*/MTW_/5OTI6 N?V/8?VM_:GV*W_ +3\KR/MGDKYWEYSLWXW;<\X
MSC-1+X=TJ'6IM833;1=6DC$,E^L""=XQT0R8W%1Z$XJ#[=-_SU;]*/MTW_/5
MOTI ;E%8?VZ;_GJWZ4?;IO\ GJWZ4[ &H+ ?$6F&3[/YP2;R_,G*2]%SL3HX
MZ9)Z5N5@M<.SARV74<-@9%.^W3?\]6_2BP&Y16']NF_YZM^E'VZ;_GJWZ46
MW**P_MTW_/5OTH^W3?\ /5OTHL!N45A_;IO^>K?I1]NF_P">K?I18#<HK#^W
M3?\ /5OTH^W3?\]6_2BP&Y16']NF_P">K?I1]NF_YZM^E%@-RBL/[=-_SU;]
M*/MTW_/5OTHL!N45A_;IO^>K?I1]NF_YZM^E%@-RBL/[=-_SU;]*/MTW_/5O
MTHL!N45A_;IO^>K?I1]NF_YZM^E%@-RHY,>6V<8QW.*Q_MTW_/5OTH^V3?\
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M:H>&EB70;$0>1Y(B79]EF,T6,<;7/+#W[U#]LF.096Q]*1+J2-0J/L1> J@
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MQP?\\E_*IJ* (?L<'_/)?RH^QP?\\E_*IJ* (?L<'_/)?RH^QP?\\E_*IJ*
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M_*IJ* (?L<'_ #R7\J/L<'_/)?RJ:B@"'['!_P \E_*LRYL-VL6;+#<&%8Y
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MYXATJTU)B +.>]B28D]!L+9Y^E2:QXRT#P_=);ZKK>FZ9.R[UCO+N.)RN<9
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M>M "T4FX>M&X>M "T4FX>M&X>M "T4E+0 4444 %%%% !1110 4444 %%%%
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M@AX_TKXH>!])\/:W>6=U8V.FV-S]HBN5>W(4L6) .\X_ &NN32E&2[(#YO\
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MXZ6ONKV[VWL5RNUSV?Z"C^5>'_'W]I#_ (4WJVF:;9Z2NLWMS$]S-&92GDQ
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M7?\ :?W>=YX\K/7_ &\>U:U8G[G_ (2P@"S\_P"Q#+;3]IV^8>,]/+SV]<T
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M<PZ?J+GY5O$(_P!5.G!8@?O%!!^;!JY)-NXV=?\ &+XS_P#" R:=X=T#3_\
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MJ:A?1)TCE=B5&X##,HSS7=>!O@C?>$_VA/B%\19=3M[BS\46=C:PV*1L)(#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M>Z?L9ZG+8_&>W@1F$5Y931NN>#MVL#^&#^9K]!OYU\*_L/>%9=3^(FH:X5/V
M;3;4Q!L<&24]/P53^=?=5?SSQC.$LUDH=$K^ISU-Q:***^*,@HHHH **** "
MBBB@"&;_ %+@ D[3T;;V]>U4M"C>/1[-'61&$:@K+/Y[#CO)_$??O5VXQY$F
M=N-ISO\ N]._M6=X9:-M!L3"+58O*7:+)2L.,?P \A?2@#7HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RID=M<MG5)"@A<%EN-J
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M0 4444 %9>^7^WBOF7'D_9P?+\H>3NW]=^,[L?PYQCFM2LCRV_X20OY38^R
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MZ&75O^^8O_B:/]<LI_F?_@+#GB?%%%?:_P#PP3X=_P"AEU;_ +YB_P#B:/\
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M(=*C\HVQ3?)_QZ1&./\ UC9P#W]?4Y-;%9FB-*U@AE:[>3>^6O$5)/OG&0H
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M;*/P?(=2MAK8N$-GODA'EYE!V@'USC@U]0>,O /AWXBZ.=)\3Z)8Z]IV\/\
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MXC'%_P !4\@5KUF:$TK:3;&9[IY-GS->HJ3$_P"T% 4'Z5IT %%%% !1110
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M+/\ P1S?X4<K ]&HKSG_ (79I_\ T+/BS_P1S?X4?\+LT_\ Z%GQ9_X(YO\
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M'_"[-/\ ^A9\6?\ @CF_PI\K ]&HKSG_ (79I_\ T+/BS_P1S?X4?\+LT_\
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MQC_MH?O?6M:O)O#?QIT_^Q+/;X<\2.OEC#6OAR>"/_@*')4>U:?_  NS3_\
MH6?%G_@CF_PHY7V ]&HKSG_A=FG_ /0L^+/_  1S?X4?\+LT_P#Z%GQ9_P""
M.;_"GRL#T:BO.?\ A=FG_P#0L^+/_!'-_A1_PNS3_P#H6?%G_@CF_P *.5@>
MC45YS_PNS3_^A9\6?^".;_"C_A=FG_\ 0L^+/_!'-_A1RL#T:BO.?^%V:?\
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M_A1_PNS3_P#H6?%G_@CF_P *.5@>C45YS_PNS3_^A9\6?^".;_"C_A=FG_\
M0L^+/_!'-_A1RL#T:BO.?^%V:?\ ]"SXL_\ !'-_A1_PNS3_ /H6?%G_ ((Y
MO\*.5@>C45YS_P +LT__ *%GQ9_X(YO\*/\ A=FG_P#0L^+/_!'-_A1RL#T:
MBO.?^%V:?_T+/BS_ ,$<W^%'_"[-/_Z%GQ9_X(YO\*.5@>C45YS_ ,+LT_\
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MJ^G^1M).IV+VV[.?N[NO3]:Z>D 4444 )M%&T4M% ";11M%+10 FT4;12T4
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MV/:^8;POL&[[?M\__@>T8S]*TMHK+\-QK'H=HJ)&B^6,+#<&=!])#RWUK5H
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MNA^D9)*_2M:LW05==(MA(+L/LY^W%3-_P,KQGZ5I4 %%%)F@!:*** "BBB@
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MU74;S7KB22[OYT(:.-2YS@,BX & "Q)Z5^J-8UK75B6%%%%8""BBB@ HHHH
MR/#:JNEH$CMT7S)/EM9C*G^L;^(@9/KZ'(K7K(\.R"328B)?.'F2?,+?R/XV
MXV=L>O?&>]>6^)OVQO@MX+\1:AH.N?$71=-UG3YVMKJSGE8/#(O56^7J*$F]
MD![316%X3\9:'X\T*WUKP[JMGK6DW S%>6,RRQMCKR.X]*\X\8?M>?!KP!XD
MET'7_B)HFG:O"VV6U:<L8F)QARH(4_4T*+O9(#V2BL:W\4:3>^'1K]MJ-M<Z
M*;<W0OX)0\)A"[BX89!& ?RKR33?VWO@3JE]#:6WQ1\///,P1%:Y* D].6
M_$T*+Z(#W2BLC4/$VD:/HS:M?:G9V>EA!*;Z>=4AV$9#;R<8QWS6'\-_BYX/
M^,&FWFH^#/$%GXCL;.Y-K/<6+ET24 $KG'H0>/6BSW [.BBB@ HHHH ****
M"L;:G_"4$[+;S/L8&_SCY^-_3R\8V?[6>O%;-8^X?\)0R^:-WV,'ROLW/WS\
MWF_^R?C0!L4444 %%%<#\9/B7_PJWP:^HVU@VL:Y=SQZ?H^DQMA[V]E.V*//
M9<Y9F_A56/:BP&C\0/BEX5^%NDKJ/BK7;/1;>1MD0N'_ 'DS?W8XQEI&_P!E
M037FO_#6.GW69=-^'/Q'U6R'/VR#PS,B,O\ >42%68=.@[UL?"WX$P>';\>+
M_&4T?BSXDWB;KK6KA-R6>>?L]DAX@A7H-N&;&6))KU['XU7NKS \K\"_M)>!
MO'FLIHD-_=:%XB?[NB>(K*73KQ_]R.95W_\  ":]4KDOB'\,O#/Q5T&31_%.
MD6^JV3?,GF#$D#]I(I!AHW'!#*01BO.?A3XF\0?#GQZ_PK\::G-KC2VTE]X8
M\0W6T2W]HA DMIR  ;B'*Y;^-"&ZAJ+)K0#W2BBBI *R]8WB.U\LW@/VF//V
M,*3C/._=_!ZXYQTK4K(UY%:*TW1QR?Z5$0)IS#@[NH(^\1V7O0!KT4B_=%+0
M 445R/Q0^(FG_"GP/J?B74HY;B&S0".UMP#-=3,P2*&,=W=V51]: +7C3Q]X
M=^'.BR:MXFUFRT33H^#<7LPC!/\ =4'EF/90"37EO_#6>D:@2^A> OB#XCLN
MJWUCX:F2!U_O(9=A8?05/\,_@G<:KJ=OX_\ B@D&O>/;@>;;VT@\RST"-N1;
M6B'@,O :;&]V&<@8%>W8VC@56D=]0/'_  E^U'X%\3:S!HUY/J7A#7+@[8--
M\5Z?+IDLY](S* KGV5B>#7L'6N?\8^!]!^(.AW&B^)=)L]:TJX&)+6\B#I]1
MGH?0C!'8UY!X&O\ 6?@3\0=,^'6MZC=:WX-US>OA36-0DWW%I+&A=M-GD/+_
M "*S12-EB%93DJ*+*6P'T!1114@%5KS!M9@=N-C9WDA>G<^E6:@NL_9Y<'!V
MGG;N[>G?Z4 4/#:QQZ#IZ0BW$0@0(+1R\(&T8V$\E?0UK5F>'V=M%L3)(TK^
M2F9&@\@L<=3'_!_N]JTZ "BBB@"&2588V>0JB*"Q9C@ #O7C6M?M8>"+75)]
M-T"#7/'E[;N8YE\(Z5-J,43C^%ID'E@_\"XK!U"UN_VH_&FL:5+=36OPC\/W
M;6%W!;R&-O$=ZA_>QLZG(M8CA2 1YCA@?E7GW;0M TWPUI=OINDZ?;Z9IUL@
MCAM;2)8HHU'0*J\"G91W \;7]KCPUIL@_P"$H\+^-/!=KU:^UWP_.EHG;YYD
M#JOXXKV/0?$.E^*M)M]4T;4+75=-N4#PW=G*LL4BGN&4D&K\D*S1LCJ'5A@J
MPR#^%?/7Q$^']S\ ]0N_B5\.+-H=*C=KOQ1X.LU M]2@ _>75O'TCN8Q\_RX
M$@4@C.#1H]@/HJBLSP_KUCXHT/3]9TRX6[T[4+>.ZMIT/RR1NH96'U!%:=(
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MT^&GB#PYX'\/:S,7NM:MUCNWD>W<-(T2L?+A&%4,QY8FONA>E93Z$BT445D
M4R3[C?3O3Z9)Q&><<>F: ,GP[Y<.@VF!;11B/_EUF,L0'^RYP2/>O _BU^V3
MHO@Z\FTOPS;+XAU",E)+C?MMHV'8$<OCVX]ZYO\ :G^-%SX=\*Z9X/T>\87F
MH6_G7MU%!]F(@)("!.J%B.1Z#WKX]]/2OTWAKA>&.@L7C/A>RVOYLWC#JSW#
M4/VR/B3>S,\5[I]E&3E8X;,''XL2357_ (:\^)O_ $&+;_P#2O&:*_3H\/Y7
M%65"/W&MEV/9O^&O/B;_ -!BV_\  -*/^&O/B;_T&+;_ , TKQFBG_8.6?\
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M!&H?#OX>>#KA]1B@UYT6_P!2NRNU"(T)V(HYY/8^O"Z*^UA'V OW12TE+7*
M4444 %%%% !1110 REKRCXI?M%>%_A;JB:3=&ZU/6G4.-.T^+S)%!Z;NPSU
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MK\*SX(NP(M7\$WDWAZ[MR,$+$Q\A\=U>$QL#T.37,^(? _C+]G'Q%>ZY\*-
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M#K5I'?Z3J,#V]U;2C*R1L,$?_7[<5M44 ?.>A^/-?_9L5/#?Q"CU#6_!%O\
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M#H*+I; 4M'T>S\/Z39Z7I]M':6%G"EO;V\0PL<:KM50/0  ?A5^BBD 4444
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MH_UORG^?\'_D%X]SY!HKZ^_X8&B_Z&^;_P  U_\ BJ/^&!HO^AOF_P# -?\
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M^_Z&*/\ \!IO_B*.5]@/2**\W_X:(^'W_0Q1_P#@--_\11_PT1\/O^ABC_\
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MABC_ / :;_XBCE?81Z117F__  T1\/O^ABC_ / :;_XBC_AHCX??]#%'_P"
MTW_Q%'*^P'I%%>;_ /#1'P^_Z&*/_P !IO\ XBC_ (:(^'W_ $,4?_@--_\
M$4<K[ >D45YO_P -$?#[_H8H_P#P&F_^(H_X:(^'W_0Q1_\ @--_\11ROL!Z
M117F_P#PT1\/O^ABC_\  :;_ .(H_P"&B/A]_P!#%'_X#3?_ !%'*^P'I%%>
M;_\ #1'P^_Z&*/\ \!IO_B*/^&B/A]_T,4?_ (#3?_$4<K[ >D5E8?\ X20M
MLD\O[*!YGVCY,[SQY7K_ +?X5QG_  T1\/O^ABC_ / :;_XBLO\ X7]\/O\
MA(C<?\)!8X^RB/=]EG^T??SC.S&S^N:.678#URBO-_\ AHCX>_\ 0QQ_^ T_
M_P 11_PT1\/O^ABC_P# :;_XBIY9=@/2**\W_P"&B/A]_P!#%'_X#3?_ !%'
M_#1'P^_Z&*/_ ,!IO_B*KE?8#TBBO-_^&B/A]_T,4?\ X#3?_$4?\-$?#[_H
M8H__  &F_P#B*.5]@/2**\W_ .&B/A]_T,4?_@--_P#$4?\ #1'P^_Z&*/\
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M^_Z&*/\ \!IO_B*.5]@/2**\W_X:(^'W_0Q1_P#@--_\11_PT1\/O^ABC_\
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MI%%>;_\ #1'P^_Z&*/\ \!IO_B*/^&B/A]_T,4?_ (#3?_$4<K[ >D45YO\
M\-$?#[_H8H__  &F_P#B*/\ AHCX??\ 0Q1_^ TW_P 11ROL!Z14<GW&]<>N
M*\[_ .&B/A__ -#%'_X#S?\ Q%,D_:&^'S*P_P"$BC)QWMI__B*.5]AV.W\/
M))'HMJLD<D3A.4EN//8>QD'WOK6I7DOAW]H#X?6NBVD1\06*%$ VV-K.(?\
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M $,4?_@--_\ $4<K[ >D45YO_P -$?#[_H8H_P#P&F_^(H_X:(^'W_0Q1_\
M@--_\11ROL!Z117F_P#PT1\/O^ABC_\  :;_ .(H_P"&B/A]_P!#%'_X#3?_
M !%'*^P'I%%>;_\ #1'P^_Z&*/\ \!IO_B*/^&B/A]_T,4?_ (#3?_$4<K[
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M6U65YDG_  D!3_2O)^R[L;%^S[M_][KOQVZ8H U:*** "BBB@ HHHH ****
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MUVT6VN+/1[""[F^TW<4$:33?\]'"@,WXG)_&LJRV9++]%%%<X@HHHH ****
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MQ*T:#X*6?PKN?MUEX[T&WOFU'2[JPFB,($[]79-ASO7 SD\^E> >*+.[L?\
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M"JIR9&+<#&, DFM#X'?M0^&OCEKFN:!::7K?ACQ1HH62]T/Q%9_9KI(V.%D
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M+;?]"7<?^!Z?_$5\:T4?V7A/Y?Q#_7+-_P"=?<C[*_X>"VW_ $)=Q_X'I_\
M$4?\/!;;_H2[C_P/3_XBOC6BC^R\)_+^(?ZY9O\ SK[D?97_  \%MO\ H2[C
M_P #T_\ B*/^'@MM_P!"7<?^!Z?_ !%?&M%']EX3^7\0_P!<LW_G7W(^RO\
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MK)Y2[A>%3,#C^/;QN]<<5I5D^'/+70M/\H0B/R$VBWE,L6-H^XYY8>_>M:@
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M)\)^-M$\0:E:@F6UT^]220 '!8 'D#U&1S2M(#NOL<)F2;RH_-0;4DVC<%]
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M:?,V#=]L"B;./XPO&[Z<5<N,>1)D<;3U;;V]>U4/#ZHNB62QK&J")<+%.9D
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M/;NQG.*]"-9>SA%O9ZGRLLOE]9Q%50TE%)>MF?*&FY_X8)NO^NA_]+EKZ9^
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M .!L'_Q='_#(OQ4_Z%M?_ V#_P"+I?6\/_.OO%_869?\^)?<>.T5[#_PR/\
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M_P 71]<P_P#.@_L+,O\ GQ+[CQZBO8?^&1_BI_T+:_\ @;!_\71_PR/\5/\
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M,#@#I1[5\16JRKU'4ENS^@\#@Z>7X>&'I+2*)****R/0"BBB@ HHHH ****
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MYS,G^L;/SGOZCL<CM6Q65X?D\S2T8/O^>0;OLQM_XV_@/(^O?KWK5H ****
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MK,#R* .HHKB_^%T> /\ H=_#O_@U@_\ BZ/^%T> /^AW\._^#6#_ .+HY7V
M[2BN+_X71X _Z'?P[_X-8/\ XNC_ (71X _Z'?P[_P"#6#_XNCE?8#M**XO_
M (71X _Z'?P[_P"#6#_XNC_A='@#_H=_#O\ X-8/_BZ.5]@.THKB_P#A='@#
M_H=_#O\ X-8/_BZ/^%T> /\ H=_#O_@U@_\ BZ.5]@.THKB_^%T> /\ H=_#
MO_@U@_\ BZ/^%T> /^AW\._^#6#_ .+HY7V [2BN+_X71X _Z'?P[_X-8/\
MXNC_ (71X _Z'?P[_P"#6#_XNCE?8#M**XO_ (71X _Z'?P[_P"#6#_XNC_A
M='@#_H=_#O\ X-8/_BZ+/L!VE%<7_P +H\ ?]#OX=_\ !K!_\71_PNCP!_T.
M_AW_ ,&L'_Q=.S Z'0UD73U$JW"ON?BZ97D^\<9*\8QC'MBM.O.M#^+7@&PT
MU(3XQ\+6^UY&\NWUB%DY=CG);.3G)]R:T?\ A='@#_H=_#O_ (-8/_BZ+,#M
M**XO_A='@#_H=_#O_@U@_P#BZ/\ A='@#_H=_#O_ (-8/_BZ7*^P':45Q?\
MPNCP!_T._AW_ ,&L'_Q='_"Z/ '_ $._AW_P:P?_ !='*^P':45Q?_"Z/ '_
M $._AW_P:P?_ !='_"Z/ '_0[^'?_!K!_P#%T<K[ =I17%_\+H\ ?]#OX=_\
M&L'_ ,71_P +H\ ?]#OX=_\ !K!_\71ROL!VE%<7_P +H\ ?]#OX=_\ !K!_
M\71_PNCP!_T._AW_ ,&L'_Q='*^P':45Q?\ PNCP!_T._AW_ ,&L'_Q='_"Z
M/ '_ $._AW_P:P?_ !=%GV [2LO;)_;Q;%UY7V8#=N7R-V\\;>N_'?IBN?\
M^%T> ?\ H=_#O_@VM_\ XNLS_A;'@+_A(#=_\)AX5V_9O*\[^UX?-^_G;C=C
M;WSUS3LP/1Z*XO\ X71X _Z'?P[_ .#6#_XNC_A='@#_ *'?P[_X-8/_ (NE
M9]@.THKB_P#A='@#_H=_#O\ X-8/_BZ/^%T> /\ H=_#O_@U@_\ BZ+/L!VE
M%<7_ ,+H\ ?]#OX=_P#!K!_\71_PNCP!_P!#OX=_\&L'_P 719]@.THKB_\
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M#-&$82$@D   C!%<G^TM^R-X5_:8F\.W>KW=YH^K:)<"2#4-/5#(\>X,87W
M@IN53Z@CCK7HO_"Z/ '_ $._AW_P:P?_ !='_"Z/ '_0[^'?_!K!_P#%T)R3
MT X[XU?LV:7\8KK0M5C\1:]X1\4Z$C1Z=KFA79CEB5\;U9#E'!P,Y%9/PG_9
M5A\#_$0^/?%'C?Q!\1O%T-JUE97^N-&B64+'+K%'& H+=S7H_P#PN?P!_P!#
MQX=_\&L'_P 71_PN?P!_T/'AW_P:P?\ Q=%YVL,\=\1?L6VL7C#5O$/P[^(7
MBCX63ZS*9]3LM!DC:SN9#UD$4BD(QYY7UKK_ (>_LTZ1\/? /BSPZ/$&O:Y>
M^*8YAJVN:Q>&XN9I)(C&9 #\BX4]  .!G-=G_P +H\ ?]#OX=_\ !K!_\71_
MPNCP!_T._AW_ ,&L'_Q=/FD] U/GOPO^PGXA\$^'K+0=!_:#^(6D:/8Q"&UL
M[8VJQPH.BJ/+Z<FN\^*'[)FC_$>^T'7[?Q/KWA?Q_H]FME'XNT6=8KNYC  (
MG4C9("03@CN>U>D?\+G\ ?\ 0\>'?_!K!_\ %T?\+G\ ?]#QX=_\&L'_ ,71
MS3O<#SOX5?LN_P#"">/$\:>)/B#XJ^(/B6&W>TM;C6KH)!;1/C<JP1A4R<=2
M#^=>\5Q?_"Z/ '_0[^'?_!K!_P#%T?\ "Z/ '_0[^'?_  :P?_%U+YI;B.TH
MKB_^%T> /^AW\._^#6#_ .+H_P"%T> /^AW\._\ @U@_^+I<K[ =I3)/NL.>
MG;K7'?\ "Z/ '_0[^'?_  :P?_%TV3XS> &5A_PFWATY'0ZK!_\ %T^5]@.D
MT-9(])MEF6Y60)\RW;J\O_ BO!/TK2KSKP_\6/ .GZ/:VY\8^%;<QICR[75X
M6C7V4E\D5H_\+H\ ?]#OX=_\&L'_ ,72L^P':45Q?_"Z/ '_ $._AW_P:P?_
M !='_"Z/ '_0[^'?_!K!_P#%T<K[ =I17%_\+H\ ?]#OX=_\&L'_ ,71_P +
MH\ ?]#OX=_\ !K!_\71ROL!VE%<7_P +H\ ?]#OX=_\ !K!_\71_PNCP!_T.
M_AW_ ,&L'_Q='*^P':45Q?\ PNCP!_T._AW_ ,&L'_Q='_"Z/ '_ $._AW_P
M:P?_ !='*^P':45Q?_"Z/ '_ $._AW_P:P?_ !='_"Z/ '_0[^'?_!K!_P#%
MT<K[ =I17%_\+H\ ?]#OX=_\&L'_ ,71_P +H\ ?]#OX=_\ !K!_\71ROL!V
ME%<7_P +H\ ?]#OX=_\ !K!_\71_PNCP!_T._AW_ ,&L'_Q='*^P':45Q?\
MPNCP!_T._AW_ ,&L'_Q='_"Z/ '_ $._AW_P:P?_ !='*^P':45Q?_"Z/ '_
M $._AW_P:P?_ !='_"Z/ '_0[^'?_!K!_P#%T<K[ =I67<+(=8LRJW)C$<@9
MD=1"#E<;QU)],=.:Y_\ X71X _Z'?P[_ .#6#_XNLVX^+/@*36[*Y'C'PJPB
MCD7SGU>'S$W;>%&_&#CGZ"BS[ >C45Q?_"Z/ '_0[^'?_!K!_P#%T?\ "Z/
M'_0[^'?_  :P?_%T<K[ =I17%_\ "Z/ '_0[^'?_  :P?_%T?\+H\ ?]#OX=
M_P#!K!_\71ROL!VE%<7_ ,+H\ ?]#OX=_P#!K!_\71_PNCP!_P!#OX=_\&L'
M_P 71ROL!VE%<7_PNCP!_P!#OX=_\&L'_P 71_PNCP!_T._AW_P:P?\ Q='*
M^P':45Q?_"Z/ '_0[^'?_!K!_P#%T?\ "Z/ '_0[^'?_  :P?_%T<K[ =I17
M%_\ "Z/ '_0[^'?_  :P?_%T?\+H\ ?]#OX=_P#!K!_\71ROL!VE%<7_ ,+H
M\ ?]#OX=_P#!K!_\71_PNCP!_P!#OX=_\&L'_P 71ROL!VE%<7_PNCP!_P!#
MOX=_\&L'_P 71_PNCP!_T._AW_P:P?\ Q='*^P':45Q?_"Z/ '_0[^'?_!K!
M_P#%T?\ "Z/ '_0[^'?_  :P?_%T<K[ =I17%_\ "Z/ '_0[^'?_  :P?_%T
M?\+H\ ?]#OX=_P#!K!_\719]@.OF_P!4^-Q.#C;U_"J>BK(NDVHE6X20(-RW
M3!Y0<?Q$<$_2N9F^,G@"2-U'C;PXQ*D8;5H,?^AU3T/XM> K'2;6 ^,_"\!C
M0+Y5OJ\+1K@=%)?./K3LP/0Z*XO_ (71X _Z'?P[_P"#6#_XNC_A='@#_H=_
M#O\ X-8/_BZ7*^P':45Q?_"Z/ '_ $._AW_P:P?_ !='_"Z/ '_0[^'?_!K!
M_P#%T<K[ =I17%_\+H\ ?]#OX=_\&L'_ ,71_P +H\ ?]#OX=_\ !K!_\71R
MOL!VE%<7_P +H\ ?]#OX=_\ !K!_\71_PNCP!_T._AW_ ,&L'_Q='*^P':45
MQ?\ PNCP!_T._AW_ ,&L'_Q='_"Z/ '_ $._AW_P:P?_ !='*^P':45Q?_"Z
M/ '_ $._AW_P:P?_ !='_"Z/ '_0[^'?_!K!_P#%T<K[ =I17%_\+H\ ?]#O
MX=_\&L'_ ,71_P +H\ ?]#OX=_\ !K!_\71ROL!VE%<7_P +H\ ?]#OX=_\
M!K!_\71_PNCP!_T._AW_ ,&L'_Q='*^P':45Q?\ PNCP!_T._AW_ ,&L'_Q=
M'_"Z/ '_ $._AW_P:P?_ !='*^P':45Q?_"Z/ '_ $._AW_P:P?_ !='_"Z/
M '_0[^'?_!K!_P#%T6?8#H9ED.LV[!;DQ>4X+*ZB+.1C<O4MUP>F,UIUYU-\
M6O ,FM6US_PF/A9@D3IYS:O#YHR5. -V-IQS[@5H_P#"Z/ '_0[^'?\ P:P?
M_%T[,#M**XO_ (71X _Z'?P[_P"#6#_XNC_A='@#_H=_#O\ X-8/_BZ7*^P'
M:45Q?_"Z/ '_ $._AW_P:P?_ !='_"Z/ '_0[^'?_!K!_P#%T<K[ =I17%_\
M+H\ ?]#OX=_\&L'_ ,71_P +H\ ?]#OX=_\ !K!_\71ROL!VE%<7_P +H\ ?
M]#OX=_\ !K!_\71_PNCP!_T._AW_ ,&L'_Q='*^P':45Q?\ PNCP!_T._AW_
M ,&L'_Q='_"Z/ '_ $._AW_P:P?_ !='*^P':45Q?_"Z/ '_ $._AW_P:P?_
M !='_"Z/ '_0[^'?_!K!_P#%T<K[ =I17%_\+H\ ?]#OX=_\&L'_ ,71_P +
MH\ ?]#OX=_\ !K!_\71ROL!VE%<7_P +H\ ?]#OX=_\ !K!_\71_PNCP!_T.
M_AW_ ,&L'_Q='*^P':45Q?\ PNCP!_T._AW_ ,&L'_Q='_"Z/ '_ $._AW_P
M:P?_ !='*^P':45@>'_&WAWQ<\RZ'KNFZPT('F"PNXYRF>F[:3C.._I6]0 M
M9=YX<TK4)C-<Z99W$S<&2:W1V./<BM2B@#&_X0_0O^@)IW_@)'_A1_PA^A?]
M 33O_ 2/_"MFBG=@8W_"'Z%_T!-._P# 2/\ PH_X0_0O^@)IW_@)'_A6S11=
M@8W_  A^A?\ 0$T[_P !(_\ "C_A#]"_Z FG?^ D?^%;-%%V!C?\(?H7_0$T
M[_P$C_PH_P"$/T+_ * FG?\ @)'_ (5LT478&-_PA^A?] 33O_ 2/_"C_A#]
M"_Z FG?^ D?^%;-%%V!C?\(?H7_0$T[_ ,!(_P#"C_A#]"_Z FG?^ D?^%;-
M%%V!C?\ "'Z%_P! 33O_  $C_P */^$/T+_H":=_X"1_X5LT478&-_PA^A?]
M 33O_ 2/_"C_ (0_0O\ H":=_P" D?\ A6S11=@<IH?A?1+C34=]*LIG+N-\
MNG)"W#D#Y".W SWQGO6E_P (?H7_ $!-._\  2/_  J70XY8=/19DN(Y-\F5
MN91*^-YQ\P[8Z>@P*U*+L#&_X0_0O^@)IW_@)'_A1_PA^A?] 33O_ 2/_"MF
MBB[ QO\ A#]"_P"@)IW_ ("1_P"%'_"'Z%_T!-._\!(_\*V:*+L#&_X0_0O^
M@)IW_@)'_A1_PA^A?] 33O\ P$C_ ,*V:*+L#&_X0_0O^@)IW_@)'_A1_P (
M?H7_ $!-._\  2/_  K9HHNP,;_A#]"_Z FG?^ D?^%'_"'Z%_T!-._\!(_\
M*V:*+L#&_P"$/T+_ * FG?\ @)'_ (4?\(?H7_0$T[_P$C_PK9HHNP,;_A#]
M"_Z FG?^ D?^%8T_AG15\0>3_95CL^R[_)_LQ-F=^-WF[<9[;/QKL?K6)<12
M_P!O>9LN/(^R[0_G#R=V_IY?7?C^+TXI-NPT5/\ A$]"_P"@+IO_ (!Q?X4?
M\(GH7_0%TW_P#B_PK4HK'F91E_\ ")Z%_P! 73?_  #B_P */^$3T+_H"Z;_
M . <7^%:E%5S,#+_ .$3T+_H"Z;_ . <7^%'_")Z%_T!=-_\ XO\*U**.9@9
M?_")Z%_T!=-_\ XO\*/^$3T+_H"Z;_X!Q?X5J44<S R_^$3T+_H"Z;_X!Q?X
M4?\ ")Z%_P! 73?_  #B_P *U**.9@9?_")Z%_T!=-_\ XO\*3_A$]#_ .@+
MIO\ X!Q_X5JT5/,P,O\ X1/0O^@+IO\ X!Q?X4?\(GH7_0%TW_P#B_PK4HHY
MF!E_\(GH7_0%TW_P#B_PH_X1/0O^@+IO_@'%_A6I15<S R_^$3T+_H"Z;_X!
MQ?X4?\(GH7_0%TW_ , XO\*U**.9@9?_  B>A?\ 0%TW_P  XO\ "C_A$]"_
MZ NF_P#@'%_A6I11S,#+_P"$3T+_ * NF_\ @'%_A1_PB>A?] 73?_ .+_"M
M2BCF8&7_ ,(GH7_0%TW_ , XO\*/^$3T+_H"Z;_X!Q?X5J45/,P,O_A$]#_Z
M FF?^ <?^%'_  B>A?\ 0%TW_P  XO\ "M2BCF8&7_PB>A?] 73?_ .+_"C_
M (1/0O\ H"Z;_P" <7^%:E%',P,O_A$]"_Z NF_^ <7^%'_")Z%_T!=-_P#
M.+_"M2BJYF!E_P#")Z%_T!=-_P# .+_"C_A$]"_Z NF_^ <7^%:E%',P,O\
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M+N(9CK=DZI<&%8Y [+,!$"2N-R=6/7![<^M&H$7_  A^A?\ 0$T[_P !(_\
M"C_A#]"_Z FG?^ D?^%;-%%V!C?\(?H7_0$T[_P$C_PH_P"$/T+_ * FG?\
M@)'_ (5LT478&-_PA^A?] 33O_ 2/_"C_A#]"_Z FG?^ D?^%;-%%V!C?\(?
MH7_0$T[_ ,!(_P#"C_A#]"_Z FG?^ D?^%;-%%V!C?\ "'Z%_P! 33O_  $C
M_P */^$/T+_H":=_X"1_X5LT478&-_PA^A?] 33O_ 2/_"C_ (0_0O\ H":=
M_P" D?\ A6S11=@8W_"'Z%_T!-._\!(_\*/^$/T+_H":=_X"1_X5LT478&-_
MPA^A?] 33O\ P$C_ ,*/^$/T+_H":=_X"1_X5LT478&-_P (?H7_ $!-._\
M 2/_  H_X0_0O^@)IW_@)'_A6S11=@8W_"'Z%_T!-._\!(_\*/\ A#]"_P"@
M)IW_ ("1_P"%;-%%V!A3>$-"6%S_ &-IX(!.19H>WICFJ>B^%-$N-*M9'TFR
ME=XU8R2:<D+,2.I0K\I]NU=),"T;  DX.-IP?P-4M"BEBTJU2=9TE5 &6XE$
ML@./XG'WC[T78$'_  A^A?\ 0$T[_P !(_\ "C_A#]"_Z FG?^ D?^%;-%%V
M!C?\(?H7_0$T[_P$C_PH_P"$/T+_ * FG?\ @)'_ (5LT478&-_PA^A?] 33
MO_ 2/_"C_A#]"_Z FG?^ D?^%;-%%V!C?\(?H7_0$T[_ ,!(_P#"C_A#]"_Z
M FG?^ D?^%;-%%V!C?\ "'Z%_P! 33O_  $C_P */^$/T+_H":=_X"1_X5LT
M478&-_PA^A?] 33O_ 2/_"C_ (0_0O\ H":=_P" D?\ A6S11=@8W_"'Z%_T
M!-._\!(_\*/^$/T+_H":=_X"1_X5LT478&-_PA^A?] 33O\ P$C_ ,*/^$/T
M+_H":=_X"1_X5LT478&-_P (?H7_ $!-._\  2/_  H_X0_0O^@)IW_@)'_A
M6S11=@8W_"'Z%_T!-._\!(_\*/\ A#]"_P"@)IW_ ("1_P"%;-%%V!R<WA71
M%UJVA&E601HG)C&FH48AEP3)MPI'/R]^O:M/_A#]"_Z FG?^ D?^%2SQRMK5
MM(J7'D+$^YEE BW$K@,G4MZ'M@^M:E%V!C?\(?H7_0$T[_P$C_PH_P"$/T+_
M * FG?\ @)'_ (5LT478&-_PA^A?] 33O_ 2/_"C_A#]"_Z FG?^ D?^%;-%
M%V!C?\(?H7_0$T[_ ,!(_P#"C_A#]"_Z FG?^ D?^%;-%%V!C?\ "'Z%_P!
M33O_  $C_P */^$/T+_H":=_X"1_X5LT478&-_PA^A?] 33O_ 2/_"C_ (0_
M0O\ H":=_P" D?\ A6S11=@8W_"'Z%_T!-._\!(_\*/^$/T+_H":=_X"1_X5
MLT478&-_PA^A?] 33O\ P$C_ ,*/^$/T+_H":=_X"1_X5LT478&-_P (?H7_
M $!-._\  2/_  H_X0_0O^@)IW_@)'_A6S11=@8W_"'Z%_T!-._\!(_\*/\
MA#]"_P"@)IW_ ("1_P"%;-%%V!GV&AZ?I9<V5C;69?&XV\*INQTS@<UH444@
M"BBB@ HI,BEH ***PK[QCHFF>)M-\/W6JVMOK>I1R2V=A)(!-.L8R[(O4@9Y
MH W:**3(H 6BBB@ HHHH **** "BBB@ HHHH QO"_D?V-']F%F(O,EQ]@;,6
M?,;.#ZYSGWS6S69HDC36*/)))*^^0%I8?*;AS_#],<]P >]:610 M%)D4M !
M1110 4444 %%%% !1110 4444 )]:YZX\C_A+#Q9_:OL(YW?Z5L\P]O^>>>_
MK70_6L6XF<Z]Y?F2;/LV[R_(^3._&[S/7_9].:3V&BQ1116!04444 %%%% !
M1110 4444 %%%% !1110 4444 %%%'X8H **** "BBB@ HHHH **,%<9&!10
M 44FZEH **/UHH **** "BBB@ HHHH **/UH_#% !1110 4444 %%%% !111
M0 4444 9T_V?_A(])WBR^T>7-Y9F;_2,87/E#N/[WX5TE81F=-:LHUEE6-DD
MW1K!N1L!<;G_ (,=AWR?2MVMH[$L****H04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !4<N/+;.,8_BZ5)3)/NDYP<>F: ,KPKY'_"/6/V868@\
MOY/[/;,&/]@^E;%9N@R/-I%L\LDDKLF2\T'DN?JG\/TK2H **** "BBB@ HH
MHH **** "BBB@ HHI* %HI,TM !1124 +1110 5B7GV?_A)M.WBR-SY,WE^8
MW^D;<IG8.Z]-W_ :VZS+B1UUJSC$D@1HY"8U@W(Q!7!,G\)'IWS[4 :=%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $-QCR)-VW;M.
M=_W>G?VK.\,^3_8-A]F%H(/*79]A.8,8XV'^[Z5I3?+&Y!(.T\@9_2J>BL\V
MDVKRO)*[1J2\L/DN3CJ4_A/MVH T:*** "BBB@ HHHH **** "BBB@ HHHH
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M!/XQ?#GX$_LHZ3XK3Q%XIUSP=)JSVBZGX@ FO5DEN#'\XW?+&K ]^!DUD?\
M!/\ ^)OA>X_9XTOX?)K5J/&VCVVH-?Z"S;;NV"W$@)>,\K]]?SKYT\0,C?\
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MM^U?\4?#MI-;^ M9\.O8Z??21-%'J<\-I*);A 0,KT&[OGUKFX[.^T']G?\
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M?'&O>&?&>L>.=.\3>---NKK4M:LA:&687422.B[5#*_#;@,'->^?M[V\%KX
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M_P -L?#3_G]OO_ )Z_/*BG_8^'[L7^O>8_RQ^Y_YGZ&?\-L?#/\ Y_K[_P
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MP&CS\QZX..,'UK4K&O/L_P#PDFG[A9_:/)EV>8O^D;<KG8>R],_A0!LT444
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MVLH[2!+1@0UNL2B,@]05QCGFG2Z;:W%D;*6VADLRNPV[QJ8RH[;<8Q[5<HH
MS;/0=-TY8%M-.M;98,^4L,"H(\]=N!QGOBI[>RM[62:2""*%YFWRM&@4NWJQ
M'4_6JK>(M+BUR+17U*T36)(C<1Z>TZBX:('!<1YW%0>-V,5Q6K_&[1M)^.&B
M_"Z:PU9];U739-3AO([0FR2-"V5>7LWR-VQRH/WA3U [FWT+3;.^GO8-.M8;
MV?\ UMQ' JR2?[S 9/XUY#^U-\";_P"-WPCB\)>')M/TB=-7LM15KE62$+#.
M)'&$4G) /;J:]OHH4FG<#-AT'3+?4)+Z'3K2*^D_UERD"K*V?5@,G\ZL&QMV
MNEN3!&;E5*+,4&\*>P/7%6J*+@9FI>']+UAHFO\ 3;2^>/[C7,"R%?H6!Q5]
M5$:A0-JC@ #BI**0!1110 GUK$N))/\ A(-F^?R?LN[9Y*^3NW]=_7=_L],<
MUM_6L2XC;_A("^R3;]EQYGVD[,[^GE9QG_;QTXI/8:+-%%%8%!1110 4444
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M74C,T@/VQ%23&X]0H QCI[8KY;\,? 7XW? V;7?#'PN\3>%)/ >J:A/?6/\
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M^,/#UKIRHVLZ3;L'D/EKJ:3 9<G[Q.>>N.V<=JT?^$Z\.?\ 0P:7_P"!L?\
M\518#=HK"_X3KPY_T,&E_P#@;'_\51_PG7AS_H8-+_\  V/_ .*HLP-VBL+_
M (3KPY_T,&E_^!L?_P 51_PG7AS_ *&#2_\ P-C_ /BJ+,#=HK"_X3KPY_T,
M&E_^!L?_ ,51_P )UX<_Z&#2_P#P-C_^*HLP-VBL+_A.O#G_ $,&E_\ @;'_
M /%4?\)UX<_Z&#2__ V/_P"*HLP-VBL+_A.O#G_0P:7_ .!L?_Q5'_"=>'/^
MA@TO_P #8_\ XJBS W:*PO\ A.O#G_0P:7_X&Q__ !5'_"=>'/\ H8-+_P#
MV/\ ^*HLP-QJQKCS/[< W71A^S_=VI]GW;O7&[?CMG&/>H_^$X\.?]#!I?\
MX&Q__%5D3^+M ;7O/&KZ3M^R[//_ +43=G?G;Y><8[[NO:DT[#1T5%8__"8^
M'_\ H/:7_P"!T7_Q5'_"9>'_ /H/:5_X'1?_ !58\K*-BBL?_A,O#_\ T'M*
M_P# Z+_XJC_A,O#_ /T'M*_\#HO_ (JCE8&Q16/_ ,)EX?\ ^@]I7_@=%_\
M%4?\)EX?_P"@]I7_ ('1?_%4<K V**Q_^$R\/_\ 0>TK_P #HO\ XJC_ (3+
MP_\ ]![2O_ Z+_XJCE8&Q16/_P )EX?_ .@]I7_@=%_\51_PF7A__H/:5_X'
M1?\ Q5'*P-BBL?\ X3+P_P#]![2O_ Z+_P"*H_X3+P__ -![2O\ P.B_^*HY
M6!L45C_\)EX?_P"@]I7_ ('1?_%4?\)EX?\ ^@]I7_@=%_\ %4<K V**Q_\
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M_"9>'_\ H/:5_P"!T7_Q5'_"9>'_ /H/:5_X'1?_ !5'*P-BBL?_ (3+P_\
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M'_\ %4?\)UX<_P"A@TO_ ,#8_P#XJBS W:*PO^$Z\.?]#!I?_@;'_P#%4?\
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MJC_A.O#G_0P:7_X&Q_\ Q5%F!NT5A?\ "=>'/^A@TO\ \#8__BJ/^$Z\.?\
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MI?\ X&Q__%468&[16%_PG7AS_H8-+_\  V/_ .*H_P"$Z\.?]#!I?_@;'_\
M%468&[16%_PG7AS_ *&#2_\ P-C_ /BJ/^$Z\.?]#!I?_@;'_P#%468&[16%
M_P )UX<_Z&#2_P#P-C_^*H_X3KPY_P!#!I?_ (&Q_P#Q5%F!NT5A?\)UX<_Z
M&#2__ V/_P"*H_X3KPY_T,&E_P#@;'_\519@;M%87_"=>'/^A@TO_P #8_\
MXJC_ (3KPY_T,&E_^!L?_P 519@;M%87_"=>'/\ H8-+_P# V/\ ^*H_X3KP
MY_T,&E_^!L?_ ,519@;$N?+;&[.#]WK^&:IZ.TATNV,K7+R;/F:\55E)Q_$%
M 4'Z#%9\WCCPZT+ :_I;9!P/MT8S[9W53T7QEX>M=*M8FUG2;=EC4&%=224)
MQT#DY;ZFBP'6T5A?\)UX<_Z&#2__  -C_P#BJ/\ A.O#G_0P:7_X&Q__ !5%
MF!NT5A?\)UX<_P"A@TO_ ,#8_P#XJC_A.O#G_0P:7_X&Q_\ Q5%F!NT5A?\
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M7_"=>'/^A@TO_P #8_\ XJC_ (3KPY_T,&E_^!L?_P 519@;M%87_"=>'/\
MH8-+_P# V/\ ^*H_X3KPY_T,&E_^!L?_ ,519@6I?,_MB#:UUY?EOE45/)SE
M<;CC=N],'&,Y[5IUR$WC#P\VM6LPUG2F58G4S?VD@*Y*_+Y><$''WNHQCO6E
M_P )UX<_Z&#2_P#P-C_^*HLP-VBL+_A.O#G_ $,&E_\ @;'_ /%4?\)UX<_Z
M&#2__ V/_P"*HLP-VBL+_A.O#G_0P:7_ .!L?_Q5'_"=>'/^A@TO_P #8_\
MXJBS W:*PO\ A.O#G_0P:7_X&Q__ !5'_"=>'/\ H8-+_P# V/\ ^*HLP-VB
ML+_A.O#G_0P:7_X&Q_\ Q5'_  G7AS_H8-+_ / V/_XJBS W:*PO^$Z\.?\
M0P:7_P"!L?\ \51_PG7AS_H8-+_\#8__ (JBS W:*PO^$Z\.?]#!I?\ X&Q_
M_%4?\)UX<_Z&#2__  -C_P#BJ+,#=HK"_P"$Z\.?]#!I?_@;'_\ %4?\)UX<
M_P"A@TO_ ,#8_P#XJBS W:*PO^$Z\.?]#!I?_@;'_P#%4?\ "=>'/^A@TO\
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M .*H_P"&*?@=_P!$TT3_ +]M_P#%5[=11S/N!XC_ ,,4_ [_ *)IHG_?MO\
MXJC_ (8I^!N<_P#"M-$S_P!<V_\ BJ]NHHYGW \1_P"&*?@=_P!$TT3_ +]M
M_P#%4?\ #%/P._Z)IHG_ '[;_P"*KVZBCF?<#Q'_ (8I^!W_ $331/\ OVW_
M ,51_P ,4_ [_HFFB?\ ?MO_ (JO;J*.9]P/$?\ ABGX'?\ 1--$_P"_;?\
MQ5'_  Q3\#O^B::)_P!^V_\ BJ]NHHYGW \1_P"&*?@=_P!$TT3_ +]M_P#%
M4?\ #%/P._Z)IHG_ '[;_P"*KVZBCF?<#Q'_ (8I^!W_ $331/\ OVW_ ,51
M_P ,4_ [_HFFB?\ ?MO_ (JO;J*.9]P/$?\ ABGX'?\ 1--$_P"_;?\ Q5'_
M  Q3\#O^B::)_P!^V_\ BJ]NHHYGW \1_P"&*?@=_P!$TT3_ +]M_P#%4?\
M#%/P._Z)IHG_ '[;_P"*KVZBCF?<#Q'_ (8I^!W_ $331/\ OVW_ ,51_P ,
M4_ [_HFFB?\ ?MO_ (JO;J*.9]P/$?\ ABGX'?\ 1--$_P"_;?\ Q5'_  Q3
M\#O^B::)_P!^V_\ BJ]NHHYGW \1_P"&*?@=_P!$TT3_ +]M_P#%4?\ #%/P
M._Z)IHG_ '[;_P"*KVZBCF?<#Q'_ (8I^!W_ $331/\ OVW_ ,51_P ,4_ [
M_HFFB?\ ?MO_ (JO;J*.9]P/$?\ ABGX'?\ 1--$_P"_;?\ Q5'_  Q3\#O^
MB::)_P!^V_\ BJ]NHHYGW \1_P"&*?@=_P!$TT3_ +]M_P#%4?\ #%/P._Z)
MIHG_ '[;_P"*KVZBCF?<#Q'_ (8I^!W_ $331/\ OVW_ ,51_P ,4_ [_HFF
MB?\ ?MO_ (JO;J*.9]P/$?\ ABGX'?\ 1--$_P"_;?\ Q5'_  Q3\#O^B::)
M_P!^V_\ BJ]NHHYGW \1_P"&*?@=_P!$TT3_ +]M_P#%4?\ #%/P._Z)IHG_
M '[;_P"*KVZBCF?<#Q'_ (8I^!W_ $331/\ OVW_ ,51_P ,4_ [_HFFB?\
M?MO_ (JO;J*.9]P/$?\ ABGX'?\ 1--$_P"_;?\ Q5'_  Q3\#O^B::)_P!^
MV_\ BJ]NHHYGW \1_P"&*?@=_P!$TT3_ +]M_P#%4?\ #%/P._Z)IHG_ '[;
M_P"*KVZBCF?<#Q'_ (8I^!W_ $331/\ OVW_ ,51_P ,4_ [_HFFB?\ ?MO_
M (JO;J*.9]P/$?\ ABGX'?\ 1--$_P"_;?\ Q5'_  Q3\#O^B::)_P!^V_\
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M^*KVZBCF?<#Q'_ABGX'?]$TT3_OVW_Q5'_#%/P._Z)IHG_?MO_BJ]NHHYGW
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MFMR@ HHHH ***P_$'BRP\-7>CV]Z9!)JEV+*W\M"P\PJS#/H,*>: -RBBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O _C%I.M?$;Q]%HECH(UK1]'TZ1[E9[K[*GVFZ1XXV5RK!FC0,PQT+C
MVKWRN<U_Q]X;\*7D5KK6NZ?I5S(GF)%=W*1,RYQD GIG/Y41T>@'SUKU\VO:
M-\*SXPL]31=)NKW3]=%G'*65H8O++,T8W&-L*Q(ZAOK61JUB)])MO)@UU_A]
M'XPADT_8LYN%M/LS_:"F?WHBWYQWP6Q7U/J7BG1]'T4:O?:K9VNELJLMY+<*
ML)!Z8?.#GMCK4.G^,M!U;19=8LM8L;O2H5+27D,ZO$@49;<P.!@>M6I>0'S=
MJ5E)>>%?'%MX3?6(?!DVHZ2FFOF=664S*+DP%_G"8VY/3.<=Z9\5/")\/^-+
MG2GF;2?#L.F1)H;S1W]R(Y2SF5HC ^?.W[3\^21C'&:^D- \>>&_%32IHVO:
M=JC0KOD6TN4D*KZD \#WJYHOB32?$0N?[*U*TU+[-)Y4QM9ED$;X!VL5)P<$
M4<S[ >"^,+'Q9H=];:-97%Y?OXXTNTL)M15'46UW&%2><J>8]UN6;G'S(.]0
M>--,U33=1\=65LNK?\([!?:'#>BT:1I?[.6#$_ED?,>B[MG.-U?2S=*3TI<P
M'R-J/AW3/$4?Q1M/"UEJUWX>?PPDNG0S?:/*>Y5I"?($GS$;@..YSVKL[A=U
MQX /@(7 M_[(UH6_^M$?VKR(MF_S/^FF<;O?%?1%)ZT^<#Y=\%QVBZKX6/AE
M-=&N?9+G_A*_MXN/^>#;O/\ ,^7S/.QMV=LXXI?!?A&?PO9_"W4K6;6H+_6-
M+O(]9NO-FFD?_0V="R,2 RN%VC Y %?455)KR"WFACEGCADF;9$CN 7.,X4'
MJ< ]/2CF ^;_ (+-IUC%XJTJYANM2TJ/1]]YK5H+^)YA\P9)8)<E+G&6_=FO
M7-=T7_A(/@O?:5X9::+[9H;6^G?:&=),-!B,,7^8'D EN1GFN]]^E+]*EO6X
M'DGP^^)GAR;2O#7AE=+U"VU>WCCMY--?3)5^PO&F&9V*[548.'!YR,=:\MO(
M_%UWJ5[\38O#+2I#K*ZA;7OVG;<C2XE,!A%OLW'?&7?&022IQ7U']K@-T;43
M1_:53S##N&\*20&QUQGO5K^&FI6Z ?-/C33_ !C?>*OBG>>%Y@MA<6^F_:;;
M[%OGN[=K<B3[.[':) A;"E3DG'!KUSP'XH\-V]OH'A71Y[ABFBQ7=I%/"X;[
M*N(@6)  8$ $'G-=U_/Z5GKH]E'J\NJ+;1C4)(5MWN,?.8U)8)GTR2?QI.5U
M8#QGXN1Z6WQ,@/CE=2;PA_91&G_8Q<&'[9O/F;_)Y\S9LV9_VL<UR6J^ +3Q
M!<?$C5UAUI9=/T.PETAYIIXIUD6T9E<C(+2@JH.[)&2*^C;KQ'I]EKUEH\LY
M74;V.2:"+RV(94QO.X# QD=36O3YK ?+WCS^W-4T[Q;(7U%9[GPWHI$D.]6$
MK7 \PICHW)SCGUK6NO@SI'_"QM<T5(]6_L&/0DOH[<7]QY9O2[IYV=_,FT#O
MWSBOHK\*S%UZQ;7GT47*?VFEN+MK?G=Y18J'^FX$?A1S=@/DC6&\0:U9^&KG
MQ7>R6UG-X7L_L-Q>6][)B[*GSV46Y!$^=GWQR,8[UZIX,\&2ZQ\5A=^(;B^U
M272]!TR6":4S0Q/<YEW2F/(&_ &0V2,G->P0^(K"ZU^[T6.<G4K6&.XEA\M@
M%C<L%.[&#G:> <\5K?AFFY>0'R9H4<7]@^ ?^$_75CX0&D7/W1<;?M_VAL>?
MY?SY\O&S/&<U[C??;?\ A2=X/" U(7W]D2#3!J ?[7NV'9N\SYM_3&[VKT'^
M&E_SS2<K@?(/D:,NI>'&\()KXN!HFI+K'GBZ"?:?L3;?,\SCSMV_I[>U=CX+
M\")H>L?#^-!J<R>(/#UQ'KGVJXF<3MY,;)YF3\C EE&,''%?1U96L>(-/T%K
M%;^Y6V-]=)9VVX']Y,P)5!CN=I_*GS= /FGP'I]MIOPM\!66EV]Y;:O;>*M/
MCUF%4F5D<229#!N-NW&<?+ZUB^)HUT_33+K,'B.'XA-XCC%W> 7"VS6[7:A
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MQ-=I$20BGY>F_&<M7TRUC;26HMVMXF@Z"(Q@I],=*233[::W%O);Q/ ,8B9
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MQ/<?>56E<+O/(! SWKZ46TA54411A8SN10HPI]1Z=_SH>S@D65'AC=93EU9
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M=>%+B6SO8[TS$S"91'+YA)W$'C/ID5R5Q\3/&/BSP5XG\3Z3-=63Z'ID.F/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
I44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934488887168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>May 02, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lyell Immunopharma, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-1300510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Line</a></td>
<td class="text">201 Haskins Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">695-0677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LYEL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,939,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001806952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934488815792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 125,650<span></span>
</td>
<td class="nump">$ 145,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">400,650<span></span>
</td>
<td class="nump">400,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,865<span></span>
</td>
<td class="nump">8,463<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">534,165<span></span>
</td>
<td class="nump">554,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Other investments</a></td>
<td class="nump">19,000<span></span>
</td>
<td class="nump">32,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">97,836<span></span>
</td>
<td class="nump">102,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">38,695<span></span>
</td>
<td class="nump">39,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">4,238<span></span>
</td>
<td class="nump">4,235<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">694,220<span></span>
</td>
<td class="nump">750,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,895<span></span>
</td>
<td class="nump">4,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued liabilities and other current liabilities</a></td>
<td class="nump">24,914<span></span>
</td>
<td class="nump">28,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilitiesCurrent', window );">Success payment liabilities</a></td>
<td class="nump">2,544<span></span>
</td>
<td class="nump">1,576<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">32,353<span></span>
</td>
<td class="nump">34,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">55,159<span></span>
</td>
<td class="nump">56,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">3,551<span></span>
</td>
<td class="nump">3,664<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">91,063<span></span>
</td>
<td class="nump">95,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000 shares authorized at March&#160;31, 2024 and December&#160;31, 2023; no shares issued and outstanding at March&#160;31, 2024 and December&#160;31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 500,000 shares authorized at March&#160;31, 2024 and December&#160;31, 2023; 254,927 and 253,958 shares issued and outstanding at March&#160;31, 2024 and December&#160;31, 2023, respectively</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,666,315<span></span>
</td>
<td class="nump">1,657,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(404)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,062,779)<span></span>
</td>
<td class="num">(1,002,112)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">603,157<span></span>
</td>
<td class="nump">654,952<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 694,220<span></span>
</td>
<td class="nump">$ 750,029<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_SuccessPaymentLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success Payment Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_SuccessPaymentLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934574628432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="nump">254,927,000<span></span>
</td>
<td class="nump">253,958,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="nump">254,926,880<span></span>
</td>
<td class="nump">253,957,709<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934574561488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">43,174<span></span>
</td>
<td class="nump">44,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">13,494<span></span>
</td>
<td class="nump">19,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating income, net</a></td>
<td class="num">(1,090)<span></span>
</td>
<td class="num">(1,288)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">55,578<span></span>
</td>
<td class="nump">62,621<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(55,575)<span></span>
</td>
<td class="num">(62,556)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">6,819<span></span>
</td>
<td class="nump">4,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">1,090<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="num">(13,001)<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other loss, net</a></td>
<td class="num">(5,092)<span></span>
</td>
<td class="num">(4,403)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(60,667)<span></span>
</td>
<td class="num">(66,959)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized (loss) gain on marketable securities</a></td>
<td class="num">(310)<span></span>
</td>
<td class="nump">3,720<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (60,977)<span></span>
</td>
<td class="num">$ (63,239)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic (in dollars per share)</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used to compute net loss per common share, basic (in shares)</a></td>
<td class="nump">254,252<span></span>
</td>
<td class="nump">249,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used to compute net loss per common share, diluted (in shares)</a></td>
<td class="nump">254,252<span></span>
</td>
<td class="nump">249,591<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934580991712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,567,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 833,252<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 1,608,306<span></span>
</td>
<td class="num">$ (7,599)<span></span>
</td>
<td class="num">$ (767,480)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock in connection with restricted stock units, net of tax</a></td>
<td class="num">(69)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">13,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">3,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(66,959)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,959)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,609,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 783,826<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">1,622,119<span></span>
</td>
<td class="num">(3,879)<span></span>
</td>
<td class="num">(834,439)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">253,957,709<span></span>
</td>
<td class="nump">253,958,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 654,952<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">1,657,133<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="num">(1,002,112)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">868,826<span></span>
</td>
<td class="nump">869,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock in connection with restricted stock units, net of tax</a></td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">9,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (60,667)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,667)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="nump">254,926,880<span></span>
</td>
<td class="nump">254,927,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">$ 603,157<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 1,666,315<span></span>
</td>
<td class="num">$ (404)<span></span>
</td>
<td class="num">$ (1,062,779)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934573815248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (60,667)<span></span>
</td>
<td class="num">$ (66,959)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="nump">13,001<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">9,155<span></span>
</td>
<td class="nump">13,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">5,024<span></span>
</td>
<td class="nump">5,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization and accretion on marketable securities</a></td>
<td class="num">(4,367)<span></span>
</td>
<td class="num">(1,850)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Gain on marketable equity securities</a></td>
<td class="num">(1,535)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities', window );">Change in fair value of success payment liabilities</a></td>
<td class="nump">968<span></span>
</td>
<td class="num">(1,708)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_NonCashLeaseIncomeExpense', window );">Non-cash lease income</a></td>
<td class="num">(373)<span></span>
</td>
<td class="num">(293)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on property and equipment disposals, net</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, other current assets and other assets</a></td>
<td class="nump">595<span></span>
</td>
<td class="num">(408)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(113)<span></span>
</td>
<td class="nump">2,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued liabilities and other current liabilities</a></td>
<td class="num">(3,606)<span></span>
</td>
<td class="num">(5,860)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="num">(113)<span></span>
</td>
<td class="num">(112)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(42,016)<span></span>
</td>
<td class="num">(46,212)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(1,533)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(108,011)<span></span>
</td>
<td class="num">(108,560)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">130,035<span></span>
</td>
<td class="nump">142,247<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">21,994<span></span>
</td>
<td class="nump">32,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(76)<span></span>
</td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">27<span></span>
</td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(19,995)<span></span>
</td>
<td class="num">(14,127)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">145,931<span></span>
</td>
<td class="nump">123,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">125,936<span></span>
</td>
<td class="nump">109,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract', window );"><strong>Represented by:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">125,650<span></span>
</td>
<td class="nump">109,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total</a></td>
<td class="nump">125,936<span></span>
</td>
<td class="nump">109,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">2,659<span></span>
</td>
<td class="nump">2,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 395<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value adjustment of success payment liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_FairValueAdjustmentOfSuccessPaymentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_NonCashLeaseIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Lease Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_NonCashLeaseIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represented by Cash and Cash Equivalents and Restricted Cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934574580784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text">Organization<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lyell Immunopharma, Inc. (the &#8220;Company&#8221;) was incorporated in Delaware in June 2018. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a clinical-stage cell therapy company advancing a pipeline of product candidates for patients with solid tumors utilizing its proprietary </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ex&#160;vivo</span> genetic and epigenetic T&#8209;cell reprogramming technologies. The Company&#8217;s primary activities since incorporation have been to develop T&#8209;cell therapies, conduct research and development, acquire technology, enter into strategic collaboration and license arrangements, enable and execute manufacturing activities in support of its product candidate development efforts, organize and staff the Company, conduct business planning, establish its intellectual property portfolio, submit regulatory submissions, execute clinical trials, raise capital and provide general and administrative support for these activities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934482781008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany transactions and balances have been eliminated in consolidation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Condensed Consolidated Balance Sheet as of December&#160;31, 2023 included herein was derived from the audited consolidated financial statements as of that date. Certain information and footnote disclosures typically included in the Company&#8217;s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited Condensed Consolidated Financial Statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company&#8217;s financial position, results of operations and cash flows for the periods presented, but are not necessarily indicative of results to be expected for any future annual or interim period. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Company&#8217;s audited financial statements and notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Management&#8217;s Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company discovers and develops product candidates that involve experimental technologies. The product candidates may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources or from the issuance of equity or debt securities. The Company believes that its available cash, cash equivalents and marketable securities as of March&#160;31, 2024 will be adequate to fund its operations at least through the next 12&#160;months from the date these unaudited Condensed Consolidated Financial Statements are issued. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect reported amounts and related disclosures. Specific accounts that require management estimates include, but are not limited to, stock-based compensation, valuation of success payments, valuation of other investments and accrued expenses. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-balance Sheet Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash, cash equivalents and restricted cash with high quality, accredited financial institutions. Restricted cash is cash held in a bank account and is used as collateral associated with the Company&#8217;s corporate credit card program. Cash, cash equivalents and restricted cash amounts, at times, may exceed federally insured limits. The Company also makes short-term investments in money market funds, U.S. Treasury securities, U.S. government agency securities and corporate debt securities, which can be subject to certain credit risk. However, the Company mitigates the risks by investing in high&#8209;grade instruments, limiting exposure to any one issuer or type of investment and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">credit losses in such accounts and does not believe it is exposed to significant risk on these funds. The Company has no off&#8209;balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the significant accounting policies from the Annual Report on Form 10-K for the year ended December&#160;31, 2023, except as set forth below regarding the Company&#8217;s stock-based compensation policy for performance-based restricted stock units (&#8220;PSUs&#8221;).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 718, the Company measures and recognizes expense for PSUs that settle in stock. The Company granted PSUs that vest upon the achievement of certain performance conditions to certain key employees. For awards with performance conditions that do not vest unless a performance condition is met, the Company recognizes expense if, and to the extent that, the Company estimates that the achievement of the performance condition is probable. At each reporting date, the Company is required to evaluate whether achievement of a performance condition is probable. Compensation expense is recorded over the appropriate service period based upon the Company&#8217;s assessment of accomplishing each performance condition. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s PSUs that have market-based metrics are estimated using Monte Carlo simulations. The Company applies an accelerated attribution method to recognize stock-based compensation expense over the applicable service period for these awards. The number of shares expected to be earned is considered in the grant date valuation; therefore, the expense is not subsequently adjusted to reflect the actual shares ultimately earned. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of PSUs that do not have market-based metrics are based upon the grant date stock price. Compensation expense is recognized for the number of shares expected to be earned after assessing the probability that a certain performance condition will be met and the targeted payout level associated with the performance condition expected to be achieved. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled. If performance conditions are not met or not expected to be met, any compensation expense previously recognized associated with the awards will be reversed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Recently Adopted</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Not Yet Adopted</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which expands required disclosures about a public entity&#8217;s reportable segments and requires more enhanced information about a reportable segment&#8217;s expenses, interim segment profit or loss, and how a public entity&#8217;s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. Entities with a single reportable segment are required to provide all the updated and existing segment disclosures required by Topic 280. The amendments are effective for annual periods beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company is assessing the effect of the new disclosure requirements and does not anticipate the adoption will have a material impact to the Company&#8217;s financial statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for annual periods beginning after December 15, 2024 and may be applied either prospectively or retrospectively. The Company is assessing the effect of the new disclosure requirements and does not anticipate the adoption will have a material impact to the Company&#8217;s financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934574580784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration, and Success Payment Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License, Collaboration, and Success Payment Agreements</a></td>
<td class="text">License, Collaboration and Success Payment Agreements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fred Hutch</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2018, the Company entered into a license agreement with Fred Hutchinson Cancer Center (&#8220;Fred Hutch&#8221;) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that grants the Company a worldwide, sublicensable license under certain patent rights (exclusive) and certain technology (non-exclusive) to research, develop and commercialize products and processes for all fields of use utilizing chimeric antigen receptors (&#8220;CARs&#8221;) and/or T-cell receptors (&#8220;TCRs&#8221;), subject to certain exceptions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay Fred Hutch annual license maintenance payments of $50,000 on the second anniversary of the effective date, and each anniversary of the effective date thereafter until the first commercial sale of a licensed product.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2018, the Company entered into a research and collaboration agreement with Fred Hutch (&#8220;Fred Hutch Collaboration Agreement&#8221;) focused on research and development of cancer immunotherapy products. The Company funded aggregate research performed by Fred Hutch of $12.0&#160;million under the Fred Hutch Collaboration Agreement, with the research conducted in accordance with a research plan and budget approved by the parties. The Fred Hutch Collaboration Agreement has a six-year term. The Company incurred $0.1&#160;million and $0.3&#160;million in expense in connection with the Fred Hutch Collaboration Agreement for the three months ended March&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Success Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2018, the Company granted Fred Hutch rights to certain success payments, pursuant to the terms of the Fred Hutch Collaboration Agreement. The potential payments for the Fred Hutch success payments are based on multiples of increased value ranging from 10 times to 50 times based on a comparison of the per share fair market value of the Company&#8217;s common stock relative to the original $1.83 per share issuance price of the Company&#8217;s Series&#160;A convertible preferred stock, which converted into an equal number of shares of the Company&#8217;s common stock in connection with the closing of the Company&#8217;s initial public offering (&#8220;IPO&#8221;). The aggregate success payments to Fred Hutch are not to exceed $200.0&#160;million, which would only occur upon a 50 times increase in value. Each threshold is associated with a success payment, ascending from $10.0&#160;million at $18.29 per share to $200.0&#160;million at $91.44 per share, payable if such threshold is reached during the measurement period. Any previous success payments made are credited against the success payment owed as of any valuation date, such that Fred Hutch does not receive multiple success payments in connection with the same threshold. The term of the success payment agreement ends on the earlier to occur of (i)&#160;the nine-year anniversary of the date of the agreement and (ii)&#160;a change in control transaction.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate potential success payments, which are payable to Fred Hutch in cash or cash equivalents, or at the Company&#8217;s discretion, publicly-tradeable shares of the Company&#8217;s common stock:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Multiple of initial equity value at issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">10x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">20x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">30x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">40x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">50x</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Per share common stock price required for payment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.29&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">36.58&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">54.86&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">73.15&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">91.44&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Aggregate success payment(s) (in millions)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success payments will be owed if the per share fair value of the Company&#8217;s common stock on the contractually specified valuation measurement dates during the term of the success payment agreement equals or exceeds the above outlined multiples. The valuation measurement dates are triggered by the following events: the one-year anniversary of the Company&#8217;s IPO and each two-year anniversary of the Company&#8217;s IPO thereafter, the closing of a change in control transaction and the last day of the term of the success payment agreement, unless the term has ended due to the closing of a change of control transaction. As of March&#160;31, 2024, no success payments have been incurred as the per share fair value of the Company&#8217;s common stock was below the price required for payment. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success payment liability was $1.1&#160;million and $0.7&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively. With respect to the Fred Hutch Collaboration Agreement success payment obligations, the Company recognized success payment expense of $0.4&#160;million and expense reversal of $1.1&#160;million for the three months ended March&#160;31, 2024 and 2023, respectively, which are recognized in other income, net.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stanford</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In 2019, the Company entered into a license agreement with The Board of Trustees of the Leland Stanford Junior University (&#8220;Stanford&#8221;) to license specified patent rights. The Company is required to pay Stanford annual license maintenance payments of $50,000 on the second anniversary of the effective date, and each anniversary of the effective date thereafter until the date of the first commercial sale of a licensed product.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone payments to Stanford of up to a maximum of $3.7&#160;million per target are payable upon achievement of certain specified clinical and regulatory milestones. The Company is also obligated to pay Stanford $2.5&#160;million </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collectively for all licensed products upon the achievement of a certain commercial milestone. Additionally, low single&#8209;digit tiered royalties based on annual net sales of the licensed products are payable to Stanford.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In October 2020, the Company entered into a research and collaboration agreement with Stanford (&#8220;Stanford Collaboration Agreement&#8221;), focused on research and development of cellular immunotherapy products. The Stanford Collaboration Agreement has a four-year term. The Company is committed to fund aggregate research performed by Stanford of $12.0&#160;million under the Stanford Collaboration Agreement, and the research will be conducted in accordance with a research plan and budget approved by the parties. The Company incurred $0.8&#160;million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in expense in connection with the Stanford Collaboration Agreement for both of the three months ended March&#160;31, 2024 and 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Success Payments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In October 2020, the Company granted Stanford rights to certain success payments, pursuant to the terms of the Stanford Collaboration Agreement. The potential payments for the Stanford Collaboration Agreement success payments are based on multiples of increased value ranging from 10 times to 50 times based on a comparison of the per share fair market value of the Company&#8217;s common stock relative to the original $1.83 per share issuance price of the Company&#8217;s Series&#160;A convertible preferred stock, which converted into an equal number of shares of the Company&#8217;s common stock in connection with the closing of the Company&#8217;s IPO. The aggregate success payments to Stanford are not to exceed $200.0&#160;million, which would only occur upon a 50 times increase in value. Each threshold is associated with a success payment, ascending from $10.0&#160;million at $18.29 per share to $200.0&#160;million at $91.44 per share, payable if such threshold is reached during the measurement period. Any previous success payments made are credited against the success payment owed as of any valuation date, so that Stanford does not receive multiple success payments in connection with the same threshold. The term of each success payment agreement ends on the earlier to occur of (i)&#160;the nine-year anniversary of the date of the agreement and (ii)&#160;a change in control transaction.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate potential success payments, which are payable to Stanford in cash or cash equivalents, or at the Company&#8217;s discretion, publicly-tradeable shares of the Company&#8217;s common stock:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Multiple of initial equity value at issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">10x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">20x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">30x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">40x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">50x</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Per share common stock price required for payment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">18.29&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">36.58&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">54.86&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">73.15&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">91.44&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Aggregate success payment(s) (in millions)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success payments will be owed if the per share fair value of the Company&#8217;s common stock on the contractually specified valuation measurement dates during the term of the success payment agreement equals or exceeds the above outlined multiples. The valuation measurement dates are triggered by the following events: the one-year anniversary of the Company&#8217;s IPO and each two-year anniversary of the Company&#8217;s IPO thereafter, the closing of a change in control transaction and the last day of the term of the success payment agreement, unless the term has ended due to the closing of a change of control transaction. As of March&#160;31, 2024, no success payments have been incurred as the per share fair value of the Company&#8217;s common stock was below the price required for payment. </span></div>The estimated fair values of the success payments to Stanford as of March&#160;31, 2024 and December&#160;31, 2023 were $1.7&#160;million and $1.1&#160;million, respectively. The success payment liability is estimated at the fair value at inception and at each subsequent reporting period and the expense is accreted over the service period of the Stanford Collaboration Agreement as research and development expense. The success payment liability was $1.5&#160;million and $0.9&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively. With respect to the Stanford Collaboration Agreement success payment obligations, the Company recognized success payment expense of $0.5&#160;million and expense reversal of $0.6&#160;million for the three months ended March&#160;31, 2024 and 2023, respectively<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934482228272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash Equivalents and Marketable Securities</a></td>
<td class="text">Cash Equivalents and Marketable Securities<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of cash equivalents and fixed income marketable securities by major security type are as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">50,808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">50,808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">343,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">343,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">38,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">38,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">68,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">68,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and fixed income marketable securities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">501,515&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(406)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">501,111&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Classified as:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">101,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">399,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and fixed income marketable securities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">501,111&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">62,075&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">62,075&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">374,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">374,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">48,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">48,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">59,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">59,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and fixed income marketable securities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">544,881&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">240&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(334)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">544,787&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Classified as:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">127,705&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">400,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">16,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and fixed income marketable securities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">544,787&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of money market and fixed income marketable securities held by the Company in an unrealized loss position for less than 12&#160;months were $358.6&#160;million and $117.8&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively. The fair values of money market and fixed income marketable securities held by the Company in an unrealized loss position for greater than 12&#160;months were $11.5&#160;million and $43.6&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively. As of March&#160;31, 2024 and December&#160;31, 2023, all of the Company&#8217;s money market and fixed income marketable securities had a maturity date of two years or less, were available for use and were classified as available&#8209;for&#8209;sale. The Company does not intend to sell these securities nor does the Company believe that it will be required to sell these securities before recovery of their amortized cost basis. The Company determined that there was no material change in the credit risk of the above investments as of both March&#160;31, 2024 and December&#160;31, 2023. As such, an allowance for credit losses has not been recognized. Gross realized gains and losses were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three months ended March&#160;31, 2024 and 2023 and as a result, amounts reclassified out of accumulated other comprehensive loss for the three months ended March&#160;31, 2024 and 2023 were also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de&#160;minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See Note&#160;6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information regarding cash equivalents and fixed income marketable securities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934482876640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_OtherInvestmentsTextBlock', window );">Other Investments</a></td>
<td class="text">Other Investments<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In prior years the Company made minority ownership strategic investments. As of March&#160;31, 2024 and December&#160;31, 2023, the aggregate carrying amount of the Company&#8217;s strategic investments in non-publicly traded companies was $19.0&#160;million and $32.0 million, respectively. These investments are measured at initial cost, minus impairment, if any, and plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Cumulative impairments of strategic investments in equity investments without readily determinable fair values still held as of March&#160;31, 2024 and December&#160;31, 2023 were $23.0&#160;million and $15.0&#160;million, respectively. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a part of the acquisition of each of the Company&#8217;s other investments, the Company determines whether an investment or other interest is considered a variable interest. As of both March&#160;31, 2024 and December&#160;31, 2023, the Company held an interest in one entity that was concluded to be a variable interest for which the Company was not the primary beneficiary as the Company did not have the power to direct the activities that most significantly impact the economic performance of the variable interest entity. As of March&#160;31, 2024 and December&#160;31, 2023, the carrying value and maximum exposure to loss of the Company&#8217;s variable interests were zero and $13.0&#160;million, respectively, which are recorded in other investments in the Company&#8217;s Condensed Consolidated Balance Sheets.</span></div>In connection with the preparation of the financial statements for the three months ended March&#160;31, 2024 and 2023, the Company performed a qualitative assessment of potential indicators of impairment and determined that indicators existed for certain of its other investments with carrying amounts of $13.0&#160;million and $10.0&#160;million, respectively. During the three months ended March&#160;31, 2024, the anticipated funding for one of its other investments was not secured within the expected timeframe. The Company considered both of the underlying companies&#8217; operating cash flow requirements over the next year, liquid asset balances to fund those requirements and the underlying companies&#8217; inability to raise funds as indicators of impairment. Due to these indicators, the Company assessed the valuation of these investments and determined the fair values to be negligible and the impairments to be other-than-temporary in nature. As a result, the Company recorded an impairment expense of $13.0 million for the three months ended March&#160;31, 2024 and $10.0&#160;million for the three months ended March&#160;31, 2023, which consisted of the full impairment of one of our other investments in each period. The impairment expenses were recorded within impairment of other investments on the Condensed Consolidated Statements of Operations and Comprehensive Loss and as a reduction to the investment balances within other investments on the Condensed Consolidated Balance Sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_OtherInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_OtherInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934487972496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">50,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">50,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">343,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">343,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">38,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">38,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">68,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">68,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">52,343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">450,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">502,646&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Success payment liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,544&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,544&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">62,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">62,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">374,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">374,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">48,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">48,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">59,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">59,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">62,075&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">482,712&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">544,787&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Success payment liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,576&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,576&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of money market funds based on quoted prices in active markets for identical assets or liabilities. The Company measures the fair value of marketable equity securities traded in active markets based on quoted prices of identical assets. The Level&#160;2 marketable securities include U.S. Treasury securities, U.S. government agency securities and corporate debt securities, which are valued using third-party pricing sources. The pricing services applied industry standard valuation models. Inputs utilized include market pricing based on real-time trade data for the same or similar securities and other significant inputs derived from or corroborated by observable market data.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketable equity securities were comprised of a company that began being publicly traded on the Nasdaq Global Market in February 2024 and had a fair value of $1.5 million as of March&#160;31, 2024. The Company recorded unrealized gains of $1.5 million and zero for the three months ended March&#160;31, 2024 and 2023, respectively, within other income, net in the Company&#8217;s Condensed Consolidated Statement of Operations and Comprehensive Loss. As of December&#160;31, 2023, the investment was fully impaired and classified in the Company&#8217;s Condensed Consolidated Balance Sheet as other investments</span><span style="background-color:#f8f8f8;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s success payment liabilities are Level&#160;3 financial instruments, which were estimated using Monte&#160;Carlo simulations through December 31, 2023. Monte Carlo simulations model the future movement of stock prices based on several key variables combined with empirical knowledge of the process governing the behavior of the stock price. The following variables were incorporated in the Monte Carlo simulation to determine the estimated fair value of the success payment liabilities: fair value of the Company&#8217;s common stock, expected volatility, the risk-free interest rate and the estimated number and timing of valuation measurement dates on the basis of which payments may be triggered. The computation of expected volatility was estimated based on available information about the historical volatility of stocks of similar publicly traded companies for a period matching the expected term assumption. As of March 31, 2024, success payment liabilities were estimated by management using its historical experience of the correlation of success payment fair values relative to the Company&#8217;s stock price.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were incorporated into the calculation of the estimated fair value of the Fred Hutch success payment liability as of December&#160;31, 2023:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Fair value of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.51% - 5.19%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">80.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.46 - 3.97</span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were incorporated into the calculation of the estimated fair value of the Stanford success payment liability as of December&#160;31, 2023:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Fair value of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.51% - 5.19%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">80.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.46 - 5.75</span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes estimates and assumptions in determining the estimated success payment liabilities and associated changes in fair value. A small change in the valuation of the Company&#8217;s common stock may have a relatively large change in the estimated fair value of the success payment liability and associated changes in fair value.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in the fair value of the Company&#8217;s Level 3&#160;financial liabilities (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Success Payment<br/>Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Balance at December&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,576&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Change in fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Balance at March&#160;31, 2024</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,544&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The change in the fair value associated with the Fred Hutch success payment liabilities is recorded in <span style="-sec-ix-hidden:f-479">other income, net</span>. The change in the fair value associated with the Stanford success payment liabilities is recorded as research and development expenses. (See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934488063968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease portfolio is comprised of operating leases for laboratory, office and manufacturing facilities located in South San Francisco, California, and Seattle and Bothell, Washington with contractual periods expiring between December 2028 and March 2031. In addition to minimum rent, the leases require payment of real estate taxes, insurance, common area maintenance charges and other executory costs. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s future minimum operating lease commitments, including expected lease incentives to be received, as of March&#160;31, 2024 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Year Ending December&#160;31:</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2024 (remaining nine months)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">8,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">11,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">22,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">80,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(19,024)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">61,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Reported as of March&#160;31, 2024:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">55,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">61,826&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease costs for all operating leases were $2.3&#160;million and $2.1 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three months ended March&#160;31, 2024 and 2023, respectively. The operating lease costs and total commitments for short-term leases were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de&#160;minimis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three months ended March&#160;31, 2024 and 2023. Variable lease costs for operating leases were $2.3&#160;million and $1.4 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three months ended March&#160;31, 2024 and 2023, respectively. The weighted-average remaining lease terms for operating leases were 6.6&#160;and 6.8 years as of March&#160;31, 2024 and December&#160;31, 2023, respectively. The weighted&#8209;average discount rate for operating leases was 8.5% as of both March&#160;31, 2024 and December&#160;31, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a sublease, whereby the Company agreed to sublease approximately 11,000 square feet of its space in South San Francisco, California currently leased by the Company. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized sublease income for this sublease of $0.2&#160;million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for both the three months ended March&#160;31, 2024 and 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into a sublease with Sonoma Biotherapeutics, Inc. (&#8220;Sonoma&#8221;), a related party, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company. See Note&#160;12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Transactions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As a part of the sublease, in September 2021, the Company received a $4.6&#160;million tenant improvement contribution payment, which is recognized over the term of the sublease. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized Sonoma sublease income of $0.5&#160;million for both the three months ended March&#160;31, 2024 and 2023. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's sublease income is recognized within other operating income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease portfolio is comprised of operating leases for laboratory, office and manufacturing facilities located in South San Francisco, California, and Seattle and Bothell, Washington with contractual periods expiring between December 2028 and March 2031. In addition to minimum rent, the leases require payment of real estate taxes, insurance, common area maintenance charges and other executory costs. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s future minimum operating lease commitments, including expected lease incentives to be received, as of March&#160;31, 2024 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Year Ending December&#160;31:</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2024 (remaining nine months)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">8,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">11,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">22,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">80,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(19,024)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">61,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Reported as of March&#160;31, 2024:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">55,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">61,826&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease costs for all operating leases were $2.3&#160;million and $2.1 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three months ended March&#160;31, 2024 and 2023, respectively. The operating lease costs and total commitments for short-term leases were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de&#160;minimis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three months ended March&#160;31, 2024 and 2023. Variable lease costs for operating leases were $2.3&#160;million and $1.4 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three months ended March&#160;31, 2024 and 2023, respectively. The weighted-average remaining lease terms for operating leases were 6.6&#160;and 6.8 years as of March&#160;31, 2024 and December&#160;31, 2023, respectively. The weighted&#8209;average discount rate for operating leases was 8.5% as of both March&#160;31, 2024 and December&#160;31, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a sublease, whereby the Company agreed to sublease approximately 11,000 square feet of its space in South San Francisco, California currently leased by the Company. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized sublease income for this sublease of $0.2&#160;million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for both the three months ended March&#160;31, 2024 and 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into a sublease with Sonoma Biotherapeutics, Inc. (&#8220;Sonoma&#8221;), a related party, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company. See Note&#160;12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Transactions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As a part of the sublease, in September 2021, the Company received a $4.6&#160;million tenant improvement contribution payment, which is recognized over the term of the sublease. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized Sonoma sublease income of $0.5&#160;million for both the three months ended March&#160;31, 2024 and 2023. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's sublease income is recognized within other operating income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessor's operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLessorDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934482228272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue 10.0&#160;million shares of preferred stock with a par value of $0.0001 per share. As of March&#160;31, 2024 and December&#160;31, 2023, no shares of preferred stock were outstanding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue 500.0&#160;million shares of common stock with a par value of $0.0001 per share. As of March&#160;31, 2024 and December&#160;31, 2023, there were 254,926,880 shares and 253,957,709 shares of the Company&#8217;s common stock outstanding, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2024, the Company entered into a sales agreement with Cowen and Company, LLC (&#8220;Cowen&#8221;) acting as the Company&#8217;s sales agent (the &#8220;Sales Agreement&#8221;), pursuant to which the Company may offer and sell shares of common stock having an aggregate offering price of up to $150.0&#160;million from time to time&#160;in a series of one or more at&#8209;the&#8209;market equity offerings. The Company will pay Cowen commissions of up to 3.0% of the gross proceeds of the sale, and reimbursement of certain expenses, under this agreement. Neither the Company nor Cowen is obligated to sell any shares and, to date, the Company has not made any sales under the Sales Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934486353744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">Stock-based Compensation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company adopted the 2021 Equity Incentive Plan (&#8220;2021 Plan&#8221;), which on the date of the underwriting agreement related to the Company&#8217;s IPO became effective with an initial reserve of 26,662,087 shares, plus any shares subject to outstanding awards granted under the 2018 Equity Incentive Plan (&#8220;2018 Plan&#8221;) that, on or after the effectiveness of the 2021 Plan, terminate or expire before exercise or settlement, are not issued because the award is settled in cash, are forfeited because of the failure to vest, or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price. In addition, the number of shares reserved for issuance under the 2021 Plan automatically increases on January&#160;1 of each year for a period of ten years, beginning on January&#160;1, 2022 and continuing through January&#160;1, 2031, in an amount equal to (1)&#160;5% of the total number of shares of the Company&#8217;s common stock outstanding on December&#160;31 of the immediately preceding year, or (2)&#160;a lesser number of shares determined by the Company&#8217;s board of directors no later than December&#160;31 of the immediately preceding year. On January&#160;1, 2024, the Company reserved an additional 12,697,885 shares of common stock for issuance under the 2021 Plan representing 5% of the total common shares outstanding as of December&#160;31, 2023. Under the 2021 Plan, the Company may grant incentive stock options, non-statutory stock options, restricted stock awards (&#8220;RSAs&#8221;), restricted stock units (&#8220;RSUs&#8221;), PSUs, stock appreciation rights, performance awards and other stock-based awards. Terms of stock awards, including vesting requirements, are determined by the Company&#8217;s board of directors or by a committee authorized by the Company&#8217;s board of directors, subject to provisions of the 2021 Plan. The term of any stock option granted under the 2021 Plan cannot exceed ten years. Generally, option and RSU awards granted by the Company vest over four years but may be granted with different vesting terms. PSUs generally vest over three years, subject to the achievement of the associated performance conditions. In conjunction with adopting the 2021 Plan, the Company discontinued the 2018 Plan with respect to new equity awards.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, 33,623,495 shares were available for future issuance pursuant to the 2021 Plan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company adopted the 2021 Employee Stock Purchase Plan (&#8220;2021 ESPP&#8221;), which became effective immediately prior to the execution of the underwriting agreement related to the Company&#8217;s IPO with an initial reserve of 2,470,000 shares. The 2021 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 15% of their earnings, subject to plan limitations. Unless otherwise </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determined by the Company&#8217;s board of directors, employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#8217;s common stock on the first date of an offering or on the purchase date. The number of shares of the Company&#8217;s common stock reserved for issuance under the 2021 ESPP automatically increases on January&#160;1 of each year for a period of ten years, beginning on January&#160;1, 2022 and continuing through January&#160;1, 2031, by the lesser of (1)&#160;1% of the total number of shares of the Company&#8217;s common stock outstanding on December&#160;31 of the immediately preceding year, and (2)&#160;4,940,000 shares; provided, however, that the Company&#8217;s board of directors may act to provide a lesser increase in number of shares. On January&#160;1, 2024, the Company reserved an additional 2,539,577 shares of common stock for issuance under the 2021 ESPP representing 1% of the total common shares outstanding as of December&#160;31, 2023. The Company may specify offerings with durations not more than <span style="-sec-ix-hidden:f-541">27&#160;months</span> and may specify shorter purchase periods within each offering. Under the 2021 ESPP, no shares were issued for both the three months ended March&#160;31, 2024 and 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, 6,001,206 shares were available for future issuance pursuant to the 2021 ESPP.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company established the 2018&#160;Plan that provided for the grant of incentive stock options, non&#8209;statutory stock options, RSAs, RSUs, stock appreciation rights and other stock-based awards. Terms of stock awards, including vesting requirements, were determined by the board of directors or by a committee authorized by the Company&#8217;s board of directors, subject to provisions of the 2018&#160;Plan. The term of any stock option granted under the 2018&#160;Plan cannot exceed ten years. Generally, awards granted by the Company vest over four years, but could have been granted with different vesting terms. Pursuant to the terms of the 2021&#160;Plan, any shares subject to outstanding options originally granted under the 2018&#160;Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof become available for issuance pursuant to awards granted under the 2021&#160;Plan. While no shares are available for future issuance under the 2018&#160;Plan, it continues to govern outstanding equity awards granted thereunder.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by classification included within the Condensed Consolidated Statements of Operations and Comprehensive Loss was as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3,792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,612&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">9,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">9,155&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">13,882&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2024, total stock-based compensation cost related to unvested awards not yet recognized was $66.0&#160;million, which is expected to be recognized over a remaining weighted-average period of 2.7 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options Repricing</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Board of Directors of the Company approved, effective November 16, 2023, a one-time repricing of certain stock option awards that had been granted to date under the 2021 Plan and 2018 Plan. The repricing impacted stock options with exercise prices greater than $2.37 held by employees who remained employed as of November&#160;16, 2023 and were not impacted by the Company&#8217;s November 2023 reduction in workforce. The original exercise prices of the repriced stock options ranged from $2.61 to $17.95 per share for 200 total grantees with 23,416,860 shares repriced. Each stock option was repriced to have a per share exercise price of $1.87, which was the closing price of the Company&#8217;s common stock on November 16, 2023. To receive the new exercise price, option holders must remain employed with the Company through November 15, 2024. Additionally, the vesting schedule for the unvested shares underlying repriced stock options held by executives at the level of senior vice president and above was extended for an additional year. There were no changes to the vesting schedules for employees below the level of senior vice president. No changes were made to the expiration dates of, or the number of shares underlying, the repriced stock options. Incremental stock-based compensation expense resulting from the repricing was $8.9 million in the aggregate. Expense for vested awards will be recognized through November 15, 2024 and expense for unvested awards will be recognized over the remaining service life of the option.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based Restricted Stock Units</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024, the Company granted PSU awards to certain key employees. PSUs awarded to employees have a three-year performance period and vest based upon the Company&#8217;s performance against a <span style="-sec-ix-hidden:f-565">two</span> and three-year relative total shareholder return (&#8220;rTSR&#8221;) metric, as well as upon the achievement of certain </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical development milestones. For the portion of PSUs subject to certain clinical development milestones (other than the bonus clinical development milestone), 50% vest upon the achievement of the applicable milestone, and the remaining 50% vest upon the earlier of (a) one year of service from the date of such achievement and (b) the end of the three-year performance period. The vesting of all PSU awards granted is also subject to the respective employee&#8217;s continued employment. The Company valued the portion of PSUs subject to the rTSR metric using a Monte Carlo simulation. The number of PSUs granted subject to the rTSR metrics represents the target number of units that are eligible to be earned based on the achievement of the metrics established at the beginning of the performance period, which ends on December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the three year performance period. For the portion of PSUs subject to the rTSR metrics, employees may ultimately earn between zero and 200% of the target number of PSUs granted based on the degree of achievement of the applicable rTSR metric. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s PSU activity was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Performance-Based Restricted Stock Units Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Value at Grant<br/>Date Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unvested PSUs as of December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">PSUs granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,703,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">PSUs vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">PSUs forfeited or canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unvested PSUs as of March&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,703,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;PSU grants reflect the target number of shares eligible to be earned at the time of grant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s RSU activity was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Value at Grant<br/>Date Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unvested RSUs as of December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,072,855&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2.96&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3,477,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(142,430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs forfeited or canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(73,298)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unvested RSUs as of March&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5,334,478&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Stock Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options outstanding as of December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">55,596,831</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.75&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6.89</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">7,368&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,495,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(868,826)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(3,096,127)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options outstanding as of March&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">54,127,378</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">7.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">8,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options exercisable as of March&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">31,963,665</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6.19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to employees and directors was estimated on the date of grant using the Black-Scholes option pricing model using the following weighted-average assumptions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">75.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">91.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6.04</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6.02</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr></table></div>The weighted-average grant date fair value of options granted for the three months ended March&#160;31, 2024 and 2023 were $1.26 per share and $1.66 per share, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934486390720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per ShareBasic and diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. The Company&#8217;s potentially dilutive shares, which include unvested RSUs, unvested PSUs and options to purchase common stock, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Shares subject to options to purchase common stock, unvested RSUs and unvested PSUs were all excluded from consideration in the calculation of diluted net loss per share in all periods presented due to their anti-dilutive effects.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934482993952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into certain license and collaboration agreements, including those identified in Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">above, with third parties that include the funding of certain development, manufacturing and commercialization efforts with the potential for future milestone and royalty payments upon the achievement of pre-established developmental, regulatory and/or commercial milestones. The Company&#8217;s obligation to fund these efforts is contingent upon continued involvement in the programs and/or the lack of any adverse events that could cause the discontinuance of the programs, including termination of such agreements. Due to the nature of these agreements, the future potential payments are inherently uncertain, and accordingly no amounts had been recorded for the potential future achievement of these targets as of both March&#160;31, 2024 and December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934482228272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-party Transactions</a></td>
<td class="text">Related-party Transactions<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into a sublease with Sonoma (&#8220;Sonoma Sublease&#8221;), with whom the Company has common stockholders with board seats, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company. Dr.&#160;Klausner, the Chair of the Company&#8217;s board of directors, also serves as Board Chair of the board of directors of Sonoma. As a part of the Sonoma Sublease, a $4.6&#160;million tenant improvement contribution payment was made by Sonoma, which is recognized over the term of the Sonoma Sublease. As of both March&#160;31, 2024 and December&#160;31, 2023, there were accrued liabilities and other current liabilities of $0.5&#160;million and as of March&#160;31, 2024 and December&#160;31, 2023, other non-current liabilities of $2.9&#160;million and $3.0&#160;million, respectively, in connection with the Sonoma Sublease. Total operating income from Sonoma and income solely attributable to the Sonoma Sublease are shown in the table below (in thousands). Total operating income includes income attributable to the sublease, as well as additional operating fees recognized in &#8220;other operating income, net&#8221; such as common area maintenance charges. See Note&#160;7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for more detail on the Sonoma Sublease.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Sonoma other operating income, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Sonoma sublease income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934573761632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (60,667)<span></span>
</td>
<td class="num">$ (66,959)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934580779792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934580989024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div>The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiary.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidations</a></td>
<td class="text">All significant intercompany transactions and balances have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div>The preparation of the Company&#8217;s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect reported amounts and related disclosures. Specific accounts that require management estimates include, but are not limited to, stock-based compensation, valuation of success payments, valuation of other investments and accrued expenses. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-balance Sheet Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash, cash equivalents and restricted cash with high quality, accredited financial institutions. Restricted cash is cash held in a bank account and is used as collateral associated with the Company&#8217;s corporate credit card program. Cash, cash equivalents and restricted cash amounts, at times, may exceed federally insured limits. The Company also makes short-term investments in money market funds, U.S. Treasury securities, U.S. government agency securities and corporate debt securities, which can be subject to certain credit risk. However, the Company mitigates the risks by investing in high&#8209;grade instruments, limiting exposure to any one issuer or type of investment and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any </span></div>credit losses in such accounts and does not believe it is exposed to significant risk on these funds.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock', window );">Off-balance Sheet Risk</a></td>
<td class="text">The Company has no off&#8209;balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SignificantAccountingPoliciesPolicyTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the significant accounting policies from the Annual Report on Form 10-K for the year ended December&#160;31, 2023, except as set forth below regarding the Company&#8217;s stock-based compensation policy for performance-based restricted stock units (&#8220;PSUs&#8221;).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 718, the Company measures and recognizes expense for PSUs that settle in stock. The Company granted PSUs that vest upon the achievement of certain performance conditions to certain key employees. For awards with performance conditions that do not vest unless a performance condition is met, the Company recognizes expense if, and to the extent that, the Company estimates that the achievement of the performance condition is probable. At each reporting date, the Company is required to evaluate whether achievement of a performance condition is probable. Compensation expense is recorded over the appropriate service period based upon the Company&#8217;s assessment of accomplishing each performance condition. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s PSUs that have market-based metrics are estimated using Monte Carlo simulations. The Company applies an accelerated attribution method to recognize stock-based compensation expense over the applicable service period for these awards. The number of shares expected to be earned is considered in the grant date valuation; therefore, the expense is not subsequently adjusted to reflect the actual shares ultimately earned. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of PSUs that do not have market-based metrics are based upon the grant date stock price. Compensation expense is recognized for the number of shares expected to be earned after assessing the probability that a certain performance condition will be met and the targeted payout level associated with the performance condition expected to be achieved. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled. If performance conditions are not met or not expected to be met, any compensation expense previously recognized associated with the awards will be reversed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Recently Adopted</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Not Yet Adopted</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which expands required disclosures about a public entity&#8217;s reportable segments and requires more enhanced information about a reportable segment&#8217;s expenses, interim segment profit or loss, and how a public entity&#8217;s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. Entities with a single reportable segment are required to provide all the updated and existing segment disclosures required by Topic 280. The amendments are effective for annual periods beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company is assessing the effect of the new disclosure requirements and does not anticipate the adoption will have a material impact to the Company&#8217;s financial statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for annual periods beginning after December 15, 2024 and may be applied either prospectively or retrospectively. The Company is assessing the effect of the new disclosure requirements and does not anticipate the adoption will have a material impact to the Company&#8217;s financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_SignificantAccountingPoliciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_SignificantAccountingPoliciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934582819360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration, and Success Payment Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Aggregate Potential Success Payments</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate potential success payments, which are payable to Fred Hutch in cash or cash equivalents, or at the Company&#8217;s discretion, publicly-tradeable shares of the Company&#8217;s common stock:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Multiple of initial equity value at issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">10x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">20x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">30x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">40x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">50x</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Per share common stock price required for payment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.29&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">36.58&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">54.86&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">73.15&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">91.44&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Aggregate success payment(s) (in millions)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate potential success payments, which are payable to Stanford in cash or cash equivalents, or at the Company&#8217;s discretion, publicly-tradeable shares of the Company&#8217;s common stock:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Multiple of initial equity value at issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">10x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">20x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">30x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">40x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">50x</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Per share common stock price required for payment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">18.29&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">36.58&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">54.86&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">73.15&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">91.44&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Aggregate success payment(s) (in millions)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934488064816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Fair Value and Amortized Cost of Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of cash equivalents and fixed income marketable securities by major security type are as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">50,808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">50,808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">343,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">343,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">38,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">38,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">68,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">68,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and fixed income marketable securities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">501,515&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(406)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">501,111&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Classified as:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">101,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">399,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and fixed income marketable securities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">501,111&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">62,075&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">62,075&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">374,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">374,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">48,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">48,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">59,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">59,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and fixed income marketable securities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">544,881&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">240&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(334)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">544,787&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Classified as:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">127,705&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">400,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">16,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and fixed income marketable securities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">544,787&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Fair Value and Amortized Cost of Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of cash equivalents and fixed income marketable securities by major security type are as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">50,808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">50,808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">343,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">343,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">38,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">38,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">68,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">68,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and fixed income marketable securities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">501,515&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(406)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">501,111&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Classified as:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">101,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">399,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and fixed income marketable securities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">501,111&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">62,075&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">62,075&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">374,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">374,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">48,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">48,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">59,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">59,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and fixed income marketable securities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">544,881&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">240&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(334)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">544,787&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Classified as:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">127,705&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">400,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">16,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and fixed income marketable securities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">544,787&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934488563984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">50,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">50,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">343,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">343,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">38,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">38,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">68,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">68,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">52,343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">450,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">502,646&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Success payment liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,544&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,544&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">62,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">62,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">374,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">374,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">48,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">48,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">59,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">59,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">62,075&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">482,712&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">544,787&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Success payment liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,576&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,576&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Estimated Fair Value of Success Payment Liability Assumptions</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were incorporated into the calculation of the estimated fair value of the Fred Hutch success payment liability as of December&#160;31, 2023:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Fair value of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.51% - 5.19%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">80.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.46 - 3.97</span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were incorporated into the calculation of the estimated fair value of the Stanford success payment liability as of December&#160;31, 2023:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Fair value of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.51% - 5.19%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">80.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.46 - 5.75</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in the Estimated Fair Value of Level 3 Financial Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in the fair value of the Company&#8217;s Level 3&#160;financial liabilities (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Success Payment<br/>Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Balance at December&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,576&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Change in fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Balance at March&#160;31, 2024</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,544&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The change in the fair value associated with the Fred Hutch success payment liabilities is recorded in <span style="-sec-ix-hidden:f-479">other income, net</span>. The change in the fair value associated with the Stanford success payment liabilities is recorded as research and development expenses. (See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934487349488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Operating Lease Commitments, Including Expected Lease Incentives to be Received</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s future minimum operating lease commitments, including expected lease incentives to be received, as of March&#160;31, 2024 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Year Ending December&#160;31:</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2024 (remaining nine months)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">8,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">11,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">22,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">80,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(19,024)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">61,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Reported as of March&#160;31, 2024:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">55,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">61,826&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_LesseeCurrentAndNonCurrentLiabilitiesTableTextBlock', window );">Schedule of Current and Non-current Lease Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s future minimum operating lease commitments, including expected lease incentives to be received, as of March&#160;31, 2024 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Year Ending December&#160;31:</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2024 (remaining nine months)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">8,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">11,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">22,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">80,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(19,024)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">61,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Reported as of March&#160;31, 2024:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">55,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">61,826&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_LesseeCurrentAndNonCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Current and Non-Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_LesseeCurrentAndNonCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934574359216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense by Classification</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by classification included within the Condensed Consolidated Statements of Operations and Comprehensive Loss was as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3,792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,612&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">9,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">9,155&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">13,882&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock', window );">Schedule of PSU Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s PSU activity was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Performance-Based Restricted Stock Units Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Value at Grant<br/>Date Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unvested PSUs as of December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">PSUs granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,703,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">PSUs vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">PSUs forfeited or canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unvested PSUs as of March&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,703,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;PSU grants reflect the target number of shares eligible to be earned at the time of grant.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Schedule of RSU Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s RSU activity was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Value at Grant<br/>Date Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unvested RSUs as of December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,072,855&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2.96&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3,477,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(142,430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs forfeited or canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(73,298)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unvested RSUs as of March&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5,334,478&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Stock Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options outstanding as of December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">55,596,831</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.75&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6.89</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">7,368&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,495,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(868,826)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(3,096,127)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options outstanding as of March&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">54,127,378</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">7.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">8,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options exercisable as of March&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">31,963,665</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6.19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to employees and directors was estimated on the date of grant using the Black-Scholes option pricing model using the following weighted-average assumptions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">75.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">91.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6.04</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6.02</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934486390720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Total Income Attributable to Sonoma Sublease</a></td>
<td class="text">Total operating income from Sonoma and income solely attributable to the Sonoma Sublease are shown in the table below (in thousands). Total operating income includes income attributable to the sublease, as well as additional operating fees recognized in &#8220;other operating income, net&#8221; such as common area maintenance charges. See Note&#160;7, <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for more detail on the Sonoma Sublease.</span><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Sonoma other operating income, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Sonoma sublease income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934477210128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration, and Success Payment Agreements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 43,174,000<span></span>
</td>
<td class="nump">$ 44,630,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lyel_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Convertible preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_FredHutchMember', window );">Fred Hutch | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments', window );">Annual license maintenance payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments', window );">Aggregate research payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm', window );">Term of collaborative arrangement for research</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm', window );">Term of success payment agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate', window );">Trigger period from IPO date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering', window );">Trigger period thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability', window );">Fair value of potential success payments due</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain', window );">Success payment expense (reversal)</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="num">(1,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_FredHutchMember', window );">Fred Hutch | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_FredHutchMember', window );">Fred Hutch | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91.44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_StanfordMember', window );">Stanford | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments', window );">Annual license maintenance payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments', window );">Aggregate research payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm', window );">Term of collaborative arrangement for research</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm', window );">Term of success payment agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate', window );">Trigger period from IPO date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering', window );">Trigger period thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability', window );">Fair value of potential success payments due</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain', window );">Success payment expense (reversal)</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="num">$ (600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability', window );">Success payment liability</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_StanfordMember', window );">Stanford | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments', window );">Potential milestone payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_StanfordMember', window );">Stanford | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_StanfordMember', window );">Stanford | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_StanfordMember', window );">Stanford | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments', window );">Potential milestone payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments, Share Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Annual License Maintenance Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Commercial Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Potential Payment Multiplier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Research Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsResearchPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Research Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Fair Value Of Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period Thereafter</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period From Initial Public Offering Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Success Payment Expense (Gain)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lyel_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lyel_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_FredHutchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_FredHutchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_StanfordMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_StanfordMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934484408320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License, Collaboration, and Success Payment Agreements - Schedule of Aggregate Potential Success Payments (Details) - Collaborative Arrangement, Transaction with Party to Collaborative Arrangement<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Fred Hutch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Stanford</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Ten Times | Fred Hutch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Ten Times | Stanford</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Twenty Times | Fred Hutch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Twenty Times | Stanford</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Thirty Times | Fred Hutch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Thirty Times | Stanford</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Forty Times | Fred Hutch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Forty Times | Stanford</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Fifty Times | Fred Hutch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Fifty Times | Stanford</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments, Share Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Potential Payment Multiplier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_FredHutchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_FredHutchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_StanfordMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_StanfordMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_EquityMultipleAxis=lyel_TenTimesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_EquityMultipleAxis=lyel_TenTimesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_EquityMultipleAxis=lyel_TwentyTimesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_EquityMultipleAxis=lyel_TwentyTimesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_EquityMultipleAxis=lyel_ThirtyTimesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_EquityMultipleAxis=lyel_ThirtyTimesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_EquityMultipleAxis=lyel_FortyTimesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_EquityMultipleAxis=lyel_FortyTimesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_EquityMultipleAxis=lyel_FiftyTimesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_EquityMultipleAxis=lyel_FiftyTimesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934477952688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Schedule of Fair Value and Amortized Cost of Cash Equivalents and Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 501,515<span></span>
</td>
<td class="nump">$ 544,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(406)<span></span>
</td>
<td class="num">(334)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">501,111<span></span>
</td>
<td class="nump">544,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract', window );"><strong>Classified as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">501,111<span></span>
</td>
<td class="nump">544,787<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">101,996<span></span>
</td>
<td class="nump">127,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract', window );"><strong>Classified as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">101,996<span></span>
</td>
<td class="nump">127,705<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=lyel_MarketableSecuritiesCurrentMember', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">399,115<span></span>
</td>
<td class="nump">400,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract', window );"><strong>Classified as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">399,115<span></span>
</td>
<td class="nump">400,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=lyel_MarketableSecuritiesNoncurrentMember', window );">Marketable securities, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract', window );"><strong>Classified as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">50,808<span></span>
</td>
<td class="nump">62,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">50,808<span></span>
</td>
<td class="nump">62,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract', window );"><strong>Classified as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">50,808<span></span>
</td>
<td class="nump">62,075<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">343,389<span></span>
</td>
<td class="nump">374,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(197)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">343,194<span></span>
</td>
<td class="nump">374,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract', window );"><strong>Classified as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">343,194<span></span>
</td>
<td class="nump">374,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">38,566<span></span>
</td>
<td class="nump">48,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(139)<span></span>
</td>
<td class="num">(177)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">38,427<span></span>
</td>
<td class="nump">48,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract', window );"><strong>Classified as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">38,427<span></span>
</td>
<td class="nump">48,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">68,752<span></span>
</td>
<td class="nump">59,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(70)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">68,682<span></span>
</td>
<td class="nump">59,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract', window );"><strong>Classified as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 68,682<span></span>
</td>
<td class="nump">$ 59,606<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents And Debt Securities, Available-For-Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=lyel_MarketableSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=lyel_MarketableSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=lyel_MarketableSecuritiesNoncurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=lyel_MarketableSecuritiesNoncurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934574294256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair value of securities held in a continuous unrealized loss position for less than twelve months</a></td>
<td class="nump">$ 358.6<span></span>
</td>
<td class="nump">$ 117.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair value of securities held in a continuous unrealized loss position for greater than twelve months</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 43.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Maturity of marketable securities</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934573832064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Investments (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>entity</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>entity</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Other investments</a></td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary', window );">Variable interest entity, number of entities company is not primary beneficiary | entity</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount', window );">Variable interest entity maximum loss exposure, amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="nump">13,001<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember', window );">Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_OtherInvestmentMember', window );">Other Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount', window );">Cumulative impairments of strategic investments</a></td>
<td class="nump">23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_OtherInvestmentMember', window );">Other Investment | Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Other investments</a></td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Variable Interest Entity, Number of Investments that Company is Not the Primary Beneficiary</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative impairment loss on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The reporting entity's maximum amount of exposure to loss as a result of its involvement with the Variable Interest Entity (VIE).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph b<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_OtherInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_OtherInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934477841904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 501,111<span></span>
</td>
<td class="nump">$ 544,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Marketable equity securities</a></td>
<td class="nump">1,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">502,646<span></span>
</td>
<td class="nump">544,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilitiesFairValueDisclosure', window );">Success payment liabilities</a></td>
<td class="nump">2,544<span></span>
</td>
<td class="nump">1,576<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">2,544<span></span>
</td>
<td class="nump">1,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">343,194<span></span>
</td>
<td class="nump">374,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">38,427<span></span>
</td>
<td class="nump">48,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">68,682<span></span>
</td>
<td class="nump">59,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">50,808<span></span>
</td>
<td class="nump">62,075<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Marketable equity securities</a></td>
<td class="nump">1,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">52,343<span></span>
</td>
<td class="nump">62,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilitiesFairValueDisclosure', window );">Success payment liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">50,808<span></span>
</td>
<td class="nump">62,075<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">450,303<span></span>
</td>
<td class="nump">482,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilitiesFairValueDisclosure', window );">Success payment liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">343,194<span></span>
</td>
<td class="nump">374,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">38,427<span></span>
</td>
<td class="nump">48,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">68,682<span></span>
</td>
<td class="nump">59,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilitiesFairValueDisclosure', window );">Success payment liabilities</a></td>
<td class="nump">2,544<span></span>
</td>
<td class="nump">1,576<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">2,544<span></span>
</td>
<td class="nump">1,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_SuccessPaymentLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success Payment Liabilities, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_SuccessPaymentLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934581041200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Marketable equity securities</a></td>
<td class="nump">$ 1,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Unrealized gain on marketable equity securities</a></td>
<td class="nump">$ 1,535<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934487320544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Estimated Fair Value of Success Payment Liability Assumptions (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>yr </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_FredHutchSuccessPaymentLiabilityMember', window );">Fred Hutch</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityFairValueOfCommonStock', window );">Fair value of common stock (USD per share) | $ / shares</a></td>
<td class="nump">$ 1.94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_FredHutchSuccessPaymentLiabilityMember', window );">Fred Hutch | Risk-free interest rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">3.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_FredHutchSuccessPaymentLiabilityMember', window );">Fred Hutch | Risk-free interest rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">5.19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_FredHutchSuccessPaymentLiabilityMember', window );">Fred Hutch | Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">0.800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_FredHutchSuccessPaymentLiabilityMember', window );">Fred Hutch | Expected term (in years) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">0.46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_FredHutchSuccessPaymentLiabilityMember', window );">Fred Hutch | Expected term (in years) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">3.97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_StanfordSuccessPaymentLiabilityMember', window );">Stanford</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityFairValueOfCommonStock', window );">Fair value of common stock (USD per share) | $ / shares</a></td>
<td class="nump">$ 1.94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_StanfordSuccessPaymentLiabilityMember', window );">Stanford | Risk-free interest rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">3.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_StanfordSuccessPaymentLiabilityMember', window );">Stanford | Risk-free interest rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">5.19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_StanfordSuccessPaymentLiabilityMember', window );">Stanford | Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">0.800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_StanfordSuccessPaymentLiabilityMember', window );">Stanford | Expected term (in years) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">0.46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_StanfordSuccessPaymentLiabilityMember', window );">Stanford | Expected term (in years) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">5.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_SuccessPaymentLiabilityFairValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success Payment Liability, Fair Value of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_SuccessPaymentLiabilityFairValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_SuccessPaymentLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success Payment Liability, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_SuccessPaymentLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=lyel_FredHutchSuccessPaymentLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=lyel_FredHutchSuccessPaymentLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=lyel_StanfordSuccessPaymentLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=lyel_StanfordSuccessPaymentLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934580991776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Changes in Estimated Fair Value of Financial Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Success Payment Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Other income, net, Research and development<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Success Payment Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Success Payment Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">$ 1,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">$ 2,544<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=lyel_SuccessPaymentLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=lyel_SuccessPaymentLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934574615936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Operating Lease Commitments Including Expected Lease Incentives to be Received (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2024 (remaining nine months)</a></td>
<td class="nump">$ 8,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">11,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">12,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">12,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">12,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">22,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">80,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(19,024)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">61,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)</a></td>
<td class="nump">6,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">55,159<span></span>
</td>
<td class="nump">$ 56,894<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 61,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934483729184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> ft&#178; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term of operating leases</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted average discount rate (as a percent)</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=lyel_SouthSanFranciscoCaliforniaMember', window );">South San Francisco, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable area (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable area (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Sonoma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable area (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 465<span></span>
</td>
<td class="nump">$ 465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=lyel_SouthSanFranciscoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=lyel_SouthSanFranciscoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_SonomaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_SonomaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934574262816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Feb. 28, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,926,880<span></span>
</td>
<td class="nump">253,957,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_CowenAndCompanyLLCMember', window );">Cowen and Company, LLC | At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SaleOfStockMaximumConsiderationReceived', window );">Sale of stock, maximum aggregate offering amount</a></td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds', window );">Commissions payment, percentage of gross sale proceeds</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Commissions Payment, Percentage of Gross Sale Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_SaleOfStockMaximumConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Maximum Consideration Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_SaleOfStockMaximumConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_CowenAndCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_CowenAndCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lyel_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lyel_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934477131408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 16, 2023 </div>
<div>USD ($) </div>
<div>grantee </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total stock-based compensation cost related to unvested awards not yet recognized | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period compensation cost to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.26<span></span>
</td>
<td class="nump">$ 1.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod', window );">Award performance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate', window );">Service period from the milestone achievement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Achievement of applicable milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Earlier of one year of service from achievement date and three-year performance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_DateOfEquityModificationsAxis=lyel_A2023Member', window );">2023 | Stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum', window );">Minimum exercise price of plan modifications (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Original exercise price lower range (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Original exercise price upper range (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected', window );">Share-based payment arrangement, plan modification, number of grantees affected | grantee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced', window );">Shares repriced (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,416,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_ShareBasedPaymentArrangementPlanModificationExercisePrice', window );">Plan modification, exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental stock-based compensation expense of modifications | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn', window );">Performance period relative to total shareholder return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget', window );">Awards granted, percentage of target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn', window );">Performance period relative to total shareholder return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget', window );">Awards granted, percentage of target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyel_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,662,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding', window );">Proportion of stock outstanding (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized for issuance (in shares)</a></td>
<td class="nump">12,697,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding', window );">Increase in proportion of common shares reserved for future issuance (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Future issuance of common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,623,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyel_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Plan | Stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyel_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Plan | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyel_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Plan | Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyel_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember', window );">2021 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding', window );">Proportion of stock outstanding (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized for issuance (in shares)</a></td>
<td class="nump">2,539,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Future issuance of common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,001,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Purchase of common stock at discount (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Employee purchase of shares, proportion of fair value (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable', window );">Maximum number of shares to be purchased under ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,940,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod', window );">Maximum offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">27 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Stock-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyel_TwoThousandEighteenEquityIncentivePlanMember', window );">2018 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Future issuance of common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Additional Shares Authorized, Number Of Shares As Percentage Of Common Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Award Performance Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Awards Granted, Percentage of Target</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number Of Shares Available For Grant, Percentage Of Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Maximum Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Maximum Shares Issuable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Period Relative to Total Shareholder Return</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Service Period from Milestone Achievement Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_ShareBasedPaymentArrangementPlanModificationExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Plan Modification, Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_ShareBasedPaymentArrangementPlanModificationExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Plan Modification, Exercise Price, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Plan Modification, Number of Shares Repriced</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of grantees affected by modification of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_DateOfEquityModificationsAxis=lyel_A2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_DateOfEquityModificationsAxis=lyel_A2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lyel_TwoThousandTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lyel_TwoThousandTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lyel_TwoThousandEighteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lyel_TwoThousandEighteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934481454192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Stock-Based Compensation Expense by Classification (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 9,155<span></span>
</td>
<td class="nump">$ 13,882<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">3,792<span></span>
</td>
<td class="nump">4,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 5,363<span></span>
</td>
<td class="nump">$ 9,270<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934487416464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Performance Shares Units (Details) - Performance Shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Performance-Based Restricted Stock Units Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at beginning of period (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">PSUs granted (in shares) | shares</a></td>
<td class="nump">2,703,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">PSUs vested (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">PSUs forfeited or canceled (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at end of period (in shares) | shares</a></td>
<td class="nump">2,703,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Value at Grant Date Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">PSUs granted (in dollars per share) | $ / shares</a></td>
<td class="nump">1.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">PSUs vested (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">PSUs forfeited or canceled (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.88<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934574552112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Restricted Stock Units (Details) - RSUs<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at beginning of period (in shares) | shares</a></td>
<td class="nump">2,072,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (in shares) | shares</a></td>
<td class="nump">3,477,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSUs vested (in shares) | shares</a></td>
<td class="num">(142,430)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs forfeited or canceled (in shares) | shares</a></td>
<td class="num">(73,298)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at end of period (in shares) | shares</a></td>
<td class="nump">5,334,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Value at Grant Date Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSUs granted (in dollars per share) | $ / shares</a></td>
<td class="nump">1.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">RSUs vested (in dollars per share) | $ / shares</a></td>
<td class="nump">3.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">RSUs forfeited or canceled (in dollars per share) | $ / shares</a></td>
<td class="nump">2.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934574451680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">55,596,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,495,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(868,826)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Canceled or forfeited (in shares)</a></td>
<td class="num">(3,096,127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">54,127,378<span></span>
</td>
<td class="nump">55,596,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">31,963,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 4.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">1.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled or forfeited (in dollars per share)</a></td>
<td class="nump">5.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">4.64<span></span>
</td>
<td class="nump">$ 4.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 5.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- Average Remaining Contractual Life (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 10 months 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable</a></td>
<td class="text">6 years 2 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>Aggregate Intrinsic Value (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options Outstanding</a></td>
<td class="nump">$ 8,295<span></span>
</td>
<td class="nump">$ 7,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options Exercisable</a></td>
<td class="nump">$ 6,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934488373088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.15%<span></span>
</td>
<td class="nump">4.13%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">75.90%<span></span>
</td>
<td class="nump">91.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 14 days<span></span>
</td>
<td class="text">6 years 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934488918960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related-party Transactions - Narrative (Details)<br> ft&#178; in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued liabilities and other current liabilities</a></td>
<td class="nump">$ 24,914<span></span>
</td>
<td class="nump">$ 28,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">3,551<span></span>
</td>
<td class="nump">3,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable area (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Sonoma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable area (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued liabilities and other current liabilities</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_SonomaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_SonomaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139934488692912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-party Transactions - Schedule of Total Income Attributable to Sonoma Sublease (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Sonoma other operating income, net</a></td>
<td class="nump">$ 1,090<span></span>
</td>
<td class="nump">$ 1,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Sonoma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Sonoma other operating income, net</a></td>
<td class="nump">807<span></span>
</td>
<td class="nump">669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sonoma sublease income</a></td>
<td class="nump">$ 465<span></span>
</td>
<td class="nump">$ 465<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_SonomaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_SonomaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>59
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" #(0*98LS]V1L4%  "Z'@  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+6977/B-AB%_XJ&=GJU!$L&\E'"#'&2;J;)+AO2[J2=7@A;@">VY4HRA'_?
M5S;824:6J6>Y"?XZ)WHL2SJ21ALN7N2*,85>XRB1EYV54NE%KR?]%8NI/.$I
M2^#.@HN8*C@5RYY,!:-!+HJC'G&<82^F8=(9C_)K4S$>\4Q%8<*F LDLCJG8
M7K&(;RX[N+._\!@N5TI?Z(U'*5VR&5-_I%,!9[W2)0ACELB0)TBPQ65G@B\\
MEVA!_L2?(=O(-\=(H\PY?]$G=\%EQ]$E8A'SE;:@\+-F'HLB[03E^'=GVBG_
MIQ:^/=Z[W^;P #.GDGD\^AX&:G79.>N@@"UH%JE'OOG,=D #[>?S2.9_T:9X
MMN]TD)])Q>.=&$H0ATGQ2U]W+^*M@-0(R$Y /@BP6R-P=P(W!RU*EF-=4T7'
M(\$W2.BGP4T?Y.\F5P--F.AJG"D!=T/0J;''UTR@+I(K*I@<]11XZCL]?Z>_
M*O2D1N^B!YZHE40W2<""]_H>E*4L$-D7Z(I8#1^H.$$N_H2(0_J&\GA-\BUR
MB$G]KC1N^7K<W,ZUOIZ_)W.I!'QQ_YA>4.'0-SOH9G@A4^JSRPZT,\G$FG7&
MO_R$A\ZO)KH?9/8.ME_"]FWNXVON9]!"%7K:ILQ$:I=CI_O-A&15M40:E$B#
MPY"^950H)J(M>F0I%\J$9[=2(C.]%,^J:HDW+/&&A^%-F0AYH!LA@F[ 6'EV
MI[+9U;8[J[XEYVG)>7K@ERDHC"#Y %!?CW:O!8VDL2*MLI: 9R7@F;50-XD*
MU1;=AA%#7[)XSH0)S.[A.+C;=P8.,<%9I2WASDNX\T/@'MDRU-TH5.,7&AN_
M4;O/_19&>W07QUG"4QBO8OH)W27^B8G7ZM22%SO5H.H<0@R%XP*^4II_L#,%
M+1-Y/$N4V,)O8'P%#<[7-R9:NZ@M[IL,@0_!?:*OZ"Z 9AHN0K]@KO^6&RS/
MW"YV'6> '2.O5=R6EU2\Y!#>21" NT3W<-N(:'<A#D:?J7P)$XF^TZV1T^K0
MEK,*/]@:-SYR>OKDJT!/?),8>>UN,YA%K-",)N@6.@$_E#XW,A\C N$J V%[
MBOG 7#1:@)X*O@X3WUS1=DMO8N0\1B["53#"]CCS@7/*I:(1^BM,ZWLFN^%Y
MWSDS-]9C)"1<121L3S;Y5SN!*6X]F-U@.#!C'2,0X2H187N,N><^U-=TQ1-;
M8F@P&9X/NL[P]-3(=XP\A*M A.UI9L;\3$#583)'3Z&*S#5G]_!X'.<#+_=?
M/J&?G1,',A)*J4!K&F4,I3"WRR>^1OYC1"9<929L#SN0=(,P6:+9-I[SR C?
MD):>;^Z-7,>(1J2*1L0>8/;UBFY>_15-EJPV##88?9G,KB?&":==V):P2D/D
MH#3D94+H*4LQ3\FK$L:2S+C&TN#X;%R9\>RJMIQ5"B('I:"[!.;5Q6J<GGO2
M/;B1T^Y8QWF,%$2J%$0.2D%Z;B:0!W%@R84IK5TU^-Q3 5_[Q/<9&(%-4%@:
MB8^1@4B5@<A!&6@64YAO7642;DOS=VOWJ9UJVW5M^:KL0P[*/C<Q$TO=,'\#
M!XBF,%RD-#%7K=VP'O08V8=4V8?8H\N^(E=ZXFS#L]O4XQTC Y$J Q%[?-GW
MM.^&^5F^DHV^9@H2;:+'4"/Q#THWN_=0N UR-[USLAZ30?_</2>$C'IK$V05
MA,A!2T,>=*D"$M]=$K!7]#LSUV/3"I&#SQP(?<8E(KNX;656@8?8\\I^O+R%
MB2%P/C.(:;;US :[;A>3KHN-H,=(0&Z5@-R&)9S]8N9;TENX:.QB&\SJ5FOM
MLK:,509R[8GE(^-N?;J>TF[WS5B/=E%;QBK_N/:T,@' H(",J+&3:3"H[5;M
MNO\+UGNS.ZA'O'S35")?+T06&X7EU7)C=I)O1_:JQXM=W0>J!TR)(K8 J7-R
M"CV>*#9*BQ/%TWRO<<Z5XG%^N&(T8$(_ /<7G*O]B?X'Y7;U^#]02P,$%
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M&@)_]>47ST]/CU_^>'EYPQ]/7GX]9X%_GXP@7'>E$B&IW-%#V(/^OHX&$-)
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M;#+G0$^]3C5>\4$OEKND%B6--APEY)3C[U["\AB<*"9<E["&;44G 0F,AB0
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MZ<Q?S@70S- "O)]J(&QU0PSB%WQ7_P%02P,$%     @ R$"F6$6>[DJ6!0
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M:1ZR]\IR^>1](5<#+PD2;(7X=QS[Z;CO#8* 74MNC%@(Q.'F9!C4Z[LK'K$
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ME.9]=3 \3,O,"EQB)3>3_]GE)8Y99'>OUT$P20Z=CJ-A&)[L\^5W6'(I:?+
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M6"FZ9H6E.6B:@.,+A>'I/VB!7;%_\1]02P,$%     @ R$"F6 S[@^59!
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M$"4PEU?;!4#H3$0L#UX>:XCN-*3G%% \6:UDXC?NT>''IP)L_6>!)H:0%Z!
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MLDZ7?IA+@5,Q"V!^IL'KYH$7:#^[GO\-4$L#!!0    ( ,A IEB0U.MQZP,
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MJ%9&U\M5=QDE05B#^"ITC3!0?]1P9.CN=' FQD^#+2I=X><]L?W=W6!)=%&
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M9=*<:GZ+S1'X6*T9DR<9+G GX8#I/;0B<BT+3H,0B'6\O6P*WI[DU#D&%V$
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M[R\RX=(T3(M@NSB!B#'-L_C9T \(=.Q ^Y4E^<."$XP_27;_ %!+ P04
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M$QJ-3]OGOL.D]^+H+QG>A0M.B$"M?7,+V.YN[U!7S=7A6;RY@,&)I<305[R
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M.Z?AT/T^U%^L:OT.LE*6-AI_K&F%1.T<R+Y6RNXN+L&XE"[_ 5!+ P04
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MPA!K8[7,^#%"ZQWX?&FXI8WA$VR>M^D_4$L#!!0    ( ,A IEBZ".JP @L
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M_5VA<MB^J2MX*.37IMFCOP%02P,$%     @ R$"F6$;9]%5P!P  DDT  !D
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M]E=.\4F8SF;:?;3YA=_)/--^IOU:HRLZ #W"KSO+LJ><%(TUTQWHNO1KW56
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MS$",!#UZU%E"4].5/$VF\#31\*^N%ETS4RTD2Q/SPG>5%_N\B#@%&WK/A_C
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M:&5E=',O<VAE970S,RYX;6RUG&]OVS80QK\*X15#"VRQ1)&2DSD&V@3%!K1
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M:A= ^S.E['KB$G3_I.PG4$L#!!0    ( ,A IEA,NW]KG00  +T>   9
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M'3[#_2\1EVB WZ(P"(<6\[G;_)JFG?E@W]R'&>RF,>RF,33^!NYI_/Y^*96
MK?G#IFCK8FAWH<_KE:Q)2J<>'$A)Q3WU9G_^@>/@G4W?*SG;4SOHU Y<WF=Z
MSM&9H/HSH7<"_%!4\DKE\MPF?.LM-M[T=^5^EL1),O'O^X*<(4\4-.P$#5\2
M%-G MU91#QSC)!H?D#M]GT@>=>312^2QC3PZ)@_#X)#<Z?M$\K@CCU\B']G(
M8PMY%!^2.WV?2#[JR$<OD2<V\I&%?#P,#LB=OD\D3SKRQ$G^.:>0ZU>*"AM_
M<L0?AE$2'? [(YS(/^[XQVY^KDB!FBIC,N5-I9-/89)/31Y->K+)&A_)2H(D
M.EP69^ 39>%@EX4#I[ ;*N458F7=:$T,E$$494V+P9&<"SPV27!/CSO@J8)Z
M907^A97B72&Q7::"D24KF&+4GO+QD;88)_H#MR_-&?I4:;M4C]VY_K ZNFE%
M/5HEO6K2?RUO^\IW:1^[\_XBYT)=P-XL40U/N@R':O%H:=$9,T6BV<E0J*>B
MT0>U-P!J/L05?(R@Q!4"#FZ_UUI"M&1[6R..1X<[XW<4$7A716!W&?'I^>W^
M%E6\NFC56@4>UQI1A(]JC798OY:*XF2\._W[Z+LR KOK"'->K5S144#KF7S5
M4L+O76CT;1*J_36K)$SK"MP'ER.()K87M&U#\=K<<99<P8W)/.9PJ:5"#X#^
M%>?JJ:&O3=TU>?8_4$L#!!0    ( ,A IEB.SW*9+ 4  -XC   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;+6:6V_B.!3'OXJ5':U:B6WB (%V 6E*
M$NU(T]VJS.5AM0]N,!!-$C.V@:FT'WZ="PFFP2T[IWTH<?#Y^=A_7P\>[1C_
M)E:42O0C33(QME92KF]L6T0KFA)QQ=8T4]\L&$^)5$F^M,6:4S(OC-+$=AW'
MLU,29]9D5+R[YY,1V\@DSN@]1V*3IH0_W=*$[<86MO8O'N+E2N8O[,EH399T
M1N7G]3U7*;NFS..49B)F&>)T,;;>XYL07^<&18XO,=V)@V>45^61L6]YXL-\
M;#FY1S2AD<P11'ULZ90F24Y2?GROH%9=9FYX^+RGAT7E564>B:!3EGR-YW(U
MMH86FM,%V23R@>W^H%6%^CDO8HDH_J-=F=?K6BC:",G2REAYD,99^4E^5 UQ
M8.#V3ABXE8%[;.">,.A6!MUC@_X)@UYET#LV\$X8]"N#_I$!'IPP\"H#KVC[
MLK&*EO:))),19SO$\]R*EC\4<A76JH'C+.]9,\G5M[&RDY./5,DBT&_H3\(Y
MR55&%SZ5)$[$)5K(7W_!@^'O*,[0IQ7;")+-10>]T](C6RH_<IH=567>EF6Z
M)\KLHCN6R95 03:G<]W>5O[7E7#WE;AUC< [PJ]0%W>0Z[@]]'GFHXMWERU^
M35^/Z1HPOAGCTZC!M)@'9O,972MSIS#'>R]J*5IXX4NU>MI[@T]@M$;OUCVG
M6W"[)WN.$)1V4-&#.LBG(N+QNI@N_OZH\J(/DJ;BG[;N48)[[>!\+KT1:Q+1
ML:4F2T'YEEH3Y;;GM-5^"@GS(6$!)"P$@FE2]VJI>R;ZY*\US>>&;(F27&P4
M,2';="TI7D')E[3MQ.TZSLC>'NK5D@D?9_*-_IRK R0L!()I.O1K'?I&';X0
M'I/'A+X@0_\U,I29^@>9<.^9#$9WSI4!$A8"P309O%H&SRC#UV*[0N>(;-6X
M6%*UP\KW<,WXD)2GB"T0T\=-ZU)I+LI#3Y1P@08H+9=,#\W)4QMH:@2=.P^^
MSJOKO5=X>,JM -*M$ BFJ3ZH51^<,PEVT.ZX&\QC$;%-)I'*I[911"""E%%$
M,]FVC;@MR\/NP1ATKIQAWSG\PT?CUNCDN3+_'P\"2 ]"()BFZ+!6=&A4=*9.
M6BLT(QD*.<FB7+T.FI(D5@>V+"9MDAF!Y^Y<(&$^)"R A(5 ,$WBZUKBZ[?:
MI%Y#2@T)\R%A 20L!()I4F.G.<HZQO'\H";:8GM$."7H0AU2Q?>->D8+=3J^
M1/^:#E&W9O:Y>H/2?%!: $H+*YJVD6Q6#%W)@Z $-L_,F\=R)Q5G$4MIJU[X
M^2[WV2:WRM0W9?+-OIS=NI"T$(JFZ^ V.K@OC*B$Y#N<>\+E4ZL*1ONS1PTD
MS0>E!:"T$(JFZ]J$;O";Q6XP:/ &E.:#T@)06@A%TQ5O(CC8',+YN;41,H(R
M!:7YH+2@HFFKV5!?+T*H$G4EFQ@0-@>!M#E9"3=C&4M;#RMFT-FR0=)\4%H
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M95[@YATMTJSDNQ,:"\BL&0'%&L],P.<;(?1CQU21Y<\,BQ]02P,$%     @
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MEP[2!.#^7 A]/S$OJ/O^Z"]02P,$%     @ R$"F6):M(JHY P  .PL  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#(N>&ULM999;]LP#(#_BN -0P<L\9&S
M76*@:7<]% L:M'U6;"86*DN>)"<=L!\_'8Z3HKF'O222+)(?*9'B8,G%L\P
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MP+6!NK]F3#X,]':^_=Z3_ =02P,$%     @ R$"F6)T6$R3J @  /PD  !D
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M;W!S+V%P<"YX;6Q02P$"% ,4    " #(0*98JHGA>N\    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #(0*98
MF5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( ,A IEBS/W9&Q04  +H>   8              "
M@0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #(0*98
MV5X#<0H&  "6&0  &               @($)#@  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ R$"F6$ENM@8! P  .0H  !@
M     ("!210  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M ,A IE@U$TS?[P0  "<3   8              " @8 7  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " #(0*98/<1"JRH&  #I*   &
M            @(&E'   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ R$"F6*+.'\2*!P  :B$  !@              ("!!2,  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( ,A IECH=LT+K@(  ,(%
M   8              " @<4J  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " #(0*98#L2V&QT-  #=)   &               @(&I+0
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ R$"F6)\+0ZWZ
M"0  S2<  !@              ("!_#H  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( ,A IEA%GNY*E@4  /@/   9              "
M@2Q%  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ R$"F
M6 S[@^59!   G0H  !D              ("!^4H  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " #(0*98P## )2,(  #4&   &0
M        @(&)3P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( ,A IE@2A43@D 8  ((=   9              " @>-7  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ R$"F6)#4ZW'K P  5@D
M !D              ("!JEX  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " #(0*98I[-1JL$.  "_+0  &0              @(',8@
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( ,A IEB=&]CO
M) ,  &@'   9              " @<1Q  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ R$"F6* Y8Z>_ P  G@@  !D
M ("!'W4  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #(
M0*98O8L['UX$  !E"@  &0              @($5>0  >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( ,A IEA#W[ G00(  )H%   9
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M970R,RYX;6Q02P$"% ,4    " #(0*98\A64(Q0%  "F#P  &0
M    @(&CE   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M ,A IEC<6L+D@ ,  * *   9              " @>Z9  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ R$"F6'9FXG:K!0  *P\  !D
M             ("!I9T  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " #(0*98BA FUOX"  #J!@  &0              @(&'HP  >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( ,A IEBZ".JP @L
M "Z!   9              " @;RF  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ R$"F6$;9]%5P!P  DDT  !D              ("!
M];$  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #(0*98
MQBYFUXD&  " +0  &0              @(&<N0  >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( ,A IEC2_/#,U@(  " )   9
M      " @5S   !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ R$"F6$P\O@Q$!   ,Q<  !D              ("!:<,  'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #(0*98.AZE/LT'  !-0P
M&0              @('DQP  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( ,A IEA'C?S6A@(  )\&   9              " @>C/  !X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ R$"F6$R[?VN=
M!   O1X  !D              ("!I=(  'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " #(0*98#K@WQ"\#  !Y"   &0
M@(%YUP  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( ,A
MIEA#'('WV@,  #(/   9              " @=_:  !X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ R$"F6([/<IDL!0  WB,  !D
M         ("!\-X  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
M    " #(0*98,-S XLX#  !R$   &0              @(%3Y   >&PO=V]R
M:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( ,A IEB0MG&<JPT  ""=
M   9              " @5CH  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL
M4$L! A0#%     @ R$"F6#!4>PD\ P   PP  !D              ("!.O8
M 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " #(0*98EJTB
MJCD#   ["P  &0              @(&M^0  >&PO=V]R:W-H965T<R]S:&5E
M=#0R+GAM;%!+ 0(4 Q0    ( ,A IE@@8UP)6@,  #4+   9
M  " @1W]  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
MR$"F6*L20/.W!   L14  !D              ("!K@ ! 'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    " #(0*98!S%84P<#   \"   &0
M            @(&<!0$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( ,A IEB=^2,KF ,  /L1   9              " @=H( 0!X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ R$"F6)T6$R3J @
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M2P$"% ,4    " #(0*98N2/:-[(!  !4'   &@              @ %E& $
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #(0*989>&9
MM;<!  !E'   $P              @ %/&@$ 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     -P W /@.   W' $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>173</ContextCount>
  <ElementCount>255</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - License, Collaboration, and Success Payment Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreements</Role>
      <ShortName>License, Collaboration, and Success Payment Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CashEquivalentsandMarketableSecurities</Role>
      <ShortName>Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Other Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/OtherInvestments</Role>
      <ShortName>Other Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Related-party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/RelatedpartyTransactions</Role>
      <ShortName>Related-party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://lyell.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - License, Collaboration, and Success Payment Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsTables</Role>
      <ShortName>License, Collaboration, and Success Payment Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CashEquivalentsandMarketableSecuritiesTables</Role>
      <ShortName>Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyell.com/role/CashEquivalentsandMarketableSecurities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyell.com/role/FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyell.com/role/Leases</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyell.com/role/StockbasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Related-party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/RelatedpartyTransactionsTables</Role>
      <ShortName>Related-party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyell.com/role/RelatedpartyTransactions</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - License, Collaboration, and Success Payment Agreements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails</Role>
      <ShortName>License, Collaboration, and Success Payment Agreements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - License, Collaboration, and Success Payment Agreements - Schedule of Aggregate Potential Success Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails</Role>
      <ShortName>License, Collaboration, and Success Payment Agreements - Schedule of Aggregate Potential Success Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Fair Value and Amortized Cost of Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Schedule of Fair Value and Amortized Cost of Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Cash Equivalents and Marketable Securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Other Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/OtherInvestmentsDetails</Role>
      <ShortName>Other Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lyell.com/role/OtherInvestments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Fair Value Measurements - Schedule of Estimated Fair Value of Success Payment Liability Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Estimated Fair Value of Success Payment Liability Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Fair Value Measurements - Schedule of Changes in Estimated Fair Value of Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Changes in Estimated Fair Value of Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Leases - Schedule of Operating Lease Commitments Including Expected Lease Incentives to be Received (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails</Role>
      <ShortName>Leases - Schedule of Operating Lease Commitments Including Expected Lease Incentives to be Received (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lyell.com/role/StockholdersEquity</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Stock-based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockbasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Stock-based Compensation - Schedule of Stock-Based Compensation Expense by Classification (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Stock-Based Compensation Expense by Classification (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Stock-based Compensation - Schedule of Performance Shares Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockbasedCompensationScheduleofPerformanceSharesUnitsDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Performance Shares Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Stock-based Compensation - Schedule of Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Stock-based Compensation - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Related-party Transactions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails</Role>
      <ShortName>Related-party Transactions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="lyel-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Related-party Transactions - Schedule of Total Income Attributable to Sonoma Sublease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails</Role>
      <ShortName>Related-party Transactions - Schedule of Total Income Attributable to Sonoma Sublease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod, lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn -  lyel-20240331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="lyel-20240331.htm">lyel-20240331.htm</File>
    <File>lyel-20240331.xsd</File>
    <File>lyel-20240331_cal.xml</File>
    <File>lyel-20240331_def.xml</File>
    <File>lyel-20240331_lab.xml</File>
    <File>lyel-20240331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>lyel-20240331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="485">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lyel-20240331.htm": {
   "nsprefix": "lyel",
   "nsuri": "http://lyell.com/20240331",
   "dts": {
    "inline": {
     "local": [
      "lyel-20240331.htm"
     ]
    },
    "schema": {
     "local": [
      "lyel-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "lyel-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lyel-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "lyel-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lyel-20240331_pre.xml"
     ]
    }
   },
   "keyStandard": 216,
   "keyCustom": 39,
   "axisStandard": 21,
   "axisCustom": 2,
   "memberStandard": 28,
   "memberCustom": 22,
   "hidden": {
    "total": 8,
    "http://lyell.com/20240331": 2,
    "http://xbrl.sec.gov/dei/2023": 5,
    "http://fasb.org/us-gaap/2023": 1
   },
   "contextCount": 173,
   "entityCount": 1,
   "segmentCount": 51,
   "elementCount": 499,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 485,
    "http://xbrl.sec.gov/dei/2023": 29,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://lyell.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://lyell.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "us-gaap:PreferredStockSharesIssued",
       "us-gaap:PreferredStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://lyell.com/role/Organization",
     "longName": "0000007 - Disclosure - Organization",
     "shortName": "Organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://lyell.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "0000008 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreements",
     "longName": "0000009 - Disclosure - License, Collaboration, and Success Payment Agreements",
     "shortName": "License, Collaboration, and Success Payment Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://lyell.com/role/CashEquivalentsandMarketableSecurities",
     "longName": "0000010 - Disclosure - Cash Equivalents and Marketable Securities",
     "shortName": "Cash Equivalents and Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://lyell.com/role/OtherInvestments",
     "longName": "0000011 - Disclosure - Other Investments",
     "shortName": "Other Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lyel:OtherInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lyel:OtherInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://lyell.com/role/FairValueMeasurements",
     "longName": "0000012 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://lyell.com/role/Leases",
     "longName": "0000013 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://lyell.com/role/StockholdersEquity",
     "longName": "0000014 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://lyell.com/role/StockbasedCompensation",
     "longName": "0000015 - Disclosure - Stock-based Compensation",
     "shortName": "Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://lyell.com/role/NetLossPerShare",
     "longName": "0000016 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://lyell.com/role/CommitmentsandContingencies",
     "longName": "0000017 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://lyell.com/role/RelatedpartyTransactions",
     "longName": "0000018 - Disclosure - Related-party Transactions",
     "shortName": "Related-party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R20": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsTables",
     "longName": "9954472 - Disclosure - License, Collaboration, and Success Payment Agreements (Tables)",
     "shortName": "License, Collaboration, and Success Payment Agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesTables",
     "longName": "9954473 - Disclosure - Cash Equivalents and Marketable Securities (Tables)",
     "shortName": "Cash Equivalents and Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://lyell.com/role/FairValueMeasurementsTables",
     "longName": "9954474 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://lyell.com/role/LeasesTables",
     "longName": "9954475 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://lyell.com/role/StockbasedCompensationTables",
     "longName": "9954476 - Disclosure - Stock-based Compensation (Tables)",
     "shortName": "Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://lyell.com/role/RelatedpartyTransactionsTables",
     "longName": "9954477 - Disclosure - Related-party Transactions (Tables)",
     "shortName": "Related-party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
     "longName": "9954478 - Disclosure - License, Collaboration, and Success Payment Agreements - Narrative (Details)",
     "shortName": "License, Collaboration, and Success Payment Agreements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-53",
      "name": "us-gaap:SharesIssuedPricePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails",
     "longName": "9954479 - Disclosure - License, Collaboration, and Success Payment Agreements - Schedule of Aggregate Potential Success Payments (Details)",
     "shortName": "License, Collaboration, and Success Payment Agreements - Schedule of Aggregate Potential Success Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-43",
      "name": "lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-38",
      "name": "lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
     "longName": "9954480 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Fair Value and Amortized Cost of Cash Equivalents and Marketable Securities (Details)",
     "shortName": "Cash Equivalents and Marketable Securities - Schedule of Fair Value and Amortized Cost of Cash Equivalents and Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails",
     "longName": "9954481 - Disclosure - Cash Equivalents and Marketable Securities - Narrative (Details)",
     "shortName": "Cash Equivalents and Marketable Securities - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://lyell.com/role/OtherInvestmentsDetails",
     "longName": "9954482 - Disclosure - Other Investments (Details)",
     "shortName": "Other Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OtherInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "lyel:VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary",
      "unitRef": "entity",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "longName": "9954483 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://lyell.com/role/FairValueMeasurementsNarrativeDetails",
     "longName": "9954484 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails",
     "longName": "9954485 - Disclosure - Fair Value Measurements - Schedule of Estimated Fair Value of Success Payment Liability Assumptions (Details)",
     "shortName": "Fair Value Measurements - Schedule of Estimated Fair Value of Success Payment Liability Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-117",
      "name": "lyel:SuccessPaymentLiabilityFairValueOfCommonStock",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-117",
      "name": "lyel:SuccessPaymentLiabilityFairValueOfCommonStock",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
     "longName": "9954486 - Disclosure - Fair Value Measurements - Schedule of Changes in Estimated Fair Value of Financial Liabilities (Details)",
     "shortName": "Fair Value Measurements - Schedule of Changes in Estimated Fair Value of Financial Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-129",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-129",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails",
     "longName": "9954487 - Disclosure - Leases - Schedule of Operating Lease Commitments Including Expected Lease Incentives to be Received (Details)",
     "shortName": "Leases - Schedule of Operating Lease Commitments Including Expected Lease Incentives to be Received (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lyel:LesseeCurrentAndNonCurrentLiabilitiesTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lyel:LesseeCurrentAndNonCurrentLiabilitiesTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://lyell.com/role/LeasesNarrativeDetails",
     "longName": "9954488 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://lyell.com/role/StockholdersEquityDetails",
     "longName": "9954489 - Disclosure - Stockholders' Equity (Details)",
     "shortName": "Stockholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-139",
      "name": "lyel:SaleOfStockMaximumConsiderationReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://lyell.com/role/StockbasedCompensationNarrativeDetails",
     "longName": "9954490 - Disclosure - Stock-based Compensation - Narrative (Details)",
     "shortName": "Stock-based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails",
     "longName": "9954491 - Disclosure - Stock-based Compensation - Schedule of Stock-Based Compensation Expense by Classification (Details)",
     "shortName": "Stock-based Compensation - Schedule of Stock-Based Compensation Expense by Classification (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://lyell.com/role/StockbasedCompensationScheduleofPerformanceSharesUnitsDetails",
     "longName": "9954492 - Disclosure - Stock-based Compensation - Schedule of Performance Shares Units (Details)",
     "shortName": "Stock-based Compensation - Schedule of Performance Shares Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-166",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-166",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails",
     "longName": "9954493 - Disclosure - Stock-based Compensation - Schedule of Restricted Stock Units (Details)",
     "shortName": "Stock-based Compensation - Schedule of Restricted Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-168",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-168",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails",
     "longName": "9954494 - Disclosure - Stock-based Compensation - Schedule of Stock Option Activity (Details)",
     "shortName": "Stock-based Compensation - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails",
     "longName": "9954495 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted (Details)",
     "shortName": "Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
     "longName": "9954496 - Disclosure - Related-party Transactions - Narrative (Details)",
     "shortName": "Related-party Transactions - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccruedLiabilitiesAndOtherLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-173",
      "name": "us-gaap:AccruedLiabilitiesAndOtherLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:AccruedLiabilitiesAndOtherLiabilities",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails",
     "longName": "9954497 - Disclosure - Related-party Transactions - Schedule of Total Income Attributable to Sonoma Sublease (Details)",
     "shortName": "Related-party Transactions - Schedule of Total Income Attributable to Sonoma Sublease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherOperatingIncomeExpenseNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-138",
      "name": "us-gaap:OtherOperatingIncomeExpenseNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20240331.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "lyel_A2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "A2023Member",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023",
        "label": "2023 [Member]",
        "documentation": "2023"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r666"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net amortization and accretion on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities and other current liabilities",
        "label": "Accrued Liabilities and Other Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r67",
      "r114",
      "r444",
      "r464",
      "r465"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r6",
      "r23",
      "r342",
      "r345",
      "r378",
      "r460",
      "r461",
      "r768",
      "r769",
      "r770",
      "r776",
      "r777",
      "r778"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r666",
      "r861"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r477",
      "r776",
      "r777",
      "r778",
      "r841",
      "r862"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r286"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r687",
      "r698",
      "r708",
      "r733"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r690",
      "r701",
      "r711",
      "r736"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r694",
      "r702",
      "r712",
      "r729",
      "r737",
      "r741",
      "r749"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r332"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r109",
      "r136",
      "r171",
      "r177",
      "r181",
      "r224",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r337",
      "r339",
      "r359",
      "r440",
      "r514",
      "r666",
      "r678",
      "r806",
      "r807",
      "r847"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r115",
      "r136",
      "r224",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r337",
      "r339",
      "r359",
      "r666",
      "r806",
      "r807",
      "r847"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At The Market Offering",
        "label": "At The Market Offering [Member]",
        "documentation": "At The Market Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r233",
      "r439"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      },
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "verboseLabel": "Marketable securities",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r233",
      "r432",
      "r781"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails",
      "http://lyell.com/role/StockbasedCompensationScheduleofPerformanceSharesUnitsDetails",
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued liabilities",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets",
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r107",
      "r642"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Money market funds",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents and Marketable Securities",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "totalLabel": "Total",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r74",
      "r134"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r74"
     ]
    },
    "lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classified as:",
        "label": "Cash Equivalents And Debt Securities, Available-For-Sale [Abstract]",
        "documentation": "Cash Equivalents And Debt Securities, Available-For-Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsMember",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash Equivalents [Member]",
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities",
        "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities",
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r111",
      "r112",
      "r113",
      "r136",
      "r158",
      "r159",
      "r161",
      "r163",
      "r169",
      "r170",
      "r224",
      "r246",
      "r248",
      "r249",
      "r250",
      "r253",
      "r254",
      "r259",
      "r260",
      "r263",
      "r266",
      "r273",
      "r359",
      "r469",
      "r470",
      "r471",
      "r472",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r502",
      "r523",
      "r545",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r755",
      "r774",
      "r779"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r169",
      "r259",
      "r260",
      "r261",
      "r263",
      "r266",
      "r271",
      "r273",
      "r469",
      "r470",
      "r471",
      "r472",
      "r655",
      "r755",
      "r774"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License, Collaboration, and Success Payment Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r96",
      "r101"
     ]
    },
    "lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate success payments",
        "terseLabel": "Aggregate success payment(s) (in millions)",
        "label": "Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Per share common stock price required for payment (in dollars per share)",
        "label": "Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments, Share Price",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments, Share Price"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual license maintenance payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Annual License Maintenance Payments",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Annual License Maintenance Payments"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential milestone payments due",
        "label": "Collaborative Arrangement, Rights And Obligations, Commercial Milestone Payments",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Commercial Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "CollaborativeArrangementRightsAndObligationsMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential milestone payments due",
        "label": "Collaborative Arrangement, Rights And Obligations, Milestone Payments",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier": {
     "xbrltype": "pureItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Multiple of initial equity value at issuance",
        "label": "Collaborative Arrangement, Rights And Obligations, Potential Payment Multiplier",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Potential Payment Multiplier"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_CollaborativeArrangementRightsAndObligationsResearchPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "CollaborativeArrangementRightsAndObligationsResearchPayments",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate research payments due",
        "label": "Collaborative Arrangement, Rights And Obligations, Research Payments",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Research Payments"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_CollaborativeArrangementRightsAndObligationsResearchTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "CollaborativeArrangementRightsAndObligationsResearchTerm",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of collaborative arrangement for research",
        "label": "Collaborative Arrangement, Rights And Obligations, Research Term",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Research Term"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of potential success payments due",
        "label": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Fair Value Of Liability",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Fair Value Of Liability"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Success payment liability",
        "label": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Liability",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Liability"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of success payment agreement",
        "label": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Term",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Term"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering": {
     "xbrltype": "durationItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trigger period thereafter",
        "label": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period After Initial Public Offering",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trigger period from IPO date",
        "label": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period From Initial Public Offering Date",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period From Initial Public Offering Date"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Success payment expense (reversal)",
        "label": "Collaborative Arrangement, Rights And Obligations, Success Payment Expense (Gain)",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Success Payment Expense (Gain)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 11)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r56",
      "r441",
      "r501"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://lyell.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r240",
      "r241",
      "r627",
      "r802"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future issuance of common shares (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r669",
      "r670",
      "r671",
      "r673",
      "r674",
      "r675",
      "r676",
      "r776",
      "r777",
      "r841",
      "r860",
      "r862"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r502"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r61",
      "r502",
      "r520",
      "r862",
      "r863"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001 par value; 500,000 shares authorized at March\u00a031, 2024 and December\u00a031, 2023; 254,927 and 253,958 shares issued and outstanding at March\u00a031, 2024 and December\u00a031, 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r443",
      "r666"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r120",
      "r122",
      "r128",
      "r434",
      "r451"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r98"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Axis]",
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r141",
      "r337",
      "r338",
      "r339",
      "r340",
      "r387",
      "r637",
      "r805",
      "r808",
      "r809"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Domain]",
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r141",
      "r337",
      "r338",
      "r339",
      "r340",
      "r387",
      "r637",
      "r805",
      "r808",
      "r809"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidations",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r646"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r658",
      "r660",
      "r859"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails",
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r255",
      "r261",
      "r385",
      "r643",
      "r645"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "lyel_CowenAndCompanyLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "CowenAndCompanyLLCMember",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cowen and Company, LLC",
        "label": "Cowen and Company, LLC [Member]",
        "documentation": "Cowen and Company, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "lyel_DateOfEquityModificationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "DateOfEquityModificationsAxis",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Date Of Equity Modifications [Axis]",
        "label": "Date Of Equity Modifications [Axis]",
        "documentation": "Date Of Equity Modifications"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_DateOfEquityModificationsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "DateOfEquityModificationsDomain",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Date Of Equity Modifications [Domain]",
        "label": "Date Of Equity Modifications [Domain]",
        "documentation": "Date Of Equity Modifications [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of securities held in a continuous unrealized loss position for greater than twelve months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r235",
      "r652"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of securities held in a continuous unrealized loss position for less than twelve months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r235",
      "r652"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value and Amortized Cost of Marketable Securities",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity of marketable securities",
        "label": "Debt Securities, Available-for-Sale, Term",
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r174"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r288",
      "r319",
      "r320",
      "r324",
      "r662"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per common share, basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r156",
      "r158",
      "r161",
      "r162",
      "r163",
      "r167",
      "r350",
      "r351",
      "r435",
      "r452",
      "r648"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per common share, diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r158",
      "r161",
      "r162",
      "r163",
      "r167",
      "r350",
      "r351",
      "r435",
      "r452",
      "r648"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://lyell.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r164",
      "r165",
      "r166"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation cost related to unvested awards not yet recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected weighted-average period compensation cost to be recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address Line",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address City Or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address State Or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation State Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r103",
      "r123",
      "r124",
      "r125",
      "r142",
      "r143",
      "r144",
      "r146",
      "r152",
      "r154",
      "r168",
      "r225",
      "r226",
      "r274",
      "r325",
      "r326",
      "r327",
      "r334",
      "r335",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r349",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r378",
      "r460",
      "r461",
      "r462",
      "r477",
      "r545"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r221",
      "r222",
      "r223"
     ]
    },
    "lyel_EquityMultipleAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "EquityMultipleAxis",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Multiple [Axis]",
        "label": "Equity Multiple [Axis]",
        "documentation": "Equity Multiple Axis."
       }
      }
     },
     "auth_ref": []
    },
    "lyel_EquityMultipleDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "EquityMultipleDomain",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Multiple [Domain]",
        "label": "Equity Multiple [Domain]",
        "documentation": "Equity Multiple Domain."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsNarrativeDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Marketable equity securities",
        "terseLabel": "Marketable equity securities",
        "label": "Equity Securities, FV-NI",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r358",
      "r438"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiUnrealizedGain",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://lyell.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on marketable equity securities",
        "terseLabel": "Unrealized gain on marketable equity securities",
        "label": "Equity Securities, FV-NI, Unrealized Gain",
        "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiUnrealizedLoss",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      },
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Impairment of other investments",
        "terseLabel": "Impairment of other investments",
        "label": "Equity Securities, FV-NI, Unrealized Loss",
        "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative impairments of strategic investments",
        "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount",
        "documentation": "Amount of cumulative impairment loss on investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r687",
      "r698",
      "r708",
      "r733"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r684",
      "r695",
      "r705",
      "r730"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "lyel_FairValueAdjustmentOfSuccessPaymentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "FairValueAdjustmentOfSuccessPaymentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of success payment liabilities",
        "label": "Fair Value Adjustment Of Success Payment Liabilities",
        "documentation": "Fair value adjustment of success payment liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r357"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r357"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Fair Value of Success Payment Liability Assumptions",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r354",
      "r391",
      "r392",
      "r393",
      "r653",
      "r654",
      "r658",
      "r659",
      "r660"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Class [Axis]",
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r88"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r276",
      "r281",
      "r354",
      "r391",
      "r658",
      "r659",
      "r660"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r276",
      "r281",
      "r354",
      "r392",
      "r653",
      "r654",
      "r658",
      "r659",
      "r660"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r354",
      "r393",
      "r653",
      "r654",
      "r658",
      "r659",
      "r660"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value by Liability Class [Domain]",
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Success Payment Liabilities",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in the Estimated Fair Value of Level 3 Financial Liabilities",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r53"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r391",
      "r392",
      "r393",
      "r653",
      "r654",
      "r658",
      "r659",
      "r660"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "lyel_FiftyTimesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "FiftyTimesMember",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fifty Times",
        "label": "Fifty Times [Member]",
        "documentation": "Fifty Times (50x)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r234",
      "r236",
      "r237",
      "r257",
      "r271",
      "r347",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r450",
      "r652",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r794",
      "r795",
      "r796",
      "r797"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial liabilities",
        "label": "Financial Liabilities Fair Value Disclosure",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r691",
      "r702",
      "r712",
      "r737"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r691",
      "r702",
      "r712",
      "r737"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r691",
      "r702",
      "r712",
      "r737"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r691",
      "r702",
      "r712",
      "r737"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r691",
      "r702",
      "r712",
      "r737"
     ]
    },
    "lyel_FortyTimesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "FortyTimesMember",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forty Times",
        "label": "Forty Times [Member]",
        "documentation": "Forty Times (40x)."
       }
      }
     },
     "auth_ref": []
    },
    "lyel_FredHutchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "FredHutchMember",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fred Hutch",
        "label": "Fred Hutch [Member]",
        "documentation": "Fred Hutch"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_FredHutchSuccessPaymentLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "FredHutchSuccessPaymentLiabilityMember",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fred Hutch",
        "label": "Fred Hutch Success Payment Liability [Member]",
        "documentation": "Fred Hutch Success Payment Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on property and equipment disposals, net",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r772",
      "r799",
      "r800"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r525"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r530"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r530"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses, other current assets and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r694",
      "r702",
      "r712",
      "r729",
      "r737",
      "r741",
      "r749"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r683",
      "r753"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r683",
      "r753"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r683",
      "r753"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income, net",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "documentation": "The net amount of nonoperating interest income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_LesseeCurrentAndNonCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "LesseeCurrentAndNonCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://lyell.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Current and Non-current Lease Liabilities",
        "label": "Lessee, Current and Non-Current Liabilities [Table Text Block]",
        "documentation": "Lessee, Current and Non-Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://lyell.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Operating Lease Commitments, Including Expected Lease Incentives to be Received",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 (remaining nine months)",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://lyell.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r136",
      "r224",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r338",
      "r339",
      "r340",
      "r359",
      "r500",
      "r649",
      "r678",
      "r806",
      "r847",
      "r848"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r90",
      "r446",
      "r666",
      "r775",
      "r798",
      "r844"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r106",
      "r136",
      "r224",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r338",
      "r339",
      "r340",
      "r359",
      "r666",
      "r806",
      "r847",
      "r848"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities:",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseMember",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "lyel_MarketableSecuritiesCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "MarketableSecuritiesCurrentMember",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities, Current [Member]",
        "documentation": "Marketable Securities, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesLineItems",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities [Line Items]",
        "label": "Marketable Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities, non-current",
        "label": "Marketable Securities, Noncurrent",
        "documentation": "Amount of investment in marketable security, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "lyel_MarketableSecuritiesNoncurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "MarketableSecuritiesNoncurrentMember",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities, non-current",
        "label": "Marketable Securities, Noncurrent [Member]",
        "documentation": "Marketable Securities, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesTable",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities [Table]",
        "label": "Marketable Securities [Table]",
        "documentation": "Disclosure of information about investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r283",
      "r418",
      "r459",
      "r492",
      "r493",
      "r556",
      "r575",
      "r580",
      "r581",
      "r610",
      "r638",
      "r639",
      "r651",
      "r655",
      "r661",
      "r668",
      "r810",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r283",
      "r418",
      "r459",
      "r492",
      "r493",
      "r556",
      "r575",
      "r580",
      "r581",
      "r610",
      "r638",
      "r639",
      "r651",
      "r655",
      "r661",
      "r668",
      "r810",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r76",
      "r91",
      "r104",
      "r118",
      "r121",
      "r125",
      "r136",
      "r145",
      "r147",
      "r148",
      "r149",
      "r150",
      "r153",
      "r154",
      "r160",
      "r171",
      "r176",
      "r180",
      "r182",
      "r224",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r351",
      "r359",
      "r448",
      "r522",
      "r543",
      "r544",
      "r650",
      "r677",
      "r806"
     ]
    },
    "us-gaap_NetRentableArea": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetRentableArea",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rentable area (in square feet)",
        "label": "Net Rentable Area",
        "documentation": "Net rentable area for properties owned."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "lyel_NonCashLeaseIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "NonCashLeaseIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Non-cash lease income",
        "label": "Non-Cash Lease Income (Expense)",
        "documentation": "Non-Cash Lease Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r691",
      "r702",
      "r712",
      "r729",
      "r737"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash investing and financing activities:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other loss, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OffBalanceSheetCreditExposurePolicyPolicyTextBlock",
     "presentation": [
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Off-balance Sheet Risk",
        "label": "Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block]",
        "documentation": "Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r231"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r176",
      "r180",
      "r182",
      "r650"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r665"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total operating lease liabilities",
        "totalLabel": "Total",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityAbstract",
     "presentation": [
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease Liability",
        "label": "Operating Lease, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets",
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, non-current",
        "verboseLabel": "Operating lease liabilities, non-current",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, weighted average discount rate (as a percent)",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r665"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term of operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r665"
     ]
    },
    "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesOfLessorDisclosureTextBlock",
     "presentation": [
      "http://lyell.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessor, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for lessor's operating leases."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://lyell.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r77",
      "r78",
      "r87"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://lyell.com/role/Organization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r87",
      "r466",
      "r467"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r14",
      "r119",
      "r122",
      "r127",
      "r360",
      "r361",
      "r366",
      "r433",
      "r449",
      "r768",
      "r769"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net unrealized (loss) gain on marketable securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r218"
     ]
    },
    "lyel_OtherInvestmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "OtherInvestmentMember",
     "presentation": [
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Investment",
        "label": "Other Investment [Member]",
        "documentation": "Other Investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherInvestments",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets",
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other investments",
        "label": "Other Investments",
        "documentation": "Amount of investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "lyel_OtherInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "OtherInvestmentsTextBlock",
     "presentation": [
      "http://lyell.com/role/OtherInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Investments",
        "label": "Other Investments [Text Block]",
        "documentation": "The entire disclosure for other investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other operating income, net",
        "terseLabel": "Sonoma other operating income, net",
        "label": "Other Operating Income (Expense), Net",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r689",
      "r700",
      "r710",
      "r735"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r692",
      "r703",
      "r713",
      "r738"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r692",
      "r703",
      "r713",
      "r738"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r130",
      "r187"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails",
      "http://lyell.com/role/StockbasedCompensationScheduleofPerformanceSharesUnitsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Shares",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r259"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r502"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r259"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r502",
      "r520",
      "r862",
      "r863"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000 shares authorized at March\u00a031, 2024 and December\u00a031, 2023; no shares issued and outstanding at March\u00a031, 2024 and December\u00a031, 2023",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r442",
      "r666"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of marketable securities",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r782"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r12"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r183",
      "r419",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r640",
      "r656",
      "r667",
      "r756",
      "r803",
      "r804",
      "r811",
      "r858"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r183",
      "r419",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r640",
      "r656",
      "r667",
      "r756",
      "r803",
      "r804",
      "r811",
      "r858"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r437",
      "r447",
      "r666"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r275",
      "r283",
      "r314",
      "r315",
      "r316",
      "r394",
      "r418",
      "r459",
      "r492",
      "r493",
      "r556",
      "r575",
      "r580",
      "r581",
      "r610",
      "r638",
      "r639",
      "r651",
      "r655",
      "r661",
      "r668",
      "r671",
      "r801",
      "r810",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r275",
      "r283",
      "r314",
      "r315",
      "r316",
      "r394",
      "r418",
      "r459",
      "r492",
      "r493",
      "r556",
      "r575",
      "r580",
      "r581",
      "r610",
      "r638",
      "r639",
      "r651",
      "r655",
      "r661",
      "r668",
      "r671",
      "r801",
      "r810",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r684",
      "r695",
      "r705",
      "r730"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r382",
      "r383",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r519",
      "r521",
      "r552"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r382",
      "r383",
      "r384",
      "r385",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r519",
      "r521",
      "r552"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r527",
      "r530"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions [Abstract]",
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r382",
      "r383",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r519",
      "r521",
      "r552",
      "r846"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related-party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r383",
      "r386",
      "r474",
      "r475",
      "r476",
      "r528",
      "r529",
      "r530",
      "r549",
      "r551"
     ]
    },
    "lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Represented by:",
        "label": "Represented By Cash And Cash Equivalents And Restricted Cash [Abstract]",
        "documentation": "Represented by Cash and Cash Equivalents and Restricted Cash."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails",
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r255",
      "r261",
      "r385",
      "r644",
      "r645"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r333",
      "r855"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r685",
      "r696",
      "r706",
      "r731"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r686",
      "r697",
      "r707",
      "r732"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r693",
      "r704",
      "r714",
      "r739"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      },
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets",
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r765",
      "r773"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails",
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r84",
      "r445",
      "r463",
      "r465",
      "r473",
      "r503",
      "r666"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r142",
      "r143",
      "r144",
      "r146",
      "r152",
      "r154",
      "r225",
      "r226",
      "r325",
      "r326",
      "r327",
      "r334",
      "r335",
      "r341",
      "r343",
      "r344",
      "r346",
      "r349",
      "r460",
      "r462",
      "r477",
      "r862"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r136",
      "r172",
      "r173",
      "r175",
      "r178",
      "r179",
      "r183",
      "r184",
      "r186",
      "r224",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r359",
      "r436",
      "r806"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "lyel_SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commissions payment, percentage of gross sale proceeds",
        "label": "Sale of Stock, Commissions Payment, Percentage of Gross Sale Proceeds",
        "documentation": "Sale of Stock, Commissions Payment, Percentage of Gross Sale Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_SaleOfStockMaximumConsiderationReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "SaleOfStockMaximumConsiderationReceived",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, maximum aggregate offering amount",
        "label": "Sale of Stock, Maximum Consideration Received",
        "documentation": "Sale of Stock, Maximum Consideration Received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value and Amortized Cost of Cash Equivalents",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Aggregate Potential Success Payments",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-based Compensation Expense by Classification",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r221",
      "r222",
      "r223"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInvestmentsLineItems",
     "presentation": [
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments [Line Items]",
        "label": "Schedule of Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInvestmentsTable",
     "presentation": [
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments [Table]",
        "label": "Schedule of Investments [Table]",
        "documentation": "Disclosure of information about investments owned by investment company."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r526",
      "r527",
      "r530"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Total Income Attributable to Sonoma Sublease",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails",
      "http://lyell.com/role/StockbasedCompensationScheduleofPerformanceSharesUnitsDetails",
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r287",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r42"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r82",
      "r83",
      "r84",
      "r111",
      "r112",
      "r113",
      "r169",
      "r259",
      "r260",
      "r261",
      "r263",
      "r266",
      "r271",
      "r273",
      "r469",
      "r470",
      "r471",
      "r472",
      "r655",
      "r755",
      "r774"
     ]
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of RSU Activity",
        "label": "Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security12b Title",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r489",
      "r490",
      "r491",
      "r562",
      "r576",
      "r597",
      "r616",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r641",
      "r657",
      "r671",
      "r811",
      "r858"
     ]
    },
    "lyel_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Convertible Preferred Stock",
        "label": "Series A Convertible Preferred Stock [Member]",
        "documentation": "Series A Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in proportion of common shares reserved for future issuance (as a percent)",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Additional Shares Authorized, Number Of Shares As Percentage Of Common Shares Outstanding",
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Additional Shares Authorized, Number Of Shares As Percentage Of Common Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award performance period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Performance Period",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Performance Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards granted, percentage of target",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Awards Granted, Percentage of Target",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Awards Granted, Percentage of Target"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofPerformanceSharesUnitsDetails",
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "PSUs forfeited or canceled (in shares)",
        "negatedTerseLabel": "RSUs forfeited or canceled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofPerformanceSharesUnitsDetails",
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PSUs forfeited or canceled (in dollars per share)",
        "verboseLabel": "RSUs forfeited or canceled (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofPerformanceSharesUnitsDetails",
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "PSUs granted (in shares)",
        "terseLabel": "RSUs granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofPerformanceSharesUnitsDetails",
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PSUs granted (in dollars per share)",
        "verboseLabel": "RSUs granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofPerformanceSharesUnitsDetails",
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "periodEndLabel": "Balance at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofPerformanceSharesUnitsDetails",
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Performance-Based Restricted Stock Units Outstanding",
        "terseLabel": "Restricted Stock Units Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofPerformanceSharesUnitsDetails",
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period (in dollars per share)",
        "periodEndLabel": "Balance at end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofPerformanceSharesUnitsDetails",
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Value at Grant Date Per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofPerformanceSharesUnitsDetails",
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "PSUs vested (in shares)",
        "negatedLabel": "RSUs vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofPerformanceSharesUnitsDetails",
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PSUs vested (in dollars per share)",
        "verboseLabel": "RSUs vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proportion of stock outstanding (as a percent)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number Of Shares Available For Grant, Percentage Of Shares Outstanding",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number Of Shares Available For Grant, Percentage Of Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails",
      "http://lyell.com/role/StockbasedCompensationScheduleofPerformanceSharesUnitsDetails",
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r287",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of common stock at discount (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum offering period",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Maximum Offering Period",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Maximum Offering Period"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum number of shares to be purchased under ESPP (in shares)",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Maximum Shares Issuable",
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Maximum Shares Issuable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of additional shares authorized for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares reserved for future issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Remaining Contractual Life (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Canceled or forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled or forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Stock Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price Per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value (in thousands)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn": {
     "xbrltype": "durationItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance period relative to total shareholder return",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Period Relative to Total Shareholder Return",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Period Relative to Total Shareholder Return"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental stock-based compensation expense of modifications",
        "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost",
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangement, plan modification, number of grantees affected",
        "label": "Share-Based Payment Arrangement, Plan Modification, Number of Grantees Affected",
        "documentation": "Number of grantees affected by modification of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service period from the milestone achievement date",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Service Period from Milestone Achievement Date",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Service Period from Milestone Achievement Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails",
      "http://lyell.com/role/StockbasedCompensationScheduleofPerformanceSharesUnitsDetails",
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Achievement of applicable milestone",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earlier of one year of service from achievement date and three-year performance period",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r292",
      "r311",
      "r312",
      "r313",
      "r314",
      "r317",
      "r328",
      "r329",
      "r330",
      "r331"
     ]
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of PSU Activity",
        "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Original exercise price lower range (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Original exercise price upper range (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "lyel_ShareBasedPaymentArrangementPlanModificationExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "ShareBasedPaymentArrangementPlanModificationExercisePrice",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan modification, exercise price (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Plan Modification, Exercise Price",
        "documentation": "Share-Based Payment Arrangement, Plan Modification, Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum exercise price of plan modifications (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Plan Modification, Exercise Price, Minimum",
        "documentation": "Share-Based Payment Arrangement, Plan Modification, Exercise Price, Minimum"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares repriced (in shares)",
        "label": "Share-Based Payment Arrangement, Plan Modification, Number of Shares Repriced",
        "documentation": "Share-Based Payment Arrangement, Plan Modification, Number of Shares Repriced"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting rights, percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee purchase of shares, proportion of fair value (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, par value (in dollars per share)",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "lyel_SignificantAccountingPoliciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "SignificantAccountingPoliciesPolicyTextBlock",
     "presentation": [
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Accounting Policies",
        "label": "Significant Accounting Policies [Policy Text Block]",
        "documentation": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_SonomaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "SonomaMember",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sonoma",
        "label": "Sonoma [Member]",
        "documentation": "Sonoma"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_SouthSanFranciscoCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "SouthSanFranciscoCaliforniaMember",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "South San Francisco, California",
        "label": "South San Francisco, California [Member]",
        "documentation": "South San Francisco, California"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_StanfordMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "StanfordMember",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stanford",
        "label": "Stanford [Member]",
        "documentation": "Stanford."
       }
      }
     },
     "auth_ref": []
    },
    "lyel_StanfordSuccessPaymentLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "StanfordSuccessPaymentLiabilityMember",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stanford",
        "label": "Stanford Success Payment Liability [Member]",
        "documentation": "Stanford Success Payment Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r111",
      "r112",
      "r113",
      "r136",
      "r158",
      "r159",
      "r161",
      "r163",
      "r169",
      "r170",
      "r224",
      "r246",
      "r248",
      "r249",
      "r250",
      "r253",
      "r254",
      "r259",
      "r260",
      "r263",
      "r266",
      "r273",
      "r359",
      "r469",
      "r470",
      "r471",
      "r472",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r502",
      "r523",
      "r545",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r755",
      "r774",
      "r779"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r21",
      "r103",
      "r123",
      "r124",
      "r125",
      "r142",
      "r143",
      "r144",
      "r146",
      "r152",
      "r154",
      "r168",
      "r225",
      "r226",
      "r274",
      "r325",
      "r326",
      "r327",
      "r334",
      "r335",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r349",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r378",
      "r460",
      "r461",
      "r462",
      "r477",
      "r545"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r489",
      "r490",
      "r491",
      "r562",
      "r576",
      "r597",
      "r616",
      "r626",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r641",
      "r657",
      "r671",
      "r811",
      "r858"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r168",
      "r419",
      "r468",
      "r488",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r502",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r521",
      "r524",
      "r525",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r545",
      "r672"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r168",
      "r419",
      "r468",
      "r488",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r502",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r521",
      "r524",
      "r525",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r545",
      "r672"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r688",
      "r699",
      "r709",
      "r734"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with restricted stock units, net of tax (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r60",
      "r61",
      "r84"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r60",
      "r61",
      "r84",
      "r298"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with restricted stock units, net of tax",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r84"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r21",
      "r84"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets",
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r64",
      "r65",
      "r79",
      "r504",
      "r520",
      "r546",
      "r547",
      "r666",
      "r678",
      "r775",
      "r798",
      "r844",
      "r862"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://lyell.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r135",
      "r258",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r272",
      "r274",
      "r348",
      "r548",
      "r550",
      "r625"
     ]
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease income",
        "verboseLabel": "Sonoma sublease income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r665"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "lyel_SuccessPaymentLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "SuccessPaymentLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Success payment liabilities",
        "label": "Success Payment Liabilities, Current",
        "documentation": "Success Payment Liabilities, Current"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_SuccessPaymentLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "SuccessPaymentLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Success payment liabilities",
        "label": "Success Payment Liabilities, Fair Value Disclosure",
        "documentation": "Success Payment Liabilities, Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_SuccessPaymentLiabilityFairValueOfCommonStock": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "SuccessPaymentLiabilityFairValueOfCommonStock",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of common stock (USD per share)",
        "label": "Success Payment Liability, Fair Value of Common Stock",
        "documentation": "Success Payment Liability, Fair Value of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_SuccessPaymentLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "SuccessPaymentLiabilityMeasurementInput",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Success payment liability, measurement input (as a percent)",
        "label": "Success Payment Liability, Measurement Input",
        "documentation": "Success Payment Liability, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_SuccessPaymentLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "SuccessPaymentLiabilityMember",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Success Payment Liabilities",
        "label": "Success Payment Liability [Member]",
        "documentation": "Success Payment Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUPPLEMENTAL CASH FLOW INFORMATION",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "lyel_TenTimesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "TenTimesMember",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ten Times",
        "label": "Ten Times [Member]",
        "documentation": "Ten Times (10x)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TenantImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TenantImprovements",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tenant improvements",
        "label": "Tenant Improvements",
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "lyel_ThirtyTimesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "ThirtyTimesMember",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thirty Times",
        "label": "Thirty Times [Member]",
        "documentation": "Thirty Times (30x)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r257",
      "r271",
      "r347",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r450",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r794",
      "r795",
      "r796",
      "r797"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "lyel_TwentyTimesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "TwentyTimesMember",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Twenty Times",
        "label": "Twenty Times [Member]",
        "documentation": "Twenty Times (20x)."
       }
      }
     },
     "auth_ref": []
    },
    "lyel_TwoThousandEighteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "TwoThousandEighteenEquityIncentivePlanMember",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2018 Equity Incentive Plan",
        "label": "Two Thousand Eighteen Equity Incentive Plan [Member]",
        "documentation": "Two Thousand Eighteen Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "TwoThousandTwentyOneEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 ESPP",
        "label": "Two Thousand Twenty One Employee Stock Purchase Plan [Member]",
        "documentation": "Two thousand twenty one employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "lyel_TwoThousandTwentyOneEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "TwoThousandTwentyOneEquityIncentivePlanMember",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Plan",
        "label": "Two Thousand Twenty One Equity Incentive Plan [Member]",
        "documentation": "Two thousand twenty one equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government agency securities",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r658",
      "r856"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r658",
      "r660",
      "r856"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r95",
      "r97",
      "r99",
      "r100"
     ]
    },
    "us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityEntityMaximumLossExposureAmount",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable interest entity maximum loss exposure, amount",
        "label": "Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount",
        "documentation": "The reporting entity's maximum amount of exposure to loss as a result of its involvement with the Variable Interest Entity (VIE)."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49"
     ]
    },
    "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember",
     "presentation": [
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity, Not Primary Beneficiary",
        "label": "Variable Interest Entity, Not Primary Beneficiary [Member]",
        "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity."
       }
      }
     },
     "auth_ref": []
    },
    "lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary": {
     "xbrltype": "integerItemType",
     "nsuri": "http://lyell.com/20240331",
     "localname": "VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary",
     "presentation": [
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable interest entity, number of entities company is not primary beneficiary",
        "label": "Variable Interest Entity, Number of Investments that Company is Not the Primary Beneficiary",
        "documentation": "Variable Interest Entity, Number of Investments that Company is Not the Primary Beneficiary"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r665"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used to compute net loss per common share, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r163"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used to compute net loss per common share, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r163"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "310",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-9"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "b",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-6"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-21"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-30/tableOfContent"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001628280-24-020467-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-24-020467-xbrl.zip
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M+_ 0B*[=FM=DIH,M513P]XH.?A6<-,_ \!OS)/ Z,&+Q::^4NQ)%046_X*@
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M6D!\["5SPJZ=_&4K73O9;OAOP1/2M^WL"N?Z\B--T[$,7<-1!3>X+$Q-7C!
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M82\6*F>@V^![H+EPX3B@UXN>9/&QM":(658ZSN?,XG!@A@WXF;.B [+%('9
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MLVU8//M"K0%=:U35I\1P?JW@7R:94KRR]D+([ KI8VAJ^)^;B#B&[C6Q[3E
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MC5ZUV5CMG%ZR5\E>!6.O3/E]RLJ<J,/E]_4K@VZUW<\OMZ_DKY*_1.>O3,-
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M+AQ?\K+:JM^6^PYFY@ZY,NA7Y79>\W#+^E>12&B+L,V)A)3S;$I9# '[A<[
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MW)>=2"B;.N_C25VUVUBEL**:Q,40P7>666/)+P8E#HIB3&VZL)!Q'H8N8Q$
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MKL>PT01H:Y:'Q3 "UNFG6=U%=;J\9K:?J:T8B?N<Y)ZI(CE73;%=48 N6-(
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M3@QJT;H_.<;<B1JS_I'G3@QJT0 ^>95S)QP^=2+43\>=.4$YW)<8.G% L.K
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MQB_CY/YP'<_[Q]3]]?I/&QP4"P^1?D17UJOM06ZLBGA)Y[+,*1<I[YHL,D8
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MGF@8TZAS=:UIV>1K WS=<''#Q4?6QU4% T9=;EV/QE7-4&V KQO@ZU.W\#?
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ML;+@CT"P_%/<7?2$,X"D,W>=I>),@1^>2)H#>8-+)S\'1$)9 4X?ML>7'OD
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M.'(\5F*ML$1\L6D_,<^G1SX#D<X#"]C7A,68+KR/M(4%:@J$)==R)1;[7K?
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M+ZES0T^1GE46U&0T/ JHR2YW7>/T3%XH1#RBA9]_-SF%]<%GOX<F8V1(Y+5
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MV3H;Y5IG8?!SJX(NND.0GGX8/J8[>$3&LA.TD:BF" ^8;HB>>W9*OJC]2/G
M^]@R;4<EH&!FH%L#[-H+<X!P^^:,%8@>RW)F]*]O\[L0ZH=+&.JZRO988>HR
MV4U5?V,D?N"S^(&+QD&4\!*Z:R82''*\H' MJ\,U(JQO'='<>=[Z#3W="6"#
MAO?VW>[$3,A]42Z4YM7 B9+P>R?_\9MA>BM+7[\S;3H7^M)OXEDB@8I)P_2P
M*KPX_N<HGX@M_)A3%+.RQ)O%G]OPIU^SOQ]UVQ,M_T^==C?W]T6/ZO;:G7'^
M5XH>5?S[?F=8W:*T;8_*&2LF[P5XFYWF4UOFGFT<&3O)?"QGTA?/L+_,7*OQ
MML[4#@<)P>C %QX=^(#1@7],W5^O.00?N-*%8P)/>=:Q472[#J6J[2UHH@"M
MO\-);]_MQ1R7=C3"?$$BKVK:Z$D'XZ$Y3=("E;O!GICEK)8Y T:W[?DR!RA>
MZFS[[F"X&8M9&.+,R+?3A6-0<F;BH#^YNM;4T20[!:%NL^X/G8O><%S#<2F.
M&YV"XP8=K$$8=L^5X\[0B-AO&O-)"5F$FLF&T V<P^CY+M4Z[S6G/.<$7N&<
M\NY@?!*.[EY=#U1M6#2NL>S8X9?2E*G7Y;I*#5%U!Y.3$%7OZGJB]D9%T'+U
M(*HS5 ;Y'B6GVT[-M<(#U6AY6V+5>UH0^6/..\E)YYWV(&%D7)9Q7,T1O2+9
M>!+)J*%D[ ZRO0@'&="5W&V]'=N&PQL.+\GA6P:$'8G#L>%44\?CBGWDFK%X
M38RG7RGA&V_"C0..U#YS?^/G%[OZFVVEF>,EFNL#&\N7PEH^JD]?,S\QWDCW
MRF%2;QFFNU/]Q5='+(P*O#RR .-_QQJ,KX[_7SBI3ZZT+(SU8'!U/1QN0[&.
MC3]#0W,F#F[*,M/0]-AT^LS@^EU;X5[LM'@MRT?'%;_"S^TP+WXPO+KNM4<9
M1!ZJHSO/@B/EFZBQNV,(T0G7=WXEQ5]Q@I^84\AG/RCO90'L[U$=;:*1CL_0
M?,*&KPBY(WQ0=R@'2>@(T=XB''=7GE <9#Q1&"OD")4@+G0C63DIL,+SH4RI
M\4" !_'JV^AM)BPXA@,GBR*I$C.)KXIU<"S"<=QKV =P?VX'<JK%2=:A1E6J
MN/0OCA$62WT02Z..XR\@&9;!,J>*<#!"GM)R6KP(BW:ZCO5:/R\<(6;@-,2O
M#=&E).].=-&)"^2C%9E$U)4G65 VG2 D>). ],#&O6?'_0'B828:CV5%:N8"
M!)7QV\O<&1V6P6<#5'H[FVN)T[UXU )%[,^Y'Z_.2]S7'2[T,[9W\W\AI$?>
MY>$ D_8P9X++MED.M=C@GZO5M@U.P"P=M?- HL(9-53;6KA7SO[;]EEETU6:
M$653H=2FW@T)/+09,ON%55WW\OIDN6DE-B.$3]EJY<(MEY8MR3[).\%L93N-
MAMABJ*E]$!;C8?'T'<G+;>4#=A(F)#[:AR&O \U3P;P>HXVD?-A[!--QI'+>
MF>"4O78.^+HT!9_%>!D<S9 8X+(+U$-&P8(T=>0P88X'CD!YB3,+P2G%Q$EE
M&9 9OZ09'U()$$'&];N$(8A>.>!N0EN)FI2QK0._)-L8/%$H';89A2Z"H 4.
MI++F_3RY(C[46ASLZXG#@'#,@R=F46\!LQ$5#$U:[,/'F32VS]-^4P<Q_W4T
MMWW>I\C[%>)=WQQP^2&:<&4[RFR!%Q[V*Z3WX]%C(D4Z99;SO,.BVG!\X;/I
M7334),0SD_TV9-F@\E,E"'P&QR Z.76#AD0PQAEODMHAZHU]\8%%.^7C=A)V
M4VG?+<5D.:.'JQ+)L4VF796RCMQ0P]FP.4.WY" B4:8>SEYJRX8"HHFD!TRC
MA)+>72$?$<&RV*/2[G3.P\+!V9&SZ''?3K',>2A&.#&<G4/U/<(7;1$)@%,5
M@CAS;^M/!'$^,P_K]\"50*B[]5$GVSNE__,]PA4&^2']IQ\L9N +J%KZ%->G
MD<@2FG5S &'8K0:1@3-M=)TE^@F'?0%9VT(YG0D5Q#%H15@$^8BZ![F@"U:.
MG:M,$QC>CW!X'B(2;H%1&&)[X[,3QT[8<H1:-4>8.;T[ =SWX%"(AK[%5?H=
M\P/7WNUTAQM/5X(#RDA@] [X$[XDA/-T'^[OPM$N2X9<JJ(G^4QCOKSH%E*0
MPI)N&QC##3"&PP;&L($QK,\F]H<QU')A#/LUA#&<P:\P#Q7O/D 3$/2*8Z-F
M_2BG,SDN;1+NE)1MK/5:RK8MSU+>.&)NHFX+T ([\+9\Z^T&*)("M*5A_SA0
MB/&V^3N">(APE?) E(8X=21O0"4I[2)%0;]:K<!R)!8*#X)#K25MX-(G,ZC)
MR8QW.AG0U)8IT/[TMR]DPHF<D<CT@'?X1=[ 3711OQ/\\2YVQ^3J&F>UYEH=
MY#US+R9T0R64I1=@5U",- AH;_J6'XQM2%*IO5V+HT5+V;4\4"XC$8@C I;5
M]^QP$1S*:GE.>I1#-/LY= )B824Y=8'_B<]SC>.1$0"IL4W@T7O $!0&H!)0
M1$NG5E!X%I M+,M<!A:=;QIRE(_5$+LH?JH78<[QR)D/^H+YL0?QR3Z4-:*0
MH80LYYE6!-K&E 4Y!\6R1KXLCJ8C D\Q"$_^V>QER>@>4*07AY!4M*[4F)5J
MM2%67&PW ++F,FK9EM;.:4[' ^+&EN<?9<T[:N+SX>C$<)6=.'H'(R)-_7&L
M9$3MPWC=DF.0(F4#<?K/F"8MK0./-,.,A-,?G*OC>(L/Q+5;X5%BVG'4N[K&
MOV5#<S$O?/?]%@&S'7F_.?O2\G-$$:QD6L E)&5"D!D,IUZ0=MAH/L4HJJW<
MS, CP.(L0F6* N/T&C$92:   KW. A>ABH#>XO Q\<_.D,8M2\9>YI38E=A<
MNB3T9%2;RVPNF]O*(=@LN3<7XVB1V\1[^E-6NJ!>-/TU>6=9,)91__S 6&Y
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MW6\9%LZB%M$]RE>**5$.86Y:V1QZ2JC(2EOD#;2@Q'7SK#'%[M"F:>-4/2[
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MY#K <5EGM2DI1L]-2@E8L482<GH@<#;@GYX_<"[H!RFCXGS*O4C\0H]L= _
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MJ& Y^9['; ]7[TV96(Q-5 M<M:0/JP^([$,3'4Q&:=&24[<J+H\F_ULTB!O
M@M ,/K!H,!(A8(AFMA@0U/IBIR5 .09"T@EM2:IIP.NH&(64T^V3_4$]D6T8
M _#TMY7C,F"=U2AL3E+!QR]^]/D1GUO#S')359I4?0F1V!:[  J;D'CEM0+Q
M,[^$!H*W02R.;G'R@H GQ4RJ>]X02_J39%<KUG[U:K:=(1<5SF4* Q8+&_;(
M%^Y2.SPOB\N:K!Z5'UG^E0QAFO.S<.9$*LZ;,IOUBH;* X'+BTN4+KV%U83>
M :9/,?%'"I)I29G<;8RQL4P,LL;P"K%YI?.2ZY:P:C[DQ67.ZIP3PO"*C%_
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M"R'2.%&I(-H/-AY6RI*BC(H"M]J9].Q$4IL3$6*!>@E@[@D-Z/'::$7K903
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M7WD;E63[CS7\$D3'"-@B?-%F@]9VB7&HF<MD0H9O4BW!H848&3>#"/O15.,
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M&!#L-LT[,6^MLP1[=U95D5QQ25GZ1/)KR8W(=&9E8*/G!=Q4/H?#:S)CRLK
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MO<FY\PVIJ=$N6[FKG9.>^;R%'\+9JD_BC+!_H(8C"SS5F+3#S:3+F^"IOE5
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M%,:XN.'@7AW:AHI_WGAR"A?<>QHF]D,IT5D,\((7%3:8LFPH0^VF.;>E[F(
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M1:,GQ9NZ=QT5_=,ZH\L1L=K4F%;!$/VFA4H3P2+G?V#MG4,E)-/NTE+=Y[S
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MAA$9D,P S8M &/D"9(N9/"38YS! \GPT1]^0I.G^%N^9S*V=(7'O,8Z)YYK
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ME"K5XKIFM6,W0P5+P;K.M#*([J1''8!J %2]2#Z>L!!HCE;XJZ"D,SM<'GV
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M9<89XB(UX9CS2=8DX!N^J(7M(5\%HY6Q%3;\:\;<<CRS[(>A82VK5;-I]G$
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M1QGI!O(CQX0N<1Q9T!75+9XNGGF23>DS>!],79S<ZHB0J^F$^_$G$DG:H^C
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MO9:I9D&?!8L9WB"L!D:'4'O8%^$67SWA2#"YG%['>K4F(S/L;TBRI*.&<QJ
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M;JI ;(*M[CBZP+!7'WMEH8_;^$6)/ "GN:7S$EHQ81.WB],H3&&>#\KTTX/
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M3HU2NDMXU<!W:@C6R@K00CD00[MO [,1&A!P[ ,P#H*U7[J]-<D2X(B.Z<^
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MZ"AB4&IQL!"A19U8=,HQKT(&R#PHUWI WQ5KG\;Y_I!P7Z4>G(*UD[S],!E
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MU;>#Y%J??UV'D[R1F45 C4A+F\ODI,?J-#(65/!1N8TR0PZMP'O.L!KKKX/
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M>MZ/J5TVU9HWS7[\=N,WBT0*F[.)64N:JE40@:P-IU.!PI+RSAA4L?E-VC9
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M3\^)KT Y?/:#9,_#A*;U\P+H<[#^EXCG^'@.+ M__=K3>QP9XO("=?JQ]76
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M=9!@@G*CS5 ;"QCX,C&0$4LQ;F.,<GTG5CU@/OSUPC-12^E71&&19H^CRM3
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M!46/NM?W8N(6:G:8GF 2\8UXL<>FZB ()^ ;W\EQ$%G-/.9E0U/N<GMIZ$9
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M+'SS/Q26KG!ET#&[Q=B!XJ#CCH4>2?/!1_D1\"7$%8B@26PE4N:"%C03/27
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M5C+_&V7O'=;4UZV+!I&B-)'>4:K2I",M( (B(@+2F_0.TELHBH#44*0+J("
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M!_[N($B#(ZIV#_>L</S;)(NAU-9Q@9P9O]!:R+8;C^=GFSKV'M'1DY_;(5<
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MW0'\(XQ[%H?L>N6$@"BDY7T3=_@^TS2C$4B]Q-?2H"]TT^,*(+BLO"8;G\+
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M.[-OJ!KG$U!)S/TGJD+W#XN^4 %PN><F?Q9NM3IJDX$DD#Z_K&N0Y04-S%>
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M<).%-FH"\\GR"K$OZ#(V$-QA[F_4,"-@J3!^Q*KYX/:X2SF7  .M#-N%9[X
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ME9-MQAP- 9S&SMVBX6N?=]".ASA;'U '(JIN5)8CL&2^Q\_W8*';T90M]P(
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M0)_U!;J&P':ZHV1RB>TI=?$7\#A,CX%^T]-%0*0<NZ83VYH3RPQ 9W_'3#^
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M1;9.!;1>J@ADSJ*DL'FB;K:G@SW1Z.+"FWAELNGF?G[+'#8:U#$"'$WD)TY
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M%</%3R6,!^PSC >+__PG#_L:^, *'[33>YL3UFY3/Q>\:W$-VN6'7ZQ0]MO
M^ZZTD3E(ID-CFDT+-I,U$/ DY(S>I+[;BROX7:;Z6U3PNE<OSE%'TC<:^XW
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M?T,M:O6?H8;X+R;>7$KM\O^K4,=<TQ X30CAR#LY]MXN/EZ7#F>X8CBV!N8
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MQQJFVFHJP,7TV=QAH,Z*ZX*@4O*VS\+:S,5BE:PRX:<@@4J7N*2SWVA2WY2
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MU:<?5@<>B&G-@A)_\;..5\#A\V<BJ( .$$W3Z#.=Y*<C4*O\KJL&%LJ#8LF
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M#ZK$#LRT)#&GNW5-1S=%.W'OW U\WN-Q#3BG91V;L*7BD)>66$4SM3=36N"
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M7<0'(.>)<^XL-CUB(<CX8 S63@#,GM^VA&#SXE69)C_.H[Y4!+$7)^1)9U^
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MZY0$F8SN0(<*<M%/[__TVYM::EB>AZU/?CJ2P],1POLUD;C9,,#%\4.[N:^
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MF4Q,4141ZMMMV59;_7G.A(4T##J+*^I4*Q]5C( J81E)'+AOPIN?'5O-S8.
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MW"3,S4:B@:VP2%;QH'A"'$O.P-%#3&+2^G 7W<^X"]SQ@M%,/.QSXU<Q*+0
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M19%;>>1G [_F0>6(]IY236C*H%UU9NL,'EPRGFL:@<C(R3T!9'<,L-M[CD9
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MHRR<!*&#E)4JPC,P@6_I\\K'ITCR&!^R_; OS/V89UA@DZ /K%/(_030"J:
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M@<<%9P_&IV(J4)BYZMF=&U.P.>\_$@#_#L"IF/G^%!=P+1%RM/93<<($AS.
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M(0WW()R;0[7\:B5W1# 0V]RUP#&TRS[[ ,T?Z\ Q<ZN'4-YWMEVK.G]&GO)
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M8" Z;^<'&J:/)H?;%<QM^*NGB!CM,Z7)IMUYYD/9$C]E8<?6*K5S"J ]!=C
MPF&4@7>;>%"#3[U.0*9Q$NT^G=\"W/R?52=_@M7'[%8@HH!<0X%.1=BR[GL)
MLQWR8V[ML,#"SCR3T(M/SW<#,I\F>+U\#G_3;*U-/]AZ"F ]!=C#:38NB"1$
M/$':/ZG\%/Y8D#IE<[#47U#@TT'.2>QA 9<$=\+"Y;J&,%W4-+H1'^WKSI/
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M5I^ZFY&LX^BVKB]3LGK)F6Y"X>D8#M2U0)^1!@>[Y3W:&:AKGY:3\1#+O?O
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MVMYZ+]:M!8XQ8RX)6)ZWU8*4.3'[W(F<-7D6-*AD8B./\>9!"26A![<]'Q5
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MD6.26_0CDZ3;^RH60)#LU;W2>';#>CQBXQA01/11.<H%<8-;Z]A-DC7<#^E
MRHNT\T;YPG*6VV>G4KAD\[B,P![;%!O "6!7$KI]:Z*I.>T6@7%E:K=8IWW
M[:7V$Q^O$HE  !U@5<&@%!U*[C#G' 4)' J0I$:D--0%89G#,8M5[Y]FT6U\
M/[?A_H7LAHOOT9GN;SZ9J-G\TP^:;EUQQX#S3/%U&VG.48YIKBIYJS7;4YE1
MR>7HL#6!<Q6(*29EXU55'<U>#H?!M+,R9>SO#RQV^J'NE5'MGS/#^-_^5]-#
M1@[$]ZF\N_O!C+^NN8&9NJ_?!M+ZHX$74I__0'#:BYHHOGUW [F_Y\LK:VEQ
M7YV1GC_;M^FQ(G0)LS7<9#P_/(^N%Z_T3A&?;7&^%&6WRZ)MUO*=D^$,\%7I
M.W]A__:DU-3=SHQY>YV#H5#81EWP>1[S[I4@KN3/?GU^YF8?E)6UBW".'XD#
M#/@&A_B<R):NY&37JB97WRR-/G>9N;,DC]QO0P,86FNC1^*53LU'YRC9"OR9
MB+WD0$WH,>#,]C& (/6#OT&F(!8LD  )#U]R14SWFX=]!V/T?X',_@TD"6\M
M)B0>7:A%DZE/G#/6H:$8O'SO2(WQ&* T]Z=JV.U5-'VD&G6&[.".OBVMEF21
M&6$13:MZJ"8\1.2W\P?XYUCA@X7%\/E&")DW&JKQ\YW?_U?R+<,>_'J 9S?B
M)Z-4*8FY]QC0CE;'P"::L"+A3@D"<!IS(U7O@?S2B04*M% /Z51^PO7WC$LW
M]I.&>\7B<WHNZ,"&TKSR[/?9*C-@UM;4TS/3\AT,8A'E-;( /^B/K7EP6R#1
M!#^E,00Y2WC27^?<OX9())V:]SEE:M ,F8 ](&J*.TR^+RSR#"DYT_)0#1;3
M'<'E,N6\PA6_=4W-^R='+R>'ANX:28  ?H%YQ)EFP!S:#K]L;/+E&"#V0UO%
M4VT58UCE?Y_ FWIBY[ XX0'QZ[:=!@KLF:4/HTC>^F/6II(GAAY6ZGI=K*?&
M,O(A#ZE:N-V):I#B3;\=A?Z?7*@XYR2V>)]NVE%N6KQ!(?I!/WX@\>B-Y>)1
M\M?MH+FR3LM@%O(94 #.6,+VZTMJBC>1]6FI!;EAP]*)SX>1;=V6ILAA_@>/
MP*&Z /K/V#^_Q:VSQJX)PU-.M='H$<,[,W1%2;QF\NCT0=2):LJ-7%C!E<6C
M4L-=2W+\(;F77U9/CT^S#U)$V"#_U%K2[TIVSC_;1OBW(EYQKMW;.-\, 0J&
M31HO%%81TK1&JAZ-%1IQL5LY\DH )[["XH#6 1G11Y:N3_J]%_?E%-?-_[TZ
M:+\3 6AD][V'XAZKUYHWHX",C@#,(?8$C5L4Z8*JAO1WDW 51TI3&N5!P_VS
M AIVC]48+J;?BU0[I:<&H%<VN)FY\1\[@M*AK3J:S ^4L"75XF;VXH[(:5I:
M1*#Y6)TA,RV0=..,"VSY*(+#BW;%\L2;IZ5*P\O1H&$?6N83?3:G_Y]TL+8!
MI6]3.C<(8N<MY W.GEI[Z5#E"/=%K4=7F(JVW9_#<?C'U_S=[_5Y+F 0;QMY
MUPCCQ*HV8TBH$+?C4,>GR>Q6Z5VSYGCP@S6[W&234\'S6Z>)+IC9J%J#P!]"
MX+9)A\ICP)>UREX:ZVC]:[=[UGJ6JVYFAL^].%'4N]]MJ?3:G=O8P3<>=H#Q
ML:8D)?SHP=XQ0.90^4=W1$Z70D^7T,CRNOD;%9TX$]&3NMG_F=E>B&9Q=-'R
M2P[+SO*8_"CVKFG[FS/?Z-'L#-2[9BT)3+POV3QG>YDAV2[VK)>WL+LLAJK$
MFQ 5/X@:&D\X:>CCU__5J_&1;P9D&VWZY+N<V%*E<X0'PRD$AMCN+95).7YZ
MX9>Y /<&M^>>&/NHY5@1G>[/*7^Q:^P?^D!^ J6XRTPZ0_<@VM+X!V! 2$L/
M&,]E#'?UU\5E1F:F3H */\_= -?>W'YRF)E:H5VA[<Y1MB'3H[49!GI/7LUS
M9'!D, L6]*']]7_T"?#6E J["O/37JXVWY/_LWX!W8=4AU3&7W;],T&]6IO1
M7Q,M-L0T?OWDO%W2.J3"$/1;U\:YL3B^[-BS*M*AG;.W[GQP,K47CMX%>Q"*
M';IJ/;M"!!E^<MF'F67,VR2RFN+B,J,^4I5RO3]5]B>SC"B?T Y6=_H_F8/!
MS,?4E"/4LB;2S0(LM:MP9WV=CP&*]$*[B@ZX+M&>%$O[PS;N/&==D'SWY(TX
M50NQ#VB@[=LV)C'232_M#>_'?_ZZ^">=X"I'B WVVCNG0W66GXG1 EGPAE%+
MSG7]LA)6YG;],,VF#Q;O(@?%DMD3%:Q6J0IV05QCY7]*]M^*ON)^6(6C^.+4
MK,.>='G)^3"?]VJL:RURZ;1A M3D*Z5T\,&6G%^7I\%)>D!\JJ<+.8CV)"Y1
M6)[$KD\3 74J3^&M;IB! Q;))A)M],F\.>L/E9@LG(8,(7^HF7\R45IO0_P0
MM8<3V8'' $:5#^P5^LPD/G..8T#&&XU?MZ = X@%8(P\?N6(A@U"/MMU,MW2
MMCF+8PP\&1BA@\&K%L/' +PTF,P?37Q4+W<,N'LV\1@04'828W6-_N_SDOLW
M7FJ_\3K3P-&-NK6,'&E<629H6QUVL5X =.552O39&W!G$-O:4+4OLZ#RFG54
M[WY"/V4W6_<<MJ^D5>-2W(N!_\#>D';ROU1]?CF%>UCK']FJ_0-1P>:9S,]-
M?]#B'Q48+BIC5R3R#SS^H,#,;_^MO*8=.JMWP%6 &=>GA^"9283M3!V:O6JA
MTCG:.YI\)?H_/L1*"XL[A=P".1P\FONRL7,,0%YQ]UB!):98-FXV?)+<D'35
MU0>3>)5.'I6^]XO^$/P7>VO,,>" WAY"Y&0^X6"X_24R3.!DNB="?PP8]#EQ
M#LVK3;]Z4AQ_##BBJB@ET87_,I/X@#*5DY;\H;8:B=?\-_'Q?Q?_\K/TS2(X
M\6$]^!B@C!,X:7[FW^VGM^T8\(-KN DO+T+FC](_V\%XHKWSB<''@%7%'/B\
M*^27UCYZPLEO)@W(5"J_.N1K\WCFB<K_2.6/7.4,V1E^-?3W3/[84#4!BF=A
M77\D$OT/5)<LGFL;GEC [ZG\D2I'$>U?6OM+:_]/M>;[&U61_ZTU"$QRG<G'
M?%6E4G/]0L9;O-CR91D*M-/(>M)TR0V24;IT^5.9O<;8=;;[-%VZ*K?>U5-2
MT:=Y*8IU&4^<B-\Z\29<O[FK$_$58>XWDO]$M-";"/E7=7[_LKQRU?>US%-K
M42+_\*=5FBQ^@9L>=R1(&,']/<K"[]FS:U1)2(VH5RU#QU0^' /J+YX9&-2/
M?"E/'P%2M,^:;)WLC'O>_4$T-S_NS!Y=E]"N5-8_-/34_]A!Q/]-7BBKOJMC
MN!?H9R+"FCUL&6]32F1B99S6(SA>NDP6G/B<W]4OFBIE\?1#%LIUEF5_CKK%
M\,U-4O]A_#SOBXFN)R-</XP"T/^JS?R?P*N]9GN*O?S-OC>9M<!;X;YKG:6
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MRL4XM%+]+$G0P#U&BSKHD!][U? =P.(V)9>+&7KG0-][=4_[^_;W<$>649Y
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MB(,@T<UD&0;E6!1;@$I'70 %=$16RQ%6#<NC70:81H=,:3=*>M$CZX0\F",
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M(*^;!-2[!U)TO0"^E&T;<KXSC^17N70S/6'MS_LJ3_J/9:56G5&":,)Q!'%
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MS6#.D%U%,6*%,5VZQX;*FW]N1)65U:-*-FH#XS.&,$V#,(&10%*SI,2'\O<
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MM6DD4J]F6\Z\*$)QF##H>2K]3(0>Q-@+(4TR+Q L1#XQ\AT. 7-\JO5F=_:
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M4TUXB[8BJO?13/@^I2$+H!_Q6'5+Y!!'*()QDF91%,1IE)I62!Z'ZECZ.QS
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M1NAH=WOEVQ78D+?-'YS1EFGBX'(=.&4,.K*]7,&H_ YY@F'A+D@0G!EXXLS
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M2Z8:1%WWP8YGB"4E3;("IG&B=M.4)I#FG$/=XU@6DC/UP"0 @J.L!G8K&UI
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MY\WB&.KEVZXC^(S+C.9%R6$>D1*B1$J(2:1[*Q6"$I[1.+<J>K&D']BD-]R
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MA;&SWOL5:7K%[04CBFSU7/$G,@?#<EKM/T^+Y+3Y/!AJLIWG:1'ZV\XS3UP
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MBYTWN-!X=1.Z95N*WUW0)+2,99EBR L-2*E;!9&LQ##F"-%(Q?C4K,+V+(7
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MC1LPJP7,>S,=[I.C0*_]9*9MBTZ@\:GO&-E0;QBWN;8#O!@CU_88^/>3:SO
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MGC9[O+,1IG[ '/1@"9W%$BN[R [B:%;260SIVDSG+61G05W/E""+974]4X:
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MI:1\G(GO>DJKF5%E#MQ(.,I&.+HH&,O&G?K[D^XRK;__+VLTZM)&T>( L[L
MC#4SQ!PSRTH3MSCH2.\:BZ!%HRE,JBYJIGTZR32PN0:GWY']!@ \JD$'9\B^
MA6>Q@DTJU5Z?V<OGRCQOZO#=$9*DCK8TOGS6^?^0O*@C=)^.!IY+,DR@;:D%
MYC7UDV29Q'1DP1$SEOK)V4U/&GC.QG6JR$RJIT^,Q4UT]ZRR1!&6#&&)0T3"
M,$?*>$H$SC(AS0K;S$%Z%L@6!XA!;\0I$P?(-?U QV<-/G [(->(.Q WQS67
M+-V;D]QRY<M Z!WV88Q6&M%W@5"VZ[. WK0LQ]A<(^MLS^O9%7F95&3:?F&E
M4F^<$930.$0X8A$J*8\09[&D&8MPEL2@4HPA:)YU7B=ZHX&CR2Q8@P?68PQR
MS,SO<,8'F.[K9X&';L!&-+HJOQB$-6[IA0G9!V471B_92?C/9-JTU1.B^C)O
M6@;476^QLF9*KJ29\(0JX2;J)UP2%,D,TYBG.!6@2'X?(,]RO08;U'"#%K!5
MB^!>5IE)M0L&P 3:CG:P*)\BS)$4]X(958!/$;LONR>?/Z=.\I&'94S*7**8
MR0AA$2G7(^(YHIG$4@@FRZ)XK.9*61B>P/6R()'<+&[\M7S0KZRK'6V*'4$5
MC1Z/RV$"+(L271]]S:)O4%[8>YCM?@J_W:KS')97T_E2/,R_SEXFN@P1./!Z
M: W?>6&@^=>#Q)Z^VG)%)U R:JA!#58W&WB8/ M]?_WUYNZZ.X;>T\AL$Z*M
M+L$&%Q[M,LR$O.ZEF-'S%I=CGQ>"_VU5L:?A6PV1EJFD.4,9#1.$X[) 1"JS
M,L^CA+(T3O/0_';,#*;O3 *%1%!C ;@",N26P0V9>Q[ I'M+OMM+,D,. 6[)
MW'/*[IK,A&..+LI@) _>E!DN-=Y5&8RVG;LRX*OP"7%7NK9GD^<786639WF,
M! ESA-.4(YI2CO*"DRSG$E-B-&/G8&7OD3@%"SRZ_9#^82UV%E4P765,$&A*
MW%'DK:;$[:XTVI2XHP1TI\0=?\ F@F;=QG([\J%I+'0OINK='\J&J?W'^JVG
M^53A<2^JU6+VB#%).(\*1%F2(1QF%)59E"MK0R?.Y"+'I9%_,#+>GD6Z.WSE
MI48H6*PQTB9Y[;XW>8\-4NI3C14DN#7>%AM81^]SXV!:RT%92G?;&W*"^\ZV
M-U<P'9*"^W>\[9# Z+O<?LOHZOO[&@"CMJ-OQG#H=SQT1HP?C\[CW2#T^. M
MK) ',=-W4.T0U@A'"2G3%$G&E*50Q 217,2(92R/HC)5/QOU"SJRMN?37 &K
M;],@$YOVB#<X0^U)@IUS&VILK@OVR *<$?;D64Y>VI#Y(0K_^,G5=*7C9 QJ
MP+U7QM-2QW'=T20]C]CFK?QCU0YAFO>$SVL-0_=5U[U./E].*O%-+'Y,MLJ)
MS;_/ZE6:64$Q4\X&$PPQ22+EX1<IHB(ID,PC%A8BY!EL"HIOA#WKI;Y^T-#<
M&<^[9A@X?$=[ 0R\W%U?71RW![OC3*YG;*$;KM?-!Z[FRRKHH.@RQ6<</CK+
M$O*,[LB)1N,P_S!7:22XEN7KNEUE>^T[$<L;Q<W58J%K@DI<T"(O8V40\D3]
M4Y2(YHGZAQ-)XC(A-(+-)^D%Y5D9-TU39_,96L,+IELL@*7L_>PRTZ5NF #3
M@@W]':!UQZ,U6(?%["=)<U7-W@]HW'+VDP0?U+.??F/D%D:ZO*IZO9XMJT5M
MR3?]:Q^>R.SV12^Q_'L]4KCM9K_7-K(>]?615&)3&*JG;A8T*07B1"BM4>94
M:0W*$$W"HN"8D3R1HS0\<DV9[WOI;[\N@V9^<]WVB,^G4[)8@LOPWQW?'D48
M,<PS@4@2280Q$Z@D489TPBP6>9R6A#VJM^G\O_H[T:70^%MQ_U_[K3 [+M\-
MON\ZN-$0&W2H73>*KQ2]P9K@BZ A>3OMYL@4L9KP0%/>Z<?P#IIU^=K.MV[M
MY9RN/T<C,%_;Z:QMF#<$X>F]RD:\$?/V6M<PGW?G)=\)O,JQNOET:^A)'9(T
M?!*<10U,$[>$.*SNZL7>*M]V=Z71$FR/$M#-J#W^P,B>S%HP/\\74DPJG4ZM
MNT?\\3)9U"LL-[/PBC).LTCY)5%8Z"I-DJ(BBB7*HS K8UQRRB6LB8QWG(V^
M\^?TGKG2<<>I,@3F"WT)JK$Y9SR&_TWT;#XZW9BW,@LWAE^'C*8USI:0=S7[
M$,KUM[;>C/']<UAE4/8[L[; @.V.EB]BN11B=\;N)N.Y;43T4?FFF90TRK,,
M92''"*<2HQ*3$C$2)CR*(QXR!JDB- 4,,M1LZPQ7LW;NMM(8]6CNX&6- DS)
M&[/33%?[8!),Y388:+VY-VR[TZ6PF@=4U.T W.E+*.6.U)XQV%&U%Y09^TH(
M_/Z9;9]W 6PR_DN9<BS#&'&6Z4+D/$<TBC!*2,92'H=128A5\^?C\'Q'T'8E
MPJ!*QXIIAB$T=ZP QM%Z]8+?YM##=+IN$=T#[6T:10^3WMLN^L1KCCJ]/[(P
M+J,R+) @@B,<*I^2R PCGJ590D.:4P+J-G  812#8#-)9=/?_<SV[K9MW<>0
MW$^G2#R_A[LOP=RL_[8]VT\*W\&#=N)V199/^C]]%?N#3/6Q?2^4($]T.T/]
M@?(1=O_0>;+Q%]J\KH^B^;_Z?;KB-8KL23LE]Z02GZ04ZNR)A2 )BPK$RRA!
M.$EB1&,=P<ZS5&:<"B)!LCPN^IX5Q8VH K[&0M\8,(7N1?UOW9MXC75]M[#8
MT%1_#E,E(^^YF9YZOSL)4X)7]:;I?X,.@A?!%O>@>41OX]X?=]]85\YLTB8_
MM'3]5.=2-J0%+6V!)BYHJ'.G=M]F5QSI])&1'_7 >)N-V3^-W@@+NZ-.J5>-
MP=UB_F/"!?_Y]=>ECBU^GLS(C"F EZR:_*@3QC:NDB@*&9(H509G+)7I&3-$
M,\I1E)=1')*BS'-0JTDX"IY=SJO+;W\+/G^Y_?]OP>?[VZ_!Y^N;RYNKZYM?
M@LNKA^N_7S]<?_H&.UPLN&QV0/CE'3"&J4[J6F&WV.@8P0>-D#JW?PHV. 5;
MI+PXK_8\<:1B+1 854W:,VA?U9VQDE4VPIV8WX@Y.!^A^]H(&0EWGVZ#FT^W
MH*2$'<J,TA)LB8(G)JSI<9^;<(P$V^R$G;7&S$\X1L1>AL+11VQJ9W^?/SS-
M5TME)3_\KJR%U]N9^/3\,IV_"E&7?;5S7/0$B_5WB<HB8UQ*Q(3,$([R'!62
MQBB.BRPD<9C1S*C_C2T"GN5-?0VBX-.WNSM(N:H%&X=%<@SFP.16(1.TV 0-
M.H'")V@1:L9;!2U*]?0:J])?"UY"ZH/]\M2RB%CQMFIY6S6\G2O>BI:WS2B[
MEY:W>LB\LTIC>X8,ER-;K#MBS;(]U;N%S6>L8^=?-=F<.BE!?4-FU<?Y,YG,
M'B7+>)B(4FV$GL\J68**6(2(Y5&<\USI[ )4LGP4BF?-N\[\W@ -?FO  CMY
M'V>0F?=S-MDPG0JG&.R[#%+DR#TY#F-4#V20S'TG8_AA"S.JB=-?-=5OES.N
M++3U+YWZN ="I^)!_%']/-5S+Q.29:0L"I3FI= =S0@J$DQ1260:19A3&IEW
M-+- P+,P?V-/@J^FS?S+=:6J/MUN.I6KN_%WX_I5:Y8;F%R>&0E3#VT.SS[_
MVM\[* 6_U4@%&JN@1@MB<]DP$V!S>6:JG<T%8*XC2^L,-@Q:6C;KCF=IG4'U
MCJ5USCH6?>CY/Q[F^H2H9X"8-I[OON19OVY;,>@TOFZ.JN% ^T,J3U\261,(
MTWO]M#D;;])+C5WO^)V5QFL6?XR G>[P1Q\XHY;EH*_'84(T/6@&UWI BPG;
MG;5\)]3^SZI'66*9X9(B(CC1+=M*5$19B,H<4U%DN$@5'M R>R^H^O: 6G]_
MX^DKZZDI6KFHIRC/%[44J+_*[<3[#V09$%U%K3&T*6[QLZMF'M?[V"N8?G+1
MNW-S3:;1WQ\27V<E:!H<U[%XY;/+ A8_B(Y?N>*5X4=+5OQ"M(JQ_:*06X_L
M_2B6;#&I*V2VGH1YV.W$2B-$XGZYO+S;#'7NX  *S9UBB%&TSB$OX &\/C8H
M-]3  85&]0Q)M0WTG5I^S-B?(:E[X4#3MZPBA/I6N]N,M8C"DL0X0V&1YPCC
MG*&29Q$2N"R8$(+$F5&VSO'E/<OP.G %;K-[P 6C\-T9M$&#<UNR[()N^_2!
M0FIGT&D;,.O0^R%VV7BWCY@3P:[]M\8,9?5@O!>HZGO*SAW<ZQ)RL])KWLK:
MP%C>KJIE168ZOU!9OQ/VF$5$AI*4*$EXBG L,U2R4*"88D&4UY>$,H=X>"#H
MGE5*BPLBZ[Y#C<,6K+397\WKEKFK2@0S4073^;+I=\4::[]^]"*@&DW[#@6P
MO3#SR[QQ&*;8#IHZ-8AHAZE!)>C@<A'4V+ASFJR8X,@/@L$>U;6Q8LN^MV*W
M"'QXUZ=9I8-]S57QO:BO4&;?OZD#9[5\S+(\(3$GB.&T0+B,)2JD3%%$:9K&
M*2\E,VH+>PJ0[WNC&O0FE+$!'C30S2=]#3)K6'&X9 %,1]A2#QH+9D*:U92P
MP85'&QIF0EYWAIC1\V>6IE[/U"DIOJ@C\S')XXS35")!RTR/PLY00=((Y2'C
MDO&PE%EB59RZA0$247C5F081:)ZW):KSF6UI:H<O9F?YF=3"I'%;GMI "SYH
M>/T6C7V-ZB$UKJM4.Q#>ID[UD,3>2M4CC\+D;[FH'J_4MW(^G7#==*L6\8E8
MMAEFG"91F$@D\X(AG.(2$59(5(HR3F-9<%(:-8$8!N/YH.P"#EK(P#RS$WP:
M%DEWU,.DTI)P8^$THVM(/M4*'=E4OVWE\L3BHXBF&8&M=!H^;5E,KOLFT_FB
MGJC5N=Y?-ED1K.?C!_73DK#ZY/DRF8GK2CPO'P4G65%&)2ICK,2:8HP(X1C)
M*&:2)TDDN%$VOP_DO"N##BX[L3N="]3]O=. >/>EWS2N08TL,$O5Z2::F0%O
MM350337.KL"+M#VPSU4)MDO4QBVP]L#4@_)I'S#@D="['R]U>IIIO+-]WK,6
MO".OP8_ESC#1CY,EF\YU-,D\K+FA;E@7V1(&TR&#-*U391V%)_>)L0I";A89
M+=2XCW8WH'CPF67"6*4LG^<Z/[,]IS@M>)BDRL20:8IP'H:H2%F(0H8QS;-8
M< 8* QR"\"PL&X!GG/Q'^&)V?I]'+4R"@(3"TY%Z:7&51G0(8-STGUX"#])V
M^I\\8PR:3@%:B"<Q6ZI3;7LW<".J6_E _CC>%633*P)'I4@SW9&C"".$&4T1
M38H"R9!EO,@%C0J0H)Z/DF?!;FQ)UL6P#M89)E,[9+WAE=ZH# 7> -:\W$%N
M]R[P(M"=/>8R4$CZZ3;IC#LNI[R=A]#XT^"<,/#HU#@W*[_-3(;MV,NM2;EM
MLH-Y)&A9Y*B@M$18Q@)1SF,DLS"7(8\IY48.P"C8CI48L0G>WPM]_:5C U?S
M68W"BDR#+Q,IZN2'5T$68T]G&-Y.0\/LO6P2T,9S.)5A2T+'T_+3C6D4;K^3
M:0S#N/ZI)C$8L=WU% 8SH/"[G,^*B_.9T/.+E6I[_;@2#W,%X5]*G4WDA-58
MUD?9SV(FY*1:7CY7IO<^-FM[UN1KE((6IX"OA$YMVT>KM>E:S)1>>-;#&<RO
MD:P8>_K*R3=/88K7&SM!-U?G\,3JELL*X&@W8N>PHWM[=M8Z%H7*6MLMKY1J
M4W"^SEXF6M&![IG[5_"L51K 00U9-V+6R<E:#+[>W%UWK0A /7,_,T[K"#=\
M@&D"4Q:XO;,^3:E=%73_LN.51)\D;:<^^O33=D[F1T&K;X*M%DVKRA]D,M6K
M*MWPC4S%7B<-*7 1AJQ J:!4^8P\0T5:1"@O"R[B."E+R2$^(P2X[_OR3A>8
M[0S>)I+[K',&_UW['LOZ-N@K6?Q35'4;DRWZ,&\0Q'<SY\X7-V&*0F/1X8JR
M!%I$D)POD$8%T@(&['39<,&1#P4"/:I+9,.4?0_':@V+.KZ^(/B]OJ/1D?!;
M.IU\;_)2[\52J-6?V@E3CZ1@3&+=6"Z*<X29;M =A27*L<AQ5N B8YEQR=\Y
MF/BV2+Y_7]031_7DAQKP9IR<MM$!!75GL7M8,8W*1)B6ZLW=N0@:Q *%6=!!
MK1[8T##Z#C2W[WPF PH<QV*V72VD5Z;#BB==,&JPSO(L ..59+K@PT[UII,%
M;=,XU,GS-)^J-Y;M)/GU[(B[IAW-954M)G156VX/\SJC:E8I7DWKK'2EAL6R
MVMRH9SC/<B$8XGG,$4X+C"@)$U2&2<JI3$2*0;,$W:+G/7UDB^S__D\11_G_
MU3.'JE=@G-GQIAB&.=Z,U;!3J,&M.[UGC5[0Q4^[V;L8!BV*?L(67KCG+%O&
M*7(C9]KX8.QAEHX7*$YCV/HV0V>M*J?[=B;6C1R(R 7+:(H(#2G"H4[J$:1$
M,<["HF DCV/F(")]#+9O:YT]3<2/)DPYEP%Y>9E.6"W:SY.I8O9\9FBQV[#5
M4&7Z819,'QZ-WW;-Q#4J=3M_=R,YSN"!W^CK4<CO(98ZQ!+#R.C@$GW*IKO7
M7]1/?_U+^Q?UC^X6]M>__ =02P,$%     @ R$"F6 0##N#7?P  5T8& !4
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M)\)ZP-)1 )@/K8T.(/9+6/P=5R&>X67JRA2OA#:)LIA S@MHSEPMODTU*4%
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MMHY21(^8NMSF!<J0K6<@U@<M=:R8X]9#'>6@C RN\-;[XB.DC'OL=7HL':"
M'G%T>T^W7"2+(D'QKE;\I4*\A$1;O+/<6(I[PX"Y'8=Y6(/U%C@]H@Y5Q;?1
M@?]:GLMYN2RIH)^&FG9ZZZ*V7M$V.U#=XY4#'+ >RG#[ ]?-[?>SK3=??O<*
MRK9H9Q)%B/3JFN^K @6,+$+V*9DHB]:Z=8>(/4D\_@K],\XN<#D1UAI7? 2>
M+,7&)GMPA94:*FN-.6/[_**K=W=SE-H<$_?ONP^0=@<[Y'6YUV4OWIOV,D6@
MUBP@D-71) VOP8=BP6F/)1:F4FC>*/ Q8KHY+1T<1VWTT0&PWI*.B(#:BOXG
M6AMG\W6/NTNN)D:M-WP%V1@/*J<ZEHU628S*R<"B8Z6U[_4D0>,:JD9*O]\)
MMY$&.H#37W%&,CHC7I[E\^EL6N531\]?L:-8LLH$!3)B!.6T *=*]25UY%PG
M"G1;1X9?(6E<FS4,I%IJH0-0K3,GKR6UL>*7K-1FG"R):(7@P%RIC12Y@X#U
M9B'GI)*@;[K61NIIBL:]WQD&4@UUL#^B_ 91,_Q00YAA'*I)8-RB#;8V'B=+
MRX2'F"*"-UE$5@J+MK7_?8^(<:]O!D+.49+N(-UO"_4U-JYYVDX@UA)X01^8
MLQ"2X[4B%1,6BX:UCDL?(*.;B^33^=L'ZJ #&%TET=ZUG?/9_(JU:D>#*=&%
M%$!8BDA5X;8F]DB0.><06"C2MLY3V(6N;JZ5!P=:<RWUXC_=YN$.<Q,;@_-%
M)7#,K,VQ@N!1$E*RD5*F6G(_A/_T*$7=7"X/;];:::8#G&W2K&_&<?S\^=?I
M;[,%AK-ZN;FVV<Q8LLOHP2@6JI\HP7OR)B(C":J"DLG6^^;7J>KFPGEPO#76
MT+&>_/MFT'M\#1DT13&;P$A'KBNOM^F:EE2.3/,<A4?;.GO[.,-VBMOHP8'6
M1A\=>&VTW=]R.7F=C%8\.9KUPD#QR.DS9\#G8*VV"F5L?=A^AX!N+I^'!]#!
M<N\ -+N4^K[!Q72>Z?N+VL#O)]S\>RT[9@7Q6B@R-MZ0B^DE.(,*<F#*)B0O
MDPURJ'44U3O!TW\/\#RQACMP[A[C^,9]^/?Y6<T2^6N8SJH87L]N_(QGB^F2
M?O03?3G[L)'+=<F[S];PY!5PK&,,A+#@@M$@'+IHBS6V^;#RH7@9^7KJQ)C<
M<4F<%" =+)0'1'#-2@C1>I83J%BG$GK)P:LHP609<A#U(+4UUI\@9S>XLN_!
M7K=22@?.Q56KAJM$]!_#<IHFRGIGK) @O2\D',' )9,A4P2750RE-#\X?)"0
MW3#U7>02':^(#JS5-A,_3<\N*#*?U"[1Q'^$$EVN.:3$1K$9-%GB$(E%*5I;
MJD=(V0U1WT5640ME=("IOV$==8CYV6=<A _XZ\5YQ,7K<B^?>+-@?-%8(KD;
MB+6E:V8%'"NU*X,,7!GNG6H=Z>Q%X&[X^RYNV8937+^HO%QC]Y/=><!@?(I
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MJQX_=T^^)TX[7IR48%*NE<&.UKN6=19PCC'$D)P3K9WJ!RD9UU)V!\ &ZNH
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M"YY'7$R*DR5D6EE!9O*JHTX0<JIW&RDZBR$KF[[F:3[TX/% ,)#>YHV$.#8
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M*OBHW$XW8[L@9_1P\3!E;:O[ ,F-K/!?IK/I^<7Y)>&9HE97,P X9Q3$",G
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M=FL:V8:><<\T1P?J6)KMP*!NFEZ]7"XO,+]9D.?]!A?K[TU"1NF#4N"%H?T
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M5_35#=,N6L5=9B!LJ-=JS(/G2@,6:]'8[%5I?0O0A/#^=OUQH7RX5O>'LM]
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M?))IG$_7@,H<39V%D&7PH*R.$*,G[]Z)I(M-Q8GFF4\#UASO'L8(EY-+AM9
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M<6K&W87;:'L'"!T@^@Y!]':Z_#MY!]<]R=^&%5Z:8UL')W$3(&7MH4YN(&^
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M1/<BW&D,=W=OLYT%8Y\1I((A2T(9C#G28)Y9XTB@H;1M\WP7=7$T%+^WP.H
MXC<&G]4;?!-8E)KKW"$ZI[<UF&>&6^2TUQ(G99(;4CVUT#_A6+YN@<D!1*X\
M">"^Y/O7V%U/[>=/(V^7G<>",@2VJU 4,2&N*4$F$84T!5I%4-.,]WHTL&,J
MP,8-U"["*WM7E:-U;<#$ZZ='6 F1!?_.IFB1#CY[?C@BBS-9'!:><A-3HB4
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M)I$D"OF"X1[K;!(Q%".V$BL#OGGI=D/%#]%X1+ P"DL)01%(M"(3SYZ//B>
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M@NL0$#P?HE>4(PV [-<X 1=Q#">Z"#>CR2B;)#FU]?A03%"J##BUC(=%5],
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MF9 ?+ZR'$YP&E<!>*/[N0K^[R:=5="&/LB6+9C-!"F0)4T@E[V-0D@K33*'
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MNZL([4\FT\R9Y-P2@C!A&DS/*)#F!J,H(U$)U##3I@"@3C73O!?/#\HT[\.
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M/M]V\]56RX21^W^ED:CRD7S>0K_A-?KJ!_D_SL[B__D?_Q]02P,$%     @
MR$"F6 >58JP>"   &2D  !P   !L>65L+3(P,C0P,S,Q>#$P<7AE>'@S,3$N
M:'1M[5IK3R,Y%OV^O\)+:[M!2D(J":] (Z4AO1.)@5X(FNE/*Z?*15E4E6ML
M5T+VU^^Y=@4""=-I,=.3C;:E!JI\;=_'\;G7+I\D-DM/3Q+!H]._G?R]7F?G
M*BPSD5L6:L&MB%AI9'['?HF$N6?U>B5UIHJIEG>)9:UFJ\-^4?I>CKEOM]*F
MXG0VSLFN?S[9=9.<C%0T/3V)Y)C)Z..6/&S%K79G/SQJA?N=9AB.1-#AP4&K
M=7!T$ ;1X;^#+72%N.]C[#05'[<RF=<30?-W.WN%/9[(R";=H-G\QY:3.SV)
M56XQF49G_Z<?8W$DKN\PF%5%-VAA)"L>;)VG\B[O.ONV_% S\5"E2G??-=V_
M8VJIQSR3Z;3[82@S8=BEF+!KE?'\0\WPW-2-T#+V@D;^1T!'3.(>)U[_ XR3
MRES,[ E:9$3_(9$C:5D[: 3/+5A-]Q">%_HO4OZL?ST<?!Z<]8:#JTOVY?;Z
MYK9W.63#JU<M61?-KV\O^C<L:/-ZT-GF.ZQW><Z"O:AZNKT\[U^SX4]]=M,_
MN[T># <0[O]Z]E/O\I]]UCL;LJO/+#AJ=VIK;VCOAO7.K[X,^^?S\2&[7,S:
MS1;9XDSM77_J7?9OZE>_7O2_SJQL-9NME7%9\"@"A]13$6/^PQE291[!!=TZ
MO?G3W=!9ZH9!C5U,\YS=")%.:RP4VLIXRFS"[?MW>X?'&V!BT)@9\>-G?^&6
M9F./W#!@"1\+IL58B@D2C$VD8;^57&,YI%.\+Y2V3.7LL](9"YKU?S$5(TXB
M3=D@R\I<%0G7&:^Q01XV$*>C38A3:^WB](D;1 =QR*;L/E>35$1WHN;#504I
M4E A5R@6, .7.>/YE)6YU:6 !2@?7"6!Z'&6X4E+GK*8AWBEF<J0WZSR<@L"
MN0B%,5Q/223C]P+SSHUI\"Z",I@R=64(YB"!4&J4'1#+T1V:1$*S22+#A)F2
M?CSUGP@MJD'(@$R:%/4)E3H3:1,8: H1.@5IW *JJ0AFCM$M8J/IO!LV!8+M
M_QT("A;+'$$FO#P%M0;\01S->JY=YC&(A%N)<60>IF6$,0&<N0C6 #I)Y%,@
M[@19@C+HYA&3%1S,BZD!^TC2P#62*%,( (@*:''3&:=/R$W"XE1-S RE6MQ)
M8S7'1)Q>>KVA96T.;&:FS(*VFX*WSMKA;?@L.!],A:6J+B!R4'$L\;AM=ES,
M!HQKX="!:,M1*BB*3 "2HU2:A'J06 9N)'ZDYTB:,%6F1#]B3:U2#Y-"JU!$
M>&W8-E 1"<#,A[[_$"8\OQ.L!T*Z+E-(N!)U;UMX+5R)2D_^45)AF7MXTOB,
M6&L.M1Y%I,O*$\7/)HHQ$=GY$LN0H-3^AM)IK[-&^$3-ORX W6\<!>2'<V&P
M=T"T7#K[-I1JE&E#7IK5NU#*&PG HIK))U%5:@P 9AI+X_@.4B)WXU"U_,24
M\VRK1<H=SJHL^H256L7$U"C!FM#%J%1&[L3!E",C(\FU) .DS_6._W,:J324
M?]W*-"Y9.W941D A"S:F3@6J21F6*2=2AUE.B:<\CAZ^*I@O9O#72) @>!?]
M1?0&GETO'(_6",?MSB*.5R:L!3BO3G4KHQHK82PC BLW*N?$Z=P Z%12$H*Y
MCF9H KXE'\E4VBFE]F73TMIRP'.8\LOBF>A<2>I2QT-E4%'J I@VKA0)0Z4C
MIX K3N]$C@HC!;31(@I:,R2"PMO#%VM+%F#OC0%PN$8 ]D3<'_.T=&Q%T15Q
MC.I0CA$7LZ3*0R&Q N_ZQ^4EGT,J.H(SC2\L1ZJTK\^]2F;@C]*"JN;XVQL=
M-IK5XV[Q">\#Z.. 1A-L MBB-0);Q98^FHNHH.UV5;*YEA>@^PYVI!RNPK#4
M%/6YA/ELO$P9BS=T<HE13(@AJG,;MKT@' .RX*H7<I6:V!,)=RY 1P9Y^:C+
MCM<DX>:QHB"6<Q 7D:-_9WU%S5/L_N]%6AT2O)"OO<$A;P3T6FVS]C9AF^6.
M#*/9.J@],1$1XSPNGTB)\/4=E<5"C0J]."I4J[1Y3./N!0;+,FFM$$NI?J10
M(E!+)*&3Z[X-W()9#3$W?E.%/%M@XK=20F6WI,H\=,<&.__?0?UIB;N7HN9"
M#2@!,-JTTO8WE )PJ%+PXTYF(O@]Y51?@[FLZJI'=W@Y.^+Y+I!5FPY_9+"$
MPGB$CD8\,M@20%;5)H2!+12%-9_2#?*Y*3,@ ^YQ9E098NDQV$:EZ_7;W/20
ME6,-JJ@AX,)1&R#C3IDK;-5\FI/Y6*5C0;DNYW?58;FNV%!D1:JF JV31'G^
MX\^0"Z2],>TW5HT_8FO=3JAJ'@%Y0M?AY)071G1G?QR#H8N43[LR=ZYRG8ZK
MP4;*6I5UZ7O]F)@>94'U*=1AR3=7G_*/CAJ'G4/ZFF\U_D>SB:L/_0WWH7_7
M1HMMG?W&7N?@U>9F(WBU[?>&;3?VFYT_?%2G[-%*P^XZ1WAGP-VFX/G'K?;6
MK$,%Q&ZK>&#!\[L A,V7'O?.GK\L\0,73IL<<HZEX-(<^YE/W[\+]IO'^S5W
MF^3%C8W*,6^W&6#^\1SE;/TT?9[0_S"3YL.X/K="ECOA_;O.P;%Q/]G%U\M+
M=M/O7WQ=$NP5D=YD+I^OXLT51"M&<UXKX!LZC&3DE..-",G"+1 7DOF[#S\W
MSAOK$HS-=+DK5[YHU)!4-+DB[2R1(F;]!Q&6=(+#KORVAZW]_:'M+_Z0$=7$
M@O8[K\%HUY4#2ZR:O\I7*..^J';]QX.Q6+C<][1D73W1?.K"1UBWI5WL\HW[
M@-5/?S5QUUV)_"]02P,$%     @ R$"F6!*0@:T7"   ^R@  !P   !L>65L
M+3(P,C0P,S,Q>#$P<7AE>'@S,3(N:'1M[5IM4QLY$OY^OT)'ZA*HLHW? 4.H
M<L#9N"H'.3"5W4]7\HR&43$SFI4T-KY??T]+8VRPV3C%;M9+;:H"S*C5ZE8_
M>KJET4ELT^3T)!8\//W'R3^K57:N@B(5F66!%MR*D!5&9K?L:RC,':M62ZDS
ME<^TO(TM:]:;;?95Z3LYX;[=2IN(T[F>DWW_?++O!CD9JW!V>A+*"9/A^QUY
MU.Q&A^-V=]P].&P?A%T>=.L-SL-NNW/4;=;K_VWLH"O$?1]C9XEXOY/*K!H+
M&K_7[N3V>"I#&_<:]?J_=IS<Z4FD,HO!-#K[/[V.54U<WT*957FOT80F*^YM
ME2?R-NLY_W:\JKEXH!*E>V_J[M\QM50CGLIDUGLWDJDP[$),V95*>?:N8GAF
MJD9H&7E!(_\G8",&<8]3;_\!]"0R$W-_&DUR8G ?R[&TK-6H-1][L)GM 69>
MZ#_)^+/!U6CX<7C6'PTO+]B7FZOKF_[%B(TNG_5D6RR_NOD\N&:-%J\VVKM\
MC_4OSEFC$Y9/-Q?G@RLV^C1@UX.SFZOA: CAP<]GG_H7/PU8_VS$+C^RQE&K
M7=EZ1_O7K']^^64T.%^.#_GE8M:J-\D7YVK_ZD/_8G!=O?SY\^"7N9=8F1OC
M\@]WL;W6Q6&%G<5<)UZC55F%!4);&<V8C;E]^Z9S>+SQTLIY&((&JXF(H/]P
MOMAD%B**O2J]^9/<;-3F3OSXT9],2[W6H6D8LIA/!--B(L44"<3&TK!?"ZX!
M]V2&][G2EJF,?50Z98UZ]3],1>SS3"0)&Z9ID:D<<4MYA0VSH(8X';V&.#6W
M+DX?N$%T$(=TQNXR-4U$>"LJ/EQED$(%$S*%8@ C<)DQGLU8D5E="'B \L!5
M"H@>9RF>M.0)BWB 5YJI%/G+*B^W(I")0!C#]8Q$4GXG,.Z23H-W(8S!D(DK
M,S &"012HZR 6(;NL"04FDUC&<3,%/1CT7\JM"B5D .I- GJ#RIEIM+&<-#D
M(G &DMX<IJD0;D[0+63CV?(TO!8(MOXZ$!0LDAF"3'A9!+4"_$$<S7JI7681
MB(1;"3TR"Y(BA$X 9RF"%8!.$OGDB#M!EJ ,NGG 9 D'\V1HP#Z4I+A"$D4"
M 0!1 2UN../L";B)692HJ9FC5(M;::SF&(C32V\WK*PL@<W,C5FQ]K7@K;UU
M>!L]"LX[4V*IK N('%0423SNFCT7LR'C6CAT(-IRG B*(A. Y#B1)J8>)):"
M&XD?Z3F4)DB4*="/6%.KQ,,DURH0(5X;M@M4A (P\Z$?W <QSVX%ZX.0K@JJ
M6%P)VMD5W@I7@M*3?Y14.&8>GJ2?$6LMH=:CB&S9>*#HT4 1!B(_GV(9$I3:
M7U Z==I;A$_4]-L"T&[MJ$'S<"X,]@:(EDMGWX92A3)MP NS>1=*>6,!6)0C
M^22J"@T%8*:)-([O("4RIX>JY053+K.M%@EW."NSZ (KE9*)J5&"-6&+48D,
MW8F"*<9&AI)K20Y(G^L=_V>DJ3"4?]W*-"Y9.W941L @"S:F3CFJ21D4"2=2
MAUO.B$4>1P]?%2P7,_AK+$@0O(O^(GP!SVX7CL=;A.-6>Q7'&Q/6"IPWI[J-
M48V5,)$A@94;E7'B=&X ="HI"<%<AW,T =^2CV4B[8Q2^[IA:6TYX#E,^67Q
M2'2I)'6IX[YT*"]T#DP;5XH$@=*A,\ 5I[<B0X61 -IH$3FM&1)!X>WAB[4E
M<[#WJP%PL$4 ]D0\F/"D<&Q%T151A.I03A 7LZ;*0R&Q >_ZQ_4EGT,J.H(S
MC2\LQZJPSX^]26;@#]*"JN;HVQL=-I[7XV[Q"3\'L,<!C09X#6 +MPAL)5OZ
M:*ZB@K;;9<GF6IZ [CO8D7*X"H)"4]27$N8C?:DR%F_H9!):3  5Y;D-VUT1
MC@!9<-43N=),[(F$.Q>@(X.L>+!ESUL2<_-041#+.8B+T-&_\[ZDYAEV_W<B
M*0\)GLA77C A+P3T5FVS.J]AF^6.#,/Y.J@LF(B(<1F7"U(B?'U'9;%2H\(N
MC@K5*FT>TKA[ 65I*JT58BW5CQ5*!&H))6QRW7>!6S"K(>;&;ZJ0YPM,_%I(
MF.R65)$%[MA@[^\=U!^6N/L):B[4@!( HTTK;7\#*0"',@4_[&2F@M]13O4U
MF,NJKGITAY?S(Y[O EFYZ?!'!FLHC(?H:,0#@ZT!9%EM0AC80E%8\2G=()^;
M(@4R,#W.C3)#K#T&>U7I>OLV-WUDY4B#*BH(N'#4!LBX4^826Q6?YF0V4<E$
M4*[+^&UY6*Y+-A1IGJB90.LT5I[_^"/D FDO3/NU[_A$9]U.J&P> WE"5S')
M"<^-Z,W_. 9#YPF?]63FILIU.BZ5C96U*NW1]_@),3W*@O)3I\.2;RX_U1^U
M:ZVC%GVMMQK_P_G Y8?\FON0OV_#U;9VM]9N-)]MKM<:S[;]EMI6[?"@\[MK
M=<:V-E*[[R;"3P:FV^0\>[_3VIEW*('8:^;WK/'X6S]A\^F,^\E>O@SQ Q=.
MBR;D'$O!I3GV;SY[^Z;1K1]W*^ZVR),;&>7$O-QG@/G'<Y3S]</L<4+_W5Q:
M#N/VW/I8/PEOW[0/CHW[R<X^]:_H)L7%X.OH\F)-P#=$>YVYG+[)C&X@6K*:
MF[D<\T,'DHPFYOA5A&7EIH<+R^,[$-L2BM<YX?[V4RQ%Q#X^9.-+O]79^BM!
MNU_\N2),7AA/E69_<?18^K+W'(SV74&PQLGERWJY,NZ;:L]_/IB(E>M[BP7K
M*HKZH@L?8]46=K7+-V[\E3_]Y<-]=^GQ_U!+ P04    " #(0*98/:']R%<%
M  #$'   '    &QY96PM,C R-# S,S%X,3!Q>&5X>#,R,2YH=&WM66USVC@0
M_GZ_8H_,M60&.S;F)6":&4K(-#,II$"FUT\WPI9C36W)9\M)?+_^5K))(&FN
M="Z7TE[XP&!+N]J79U>/T""4<70T""GQCWX9_&H8<"R\/*9<@I=2(JD/><;X
M)7ST:?89#*.:-1))D;++4$+3:K;@HT@_LRM2CDLF(WJTTC,X*)\'!WJ1P5+X
MQ=' 9U? _#<UUNYU+4IH0(..TUJV[*5-*.WYWK)K];I.K_>'74-1G%[*9+*(
MZ)M:S+@14K5^O]M,I'O-?!GV;<OZK:;G'0T"P24NEJ)P^;/4\5 322]1F11)
MWU::)+V1!HG8)>]K_VJEJM5T3T0B[>]9^N.J$2,@,8N*_NL%BVD&$WH-,Q$3
M_KJ1$9X9&4U94$[,V%\4;<1%].-U93_JB1BG*W_LIG)B?!.R)9/@-$U[TX/M
M;/<P\C3]3L:/QK/%Z<GI:+@XG4[@_&(VOQA.%K"8/NK)KEAN'\*%.3=')LS'
M(VV][;2M!@SG,#R>GB_&QS^4.RLG>E8'IB>P>#>&^7#V=C@9SXWI[V?C3S <
M+=1(T[*:WP8SQGWTK.]TDO^^1%KWG7-ZZ-QYGF8YP76E !E22.F?.4NI[ET9
ME1"(5(; .,SRB&(>B6&WZLM]$(&>/J=>GC+)T*#QC1<2?DEAZ$DU;/><5@-(
M!@25^=1O0%U)O-H[;#8M=WVV?F6[^T"XKS1*)KB&C%(S"DF"N8>.HYX6J@L"
M JQ:_X(SU5WG$IMLAOW4IU"_@]^K/;O3=96F_090XH4KL1P-2C-$%LJ&-*7+
M CR:2A8H1]!9? <BA9!EX)&$>$P6VA.."@+FJ=$ S@H:17 :QSD724C2F#3@
ME'OZR]3.JO4MM_)X).*$\&+E; ,-(;*QBON29CIJ:RM_YN(ZHOXEJFD?NML"
MJ_9HUUZ328COXWYD1#0HT;<!1\,^_!YX[+80CW5[?V7U\R_O;L2E8SHM%8<%
MIF<M>7;7S>!#3E)$953 C"98(H"(/1%I#+9E?%!%HY.:H!'"!PU_>$]2+RP1
MX=@-O>/K[%^'#($I5<9')08]HBL 7Q I$;4H3%1]W6UF&Z546G!;1$$>H5D>
M&API-%\S&=ZO[$PAK2JTTB+;J9-]!;S;\FO7_=LJWRS6=L]5E;H]N'YT2#9W
M$I*,(\SB$BH>:B%,=3-L7BIC%2H#PA1&DY1F*NT--4RP::$8&D,B!$668,:S
MAI8*&"?<4^]1H<^T:M63<58>E:@1B&F]9K8"1U4:YC<T*$F6V,6KX:5(L1D;
M&,Z()!GMKWZX/LN2B!1]QG50M)!;*5L**47<;V,$KU31>"2JJ()&33E<$=I>
MSSS4>]U (OZDOUJXHKNFIKL'TG\XUNJ8+;OYZ+!EVH^._9-:QSSLMI]<JS;6
MV4KM@0Y$&0P,=X;Y>U-S:O=*L=],;L#>9,0*A?<C7@9[_<CPG"1&!>08X:PW
M26RR1=G0.F6'O7=NJ0+S[WU&,'\'PJ9\?5MLTH$G<VD]C;MS-OIR$%[MM7 7
MUM]P]FDRP8/&^.S3%Y*])=(M%:#:5M'<8FK5T734$HR-B)@/*BCN3Y&2!Z<D
MG9*S@G-D#S0J&O#>/#9W)1D_9\CUP?0<]V6FZ)'>I$<AHP%2-3R1279%85J=
M5';^?%T_3QFRC@1IQP/K]Q^#T8&F R]LXX5MO+"-%[;Q?&QC]&XX.QO/83+^
MN)A.=F63^U\RCE%(TJA4)P7?E53\G $O;R0TPSBY_9/@1V08=]8KSC3T/)%S
MJ:[FGI!P?/W/KO5;MT1D^I^6?DHCHKC/@WNXNRK7-,2Z$R%++/5</A3YRM5=
M]5W>(A[HV\N_ 5!+ 0(4 Q0    ( ,A IEAP,#9!CP " -Y;$@ 1
M      "  0    !L>65L+3(P,C0P,S,Q+FAT;5!+ 0(4 Q0    ( ,A IE@/
M!=0#Q \  (JF   1              "  ;X  @!L>65L+3(P,C0P,S,Q+GAS
M9%!+ 0(4 Q0    ( ,A IE@4!TM4P14  %C,   5              "  ;$0
M @!L>65L+3(P,C0P,S,Q7V-A;"YX;6Q02P$"% ,4    " #(0*98WN-A[U-&
M  "720, %0              @ &E)@( ;'EE;"TR,#(T,#,S,5]D968N>&UL
M4$L! A0#%     @ R$"F6*^<\QT,\P$ 8FH" !0              ( !*VT"
M &QY96PM,C R-# S,S%?9S$N:G!G4$L! A0#%     @ R$"F6)7?[_RKW
MM/@( !4              ( !:6 $ &QY96PM,C R-# S,S%?;&%B+GAM;%!+
M 0(4 Q0    ( ,A IE@$ P[@UW\  %=&!@ 5              "  4<]!0!L
M>65L+3(P,C0P,S,Q7W!R92YX;6Q02P$"% ,4    " #(0*98!Y5BK!X(   9
M*0  '               @ %1O04 ;'EE;"TR,#(T,#,S,7@Q,'%X97AX,S$Q
M+FAT;5!+ 0(4 Q0    ( ,A IE@2D(&M%P@  /LH   <              "
M :G%!0!L>65L+3(P,C0P,S,Q>#$P<7AE>'@S,3(N:'1M4$L! A0#%     @
MR$"F6#VA_<A7!0  Q!P  !P              ( !^LT% &QY96PM,C R-# S
G,S%X,3!Q>&5X>#,R,2YH=&U02P4&      H "@"J @  B],%

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>lyel-20240331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lyel="http://lyell.com/20240331"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lyel-20240331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <instant>2024-05-02</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyel:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:TenTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:TwentyTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:ThirtyTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:FortyTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:FiftyTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyel:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:TenTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:TwentyTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:ThirtyTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:FortyTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:FiftyTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">lyel:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">lyel:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">lyel:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">lyel:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:CowenAndCompanyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lyel:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-28</startDate>
            <endDate>2024-02-28</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:DateOfEquityModificationsAxis">lyel:A2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-16</startDate>
            <endDate>2023-11-16</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="entity">
        <measure>lyel:entity</measure>
    </unit>
    <unit id="y">
        <measure>utr:Y</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="grantee">
        <measure>lyel:grantee</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0001806952</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-26">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-29">false</dei:AmendmentFlag>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList contextRef="c-1" id="f-479">http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2023#ResearchAndDevelopmentExpense</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod contextRef="c-149" id="f-541">P27M</lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod>
    <lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn contextRef="c-162" id="f-565">P2Y</lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-40502</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">Lyell Immunopharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">83-1300510</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">201 Haskins Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">695-0677</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">LYEL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">254939222</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-30" unitRef="usd">125650000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-31" unitRef="usd">145647000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-3" decimals="-3" id="f-32" unitRef="usd">400650000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">400576000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">7865000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">8463000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">534165000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">554686000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">286000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">284000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">0</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">16506000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OtherInvestments contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">19000000</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">32001000</us-gaap:OtherInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">97836000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">102654000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">38695000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">39663000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-48" unitRef="usd">4238000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">4235000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-50" unitRef="usd">694220000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">750029000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">4895000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">4817000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">24914000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">28126000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <lyel:SuccessPaymentLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-56" unitRef="usd">2544000</lyel:SuccessPaymentLiabilitiesCurrent>
    <lyel:SuccessPaymentLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">1576000</lyel:SuccessPaymentLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-58" unitRef="usd">32353000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">34519000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-60" unitRef="usd">55159000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">56894000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-62" unitRef="usd">3551000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">3664000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-64" unitRef="usd">91063000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">95077000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-66" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-67" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-68"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-69"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="-3" id="f-70" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="-3" id="f-71" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-72" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="-3" id="f-73" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="-3" id="f-74" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="-3" id="f-75" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="-3" id="f-76" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-78"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-79"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="-3" id="f-80" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="-3" id="f-81" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="-3" id="f-82" unitRef="shares">254927000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="-3" id="f-83" unitRef="shares">254927000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-3" id="f-84" unitRef="shares">253958000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-85" unitRef="shares">253958000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-86" unitRef="usd">25000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-87" unitRef="usd">25000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-88" unitRef="usd">1666315000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-89" unitRef="usd">1657133000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-90" unitRef="usd">-404000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-91" unitRef="usd">-94000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-92" unitRef="usd">-1062779000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-93" unitRef="usd">-1002112000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-94" unitRef="usd">603157000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-95" unitRef="usd">654952000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-96" unitRef="usd">694220000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-97" unitRef="usd">750029000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-98" unitRef="usd">3000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-5" decimals="-3" id="f-99" unitRef="usd">65000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-100" unitRef="usd">43174000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-3" id="f-101" unitRef="usd">44630000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-102" unitRef="usd">13494000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-103" unitRef="usd">19279000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-1" decimals="-3" id="f-104" unitRef="usd">1090000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-5" decimals="-3" id="f-105" unitRef="usd">1288000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-106" unitRef="usd">55578000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-107" unitRef="usd">62621000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-108" unitRef="usd">-55575000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-109" unitRef="usd">-62556000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-1" decimals="-3" id="f-110" unitRef="usd">6819000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-5" decimals="-3" id="f-111" unitRef="usd">4497000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-112" unitRef="usd">1090000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-113" unitRef="usd">1100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-1" decimals="-3" id="f-114" unitRef="usd">13001000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-5" decimals="-3" id="f-115" unitRef="usd">10000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-116" unitRef="usd">-5092000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-117" unitRef="usd">-4403000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-118" unitRef="usd">-60667000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-119" unitRef="usd">-66959000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-120" unitRef="usd">-310000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-5" decimals="-3" id="f-121" unitRef="usd">3720000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-122" unitRef="usd">-60977000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="-3" id="f-123" unitRef="usd">-63239000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-124"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-125"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-126"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-127"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-128" unitRef="shares">254252000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-129" unitRef="shares">254252000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-130" unitRef="shares">249591000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-131" unitRef="shares">249591000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="-3" id="f-132" unitRef="shares">253958000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-133" unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-134" unitRef="usd">1657133000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-135" unitRef="usd">-94000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-136" unitRef="usd">-1002112000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-137" unitRef="usd">654952000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-10" decimals="-3" id="f-138" unitRef="shares">869000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-11" decimals="-3" id="f-139" unitRef="usd">103000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-140" unitRef="usd">103000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-10" decimals="-3" id="f-141" unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-11" decimals="-3" id="f-142" unitRef="usd">-76000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-1" decimals="-3" id="f-143" unitRef="usd">-76000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-11" decimals="-3" id="f-144" unitRef="usd">9155000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-145" unitRef="usd">9155000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-12" decimals="-3" id="f-146" unitRef="usd">-310000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-3" id="f-147" unitRef="usd">-310000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-148" unitRef="usd">-60667000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-149" unitRef="usd">-60667000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-14" decimals="-3" id="f-150" unitRef="shares">254927000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-3" id="f-151" unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-152" unitRef="usd">1666315000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-153" unitRef="usd">-404000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-154" unitRef="usd">-1062779000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-155" unitRef="usd">603157000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-18" decimals="-3" id="f-156" unitRef="shares">249567000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-157" unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-158" unitRef="usd">1608306000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-159" unitRef="usd">-7599000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-160" unitRef="usd">-767480000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-161" unitRef="usd">833252000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-23" decimals="-3" id="f-162" unitRef="shares">42000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-24" decimals="-3" id="f-163" unitRef="usd">-69000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-5" decimals="-3" id="f-164" unitRef="usd">-69000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-24" decimals="-3" id="f-165" unitRef="usd">13882000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-166" unitRef="usd">13882000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-25" decimals="-3" id="f-167" unitRef="usd">3720000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-168" unitRef="usd">3720000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-26" decimals="-3" id="f-169" unitRef="usd">-66959000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-170" unitRef="usd">-66959000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-27" decimals="-3" id="f-171" unitRef="shares">249609000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-172" unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-173" unitRef="usd">1622119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-174" unitRef="usd">-3879000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-175" unitRef="usd">-834439000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-176" unitRef="usd">783826000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-177" unitRef="usd">-60667000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-178" unitRef="usd">-66959000</us-gaap:NetIncomeLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-1" decimals="-3" id="f-179" unitRef="usd">13001000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-5" decimals="-3" id="f-180" unitRef="usd">10000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-181" unitRef="usd">9155000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-5" decimals="-3" id="f-182" unitRef="usd">13882000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-183" unitRef="usd">5024000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-5" decimals="-3" id="f-184" unitRef="usd">5027000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-185" unitRef="usd">4367000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-5" decimals="-3" id="f-186" unitRef="usd">1850000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain contextRef="c-1" decimals="-3" id="f-187" unitRef="usd">1535000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain contextRef="c-5" decimals="-3" id="f-188" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <lyel:FairValueAdjustmentOfSuccessPaymentLiabilities contextRef="c-1" decimals="-3" id="f-189" unitRef="usd">968000</lyel:FairValueAdjustmentOfSuccessPaymentLiabilities>
    <lyel:FairValueAdjustmentOfSuccessPaymentLiabilities contextRef="c-5" decimals="-3" id="f-190" unitRef="usd">-1708000</lyel:FairValueAdjustmentOfSuccessPaymentLiabilities>
    <lyel:NonCashLeaseIncomeExpense contextRef="c-1" decimals="-3" id="f-191" unitRef="usd">373000</lyel:NonCashLeaseIncomeExpense>
    <lyel:NonCashLeaseIncomeExpense contextRef="c-5" decimals="-3" id="f-192" unitRef="usd">293000</lyel:NonCashLeaseIncomeExpense>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c-1" decimals="-3" id="f-193" unitRef="usd">-15000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c-5" decimals="-3" id="f-194" unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-195" unitRef="usd">-595000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-5" decimals="-3" id="f-196" unitRef="usd">408000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">-113000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-5" decimals="-3" id="f-198" unitRef="usd">2069000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">-3606000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-5" decimals="-3" id="f-200" unitRef="usd">-5860000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">-113000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-5" decimals="-3" id="f-202" unitRef="usd">-112000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">-42016000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-5" decimals="-3" id="f-204" unitRef="usd">-46212000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">30000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-206" unitRef="usd">1533000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">108011000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-5" decimals="-3" id="f-208" unitRef="usd">108560000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">130035000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-5" decimals="-3" id="f-210" unitRef="usd">142247000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">21994000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-5" decimals="-3" id="f-212" unitRef="usd">32154000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">103000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-5" decimals="-3" id="f-214" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">76000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-5" decimals="-3" id="f-216" unitRef="usd">69000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">27000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-5" decimals="-3" id="f-218" unitRef="usd">-69000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-219" unitRef="usd">-19995000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-5" decimals="-3" id="f-220" unitRef="usd">-14127000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-221" unitRef="usd">145931000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-22" decimals="-3" id="f-222" unitRef="usd">123834000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-223" unitRef="usd">125936000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-31" decimals="-3" id="f-224" unitRef="usd">109707000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-225" unitRef="usd">125650000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-31" decimals="-3" id="f-226" unitRef="usd">109426000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-3" decimals="-3" id="f-227" unitRef="usd">286000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-31" decimals="-3" id="f-228" unitRef="usd">281000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-229" unitRef="usd">125936000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-31" decimals="-3" id="f-230" unitRef="usd">109707000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <lyel:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities contextRef="c-1" decimals="-3" id="f-231" unitRef="usd">2659000</lyel:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <lyel:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities contextRef="c-5" decimals="-3" id="f-232" unitRef="usd">2406000</lyel:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-233" unitRef="usd">220000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-5" decimals="-3" id="f-234" unitRef="usd">395000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-235">Organization&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lyell Immunopharma, Inc. (the &#x201c;Company&#x201d;) was incorporated in Delaware in June 2018. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a clinical-stage cell therapy company advancing a pipeline of product candidates for patients with solid tumors utilizing its proprietary &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ex&#160;vivo&lt;/span&gt; genetic and epigenetic T&#x2011;cell reprogramming technologies. The Company&#x2019;s primary activities since incorporation have been to develop T&#x2011;cell therapies, conduct research and development, acquire technology, enter into strategic collaboration and license arrangements, enable and execute manufacturing activities in support of its product candidate development efforts, organize and staff the Company, conduct business planning, establish its intellectual property portfolio, submit regulatory submissions, execute clinical trials, raise capital and provide general and administrative support for these activities.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-236">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). The unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany transactions and balances have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Condensed Consolidated Balance Sheet as of December&#160;31, 2023 included herein was derived from the audited consolidated financial statements as of that date. Certain information and footnote disclosures typically included in the Company&#x2019;s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited Condensed Consolidated Financial Statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company&#x2019;s financial position, results of operations and cash flows for the periods presented, but are not necessarily indicative of results to be expected for any future annual or interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Company&#x2019;s audited financial statements and notes included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Management&#x2019;s Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company discovers and develops product candidates that involve experimental technologies. The product candidates may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources or from the issuance of equity or debt securities. The Company believes that its available cash, cash equivalents and marketable securities as of March&#160;31, 2024 will be adequate to fund its operations at least through the next 12&#160;months from the date these unaudited Condensed Consolidated Financial Statements are issued. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Company&#x2019;s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect reported amounts and related disclosures. Specific accounts that require management estimates include, but are not limited to, stock-based compensation, valuation of success payments, valuation of other investments and accrued expenses. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Off-balance Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its cash, cash equivalents and restricted cash with high quality, accredited financial institutions. Restricted cash is cash held in a bank account and is used as collateral associated with the Company&#x2019;s corporate credit card program. Cash, cash equivalents and restricted cash amounts, at times, may exceed federally insured limits. The Company also makes short-term investments in money market funds, U.S. Treasury securities, U.S. government agency securities and corporate debt securities, which can be subject to certain credit risk. However, the Company mitigates the risks by investing in high&#x2011;grade instruments, limiting exposure to any one issuer or type of investment and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;credit losses in such accounts and does not believe it is exposed to significant risk on these funds. The Company has no off&#x2011;balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to the significant accounting policies from the Annual Report on Form 10-K for the year ended December&#160;31, 2023, except as set forth below regarding the Company&#x2019;s stock-based compensation policy for performance-based restricted stock units (&#x201c;PSUs&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 718, the Company measures and recognizes expense for PSUs that settle in stock. The Company granted PSUs that vest upon the achievement of certain performance conditions to certain key employees. For awards with performance conditions that do not vest unless a performance condition is met, the Company recognizes expense if, and to the extent that, the Company estimates that the achievement of the performance condition is probable. At each reporting date, the Company is required to evaluate whether achievement of a performance condition is probable. Compensation expense is recorded over the appropriate service period based upon the Company&#x2019;s assessment of accomplishing each performance condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the Company&#x2019;s PSUs that have market-based metrics are estimated using Monte Carlo simulations. The Company applies an accelerated attribution method to recognize stock-based compensation expense over the applicable service period for these awards. The number of shares expected to be earned is considered in the grant date valuation; therefore, the expense is not subsequently adjusted to reflect the actual shares ultimately earned. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of PSUs that do not have market-based metrics are based upon the grant date stock price. Compensation expense is recognized for the number of shares expected to be earned after assessing the probability that a certain performance condition will be met and the targeted payout level associated with the performance condition expected to be achieved. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled. If performance conditions are not met or not expected to be met, any compensation expense previously recognized associated with the awards will be reversed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which expands required disclosures about a public entity&#x2019;s reportable segments and requires more enhanced information about a reportable segment&#x2019;s expenses, interim segment profit or loss, and how a public entity&#x2019;s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. Entities with a single reportable segment are required to provide all the updated and existing segment disclosures required by Topic 280. The amendments are effective for annual periods beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company is assessing the effect of the new disclosure requirements and does not anticipate the adoption will have a material impact to the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for annual periods beginning after December 15, 2024 and may be applied either prospectively or retrospectively. The Company is assessing the effect of the new disclosure requirements and does not anticipate the adoption will have a material impact to the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-237">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). The unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiary.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-238">All significant intercompany transactions and balances have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-239">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;The preparation of the Company&#x2019;s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect reported amounts and related disclosures. Specific accounts that require management estimates include, but are not limited to, stock-based compensation, valuation of success payments, valuation of other investments and accrued expenses. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-240">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Off-balance Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its cash, cash equivalents and restricted cash with high quality, accredited financial institutions. Restricted cash is cash held in a bank account and is used as collateral associated with the Company&#x2019;s corporate credit card program. Cash, cash equivalents and restricted cash amounts, at times, may exceed federally insured limits. The Company also makes short-term investments in money market funds, U.S. Treasury securities, U.S. government agency securities and corporate debt securities, which can be subject to certain credit risk. However, the Company mitigates the risks by investing in high&#x2011;grade instruments, limiting exposure to any one issuer or type of investment and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any &lt;/span&gt;&lt;/div&gt;credit losses in such accounts and does not believe it is exposed to significant risk on these funds.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock contextRef="c-1" id="f-241">The Company has no off&#x2011;balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock>
    <lyel:SignificantAccountingPoliciesPolicyTextBlock contextRef="c-1" id="f-242">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to the significant accounting policies from the Annual Report on Form 10-K for the year ended December&#160;31, 2023, except as set forth below regarding the Company&#x2019;s stock-based compensation policy for performance-based restricted stock units (&#x201c;PSUs&#x201d;).&lt;/span&gt;&lt;/div&gt;</lyel:SignificantAccountingPoliciesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-243">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 718, the Company measures and recognizes expense for PSUs that settle in stock. The Company granted PSUs that vest upon the achievement of certain performance conditions to certain key employees. For awards with performance conditions that do not vest unless a performance condition is met, the Company recognizes expense if, and to the extent that, the Company estimates that the achievement of the performance condition is probable. At each reporting date, the Company is required to evaluate whether achievement of a performance condition is probable. Compensation expense is recorded over the appropriate service period based upon the Company&#x2019;s assessment of accomplishing each performance condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the Company&#x2019;s PSUs that have market-based metrics are estimated using Monte Carlo simulations. The Company applies an accelerated attribution method to recognize stock-based compensation expense over the applicable service period for these awards. The number of shares expected to be earned is considered in the grant date valuation; therefore, the expense is not subsequently adjusted to reflect the actual shares ultimately earned. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of PSUs that do not have market-based metrics are based upon the grant date stock price. Compensation expense is recognized for the number of shares expected to be earned after assessing the probability that a certain performance condition will be met and the targeted payout level associated with the performance condition expected to be achieved. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled. If performance conditions are not met or not expected to be met, any compensation expense previously recognized associated with the awards will be reversed.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-244">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which expands required disclosures about a public entity&#x2019;s reportable segments and requires more enhanced information about a reportable segment&#x2019;s expenses, interim segment profit or loss, and how a public entity&#x2019;s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. Entities with a single reportable segment are required to provide all the updated and existing segment disclosures required by Topic 280. The amendments are effective for annual periods beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company is assessing the effect of the new disclosure requirements and does not anticipate the adoption will have a material impact to the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for annual periods beginning after December 15, 2024 and may be applied either prospectively or retrospectively. The Company is assessing the effect of the new disclosure requirements and does not anticipate the adoption will have a material impact to the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-245">License, Collaboration and Success Payment Agreements&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fred Hutch&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;License Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In 2018, the Company entered into a license agreement with Fred Hutchinson Cancer Center (&#x201c;Fred Hutch&#x201d;) &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;that grants the Company a worldwide, sublicensable license under certain patent rights (exclusive) and certain technology (non-exclusive) to research, develop and commercialize products and processes for all fields of use utilizing chimeric antigen receptors (&#x201c;CARs&#x201d;) and/or T-cell receptors (&#x201c;TCRs&#x201d;), subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to pay Fred Hutch annual license maintenance payments of $50,000 on the second anniversary of the effective date, and each anniversary of the effective date thereafter until the first commercial sale of a licensed product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaboration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In 2018, the Company entered into a research and collaboration agreement with Fred Hutch (&#x201c;Fred Hutch Collaboration Agreement&#x201d;) focused on research and development of cancer immunotherapy products. The Company funded aggregate research performed by Fred Hutch of $12.0&#160;million under the Fred Hutch Collaboration Agreement, with the research conducted in accordance with a research plan and budget approved by the parties. The Fred Hutch Collaboration Agreement has a six-year term. The Company incurred $0.1&#160;million and $0.3&#160;million in expense in connection with the Fred Hutch Collaboration Agreement for the three months ended March&#160;31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Success Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In 2018, the Company granted Fred Hutch rights to certain success payments, pursuant to the terms of the Fred Hutch Collaboration Agreement. The potential payments for the Fred Hutch success payments are based on multiples of increased value ranging from 10 times to 50 times based on a comparison of the per share fair market value of the Company&#x2019;s common stock relative to the original $1.83 per share issuance price of the Company&#x2019;s Series&#160;A convertible preferred stock, which converted into an equal number of shares of the Company&#x2019;s common stock in connection with the closing of the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;). The aggregate success payments to Fred Hutch are not to exceed $200.0&#160;million, which would only occur upon a 50 times increase in value. Each threshold is associated with a success payment, ascending from $10.0&#160;million at $18.29 per share to $200.0&#160;million at $91.44 per share, payable if such threshold is reached during the measurement period. Any previous success payments made are credited against the success payment owed as of any valuation date, such that Fred Hutch does not receive multiple success payments in connection with the same threshold. The term of the success payment agreement ends on the earlier to occur of (i)&#160;the nine-year anniversary of the date of the agreement and (ii)&#160;a change in control transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate potential success payments, which are payable to Fred Hutch in cash or cash equivalents, or at the Company&#x2019;s discretion, publicly-tradeable shares of the Company&#x2019;s common stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Multiple of initial equity value at issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;10x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;20x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;30x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;40x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;50x&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Per share common stock price required for payment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;36.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;54.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;73.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;91.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Aggregate success payment(s) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The success payments will be owed if the per share fair value of the Company&#x2019;s common stock on the contractually specified valuation measurement dates during the term of the success payment agreement equals or exceeds the above outlined multiples. The valuation measurement dates are triggered by the following events: the one-year anniversary of the Company&#x2019;s IPO and each two-year anniversary of the Company&#x2019;s IPO thereafter, the closing of a change in control transaction and the last day of the term of the success payment agreement, unless the term has ended due to the closing of a change of control transaction. As of March&#160;31, 2024, no success payments have been incurred as the per share fair value of the Company&#x2019;s common stock was below the price required for payment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The success payment liability was $1.1&#160;million and $0.7&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively. With respect to the Fred Hutch Collaboration Agreement success payment obligations, the Company recognized success payment expense of $0.4&#160;million and expense reversal of $1.1&#160;million for the three months ended March&#160;31, 2024 and 2023, respectively, which are recognized in other income, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stanford&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;License Agreement &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- In 2019, the Company entered into a license agreement with The Board of Trustees of the Leland Stanford Junior University (&#x201c;Stanford&#x201d;) to license specified patent rights. The Company is required to pay Stanford annual license maintenance payments of $50,000 on the second anniversary of the effective date, and each anniversary of the effective date thereafter until the date of the first commercial sale of a licensed product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestone payments to Stanford of up to a maximum of $3.7&#160;million per target are payable upon achievement of certain specified clinical and regulatory milestones. The Company is also obligated to pay Stanford $2.5&#160;million &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;collectively for all licensed products upon the achievement of a certain commercial milestone. Additionally, low single&#x2011;digit tiered royalties based on annual net sales of the licensed products are payable to Stanford.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaboration Agreement &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- In October 2020, the Company entered into a research and collaboration agreement with Stanford (&#x201c;Stanford Collaboration Agreement&#x201d;), focused on research and development of cellular immunotherapy products. The Stanford Collaboration Agreement has a four-year term. The Company is committed to fund aggregate research performed by Stanford of $12.0&#160;million under the Stanford Collaboration Agreement, and the research will be conducted in accordance with a research plan and budget approved by the parties. The Company incurred $0.8&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in expense in connection with the Stanford Collaboration Agreement for both of the three months ended March&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Success Payments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- In October 2020, the Company granted Stanford rights to certain success payments, pursuant to the terms of the Stanford Collaboration Agreement. The potential payments for the Stanford Collaboration Agreement success payments are based on multiples of increased value ranging from 10 times to 50 times based on a comparison of the per share fair market value of the Company&#x2019;s common stock relative to the original $1.83 per share issuance price of the Company&#x2019;s Series&#160;A convertible preferred stock, which converted into an equal number of shares of the Company&#x2019;s common stock in connection with the closing of the Company&#x2019;s IPO. The aggregate success payments to Stanford are not to exceed $200.0&#160;million, which would only occur upon a 50 times increase in value. Each threshold is associated with a success payment, ascending from $10.0&#160;million at $18.29 per share to $200.0&#160;million at $91.44 per share, payable if such threshold is reached during the measurement period. Any previous success payments made are credited against the success payment owed as of any valuation date, so that Stanford does not receive multiple success payments in connection with the same threshold. The term of each success payment agreement ends on the earlier to occur of (i)&#160;the nine-year anniversary of the date of the agreement and (ii)&#160;a change in control transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate potential success payments, which are payable to Stanford in cash or cash equivalents, or at the Company&#x2019;s discretion, publicly-tradeable shares of the Company&#x2019;s common stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Multiple of initial equity value at issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;10x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;20x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;30x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;40x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;50x&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Per share common stock price required for payment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;18.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;36.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;54.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;73.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;91.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Aggregate success payment(s) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The success payments will be owed if the per share fair value of the Company&#x2019;s common stock on the contractually specified valuation measurement dates during the term of the success payment agreement equals or exceeds the above outlined multiples. The valuation measurement dates are triggered by the following events: the one-year anniversary of the Company&#x2019;s IPO and each two-year anniversary of the Company&#x2019;s IPO thereafter, the closing of a change in control transaction and the last day of the term of the success payment agreement, unless the term has ended due to the closing of a change of control transaction. As of March&#160;31, 2024, no success payments have been incurred as the per share fair value of the Company&#x2019;s common stock was below the price required for payment. &lt;/span&gt;&lt;/div&gt;The estimated fair values of the success payments to Stanford as of March&#160;31, 2024 and December&#160;31, 2023 were $1.7&#160;million and $1.1&#160;million, respectively. The success payment liability is estimated at the fair value at inception and at each subsequent reporting period and the expense is accreted over the service period of the Stanford Collaboration Agreement as research and development expense. The success payment liability was $1.5&#160;million and $0.9&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively. With respect to the Stanford Collaboration Agreement success payment obligations, the Company recognized success payment expense of $0.5&#160;million and expense reversal of $0.6&#160;million for the three months ended March&#160;31, 2024 and 2023, respectively</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <lyel:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments contextRef="c-32" decimals="-3" id="f-246" unitRef="usd">50000</lyel:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments>
    <lyel:CollaborativeArrangementRightsAndObligationsResearchPayments contextRef="c-32" decimals="-5" id="f-247" unitRef="usd">12000000</lyel:CollaborativeArrangementRightsAndObligationsResearchPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsResearchTerm contextRef="c-32" id="f-248">P6Y</lyel:CollaborativeArrangementRightsAndObligationsResearchTerm>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-33" decimals="-5" id="f-249" unitRef="usd">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-34" decimals="-5" id="f-250" unitRef="usd">300000</us-gaap:ResearchAndDevelopmentExpense>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier contextRef="c-35" decimals="0" id="f-251" unitRef="number">10</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier contextRef="c-36" decimals="0" id="f-252" unitRef="number">50</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c-37"
      decimals="2"
      id="f-253"
      unitRef="usdPerShare">1.83</us-gaap:SharesIssuedPricePerShare>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-36" decimals="-5" id="f-254" unitRef="usd">200000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier contextRef="c-36" decimals="0" id="f-255" unitRef="number">50</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-35" decimals="-5" id="f-256" unitRef="usd">10000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-35"
      decimals="2"
      id="f-257"
      unitRef="usdPerShare">18.29</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-36" decimals="-5" id="f-258" unitRef="usd">200000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-36"
      decimals="2"
      id="f-259"
      unitRef="usdPerShare">91.44</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm contextRef="c-32" id="f-260">P9Y</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock contextRef="c-1" id="f-261">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate potential success payments, which are payable to Fred Hutch in cash or cash equivalents, or at the Company&#x2019;s discretion, publicly-tradeable shares of the Company&#x2019;s common stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Multiple of initial equity value at issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;10x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;20x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;30x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;40x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;50x&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Per share common stock price required for payment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;36.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;54.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;73.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;91.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Aggregate success payment(s) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate potential success payments, which are payable to Stanford in cash or cash equivalents, or at the Company&#x2019;s discretion, publicly-tradeable shares of the Company&#x2019;s common stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Multiple of initial equity value at issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;10x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;20x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;30x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;40x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;50x&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Per share common stock price required for payment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;18.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;36.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;54.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;73.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;91.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Aggregate success payment(s) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-38"
      decimals="INF"
      id="f-262"
      unitRef="number">10</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-39"
      decimals="INF"
      id="f-263"
      unitRef="number">20</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-40"
      decimals="INF"
      id="f-264"
      unitRef="number">30</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-41"
      decimals="INF"
      id="f-265"
      unitRef="number">40</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-42"
      decimals="INF"
      id="f-266"
      unitRef="number">50</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-38"
      decimals="2"
      id="f-267"
      unitRef="usdPerShare">18.29</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-39"
      decimals="2"
      id="f-268"
      unitRef="usdPerShare">36.58</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-40"
      decimals="2"
      id="f-269"
      unitRef="usdPerShare">54.86</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-41"
      decimals="2"
      id="f-270"
      unitRef="usdPerShare">73.15</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-42"
      decimals="2"
      id="f-271"
      unitRef="usdPerShare">91.44</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-38" decimals="-6" id="f-272" unitRef="usd">10000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-39" decimals="-6" id="f-273" unitRef="usd">40000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-40" decimals="-6" id="f-274" unitRef="usd">90000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-41" decimals="-6" id="f-275" unitRef="usd">140000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-42" decimals="-6" id="f-276" unitRef="usd">200000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate contextRef="c-32" id="f-277">P1Y</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering contextRef="c-32" id="f-278">P2Y</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-43" decimals="INF" id="f-279" unitRef="usd">0</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability contextRef="c-43" decimals="-5" id="f-280" unitRef="usd">1100000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability contextRef="c-44" decimals="-5" id="f-281" unitRef="usd">700000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain contextRef="c-33" decimals="-5" id="f-282" unitRef="usd">400000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain contextRef="c-34" decimals="-5" id="f-283" unitRef="usd">-1100000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain>
    <lyel:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments contextRef="c-45" decimals="-3" id="f-284" unitRef="usd">50000</lyel:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments>
    <lyel:CollaborativeArrangementRightsAndObligationsMilestonePayments contextRef="c-46" decimals="-5" id="f-285" unitRef="usd">3700000</lyel:CollaborativeArrangementRightsAndObligationsMilestonePayments>
    <lyel:CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments contextRef="c-47" decimals="-5" id="f-286" unitRef="usd">2500000</lyel:CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments>
    <lyel:CollaborativeArrangementRightsAndObligationsResearchTerm contextRef="c-48" id="f-287">P4Y</lyel:CollaborativeArrangementRightsAndObligationsResearchTerm>
    <lyel:CollaborativeArrangementRightsAndObligationsResearchPayments contextRef="c-48" decimals="-5" id="f-288" unitRef="usd">12000000</lyel:CollaborativeArrangementRightsAndObligationsResearchPayments>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-49" decimals="-5" id="f-289" unitRef="usd">800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-50" decimals="-5" id="f-290" unitRef="usd">800000</us-gaap:ResearchAndDevelopmentExpense>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier contextRef="c-51" decimals="0" id="f-291" unitRef="number">10</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier contextRef="c-52" decimals="0" id="f-292" unitRef="number">50</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c-53"
      decimals="2"
      id="f-293"
      unitRef="usdPerShare">1.83</us-gaap:SharesIssuedPricePerShare>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-52" decimals="-5" id="f-294" unitRef="usd">200000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier contextRef="c-52" decimals="0" id="f-295" unitRef="number">50</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-51" decimals="-5" id="f-296" unitRef="usd">10000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-51"
      decimals="2"
      id="f-297"
      unitRef="usdPerShare">18.29</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-52" decimals="-5" id="f-298" unitRef="usd">200000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-52"
      decimals="2"
      id="f-299"
      unitRef="usdPerShare">91.44</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm contextRef="c-48" id="f-300">P9Y</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-54"
      decimals="INF"
      id="f-301"
      unitRef="number">10</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-55"
      decimals="INF"
      id="f-302"
      unitRef="number">20</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-56"
      decimals="INF"
      id="f-303"
      unitRef="number">30</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-57"
      decimals="INF"
      id="f-304"
      unitRef="number">40</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-58"
      decimals="INF"
      id="f-305"
      unitRef="number">50</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-54"
      decimals="2"
      id="f-306"
      unitRef="usdPerShare">18.29</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-55"
      decimals="2"
      id="f-307"
      unitRef="usdPerShare">36.58</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-56"
      decimals="2"
      id="f-308"
      unitRef="usdPerShare">54.86</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-57"
      decimals="2"
      id="f-309"
      unitRef="usdPerShare">73.15</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-58"
      decimals="2"
      id="f-310"
      unitRef="usdPerShare">91.44</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-54" decimals="-6" id="f-311" unitRef="usd">10000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-55" decimals="-6" id="f-312" unitRef="usd">40000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-56" decimals="-6" id="f-313" unitRef="usd">90000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-57" decimals="-6" id="f-314" unitRef="usd">140000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-58" decimals="-6" id="f-315" unitRef="usd">200000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate contextRef="c-48" id="f-316">P1Y</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering contextRef="c-48" id="f-317">P2Y</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-59" decimals="INF" id="f-318" unitRef="usd">0</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability contextRef="c-59" decimals="-5" id="f-319" unitRef="usd">1700000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability contextRef="c-60" decimals="-5" id="f-320" unitRef="usd">1100000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability contextRef="c-59" decimals="-5" id="f-321" unitRef="usd">1500000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability contextRef="c-60" decimals="-5" id="f-322" unitRef="usd">900000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain contextRef="c-50" decimals="-5" id="f-323" unitRef="usd">500000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain contextRef="c-49" decimals="-5" id="f-324" unitRef="usd">-600000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="c-1" id="f-325">Cash Equivalents and Marketable Securities&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value and amortized cost of cash equivalents and fixed income marketable securities by major security type are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Amortized Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;50,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;50,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;343,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;343,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;38,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;38,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;68,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;68,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and fixed income marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;501,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;501,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;101,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;399,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and fixed income marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;501,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Amortized Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;62,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;62,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;374,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;374,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;48,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;48,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;59,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;59,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and fixed income marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;544,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;544,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;127,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;400,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;16,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and fixed income marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;544,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of money market and fixed income marketable securities held by the Company in an unrealized loss position for less than 12&#160;months were $358.6&#160;million and $117.8&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively. The fair values of money market and fixed income marketable securities held by the Company in an unrealized loss position for greater than 12&#160;months were $11.5&#160;million and $43.6&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively. As of March&#160;31, 2024 and December&#160;31, 2023, all of the Company&#x2019;s money market and fixed income marketable securities had a maturity date of two years or less, were available for use and were classified as available&#x2011;for&#x2011;sale. The Company does not intend to sell these securities nor does the Company believe that it will be required to sell these securities before recovery of their amortized cost basis. The Company determined that there was no material change in the credit risk of the above investments as of both March&#160;31, 2024 and December&#160;31, 2023. As such, an allowance for credit losses has not been recognized. Gross realized gains and losses were &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;de minimis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the three months ended March&#160;31, 2024 and 2023 and as a result, amounts reclassified out of accumulated other comprehensive loss for the three months ended March&#160;31, 2024 and 2023 were also &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;de&#160;minimis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. See Note&#160;6, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information regarding cash equivalents and fixed income marketable securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="c-1" id="f-327">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value and amortized cost of cash equivalents and fixed income marketable securities by major security type are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Amortized Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;50,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;50,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;343,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;343,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;38,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;38,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;68,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;68,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and fixed income marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;501,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;501,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;101,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;399,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and fixed income marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;501,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Amortized Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;62,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;62,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;374,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;374,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;48,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;48,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;59,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;59,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and fixed income marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;544,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;544,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;127,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;400,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;16,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and fixed income marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;544,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-326">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value and amortized cost of cash equivalents and fixed income marketable securities by major security type are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Amortized Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;50,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;50,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;343,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;343,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;38,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;38,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;68,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;68,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and fixed income marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;501,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;501,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;101,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;399,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and fixed income marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;501,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Amortized Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;62,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;62,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;374,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;374,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;48,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;48,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;59,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;59,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and fixed income marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;544,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;544,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;127,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;400,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;16,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and fixed income marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;544,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-61" decimals="-3" id="f-328" unitRef="usd">50808000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-61" decimals="-3" id="f-329" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-61" decimals="-3" id="f-330" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-61" decimals="-3" id="f-331" unitRef="usd">50808000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-62" decimals="-3" id="f-332" unitRef="usd">343389000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-62" decimals="-3" id="f-333" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-62" decimals="-3" id="f-334" unitRef="usd">197000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-62" decimals="-3" id="f-335" unitRef="usd">343194000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-63" decimals="-3" id="f-336" unitRef="usd">38566000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-63" decimals="-3" id="f-337" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-63" decimals="-3" id="f-338" unitRef="usd">139000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-63" decimals="-3" id="f-339" unitRef="usd">38427000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-64" decimals="-3" id="f-340" unitRef="usd">68752000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-64" decimals="-3" id="f-341" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-64" decimals="-3" id="f-342" unitRef="usd">70000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-64" decimals="-3" id="f-343" unitRef="usd">68682000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-3" decimals="-3" id="f-344" unitRef="usd">501515000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-3" decimals="-3" id="f-345" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="-3" id="f-346" unitRef="usd">406000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-3" decimals="-3" id="f-347" unitRef="usd">501111000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-65" decimals="-3" id="f-348" unitRef="usd">101996000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-66" decimals="-3" id="f-349" unitRef="usd">399115000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-67" decimals="-3" id="f-350" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-3" decimals="-3" id="f-351" unitRef="usd">501111000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-68" decimals="-3" id="f-352" unitRef="usd">62075000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-68" decimals="-3" id="f-353" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-68" decimals="-3" id="f-354" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-68" decimals="-3" id="f-355" unitRef="usd">62075000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-69" decimals="-3" id="f-356" unitRef="usd">374214000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-69" decimals="-3" id="f-357" unitRef="usd">237000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-69" decimals="-3" id="f-358" unitRef="usd">95000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-69" decimals="-3" id="f-359" unitRef="usd">374356000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-70" decimals="-3" id="f-360" unitRef="usd">48924000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-70" decimals="-3" id="f-361" unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-70" decimals="-3" id="f-362" unitRef="usd">177000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-70" decimals="-3" id="f-363" unitRef="usd">48750000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-71" decimals="-3" id="f-364" unitRef="usd">59668000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-71" decimals="-3" id="f-365" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-71" decimals="-3" id="f-366" unitRef="usd">62000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-71" decimals="-3" id="f-367" unitRef="usd">59606000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-4" decimals="-3" id="f-368" unitRef="usd">544881000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-369" unitRef="usd">240000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-370" unitRef="usd">334000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-4" decimals="-3" id="f-371" unitRef="usd">544787000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-72" decimals="-3" id="f-372" unitRef="usd">127705000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-73" decimals="-3" id="f-373" unitRef="usd">400576000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-74" decimals="-3" id="f-374" unitRef="usd">16506000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-4" decimals="-3" id="f-375" unitRef="usd">544787000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-3" decimals="-5" id="f-376" unitRef="usd">358600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-4" decimals="-5" id="f-377" unitRef="usd">117800000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-3" decimals="-5" id="f-378" unitRef="usd">11500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-4" decimals="-5" id="f-379" unitRef="usd">43600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm contextRef="c-75" id="f-380">P2Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm contextRef="c-76" id="f-381">P2Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <lyel:OtherInvestmentsTextBlock contextRef="c-1" id="f-382">Other Investments&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In prior years the Company made minority ownership strategic investments. As of March&#160;31, 2024 and December&#160;31, 2023, the aggregate carrying amount of the Company&#x2019;s strategic investments in non-publicly traded companies was $19.0&#160;million and $32.0 million, respectively. These investments are measured at initial cost, minus impairment, if any, and plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Cumulative impairments of strategic investments in equity investments without readily determinable fair values still held as of March&#160;31, 2024 and December&#160;31, 2023 were $23.0&#160;million and $15.0&#160;million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a part of the acquisition of each of the Company&#x2019;s other investments, the Company determines whether an investment or other interest is considered a variable interest. As of both March&#160;31, 2024 and December&#160;31, 2023, the Company held an interest in one entity that was concluded to be a variable interest for which the Company was not the primary beneficiary as the Company did not have the power to direct the activities that most significantly impact the economic performance of the variable interest entity. As of March&#160;31, 2024 and December&#160;31, 2023, the carrying value and maximum exposure to loss of the Company&#x2019;s variable interests were zero and $13.0&#160;million, respectively, which are recorded in other investments in the Company&#x2019;s Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;In connection with the preparation of the financial statements for the three months ended March&#160;31, 2024 and 2023, the Company performed a qualitative assessment of potential indicators of impairment and determined that indicators existed for certain of its other investments with carrying amounts of $13.0&#160;million and $10.0&#160;million, respectively. During the three months ended March&#160;31, 2024, the anticipated funding for one of its other investments was not secured within the expected timeframe. The Company considered both of the underlying companies&#x2019; operating cash flow requirements over the next year, liquid asset balances to fund those requirements and the underlying companies&#x2019; inability to raise funds as indicators of impairment. Due to these indicators, the Company assessed the valuation of these investments and determined the fair values to be negligible and the impairments to be other-than-temporary in nature. As a result, the Company recorded an impairment expense of $13.0 million for the three months ended March&#160;31, 2024 and $10.0&#160;million for the three months ended March&#160;31, 2023, which consisted of the full impairment of one of our other investments in each period. The impairment expenses were recorded within impairment of other investments on the Condensed Consolidated Statements of Operations and Comprehensive Loss and as a reduction to the investment balances within other investments on the Condensed Consolidated Balance Sheets.</lyel:OtherInvestmentsTextBlock>
    <us-gaap:OtherInvestments contextRef="c-3" decimals="-5" id="f-383" unitRef="usd">19000000</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments contextRef="c-4" decimals="-5" id="f-384" unitRef="usd">32000000</us-gaap:OtherInvestments>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount contextRef="c-77" decimals="-5" id="f-385" unitRef="usd">23000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount contextRef="c-78" decimals="-5" id="f-386" unitRef="usd">15000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount>
    <lyel:VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary contextRef="c-3" decimals="INF" id="f-387" unitRef="entity">1</lyel:VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary>
    <lyel:VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary contextRef="c-4" decimals="INF" id="f-388" unitRef="entity">1</lyel:VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary>
    <us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount contextRef="c-3" decimals="-5" id="f-389" unitRef="usd">0</us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount>
    <us-gaap:OtherInvestments contextRef="c-79" decimals="-5" id="f-390" unitRef="usd">0</us-gaap:OtherInvestments>
    <us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount contextRef="c-4" decimals="-5" id="f-391" unitRef="usd">13000000</us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount>
    <us-gaap:OtherInvestments contextRef="c-80" decimals="-5" id="f-392" unitRef="usd">13000000</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments contextRef="c-81" decimals="-5" id="f-393" unitRef="usd">13000000</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments contextRef="c-82" decimals="-5" id="f-394" unitRef="usd">10000000</us-gaap:OtherInvestments>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-83" decimals="-5" id="f-395" unitRef="usd">13000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-84" decimals="-5" id="f-396" unitRef="usd">10000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-397">Fair Value Measurements&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;50,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;50,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;343,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;343,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;38,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;38,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;68,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;68,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;52,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;450,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;502,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Success payment liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;62,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;62,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;374,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;374,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;48,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;48,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;59,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;59,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;62,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;482,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;544,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Success payment liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the fair value of money market funds based on quoted prices in active markets for identical assets or liabilities. The Company measures the fair value of marketable equity securities traded in active markets based on quoted prices of identical assets. The Level&#160;2 marketable securities include U.S. Treasury securities, U.S. government agency securities and corporate debt securities, which are valued using third-party pricing sources. The pricing services applied industry standard valuation models. Inputs utilized include market pricing based on real-time trade data for the same or similar securities and other significant inputs derived from or corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s marketable equity securities were comprised of a company that began being publicly traded on the Nasdaq Global Market in February 2024 and had a fair value of $1.5 million as of March&#160;31, 2024. The Company recorded unrealized gains of $1.5 million and zero for the three months ended March&#160;31, 2024 and 2023, respectively, within other income, net in the Company&#x2019;s Condensed Consolidated Statement of Operations and Comprehensive Loss. As of December&#160;31, 2023, the investment was fully impaired and classified in the Company&#x2019;s Condensed Consolidated Balance Sheet as other investments&lt;/span&gt;&lt;span style="background-color:#f8f8f8;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s success payment liabilities are Level&#160;3 financial instruments, which were estimated using Monte&#160;Carlo simulations through December 31, 2023. Monte Carlo simulations model the future movement of stock prices based on several key variables combined with empirical knowledge of the process governing the behavior of the stock price. The following variables were incorporated in the Monte Carlo simulation to determine the estimated fair value of the success payment liabilities: fair value of the Company&#x2019;s common stock, expected volatility, the risk-free interest rate and the estimated number and timing of valuation measurement dates on the basis of which payments may be triggered. The computation of expected volatility was estimated based on available information about the historical volatility of stocks of similar publicly traded companies for a period matching the expected term assumption. As of March 31, 2024, success payment liabilities were estimated by management using its historical experience of the correlation of success payment fair values relative to the Company&#x2019;s stock price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following assumptions were incorporated into the calculation of the estimated fair value of the Fred Hutch success payment liability as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.51% - 5.19%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.46 - 3.97&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following assumptions were incorporated into the calculation of the estimated fair value of the Stanford success payment liability as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.51% - 5.19%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.46 - 5.75&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes estimates and assumptions in determining the estimated success payment liabilities and associated changes in fair value. A small change in the valuation of the Company&#x2019;s common stock may have a relatively large change in the estimated fair value of the success payment liability and associated changes in fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the changes in the fair value of the Company&#x2019;s Level 3&#160;financial liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Success Payment&lt;br/&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Balance at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Change in fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Balance at March&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The change in the fair value associated with the Fred Hutch success payment liabilities is recorded in &lt;span style="-sec-ix-hidden:f-479"&gt;other income, net&lt;/span&gt;. The change in the fair value associated with the Stanford success payment liabilities is recorded as research and development expenses. (See Note&#160;3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;License, Collaboration and Success Payment Agreements).&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-398">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;50,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;50,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;343,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;343,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;38,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;38,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;68,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;68,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;52,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;450,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;502,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Success payment liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;62,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;62,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;374,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;374,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;48,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;48,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;59,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;59,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;62,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;482,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;544,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Success payment liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-85" decimals="-3" id="f-399" unitRef="usd">50808000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-86" decimals="-3" id="f-400" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-87" decimals="-3" id="f-401" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-88" decimals="-3" id="f-402" unitRef="usd">50808000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-89" decimals="-3" id="f-403" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-90" decimals="-3" id="f-404" unitRef="usd">343194000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-91" decimals="-3" id="f-405" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-62" decimals="-3" id="f-406" unitRef="usd">343194000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-92" decimals="-3" id="f-407" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-93" decimals="-3" id="f-408" unitRef="usd">38427000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-94" decimals="-3" id="f-409" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-63" decimals="-3" id="f-410" unitRef="usd">38427000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-95" decimals="-3" id="f-411" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-96" decimals="-3" id="f-412" unitRef="usd">68682000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-97" decimals="-3" id="f-413" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-64" decimals="-3" id="f-414" unitRef="usd">68682000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-98" decimals="-3" id="f-415" unitRef="usd">1535000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-99" decimals="-3" id="f-416" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-100" decimals="-3" id="f-417" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-3" decimals="-3" id="f-418" unitRef="usd">1535000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-98" decimals="-3" id="f-419" unitRef="usd">52343000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-99" decimals="-3" id="f-420" unitRef="usd">450303000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-100" decimals="-3" id="f-421" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-3" decimals="-3" id="f-422" unitRef="usd">502646000</us-gaap:AssetsFairValueDisclosure>
    <lyel:SuccessPaymentLiabilitiesFairValueDisclosure contextRef="c-98" decimals="-3" id="f-423" unitRef="usd">0</lyel:SuccessPaymentLiabilitiesFairValueDisclosure>
    <lyel:SuccessPaymentLiabilitiesFairValueDisclosure contextRef="c-99" decimals="-3" id="f-424" unitRef="usd">0</lyel:SuccessPaymentLiabilitiesFairValueDisclosure>
    <lyel:SuccessPaymentLiabilitiesFairValueDisclosure contextRef="c-100" decimals="-3" id="f-425" unitRef="usd">2544000</lyel:SuccessPaymentLiabilitiesFairValueDisclosure>
    <lyel:SuccessPaymentLiabilitiesFairValueDisclosure contextRef="c-3" decimals="-3" id="f-426" unitRef="usd">2544000</lyel:SuccessPaymentLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-98" decimals="-3" id="f-427" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-99" decimals="-3" id="f-428" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-100" decimals="-3" id="f-429" unitRef="usd">2544000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-3" decimals="-3" id="f-430" unitRef="usd">2544000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-101" decimals="-3" id="f-431" unitRef="usd">62075000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-102" decimals="-3" id="f-432" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-103" decimals="-3" id="f-433" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-104" decimals="-3" id="f-434" unitRef="usd">62075000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-105" decimals="-3" id="f-435" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-106" decimals="-3" id="f-436" unitRef="usd">374356000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-107" decimals="-3" id="f-437" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-69" decimals="-3" id="f-438" unitRef="usd">374356000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-108" decimals="-3" id="f-439" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-109" decimals="-3" id="f-440" unitRef="usd">48750000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-110" decimals="-3" id="f-441" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-70" decimals="-3" id="f-442" unitRef="usd">48750000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-111" decimals="-3" id="f-443" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-112" decimals="-3" id="f-444" unitRef="usd">59606000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-113" decimals="-3" id="f-445" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-71" decimals="-3" id="f-446" unitRef="usd">59606000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-114" decimals="-3" id="f-447" unitRef="usd">62075000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-115" decimals="-3" id="f-448" unitRef="usd">482712000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-116" decimals="-3" id="f-449" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-450" unitRef="usd">544787000</us-gaap:AssetsFairValueDisclosure>
    <lyel:SuccessPaymentLiabilitiesFairValueDisclosure contextRef="c-114" decimals="-3" id="f-451" unitRef="usd">0</lyel:SuccessPaymentLiabilitiesFairValueDisclosure>
    <lyel:SuccessPaymentLiabilitiesFairValueDisclosure contextRef="c-115" decimals="-3" id="f-452" unitRef="usd">0</lyel:SuccessPaymentLiabilitiesFairValueDisclosure>
    <lyel:SuccessPaymentLiabilitiesFairValueDisclosure contextRef="c-116" decimals="-3" id="f-453" unitRef="usd">1576000</lyel:SuccessPaymentLiabilitiesFairValueDisclosure>
    <lyel:SuccessPaymentLiabilitiesFairValueDisclosure contextRef="c-4" decimals="-3" id="f-454" unitRef="usd">1576000</lyel:SuccessPaymentLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-114" decimals="-3" id="f-455" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-115" decimals="-3" id="f-456" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-116" decimals="-3" id="f-457" unitRef="usd">1576000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-4" decimals="-3" id="f-458" unitRef="usd">1576000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-3" decimals="-5" id="f-459" unitRef="usd">1500000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain contextRef="c-1" decimals="-5" id="f-460" unitRef="usd">1500000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain contextRef="c-5" decimals="-3" id="f-461" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-462">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following assumptions were incorporated into the calculation of the estimated fair value of the Fred Hutch success payment liability as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.51% - 5.19%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.46 - 3.97&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following assumptions were incorporated into the calculation of the estimated fair value of the Stanford success payment liability as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.51% - 5.19%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.46 - 5.75&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <lyel:SuccessPaymentLiabilityFairValueOfCommonStock
      contextRef="c-117"
      decimals="2"
      id="f-463"
      unitRef="usdPerShare">1.94</lyel:SuccessPaymentLiabilityFairValueOfCommonStock>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-118" decimals="4" id="f-464" unitRef="number">3.51</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-119" decimals="4" id="f-465" unitRef="number">5.19</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-120" decimals="3" id="f-466" unitRef="number">0.800</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-121" decimals="2" id="f-467" unitRef="y">0.46</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-122" decimals="2" id="f-468" unitRef="y">3.97</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityFairValueOfCommonStock
      contextRef="c-123"
      decimals="2"
      id="f-469"
      unitRef="usdPerShare">1.94</lyel:SuccessPaymentLiabilityFairValueOfCommonStock>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-124" decimals="4" id="f-470" unitRef="number">3.51</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-125" decimals="4" id="f-471" unitRef="number">5.19</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-126" decimals="3" id="f-472" unitRef="number">0.800</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-127" decimals="2" id="f-473" unitRef="y">0.46</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-128" decimals="2" id="f-474" unitRef="y">5.75</lyel:SuccessPaymentLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-475">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the changes in the fair value of the Company&#x2019;s Level 3&#160;financial liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Success Payment&lt;br/&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Balance at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Change in fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Balance at March&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The change in the fair value associated with the Fred Hutch success payment liabilities is recorded in &lt;span style="-sec-ix-hidden:f-479"&gt;other income, net&lt;/span&gt;. The change in the fair value associated with the Stanford success payment liabilities is recorded as research and development expenses. (See Note&#160;3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;License, Collaboration and Success Payment Agreements).&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-129" decimals="-3" id="f-476" unitRef="usd">1576000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-130" decimals="-3" id="f-477" unitRef="usd">968000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-131" decimals="-3" id="f-478" unitRef="usd">2544000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-481">Leases&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s lease portfolio is comprised of operating leases for laboratory, office and manufacturing facilities located in South San Francisco, California, and Seattle and Bothell, Washington with contractual periods expiring between December 2028 and March 2031. In addition to minimum rent, the leases require payment of real estate taxes, insurance, common area maintenance charges and other executory costs. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s future minimum operating lease commitments, including expected lease incentives to be received, as of March&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2024 (remaining nine months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;8,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;11,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;22,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;80,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(19,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;61,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Reported as of March&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;55,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;61,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The operating lease costs for all operating leases were $2.3&#160;million and $2.1 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the three months ended March&#160;31, 2024 and 2023, respectively. The operating lease costs and total commitments for short-term leases were &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;de&#160;minimis &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the three months ended March&#160;31, 2024 and 2023. Variable lease costs for operating leases were $2.3&#160;million and $1.4 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the three months ended March&#160;31, 2024 and 2023, respectively. The weighted-average remaining lease terms for operating leases were 6.6&#160;and 6.8 years as of March&#160;31, 2024 and December&#160;31, 2023, respectively. The weighted&#x2011;average discount rate for operating leases was 8.5% as of both March&#160;31, 2024 and December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company entered into a sublease, whereby the Company agreed to sublease approximately 11,000 square feet of its space in South San Francisco, California currently leased by the Company. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized sublease income for this sublease of $0.2&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for both the three months ended March&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the Company entered into a sublease with Sonoma Biotherapeutics, Inc. (&#x201c;Sonoma&#x201d;), a related party, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company. See Note&#160;12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Transactions.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As a part of the sublease, in September 2021, the Company received a $4.6&#160;million tenant improvement contribution payment, which is recognized over the term of the sublease. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized Sonoma sublease income of $0.5&#160;million for both the three months ended March&#160;31, 2024 and 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's sublease income is recognized within other operating income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeasesOfLessorDisclosureTextBlock contextRef="c-1" id="f-480">Leases&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s lease portfolio is comprised of operating leases for laboratory, office and manufacturing facilities located in South San Francisco, California, and Seattle and Bothell, Washington with contractual periods expiring between December 2028 and March 2031. In addition to minimum rent, the leases require payment of real estate taxes, insurance, common area maintenance charges and other executory costs. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s future minimum operating lease commitments, including expected lease incentives to be received, as of March&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2024 (remaining nine months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;8,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;11,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;22,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;80,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(19,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;61,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Reported as of March&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;55,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;61,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The operating lease costs for all operating leases were $2.3&#160;million and $2.1 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the three months ended March&#160;31, 2024 and 2023, respectively. The operating lease costs and total commitments for short-term leases were &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;de&#160;minimis &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the three months ended March&#160;31, 2024 and 2023. Variable lease costs for operating leases were $2.3&#160;million and $1.4 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the three months ended March&#160;31, 2024 and 2023, respectively. The weighted-average remaining lease terms for operating leases were 6.6&#160;and 6.8 years as of March&#160;31, 2024 and December&#160;31, 2023, respectively. The weighted&#x2011;average discount rate for operating leases was 8.5% as of both March&#160;31, 2024 and December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company entered into a sublease, whereby the Company agreed to sublease approximately 11,000 square feet of its space in South San Francisco, California currently leased by the Company. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized sublease income for this sublease of $0.2&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for both the three months ended March&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the Company entered into a sublease with Sonoma Biotherapeutics, Inc. (&#x201c;Sonoma&#x201d;), a related party, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company. See Note&#160;12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Transactions.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As a part of the sublease, in September 2021, the Company received a $4.6&#160;million tenant improvement contribution payment, which is recognized over the term of the sublease. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized Sonoma sublease income of $0.5&#160;million for both the three months ended March&#160;31, 2024 and 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's sublease income is recognized within other operating income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:OperatingLeasesOfLessorDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-483">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s future minimum operating lease commitments, including expected lease incentives to be received, as of March&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2024 (remaining nine months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;8,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;11,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;22,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;80,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(19,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;61,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Reported as of March&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;55,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;61,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <lyel:LesseeCurrentAndNonCurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-482">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s future minimum operating lease commitments, including expected lease incentives to be received, as of March&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2024 (remaining nine months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;8,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;11,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;22,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;80,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(19,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;61,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Reported as of March&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;55,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;61,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lyel:LesseeCurrentAndNonCurrentLiabilitiesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-484" unitRef="usd">8688000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="-3" id="f-485" unitRef="usd">11859000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-3" decimals="-3" id="f-486" unitRef="usd">12209000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-3" decimals="-3" id="f-487" unitRef="usd">12569000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-3" decimals="-3" id="f-488" unitRef="usd">12940000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <lyel:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour contextRef="c-3" decimals="-3" id="f-489" unitRef="usd">22585000</lyel:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="-3" id="f-490" unitRef="usd">80850000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="-3" id="f-491" unitRef="usd">19024000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-492" unitRef="usd">61826000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-493" unitRef="usd">6667000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-494" unitRef="usd">55159000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-495" unitRef="usd">61826000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-5" id="f-496" unitRef="usd">2300000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-5" decimals="-5" id="f-497" unitRef="usd">2100000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-5" id="f-498" unitRef="usd">2300000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-5" decimals="-5" id="f-499" unitRef="usd">1400000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-3" id="f-500">P6Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-501">P6Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-502" unitRef="number">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-3" decimals="3" id="f-503" unitRef="number">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:NetRentableArea contextRef="c-132" decimals="-3" id="f-504" unitRef="sqft">11000</us-gaap:NetRentableArea>
    <us-gaap:SubleaseIncome contextRef="c-133" decimals="-5" id="f-505" unitRef="usd">200000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-134" decimals="-5" id="f-506" unitRef="usd">200000</us-gaap:SubleaseIncome>
    <us-gaap:NetRentableArea contextRef="c-135" decimals="-3" id="f-507" unitRef="sqft">18000</us-gaap:NetRentableArea>
    <us-gaap:TenantImprovements contextRef="c-136" decimals="-5" id="f-508" unitRef="usd">4600000</us-gaap:TenantImprovements>
    <us-gaap:SubleaseIncome contextRef="c-137" decimals="-5" id="f-509" unitRef="usd">500000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-138" decimals="-5" id="f-510" unitRef="usd">500000</us-gaap:SubleaseIncome>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-511">Stockholders&#x2019; Equity&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue 10.0&#160;million shares of preferred stock with a par value of $0.0001 per share. As of March&#160;31, 2024 and December&#160;31, 2023, no shares of preferred stock were outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue 500.0&#160;million shares of common stock with a par value of $0.0001 per share. As of March&#160;31, 2024 and December&#160;31, 2023, there were 254,926,880 shares and 253,957,709 shares of the Company&#x2019;s common stock outstanding, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 28, 2024, the Company entered into a sales agreement with Cowen and Company, LLC (&#x201c;Cowen&#x201d;) acting as the Company&#x2019;s sales agent (the &#x201c;Sales Agreement&#x201d;), pursuant to which the Company may offer and sell shares of common stock having an aggregate offering price of up to $150.0&#160;million from time to time&#160;in a series of one or more at&#x2011;the&#x2011;market equity offerings. The Company will pay Cowen commissions of up to 3.0% of the gross proceeds of the sale, and reimbursement of certain expenses, under this agreement. Neither the Company nor Cowen is obligated to sell any shares and, to date, the Company has not made any sales under the Sales Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-512" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-513"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-514" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-515" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-516" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-517"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-518" unitRef="shares">254926880</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-519" unitRef="shares">253957709</us-gaap:CommonStockSharesOutstanding>
    <lyel:SaleOfStockMaximumConsiderationReceived contextRef="c-139" decimals="-5" id="f-520" unitRef="usd">150000000</lyel:SaleOfStockMaximumConsiderationReceived>
    <lyel:SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds contextRef="c-139" decimals="3" id="f-521" unitRef="number">0.030</lyel:SaleOfStockCommissionsPaymentPercentageOfGrossSaleProceeds>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-522">Stock-based Compensation&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company adopted the 2021 Equity Incentive Plan (&#x201c;2021 Plan&#x201d;), which on the date of the underwriting agreement related to the Company&#x2019;s IPO became effective with an initial reserve of 26,662,087 shares, plus any shares subject to outstanding awards granted under the 2018 Equity Incentive Plan (&#x201c;2018 Plan&#x201d;) that, on or after the effectiveness of the 2021 Plan, terminate or expire before exercise or settlement, are not issued because the award is settled in cash, are forfeited because of the failure to vest, or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price. In addition, the number of shares reserved for issuance under the 2021 Plan automatically increases on January&#160;1 of each year for a period of ten years, beginning on January&#160;1, 2022 and continuing through January&#160;1, 2031, in an amount equal to (1)&#160;5% of the total number of shares of the Company&#x2019;s common stock outstanding on December&#160;31 of the immediately preceding year, or (2)&#160;a lesser number of shares determined by the Company&#x2019;s board of directors no later than December&#160;31 of the immediately preceding year. On January&#160;1, 2024, the Company reserved an additional 12,697,885 shares of common stock for issuance under the 2021 Plan representing 5% of the total common shares outstanding as of December&#160;31, 2023. Under the 2021 Plan, the Company may grant incentive stock options, non-statutory stock options, restricted stock awards (&#x201c;RSAs&#x201d;), restricted stock units (&#x201c;RSUs&#x201d;), PSUs, stock appreciation rights, performance awards and other stock-based awards. Terms of stock awards, including vesting requirements, are determined by the Company&#x2019;s board of directors or by a committee authorized by the Company&#x2019;s board of directors, subject to provisions of the 2021 Plan. The term of any stock option granted under the 2021 Plan cannot exceed ten years. Generally, option and RSU awards granted by the Company vest over four years but may be granted with different vesting terms. PSUs generally vest over three years, subject to the achievement of the associated performance conditions. In conjunction with adopting the 2021 Plan, the Company discontinued the 2018 Plan with respect to new equity awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, 33,623,495 shares were available for future issuance pursuant to the 2021 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company adopted the 2021 Employee Stock Purchase Plan (&#x201c;2021 ESPP&#x201d;), which became effective immediately prior to the execution of the underwriting agreement related to the Company&#x2019;s IPO with an initial reserve of 2,470,000 shares. The 2021 ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 15% of their earnings, subject to plan limitations. Unless otherwise &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determined by the Company&#x2019;s board of directors, employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#x2019;s common stock on the first date of an offering or on the purchase date. The number of shares of the Company&#x2019;s common stock reserved for issuance under the 2021 ESPP automatically increases on January&#160;1 of each year for a period of ten years, beginning on January&#160;1, 2022 and continuing through January&#160;1, 2031, by the lesser of (1)&#160;1% of the total number of shares of the Company&#x2019;s common stock outstanding on December&#160;31 of the immediately preceding year, and (2)&#160;4,940,000 shares; provided, however, that the Company&#x2019;s board of directors may act to provide a lesser increase in number of shares. On January&#160;1, 2024, the Company reserved an additional 2,539,577 shares of common stock for issuance under the 2021 ESPP representing 1% of the total common shares outstanding as of December&#160;31, 2023. The Company may specify offerings with durations not more than &lt;span style="-sec-ix-hidden:f-541"&gt;27&#160;months&lt;/span&gt; and may specify shorter purchase periods within each offering. Under the 2021 ESPP, no shares were issued for both the three months ended March&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, 6,001,206 shares were available for future issuance pursuant to the 2021 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company established the 2018&#160;Plan that provided for the grant of incentive stock options, non&#x2011;statutory stock options, RSAs, RSUs, stock appreciation rights and other stock-based awards. Terms of stock awards, including vesting requirements, were determined by the board of directors or by a committee authorized by the Company&#x2019;s board of directors, subject to provisions of the 2018&#160;Plan. The term of any stock option granted under the 2018&#160;Plan cannot exceed ten years. Generally, awards granted by the Company vest over four years, but could have been granted with different vesting terms. Pursuant to the terms of the 2021&#160;Plan, any shares subject to outstanding options originally granted under the 2018&#160;Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof become available for issuance pursuant to awards granted under the 2021&#160;Plan. While no shares are available for future issuance under the 2018&#160;Plan, it continues to govern outstanding equity awards granted thereunder.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense by classification included within the Condensed Consolidated Statements of Operations and Comprehensive Loss was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;9,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;9,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;13,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2024, total stock-based compensation cost related to unvested awards not yet recognized was $66.0&#160;million, which is expected to be recognized over a remaining weighted-average period of 2.7 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options Repricing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Board of Directors of the Company approved, effective November 16, 2023, a one-time repricing of certain stock option awards that had been granted to date under the 2021 Plan and 2018 Plan. The repricing impacted stock options with exercise prices greater than $2.37 held by employees who remained employed as of November&#160;16, 2023 and were not impacted by the Company&#x2019;s November 2023 reduction in workforce. The original exercise prices of the repriced stock options ranged from $2.61 to $17.95 per share for 200 total grantees with 23,416,860 shares repriced. Each stock option was repriced to have a per share exercise price of $1.87, which was the closing price of the Company&#x2019;s common stock on November 16, 2023. To receive the new exercise price, option holders must remain employed with the Company through November 15, 2024. Additionally, the vesting schedule for the unvested shares underlying repriced stock options held by executives at the level of senior vice president and above was extended for an additional year. There were no changes to the vesting schedules for employees below the level of senior vice president. No changes were made to the expiration dates of, or the number of shares underlying, the repriced stock options. Incremental stock-based compensation expense resulting from the repricing was $8.9 million in the aggregate. Expense for vested awards will be recognized through November 15, 2024 and expense for unvested awards will be recognized over the remaining service life of the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance-Based Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024, the Company granted PSU awards to certain key employees. PSUs awarded to employees have a three-year performance period and vest based upon the Company&#x2019;s performance against a &lt;span style="-sec-ix-hidden:f-565"&gt;two&lt;/span&gt; and three-year relative total shareholder return (&#x201c;rTSR&#x201d;) metric, as well as upon the achievement of certain &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;clinical development milestones. For the portion of PSUs subject to certain clinical development milestones (other than the bonus clinical development milestone), 50% vest upon the achievement of the applicable milestone, and the remaining 50% vest upon the earlier of (a) one year of service from the date of such achievement and (b) the end of the three-year performance period. The vesting of all PSU awards granted is also subject to the respective employee&#x2019;s continued employment. The Company valued the portion of PSUs subject to the rTSR metric using a Monte Carlo simulation. The number of PSUs granted subject to the rTSR metrics represents the target number of units that are eligible to be earned based on the achievement of the metrics established at the beginning of the performance period, which ends on December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the three year performance period. For the portion of PSUs subject to the rTSR metrics, employees may ultimately earn between zero and 200% of the target number of PSUs granted based on the degree of achievement of the applicable rTSR metric. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s PSU activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Performance-Based Restricted Stock Units Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Value at Grant&lt;br/&gt;Date Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Unvested PSUs as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;PSUs granted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,703,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;PSUs vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;PSUs forfeited or canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Unvested PSUs as of March&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,703,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1) &#160;&#160;&#160;&#160;PSU grants reflect the target number of shares eligible to be earned at the time of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s RSU activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Restricted Stock Units Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Value at Grant&lt;br/&gt;Date Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Unvested RSUs as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,072,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3,477,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;RSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(142,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;RSUs forfeited or canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(73,298)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Unvested RSUs as of March&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5,334,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Stock Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Options outstanding as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;55,596,831&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;7,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,495,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(868,826)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(3,096,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Options outstanding as of March&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;54,127,378&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;7.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;8,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Options exercisable as of March&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;31,963,665&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted to employees and directors was estimated on the date of grant using the Black-Scholes option pricing model using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;75.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;91.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The weighted-average grant date fair value of options granted for the three months ended March&#160;31, 2024 and 2023 were $1.26 per share and $1.66 per share, respectively.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-140"
      decimals="INF"
      id="f-523"
      unitRef="shares">26662087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-141" id="f-524">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding
      contextRef="c-141"
      decimals="INF"
      id="f-525"
      unitRef="number">0.05</lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-142"
      decimals="INF"
      id="f-526"
      unitRef="shares">12697885</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding
      contextRef="c-142"
      decimals="INF"
      id="f-527"
      unitRef="number">0.05</lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-143" id="f-528">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-144" id="f-529">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-145" id="f-530">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-146" id="f-531">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-147"
      decimals="INF"
      id="f-532"
      unitRef="shares">33623495</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-148"
      decimals="INF"
      id="f-533"
      unitRef="shares">2470000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate contextRef="c-148" decimals="2" id="f-534" unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="c-149" decimals="2" id="f-535" unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-149" id="f-536">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding
      contextRef="c-149"
      decimals="INF"
      id="f-537"
      unitRef="number">0.01</lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding>
    <lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable
      contextRef="c-149"
      decimals="INF"
      id="f-538"
      unitRef="shares">4940000</lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-150"
      decimals="INF"
      id="f-539"
      unitRef="shares">2539577</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding
      contextRef="c-149"
      decimals="INF"
      id="f-540"
      unitRef="number">0.01</lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-151"
      decimals="INF"
      id="f-542"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-152"
      decimals="INF"
      id="f-543"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-153"
      decimals="INF"
      id="f-544"
      unitRef="shares">6001206</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-154" id="f-545">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-154" id="f-546">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-155"
      decimals="INF"
      id="f-547"
      unitRef="shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-548">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense by classification included within the Condensed Consolidated Statements of Operations and Comprehensive Loss was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;9,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;9,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;13,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-156" decimals="-3" id="f-549" unitRef="usd">3792000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-157" decimals="-3" id="f-550" unitRef="usd">4612000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-158" decimals="-3" id="f-551" unitRef="usd">5363000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-159" decimals="-3" id="f-552" unitRef="usd">9270000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-553" unitRef="usd">9155000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-554" unitRef="usd">13882000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-3" decimals="-5" id="f-555" unitRef="usd">66000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-556">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <lyel:ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum
      contextRef="c-160"
      decimals="2"
      id="f-557"
      unitRef="usdPerShare">2.37</lyel:ShareBasedPaymentArrangementPlanModificationExercisePriceMinimum>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-160"
      decimals="2"
      id="f-558"
      unitRef="usdPerShare">2.61</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-160"
      decimals="2"
      id="f-559"
      unitRef="usdPerShare">17.95</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected
      contextRef="c-160"
      decimals="INF"
      id="f-560"
      unitRef="grantee">200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected>
    <lyel:ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced
      contextRef="c-160"
      decimals="INF"
      id="f-561"
      unitRef="shares">23416860</lyel:ShareBasedPaymentArrangementPlanModificationNumberOfSharesRepriced>
    <lyel:ShareBasedPaymentArrangementPlanModificationExercisePrice
      contextRef="c-160"
      decimals="2"
      id="f-562"
      unitRef="usdPerShare">1.87</lyel:ShareBasedPaymentArrangementPlanModificationExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost contextRef="c-160" decimals="-5" id="f-563" unitRef="usd">8900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod contextRef="c-161" id="f-564">P3Y</lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod>
    <lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn contextRef="c-163" id="f-566">P3Y</lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriodRelativeToTotalShareholderReturn>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-164" decimals="2" id="f-567" unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-165" decimals="2" id="f-568" unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate contextRef="c-161" id="f-569">P1Y</lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardServicePeriodFromMilestoneAchievementDate>
    <lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod contextRef="c-161" id="f-570">P3Y</lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod>
    <lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod contextRef="c-161" id="f-571">P3Y</lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod>
    <lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget
      contextRef="c-162"
      decimals="INF"
      id="f-572"
      unitRef="number">0</lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget>
    <lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget
      contextRef="c-163"
      decimals="INF"
      id="f-573"
      unitRef="number">2</lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantedPercentageOfTarget>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock contextRef="c-1" id="f-574">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s PSU activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Performance-Based Restricted Stock Units Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Value at Grant&lt;br/&gt;Date Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Unvested PSUs as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;PSUs granted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,703,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;PSUs vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;PSUs forfeited or canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Unvested PSUs as of March&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,703,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1) &#160;&#160;&#160;&#160;PSU grants reflect the target number of shares eligible to be earned at the time of grant.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-166"
      decimals="INF"
      id="f-575"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-166"
      decimals="2"
      id="f-576"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-161"
      decimals="INF"
      id="f-577"
      unitRef="shares">2703400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-161"
      decimals="2"
      id="f-578"
      unitRef="usdPerShare">1.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-161"
      decimals="INF"
      id="f-579"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-161"
      decimals="2"
      id="f-580"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-161"
      decimals="INF"
      id="f-581"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-161"
      decimals="2"
      id="f-582"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-167"
      decimals="INF"
      id="f-583"
      unitRef="shares">2703400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-167"
      decimals="2"
      id="f-584"
      unitRef="usdPerShare">1.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock contextRef="c-1" id="f-585">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s RSU activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Restricted Stock Units Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Value at Grant&lt;br/&gt;Date Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Unvested RSUs as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,072,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3,477,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;RSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(142,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;RSUs forfeited or canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(73,298)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Unvested RSUs as of March&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5,334,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-168"
      decimals="INF"
      id="f-586"
      unitRef="shares">2072855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-168"
      decimals="2"
      id="f-587"
      unitRef="usdPerShare">2.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-169"
      decimals="INF"
      id="f-588"
      unitRef="shares">3477351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-169"
      decimals="2"
      id="f-589"
      unitRef="usdPerShare">1.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-169"
      decimals="INF"
      id="f-590"
      unitRef="shares">142430</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-169"
      decimals="2"
      id="f-591"
      unitRef="usdPerShare">3.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-169"
      decimals="INF"
      id="f-592"
      unitRef="shares">73298</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-169"
      decimals="2"
      id="f-593"
      unitRef="usdPerShare">2.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-170"
      decimals="INF"
      id="f-594"
      unitRef="shares">5334478</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-170"
      decimals="2"
      id="f-595"
      unitRef="usdPerShare">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-596">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Stock Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Options outstanding as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;55,596,831&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;7,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,495,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(868,826)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(3,096,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Options outstanding as of March&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;54,127,378&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;7.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;8,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Options exercisable as of March&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;31,963,665&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-597" unitRef="shares">55596831</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-598"
      unitRef="usdPerShare">4.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-171" id="f-599">P6Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="-3" id="f-600" unitRef="usd">7368000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-601" unitRef="shares">2495500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-602"
      unitRef="usdPerShare">1.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-603" unitRef="shares">868826</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-604"
      unitRef="usdPerShare">0.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-605" unitRef="shares">3096127</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-606"
      unitRef="usdPerShare">5.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-607" unitRef="shares">54127378</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-608"
      unitRef="usdPerShare">4.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-609">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-3" decimals="-3" id="f-610" unitRef="usd">8295000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-3" decimals="INF" id="f-611" unitRef="shares">31963665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-612"
      unitRef="usdPerShare">5.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-613">P6Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-3" decimals="-3" id="f-614" unitRef="usd">6758000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-615">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted to employees and directors was estimated on the date of grant using the Black-Scholes option pricing model using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;75.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;91.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-1" decimals="4" id="f-616" unitRef="number">0.0415</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-5" decimals="4" id="f-617" unitRef="number">0.0413</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-1" decimals="3" id="f-618" unitRef="number">0.759</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-5" decimals="3" id="f-619" unitRef="number">0.919</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-1" id="f-620">P6Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-5" id="f-621">P6Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="2" id="f-622" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-5" decimals="2" id="f-623" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-624"
      unitRef="usdPerShare">1.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-5"
      decimals="2"
      id="f-625"
      unitRef="usdPerShare">1.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-626">Net Loss Per ShareBasic and diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. The Company&#x2019;s potentially dilutive shares, which include unvested RSUs, unvested PSUs and options to purchase common stock, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Shares subject to options to purchase common stock, unvested RSUs and unvested PSUs were all excluded from consideration in the calculation of diluted net loss per share in all periods presented due to their anti-dilutive effects.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-627">Commitments and Contingencies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License and Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into certain license and collaboration agreements, including those identified in Note&#160;3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License, Collaboration and Success Payment Agreements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;above, with third parties that include the funding of certain development, manufacturing and commercialization efforts with the potential for future milestone and royalty payments upon the achievement of pre-established developmental, regulatory and/or commercial milestones. The Company&#x2019;s obligation to fund these efforts is contingent upon continued involvement in the programs and/or the lack of any adverse events that could cause the discontinuance of the programs, including termination of such agreements. Due to the nature of these agreements, the future potential payments are inherently uncertain, and accordingly no amounts had been recorded for the potential future achievement of these targets as of both March&#160;31, 2024 and December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-628">Related-party Transactions&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the Company entered into a sublease with Sonoma (&#x201c;Sonoma Sublease&#x201d;), with whom the Company has common stockholders with board seats, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company. Dr.&#160;Klausner, the Chair of the Company&#x2019;s board of directors, also serves as Board Chair of the board of directors of Sonoma. As a part of the Sonoma Sublease, a $4.6&#160;million tenant improvement contribution payment was made by Sonoma, which is recognized over the term of the Sonoma Sublease. As of both March&#160;31, 2024 and December&#160;31, 2023, there were accrued liabilities and other current liabilities of $0.5&#160;million and as of March&#160;31, 2024 and December&#160;31, 2023, other non-current liabilities of $2.9&#160;million and $3.0&#160;million, respectively, in connection with the Sonoma Sublease. Total operating income from Sonoma and income solely attributable to the Sonoma Sublease are shown in the table below (in thousands). Total operating income includes income attributable to the sublease, as well as additional operating fees recognized in &#x201c;other operating income, net&#x201d; such as common area maintenance charges. See Note&#160;7, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for more detail on the Sonoma Sublease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Sonoma other operating income, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Sonoma sublease income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:NetRentableArea contextRef="c-136" decimals="-3" id="f-629" unitRef="sqft">18000</us-gaap:NetRentableArea>
    <us-gaap:TenantImprovements contextRef="c-136" decimals="-5" id="f-630" unitRef="usd">4600000</us-gaap:TenantImprovements>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-172" decimals="-5" id="f-631" unitRef="usd">500000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-173" decimals="-5" id="f-632" unitRef="usd">500000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-173" decimals="-5" id="f-633" unitRef="usd">2900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-172" decimals="-5" id="f-634" unitRef="usd">3000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c-1" id="f-635">Total operating income from Sonoma and income solely attributable to the Sonoma Sublease are shown in the table below (in thousands). Total operating income includes income attributable to the sublease, as well as additional operating fees recognized in &#x201c;other operating income, net&#x201d; such as common area maintenance charges. See Note&#160;7, &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for more detail on the Sonoma Sublease.&lt;/span&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Sonoma other operating income, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Sonoma sublease income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-138" decimals="-3" id="f-636" unitRef="usd">807000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-137" decimals="-3" id="f-637" unitRef="usd">669000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:SubleaseIncome contextRef="c-138" decimals="-3" id="f-638" unitRef="usd">465000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-137" decimals="-3" id="f-639" unitRef="usd">465000</us-gaap:SubleaseIncome>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-640">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-1" id="f-641">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-642">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-643">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
